<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>370</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">370</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">2nd National Congress on Medicinal Plants</style></title><secondary-title><style face="normal" font="default" size="100%">Iranian Journal of Pharmaceutical Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Iranian Journal of Pharmaceutical Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">43</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><keywords><keyword><style face="normal" font="default" size="100%">essential oil</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">fertilizer</style></keyword><keyword><style face="normal" font="default" size="100%">flavonoid</style></keyword><keyword><style face="normal" font="default" size="100%">salicylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">acid</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">plant medicinal product</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">methanol</style></keyword><keyword><style face="normal" font="default" size="100%">peppermint</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">plant extract</style></keyword><keyword><style face="normal" font="default" size="100%">heavy metal</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">phenol</style></keyword><keyword><style face="normal" font="default" size="100%">phenol derivative</style></keyword><keyword><style face="normal" font="default" size="100%">anthocyanin</style></keyword><keyword><style face="normal" font="default" size="100%">chamomile</style></keyword><keyword><style face="normal" font="default" size="100%">phytohormone</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen fertilizer</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen</style></keyword><keyword><style face="normal" font="default" size="100%">peroxidase</style></keyword><keyword><style face="normal" font="default" size="100%">free radical</style></keyword><keyword><style face="normal" font="default" size="100%">carvacrol</style></keyword><keyword><style face="normal" font="default" size="100%">rosmarinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">proline</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">marker</style></keyword><keyword><style face="normal" font="default" size="100%">phosphorus</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">silver nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">ispagula</style></keyword><keyword><style face="normal" font="default" size="100%">solvent</style></keyword><keyword><style face="normal" font="default" size="100%">jasmonic acid methyl ester</style></keyword><keyword><style face="normal" font="default" size="100%">cadmium</style></keyword><keyword><style face="normal" font="default" size="100%">fatty acid</style></keyword><keyword><style face="normal" font="default" size="100%">organic fertilizer</style></keyword><keyword><style face="normal" font="default" size="100%">cannabis</style></keyword><keyword><style face="normal" font="default" size="100%">thymol</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">sodium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">chlorophyll</style></keyword><keyword><style face="normal" font="default" size="100%">humic acid</style></keyword><keyword><style face="normal" font="default" size="100%">fumigant</style></keyword><keyword><style face="normal" font="default" size="100%">carbohydrate</style></keyword><keyword><style face="normal" font="default" size="100%">streptozocin</style></keyword><keyword><style face="normal" font="default" size="100%">hormone</style></keyword><keyword><style face="normal" font="default" size="100%">curcumin</style></keyword><keyword><style face="normal" font="default" size="100%">polyphenol</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">antifungal agent</style></keyword><keyword><style face="normal" font="default" size="100%">polymer</style></keyword><keyword><style face="normal" font="default" size="100%">ion</style></keyword><keyword><style face="normal" font="default" size="100%">pigment</style></keyword><keyword><style face="normal" font="default" size="100%">mannan</style></keyword><keyword><style face="normal" font="default" size="100%">sulfur</style></keyword><keyword><style face="normal" font="default" size="100%">vegetable oil</style></keyword><keyword><style face="normal" font="default" size="100%">carbon tetrachloride</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">carotenoid</style></keyword><keyword><style face="normal" font="default" size="100%">atropine</style></keyword><keyword><style face="normal" font="default" size="100%">putrescine</style></keyword><keyword><style face="normal" font="default" size="100%">natural product</style></keyword><keyword><style face="normal" font="default" size="100%">liver enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">oxidizing agent</style></keyword><keyword><style face="normal" font="default" size="100%">eugenol</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant agent</style></keyword><keyword><style face="normal" font="default" size="100%">metal</style></keyword><keyword><style face="normal" font="default" size="100%">alkaloid</style></keyword><keyword><style face="normal" font="default" size="100%">magnetic nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">rutoside</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">titanium dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">coumarin</style></keyword><keyword><style face="normal" font="default" size="100%">silicon</style></keyword><keyword><style face="normal" font="default" size="100%">terpene</style></keyword><keyword><style face="normal" font="default" size="100%">volatile agent</style></keyword><keyword><style face="normal" font="default" size="100%">nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">iron chelate</style></keyword><keyword><style face="normal" font="default" size="100%">Ruta graveolens extract</style></keyword><keyword><style face="normal" font="default" size="100%">chlormequat</style></keyword><keyword><style face="normal" font="default" size="100%">mineral</style></keyword><keyword><style face="normal" font="default" size="100%">DNA</style></keyword><keyword><style face="normal" font="default" size="100%">colchicine</style></keyword><keyword><style face="normal" font="default" size="100%">paclitaxel</style></keyword><keyword><style face="normal" font="default" size="100%">absorbent</style></keyword><keyword><style face="normal" font="default" size="100%">potassium nitrate</style></keyword><keyword><style face="normal" font="default" size="100%">arsenic</style></keyword><keyword><style face="normal" font="default" size="100%">corn oil</style></keyword><keyword><style face="normal" font="default" size="100%">glycoside</style></keyword><keyword><style face="normal" font="default" size="100%">flavonol</style></keyword><keyword><style face="normal" font="default" size="100%">kinetin</style></keyword><keyword><style face="normal" font="default" size="100%">imidacloprid</style></keyword><keyword><style face="normal" font="default" size="100%">fennel oil</style></keyword><keyword><style face="normal" font="default" size="100%">gum tragacanth</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">pectin</style></keyword><keyword><style face="normal" font="default" size="100%">sedative agent</style></keyword><keyword><style face="normal" font="default" size="100%">chamazulene</style></keyword><keyword><style face="normal" font="default" size="100%">parthenolide</style></keyword><keyword><style face="normal" font="default" size="100%">lavender oil</style></keyword><keyword><style face="normal" font="default" size="100%">synthetase</style></keyword><keyword><style face="normal" font="default" size="100%">medicinal plant</style></keyword><keyword><style face="normal" font="default" size="100%">germination</style></keyword><keyword><style face="normal" font="default" size="100%">Thymus (plant)</style></keyword><keyword><style face="normal" font="default" size="100%">concentration (parameter)</style></keyword><keyword><style face="normal" font="default" size="100%">Iran</style></keyword><keyword><style face="normal" font="default" size="100%">plant seed</style></keyword><keyword><style face="normal" font="default" size="100%">rat</style></keyword><keyword><style face="normal" font="default" size="100%">plant leaf</style></keyword><keyword><style face="normal" font="default" size="100%">callus (plant)</style></keyword><keyword><style face="normal" font="default" size="100%">species</style></keyword><keyword><style face="normal" font="default" size="100%">plant</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">basil</style></keyword><keyword><style face="normal" font="default" size="100%">drought stress</style></keyword><keyword><style face="normal" font="default" size="100%">gall (plant)</style></keyword><keyword><style face="normal" font="default" size="100%">thymus</style></keyword><keyword><style face="normal" font="default" size="100%">plant growth</style></keyword><keyword><style face="normal" font="default" size="100%">fennel</style></keyword><keyword><style face="normal" font="default" size="100%">parameters</style></keyword><keyword><style face="normal" font="default" size="100%">Salvia</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro study</style></keyword><keyword><style face="normal" font="default" size="100%">thyme</style></keyword><keyword><style face="normal" font="default" size="100%">date (fruit)</style></keyword><keyword><style face="normal" font="default" size="100%">chemical composition</style></keyword><keyword><style face="normal" font="default" size="100%">cock (bird)</style></keyword><keyword><style face="normal" font="default" size="100%">morphological trait</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisia</style></keyword><keyword><style face="normal" font="default" size="100%">savory</style></keyword><keyword><style face="normal" font="default" size="100%">fenugreek</style></keyword><keyword><style face="normal" font="default" size="100%">salt stress</style></keyword><keyword><style face="normal" font="default" size="100%">Satureja hortensis</style></keyword><keyword><style face="normal" font="default" size="100%">garlic</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">flower</style></keyword><keyword><style face="normal" font="default" size="100%">black cumin</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">cumin</style></keyword><keyword><style face="normal" font="default" size="100%">extraction</style></keyword><keyword><style face="normal" font="default" size="100%">cow (mammal)</style></keyword><keyword><style face="normal" font="default" size="100%">cultivar</style></keyword><keyword><style face="normal" font="default" size="100%">salinity</style></keyword><keyword><style face="normal" font="default" size="100%">Achillea</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">mouse</style></keyword><keyword><style face="normal" font="default" size="100%">broiler</style></keyword><keyword><style face="normal" font="default" size="100%">irrigation (agriculture)</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Melissa officinalis</style></keyword><keyword><style face="normal" font="default" size="100%">fruit (structure)</style></keyword><keyword><style face="normal" font="default" size="100%">antibacterial activity</style></keyword><keyword><style face="normal" font="default" size="100%">myrtle</style></keyword><keyword><style face="normal" font="default" size="100%">ecotype</style></keyword><keyword><style face="normal" font="default" size="100%">Calendula officinalis</style></keyword><keyword><style face="normal" font="default" size="100%">Aloe vera</style></keyword><keyword><style face="normal" font="default" size="100%">safflower</style></keyword><keyword><style face="normal" font="default" size="100%">plant density</style></keyword><keyword><style face="normal" font="default" size="100%">manure</style></keyword><keyword><style face="normal" font="default" size="100%">explant</style></keyword><keyword><style face="normal" font="default" size="100%">Tuber (genus)</style></keyword><keyword><style face="normal" font="default" size="100%">Crocus sativus</style></keyword><keyword><style face="normal" font="default" size="100%">rosemary</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">artichoke</style></keyword><keyword><style face="normal" font="default" size="100%">chicken</style></keyword><keyword><style face="normal" font="default" size="100%">marigold</style></keyword><keyword><style face="normal" font="default" size="100%">fruit</style></keyword><keyword><style face="normal" font="default" size="100%">Echinacea purpurea</style></keyword><keyword><style face="normal" font="default" size="100%">pomegranate</style></keyword><keyword><style face="normal" font="default" size="100%">Silybum marianum</style></keyword><keyword><style face="normal" font="default" size="100%">Zataria multiflora</style></keyword><keyword><style face="normal" font="default" size="100%">Portulacaceae</style></keyword><keyword><style face="normal" font="default" size="100%">intercropping</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">vermicompost</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisia dracunculus</style></keyword><keyword><style face="normal" font="default" size="100%">climate</style></keyword><keyword><style face="normal" font="default" size="100%">morphology</style></keyword><keyword><style face="normal" font="default" size="100%">seedling</style></keyword><keyword><style face="normal" font="default" size="100%">coriander</style></keyword><keyword><style face="normal" font="default" size="100%">weed</style></keyword><keyword><style face="normal" font="default" size="100%">microwave radiation</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">anise</style></keyword><keyword><style face="normal" font="default" size="100%">genetic variability</style></keyword><keyword><style face="normal" font="default" size="100%">grain (structure)</style></keyword><keyword><style face="normal" font="default" size="100%">Ocimum</style></keyword><keyword><style face="normal" font="default" size="100%">herb</style></keyword><keyword><style face="normal" font="default" size="100%">Mentha piperita</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">squash</style></keyword><keyword><style face="normal" font="default" size="100%">Mentha</style></keyword><keyword><style face="normal" font="default" size="100%">colocynth</style></keyword><keyword><style face="normal" font="default" size="100%">sowing date</style></keyword><keyword><style face="normal" font="default" size="100%">parsley</style></keyword><keyword><style face="normal" font="default" size="100%">Tanacetum</style></keyword><keyword><style face="normal" font="default" size="100%">tissue culture</style></keyword><keyword><style face="normal" font="default" size="100%">Ferula</style></keyword><keyword><style face="normal" font="default" size="100%">flowering</style></keyword><keyword><style face="normal" font="default" size="100%">Urtica dioica</style></keyword><keyword><style face="normal" font="default" size="100%">germander</style></keyword><keyword><style face="normal" font="default" size="100%">mycorrhiza</style></keyword><keyword><style face="normal" font="default" size="100%">dill</style></keyword><keyword><style face="normal" font="default" size="100%">Portulaca oleracea</style></keyword><keyword><style face="normal" font="default" size="100%">high performance liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">lemon</style></keyword><keyword><style face="normal" font="default" size="100%">Berberis</style></keyword><keyword><style face="normal" font="default" size="100%">chlorophyll content</style></keyword><keyword><style face="normal" font="default" size="100%">Nepeta</style></keyword><keyword><style face="normal" font="default" size="100%">cytotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">alfalfa</style></keyword><keyword><style face="normal" font="default" size="100%">Cucurbita pepo</style></keyword><keyword><style face="normal" font="default" size="100%">planting time</style></keyword><keyword><style face="normal" font="default" size="100%">Matricaria recutita</style></keyword><keyword><style face="normal" font="default" size="100%">harvesting</style></keyword><keyword><style face="normal" font="default" size="100%">hydrodistillation</style></keyword><keyword><style face="normal" font="default" size="100%">Foeniculum</style></keyword><keyword><style face="normal" font="default" size="100%">Ammi</style></keyword><keyword><style face="normal" font="default" size="100%">seed yield</style></keyword><keyword><style face="normal" font="default" size="100%">storage</style></keyword><keyword><style face="normal" font="default" size="100%">Allium</style></keyword><keyword><style face="normal" font="default" size="100%">Borago</style></keyword><keyword><style face="normal" font="default" size="100%">suspension cell culture</style></keyword><keyword><style face="normal" font="default" size="100%">Plantago</style></keyword><keyword><style face="normal" font="default" size="100%">Stachys</style></keyword><keyword><style face="normal" font="default" size="100%">fungus</style></keyword><keyword><style face="normal" font="default" size="100%">shallot</style></keyword><keyword><style face="normal" font="default" size="100%">Chrysoperla carnea</style></keyword><keyword><style face="normal" font="default" size="100%">Pelargonium</style></keyword><keyword><style face="normal" font="default" size="100%">Rubia</style></keyword><keyword><style face="normal" font="default" size="100%">weight</style></keyword><keyword><style face="normal" font="default" size="100%">antifungal activity</style></keyword><keyword><style face="normal" font="default" size="100%">Oncorhynchus mykiss</style></keyword><keyword><style face="normal" font="default" size="100%">ultrasound</style></keyword><keyword><style face="normal" font="default" size="100%">lavender</style></keyword><keyword><style face="normal" font="default" size="100%">mucilage</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">harvest period</style></keyword><keyword><style face="normal" font="default" size="100%">pollen</style></keyword><keyword><style face="normal" font="default" size="100%">growth curve</style></keyword><keyword><style face="normal" font="default" size="100%">Eucalyptus</style></keyword><keyword><style face="normal" font="default" size="100%">Lavandula angustifolia</style></keyword><keyword><style face="normal" font="default" size="100%">oak</style></keyword><keyword><style face="normal" font="default" size="100%">cell line</style></keyword><keyword><style face="normal" font="default" size="100%">temperature</style></keyword><keyword><style face="normal" font="default" size="100%">summer</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">soil</style></keyword><keyword><style face="normal" font="default" size="100%">Pistacia</style></keyword><keyword><style face="normal" font="default" size="100%">alga</style></keyword><keyword><style face="normal" font="default" size="100%">embryo (anatomy)</style></keyword><keyword><style face="normal" font="default" size="100%">metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">density</style></keyword><keyword><style face="normal" font="default" size="100%">rooting</style></keyword><keyword><style face="normal" font="default" size="100%">olive</style></keyword><keyword><style face="normal" font="default" size="100%">Hibiscus sabdariffa</style></keyword><keyword><style face="normal" font="default" size="100%">city</style></keyword><keyword><style face="normal" font="default" size="100%">galbanum</style></keyword><keyword><style face="normal" font="default" size="100%">drought</style></keyword><keyword><style face="normal" font="default" size="100%">bile</style></keyword><keyword><style face="normal" font="default" size="100%">phylogeny</style></keyword><keyword><style face="normal" font="default" size="100%">cell suspension</style></keyword><keyword><style face="normal" font="default" size="100%">growth regulation</style></keyword><keyword><style face="normal" font="default" size="100%">biomass</style></keyword><keyword><style face="normal" font="default" size="100%">Leporidae</style></keyword><keyword><style face="normal" font="default" size="100%">oregano</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">arbuscular mycorrhiza</style></keyword><keyword><style face="normal" font="default" size="100%">Agastache</style></keyword><keyword><style face="normal" font="default" size="100%">Rosa damascena</style></keyword><keyword><style face="normal" font="default" size="100%">gas</style></keyword><keyword><style face="normal" font="default" size="100%">model</style></keyword><keyword><style face="normal" font="default" size="100%">water stress</style></keyword><keyword><style face="normal" font="default" size="100%">salt tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Anthemis</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">rangeland</style></keyword><keyword><style face="normal" font="default" size="100%">Trigonella</style></keyword><keyword><style face="normal" font="default" size="100%">Lamiaceae</style></keyword><keyword><style face="normal" font="default" size="100%">weed control</style></keyword><keyword><style face="normal" font="default" size="100%">cancer cell culture</style></keyword><keyword><style face="normal" font="default" size="100%">Matricaria chamomilla</style></keyword><keyword><style face="normal" font="default" size="100%">Hyoscyamus</style></keyword><keyword><style face="normal" font="default" size="100%">heat stress</style></keyword><keyword><style face="normal" font="default" size="100%">micropropagation</style></keyword><keyword><style face="normal" font="default" size="100%">leaf area</style></keyword><keyword><style face="normal" font="default" size="100%">lipid peroxidation</style></keyword><keyword><style face="normal" font="default" size="100%">onion</style></keyword><keyword><style face="normal" font="default" size="100%">Salvia officinalis</style></keyword><keyword><style face="normal" font="default" size="100%">stem cutting</style></keyword><keyword><style face="normal" font="default" size="100%">Artemisia vulgaris</style></keyword><keyword><style face="normal" font="default" size="100%">Citrullus</style></keyword><keyword><style face="normal" font="default" size="100%">flour</style></keyword><keyword><style face="normal" font="default" size="100%">dormancy</style></keyword><keyword><style face="normal" font="default" size="100%">compost</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">Scrophulariaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Matricaria</style></keyword><keyword><style face="normal" font="default" size="100%">Glycyrrhiza glabra</style></keyword><keyword><style face="normal" font="default" size="100%">Hypericum perforatum</style></keyword><keyword><style face="normal" font="default" size="100%">callus culture</style></keyword><keyword><style face="normal" font="default" size="100%">hairy root culture</style></keyword><keyword><style face="normal" font="default" size="100%">Avicennia</style></keyword><keyword><style face="normal" font="default" size="100%">Vitex</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">harvest</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus cereus</style></keyword><keyword><style face="normal" font="default" size="100%">bark</style></keyword><keyword><style face="normal" font="default" size="100%">Chrysopidae</style></keyword><keyword><style face="normal" font="default" size="100%">color</style></keyword><keyword><style face="normal" font="default" size="100%">carp</style></keyword><keyword><style face="normal" font="default" size="100%">Rumex</style></keyword><keyword><style face="normal" font="default" size="100%">tea</style></keyword><keyword><style face="normal" font="default" size="100%">moisture</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">inoculation</style></keyword><keyword><style face="normal" font="default" size="100%">Lippia</style></keyword><keyword><style face="normal" font="default" size="100%">purification</style></keyword><keyword><style face="normal" font="default" size="100%">Calendula</style></keyword><keyword><style face="normal" font="default" size="100%">linseed</style></keyword><keyword><style face="normal" font="default" size="100%">moth</style></keyword><keyword><style face="normal" font="default" size="100%">Lycium</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">cut flower</style></keyword><keyword><style face="normal" font="default" size="100%">Euphorbia</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">chicory</style></keyword><keyword><style face="normal" font="default" size="100%">Glycyrrhiza</style></keyword><keyword><style face="normal" font="default" size="100%">Sophora</style></keyword><keyword><style face="normal" font="default" size="100%">celery</style></keyword><keyword><style face="normal" font="default" size="100%">Sargassum</style></keyword><keyword><style face="normal" font="default" size="100%">hen</style></keyword><keyword><style face="normal" font="default" size="100%">Human alphaherpesvirus 1</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">tissues</style></keyword><keyword><style face="normal" font="default" size="100%">herbal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">callus</style></keyword><keyword><style face="normal" font="default" size="100%">Salmonella enterica serovar Typhimurium</style></keyword><keyword><style face="normal" font="default" size="100%">Laurus nobilis</style></keyword><keyword><style face="normal" font="default" size="100%">disk diffusion</style></keyword><keyword><style face="normal" font="default" size="100%">sea</style></keyword><keyword><style face="normal" font="default" size="100%">medicinal species</style></keyword><keyword><style face="normal" font="default" size="100%">Mentha spicata</style></keyword><keyword><style face="normal" font="default" size="100%">watercress</style></keyword><keyword><style face="normal" font="default" size="100%">culture medium</style></keyword><keyword><style face="normal" font="default" size="100%">fertilizer application</style></keyword><keyword><style face="normal" font="default" size="100%">Ruta graveolens</style></keyword><keyword><style face="normal" font="default" size="100%">antineoplastic activity</style></keyword><keyword><style face="normal" font="default" size="100%">Cinnamomum zeylanicum</style></keyword><keyword><style face="normal" font="default" size="100%">phytochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Taxus baccata</style></keyword><keyword><style face="normal" font="default" size="100%">case study</style></keyword><keyword><style face="normal" font="default" size="100%">planting density</style></keyword><keyword><style face="normal" font="default" size="100%">Curcuma longa</style></keyword><keyword><style face="normal" font="default" size="100%">Phlomis</style></keyword><keyword><style face="normal" font="default" size="100%">season</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">DNA extraction</style></keyword><keyword><style face="normal" font="default" size="100%">clove</style></keyword><keyword><style face="normal" font="default" size="100%">vegetable</style></keyword><keyword><style face="normal" font="default" size="100%">pH</style></keyword><keyword><style face="normal" font="default" size="100%">Echinacea</style></keyword><keyword><style face="normal" font="default" size="100%">powder</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Viola tricolor</style></keyword><keyword><style face="normal" font="default" size="100%">microalga</style></keyword><keyword><style face="normal" font="default" size="100%">Gracilaria</style></keyword><keyword><style face="normal" font="default" size="100%">Tanacetum parthenium</style></keyword><keyword><style face="normal" font="default" size="100%">postharvest period</style></keyword><keyword><style face="normal" font="default" size="100%">inflorescence</style></keyword><keyword><style face="normal" font="default" size="100%">biological activity</style></keyword><keyword><style face="normal" font="default" size="100%">tomato</style></keyword><keyword><style face="normal" font="default" size="100%">developmental stage</style></keyword><keyword><style face="normal" font="default" size="100%">Carum</style></keyword><keyword><style face="normal" font="default" size="100%">embryo</style></keyword><keyword><style face="normal" font="default" size="100%">Securidaca</style></keyword><keyword><style face="normal" font="default" size="100%">motoneuron</style></keyword><keyword><style face="normal" font="default" size="100%">magnetic field</style></keyword><keyword><style face="normal" font="default" size="100%">Myricaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Sambucus</style></keyword><keyword><style face="normal" font="default" size="100%">Azerbaijan</style></keyword><keyword><style face="normal" font="default" size="100%">forest</style></keyword><keyword><style face="normal" font="default" size="100%">newborn</style></keyword><keyword><style face="normal" font="default" size="100%">grain yield</style></keyword><keyword><style face="normal" font="default" size="100%">synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">mangrove</style></keyword><keyword><style face="normal" font="default" size="100%">caraway</style></keyword><keyword><style face="normal" font="default" size="100%">grain</style></keyword><keyword><style face="normal" font="default" size="100%">genus</style></keyword><keyword><style face="normal" font="default" size="100%">symbiosis</style></keyword><keyword><style face="normal" font="default" size="100%">wound</style></keyword><keyword><style face="normal" font="default" size="100%">food</style></keyword><keyword><style face="normal" font="default" size="100%">engineering</style></keyword><keyword><style face="normal" font="default" size="100%">solvent extraction</style></keyword><keyword><style face="normal" font="default" size="100%">healing</style></keyword><keyword><style face="normal" font="default" size="100%">meat</style></keyword><keyword><style face="normal" font="default" size="100%">Fritillaria</style></keyword><keyword><style face="normal" font="default" size="100%">Coturnix japonica</style></keyword><keyword><style face="normal" font="default" size="100%">environmental factor</style></keyword><keyword><style face="normal" font="default" size="100%">biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Malva</style></keyword><keyword><style face="normal" font="default" size="100%">coastal waters</style></keyword><keyword><style face="normal" font="default" size="100%">water deficit</style></keyword><keyword><style face="normal" font="default" size="100%">regeneration</style></keyword><keyword><style face="normal" font="default" size="100%">sweet potato whitefly</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">photosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">antiinflammatory activity</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">chick</style></keyword><keyword><style face="normal" font="default" size="100%">Campylobacter jejuni</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus flavus</style></keyword><keyword><style face="normal" font="default" size="100%">sour orange</style></keyword><keyword><style face="normal" font="default" size="100%">Oman</style></keyword><keyword><style face="normal" font="default" size="100%">abiotic stress</style></keyword><keyword><style face="normal" font="default" size="100%">Mentha longifolia</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Azadirachta indica</style></keyword><keyword><style face="normal" font="default" size="100%">sperm</style></keyword><keyword><style face="normal" font="default" size="100%">bean</style></keyword><keyword><style face="normal" font="default" size="100%">petal</style></keyword><keyword><style face="normal" font="default" size="100%">flora</style></keyword><keyword><style face="normal" font="default" size="100%">brown alga</style></keyword><keyword><style face="normal" font="default" size="100%">radiation</style></keyword><keyword><style face="normal" font="default" size="100%">Chenopodium album</style></keyword><keyword><style face="normal" font="default" size="100%">Juniperus</style></keyword><keyword><style face="normal" font="default" size="100%">Ajuga</style></keyword><keyword><style face="normal" font="default" size="100%">tree</style></keyword><keyword><style face="normal" font="default" size="100%">Wistar rat</style></keyword><keyword><style face="normal" font="default" size="100%">Rheum</style></keyword><keyword><style face="normal" font="default" size="100%">Asteraceae</style></keyword><keyword><style face="normal" font="default" size="100%">ploidy</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus thuringiensis</style></keyword><keyword><style face="normal" font="default" size="100%">milk</style></keyword><keyword><style face="normal" font="default" size="100%">Laurus</style></keyword><keyword><style face="normal" font="default" size="100%">Crataegus</style></keyword><keyword><style face="normal" font="default" size="100%">fiber</style></keyword><keyword><style face="normal" font="default" size="100%">Linum</style></keyword><keyword><style face="normal" font="default" size="100%">fermentation</style></keyword><keyword><style face="normal" font="default" size="100%">Ricinus communis</style></keyword><keyword><style face="normal" font="default" size="100%">Silene</style></keyword><keyword><style face="normal" font="default" size="100%">Verbenaceae</style></keyword><keyword><style face="normal" font="default" size="100%">flax</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">Fumaria</style></keyword><keyword><style face="normal" font="default" size="100%">pepper</style></keyword><keyword><style face="normal" font="default" size="100%">dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">cinnamon</style></keyword><keyword><style face="normal" font="default" size="100%">path analysis</style></keyword><keyword><style face="normal" font="default" size="100%">fingerling</style></keyword><keyword><style face="normal" font="default" size="100%">grape</style></keyword><keyword><style face="normal" font="default" size="100%">Atropa</style></keyword><keyword><style face="normal" font="default" size="100%">anatomical concepts</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">aging</style></keyword><keyword><style face="normal" font="default" size="100%">antidiabetic activity</style></keyword><keyword><style face="normal" font="default" size="100%">prostate cancer</style></keyword><keyword><style face="normal" font="default" size="100%">sweet orange</style></keyword><keyword><style face="normal" font="default" size="100%">subspecies</style></keyword><keyword><style face="normal" font="default" size="100%">puberty</style></keyword><keyword><style face="normal" font="default" size="100%">cardamom</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">pistachio</style></keyword><keyword><style face="normal" font="default" size="100%">sciatic nerve</style></keyword><keyword><style face="normal" font="default" size="100%">Thiobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">Marrubium</style></keyword><keyword><style face="normal" font="default" size="100%">scar formation</style></keyword><keyword><style face="normal" font="default" size="100%">sprout</style></keyword><keyword><style face="normal" font="default" size="100%">willow</style></keyword><keyword><style face="normal" font="default" size="100%">Aegle marmelos</style></keyword><keyword><style face="normal" font="default" size="100%">Cirsium</style></keyword><keyword><style face="normal" font="default" size="100%">dry weight</style></keyword><keyword><style face="normal" font="default" size="100%">nonalcoholic fatty liver</style></keyword><keyword><style face="normal" font="default" size="100%">apricot</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">Salmonella enterica serovar Enteritidis</style></keyword><keyword><style face="normal" font="default" size="100%">MCF-7 cell line</style></keyword><keyword><style face="normal" font="default" size="100%">tail suspension test</style></keyword><keyword><style face="normal" font="default" size="100%">vapor</style></keyword><keyword><style face="normal" font="default" size="100%">ginger</style></keyword><keyword><style face="normal" font="default" size="100%">Valeriana officinalis</style></keyword><keyword><style face="normal" font="default" size="100%">aroma</style></keyword><keyword><style face="normal" font="default" size="100%">plant disease</style></keyword><keyword><style face="normal" font="default" size="100%">examination</style></keyword><keyword><style face="normal" font="default" size="100%">solid phase microextraction</style></keyword><keyword><style face="normal" font="default" size="100%">plant regeneration</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">bioassay</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1735-0328&#xD;1726-6890</style></isbn><abstract><style face="normal" font="default" size="100%">The proceedings contain 1453 papers. The special focus in this conference is on Medicinal Plants. The topics include: Repellency effects of commercial formulation of eucalyptus extract on red flour beetle, tribolium castaneum herbst; antifungal effects of fennel oil on the growth of aspergillus flavus; in vitro antifungal affects essential oil of origanum vulgare L. and comparison with synthetic thymol on aspergillus flavus; antimicrobial activity of avicennia marina extract against staphylococcus aureus; antimicrobial activity of avicennia marina extract against escherichia coli; study of milk thistle (silybum marianum L) germination attributes and seed vigor under salinity stress by osmopriming accelerators; evaluation of hesperidin flavonoid in different tissues during fruit development of limon (C. limon Cv. eureka); inhibitory effect of tea tree oil and aloe vera leaf gel shampoo on malassezia furfur; effect of gamma irradiation on antioxidant and antimicrobial activities of echinacea (echinacea purpurea L.); development of a validated high pressure liquid chromatography method for simultaneous determination of stevioside and rebodioside a in sweeteners; allelopathic potential of madder (rubia tinctorum) extracts on field bindweed (convolvolus arvense L.) and corn (Zea Mays L.) germination characteristics; suppressing effects of rhubarb (rheum ribe) extracts on purslane (portulaca oleracea) and alfalfa (medicago sativa) seedling growth; effect of dormancy breaking treatments on germination charachteristics of acacia (Albezia Lebbek); investigation of chemical essential oil components of chaerophyllum macrospermum in kandovan; evaluation effects of antimicrobial thyme essential oil on loads microbial and qualitative characteristics of fresh-cut carrotvilmorincultivar in duration storage; the study of effects of berberis vulgaris hydriethanolic extracts on serum bilirubin level and aenzymes of the liverin male cholestatic rats; the effect of aqueous extract of allium sativum on behavioral changes in parkinson male rat; investigation of chemical essential oil components of thymus eriocalyx in peresk area (in alashtar-lorestan province); investigation of chemical essential oil components of thymus lancifolious in zagheh area (in lorestan province); effect of different soil series and manure application on dried flower yield, essential oil and chamazulene content and essential oil yield of german chamomile; effect of manure application on essential oil content, essential oil yield and chamazulene content of German chamomile in different soil series of Chaharmahal–Va–bakhtiari province; chemical compositions and antimicrobial activity of essential oil of phlomis cancellata bunge. from mazandaran; effect of ruta graveolens extract on histopathologic changes in mice livers; composition of free and glycosidically bound volatile components of achillea tenuifolia lam. root; study gene expressions of cinnamyl alcohol--dehydrogenase, lignin and lignan compounds at different organs of linum album; antiproliferative effects of ferula gummosa extracts on different cancer cell lines; investigation antibacterial activity of essential oils from plant family lamiaceae on tree bacterial species; effects of biologic and organic fertilizers on mentha piperita in hydroponic condition; investigate effect of different nursery bed on marcotting rosemary cutting; comparative studies on phosphomolybdenum assay, DPPH and reducing power antioxidant properties in microshoots of five persian walnuts; the effects of salinity on soluble sugars and prolin in the medicinal plant borago officinalis L. on the hydroponic conditions; the effects of salinity on chlorophyll content and growth of borago officinalis L.; introduction of medicinal plants in the upper giyan region in tafresh area; comparative study of anti-inflammatory effects of rubia tinctorum L. extracts in carrageenan-induced paw edema in rats; effect of microwave radiation on seed germination and seedling growth of thyme; effect of B vitamins on germination factors of fennel; intro uction of medicinal plants of ashtian mountain protected area; effect of NaCl and gibberellic acid on seed germination and seedling growth of 5 medicinal plants; investigation of medinical plant consumption in khorram abad township viewpoint herbal grocery; effect of different levels of irrigation and plant growth promoting rhizobacteria on grain yield and root chang of chamomile (matricaria recutita L.); effect of bio-fertilizer on germination and seedling of chamomil (matricaria recutita L.) cultivars; antimicrobial effects of alcohol extract of curcuma longa L. on the some of bacteria; antioxidative, antimicrobial and cytotoxic activities of kunstlerone from beilschmiedia species; alkaloidal compounds from bark of beilschmiedia; bioactivities of kunstleramide as a dienamide from lauraceae family; alkaloidal natural products in the leaf of malaysian beilschmiedia; identification of agronomic traits influencing seed yield of some Iranian fenugreek (trigonella foenumgraecum L) ecotypes; the effect of salinity stress on germination in dracocephalum moldavica seeds; study of genetic diversity in persian shallot (allium hirtifolium) based on morphological traits; amount of micro and macro elements in leaves of medicinal plant calendula officinalis L. with foliar application of bio-stimulators; the effects of different nitrogen levels on yield, yield components and oil percentage of spring safflower cultivars in kerman, Iran; protective effects of green tea on antioxidative biomarkers in chemical laboratory workers; effect of IBA as a root promoting hormne and bio-fertilizers in propagating of lavandula (lavandula officinal ) by cutting; shoot initiation of bistort (polygonum bistorta) explants under in vitro condition; antihypertensive effect of celery seed on rat blood pressure in chronic administration; investigation of salicylic acid and kinetin effects on seed germination and seedling growth of lemon balm (melissa officinalis L.) under salinity stress; investigation the amonut of fiber and phenolic compounds in sclerorhachis leptoclada from south Khorasan; he effect of differen super absorbent polymer and drought stress on grain yield and essintial oil of chamomile; the effect of strains of pseudomonas on growth and development of root in thyme (thymus vulgaris L.); isolation, structural characterization and antioxidant activity of a new water-soluble polysaccharide from acanthophyllum squarrosum roots; the study of polyphenols profiles, carbohydrates content and antioxidant capacities in sophora pachycarpa C. A. Mey; evaluation of nutrient content (crude protein, fat content, crude fiber, neutral detergent fiber and acid detergent fiber) and heavy metals in sophora pachycarpa C. A. Mey; effects of mulching on quantity and quality yield of garlic populations (allium sativum L.); study of different weed management methods of thyme (thymus vulgaris L.); effect of humic acid and vermicompost on flower yield, seed yield and yield components of safflower in kerman, Iran; introduction of medicinal plants of zalian area in the city sareband located in the Markazi province; effect of wormwood (artemisia absinthium) essential oil on antioxidant status and lipid peroxidation in broiler chickens; effect of essential oil of cumin (cuminum cyminum) medicinal herb on antioxidant status, lipid peroxidation and serum metabolities in broiler chickens; effect of different salinity levels on germination and early seedling growth of medical plant capparis spinosa L.; studies on seed germination and seedling growth in mentha longifolia L. under abiotic stress conditions; evaluation of heavy metals in some medicinal plants growing in sistan region; antibacterial activity of teucrium polium essential oil against clinical isolates of klebsiella pneumoniae; the effect of methanol and nano-iron chalate fertilizer on chlorophyll content, some morphological and agronomical traits of ocimum basilicum L.; new trends in the utilization of medicinal and aromatic plants; response of anticancer compounds to nitrogen fertilizer in naein-E havandi (androg aphis paniculata); photosynthesis and antioxidative systems of naein-E havandi (andrographis paniculata) as affected by compost tea rates; effects of water stress (drought) on the mineral and vitamin content of the leaves of a medical plant brassica rapa L.; the effects of hydroalcoholic extract of nigella sativa on the activity of liver enzymes in female rats; influence of some environmental factors on the morphological traits of thymus daenensis celak; improvement of solvent systems in TLC chromatography of flavonoids from leaves of glycyrrhiza glabra L. and fritillaria imperialis L. using a software system; distribution of spirulina the blue-green gold of Iran; electrobotany of medicinal algae of Iran; introduction to engineering for medicinal plants of Iran; the cites and medicinal plants of Iran; the importance for aquatic medicinal plants of Iran; the prospects and challenges for algae therapy in Iran; optimization of microencapsulation of pomegranate seed oil by response surface methodology; effect of sucrose concentration on the growth and trigonelline production in hairy root culture of Iranian fenugreek (trigonella foenum-graecum L.); investigation the sustainability of mazooj gall and its inducer agent wasp in oak forests of West-Azerbaijan; volatile oil of artemisia santolina decreased the morphine withdrawal jumping in mice; species diversity and distribution of the medicinal galls by oak gall wasps species in West-Azerbaijan; identifying the best time to harvest of mazooj gall in oak forests of West-Azerbaijan province; bioactive sesquiterpene lactone from artemisia santolina; presence of monoterpene synthase in four labiatae species and SPME- GC-MS analysis of their aroma profiles; monoterpene synthase from lavandula angustifolia and solid-phase microextraction- gass chromatography-mass spectroscopy analysis of its aroma profile; antioxidant and hydroxyl radical scavenging activity of phoenix dactylifera L. var.deyry fruit and seed; GC/Mass analysis of the volatile compounds of P. hyrcanicumdiethyl ether extract and GC profiling of some Iranian polygonum species; effects of sowing date in spring and summer, and various amounts of vermicompost on growth and yield of fenugreek; effect of salt stress on germination factors of lemon balm (melissa officinalis L.); chemical composition and antioxidant activity of essential oils of three Iranian herbs (apiaceae family); effects of drought stress and different nitrogen levels on the quantitative and qualitative yield of black cumin (nigella sativa L.) in sistan region; evaluation of free radical scavenging activity of plant extracts and essential oil of mentha aquatica L.; analysis of volatile oil components extracted by SDE technique and antioxidant activity of oily components of “water mint”; analysis of the essential oil components of mentha aquatic L. collected in tehran province; changes in oil yield and chemical components of the essential oil of satureja bachtiarica bunge under five drying methods; effects of cold stress and seed scratching on seed germination and some growth related characteristics of wild pistachio (pistacia atlantica desf.); evaluation of medical and pharmaceutical effects of extract bark of tree species beech, spruce and oak; callus induction evaluation of two Iranian native seashore iris subspecies, using different explants through in vitro culture; effect of drought stress in different growth stages on some of morphological traits of peppermint (mentha piperiat L.); effect of osmoprinimg on seed germination of osimum basilicum under drought stresses; chemical constitutes of the essential oil of artemisia aucheri boiss from high altitude of chaharmahal va bakhtiari; study of effects on wounds healing of rhubarb extract in rat; local effect of eugenol oil on the skin wound healing in rat; comparison of carvacrol level and antibacterial properties of industrial and laboratory extracted essential oils of the wild and cultivated satureja khuzestanica; effect of phytohormones on composition of sambucus nigra L. essential oil; oleuropein extracted from olive tree leaves maceration and soxhlet method and measured with high performance liquid chromatography; the effect of salinity stress from NaCl on seedling growth of docrosia anethifolia herb in hydroponic irrigation condition and determination its salinity tolerance threshold; investigation of in vitro apocarotinoid gene expression in perianth of saffron (crocus sativus) Iran; effect of height on hypericin content of St. John’S wort; effect of elaegnus angustifolia L. hydroethanolic leaf extract on serum triglycerides, LDL, HDL and total cholesterol of male rats; the investigation of the some chemİCal components of volatile oil of four specİEs MİNt leaves İN the VarİOus growth stages; antifungal activity of the essential oil of salvia virgata; evaluation of the effect of organic fertilizers and mulch application on growth, development, essential oil content, and microbial load in peppermint (mentha piperita L.); the comparision GC and GC-MS of allium ampeloprasum L. Var, atroviolaceum regel and allum Iranicum wendelbo (wendelbo); in vitro antimicrobial activity of allium ampeloprasum L. var atroviolaceum regel; effect of methanol and nano-iron chelated fertilizer application on activity of polyphenol oxidase, glutathione peroxidase and essential oils content in basil (ocimum basilicum L.); diterpene compounds in essential oils of juniperusexcelsa; in vivo effect of melissa officinalis essential oil on growth and aflatoxin production by aspergillus flavus isolated from stored corn; clinical acute toxicity information of mentha longifolia essential oil investigation of medinical plant consumption in khorram abad township viewpoint customers; evaluation of different drying methods on essential oil and chamazolene contents of chamomile flowers; study of different drying methods on qualitative characteristics of thyme; analysis of seed germination in two medicinal species of salvia under different chemical treatments; the survey on effects of irrigation and weed control on yield, yield component and seed oil contents of marigold (calendula officinalis L.); the survey on effects of nitrogen fertilizer application and density on seed yield, yield components and oil content of marigold (calendula officinalis L.); evaluation of antiradical activity and antioxidant capacity of methanolic extract of gorg tigh plant (lycium ruthenicum murry); determination of total phenolic, tannin and flavonoid content in lycium ruthenicum murry; anticonvulsive effects of vitexin, a flavonoid, on pentylenetetrazole-induced seizure in rats; correlation and path coefficient analysis of seed yield and yield components of flax; effect of No on Fe deficiency-induced chlorosis in melissa officinalis; effect of valerian officinalis on FSH and estrogen in female mature rats; investigation of antioxidant enzymes activities, soil texture, and stigma-like structures in petals culture of saffron (crocus sativus L.); phylogenetic analysis of the tribe fabeae based on plastid DNA sequences; effect of UV-C radiation on some physico chemical on pomegranate in warehouse (punica granatum L.); preparation of nanoniosomal paclitaxel formulation and evaluation its effects on the breast cancer cell line (MCF-7); heavy metal accumulation in medicinal plants chenopodium album collected from environmentally different sites; aerial parts flavonoids of eleocharis uniglumis (link) schult. (cyperaceae); root flavonoids of cyperus L. (cyperaceae) species in markazi province, Iran; antibacterial activities of euphorbia splendida mobayen (euphorbiacea); chemical constituents of artemisia kopetdaghensis krasch; antimicrobial activity and essential oil composition of thymus transcaucasicus ronniger; chemical composition and antibacterial activity of essential oil of nepeta asterotricha rech. F. from Iran; the study of the essential oil constituents of various species of the mint flower in the flowering and after flowering stages; cadmium increase glycyrrhizic acid content in glycyrrhiza glabra var. glandulifera calli; the effect of salicylic acid on anthocy nin content in licorice; silymarinattenuated themycophenolate mofetil-induced villous atrophyand lipid peroxidation in the duodenum of rat; effect of cynara scolymus on the fat metabolism under heat stress condition in broiler chickens; compare of the crataegus extract and nimodipine effect on passive avoidance learning of male wistar rats; NAA and IBA as plant growth regulators for micro propagation of thymus vulgaris L.; recycling preparative high performance liquid chromatography for separation of the curcumin from curcuminoids present in curcuma longa L.; in vitro micropropagation of lavandula angustifolia l.; evaluation on the effects of nitrogen and potassium fertilizers on growth and yield of roselle (hibiscus sabdariffa var. L.) in Iranshahr; bilogical activities of stachys kermanshahensis rech. F. essential oil; effect of olive leaves as a phytobiotic feed additive on performance, antioxidant status and ascites mortality reduction in broiler chickens; streptozotocin-induced diabetic rats; effects of environmental factors on rooting of (pistacia mutica) micropropagation; studies on bacterial contamination of pistacia mutica seeds and leaves through DNA fingerprinting; evaluation of the use of herbal medicines by the people in the karaj city; investigation on development and promotion of herbal medicines in karaj pharmacies; in vitro culture of pistacia mutica (baneh); the effects of red dried stigmas of crocus sativus L.flowers (saffron) on growth and maturation of oocytes in female three spot gourami (trichogaster trichopterus); foliar application of salicylic acid changes essential oil content and compositions of peppermint (mentha piperita L.); chemical composition and biological activites of salvia compressa essential oil; evaluation of salicylic acid on tolerance to salt and alkali stresses in peppermint (mentha piperita L.); evaluation of growth response in echinacea purpurea to application of zinc sulphate under drought stress; evaluation of the achillea millefolum effect in nausea and vomiting of early pregnancy; the insecticidal effects of laurus nobilis and myrtus commonison essential oils against immature stages of ephestia kuehniella zeller; chemical constitutes of the essential oil of tanacetum persicum (boiss.) mozaff from kallar mountain; chemical composition of the essential oil of valerina sisymbriifolia vahl from kallar mountain; the oviposition deterrency of two plant essential oils from, laurus nobilis and myrtus commonis on the adults of mediterranien flour moth, ephestia kuehniella zeller; the medicinal effect of lavender on nervous system; influences of salicylic acid and droughts stress on growth characteristics of thymus daenensis celak; study of tissue culture and callus induction in papaver bracteatum; root and shoot growth of isabgol (plantago ovata) under organic manure, phosphate bio-fertilizer and chemical fertilizer treatments; analysis of the volatile compounds in origanum vulgare L. subsp.viride using HS-SPME-GC-MS and comparison with conventional method; effect of calendula officinalispowder on broiler chickens weight and lymphoid organ weights under heat stress condition; diversity ofchemical compositions of essential oil of various landraces of cuminum cyminum L from northeastIran; enhancement of extracellular baccatin III production and Dbat gene expression in cell suspension culture of taxus treated by methyl jasmonate; jasmonic and salicylic acid effects on chemical composition of melissa officinalis L.oil; effect of essential oil of thymus deanensis clelak, satureja bachtiarica bung and ziziphora clinopodioides lam on hematological parameters in rats; effects of plant density on yield, yield components of medicinal plant coneflower (echinacea purppurea); comparison on quality and quantity of essential oil six cultivated thymus species at before flowering and full flowering stages; ecological investigation of 10 aromatic plant species of asteraceae family in yazd province; survey on phenology and aeclimitization some thymus species in field; the effect of salinity on seed g rmination and early seedling growth saturega bachtiarica; survey on quality and quantity of essential oil cultivated accessions of thymus lancifolius in province yazd; survey on quality and quantity of essential oil cultivated accessions of thymus kotschyanus in province yazd; study of the effect of hydroalcoholic extract of wulnut leaves on blood factor changes of LDL, HDL, trigly ceride and full cholesterol in female hypercholestrolemic rabbits; effect of different biofertilizers on some physiological of three ecotypes of hemp under saline soils and saline waters; evaluation the response of inoculation black cumin seed (nigella sativa L.) with azospirillum and azotobacter; effect of spraying amino acid on thymoquinone, carvone and yield of black cumin (nigella sativa L.); the effect of salinity stress on germination and plantlet growth of safflower medicinal plants genotypes; inhibitory effect of medicinal plant aqueous and ethanolic extracts on alternaria solani mycelial growth; solvent effects on extraction and determination of the isoflavone daidzein in soybean and its extracts by high-performance liquid chromatography; howthorn berries hydroalcoholic extract with high triterpenic acid content reduces the experimentally-induced colitis damages in rat; in vitro establishment and control of browning in seedless berberis vulgaris; effect of different nursery bed on lavandula’s marcotting; the effects of allium hirtifolium boiss. on cardiovasicular risk factors in hypercholesterolemic rabbit; comparing various methods of seed and embryo culture and charcoal effect in optimizing in vitro culture of ferula assa-foetida; comparativ pollen morpholoy of the genera allium and calochortus of order liliales; the effect of salinity stress on seed germination and seedling growth indesert rod (eremostachys laciniata (L.) bunge); the antibacterial effect of the total methanol extract of the petal and stamen of saffron flowers (crocus sativus) against five bacterial food borne strains; allelopathy effects of lavender, absinthium and walnut on germination and growth of convolvulus arvensis, portulaca oleracea and triticum aestivum; protective effects of ocimum basilicum L. (basil) on electrocardiogram, cardiac function and histopathology in isoproterenol induced myocardial infarction in rats; study of the medicinal plants biodiversity species of dashtestan county in bushehr province; determination of total phenolic content in two extracts from cruciferous plants and its correlation with their antioxidant capacities; study of the primary ethnobotanical of genaveh county in bushehr province; allelopathic effect of different concentrations of caraway essential oil on germination characteristics in amaranth and barnyardgrass; antibacterial activity of polyphenol and anthocyanin–rich extracts of thymus kotschyanus aerial parts; antioxidant activity of flavonoid-rich fraction from thymus kotschyanus aerial parts; effect of different levels of nitrogen fertilizer on essential oil component in “ducrosia anethifolia”; computational identification of novel conserved micrornas, and their targets in eucalyptus grandis; evaluation of digitalis nervosa performance in northern parts of Iran; allelopathic potential of galbanum different tissues on germination traits and preliminary growth of lambsquarters; effect of irrigation intervals and phosphorous content carvacrol and essential oils of thymus vulgaris L.; the role of the use of the phosphorus and duration of irrigation on yield and thymol of thymus vulgaris L.; the comparison between arbescular mycorrhizal and salicylic acid on some antioxidant compounds in ocimum basilicum L. under salinity stress; evaluation of different drying methods on essential oil and estragol contents of tarragon; comparison between foeniculum vulgare and vitex agnus castus on ovulation in three spot gouirami; design and fabrication of magneticnanoparticles for herbal medicine delivery applications; chemical composition and biological activites of phlomis rigida labill essential oil; polymer coated magnetic nan particles as a novel carrier in curcumin nanomedicine; effect of altitude on the rutin and chlrojenic acid content of sambucus ebulus leaves in golestan province; the effect of irrigation interval and plant density on the amount of active ingredient linoleic acid and oleic acid in the oil of black cumin (nigella sativa); the effect of drought stress on some biochemical and physiologicalparameters of the lippiacitriodora; silymarin regulates pharmacokinetic of atorvastatin in diabetic rats; effect of salicylic acid and nitric oxide on germination and subsequently seedling growth of borago officinalis under drought stress; determination the critical period of weed control in medicinal plants of safflower (carthamus tinctorius) cultivar sofe in the arak; determination of heavy metals in lycium ruthenicum murry plant; effect of magnetic field and nano-particles of titanium dioxide (Tio2) on seed germination and seedlings early growth of ajowan (ammi copticum L.); effect of Si nano-prticles and magnetic fields on seed germination and seedling growth characteristics of (securigera securidaca L.); determination of total phenolic, flavonoid contents and antioxidant activity in aqueous and alcoholic extracts of crocus sativus L. stigma; effect of different nitrojen sources on quantitative and qualitative charactrictics of parsley (petroselinum crispum mill.) in jiroft region; woody branch and leaf anatomy of two subspecies of fraxinus angustifolia vahl.(oleaceae) in Iran; the effect of nutrition with microelements on yield of rosa damascena mill; the application of medicinal plants, antibiotic and their effects on serum composition in broiler chickens; effect of bio-fertilezers and micronutrients on germination characteristics of ajowan (carum copticum); effect of hydroalcoholic effect of citrullus colocynthis fruits on cysts of giardia lambia in invito; evidence of antifungal activity of madder (rubia tinctorum L.) on some fungal plant pathogens; diversity of chemical compositions of the essential oils of wild populations of myrtus communis L from khuzestan and lorestan provinces, southwest Iran; antimicrobial effects of zingiber officinale; extraction of volatile compounds of thymus vulgaris L. by microwave radiation and comparison with hydrodistillation method; response of costmary (tanacetum balsamita) to foliar application of urea and amino asids; influence of iron on the accumulation of some medicinal compounds in parsley; evaluation of cytotoxic effect of nanoliposomal 6-gingerol on breast cancer MCF-7 cell line; evaluation of gingerol extracted from zingiber officinale against breast cancer; effect of growth regulators on callus induction in saffron; fumigant toxicity of two essential oils on the mediterranien flour moth, ephestia kuehniella zeller and identify of their chemical component; effect of different drying methods on drying time and essential oil content of anise hyssop (agastache foeniculum L.); chemical constitutes of the essential oil of tanacetum kotschyi (boiss.) from kallar mountain; chemical composition of the essential oil of heracleum lasiopetalum boiss leaves; chemical composition of the essential oils of wild populations of myrtus communis L from chaharmahal va bakhtiari provinces, Iran; red clover hydroalcoholic extract with high phenol content scavenges free radicals; the parthenolide concentration of tanacetum parthenium in culture condition; a study on trace elements and heavy metals purchased in camel’S thorn manna, willow manna, pocks pray manna, oak manna from selected market in Tehran; effect of salicylic acid and salt stress on organosulphur anticancer compound in broccoli sprouts; investigation the cardinal temperatures of sagebrush (artemisia abrotanum) and artichoke (cynarascolymus); the effects of time harvesting and irrigation intervals on the active ingredient of stinging nettle (urtica dioica L.) leaf; effect of shallot extract on fat quality of silver carp (hypophthalmichthys molitrix) paste during frozen storage; the effects of mycorrhiza and thiobacillus inoculatuon and sulfur app ication on garlic (allium sativum) growth; analgesic property of aqueous extract of ajuga chamaecistus ssp. tomentella; analysis of diosgenin in wild yam extracts by high-performance liquid chromatography; evaluation of UV-B effects on morphological and physiological characteristics of two cultivars of coriander (coriandrum sativum L.); determination of fatty acid profile in the oils of cydonia oblonga and mespilus germanica by NMR techniques; comparative survey effects coriandrum sativumand ziziphora cliniopodiodes powder in dietary onrbc, HB, HCT in common carp (cyprinus carpio); furanocoumarins from root of prangos ferulaceae; performance and blood parameter of broiler chickens given clove powder and essential oil reared under heat stress; study the effect of salt stress on some morphological and biochemical parameters of artichoke under invitro conditions; the study of different hormons level in callus production in garlic (allium sativum) tissue culture; evaluation of phenolic compounds contents and antioxidative activity in leaf and seed of ( peganum harmala L.); effec of pectic acid (PA) on induction of apoptosis via no release in human prostate cancer cell line DU145; hypoglycemic effect of hydroalcoholic extract of parstinaca sativa seeds in normal and streptozotocin induced diabetic rats; effect of apple pectin or pectic acid and modified citrus pectin on no release and inhibition of cell proliferation in rat pituitary tumor cells GH3/B6; hypolipidemic effect of hydroalcoholic extract of parstinaca sativa seeds in normal and streptozotocin induced diabetic rats; stem anatomical structure in stellaria (caryophyllaceae) in Iran; effects of hydroalcoholic extract of parstinaca sativa seeds on activity of liver enzymes in normal and streptozotocin induced diabetic rats; assessment of salinity tolerance in Iranian fennel landraces in seed germination stage; effect of seed priming by salicylic acid on germination improvement and seedling growth parameters in garden cress (lepidium sativum) under saline conditions; investigation of different concentrations of Fe ions on rosmarinic acid biosynthesis in melissa officinalis; assessment of drought tolerance in Iranian fennel landraces in seed germination stage; role of mucilage in germination of medicinal plants; investigation of flavonoid content and anti-oxidant enzymes activity in trestedmelissa officinalisseedling with Fe ions; study of some characteristics related to primer after using rapd marker in order to evaluation of genetic diversity among cuminum cyminum L. accessions; the evaluation of vitamin C, anthocyanin and flavonoid in three cultivars of pomegranate in mazandaran provice; in vitro evaluating the effect of heavy metals on germination and growth parameters of some medicinal plants; study the effect of seed priming by plant growth regulators on seed germination and seedling growth criteria in matricaria aurea; the effect of hydro alcoholic extract of glycyrrhizaglabra on some electrocardiogram parameters and its interaction with nitric oxide system of male rat; the effect of campylobacter jejuni vaccine and extract of echinacea purpurea on colonization of campylobacter jejuni in gastrointestinal of broilers; the effect of organic acid, probiotic, and echinacea purpurea application on campylobacter jejuni colonization in gastrointestinal of broilers; effect of resvaraterol on teratogenecity in experimental model of preeclampsia in rat; microwave and ultrasound assisted hydrodistillation of rosemary antioxidants and comparison with conventional hydrodistillation; antibacterial activity of salvia limbata essential oil; nano Cuo and Zno application affect phenolic compounds production in licorice seedlings; evaluation and comparison of anti-inflammatory and analgesia effects of three plants tanacetum parthenium, anethum graveolens L., apium graveolens (celery); effect of organic and chemical fertilizers on yield and essential oil on two savory (satureja hortensis L.) ecotypes, under drought stress condition; effect of aqueous and ethanolic extracts of nigella sativa seeds on milk production in rats; study the effect of natural compounds and essential oils of medicinal plants on improving maintenance of fresh cut cucumber; study of cell cycle changes in human prostate cancer cell line DU145 after treatment with combination of β-glucan and doxorubicin; the effects of different temperatures and osmotic potentials on germination of scrophularia striata; effect of melissa officinalis hydro alcoholic extract on liver enzymes ALP, AST, ALT in mice; effects of echinacea purpurea, levamisole and propolis on serum biochemical metabolites in broiler chicks; effect of nanosilver particles on medicinal plant germination index of cumin (cuminum cyminum); effect of phytobiotic collected by honey bee on intestine morphology in broiler chicks; the effect of information and communication technologies (ICT) and technology on sustainable agriculture; analysis of the effect of different concentrations of Fe ion on the biosynthesis pathway of sulforaphane in lepidium draba seedlings; isolation and determination of sulforaphane from lepidium draba; biomass and essential oil content of spearmint (mentha spicata L.) harvested in different months in semi tropical climate; the effect of salt stress on aloe vera; effect of nitrogen different levels on yield and mucilage content of isabgol (plantago ovata L.); changes in essential oil content of myrtle myrtle (myrtus communis) during different months of year in ahvaz condition; evaluation of qualitative and quantitative yield of isabgol affected by different vermicompost levels; optimization of atropine extraction process from atropa belladonna by modified bubble column extraction with ultrasonic bath (BCE-UB) method; effect of salicylic acid on quality and essential oil componets of moldavian balm (dracocephalum moldavica L.); the study of two ecotypes of german chamomile (matricaria chamomila) in climatic condition of ahvaz; study of seed and biological yield and mucilage content of isabgol affected by different cow manure amounts; effect of arbuscularmycorrhiza on content of essential oils in mint; phylogeny of tanacetum L. sect. xanthoglossa based on CpDNA Ndhf-Rpl32 spacer sequences data; a new method based on the UV-visible spectroscopy for quantitative analysis of atropine in biological extracts; inhibitory effect of helichrysum arenarium L essential oil on growth of food contaminated fungal; marketing the medicinal plants products based on its qualities; antifungal activity of essential oil of ziziphora clinopodioides L; liquoric triterpenoids transport via CaCo-2 cells monolayer; phylogenetic relationships of some spiny astragalus (astragalus, fabaceae) using nrdnaits sequences; silymarin down regulated the varicocele-induced protein oxidation and E2F1 exxpression in the tetis; pollen morphology of some silene species of lasiostemones section in Iran; effect of different cultivars on naringin and hesperidin flavonoides contents in different fruit parts on citrus aurantium rootstock; a study on total chlorophyll content in leaves of daucus carota L. grown in two provinces of Iran and its correlation with some meteorological parameters and carotenoids levels; evaluation of agronomic characteristics, seed germination mass of thyme (thymus vulgaris L.) by gibberellic acid and salicylic acid; comparison of total phenolic contents in three infusions of black tea; antifungal activity of the essential oil of salvia officinalis; effect of deficit irrigation and salicylic acid on free proline and some of physiological characteristics of basil (ocimum basilica L.); study the effect of strip intercropping patterns on morphological characteristics of bean and dill in tabriz region, Iran; effect of strip intercropping on leaf area index of bean (phaseolus vulgaris) and dill (anethum graveolens); germination improvement in tanacetum polycephalum; evaluation of medicinal organs of plant species in miankaleh; ecological studies of salvia sahandica; evaluation of medicinal flora in summer rangeland of arjmand in firozkoh; evaluation of medicinal flora in summer angeland of arjmand in firozkoh; a new avenue for prediction of pseudo chamomile using decision tree; effect of salinity treatment on colocynth seedling growth; enzymatic treatment of aloe vera gel to reduce viscosity for pharmacutical applications; effect of potassium nitrate primingon seed germination of colocynth; the effects of bio-fertilizers and bio-stimulators on chlorophyll content and leaves properties of ocimum basilicum L.; study of ocimum (ocimum bacilicum L.) germination attributes and seed vigor under salinity stress; the effecte of drought sterss on germination of thymus species (T. Daenensis, T. Eriocalyx, T. Vulgaris); the effects of bio-fertilizers and bio-stimulators on morphophisiological properties of ocimum basilicuml; fumigant toxicity and median lethal time (LT50) on the immature stages of mediterranien flour moth, ephestia kuehniella zeller; fumigant toxicity and persistence of two medicinal plant essential oils from laurus nobilisand myrtus commonisonagainst adult stages of mediterranien flour mothephestiakuehniella zeller; the effect of Pb on leaf of matricaria chamomilla in vegetative and reproductive stages; effect of different concentrations of colchicine on ploidy levels and morphology of dracocephalum kotschyi boiss; application of natural essential oils, silver and copper nano-particles to extend the vase life of two carnation cut flower cultivars; effect of some bio and chemical fertilizers on some morphological characterestics and percent of root colonizationof dill (anethum graveolens L.); evaluation of different sowing dates on yield and yield components in saffron (crocus sativus L.); the effect of elicitor methyl jasmonate on secondary metabolites of medicinal plant pot marigold(calendula officinalis L.); effect of coronatine pretreatment in basil plant(ocimum bassilicum)subjected to arsenic toxicity on difference phenolic compounds and pal activity; study of yield and yield components in different ecotypes of saffron (crocus sativus L.); effect of coronatine pretreatment in basil plant (ocimum bassilicum); micro-morphological study of mericarp and seed in different erodium (geraniaceae) species of Iran; the effect of plant density and date of planting on total phenol and flavonoid of artichoke (cynara scolymus L.) in gorgan and ilam conditions; selenium improves growth and antioxidant defense system in melissa officinalis; interaction of the auxin hormoneand rooting media in cuttings of the medicinal plant myrtus (myrtus communis); the influence of exogenous aba on photosynthesis and antioxidative enzymes activity in melissa officinalis; the effect of application of phosphorus fertilizer and mycorrhizal fungus on yield, yield component and effective material ofpot marigold (calendula officinalisl.); the effect of different sugar on rosmarinic acid production in salvia reuterana hairy root culture; cytotoxicity effects of scorzonera grossheimii lipsch. &amp; vassilcz extract on hela cell line and Mcf-7 cell line; evaluation of in vitro culture of mohr-E khosh medicinal plant species; the effect of antioxidant attributes of aqueous garlic extract in mice; evaluation of mohr-E khosh (zhmeriamajdaerech. F. &amp;wendelbo) tissue culture; effect of bap hormone treatment on in vitro shoot regeneration and proliferation of medicine herbhenbane lattice (hyoscyamus reticulatus L.); antioxidant activity of two sea cucumber species and brown algae from persian gulf; comparison of 1,8-cineole in the essence of four wild populations of yellow yarrow (achilleawilhelmsiic.koch) in fars province; the effect of planting date and harvest stage on growing indexes and percentagethymolin saturejahortensis L; chemical analysis of hops (humulus lupulus L.) extract collected from zarrin gol zone, golestan province, Iran; local effect ofeugenol oilon the skin woundhealingin rat; influence of manure, compost and biofertilizer on growth and yield of ajowan (trachyspermum ammi sprague); variation of rutin content in caper leaves during heir phenological cyces; the changes of hypophysys hormones in pcos rats that treat d with aqueous fennel extract; the effect of aqueous and methanolic extract of caper leaf and GA3 on germination of capparis spinosal; effect of density on quantity characteristics of thmusspecies (T. Daenensis, T. Eriocalyx, T. Vulgaris) indryland condition of kermanshah; autecology and phenology study of salvia leriifolia; hairy root cultures of salvia reuterana transformed with agrobacterium rhizogenes; comparison of salvia (salvia sclarea L.) accessions according to morphological traits, essence yield and chemical compounds; the evaluation effects of plant density and sowing dates on yield and yield components of black cumin (nigella sativa) under ilam climate condition; investigation on morphology and root yield of chicory (C. Intybus) landraces for inulin production; effect of eugenol in the context of ethanol teat microbial load on dairy cow; the effect of slope direction on morphological characteristics of juniperus polycarposc.koch needels; effect of thymol and carvacrol on two cultivars of cut gerbera flowers vase life; influence of arbuscularmycorrhizal fungi and salt stress on essential oil content of summer savory (satureja hortensis L.); influence of arbuscularmycorrhizal fungi on growth and morphological characteristicsof summersavory (satureja hortensis L.) plant under salt stress conditions; antimicrobial activity of five plant essential oils on bacillus sp.; study of protective effective of pollen in proportion to royal jelly on liver tissue in experimental polycystic ovary syndrome in adult female rats; curcumin nanomidicine; appliacations of β-cyclodextrin in cuccumin solubility enhancment; investigation of the effects of different rate of nitrogen and zinc on yield of chamomile (matricaria chamomilla L.); protective effect of parsley aqueous extract versus glyburide on diabetes-induced derangement in the ovary; evidence for follicular growth and biochemical alteration; phytochemical screening, antioxidant and burn healing potential of galium odoratumm ethanolic extract; evaluation hydroalcolic extract of plantago majorleaf on sperm count and FSH, Lhlevels in streptozotocine (STZ) induced diabetic rat; the effect of indole butyric acid (IBA) and naphthalene acetic acid (NAA) on stem cuttings of myrtle (myrtus communis L.); effect of hydroalcolic extract of descurainia sophia seedon sperm morphology and FSH, lhlevelsin streptozotocine (STZ) induced diabetic rat; determination of totalphenolic,flavonoid contents and inhibitory effect of euphorbia spinidens methanolic extract against HSV1; effect of sesameoil (sesamum indicum L) on sperm parameters in streptozotocine (STZ)- induced diabetic rat; improvement in germination and seedling growth of hyoscyamus squarrosusgriff; recognition and usage of medicinal plants according to the views of local communities (sample studying of top taleghan in alborz province); comparison of morphological and agronomical traits of fenugreek (trigonella foenum-gracum L.) under drought stress and biostimulatorsingreenhouse and fieldcrops; ffect drought stress and biostimulators on morphological traits of fenugreek (trigonella foenum-gracum L.); endometrial changes in pcos female rats that treated with aqueous fennel extraction; effect of priming on seed vigor and antioxidant enzymes activities in thyme (thymus vulgaris L.) under salinity stress; effect of potassium nitrate onsome germination traits of balango (lallemantiaroyleana L.) under salinity stress; comparison of the essential oil components in wild and cultivate population of salvia lachnocalyx; effect of irrigation intervals on yield and yield components of degen &amp; Drfi (securiger securidaca L.); the anatomical properties of alyssum (sect. gamosepalum dudley); comparison of the essential oil components in wild and cultivate population of salvia verticillata; comparison of the essential oil components in wild and cultivate population of salvia virgata; the effect of different kind of salt on seed germination and seedling growth of nigella sativa L. and guizotia abyssinica cass; high-frequency in vitro direct shoots egeneretion from axillary nodal and shoot tips explants of clary sage (salvia sclarea L.); essential oil composition in stachys byzantina cultivated in Iran; antioxidant activities of the bark of pterocarya fraxinifolia L.; isolation and purification of terpenoids from aerial parts of echinophora cinerea; induction of salt stress resistance in foeniculum vulgar by application of hydro and halo seed priming; chemical composition of stem essential oils of pterocarya fraxinifolia L.; effect of sowing date and growing season on agronomical characters of isfahanian and indian black cumin; effect of different vermicompost levels and ecotype on growth parameters of basil (ocimum basilicum L.); the effect of bacterial inoculation on qualitative and quantitative yield of the aloe vera plant; triterpene constituents of euphorbia erythradenia boiss; evaluation of the effect of three biologic fertilizers on aloe vera plant; introduce some medicinal plants used for gastro-intestinal diseases in east-mazandaran region; histopathologic changes in rat liver treated with quercetin extracted from onion after infected by toxoplasma gondii; effect of growing media on rooting of stem cuttings in hana(lawsonia inermis L.); effect of colchicines treatments on some morphological and cytological characteristics of agastache foeniculum; antiradical, antioxidant and antimicrobial activities of crataegus elbursensis extracts; evaluation of somesecondary metabolitesinthree olivegenotypes and twoharvesting time; ovicidal activity of essential oils from three plants against mould mite (tyrophagusputrescentiae schrank); role of mycorrhizal fungi and salicylic acid in resistance of ocimum basilicum L. to aluminum toxicity; investigation of histological effects of humulus lupuluson ovarian tissue of female three spot gourami; phenolic acid analysis and antioxidant activity determination of froriepia subpinnata; study of antimicrobial effect thyme and mint essential oils and edta, on staphylococcus aureus; the effect of corn oil on liberkuhn glands goblet cells secrition activity in rabbit; effectsof elicitation onalkaloids production in suspension cell cultures ofpapaver somniferum; effect of plant growth regulators on in vitro culture of artemisia aucheri; effect of echinacea extract on parenteral lysozyme activity in serum of beluga (huso huso); survey of antimicrobial effect thyme and peppermint essential oils and edta, on salmonella typhimurium; total phenolic content, antiradical and antioxidant activities of eryngium caucasicum extracts; effects of plant growth regulators on callus formation fenugreek (trigonella foenumgraecum L) of in vitro; influence of different concentration of 2,4-D and kinetin on callus formation milk thistles (silymbum marianum) plants; the effect of nitrogen fertilizer and plant density on quantitative and qualitative characteristics of castor (ricinus communis L.); evaluation of genetic diversity in some linseed (linum usitatissimum L.) genotypes using EST-SSR markers; effect of altitude on some of the morphological characteristic and chlorophyll content of nettle in mazandaran and golestan conditions; evaluation of primers indices used in the study of genetic diversity of papaver macrostemum ecotypes viaissr marker; studies on the amino acids, flavonoids and total phenolics in ziziphus jujuba; comparison study of antibacterial effect essential oils oregano and cumin and edta on salmonella typhimurium by disc diffusion and broth microdilution mic testing; comparison study of antibacterial effect oregano and cumin essential oils and edta on staphylococcus aureus by disc diffusion method and broth microdilution mic testing; the study of antioxidant activity of phenol compounds inartemisia fragranswilld.and artemisia vulgaris L.; impact of planting patterns on weed density, and growth characteristics of caraway; effect of drying methods on essential oil contents and citronellal of lemon balm; a comparison on effect of the thiobacilus biological fertilizer and superabsorbent on the morphological traits and essential oil yield f thymus vulgaris t. daenensis; investigation of effect of different doses of hydroalcoholic extract of glycyrrhiza glabra’s rhizom on the mechanical activity of isolated trachea of male rat; aloe vera gelconcentration by reverse osmosis method (reduction energy consumption); the effect of drought stress on germination characteristics and preliminary growth of fleawort and purple coneflower; preparation of an herbal emulgel for treatment of hemorrhoids; effect of varying level of biological and chemical phosphors on same morphological traits summer savory (satureja hortensis L.) plant; study on the technical efficiency in rose water industray in city of kashan, Iran; the effects of corn oil on colonic mucosal thickness in rabbit; estimation of the milk thistle oil percent by using stepwise regression; the effects of mycorrhiza, thiobacillus inoculatuon and sulfur application on some physiological parmeters of garlic (allium sativum L.); the study of some medicinal-chemical characteristics in four olive cultivars; allelopathic effects of citrullus (citrullus colocynthisl.) extract on seed germination and seedling growth of ocimum (ocimum basilicuml.); the effect of polyamines (putrescin, spermidin and spermin) on growth, yield and essential oil of moldavian dracocephalum L.; effect of different density levels on marigold yield; allelopathic effects of citrullus (citrullus colocynthisl.) extract on seed germination and seedling growth of purslane (portulaca oleracea L.); sterols from nizamudiinia zanardinii, a brown alga of oman sea; analyzing of 4 medicinal plants essential Oil’S potential allelopathic activity on pigweed seeds (amaranthus retroflexus L) germination and growth; flavonol glycosides from paliurus spina-christi; physiological responses of anise hyssop (agastache foeniculum L.) to drought stress; potential allelopathicactivity of 4 medicinal plants essential oil on lamb’s-quarters weed seeds (chenopodium album) germination and growth; humic acidcounteracts the ecotoxicological effects of arsenic on seed germination and seedling growth parameters of savory; effect of different planting beds on yield and yield components of garlic (allium sativum L.); the effect of cadmium on phenol and flavonoid contents in basil(ocimumbasilicuml.); yield and yield components of different species of lallemantia. Sp; effect of temperature androsemary (rosmarinusofficinalisl.) essential oils in potato sprout inhibition and tuber quality after post harvest; comparison of anti-inflammatory and analgesic activity of the artemisia absinthiumand its main component; improvement of antioxidant production in rosmarinus officinalis by tissue culture; two new dammarane type terpenoids from geum heterocarpum; absorption spectra of chlorophyll A and B and fresh weight of leaves in different ecotypes of lallemantia.Sp as affected by deficit irrigation; morphological investigation of hairy roots induced in hyoscyamus niger; germination of balangu (lallemantia royleana) as affected by hydropriming and germination temperatures; yield potential assessment of cumin ecotypes under irrigated and water-stressed conditions; investigation of grows rate and antifungal efects of ganoderma lusidum on plant pathogen karst (basidiomycota); effects of artemisia dracunculus on the clotting time; the effects of explants and growth regulators on callus induction of lippia citriodora L., an important medicinal plant; aquatic and alcohol extract effect consideration of equsetum arvens on the wound and skin inflammations amendment; the comparison the effects of humic acid and thiobacillusbiofertilizer on morphological characteristics on two species of thymus (T.Vulgaris and T.Kotschyanus); antioxidant activities of some pepper (capsicum annuum L.) varieties phenolic extracts; antioxidant and toxicological evaluation of hydroethanol extract of trogpogon buphthalmoides aerial parts; aquatic and alcohol extract effect consideration of ephedra intermedia on the wound and skin inflammations amendment; study on different levels of annatto seed meal (bixa orellana in the diet on some biological indices of rainbow trout (oncorhynchus mykiss); cytotoxic evaluation of 24-hydroperoxy-24-vinyl cholesterol isolated from nizamuddinia zanardinii, a brown alga from oman sea; effects of salicylic acid on total phenolic and rosmarinic acid contents in lemon balm (melissa officinalis L.) plants exposed to nickel stress; determination of total phenolic and scavenging activity of free radicals in 4 species fruits of solanaceae; determination of antioxidant activities of two adonis species; in vitrochangesof cholorogenic and cafeic acidsof artichoke under salin stress; effect of PGPR inoculation on the quality and quantity of summer savory (saturejahortensis L.); the economic result of tragacanth astragalus and sell product; two new ditepenoids from the root of salvia chloroleuca; effect of putrescine spraying on the quality and quantity of summer savory (saturejahortensis L.); effect of salicylic acid spraying on the quality and quantity of summer savory (satureja hortensis L.); study of physiological and biochemical responses of saffron (crocus sativus L.)to salt stress and alleviative effects of salycilic acid; the effect of selenium (So2) on ionic content of melissa ossicinalis; of gene flow and genetic differentiation among populations of species anthemis tinctoria using peroxidase isozymes; evaluating the germination of artemisia populations in different temperatures and polyethylene glycol; study of physiological and biochemical responses of saffron (crocus sativus L.) to drought stress and alleviative effects of salycilic acid; a study of generative organs characteristics of avicennia marina (forsk.) vierh (avicenniaceae); histophatological changes of spleen in pcos female rats treated with aqueousextraction of foeniculum vulgare; semi-preparative LC-MS of taxane diterpenoids; influences of drought stress on seed germination parameters in (ruta graveolens L.); fabrication of albumin nanoparticles contains model drug; optimization of in vitro regeneration of some salvia species via nodal explants culture; medicinal and antioxidant properties of kernel and green shell a mong some pistachio genotypes; comparison of chemical constituent of essential oil of stachys lavandulifoliavahl from kaboodarahang and roodsar; effect of ecotype on total phenol and flavonoids content of sambucus ebulus leaves; anticancer activity evaluation of the acinosgraveolensaerial parts; phenotypic variation of colocynth accession from different Iran geographical area of (citrullus colocynthis); phenolic content and DPPH radical scaveningactivity and total protein of cucurbitaceae in Iran; the effect of water deficit and spraying on agronomictraits and yield of dragonhead; investigation of anti-inflammatory effect of N--hexane extract of leaves of ziziphora clinopodiodes.lam on NMRI male mice; evaluation of the antioxidant activity of the acinosgraveolensaerial parts from qamsar area; the relation of traits in artemisia of Tehran Province, Iran; study of different drying methods on essential oil and menthol contents of peppermint; genetic diversity among naked seed of cucurbita pepo var. styriaca and comparison with other varieties of pepo species; effect of osmopriming with Kno3 on seed germination of lallemantia royleana; study on seed morphological markers of naked seed and other cucurbits to evaluate genetic variation; comparison of the effects of drought and salinity stress on fennel seed germination under hydropriming condition; evaluation of allelopathic activity of juniperus sabina; effect of ethanolic extract of barberry root (berberis vulgaris (on renal toxicity of the drug cisplatin; callus induction from different parts of milk thistle(silbum marianum L.); anticancer activity of nigella sativa; radical scavening activity and total phenolic content of three species of pear(pyrus. L); effects of various salts on the germination of silybum marianum; evaluation phenol and flavonoid level in seven genotypes of olive maturity; allelopathic potential of common mallow (malva sylvestris) on the germination and t e initial growth of blanket flower, Cock’S comb and sweet william; mathematical study of dorema aucheri extraction with supercritical carbon dioxide; cheminformatics study of natural thujone like compounds for pharmacologic activity; application of response surface methodology for the optimisation of ultrasound assisted emulsification microextraction of fatty acids from pomegranate seed; study effect of parsley (petroselinum crispum) as an abortifacient on pregnant rats; phytochemical study on dichloromethane extract of artemisia ciniformis; comparison of the effects of drought and salinity stresses on linseed seed germination under hydropriming condition; salicylic acid and salinity effects on proline content and growth characteristics in thymus daenensis; optimization of ultrasound assisted emulsification microextraction for separation of fatty acids of Iranian (bandar abbas) jatrophacurcus seed; effects of dietry cinnamon oil (cinnamomum verum) supplementation on growth performance in Japanese quail; phytochemistry study on medicine plant of artemisiasieberi and assesind its allelopathic effect on agropayrum elongathum seeds; optimization of media for in vitro callus growth of taxus baccata; optimization of sterile treatmentsfor in vitro culture of taxus baccata and T.Brevifolia; identification and medicinal characteristics investigation of some of the most important medicinal trees, shrubs and grass in lorestan province (case study in yaftehkouh, khorramabad); haploid induction in medicinal pumpkin using gamma irradiated pollent technique; effect of thymus extract on meat quality in Japanese quail chicks; the effect of chamomile extract on reproductive system in male mice; the effec of biological and chemical nitrogen fertilizer on dry flower yield and essential oil content of calendus (calendula officinalis); yield potential evaluation of different cumin ecotypes in different winter sowing dates; antibacterial activity of eremurus persicus boiss. leaves and flowers; effect of leave kind on the secondary metabolits certain in olive (olea europaea L.); extraction and identification of a new ester coumarin from ferula orientalis roots; the effect of different levels of vermicompost on nutrients balance of dracocephalummoldavical; a new PH-responsive polymer coated magnetic nanoparticles for loading and delivery of quercetin; the study of genetic parameter related of salinity tolerance in sofflower; amino-silane modified magnetic nanoparticles for loading and delivery of chlorogenic acid; study of correlation between yield and yield components of cumin under different irrigation intervals treated with iron chelate nano fertilizer; evaluation of effect attract moisture substances and organic fertilizers on quality and quantity yield of purslane (portulaca oleracea L.) in ahvaz region; gene mapping of quanthitative traite for salinity tolerance in safflower; changes in the amount of essential oil eucalyptus species grown in qom and behshahr, and its relation to morphological characteristics of leaves; study of antimicrobial effects of narcissus jonquilla essence on common gram positive and negative bacterias (E.Coli, B.Cereus, S.Aureus); the effect of different levels zeolite on carotenoid and chlorophyll of calendula officinalis L.; the effect of lettuce hydro alcoholic extract on some blood parameters in mice; designing of herbal based inhibitory bioactive molecules for vegfr in angiogenesis; the effect of harvest time and density on essence yield of biennial tarragon (artemisia dracunculus L.); study effect of organic, inorganic fertilizers and cutting on agronomic characteristics in common purslane(portulacaoleracea L.); influence of calciumnitrateon the change of morphological characteristicsand mucilage content of borage; effects of drought stress induced by polyethylene glycol on germination and morphophysiological characteristics ofdracocephalummoldavica; study of the chemicalcharacteristics of somepomegranate cultivarsin mazandaran and khorasan; the effect of optimum planting date and harvest stage on essential oil of saturejahortensis in saveh; the effects of boric acid and seed osmopriming on germination and early seedling growth of petroselinum crispum; antioxidant activity of some extracts from aerial parts of ajuga chamaecistus Ssp. tomentella; evaluation of silver nanoparticles influence on abscission and oil content ofseed borage; effect of priming with polyetilene glycol and NaCl salinity on germination herb purslane (portulacaoleracea L.); effect of altitude on some of the secondary metabolits of nettle in golestan and mazandaran conditions; Effectofsowingdateandpatternongrowthphysiologic Al parametersof purslane (portulaca oleracea) under ahvazclimaticconditions; study on the tissue damage of oral administration of different doses of zataria multiflora essential oil in persian sturgeon (acipenser persicus); effect of hormons and explant in callus induction and shoot organogenesis in tissue culture of echinacea purpurea; antiaging effects of glycyrrhiza glabra, hypericum perforatum, silybum marianum and mixture of them on D-galactose induced aging in male mice; assessment of some biochemical parameters in two rosa damascene mill genotypes in dry cold weather conditions (case study of semnan city); comparison of antioxidant properties mentha longifolia L. hudson var.chlorodictya rech.F. in sabzevar and gorgan; effect of growth regulators, explants source and light/ dark condition on in vitro callus growth of artemisia vulgaris; applicability of flavonoid spot profiles in taxonomic circumscription of fritillaria L. species in Iran; optimalization suspension culture of medicinal plant artemisia deracunculus; he effect of salinity on germination factors and growth of five medicinal plants (carthamus tinctorius, carum carvi, sesamum indicum, foeniculum vulgare and cultivated endive); investigation of exclusive and synergistic antibacterial activity of edible medicinal vegetables; kinetic study of mechanism of an enzymatic reaction catalyzed with esterase enzyme; the concentration of parthenolide in native tanacetum parthenium; investigation on the effect of hormonal regulators on the adventitious shoot and root regeneration in artemisia vulgaris; effects of aloe vera cream on healing diabetic foot ulcer; antibacterial potential of some Iranian medicinal plant extracts on pseudomonas aeruginosa; survey of callogenesis by two artemisia species (artemisia vulgaris and artemisia deracunculus); enhancement of flavonoid content by squalestatin and methyl jasmonate in cell suspension culture yew; screening of anthbacterial effects of aerial shoot extracts from some medicinal vegetables; the correlation between malone dealdehyde (MDA) and proline content and stigma-like structures (SLSS) in tissue culture of saffron; a survey on the antibacterial properties of the achille millefollium against some pathogene bacteria; effect of biological and chemical fertilizer on morphological characteristics in two basil (ocimum basilicum L.) landraces; effect of cinnamomun zeylanicum neeson LH and estrogen in female rats; effect of arbuscularmycorrhizas on metals absorption on three genotype of mentha spicata; comparison the antibacterial activities of ajowan, black zira and cinnamon essential oils using agar diffusion method; investigation of mentha pulegium L. effects on broiler chickens; the economic estimate of the biological and chemical fertilizers cost toward biomass and essential oil yield in two basil (ocimum basilicum L.) landraces; expression profile of some genes involve in nicotiana benthamiana alkaloid biosyntesis pathway under abiotic stresses; ethnobotanical study of medicinal plant of sirjan district, province Kerman; evaluating antibacterial property of eucalyptus essence on superficial sores of grass carp (ctenopharyngodon idella) juveniles’ skin; evaluation effect of medicinal plants intercropping with garlic (allium sativum L.) on garlic yield in ahvaz conditions; the effects of lead heavy metal on purslane (portulaca oleraceae L.) seed germination and seedling traits; effect of drought stress and plant growth promothing r izobacteri</style></abstract><notes><style face="normal" font="default" size="100%">L75003105&#xD;2014-01-20</style></notes><work-type><style face="normal" font="default" size="100%">Conference Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L75003105</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Srinivasan, A.</style></author><author><style face="normal" font="default" size="100%">Bova, G.</style></author><author><style face="normal" font="default" size="100%">Ross, T.</style></author><author><style face="normal" font="default" size="100%">Mackie, K.</style></author><author><style face="normal" font="default" size="100%">Paquette, N.</style></author><author><style face="normal" font="default" size="100%">Merz, W.</style></author><author><style face="normal" font="default" size="100%">Perl, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Infectious Diseases, Hospital Epidemiology and Infection Control, Johns Hopkins Medical Institutions, Baltimore, Maryland, 21287, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A 17-month evaluation of a chlorine dioxide water treatment system to control Legionella species in a hospital water supply</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">575-9</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2003/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Academic Medical Centers</style></keyword><keyword><style face="normal" font="default" size="100%">Baltimore/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default" size="100%">*Chlorine Compounds/analysis/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Corrosion</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/isolation &amp; purification/pathogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/diagnosis/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance and Engineering, Hospital/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Oxides/analysis/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Sentinel Surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/*methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply/analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">12940577</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess the safety and efficacy of a chlorine dioxide water treatment system in controlling Legionella in a hospital water supply. DESIGN: For 17 months following installation of the system, we performed regular water cultures throughout the building, assessed chlorine dioxide and chlorite levels, and monitored metal corrosion. RESULTS: Sites that grew Legionella species decreased from 41% at baseline to 4% (P = .001). L. anisa was the only species recovered and it was found in samples of both hot and cold water. Levels of chlorine dioxide and chlorite were below Environmental Protection Agency (EPA) limits for these chemicals in potable water. Further, enhanced carbon filtration effectively removed the chemicals, even at chlorine dioxide levels of more than twice what was used to treat the water. After 9 months, corrosion of copper test strips exposed to the chlorine dioxide was not higher than that of control strips. During the evaluation period, there were no cases of nosocomial Legionella in the building with the system, whereas there was one case in another building. CONCLUSIONS: Our results indicate that operation of a chlorine dioxide system effectively removed Legionella species from a hospital water supply. Furthermore, we found that the system was safe, as levels of chlorine dioxide and chlorite were below EPA limits. The system did not appear to cause increased corrosion of copper pipes. Our results indicate that chlorine dioxide may hold promise as a solution to the problem of Legionella contamination of hospital water supplies.</style></abstract><notes><style face="normal" font="default" size="100%">Srinivasan, Arjun&#xD;Bova, Gregory&#xD;Ross, Tracy&#xD;Mackie, Karen&#xD;Paquette, Nicholas&#xD;Merz, William&#xD;Perl, Trish M&#xD;Evaluation Study&#xD;Journal Article&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2003 Aug;24(8):575-9. doi: 10.1086/502254.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/502254</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>205</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">2019 IDSOG Annual Meeting</style></title><secondary-title><style face="normal" font="default" size="100%">American journal of obstetrics and gynecology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of obstetrics and gynecology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A1‐A18</style></pages><volume><style face="normal" font="default" size="100%">221</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">Breast milk</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Chorioamnionitis</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Conference review</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">Cytomegalovirus</style></keyword><keyword><style face="normal" font="default" size="100%">DNA probe</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic accuracy</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic test accuracy study</style></keyword><keyword><style face="normal" font="default" size="100%">Drug safety</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gene amplification</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis C virus</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">Human respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Maternal care</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Mixed infection</style></keyword><keyword><style face="normal" font="default" size="100%">Morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Papillomavirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnant woman</style></keyword><keyword><style face="normal" font="default" size="100%">Premature fetus membrane rupture</style></keyword><keyword><style face="normal" font="default" size="100%">Prenatal care</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Reinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Retention in care</style></keyword><keyword><style face="normal" font="default" size="100%">Risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Safety net hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Third trimester pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Trichomoniasis</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine cervix carcinoma in situ</style></keyword><keyword><style face="normal" font="default" size="100%">Vagina candidiasis</style></keyword><keyword><style face="normal" font="default" size="100%">Vagina flora</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02073744</style></accession-num><abstract><style face="normal" font="default" size="100%">The proceedings contains 81 papers. The topics discussed include: Comparison of obstetric to institutional antibiograms as an approach to advance antimicrobial stewardship in maternal care;A pharmacokinetic and treatment study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus;Chorioamnionitis versus intraamniotic infection among preterm deliveries: is postpartum infectious morbidity different?;Pregnancy latency associated with oral compared to intravenous antibiotics following preterm premature rupture of membranes;HIV‐adapted group prenatal care: assessing viral suppression and postpartum retention in care;Intrapartum antibiotic therapy with cefazolin rather than clindamycin or metronidazole is associated with lower postpartum infectious morbidity among women with chorioamnionitis delivering by cesarean;The vaginal microbiota, high‐risk human papillomavirus infection, and cervical intraepithelial neoplasia: results from a population‐based study;Patterns of treatment and tests of reinfection for trichomoniasis in pregnancy at a large safety‐net hospital;A comparison of 2 g single‐dose versus 7‐dayÂ 500 mg twice daily metronidazole for the treatment trichomoniasis in women by selected clinical factors;Immunoglobulin A, immunoglobulin G, and neutralizing antibodies to respiratory syncytial virus increase in human milk following immunization with an RSV F protein vaccine;Safety of third trimester immunization with a respiratory syncytial virus F protein vaccine and protection of infants over the first 180 days of life against all‐cause lower respiratory tract infection;Randomized trial to prevent congenital cytomegalovirus;Real‐world outcomes associated with nucleic acid amplified versus direct DNA probe testing for vaginitis;Characterizing the vaginal microbiome in women with recurrent bacterial vaginosis and treatment implications;Diagnostic accuracy of clinical criteria for bacterial vaginosis, vulvovaginal candidiasis and BV/VVC co‐infections;Elevated risk of bacterial vaginosis among copper intrauterine device users: a prospective cohort analysis</style></abstract><work-type><style face="normal" font="default" size="100%">Journal: Conference Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02073744/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 2004564756</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0002-9378(19)31324-9</style></electronic-resource-num></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kalaichelvan, V.</style></author><author><style face="normal" font="default" size="100%">Maw, A. A.</style></author><author><style face="normal" font="default" size="100%">Singh, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynaecology, National University Hospital, Singapore 119074, Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Actinomyces in cervical smears of women using the intrauterine device in Singapore</style></title><secondary-title><style face="normal" font="default" size="100%">Contraception</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contraception</style></full-title></periodical><pages><style face="normal" font="default" size="100%">352-5</style></pages><volume><style face="normal" font="default" size="100%">73</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2006/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Actinomyces/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Actinomycosis/drug therapy/epidemiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Doxycycline/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Metronidazole/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillin V/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Singapore</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaginal Smears</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0010-7824 (Print)&#xD;0010-7824</style></isbn><accession-num><style face="normal" font="default" size="100%">16531165</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Reproductive tract actinomyces have been associated with the use of intrauterine contraceptive device (IUCD). Thus, there is a need to evaluate the prevalence of colonization with Actinomyces israelii in a cohort of Singaporean women using an IUCD. Second, the occurrence of actinomycosis in colonized women and the clinical need to remove the IUCD and/or possibly the need to treat asymptomatic carriers with antibiotics were evaluated. METHODS: The study population consisted of 1,108 IUCD users attending the Fertility Control Clinic, National University Hospital, Singapore. RESULTS: In our study, the prevalence of actinomyces-positive cervical smears among IUCD users was 13.7%; the incidence of actinomyces-positive smears was similar with Copper T (34.2%), Multiload (32.9%) and Nova T (32.9%) IUCDs. We found no association with the duration of use of IUCD and actinomyces infection. In our study, 150 out of 152 (98.7%) IUCD users with actinomyces-positive smears were asymptomatic, and only 2 out of 152 (1.3%) who had actinomyces-positive cervical smears developed pelvic inflammatory disease at 6 months. CONCLUSIONS: Our study suggests that removal of the IUCD in asymptomatic women with actinomyces-positive cervical smear is not necessary. Moreover, we suggest that asymptomatic carriers of actinomyces do not require preemptive antibiotic treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Kalaichelvan, Vanaja&#xD;Maw, Aye Aye&#xD;Singh, Kuldip&#xD;Journal Article&#xD;United States&#xD;Contraception. 2006 Apr;73(4):352-5. doi: 10.1016/j.contraception.2005.09.005. Epub 2005 Nov 2.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.contraception.2005.09.005</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grice, G. C.</style></author><author><style face="normal" font="default" size="100%">Hafiz, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Actinomyces in the female genital tract. A preliminary report</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Vener Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Vener Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">317-9</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">1983/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Actinomyces/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Cervix Uteri/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Devices, Female</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptives, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">Condom</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Iud, Unmedicated</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Laboratory Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">*Laboratory Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">Oral Contraceptives</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Sterilization, Sexual</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1983</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0007-134X (Print)&#xD;0007-134x</style></isbn><accession-num><style face="normal" font="default" size="100%">6616167</style></accession-num><abstract><style face="normal" font="default" size="100%">Actinomyces spp were isolated by culture of endocervical specimens from two groups of women attending the department of genitourinary medicine of the Royal Hallamshire Hospital, Sheffield. The first group consisted of 78 users of intrauterine contraceptive devices (IUCD) of whom 20 (25.6%) were culture positive. The second group contained 63 women using various forms of contraception 12 (19%) of whom were culture positive. None of these 12 women had an IUCD or foreign body in situ. The results suggest that Actinomyces spp may be part of the commensal flora of the genital tract in some women.</style></abstract><notes><style face="normal" font="default" size="100%">Grice, G C&#xD;Hafiz, S&#xD;Journal Article&#xD;England&#xD;Br J Vener Dis. 1983 Oct;59(5):317-9. doi: 10.1136/sti.59.5.317.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC1046217</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/sti.59.5.317</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Keebler, C.</style></author><author><style face="normal" font="default" size="100%">Chatwani, A.</style></author><author><style face="normal" font="default" size="100%">Schwartz, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Actinomycosis infection associated with intrauterine contraceptive devices</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Obstet Gynecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Obstet Gynecol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">596-9</style></pages><volume><style face="normal" font="default" size="100%">145</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">1983/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Actinomycosis/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genital Diseases, Female/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Papanicolaou Test</style></keyword><keyword><style face="normal" font="default" size="100%">Plastics/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal Smears</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Demographic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Iud, Copper Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">Iud, Unmedicated</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Laboratory Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">Population</style></keyword><keyword><style face="normal" font="default" size="100%">Population Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">*Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1983</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9378 (Print)&#xD;0002-9378</style></isbn><accession-num><style face="normal" font="default" size="100%">6829637</style></accession-num><abstract><style face="normal" font="default" size="100%">Papanicolaou-stained cervicovaginal smears from 478 women with intrauterine contraceptive devices (IUDs) in place were reviewed for the presence of Actinomyces colonies. The overall infection rate was 12.6%. Plastic IUDs had a significantly higher infection rate than that of Copper 7 IUDs. The infection rate was found to increase with the duration of use of IUDs. The presence or absence of Actinomyces was not related to age, race, parity, previous abortions, or financial status of the patients.&#xD;478 patients of the Temple University Hospital Family Planning Clinic who had Papanicolaou smears taken during intervals of IUD use where included in this study of the prevalence of actinomycetic infections in IUD users. The classification of the Pap smear and the presence or absence of Actinomyces in each smear were determined, and all positive slides were reviewed to confirm the presence of Gupta bodies. No Pap smears prior to IUD insertion showed evidence of Actinomyces, and once a smear showed evidence of Actinomyces, all subsequent ones were positive until the IUD was removed. Evidence of Actinomyces was found in 60 of the 478 patients, indicating a 12.6% infection rate. No correlation was found between presence of infection and race, financial status, number of previous abortions, or size of IUD. Patients with Class I smears had a 9.4% rate of infection and those with Class II smears had a 14.5% rate of infection. Nulliparous women had an 8.4% rate, compared to 13.9% for parous women. The differences in the rates of infection for these variables were not statistically significant. The Saf-T-Coil was used by approximately 77% of the patients, the Cu-7 by approximately 11%, the remainder using other plastic IUDs. Infection rates were 13.1% for the Saf-T-Coil, 13.6% for the other plastic devices, and only 2% for the Cu-7. There were no statistically significant differences in the mean age, parity, or number of abortions between the noninfected and infected group, but the mean duration of IUD use in infected patients was 30.6 months compared to 24.3 months for uninfected patients, a statistically significant difference. The Cu-7 had a significantly shorter duration of use than that of the other IUDs. Data were insufficient to determine whether the shorter duration of use of the Cu-7 was the cause of its lower infection rate. It is recommended that cytologic laboratories report Pap smears containing Gupta bodies to the clinician and that treatment be initiated.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Keebler, C&#xD;Chatwani, A&#xD;Schwartz, R&#xD;Journal Article&#xD;United States&#xD;Am J Obstet Gynecol. 1983 Mar 1;145(5):596-9. doi: 10.1016/0002-9378(83)91203-6.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/0002-9378(83)91203-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>432</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">432</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kindgen-Milles, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D. Kindgen-Milles, Department of Anesthesiology, University Hospital Duesseldorf, Duesseldorf, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acute renal failure in the ICU: Nutrition, vitamins, trace elements and anticoagulation in CRRT</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Anaesthesiologica Scandinavica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Anaesthesiologica Scandinavica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">32-33</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><keywords><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">phosphate</style></keyword><keyword><style face="normal" font="default" size="100%">citric acid</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">glutamine</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">heparin</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulant agent</style></keyword><keyword><style face="normal" font="default" size="100%">arginine</style></keyword><keyword><style face="normal" font="default" size="100%">cysteine</style></keyword><keyword><style face="normal" font="default" size="100%">uremic toxin</style></keyword><keyword><style face="normal" font="default" size="100%">adenosine triphosphate</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen radical</style></keyword><keyword><style face="normal" font="default" size="100%">scavenger</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">anion</style></keyword><keyword><style face="normal" font="default" size="100%">chelate</style></keyword><keyword><style face="normal" font="default" size="100%">calcium ion</style></keyword><keyword><style face="normal" font="default" size="100%">anticoagulation</style></keyword><keyword><style face="normal" font="default" size="100%">continuous renal replacement therapy</style></keyword><keyword><style face="normal" font="default" size="100%">acute kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">filter</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">liquid</style></keyword><keyword><style face="normal" font="default" size="100%">hemofiltration</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">dialysis</style></keyword><keyword><style face="normal" font="default" size="100%">parenteral nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">ultrafiltration</style></keyword><keyword><style face="normal" font="default" size="100%">lipolysis</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional support</style></keyword><keyword><style face="normal" font="default" size="100%">phosphate blood level</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">hypophosphatemia</style></keyword><keyword><style face="normal" font="default" size="100%">continuous hemodiafiltration</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic alkalosis</style></keyword><keyword><style face="normal" font="default" size="100%">hypernatremia</style></keyword><keyword><style face="normal" font="default" size="100%">hypocalcemia</style></keyword><keyword><style face="normal" font="default" size="100%">liver function</style></keyword><keyword><style face="normal" font="default" size="100%">machine</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic disorder</style></keyword><keyword><style face="normal" font="default" size="100%">septicemia</style></keyword><keyword><style face="normal" font="default" size="100%">renal replacement therapy</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">insulin resistance</style></keyword><keyword><style face="normal" font="default" size="100%">glycogen muscle level</style></keyword><keyword><style face="normal" font="default" size="100%">glycogen synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">muscle</style></keyword><keyword><style face="normal" font="default" size="100%">protein degradation</style></keyword><keyword><style face="normal" font="default" size="100%">oxidation</style></keyword><keyword><style face="normal" font="default" size="100%">lean body weight</style></keyword><keyword><style face="normal" font="default" size="100%">immunocompetence</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword><keyword><style face="normal" font="default" size="100%">catabolism</style></keyword><keyword><style face="normal" font="default" size="100%">energy resource</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen balance</style></keyword><keyword><style face="normal" font="default" size="100%">molecular weight</style></keyword><keyword><style face="normal" font="default" size="100%">flow rate</style></keyword><keyword><style face="normal" font="default" size="100%">membrane</style></keyword><keyword><style face="normal" font="default" size="100%">glucose metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">critical illness</style></keyword><keyword><style face="normal" font="default" size="100%">kidney injury</style></keyword><keyword><style face="normal" font="default" size="100%">dialysate</style></keyword><keyword><style face="normal" font="default" size="100%">filtration</style></keyword><keyword><style face="normal" font="default" size="100%">urinary excretion</style></keyword><keyword><style face="normal" font="default" size="100%">phosphate excretion</style></keyword><keyword><style face="normal" font="default" size="100%">extracellular fluid</style></keyword><keyword><style face="normal" font="default" size="100%">permeability</style></keyword><keyword><style face="normal" font="default" size="100%">dialyzer</style></keyword><keyword><style face="normal" font="default" size="100%">heart left ventricle failure</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory failure</style></keyword><keyword><style face="normal" font="default" size="100%">weaning</style></keyword><keyword><style face="normal" font="default" size="100%">ventilated patient</style></keyword><keyword><style face="normal" font="default" size="100%">intravenous drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">partial thromboplastin time</style></keyword><keyword><style face="normal" font="default" size="100%">blood clotting time</style></keyword><keyword><style face="normal" font="default" size="100%">clinical practice</style></keyword><keyword><style face="normal" font="default" size="100%">infusion</style></keyword><keyword><style face="normal" font="default" size="100%">transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">blood transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">adsorption</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">0001-5172</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Mortality of acute renal failure (ARF) remains high despite recent advances in critical care medicine. Acute renal failure in the intensive care unit (ICU) is a complex disorder which generally occurs in patients with more than one impaired organ system. The severity of metabolic disturbances in ARF is often under recognized as it is affected by a variety of factors including severe hypercatabolism, the profound metabolic consequences of septicaemia but also by type and intensity of renal replacement therapy (RRT). The objectives for nutritional support in such patients are not much different from those in patients with other catabolic conditions. However, the general principles differ completely from those in patients with chronic kidney disease. In addition, the impact of RRT on metabolism must be taken into account. The latter is particularly important if continuous renal replacement therapies (CRRT) are used as these may eliminate relevant amounts of nutrients from the patients&apos; blood. Nutrition: The nutritional status of patients with ARF is often characterized by pre-existing deficiencies. In-hospital mortality is increased significantly in patients with malnutrition and ARF (1). Metabolism in ARF is characterized by peripheral insulin resistance, impaired muscular glycogen synthesis and lipolysis (2). In addition, RRT itself may stimulate muscle proteolysis and alter substrate oxidation (3). Nutritional support must meet requirements for all nutrients necessary to preserve lean body mass, immunocompetence, and wound healing. Nutrient losses generated by RRT must be compensated by increased supply. In patients with a high degree of catabolism and RRT, guidelines for enteral as well as for parenteral nutrition recommend an energy supply of 20-30 kcal/kg/day. Amino acids (AA) supply should be in the range of 1.0-1.7 g/kg/day, and fat is recommended at a dose of 1.0-1.5 g/kg/day (4). Bellomo et al. provided evidence that only with high doses of AA (2.5 g/kg/day) a positive nitrogen balance occurred (5). Amino acids have molecular weights below 300 kDa. Sieving coefficients are near 1 and clinically relevant elimination occurs during CRRT. Total loss of AA is related to ultrafiltration or dialysis flow rate. In general, AA losses are 0.25-0.4 g/l ultrafiltrate which corresponds to 12-30 g of AA per day with ultrafiltration rates of 48-72 l/day (6). These losses must be substituted during CRRT. Some AA have sieving coefficients &gt;1 which indicates adsorption of negatively charged AA to the membrane. The latter is true for arginine, cysteine, and glutamine. As glutamine becomes an essential AA in critically ill patients with parenteral nutrition, separate substitution is recommended during CCRT (6). Glucose metabolism is impaired in patients with ARF but no specific considerations compared to other critically ill patients are required. Hemofiltration fluids generally contain 100 mg/dl glucose so elimination must not be considered. Impaired lipolysis requires frequent control of serumtriglycerides but without special considerations, again, in these patients. Vitamins and trace elements: ARF might affect the antioxidant state of patients. Plasma levels of ascorbate, beta-carotene, and selenium are decreased so that a depression of the anti-oxydant system is present (7). Impairment of the oxygen radical scavenger system and a resulting increase in oxidative stress might aggravate critical illness and renal injury, respectively (8). With CVVHDF (dialysate flow 1000 ml/h + filtration rate 1000 ml/h) the 24 h losses of copper were 0.3 times of the daily recommended intake (RI), 1.5 times the RI for thiamine, and two times RI for selenium (9). Losses of vitamin C were approx. 60-70 mg/session and thus more than the RI (10). Taken together, CRRT related losses of trace elements and water soluble vitamins are quantitatively relevant, especially with increased dialysis or hemofiltration dose. Since individual dose adjustments are impracticable in a clinical routine setting, simply doubling of the usual dose of t ese nutrients is a practical way to compensate the losses. Phosphate: Phosphate is mainly an intracellular anion. It is the major source of ATP production in the body. Serum-phosphate concentration is determined by renal excretion and phosphate is an accepted &apos;uremic toxin&apos;. The rate-limiting step of phosphate excretion with RRT is the mass transfer from the intracellular compartment to extracellular fluid and blood, but not the permeability of the dialyzer. Thus, for removal of phosphate the duration of the dialysis session is more important than clearance/time (11), and removal of phosphate with CRRT techniques is very effective. During CRRT, elevated phosphate levels decrease into the normal range usually within 24-18 h and in some patients, hypophosphatemia occurs (12). Hypophosphatemia can lead to left ventricular dysfunction, respiratory failure, and weaning failure in mechanically ventilated patients (11). Therefore, we recommend daily measurement of serum-phosphate in patients on CRRT, and substitution if hyposphophatemia occurs. The latter can be done by separate intravenous infusion of phosphate, phosphate addition to hemofiltration fluids, or by the use of substitution fluids containing phosphate (12). In our own experience with CVVHDF at a rate of approx. 35 ml/kg/h most patients require 30-60 mmol of phosphate per treatment day. Anticoagulation: During CRRT anticoagulation of the extracorporeal circuit is mandatory to prevent clotting, to preserve filter performance, and to avoid blood loss following sudden clotting. Excessive systemic anticoagulation, on the other hand, may cause bleeding, to which many critically ill patients are at increased risk. Unfractionated heparin (UFH) is the anticoagulant most frequently used in CRRT. In general, UFH is infused continuously into the arterial part of the extracorporeal circuit to achieve the highest concentration at the site of coagulation activation. The anticoagulant effect of UFH is monitored by activated partial thromboplastin time (aPTT) or - at the bedside - by activated clotting time (ACT). Dose recommendations of heparin vary widely, depending on individual bleeding risk, and observed and accepted filter running times. In patients with increased bleeding risk, a low target of anticoagulation with aPTT or ACT prolonged to 1-1.5 times normal is recommended (13). However, with every systemic anticoagulation, there is a struggle between filter coagulation and patient hemorrhage and risks and benefits must be outweighed carefully (14). In recent years, regional anticoagulation with citrate has been introduced into clinical practice. Infusion of citrate into the extracorporal circuit chelates ionized calcium. This way, citrate effectively leads to an effective anticoagulation in the circuit without comprising systemic coagulation. Since the first description of citrate anticoagulation (15) various regimens and techniques have been described. Without doubt, citrate anticoagulation is a safe and effective tool, leading to prolonged filter running times and sustained filter patency (13). Bleeding complications are avoided and transfusion requirements are reduced significantly. The latter is not only caused by decreased bleeding complications but also by avoidance of sudden filter clotting so that retransfusion is feasible in the majority of patients (16). Adverse effects of citrate anticoagulation are metabolic alkalosis, hypernatremia, and hypocalcemia (17). In patients with impaired liver function, citrate metabolism may be impaired leading to citrate accumulation. With introduction of new protocols and machines (18), citrate anticoagulation has become a safe and effective tool for anticoagulation especially in patients at high risk of bleeding.</style></abstract><notes><style face="normal" font="default" size="100%">L70010574&#xD;2009-11-27</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70010574</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1399-6576.2009.02001.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1399-6576.2009.02001.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>230</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ye, Y.</style></author><author><style face="normal" font="default" size="100%">Tang, S.</style></author><author><style face="normal" font="default" size="100%">Gan, C.</style></author><author><style face="normal" font="default" size="100%">Ma, X.</style></author><author><style face="normal" font="default" size="100%">Lan, T.</style></author><author><style face="normal" font="default" size="100%">Tang, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">ACUTE-ON-CHRONIC LIVER FAILURE IN A PATIENT WITH WILSON DISEASE AND GRAVES DISEASE: A CASE REPORT</style></title><secondary-title><style face="normal" font="default" size="100%">Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S-1252</style></pages><volume><style face="normal" font="default" size="100%">156</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">contrast medium</style></keyword><keyword><style face="normal" font="default" size="100%">iodine 131</style></keyword><keyword><style face="normal" font="default" size="100%">radioactive iodine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal distension</style></keyword><keyword><style face="normal" font="default" size="100%">acute on chronic liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">coma</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">decision making</style></keyword><keyword><style face="normal" font="default" size="100%">deterioration</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">Graves disease</style></keyword><keyword><style face="normal" font="default" size="100%">hepatic encephalopathy</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">iodination</style></keyword><keyword><style face="normal" font="default" size="100%">jaundice</style></keyword><keyword><style face="normal" font="default" size="100%">liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">liver function</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">liver transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">plasma exchange</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory system</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">thyroid function</style></keyword><keyword><style face="normal" font="default" size="100%">thyroidectomy</style></keyword><keyword><style face="normal" font="default" size="100%">thyrotoxicosis</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1528-0012&#xD;0016-5085</style></isbn><abstract><style face="normal" font="default" size="100%">We report the first case of acute-on-chronic liver failure (ACLF) after iodinated contrast media (ICM) exposure in a patient with Wilson disease (WD) and Graves disease (GD). A 30-year-old woman with a 2-year history of abnormal liver function was admitted to our hospital due to abdominal distension, jaundice and fever for 1 month. During hospitalization, her liver function kept deteriorating. After extensive investigations, she was diagnosed with ACLF, liver cirrhosis, WD and GD. The common causes of acute liver injury, such as hepatotoxicity prescriptions and infections, were all ruled out. In view of her uncontrolled GD and ICM exposure history combined with persistent mild fever, we highly suspected the rapid deterioration of liver function was related to ICM-induced thyrotoxicosis. The coexistence of WD and GD caused therapeutic decision making complicated. We managed to control the liver injury through controlling the thyrotoxicosis. However, ICM administration when admission made I-131 radioiodine ablation invalidated for this patient. Antithyroid medicine, thyroidectomy, copper removing and liver transplantation were not suitable either because of severe liver injury. Under symptomatic supportive treatments, she developed hepatic encephalopathy 16 days after admission. Though plasma exchange was administrated, managing to work as a rapid acting bridge to definite therapy of radioiodine ablation or thyroidectomy and liver transplantation, this patient finally progressed to coma, gastrointestinal, respiratory and urinary tracts bleeding. Her family members gave up treatments 24 days after admission. This case highlights the importance of carefully administrating ICM to patients with hyperthyroidism and concurrent liver injury. We recommend thyroid function exam before ICM administration in these patients.</style></abstract><notes><style face="normal" font="default" size="100%">L2001915644&#xD;2019-06-26</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2001915644</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S0016-5085(19)40131-5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0016-5085(19)40131-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Young, A. B.</style></author><author><style face="normal" font="default" size="100%">Ott, L. G.</style></author><author><style face="normal" font="default" size="100%">Beard, D.</style></author><author><style face="normal" font="default" size="100%">Dempsey, R. J.</style></author><author><style face="normal" font="default" size="100%">Tibbs, P. A.</style></author><author><style face="normal" font="default" size="100%">McClain, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Neurosurgery, College of Medicine, University of Kentucky Medical Center, Lexington.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The acute-phase response of the brain-injured patient</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">375-80</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">1988/09/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute-Phase Reaction/blood/*etiology/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Proteins/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Body Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/blood/*complications/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Urea/urine</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1988</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-3085 (Print)&#xD;0022-3085</style></isbn><accession-num><style face="normal" font="default" size="100%">3136234</style></accession-num><abstract><style face="normal" font="default" size="100%">The acute response to injury and infection is manifested by increased synthesis of acute-phase proteins by the liver, an increased white blood cell count, fever, a negative nitrogen balance, and altered serum mineral levels (zinc, iron, and copper). This response is thought to be partially mediated by cytokines such as interleukin-1, but has not been well studied in head-injured patients. In this study, 25 patients were studied for evidence of the acute-phase response extending from hospital admission up to 21 days postinjury. The patients were divided into two groups to determine if severity of injury influenced the response. Group 1 consisted of nine patients with admission peak 24-hour Glasgow Coma Scale (GCS) scores of 4 or less; Group 2 consisted of 16 patients with admission peak 24-hour GCS scores of 8 or greater. All patients demonstrated some evidence of the acute-phase response. Serum alpha-1 acid glycoprotein, ceruloplasmin, and C-reactive protein levels were elevated on admission and throughout the study. Serum albumin and zinc levels were depressed on admission; zinc levels gradually normalized by Day 21 in both groups, but hypoalbuminemia was observed throughout the study period. Serum copper levels were normal on admission but increased to above normal in both groups by Day 11 postinjury. Urinary urea nitrogen excretion was elevated in both groups and peaked on Day 7 for Group 1 and Day 11 for Group 2 patients. The patients with admission GCS scores equal to or less than 4 had overall higher temperatures than were seen in those with GCS scores greater than or equal to 8 (p = 0.009). All patients but one had an elevated white blood cell count on admission. It is concluded that brain-injured patients with admission GCS scores of 3 to 4 and 8 to 14 demonstrate an acute-phase response which lasts for at least 3 weeks postinjury. It is speculated that this response is at least partially mediated by increased intraventricular interleukin-1 activity.</style></abstract><notes><style face="normal" font="default" size="100%">Young, A B&#xD;Ott, L G&#xD;Beard, D&#xD;Dempsey, R J&#xD;Tibbs, P A&#xD;McClain, C J&#xD;1 R01 NS22712-01A1/NS/NINDS NIH HHS/United States&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;J Neurosurg. 1988 Sep;69(3):375-80. doi: 10.3171/jns.1988.69.3.0375.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/jns.1988.69.3.0375</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>347</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colatrella, S.</style></author><author><style face="normal" font="default" size="100%">Clair, J. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Colatrella, Health Care Planning and Research, Avanti Architecture, 1651 Potomac Ave, Pittsburgh, PA 152164, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adapt or perish-a relentless fight for survival: Designing superbugs out of the intensive care unit</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Care Nursing Quarterly</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Care Nursing Quarterly</style></full-title></periodical><pages><style face="normal" font="default" size="100%">251-267</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">adenosine triphosphate</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">hand sanitizer</style></keyword><keyword><style face="normal" font="default" size="100%">hydrogen peroxide</style></keyword><keyword><style face="normal" font="default" size="100%">hydrogen peroxide vapor</style></keyword><keyword><style face="normal" font="default" size="100%">light activated antimicrobial agent</style></keyword><keyword><style face="normal" font="default" size="100%">macrogol</style></keyword><keyword><style face="normal" font="default" size="100%">oxidizing agent</style></keyword><keyword><style face="normal" font="default" size="100%">protective agent</style></keyword><keyword><style face="normal" font="default" size="100%">stainless steel</style></keyword><keyword><style face="normal" font="default" size="100%">sulfadiazine silver</style></keyword><keyword><style face="normal" font="default" size="100%">tap water</style></keyword><keyword><style face="normal" font="default" size="100%">triclosan</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">air conditioning</style></keyword><keyword><style face="normal" font="default" size="100%">airborne infection</style></keyword><keyword><style face="normal" font="default" size="100%">ambulance</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial outer membrane</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">burn unit</style></keyword><keyword><style face="normal" font="default" size="100%">carbapenem-resistant Enterobacteriaceae</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile infection</style></keyword><keyword><style face="normal" font="default" size="100%">computational fluid dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Coronavirinae</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">disease carrier</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">gene sequence</style></keyword><keyword><style face="normal" font="default" size="100%">general device</style></keyword><keyword><style face="normal" font="default" size="100%">germicidal irradiation</style></keyword><keyword><style face="normal" font="default" size="100%">hand washing</style></keyword><keyword><style face="normal" font="default" size="100%">health care cost</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">heating</style></keyword><keyword><style face="normal" font="default" size="100%">high risk patient</style></keyword><keyword><style face="normal" font="default" size="100%">hospital building</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital personnel</style></keyword><keyword><style face="normal" font="default" size="100%">hospital service</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">microbial contamination</style></keyword><keyword><style face="normal" font="default" size="100%">microbial growth</style></keyword><keyword><style face="normal" font="default" size="100%">microfiber mop</style></keyword><keyword><style face="normal" font="default" size="100%">Middle East respiratory syndrome coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">pathogen clearance</style></keyword><keyword><style face="normal" font="default" size="100%">patient safety</style></keyword><keyword><style face="normal" font="default" size="100%">patient satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">patient transport</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">process monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">severe acute respiratory syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">surface property</style></keyword><keyword><style face="normal" font="default" size="100%">surgical ward</style></keyword><keyword><style face="normal" font="default" size="100%">survival</style></keyword><keyword><style face="normal" font="default" size="100%">textile</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet C radiation</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">vapor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1550-5111&#xD;0887-9303</style></isbn><abstract><style face="normal" font="default" size="100%">Lethal microorganisms have terrorized man since the beginning of time, killing more human beings than anything else in history. The most infamous epidemic, the Black Death, wiped out almost half the population of Europe. To quote H.G. Wells, &quot;adapt or perish, now as ever, is nature&apos;s inexorable imperative.&quot; Superbugs are nature&apos;s revenge on humans for their ingenuity. For decades antibiotics, which work by honing in on particular bacteria, have been the chief line of defense against infection. There is growing urgency for the judicious assessment of both conventional and innovative strategies with regard to antibiotic use, infection control, molecular detection of pathogens and adequate treatment of multidrug-resistant organisms in hospitals, especially critical care units. Financial restraints, changing demographics, an aging population and the limited introduction of new antibiotics have established an imperative for utilization of goal directed strategies in infection prevention and control. Research and development of both clinical and environmental weapons to combat these adversaries is essential if man is to adapt, not perish, in this fight for survival. This article will provide a snapshot of advances in infection prevention and control, including evidence based design, as they relate to the critical care environment. © 2014 Wolters Kluwer Health | Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">L373271261&#xD;2014-06-19&#xD;2014-06-27</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L373271261</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/CNQ.0000000000000029</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24896557</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/CNQ.0000000000000029</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prado, J. V.</style></author><author><style face="normal" font="default" size="100%">Esparza, M. M.</style></author><author><style face="normal" font="default" size="100%">Vidal, A. R.</style></author><author><style face="normal" font="default" size="100%">Duran, T. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Programa de Microbiologia, Instituto de Ciencias Biomedicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile. vprado@med.uchile.cl</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Adherence to copper and stainless steel metal coupons of common nosocomial bacterial strains]</style></title><secondary-title><style face="normal" font="default" size="100%">Rev Med Chil</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rev Med Chil</style></full-title></periodical><pages><style face="normal" font="default" size="100%">291-7</style></pages><volume><style face="normal" font="default" size="100%">141</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2013/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Adhesion/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Stainless Steel</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Actividad bactericida de superficies de cobre frente a bacterias asociadas a infecciones nosocomiales, en un modelo in vitro de adherencia y sobrevivencia.</style></orig-pub><isbn><style face="normal" font="default" size="100%">0034-9887</style></isbn><accession-num><style face="normal" font="default" size="100%">23900318</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Copper has a bactericidal activity against a series of bacterial strains. AIM: To measure resistance to bacterial adherence of copper (Cu) and stainless steel (SS) metal coupons. MATERIAL AND METHODS: Bacterial strains causing nosocomial infections in Chile were analyzed. Bacterial adherence was studied using a previously described method based on a system of metal coupons that are immersed in culture media containing the bacteria of interest at room temperature. RESULTS: Adherence to Cu and SS coupons was different for Methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae and Acinetobacter baumannii strains. For these strains, no adherence to Cu coupons occurred during the 48 h observation period compared to a rapidly increasing adherence to SS coupons, with a final colony count of 1.00 E + 07 cfu/mL. For two different Pseudomonas aeruginosa clinical strains, inhibition of adherence was not observed on Cu coupons, and colony counts were similar for Cu and SS using the standard inoculum (2-3 x lO7 cfu).A partial decrease in adherence was observed for Cu but not for SS coupons, when a lower inoculum was used. CONCLUSIONS: Copper surfaces represent an interesting option to reduce bacterial contamination in the hospital environment due to its resistance to bacterial adhesion of most of the common nosocomial bacterial strains.</style></abstract><notes><style face="normal" font="default" size="100%">0717-6163&#xD;Prado J, Valeria&#xD;Esparza M, Mario&#xD;Vidal A, Roberto&#xD;Duran T, Claudia&#xD;English Abstract&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Chile&#xD;Rev Med Chil. 2013 Mar;141(3):291-7. doi: 10.4067/S0034-98872013000300002.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4067/s0034-98872013000300002</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">spa</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">86</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elguindi, J.</style></author><author><style face="normal" font="default" size="100%">Hao, X.</style></author><author><style face="normal" font="default" size="100%">Lin, Y.</style></author><author><style face="normal" font="default" size="100%">Alwathnani, H. A.</style></author><author><style face="normal" font="default" size="100%">Wei, G.</style></author><author><style face="normal" font="default" size="100%">Rensing, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Soil, Water, and Environmental Science, University of Arizona, Tucson, AZ 85721, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advantages and challenges of increased antimicrobial copper use and copper mining</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Appl Microbiol Biotechnol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">237-49</style></pages><volume><style face="normal" font="default" size="100%">91</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/06/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/chemistry/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biodegradation, Environmental</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/chemistry/pharmacology/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mining</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0175-7598</style></isbn><accession-num><style face="normal" font="default" size="100%">21656137</style></accession-num><abstract><style face="normal" font="default" size="100%">Copper is a highly utilized metal for electrical, automotive, household objects, and more recently as an effective antimicrobial surface. Copper-containing solutions applied to fruits and vegetables can prevent bacterial and fungal infections. Bacteria, such as Salmonellae and Cronobacter sakazakii, often found in food contamination, are rapidly killed on contact with copper alloys. The antimicrobial effectiveness of copper alloys in the healthcare environment against bacteria causing hospital-acquired infections such as methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli O157:H7, and Clostridium difficile has been described recently. The use of copper and copper-containing materials will continue to expand and may lead to an increase in copper mining and production. However, the copper mining and manufacturing industry and the consumer do not necessarily enjoy a favorable relationship. Open pit mining, copper mine tailings, leaching products, and deposits of toxic metals in the environment often raises concerns and sometimes public outrage. In addition, consumers may fear that copper alloys utilized as antimicrobial surfaces in food production will lead to copper toxicity in humans. Therefore, there is a need to mitigate some of the negative effects of increased copper use and copper mining. More thermo-tolerant, copper ion-resistant microorganisms could improve copper leaching and lessen copper groundwater contamination. Copper ion-resistant bacteria associated with plants might be useful in biostabilization and phytoremediation of copper-contaminated environments. In this review, recent progress in microbiological and biotechnological aspects of microorganisms in contact with copper will be presented and discussed, exploring their role in the improvement for the industries involved as well as providing better environmental outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">1432-0614&#xD;Elguindi, Jutta&#xD;Hao, Xiuli&#xD;Lin, Yanbing&#xD;Alwathnani, Hend A&#xD;Wei, Gehong&#xD;Rensing, Christopher&#xD;GM079192/GM/NIGMS NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Germany&#xD;Appl Microbiol Biotechnol. 2011 Jul;91(2):237-49. doi: 10.1007/s00253-011-3383-3. Epub 2011 Jun 9.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00253-011-3383-3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>465</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">465</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Davanzo, F.</style></author><author><style face="normal" font="default" size="100%">Settimi, L.</style></author><author><style face="normal" font="default" size="100%">Faraoni, L.</style></author><author><style face="normal" font="default" size="100%">Maiozzi, P.</style></author><author><style face="normal" font="default" size="100%">Travaglia, A.</style></author><author><style face="normal" font="default" size="100%">Marcello, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">F. Davanzo, Centro antiveleni, Ospedale Niguarda Cà Granda, Milano.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Agricultural pesticide-related poisonings in Italy: cases reported to the Poison Control Centre of Milan in 2000-2001</style></title><secondary-title><style face="normal" font="default" size="100%">Epidemiologia e prevenzione</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Epidemiologia e prevenzione</style></full-title></periodical><pages><style face="normal" font="default" size="100%">330-337</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">agricultural chemical</style></keyword><keyword><style face="normal" font="default" size="100%">pesticide</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chemically induced disorder</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">health survey</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">occupational disease</style></keyword><keyword><style face="normal" font="default" size="100%">occupational exposure</style></keyword><keyword><style face="normal" font="default" size="100%">poison center</style></keyword><keyword><style face="normal" font="default" size="100%">statistics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">1120-9763</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Aim of the present study is to provide a preliminary description of agricultural pesticide-related poisonings in Italy. DESIGN: The study focuses on the cases with at least one sign or symptom due to exposure to agricultural pesticides occurred in 2000-2001 and referred to the Poison control centre of Milan, the Italian centre more frequently consulted nationwide. RESULTS: During the study period, 872 agricultural pesticide-related poisonings were identified. Most of the observed cases occurred in Sicily (n=199), Lombardy (n=100), Apulia (n=99), Veneto (n=75), Emilia-Romagna (n=67) and Campania (n=59). About 86% of the observed cases were unintentional and about 76% of them were men. Children aged 10 or less accounted for about 6% of the total. The poisonings occurred more frequently at home (about 38%) than at workplace (about 24%). The chemical classes of agents more frequently reported were: organophosphates (233 cases), copper and sulphur compounds (140 cases), carbamates (126 cases) and pyrethrins/pyrethroids (102 cases). The top six pesticides associated with poisonings were methomyl (97 cases), dimethoate (59 cases), copper sulfate (58 cases), glyphosate (53 cases), sulphur compounds other than copper sulfate (47 cases), and paraquat dichloride (41 cases). CONCLUSION: The data here presented provide an initial support to identify priorities for prevention in agricultural settings.</style></abstract><notes><style face="normal" font="default" size="100%">L40453280&#xD;2005-04-17</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L40453280</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">15792155</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">Italian</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banerjee, M.</style></author><author><style face="normal" font="default" size="100%">Rahman, M.</style></author><author><style face="normal" font="default" size="100%">Shamuzzaman, A. K.</style></author><author><style face="normal" font="default" size="100%">Akhter, S.</style></author><author><style face="normal" font="default" size="100%">Deb, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, Mymensingh Medical College, Mymensingh.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Alteration of serum copper in Kala-azar patients during SAG therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Mymensingh Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mymensingh Med J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">89-93</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2007/03/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antimony Sodium Gluconate/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antiprotozoal Agents/*adverse effects/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bangladesh</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leishmaniasis, Visceral/*blood/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1022-4742 (Print)&#xD;1022-4742</style></isbn><accession-num><style face="normal" font="default" size="100%">17344788</style></accession-num><abstract><style face="normal" font="default" size="100%">We conducted an analytic case-control study in Kala-azar patients during Sodium Antimony Gluconate (SAG) therapy to assess the changes in serum copper. A total of 89 subjects were included in the study. Diagnosed patients of Kala-azar with parasitological evidence of Leishmania Donovani (LD) bodies in bone marrow, were selected as cases (n=54). They were selected from Medicine and Paediatric wards of Mymensingh Medical College Hospital, Mymensingh and nearby Fulbaria upazila of Mymensingh district. Physically healthy volunteers of similar age, sex and body mass index (BMI) as cases, were included in control group (n=35). The study period was from July 2003 to June 2004. SAG was given intramuscularly (20 mg/kg/day) to Kala-azar patients for 30 days. Blood samples were collected from controls, Kala-azar cases before therapy and same cases during 15-20 days of SAG therapy. Serum copper was higher in cases before therapy than those of controls (p&lt;0.001). However, serum copper reduced significantly (p&lt;0.001) during SAG therapy. So biochemical monitoring may be considered in the management of the disease.</style></abstract><notes><style face="normal" font="default" size="100%">Banerjee, M&#xD;Rahman, M&#xD;Shamuzzaman, A K&#xD;Akhter, S&#xD;Deb, K&#xD;Journal Article&#xD;Bangladesh&#xD;Mymensingh Med J. 2007 Jan;16(1):89-93. doi: 10.3329/mmj.v16i1.260.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3329/mmj.v16i1.260</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>277</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parrott, D.</style></author><author><style face="normal" font="default" size="100%">Ringelman, K. M.</style></author><author><style face="normal" font="default" size="100%">Chaussee, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.S. Chaussee, Division of the Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, SD, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-microbial effects of conductive copper nanoparticle film</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pure and Applied Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pure and Applied Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">661-668</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">polymer</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial viability</style></keyword><keyword><style face="normal" font="default" size="100%">bactericidal activity</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">concentration (parameter)</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">electric conductivity</style></keyword><keyword><style face="normal" font="default" size="100%">electric current</style></keyword><keyword><style face="normal" font="default" size="100%">electric potential</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pyogenes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0973-7510</style></isbn><abstract><style face="normal" font="default" size="100%">Novel infection control methods are needed to prevent further increases in the morbidity and mortality associated with hospital acquired infections. One method is to minimize bacterial transmission is to prevent bacterial growth on hospital surfaces. Copper has anti-microbial properties but is used sparingly in health care settings due to the cost associated with retrofitting surfaces with copper sheet metal or less durable foil. However, copper nanoparticles (CNPs) embedded in a polymer matrix may be similarly anti-microbial, which would offer a viable alternative to copper metal. In this pilot study, we created films with various densities of CNPs and tested their effectiveness in killing bacteria commonly associated with hospital-acquired infections. We found that films with mass ratios greater than 1:2 of CNP to polymer matrix solution killed Streptococcus pyogenes and Staphylococcus aureus more effectively than a copper plate, while the killing of Pseudomonas aeruginosa was similar when exposed to either surface. We also found that passing an electrical current through the CNP film increased the anti-microbial effect of the films against P. aeruginosa even more so than electrified Cu plates. CNP films, which are relatively inexpensive, could be sprayed directly onto hospital surfaces to reduce the incidence of hospital-acquired infections.</style></abstract><notes><style face="normal" font="default" size="100%">L617363536&#xD;2017-07-21&#xD;2017-07-25</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L617363536</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.22207/JPAM.11.2.03</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.22207/JPAM.11.2.03</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>241</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raheem, H. Q.</style></author><author><style face="normal" font="default" size="100%">Al-Meamar, T. S.</style></author><author><style face="normal" font="default" size="100%">Almamoori, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H.Q. Raheem, DNA Research Center, University of Babylon, Hillah, Iraq</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic profile and antibacterial activity of copper oxide nanoparticles against pseudomonas fluorescens isolated from wound infection</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Drug Delivery Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Drug Delivery Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6-8</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibacterial activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium isolate</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">dilution</style></keyword><keyword><style face="normal" font="default" size="100%">disk diffusion</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">microbial identification system</style></keyword><keyword><style face="normal" font="default" size="100%">minimum bactericidal concentration</style></keyword><keyword><style face="normal" font="default" size="100%">minimum inhibitory concentration</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas fluorescens</style></keyword><keyword><style face="normal" font="default" size="100%">wound infection</style></keyword><keyword><style face="normal" font="default" size="100%">zone of inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper oxide nanoparticle</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">0975-4415</style></isbn><abstract><style face="normal" font="default" size="100%">Fifty specimens were collected from wound patients who visited Al-Hilla Teaching Hospital. The samples were grown on Blood and MacConkey agar for 24-48 hour at 37oC. The bacterial isolates, which achieved as a pure and predominant growth from clinical samples as Pseudomonas fluorescens, were identified using morphological properties and Vitek2 system. The antibacterial activity of copper oxide nanoparticles (CuO NPs) against was tested by (disk diffusion assay) using dilutions of (400, 200, 100, 50, 25, and 12.5µg/mL). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of each isolate was determined. The CuO NPs shows wide spectrum antibacterial activity against tested bacteria with rising zone of inhibition diameter that is proportionate with the increase in nanoparticle concentration. The MIC of CuO NPs extended from 100-200µg/mL, and the MBC ranged from 200-400µg/ml. The antibiotic profile was determined by Viteck 2 compact system (Biomérieux). CuO NPs found highly effective and safe in P. fluorescens wounds infections comparing with used antibiotics.</style></abstract><notes><style face="normal" font="default" size="100%">L2003243072&#xD;2019-11-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2003243072</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.25258/ijddt.v9i3.10</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.25258/ijddt.v9i3.10</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">35</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rozanska, A.</style></author><author><style face="normal" font="default" size="100%">Chmielarczyk, A.</style></author><author><style face="normal" font="default" size="100%">Romaniszyn, D.</style></author><author><style face="normal" font="default" size="100%">Bulanda, M.</style></author><author><style face="normal" font="default" size="100%">Walkowicz, M.</style></author><author><style face="normal" font="default" size="100%">Osuch, P.</style></author><author><style face="normal" font="default" size="100%">Knych, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jagiellonian University Medical College, Faculty of Medicine, Chair of Microbiology, Czysta str. 18, 31-121 Krakow, Poland.0000 0001 2162 9631grid.5522.0&#xD;Faculty of Non-Ferrous Metals, Department of Metal Working and Physical Metallurgy of Non-Ferrous Metals, AGH University of Science and Technology, al. Mickiewicza 30, 30-059 Krakow, Poland.0000 0000 9174 1488grid.9922.0</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic resistance, ability to form biofilm and susceptibility to copper alloys of selected staphylococcal strains isolated from touch surfaces in Polish hospital wards</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">80</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><edition><style face="normal" font="default" size="100%">2017/08/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilm-forming staphylococci</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital environment contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococci</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><accession-num><style face="normal" font="default" size="100%">28815023</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Despite the employment of sanitary regimes, contact transmission of the aetiological agents of hospital infections is still exceedingly common. The issue of microbe transmission becomes particularly important when facing multidrug-resistant microorganisms such as methicillin-resistant staphylococci. In the case of deficiencies in cleaning and disinfection procedures, hospital equipment made of copper alloys can play an important role, complementing traditional hospital hygiene procedures. The objective of this study was to characterize staphylococcal strains isolated from touch surfaces in Polish hospital wards in terms of their drug resistance, ability to form biofilm and susceptibility to antimicrobial activity of copper alloys. METHODS: The materials for the study were 95 staphylococcal strains isolated from touch surfaces in 13 different hospital wards from Malopolska province (the south of Poland). Phenotypic and genotypic antibiotic resistance were checked for erythromycin, clindamycin, gentamycin, ciprofloxacin, trimethoprim/sulfamethoxazole and mupirocin. Biofilm formation ability for the tested strains was checked with the use of culture on Congo red agar. Susceptibility to copper, tin bronze, brass and new silver was tested using a modification of the Japanese standard. RESULTS: Over 67% of the analysed staphylococcal strains were methicillin-resistant (MR). Four strains were resistant to all of the tested antibiotics, and 14 were resistant to all except mupirocin. Strains classified as MR had significantly increased resistance to the remaining antibiotic groups. About one-third of the analysed strains revealed biofilm-forming ability. Among the majority of species, biofilm-forming and non-biofilm-forming strains were distributed evenly; in the case of S. haemolyticus only, negative strains accounted for 92.8%. Susceptibility to copper alloys was different between strains and rather lower than in the case of the SA strain selected for comparison. CONCLUSIONS: Coagulase-negative staphylococci, the most commonly isolated in Polish hospital wards, should not be neglected as an infection risk factor due their high antibiotic resistance. Our experiments confirmed that touch surfaces made of copper alloys may play an important role in eliminating bacteria from the hospital environment.</style></abstract><notes><style face="normal" font="default" size="100%">2047-2994&#xD;Rozanska, Anna&#xD;Chmielarczyk, Agnieszka&#xD;Romaniszyn, Dorota&#xD;Bulanda, Malgorzata&#xD;Walkowicz, Monika&#xD;Osuch, Piotr&#xD;Knych, Tadeusz&#xD;Journal Article&#xD;England&#xD;Antimicrob Resist Infect Control. 2017 Aug 14;6:80. doi: 10.1186/s13756-017-0240-x. eCollection 2017.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5556671</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-017-0240-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">72</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cervantes, H. I.</style></author><author><style face="normal" font="default" size="100%">Alvarez, J. A.</style></author><author><style face="normal" font="default" size="100%">Munoz, J. M.</style></author><author><style face="normal" font="default" size="100%">Arreguin, V.</style></author><author><style face="normal" font="default" size="100%">Mosqueda, J. L.</style></author><author><style face="normal" font="default" size="100%">Macias, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine and Nutrition, University of Guanajuato, Leon, Guanajuato, Mexico.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial activity of copper against organisms in aqueous solution: a case for copper-based water pipelines in hospitals?</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e115-8</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2013/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/*drug effects/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Purification</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital construction</style></keyword><keyword><style face="normal" font="default" size="100%">Water quality</style></keyword><keyword><style face="normal" font="default" size="100%">Water supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">23870795</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: An association exists between water of poor quality and health care-associated infections. Copper shows microbiocidal action on dry surfaces; it is necessary to evaluate its antimicrobial effect against organisms in aqueous solution. OBJECTIVE: The objective was to determine the in vitro antimicrobial activity of copper against common nosocomial pathogens in aqueous solution. METHODS: Copper and polyvinyl chloride containers were used. Glass was used as control material. Fourteen organisms isolated from hospital-acquired infections, and 3 control strains were tested. Inocula were prepared by direct suspension of colonies in saline solution and water in each container tested. Bacterial counts in colony-forming units (CFU)/mL were determined at the beginning of the experiment; at 30 minutes; and at 1, 2, 24, and 48 hours. RESULTS: Organisms in glass and polyvinyl chloride remained viable until the end of the experiment. Organisms in copper showed a reduction from more than 100,000 CFU/mL to 0 CFU/mL within the first 2 hours of contact (F &gt; 4.29, P &lt; .001). CONCLUSION: Copper containers show microbiocidal action on organisms in aqueous solution. Copper may contribute to the quality of water for human use, particularly in hospitals.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Cervantes, Hilda I&#xD;Alvarez, Jose A&#xD;Munoz, Juan M&#xD;Arreguin, Virginia&#xD;Mosqueda, Juan L&#xD;Macias, Alejandro E&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 2013 Dec;41(12):e115-8. doi: 10.1016/j.ajic.2013.03.309. Epub 2013 Jul 17.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2013.03.309</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eser, O. K.</style></author><author><style face="normal" font="default" size="100%">Ergin, A.</style></author><author><style face="normal" font="default" size="100%">Hascelik, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey, ozgen.eser@hacettepe.edu.tr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial Activity of Copper Alloys Against Invasive Multidrug-Resistant Nosocomial Pathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">291-5</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/06/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/classification/*drug effects/genetics/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0343-8651</style></isbn><accession-num><style face="normal" font="default" size="100%">26044991</style></accession-num><abstract><style face="normal" font="default" size="100%">The emergence and spread of antibiotic resistance demanded novel approaches for the prevention of nosocomial infections, and metallic copper surfaces have been suggested as an alternative for the control of multidrug-resistant (MDR) bacteria in surfaces in the hospital environment. This study aimed to evaluate the antimicrobial activity of copper material for invasive MDR nosocomial pathogens isolated over time, in comparison to stainless steel. Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) (n:4), OXA-23 and OXA-58 positive, MDR Acinetobacter baumannii (n:6) and Pseudomonas aeruginosa (n:4) were evaluated. The antimicrobial activity of coupons containing 99 % copper and a brass alloy containing 63 % copper was assessed against stainless steel. All the materials demonstrated statistically significant differences within each other for the logarithmic reduction of microorganisms. Among the three materials, the highest reduction of microorganisms was seen in 99 % copper and the least in stainless steel. The result was statistically significant especially for 0, 2, and 4 h (P = 0.05). 99 % copper showed a bactericidal effect at less than 1 h for MRSA and at 2 h for P. aeruginosa. 63 % copper showed a bactericidal effect at 24 h for P. aeruginosa strains only. Stainless steel surfaces exhibited a bacteriostatic effect after 6 h for P. aeruginosa strains only. 99 % copper reduced the number of bacteria used significantly, produced a bactericidal effect and was more effective than 63 % copper. The use of metallic copper material could aid in reducing the concentration of bacteria, especially for invasive nosocomial pathogens on hard surfaces in the hospital environment.</style></abstract><notes><style face="normal" font="default" size="100%">1432-0991&#xD;Eser, Ozgen Koseoglu&#xD;Ergin, Alper&#xD;Hascelik, Gulsen&#xD;Journal Article&#xD;United States&#xD;Curr Microbiol. 2015 Aug;71(2):291-5. doi: 10.1007/s00284-015-0840-8. Epub 2015 Jun 5.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00284-015-0840-8</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>406</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">406</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kouskouni, E.</style></author><author><style face="normal" font="default" size="100%">Tsouma, I.</style></author><author><style face="normal" font="default" size="100%">Patikas, I.</style></author><author><style face="normal" font="default" size="100%">Karageorgou, K.</style></author><author><style face="normal" font="default" size="100%">Manolidou, Z.</style></author><author><style face="normal" font="default" size="100%">Tseroni, M.</style></author><author><style face="normal" font="default" size="100%">Agrafa, I.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Kouskouni, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial activity of copper alloys compared to aminoglycosides against multidrug-resistant bacteria</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S674</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">aminoglycoside</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">agar</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecium</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">blood culture</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">culture medium</style></keyword><keyword><style face="normal" font="default" size="100%">incubation time</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial load</style></keyword><keyword><style face="normal" font="default" size="100%">public health problem</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">gene</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">minimum inhibitory concentration</style></keyword><keyword><style face="normal" font="default" size="100%">disk diffusion</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">1198-743X</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: The emergence of multi-resistant bacteria against powerful antibiotics and their transborder transmission constitute some of the most threatening public health problems of the recent years. Metallic copper alloys have recently attracted attention as a new antimicrobial agent, able to minimize environmental contamination by pathogenic bacteria. We investigated the efficacy of a copper alloy (Cu63%-Zn37%) in relation to aminoglycosides. Methods: Multi-resistant bacteria, isolated from blood culture of patients with signs of infection or fever appearing any time after 8 days of admission into ICU, were selected. The samples were cultured onto suitable culture media and bacterial isolates were identified using standard methods. The isolated bacteria were: Escherichia coli, Klebsiella spp, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecium. Resistance genes were detected for up to 10 antibiotics, evaluated with VITEK 2 System (bioMérieux) for identification and antimicrobial susceptibility test and the Minimum Inhibitory Concentration (MIC) to determine the antimicrobial activity of a material against specific bacteria and to control the activity of new antimicrobiological factors were recorded and compared. In the above procedure we used coupons (1x1cm) of copper alloys containing (Cu63%-Zn37%) and Aminoglycoside discs. Susceptibility testing was conducted by Kirby Bauer disc diffusion method on “Miller Hinton Agar” in which an aminoglycoside disc was placed at 3cm distance from the copper coupon. This procedure was followed for each isolated pathogen. Results: After 24-hour and 48-hour incubation periods, the inhibition zone bacteria around the antibiotic disc as well as around the copper coupon were recorded. The inhibition zones of antimicrobial copper were equal to those of aminoglycisides for E. coli and Klebsiella spp, were smaller for Pseudomonas aeruginosa, and Enterococcus faecium and larger for Staphylococcus aureus and Acinetobacter baumannii respectively. Conclusion: The copper alloy exhibited antimicrobial activity against all multidrug resistant bacteria studied. The inhibition zone of our specific cooper alloy was increased, compared to that of aminoglycosides for Staphylococcus aureus and Acinetobacter baumannii. It should be noted that the reduction of bacterial load in a hospital where antimicrobial copper is used, leads to drastic reduction of antibiotic use.</style></abstract><notes><style face="normal" font="default" size="100%">L70600926&#xD;2011-12-08</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70600926</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1469-0691.2011.03559.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1469-0691.2011.03559.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mehtar, S.</style></author><author><style face="normal" font="default" size="100%">Wiid, I.</style></author><author><style face="normal" font="default" size="100%">Todorov, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Academic Unit for Infection Prevention and Control, Department of Community Health, University of Health Sciences, Faculty of Health Sciences, Tygerberg, Western Cape, South Africa. smehtar@sun.ac.za</style></auth-address><titles><title><style face="normal" font="default" size="100%">The antimicrobial activity of copper and copper alloys against nosocomial pathogens and Mycobacterium tuberculosis isolated from healthcare facilities in the Western Cape: an in-vitro study</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">45-51</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2007/12/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Fungal</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Fomites/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Mycobacterium tuberculosis/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">South Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701 (Print)&#xD;0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">18069086</style></accession-num><abstract><style face="normal" font="default" size="100%">Clinical isolates of meticillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Candida albicans and Mycobacterium tuberculosis (MTB) were tested against copper (Cu) and its alloys. Stainless steel and polyvinylchloride (PVC) were used as controls. The amount of Cu required to inhibit test isolates at room temperature (24 degrees C) and at 4 degrees C was determined. At room temperature, Cu, DZR Brass (Cu 62%, Pb 2.5%, arsenate 0.13% and Zn 22.5%) and Brass 70/30 (Cu 70% and zinc 30%) inhibited C. albicans and K. pneumoniae at 60 min; nickel silver (NiAg) inhibited C. albicans at 60 min and K. pneumoniae at 270 min. P. aeruginosa was inhibited by Brass 70/30 and nickel silver (NiAg) at 180 min and at 270 min by Cu and DZR. Cu and DZR inhibited A. baumannii at 180 min while the other alloys were effective at 360 min. Stainless steel and PVC showed little or no inhibitory activity. Two M. tuberculosis strains, one isoniazid resistant (R267) and the other multidrug resistant (R432), demonstrated growth inhibition with Cu of 98% and 88% respectively compared with PVC; the other alloys were less active. Time to positivity (TTP) for R267 was &gt;15 days with Cu and 11 days for the other alloys; with R432 it was 5 days. Effective inhibition of nosocomial pathogens and MTB by Cu and alloys was best when the Cu content was &gt;55%.</style></abstract><notes><style face="normal" font="default" size="100%">Mehtar, S&#xD;Wiid, I&#xD;Todorov, S D&#xD;Journal Article&#xD;Multicenter Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2008 Jan;68(1):45-51. doi: 10.1016/j.jhin.2007.10.009. Epub 2007 Dec 11.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2007.10.009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>287</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rózanska, A.</style></author><author><style face="normal" font="default" size="100%">Chmielarczyk, A.</style></author><author><style face="normal" font="default" size="100%">Romaniszyn, D.</style></author><author><style face="normal" font="default" size="100%">Bulanda, M.</style></author><author><style face="normal" font="default" size="100%">Walkowicz, M.</style></author><author><style face="normal" font="default" size="100%">Osuch, P.</style></author><author><style face="normal" font="default" size="100%">Knych, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Rózanska, Department of Microbiology, Jagiellonian University Medical College, Kraków, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial activity of selected copper alloys against bacteria from acinetobacter genus</style></title><secondary-title><style face="normal" font="default" size="100%">Postepy Mikrobiologii</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Postepy Mikrobiologii</style></full-title></periodical><pages><style face="normal" font="default" size="100%">55</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><keywords><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">stainless steel</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">bactericidal activity</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">genus</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">suspension</style></keyword><keyword><style face="normal" font="default" size="100%">touch</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0079-4252</style></isbn><abstract><style face="normal" font="default" size="100%">The aim of this study was the estimation of antibacterial properties of selected copper alloys with potential use on touch surfaces in healthcare facilities, in relation to various strains of Acinetobacter genus isolated from patients or Polish hospital environment. The study was performed using modified guidelines of the so called &quot;Japanese norm&quot;. The experiments involved brass, tin bronze, new silver, copper and stainless steel (negative control). The selected Acinetobacter spp. had diferent drug resistance profiles and biofilm formation potential. For evaluation of the antibacterial properties of copper alloys the following criteria were adopted: reduction in the density of bacterial suspension in the vicinity of 2-3 logs, over 3 logs: bactericidal activity. For the tested copper alloys, bactericidal activity was confirmed afer 240-300 min (depending on the alloy) and copper afer 180 min. No bactericidal nor static efect was observed for stainless steel. No significant diferences were observed between sensitivity to studied materials and the tested strains. Concluding, touch surfaces made from copper alloys may in fact improve elimination of bacteria from Acinetobacter genus from the hospital environment.</style></abstract><notes><style face="normal" font="default" size="100%">L623155173&#xD;2018-07-26</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L623155173</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, M. G.</style></author><author><style face="normal" font="default" size="100%">Tuuri, R. E.</style></author><author><style face="normal" font="default" size="100%">Dharsee, A.</style></author><author><style face="normal" font="default" size="100%">Attaway, H. H.</style></author><author><style face="normal" font="default" size="100%">Fairey, S. E.</style></author><author><style face="normal" font="default" size="100%">Borg, K. T.</style></author><author><style face="normal" font="default" size="100%">Salgado, C. D.</style></author><author><style face="normal" font="default" size="100%">Hirsch, B. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC. Electronic address: schmidtm@musc.edu.&#xD;Department of Emergency Medicine, University of New Mexico, Albuquerque, NM.&#xD;North Shore-Long Island Jewish Medical Group, North Shore University Hospital, New York, NY.&#xD;Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC.&#xD;Division of Pediatric Emergency Medicine, Medical University of South Carolina Children&apos;s Hospital, Charleston, SC.&#xD;Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, SC.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial copper alloys decreased bacteria on stethoscope surfaces</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">642-647</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2017/03/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacteria/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Stethoscopes/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin-Resistant Enterococci/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">Health care-associated infections</style></keyword><keyword><style face="normal" font="default" size="100%">Infection control</style></keyword><keyword><style face="normal" font="default" size="100%">Stethoscopes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">28302430</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Stethoscopes may serve as vehicles for transmission of bacteria among patients. The aim of this study was to assess the efficacy of antimicrobial copper surfaces to reduce the bacterial concentration associated with stethoscope surfaces. METHODS: A structured prospective trial involving 21 health care providers was conducted at a pediatric emergency division (ED) (n = 14) and an adult medical intensive care unit located in tertiary care facilities (n = 7). Four surfaces common to a stethoscope and a facsimile instrument fabricated from U.S. Environmental Protection Agency-registered antimicrobial copper alloys (AMCus) were assessed for total aerobic colony counts (ACCs), methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and vancomycin-resistant enterococci for 90 days. RESULTS: The mean ACCs collectively recovered from all stethoscope surfaces fabricated from the AMCus were found to carry significantly lower concentrations of bacteria (pediatric ED, 11.7 vs 127.1 colony forming units [CFU]/cm(2), P &lt; .00001) than their control equivalents. This observation was independent of health care provider or infection control practices. Absence of recovery of bacteria from the AMCu surfaces (66.3%) was significantly higher (P &lt; .00001) than the control surfaces (22.4%). The urethane rim common to the stethoscopes was the most heavily burdened surface; mean concentrations exceeded the health care-associated infection acquisition concentration (5 CFU/cm(2)) by at least 25x, supporting that the stethoscope warrants consideration in plans mitigating microbial cross-transmission during patient care. CONCLUSIONS: Stethoscope surfaces fabricated with AMCus were consistently found to harbor fewer bacteria.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Schmidt, Michael G&#xD;Tuuri, Rachel E&#xD;Dharsee, Arif&#xD;Attaway, Hubert H&#xD;Fairey, Sarah E&#xD;Borg, Keith T&#xD;Salgado, Cassandra D&#xD;Hirsch, Bruce E&#xD;Clinical Trial&#xD;Journal Article&#xD;United States&#xD;Am J Infect Control. 2017 Jun 1;45(6):642-647. doi: 10.1016/j.ajic.2017.01.030. Epub 2017 Mar 13.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2017.01.030</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rozanska, A.</style></author><author><style face="normal" font="default" size="100%">Chmielarczyk, A.</style></author><author><style face="normal" font="default" size="100%">Romaniszyn, D.</style></author><author><style face="normal" font="default" size="100%">Majka, G.</style></author><author><style face="normal" font="default" size="100%">Bulanda, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1Chair of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, ul. Czysta 18, 31-121 Krakow, Poland.&#xD;2Chair of Immunology, Faculty of Medicine, Jagiellonian University Medical College, ul. Czysta 18, 31-121 Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial effect of copper alloys on Acinetobacter species isolated from infections and hospital environment</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">10</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><edition><style face="normal" font="default" size="100%">2018/02/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acinetobacter/*drug effects/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter Infections/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii</style></keyword><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Poland</style></keyword><keyword><style face="normal" font="default" size="100%">Stainless Steel</style></keyword><keyword><style face="normal" font="default" size="100%">*Acinetobacter</style></keyword><keyword><style face="normal" font="default" size="100%">*Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital environment</style></keyword><keyword><style face="normal" font="default" size="100%">interestsSpringer Nature remains neutral with regard to jurisdictional claims in</style></keyword><keyword><style face="normal" font="default" size="100%">published maps and institutional affiliations.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><accession-num><style face="normal" font="default" size="100%">29387344</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: An increased proportion of Gram-negative bacteria have recently been reported among etiologic agents of infection. In Poland, Acinetobacter baumannii is a big problem for hospitals, especially intensive care units. Touch surfaces made from materials with antimicrobial properties, especially copper alloys, are recommended as a supplementary method of increasing biological safety in the hospital environment. Aim of the study: The objective of this study is to determine the susceptibility to selected copper alloys of three clinical Acinetobacter baumannii strains, one Acinetobacter lwoffi and an A. pittii strain isolated from the hospital environment. Material and method: The modification of the Japanese Standard, which the ISO 22196:2011 norm was used for testing antimicrobial properties of CuZn37, CuSn6 and CuNi18Zn20 and Cu-ETP and stainless steel as positive and negative control, respectively. Results: The highest cidal efficiency, expressed as both time and the degree of reduction of the initial suspension density, against all of the tested Acinetobacter strains was found for ETP copper. But, the results of our study also confirmed effective activity (bacteriocidal or bacteriostatic) of copper alloys selected for the study, contrary to the stainless steel. The reduction in bacterial suspension density is significantly different depending on the strain and copper alloy composition. Conslusions: The results of our study confirmed the effective antibacterial activity of copper and its selected alloys against clinical Acinetobacter baumannii and Acinetobacter lwoffii strains, and Acinetobacter pittii strain isolated from the hospital environment.</style></abstract><notes><style face="normal" font="default" size="100%">2047-2994&#xD;Rozanska, Anna&#xD;Chmielarczyk, Agnieszka&#xD;Romaniszyn, Dorota&#xD;Majka, Grzegorz&#xD;Bulanda, Malgorzata&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Antimicrob Resist Infect Control. 2018 Jan 22;7:10. doi: 10.1186/s13756-018-0300-x. eCollection 2018.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5778618</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-018-0300-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">83</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karpanen, T. J.</style></author><author><style face="normal" font="default" size="100%">Casey, A. L.</style></author><author><style face="normal" font="default" size="100%">Lambert, P. A.</style></author><author><style face="normal" font="default" size="100%">Cookson, B. D.</style></author><author><style face="normal" font="default" size="100%">Nightingale, P.</style></author><author><style face="normal" font="default" size="100%">Miruszenko, L.</style></author><author><style face="normal" font="default" size="100%">Elliott, T. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Microbiology, University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The antimicrobial efficacy of copper alloy furnishing in the clinical environment: a crossover study</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3-9</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2011/12/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacteriaceae/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment and Supplies/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Vancomycin Resistance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">22173515</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine whether copper incorporated into hospital ward furnishings and equipment can reduce their surface microbial load. DESIGN: A crossover study. SETTING: Acute care medical ward with 19 beds at a large university hospital. METHODS: Fourteen types of frequent-touch items made of copper alloy were installed in various locations on an acute care medical ward. These included door handles and push plates, toilet seats and flush handles, grab rails, light switches and pull cord toggles, sockets, overbed tables, dressing trolleys, commodes, taps, and sink fittings. Their surfaces and those of equivalent standard items on the same ward were sampled once weekly for 24 weeks. The copper and standard items were switched over after 12 weeks of sampling to reduce bias in usage patterns. The total aerobic microbial counts and the presence of indicator microorganisms were determined. RESULTS: Eight of the 14 copper item types had microbial counts on their surfaces that were significantly lower than counts on standard materials. The other 6 copper item types had reduced microbial numbers on their surfaces, compared with microbial counts on standard items, but the reduction did not reach statistical significance. Indicator microorganisms were recovered from both types of surfaces; however, significantly fewer copper surfaces were contaminated with vancomycin-resistant enterococci, methicillin-susceptible Staphylococcus aureus, and coliforms, compared with standard surfaces. CONCLUSIONS: Copper alloys (greater than or equal to 58% copper), when incorporated into various hospital furnishings and fittings, reduce the surface microorganisms. The use of copper in combination with optimal infection-prevention strategies may therefore further reduce the risk that patients will acquire infection in healthcare environments.</style></abstract><notes><style face="normal" font="default" size="100%">1559-6834&#xD;Karpanen, T J&#xD;Casey, A L&#xD;Lambert, P A&#xD;Cookson, B D&#xD;Nightingale, P&#xD;Miruszenko, L&#xD;Elliott, T S J&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2012 Jan;33(1):3-9. doi: 10.1086/663644. Epub 2011 Dec 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cambridge.org/core/services/aop-cambridge-core/content/view/0AEDAC712740D613D9EC0EB38E2B28BD/S0195941700030289a.pdf/div-class-title-the-antimicrobial-efficacy-of-copper-alloy-furnishing-in-the-clinical-environment-a-crossover-study-div.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1885843116/Karpanen-2012-The antimicrobial efficacy of co.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/663644</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wheeldon, L. J.</style></author><author><style face="normal" font="default" size="100%">Worthington, T.</style></author><author><style face="normal" font="default" size="100%">Lambert, P. A.</style></author><author><style face="normal" font="default" size="100%">Hilton, A. C.</style></author><author><style face="normal" font="default" size="100%">Lowden, C. J.</style></author><author><style face="normal" font="default" size="100%">Elliott, T. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial efficacy of copper surfaces against spores and vegetative cells of Clostridium difficile: the germination theory</style></title><secondary-title><style face="normal" font="default" size="100%">J Antimicrob Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Antimicrob Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">522-5</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2008/06/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment and Supplies/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability</style></keyword><keyword><style face="normal" font="default" size="100%">Spores/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stainless Steel/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0305-7453</style></isbn><accession-num><style face="normal" font="default" size="100%">18544601</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Persistent contamination of surfaces by spores of Clostridium difficile is a major factor influencing the spread of C. difficile-associated diarrhoea (CDAD) in the clinical setting. In recent years, the antimicrobial efficacy of metal surfaces has been investigated against microorganisms including methicillin-resistant Staphylococcus aureus. This study compared the survival of C. difficile on stainless steel, a metal contact surface widely used in hospitals, and copper surfaces. METHODS: Antimicrobial efficacy was assessed using a carrier test method against dormant spores, germinating spores and vegetative cells of C. difficile (NCTC 11204 and ribotype 027) over a 3 h period in the presence and absence of organic matter. RESULTS: Copper metal eliminated all vegetative cells of C. difficile within 30 min, compared with stainless steel which demonstrated no antimicrobial activity (P &lt; 0.05). Copper significantly reduced the viability of spores of C. difficile exposed to the germinant (sodium taurocholate) in aerobic conditions within 60 min (P &lt; 0.05) while achieving a &gt;or=2.5 log reduction (99.8% reduction) at 3 h. Organic material did not reduce the antimicrobial efficacy of the copper surface (P &gt; 0.05). CONCLUSIONS: The use of copper surfaces within the clinical environment and application of a germination solution in infection control procedures may offer a novel way forward in eliminating C. difficile from contaminated surfaces and reducing CDAD.</style></abstract><notes><style face="normal" font="default" size="100%">1460-2091&#xD;Wheeldon, L J&#xD;Worthington, T&#xD;Lambert, P A&#xD;Hilton, A C&#xD;Lowden, C J&#xD;Elliott, T S J&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Antimicrob Chemother. 2008 Sep;62(3):522-5. doi: 10.1093/jac/dkn219. Epub 2008 Jun 10.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/dkn219</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Montero, D. A.</style></author><author><style face="normal" font="default" size="100%">Arellano, C.</style></author><author><style face="normal" font="default" size="100%">Pardo, M.</style></author><author><style face="normal" font="default" size="100%">Vera, R.</style></author><author><style face="normal" font="default" size="100%">Galvez, R.</style></author><author><style face="normal" font="default" size="100%">Cifuentes, M.</style></author><author><style face="normal" font="default" size="100%">Berasain, M. A.</style></author><author><style face="normal" font="default" size="100%">Gomez, M.</style></author><author><style face="normal" font="default" size="100%">Ramirez, C.</style></author><author><style face="normal" font="default" size="100%">Vidal, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1Programa de Microbiologia y Micologia, Instituto de Ciencias Biomedicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.&#xD;2Instituto de Quimica, Facultad de Ciencias, Pontificia Universidad Catolica de Valparaiso, Valparaiso, Chile.&#xD;3Unidad de Cuidados Intensivos, Facultad de Medicina, Hospital Clinico Universidad de Chile, Santiago, Chile.&#xD;ATACAMALAB, Lampa, Chile.&#xD;5Instituto Milenio de Inmunologia e Inmunoterapia, Facultad de Medicina, Universidad de Chile, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial properties of a novel copper-based composite coating with potential for use in healthcare facilities</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><edition><style face="normal" font="default" size="100%">2019/01/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment and Supplies, Hospital/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot Projects</style></keyword><keyword><style face="normal" font="default" size="100%">*Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper-based composite</style></keyword><keyword><style face="normal" font="default" size="100%">*Healthcare-associated infections</style></keyword><keyword><style face="normal" font="default" size="100%">*High-touch surfaces</style></keyword><keyword><style face="normal" font="default" size="100%">*Self-sanitizing coating</style></keyword><keyword><style face="normal" font="default" size="100%">the study protocols and an informed consent was not required to obtain samples</style></keyword><keyword><style face="normal" font="default" size="100%">from hospital surfaces.Not applicable.MG and CR are Directors of ATACAMALAB, a</style></keyword><keyword><style face="normal" font="default" size="100%">for profit Company aiming to develop energy efficient products including novel</style></keyword><keyword><style face="normal" font="default" size="100%">uses for copper.Springer Nature remains neutral with regard to jurisdictional</style></keyword><keyword><style face="normal" font="default" size="100%">claims in published maps and institutional affiliations.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><accession-num><style face="normal" font="default" size="100%">30627427</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Healthcare-associated infections (HAIs) have a major impact on public health worldwide. Particularly, hospital surfaces contaminated with bacterial pathogens are often the origin of both sporadic cases and outbreaks of HAIs. It has been demonstrated that copper surfaces reduce the microbial burden of high touch surfaces in the hospital environment. Here we report the antimicrobial characterization of a novel composite coating with embedded copper particles, named Copper Armour. Methods: The Copper Armour bactericidal activity was evaluated in in vitro assays against several bacterial pathogens, including Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli O157:H7 and Listeria monocytogenes. Additionally, its antimicrobial properties were also evaluated in a pilot study over a nine-week period at an adult intensive care unit. For this, four high touch surfaces, including bed rails, overbed table, bedside table and IV Pole, were coated with Cooper Armour, and its microbial burden was determined over a nine-week period. Results: Copper Armour coated samples showed an in vitro reduction in bacterial burden of &gt; 99.9% compared to control samples. Moreover, pilot study results indicate that Copper Armour significantly reduces the level of microbial contamination on high-touch surfaces in the hospital environment, as compared with standard surfaces. Conclusions: Based on its antimicrobial properties, Copper Armour is a novel self-sanitizing coating that exhibits bactericidal activity against important human pathogens and significantly reduces the microbial burden of hospital surfaces. This composite could be used as a self-sanitizing coating to complement infection control strategies in healthcare facilities.</style></abstract><notes><style face="normal" font="default" size="100%">2047-2994&#xD;Montero, David A&#xD;Arellano, Carolina&#xD;Pardo, Mirka&#xD;Vera, Rosa&#xD;Galvez, Ricardo&#xD;Cifuentes, Marcela&#xD;Berasain, Maria A&#xD;Gomez, Marisol&#xD;Ramirez, Claudio&#xD;Vidal, Roberto M&#xD;Orcid: 0000-0003-4223-1985&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Antimicrob Resist Infect Control. 2019 Jan 5;8:3. doi: 10.1186/s13756-018-0456-4. eCollection 2019.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6321648</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-018-0456-4</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>309</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">309</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muller, M. P.</style></author><author><style face="normal" font="default" size="100%">MacDougall, C.</style></author><author><style face="normal" font="default" size="100%">Lim, M.</style></author><author><style face="normal" font="default" size="100%">Armstrong, I.</style></author><author><style face="normal" font="default" size="100%">Bialachowski, A.</style></author><author><style face="normal" font="default" size="100%">Callery, S.</style></author><author><style face="normal" font="default" size="100%">Ciccotelli, W.</style></author><author><style face="normal" font="default" size="100%">Cividino, M.</style></author><author><style face="normal" font="default" size="100%">Dennis, J.</style></author><author><style face="normal" font="default" size="100%">Hota, S.</style></author><author><style face="normal" font="default" size="100%">Garber, G.</style></author><author><style face="normal" font="default" size="100%">Johnstone, J.</style></author><author><style face="normal" font="default" size="100%">Katz, K.</style></author><author><style face="normal" font="default" size="100%">McGeer, A.</style></author><author><style face="normal" font="default" size="100%">Nankoosingh, V.</style></author><author><style face="normal" font="default" size="100%">Richard, C.</style></author><author><style face="normal" font="default" size="100%">Vearncombe, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.P. Muller, 30 Bond Street, Toronto, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial surfaces to prevent healthcare-associated infections: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-13</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">silane</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial surface</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial therapy</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium contamination</style></keyword><keyword><style face="normal" font="default" size="100%">bloodstream infection</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">descriptive research</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">intervention study</style></keyword><keyword><style face="normal" font="default" size="100%">microbial contamination</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk reduction</style></keyword><keyword><style face="normal" font="default" size="100%">silver impregnation</style></keyword><keyword><style face="normal" font="default" size="100%">surface area</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">textile</style></keyword><keyword><style face="normal" font="default" size="100%">urinary catheter</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1532-2939&#xD;0195-6701</style></isbn><abstract><style face="normal" font="default" size="100%">Contamination of the healthcare environment with pathogenic organisms contributes to the burden of healthcare-associated infection (HCAI). Antimicrobial surfaces are designed to reduce microbial contamination of healthcare surfaces. We aimed to determine whether antimicrobial surfaces prevent HCAI, transmission of antibiotic-resistant organisms (AROs), or microbial contamination, we conducted a systematic review of the use of antimicrobial surfaces in patient rooms. Outcomes included HCAI, ARO, and quantitative microbial contamination. Relevant databases were searched. Abstract review, full text review, and data abstraction were performed in duplicate. Risk of bias was assessed using the Cochrane Effective Practice and Organization Care (EPOC) Group risk of bias assessment tool and the strength of evidence determined using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Eleven studies assessed the effect of copper (N = 7), silver (N = 1), metal-alloy (N = 1), or organosilane-treated surfaces (N = 2) on microbial contamination. Copper surfaces demonstrated a median (range) reduction of microbial contamination of &lt;1 log10 (&lt;1 to 2 log10). Two studies addressed HCAI/ARO incidence. An RCT of copper surfaces in an ICU demonstrated 58% reduction in HCAI (P = 0.013) and 64% reduction in ARO transmission (P = 0.063) but was considered low-quality evidence due to improper randomization and incomplete blinding. An uncontrolled before-after study evaluating copper-impregnated textiles in a long-term care ward demonstrated 24% reduction in HCAI but was considered very-low-quality evidence based on the study design. Copper surfaces used in clinical settings result in modest reductions in microbial contamination. One study of copper surfaces and one of copper textiles demonstrated reduction in HCAI, but both were at high risk of bias.</style></abstract><notes><style face="normal" font="default" size="100%">L606964874&#xD;2015-11-24&#xD;2019-10-31</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L606964874</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jhin.2015.09.008</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">26601608</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2015.09.008</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>468</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">468</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karbasizaed, V.</style></author><author><style face="normal" font="default" size="100%">Badami, N.</style></author><author><style face="normal" font="default" size="100%">Emtiazi, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V. Karbasizaed, Dept. of Pathobiology, Faculty of Heath Sciences, Tehran Univ. of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial, heavy metal resistance and plasmid profile of coliforms isolated from nosocomial infections in a hospital in Isfahan, Iran</style></title><secondary-title><style face="normal" font="default" size="100%">African Journal of Biotechnology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">African Journal of Biotechnology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">432-439</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">ampicillin</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">cadmium</style></keyword><keyword><style face="normal" font="default" size="100%">cefalotin</style></keyword><keyword><style face="normal" font="default" size="100%">chloramphenicol</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">gentamicin</style></keyword><keyword><style face="normal" font="default" size="100%">kanamycin</style></keyword><keyword><style face="normal" font="default" size="100%">lead</style></keyword><keyword><style face="normal" font="default" size="100%">mercury</style></keyword><keyword><style face="normal" font="default" size="100%">nalidixic acid</style></keyword><keyword><style face="normal" font="default" size="100%">tetracycline</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium isolation</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">coliform bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">feces analysis</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Iran</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">minimum inhibitory concentration</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">plasmid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">1684-5315</style></isbn><abstract><style face="normal" font="default" size="100%">The antimicrobial, heavy metal resistance patterns and plasmid profiles of Coliforms (Enterobacteriacea) isolated from nosocomial infections and healthy human faeces were compared. Fifteen of the 25 isolates from nosocomial infections were identified as Escherichia coli, and remaining as Kelebsiella pneumoniae. Seventy two percent of the strains isolated from nosocomial infections possess multiple resistance to antibiotics compared to 45% of strains from healthy human faeces. The difference between minimal inhibitory concentration (MIC) values of strains from clinical cases and from faeces for four heavy metals (Hg, Cu, Pb, Cd) was not significant. However most strains isolated from hospital were more tolerant to heavy metal than those from healthy persons. There was no consistent relationship between plasmid profile group and antimicrobial resistance pattern, although a conjugative plasmid (&gt;56.4 kb) encoding resistance to heavy metals and antibiotics was recovered from eight of the strains isolated from nosocomial infections. The results indicate multidrug-resistance coliforms as a potential cause of nosocomial infection in this region.</style></abstract><notes><style face="normal" font="default" size="100%">L38813896&#xD;2004-07-05</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L38813896</style></url><url><style face="normal" font="default" size="100%">http://www.academicjournals.org/AJB/</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>489</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">489</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berger, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.M. Berger, ASIC, CHUV, 1011 Lausanne, Suisse, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antioxidant functions of micronutriments in the general population and critically ill patients</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition Clinique et Metabolisme</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition Clinique et Metabolisme</style></full-title></periodical><pages><style face="normal" font="default" size="100%">125-132</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">free radical</style></keyword><keyword><style face="normal" font="default" size="100%">glutathione peroxidase</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult respiratory distress syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">animal model</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">atherosclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">burn</style></keyword><keyword><style face="normal" font="default" size="100%">malignant neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">critical illness</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">diet supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">head injury</style></keyword><keyword><style face="normal" font="default" size="100%">heart infarction</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pancreatitis</style></keyword><keyword><style face="normal" font="default" size="100%">selenium deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin intake</style></keyword><keyword><style face="normal" font="default" size="100%">zinc deficiency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1997</style></year></dates><isbn><style face="normal" font="default" size="100%">0985-0562</style></isbn><abstract><style face="normal" font="default" size="100%">The key role of micronutriments, i.e. vitamins and trace elements, in human health has been re-emphasised during the last decade, with the discovery of their free radical scavenging functions. The reactive oxygen species (ROS) are a normal product of aerobic metabolism, and are scavenged by endogenous antioxidants. But about 1% of the produced ROS escape cellular control; this leads to local damage to proteins, carbohydrates, lipids and nucleic acids. To correct the leaks in the system, one option is to increase the nutritionally provided antioxidants. Recent research has focused on three vitamins (vitamins A, E, and C), and on four trace elements (Cu, Mn, Se, Zn), the latter being essential for the activity of the superoxide dismutases and glutathione peroxidases. A mismatch between production and scavenging of ROS appears to the basic alteration behind the ageing process, it has also been incriminated in numerous, illnesses like arthritis, arteriosclerosis, cerebro-vascular, ischemic insults, various cancers, cataract, diabetes, mellitus, and viral infections. In the critically ill, increased ROS production contributes to genesis and persistence of alterations associated with pathologies in different as ARDS, myocardial infarction, acute renal failure, pancreatitis, brain injury, major trauma, burns, and those pathologies associated with a alternation of ischemia and reperfusion (e.g. organ transplantation, cardiac surgery with cardiopulmonary bypass). Epidemiological studies show that the recommended dietary intakes are not met in a large part of the general population. In the critically ill patient, the micronutriment status is further challenged by increased losses and metabolic requirements linked with tissue repair, thus leading to high risk of deficiency. Intervention studies strongly suggest that some chronic and acute illnesses, can be modulated by micronutriment supplements, including specially Se and vitamin E. Considering the high costs involved with the analysis of micronutrient, the low price of these nutriments, and the demonstration of low levels of endogenous antioxidants in most critically ill patients, the systematic prescription of a multi-vitamin and trace element cocktail appears justified already upon admission tot he ICU.</style></abstract><notes><style face="normal" font="default" size="100%">L27362274&#xD;1997-09-09</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L27362274</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">French</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>419</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">419</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vega Patin, R.</style></author><author><style face="normal" font="default" size="100%">Ceragioli Oliveira, F. L.</style></author><author><style face="normal" font="default" size="100%">De Menezes Succi, R. C.</style></author><author><style face="normal" font="default" size="100%">Silverio Amancio, O. M.</style></author><author><style face="normal" font="default" size="100%">Thome Barbosa Gouvea, A. D. F.</style></author><author><style face="normal" font="default" size="100%">Zanin Palchetti, C.</style></author><author><style face="normal" font="default" size="100%">MacHado, D. M.</style></author><author><style face="normal" font="default" size="100%">Ancona Lopez, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Zanin Palchetti, Universidade Federal de Sao Paulo, UNIFESP, EPM, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antioxidant nutritional status and superoxide dismutase (SOD) levels in school-aged children infected with human immunodeficiency virus</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e72</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">C reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">trans fatty acid</style></keyword><keyword><style face="normal" font="default" size="100%">polyunsaturated fatty acid</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">CD4 antigen</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">school</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">city</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">sibling</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">immune deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">fat intake</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">virus load</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1201-9712</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Antioxidant micronutrients play an important role in HIV infection. Deficiencies of micronutrients are associated with immune deficiency, rapid disease progression and mortality. The aim of the study was evaluate antioxidant nutritional status in prepubertal school-aged children in two situations: HIV exposure and the control group. Methods: Prospective transversal study including 51 HIV-infected children attended at the Pediatric Infectious Disease Clinic - Universidade Federal de Sao Paulo, Sao Paulo city, Brazil and their respective exposed siblings not infected by HIV (n = 31) and the ones not exposed to HIV (n = 32). Antioxidant substances related to the clinical, dietary and biochemical variables in the groups were evaluated. Results: Vitamin A, C, E, beta-carotene, licopene, zinc and copper intake and plasma levels of vitamins A, C, E, beta-carotene, serum copper and superoxide dismutase (SOD) and protein C reactive, did not significantly differ in the groups. Major probability of vitamin A inadequacy was identified in the HIV-infected group (43.1%) as well as in the exposed but non-infected by HIV (48.4%), when compared to the non-exposed to HIV (37.5%) (P &gt; 0.05). Lower rates of dietary vitamin E in HIV-infected children with inadequate trans fatty acid intake (P &lt; 0.005) were verified. In the three studied groups, vitamin E correlated to the dietary saturated and polyunsaturated fatty acid (P &lt; 0.007). Lower rates of the erythrocyte and serum zinc (P &lt; 0.02) were verified in the HIV-infected children, when compared to the other groups. In the same group, correlation between dietary and biochemical values for vitamin C (r = 0.34; P = 0.01) and serum zinc (r = 0.37; P = 0.008); serum copper with SOD (r = 0.30) and with serum zinc (r = 0.43) and an inverse correlation of the erythrocyte zinc with the serum copper (r = -0.31) and with SOD (r = -0.50) were found. Plasma levels of vitamin E, licopene and betacarotene were related to CD4 count (P &lt; 0.05) but negatively to the viral load (P &lt; 0.02). Conclusion: HIV-infected school-aged children without severe infectious processes in the last year presented oxidative stress by the chronic viral infection, allied to infectious processes, promoting increase in the demand of antioxidant. Interdisciplinary accompaniment has become essential, emphasizing adequate dietary in antioxidant micronutrient intake by HIV-infected children.</style></abstract><notes><style face="normal" font="default" size="100%">L70125227&#xD;2010-05-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70125227</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ijid.2010.02.1648</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijid.2010.02.1648</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>495</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">495</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fuchs, J.</style></author><author><style face="normal" font="default" size="100%">Schofer, H.</style></author><author><style face="normal" font="default" size="100%">Ochsendorf, F.</style></author><author><style face="normal" font="default" size="100%">Janka, S.</style></author><author><style face="normal" font="default" size="100%">Milbradt, R.</style></author><author><style face="normal" font="default" size="100%">Buhl, R.</style></author><author><style face="normal" font="default" size="100%">Unkelbach, U.</style></author><author><style face="normal" font="default" size="100%">Freisleben, H. J.</style></author><author><style face="normal" font="default" size="100%">Oster, O.</style></author><author><style face="normal" font="default" size="100%">Siems, W.</style></author><author><style face="normal" font="default" size="100%">Grune, T.</style></author><author><style face="normal" font="default" size="100%">Esterbauer, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Fuchs, Department of Dermatology, University Hospital, Theodor-Stern-Kai 7, 6000 Frankfurt 70, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antioxidants and peroxidation products in the blood of HIV-1 infected patients with HIV associated skin diseases</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Dermatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">148-153</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">beta glucuronidase</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">glutathione</style></keyword><keyword><style face="normal" font="default" size="100%">glutathione peroxidase</style></keyword><keyword><style face="normal" font="default" size="100%">malonaldehyde</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">xanthine oxidase</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus 1</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">skin disease</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year></dates><isbn><style face="normal" font="default" size="100%">1167-1122</style></isbn><abstract><style face="normal" font="default" size="100%">The objective of this study was to investigate the hypothesis that HIV infected patients are in oxidative imbalance. In an open study we analyzed enzymic, and small molecular, lipophilic, and hydrophilic antioxidants, as well as lipid peroxidation products in the blood of HIV infected patients. All patients were seen at the Department of Dermatology, Frankfurt University Hospital, Germany and treated for HIV associated skin problems. Twenty-six HIV-1 infected patients (T helper cells &gt; 200/ul = group A, T helper cells &lt; 200/ul = group B), aged 24-49 years, were investigated; their laboratory parameters were compared with controls of a comparable age group. Antioxidant deficiencies and elevated concentrations of peroxidation products were suspected in the study participants prior to data collection. A statistically significant decrease in total plasma glutathione, plasma thiols, and plasma ascorbate was observed in the patients in group A. In addition, erythrocyte glutathione peroxidase activity and serum selenium were significantly low in patients group B. The plasma lipid peroxidation product 4-hydroxynonenal was significantly increased in patients group A and B. In conclusion HIV infected patients are in oxidative imbalance and there is evidence of molecular damage, which manifests early following HIV infection.</style></abstract><notes><style face="normal" font="default" size="100%">L24106115&#xD;1994-04-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L24106115</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">75</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prado, J. V.</style></author><author><style face="normal" font="default" size="100%">Vidal, A. R.</style></author><author><style face="normal" font="default" size="100%">Duran, T. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Programa de Microbiologia, Instituto de Ciencias Biomedicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile. vprado@med.uchile.cl</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Application of copper bactericidal properties in medical practice]</style></title><secondary-title><style face="normal" font="default" size="100%">Rev Med Chil</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rev Med Chil</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1325-32</style></pages><volume><style face="normal" font="default" size="100%">140</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2013/04/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Chile</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Aplicacion de la capacidad bactericida del cobre en la practica medica.</style></orig-pub><isbn><style face="normal" font="default" size="100%">0034-9887</style></isbn><accession-num><style face="normal" font="default" size="100%">23559292</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Copper is essential for cell metabolism in animals and plants and thus for life. Along centuries, copper has been identified as a metal containing antimicrobial properties. In recent years, laboratory assays and clinical studies have revealed that surfaces of metallic copper or its alloys, containing at least 70% copper, eliminate in a few hours several pathogenic organisms including bacterial strains associated with nosocomial infections, influenza virus, HIV, and fungi such as Candida albicans. In March 2008, the American Environmental Protection Agency (EPA), supported by scientific evidence gathered to date, registered copper as the first and only metal with antimicrobial properties. We herein review certain mechanisms proposed for the antibacterial, antiviral and antifungal activity of copper. We also discuss in vitro and clinical efficacy studies developed world wide and in Chile, focusing on bactericidal activity of copper surface areas in comparison to materials typically used in hospital environments such as stainless steel and polymers. Scientific evidence gathered to date, consistently shows that the use of copper surface areas in high contact critical points in hospitals, significantly reduces environmental bacterial load. This is associated with a decreased risk of pathogen transmission to patients and represents therefore an interesting complement to infection control programs.</style></abstract><notes><style face="normal" font="default" size="100%">0717-6163&#xD;Prado J, Valeria&#xD;Vidal A, Roberto&#xD;Duran T, Claudia&#xD;English Abstract&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Chile&#xD;Rev Med Chil. 2012 Oct;140(10):1325-32. doi: 10.4067/S0034-98872012001000014.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4067/s0034-98872012001000014</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">spa</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>289</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Almeida, D.</style></author><author><style face="normal" font="default" size="100%">Cristovam, E.</style></author><author><style face="normal" font="default" size="100%">Caldeira, D.</style></author><author><style face="normal" font="default" size="100%">Ferreira, J. J.</style></author><author><style face="normal" font="default" size="100%">Marques, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D. Almeida, Laboratory of Microbiology and Molecular Biology, Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira, 126, Lisboa, Portugal</style></auth-address><titles><title><style face="normal" font="default" size="100%">Are there effective interventions to prevent hospital-acquired Legionnaires&apos; disease or to reduce environmental reservoirs of Legionella in hospitals? A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e183-e188</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">chlorination</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Cochrane Library</style></keyword><keyword><style face="normal" font="default" size="100%">hospital acquired pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">Medline</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk reduction</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1527-3296&#xD;0196-6553</style></isbn><abstract><style face="normal" font="default" size="100%">Background Legionnaires&apos; disease (LD) is recognized as an important hospital-acquired disease. Despite the several methods available, the optimal method to control hospital-acquired LD is not well established and their overall efficacy requires further evaluation. Objective To systematically review all controlled trials evaluating the efficacy of interventions to prevent hospital-acquired LD in patients at high risk of developing the disease and its effects on environmental colonization. Methods A database search was performed through PubMed and the Cochrane Central Register of Controlled Trials (inception-November 2014). Eligible studies included all controlled studies evaluating interventions to prevent hospital-acquired LD in patients at high risk or evaluating the effect on environmental colonization. Both individual and pooled risk estimates were reported using risk ratio (RR) and 95% confidence intervals (95% CIs). Results There were no studies evaluating the risk reduction in hospital-acquired LD, but 4 studies evaluated the influence of copper-silver ionization and ultraviolet light in the reduction of environmental reservoirs of Legionella. The meta-analysis showed a significant 95% risk reduction of Legionella positivity in environmental samples using copper-silver ionization (RR, 0.05; 95% CI, 0.01-0.17) and 97% risk reduction with ultraviolet light (RR, 0.03; 95% CI, 0.002-0.41). Conclusions The best available evidence suggests that copper-silver ionization and ultraviolet light are effective in reducing Legionella positivity in environmental samples. Nevertheless, the low quality of evidence weakens the robustness of conclusions.</style></abstract><notes><style face="normal" font="default" size="100%">L611694042&#xD;2016-08-22&#xD;2016-11-14</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L611694042</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2016.06.018</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">27524259</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2016.06.018</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>434</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">434</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ritchie, P.</style></author><author><style face="normal" font="default" size="100%">Coppock, D.</style></author><author><style face="normal" font="default" size="100%">Ward, L.</style></author><author><style face="normal" font="default" size="100%">Ferrato, C.</style></author><author><style face="normal" font="default" size="100%">Roles, A.</style></author><author><style face="normal" font="default" size="100%">Ceri, H.</style></author><author><style face="normal" font="default" size="100%">Drinkwater, D.</style></author><author><style face="normal" font="default" size="100%">Louie, T.</style></author><author><style face="normal" font="default" size="100%">Louie, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Ritchie, Calgary Health Region, Calgary, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment of Copper Silver Ionization (CSI) to control waterborne Legionella in Calgary Health Region (CHR) patient care settings</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S80</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">tap water</style></keyword><keyword><style face="normal" font="default" size="100%">ion</style></keyword><keyword><style face="normal" font="default" size="100%">agar</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword><keyword><style face="normal" font="default" size="100%">emergency care</style></keyword><keyword><style face="normal" font="default" size="100%">tube</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">water quality</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">vacuum</style></keyword><keyword><style face="normal" font="default" size="100%">membrane</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">fluorescence analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">0924-8579</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives Legionella pneumophila is a water borne pathogen, known to reside in biofilms especially in aged distribution systems where old pipes and stagnant water exist. A nosocomial outbreak of legionellosis in a 40 year old CHR hospital initiated the use of CSI to control the microbial burden in four CHR acute care facilities. This study describes water quality monitoring for L. pneumophila in these four facilities before and after the implementation of CSI. Methods Hospitals H1, H2, H3, and H4 have antiquated water distribution systems with holding tanks and segments of pipes having no flow. Copper-silver ionization units (LiquiTech®) were installed in all four hospitals between 2004-2005. Copper and silver ion concentrations were maintained at levels optimal for decreasing Legionella colonization by the ionizer units and verified weekly using a colorimeter kit (LiquiTech®); and tested every 3-4 months by an external party (AGAT Laboratories). Endpoints of the water distribution system was monitored by collection of potable tap water before (n = 997) and after (n = 1360, cumulative at quarterly intervals) ionizers were installed. One liter water samples were obtained and tested within 24 hours of collection. Samples were vacuum-filtered through 0.22 μm membrane and re-suspended in 10mL of sterile water. 100 μL of suspension was planted to BCYE and BCYE-PCV agar for the detection of Legionella and cultured for up to 7 days. Colonies suspicious for L. pneumophila were Gram stained, and confirmed using an Immuno Fluorescence Assay kit (BioRad, WA). Results Of the samples taken before CSI, 16.9% (84/497), 69.9% (93/133), 52.5% (32/61) and 28.1% (86/306) of H1, H2, H3, and H4 samples respectively were found to be positive for L. pneumophila. After one year of CSI, only 1.84% (11/597) of all hospital sites tested were positive. Both H1 and H4 had one site each with low counts of L. pneumophila up until the third year post CSI. By the fourth year post CSI, no L. pneumophila was detected in any of the 200 samples collected. Conclusions L. pneumophila is readily detected within antiquated water systems of acute care facilities. CSI of water systems dramatically reduced Legionella in all four hospitals within a year of implementation, and eradicated culturable levels of Legionella in all four hospitals by the fourth year.</style></abstract><notes><style face="normal" font="default" size="100%">L70141137&#xD;2010-05-25</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70141137</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Bacteria cut by &apos;up to 95%&apos; in copper trial</style></title><secondary-title><style face="normal" font="default" size="100%">Health Estate</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Estate</style></full-title></periodical><pages><style face="normal" font="default" size="100%">58-9</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2008/12/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Organizational Case Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">19044152</style></accession-num><abstract><style face="normal" font="default" size="100%">The first results from an 18-month trial at Birmingham&apos;s Selly Oak Hospital, which has seen a range of items in one ward, including taps, door handles, sink fittings, push plates and light switches made from &quot;conventional&quot; plastic and stainless steel materials substituted with copper replacements, has proven beyond doubt the metal&apos;s effectiveness in destroying pathogens in a clinical environment. Health Estate Journal reports.</style></abstract><notes><style face="normal" font="default" size="100%">Journal Article&#xD;England&#xD;Health Estate. 2008 Nov;62(10):58-9.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>147</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cooney, T. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hamot Medical Center Research Department, Erie, Pennsylvania 16550, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bactericidal activity of copper and noncopper paints</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">444-50</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">1995/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecalis/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Facility Design and Construction/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Paint</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">7594390</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To screen copper and noncopper paints for their bactericidal effectiveness in rendering surfaces self-disinfecting. DESIGN: Tested paints were applied to glass coverslips, cured, inoculated with test organisms (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Enterococcus faecalis), and dried. After 0, 24, or 48 hours, surviving organisms were eluted and enumerated, and counts compared with those obtained from inoculated control (unpainted) coverslips for the corresponding time periods. Copper elution from select copper paints was quantified by complete immersion of coated coverslips followed by spectroscopic analysis to infer a threshold relationship between kill and copper release. RESULTS: Nearly all of the tested copper paints were capable of reducing organism counts to negligible levels within 24 hours. Exterior latex paints supplemented with a fungicide were similarly efficacious. Standard interior latex paint reduced bacterial counts to nearly zero within 24 hours for E coli and P aeruginosa, and to zero within 48 hours for E faecalis. However, substantial survival of S aureus occurred (up to 4 logs at 24 hours). Chi-squared analysis of elution and cidal data indicated that lethality was dependent on copper release in excess of 32 micrograms. CONCLUSION: The data support presumptive bactericidal claims for several copper and noncopper paints. Despite controversy over environment-based contagion, such paints could be used to render surfaces self-disinfecting in strategic locations where environmental causation of nosocomial infections is suspected.</style></abstract><notes><style face="normal" font="default" size="100%">Cooney, T E&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Infect Control Hosp Epidemiol. 1995 Aug;16(8):444-50. doi: 10.1086/648361.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/648361</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>259</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">259</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mori, T.</style></author><author><style face="normal" font="default" size="100%">Kato, J.</style></author><author><style face="normal" font="default" size="100%">Yamazaki, R.</style></author><author><style face="normal" font="default" size="100%">Okamoto, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Mori, Division of Hematology, Keio University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bactericidal effect of copper alloys applied to door handles in hematology/stem cell transplant units</style></title><secondary-title><style face="normal" font="default" size="100%">Biology of Blood and Marrow Transplantation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biology of Blood and Marrow Transplantation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S393-S394</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus subtilis</style></keyword><keyword><style face="normal" font="default" size="100%">bactericidal activity</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">coagulase negative Staphylococcus</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Corynebacterium</style></keyword><keyword><style face="normal" font="default" size="100%">hematology</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human cell</style></keyword><keyword><style face="normal" font="default" size="100%">Japan</style></keyword><keyword><style face="normal" font="default" size="100%">Moraxella</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">opportunistic infection</style></keyword><keyword><style face="normal" font="default" size="100%">stem cell</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1523-6536</style></isbn><abstract><style face="normal" font="default" size="100%">Background: The horizontal transmission through highly touched surfaces such as door handles in healthcare institutes is one of the important targets for infection control. Therefore, efforts to reduce environmental bioburden have been made to reduce health care-associated infection. Copper has been shown to possess bactericidal activity, and has been increasingly introduced to healthcare institutes. In this study, the bactericidal effect of copper alloy on door handles in hematology/stem cell transplant units was evaluated. Materials and methods: In the hematology/stem cell transplant unit of Keio University Hospital (Tokyo, Japan), door handles in three unitswere replaced with copper-impregnated handles. The samples obtained fromthe surface of the handles by using a commercially available sterile swab kit (Japan Becton Dickinson, Tokyo, Japan) were applied to bacterial culture and detected bacterium were identified by standard methods. Control samples were obtained from the standard door handles in the same ward. Results: In total, 18 samples were obtained from copperimpregnated handles and 12 from the control handles. Only 4 (22%) of 18 samples from surfaces of copper impregnated handles grew bacteria, while 100% of those from control handles did so (P &lt; .0001). The median number of colony forming units per ml was 0 (range, 0-220) in copperimpregnated handles, which was significantly lower than 300 (range, 40-1.1 × 10E6) in the control handles (P &lt; .0001). The detected isolates were Bacillus subtilis in copper-impregnated handles, while they were variable, including Bacillus subtilis, Moraxella osloensis, Coagulase-negative Staphylococcus, Corynebacterium sp. Conclusion: Copper-impregnated composite showed a significant bactericidal effect on the highly touched door handles in hematology/stem cell transplant units as compared with the standard material. Copper alloy could be a promising material with self-disinfecting activity, contributing to the reduction of opportunistic infection in healthcare institutes.</style></abstract><notes><style face="normal" font="default" size="100%">L621900090&#xD;2018-05-02</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L621900090</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mori, T.</style></author><author><style face="normal" font="default" size="100%">Kikuchi, T.</style></author><author><style face="normal" font="default" size="100%">Sakurai, M.</style></author><author><style face="normal" font="default" size="100%">Kato, J.</style></author><author><style face="normal" font="default" size="100%">Koda, Y.</style></author><author><style face="normal" font="default" size="100%">Abe, R.</style></author><author><style face="normal" font="default" size="100%">Sumiya, C.</style></author><author><style face="normal" font="default" size="100%">Yamazaki, R.</style></author><author><style face="normal" font="default" size="100%">Sugita, K.</style></author><author><style face="normal" font="default" size="100%">Hasegawa, N.</style></author><author><style face="normal" font="default" size="100%">Okamoto, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Hematology, Department of Medicine, Keio University School of Medicine.&#xD;Center for Infectious Disease and Infection Control, Keio University Hospital.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Bacteriocidal effects of introducing copper products on highly touched areas in hematology ward]</style></title><secondary-title><style face="normal" font="default" size="100%">Rinsho Ketsueki</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rinsho Ketsueki</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3-6</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/02/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Hematology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital Departments</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriocidal effect</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital environment</style></keyword><keyword><style face="normal" font="default" size="100%">Nosocomial infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">0485-1439 (Print)&#xD;0485-1439</style></isbn><accession-num><style face="normal" font="default" size="100%">30726821</style></accession-num><abstract><style face="normal" font="default" size="100%">Nosocomial infection via the hospital environment is a serious problem, and highly touched surfaces are the main route of transmission. Copper has been reported to possess bacteriocidal effects, and the introduction of copper-impregnated products is receiving attention as a potential component of hospital infection control. In this study, copper-impregnated door handles as highly touched areas were introduced in a hematology ward, and their bacteriocidal effects were evaluated in comparison with conventional products. All 12 samples obtained from conventional door handles were positive for bacterial cultures, whereas only 5 of 18 samples from copper-impregnated handles were positive (P&lt;0.0001). The mean number of bacterial colonies per milliliter of sample was 300 (range: 40-1.1x10(6)) in samples from conventional handles, but it was significantly lower in samples from copper-impregnated handles (0; range: 0-220, P&lt;0.0001). While various types of bacteria grew on conventional handles, most of the bacteria on copper-impregnated handles were Bacillus subtilis. These results suggest that the introduction of copper-impregnated products would be useful for hospital infection control by reducing the bacterial burden on highly touched areas. However, the efficacy of this approach against spore-forming bacteria should be further investigated.</style></abstract><notes><style face="normal" font="default" size="100%">Mori, Takehiko&#xD;Kikuchi, Taku&#xD;Sakurai, Masatoshi&#xD;Kato, Jun&#xD;Koda, Yuya&#xD;Abe, Ryohei&#xD;Sumiya, Chieko&#xD;Yamazaki, Rie&#xD;Sugita, Kayoko&#xD;Hasegawa, Naoki&#xD;Okamoto, Shinichiro&#xD;Journal Article&#xD;Japan&#xD;Rinsho Ketsueki. 2019;60(1):3-6. doi: 10.11406/rinketsu.60.3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.11406/rinketsu.60.3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>208</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Balanced Protein-Energy Supplement in Pregnancy and Early Lactation on Birth Outcomes and Growth in Southern Nepal</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT03668977</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT03668977</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Malnutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01706471</style></accession-num><abstract><style face="normal" font="default" size="100%">Background Undernourished women in many low and middle income countries (LMICs) enter pregnancy with low nutritional reserves, and low maternal body mass index (BMI) and short stature are associated with increased risks of a variety of adverse reproductive outcomes (Kozuki et al., 2015; Rahman et al., 2015). Balanced protein‐energy (BE‐P) supplementation during pregnancy shows moderate evidence than such dietary supplementation can decrease the risk of stillbirth and small‐for‐gestational‐age (SGA) births (Ota et al., 2015; Stevens et al., 2015). The WHO antenatal care guidelines recommend providing pregnant women in undernourished populations with balanced protein energy dietary supplementation (WHO, 2016). The current evidence base for BP‐E supplementation draws from a number of studies where BP‐E supplements varied widely in composition and form (Imad &amp; Bhutta, 2002). Recent studies using fortified blended foods found that although approximately 800 kcal/d was provided, the net energy intake increased by a much smaller amount (200‐300 kcal) (Janmohamed et al., 2016; Saville et al., unpublished trial in Nepal). Evidence regarding dietary practices and preferences among pregnant women in Nepal is generally limited, however, some studies have shown that intra‐household food allocation and specific food beliefs/behaviors do not favor adequate energy or micronutrient intake among adolescent girls and adult women (Gittelsohn, 1991; Gittelsohn et al., 1997). Christian et al showed that staple food intake can be reduced during pregnancy; which could be attributed to an aversion to food, lack of appetite, feeling unwell, or concern regarding having a &quot;large&quot; baby and difficulties with labor and delivery (Christian et al., 2006). Low nutrition knowledge may also play a role in suboptimal intake among women (Jones et al., 2005). Uptake of reproductive health services and antenatal care has increased dramatically over the past 15 years in Nepal (Ministry of Health, 2017). Approximately 80% of rural women report attending at least one antenatal care visit, but this varies by socioeconomic status (SES) with lower SES women significantly less likely to present for antenatal care (Ministry of Health, 2017; Furuta &amp; Salway, 2006). Use of antenatal care (ANC) is also influenced by other household members, especially the mother‐in‐law (Simkhada et al., 2010). A randomized study has shown that participation in women&apos;s groups can improve antenatal care uptake in Nepal (Manandhar et al., 2004). This finding, together with the government&apos;s incentive scheme for improving rates of facility deliveries, have likely played a large role in the improving use of antenatal care services in Nepal. These dynamic changes in access and use of services offer the opportunity to nest additional nutritional support services within the antenatal care system, including BP‐E supplementation. However, information is limited regarding practices and preferences for delivery of such nutritional supplements and the impact such supplementation will have on the key birth outcomes that affect child health and development. It is this lack of evidence that this project will address. Methods This project will be done in three phases. Phase one will identify preferable supplement types for use in pregnancy in the South Asian context. Phase two will use the results of phase one to conduct a medium‐term feeding trial to assess acceptability and consumption. Phase three will be a large, community‐based randomized trial using one of these supplement options for use in pregnancy and through the first 6 months post‐partum on birth outcomes and early infant growth. Specific Aim, Phase 1: Identify preferred product types for the provision of fortified BEP supplements among pregnant women in Southern Nepal. Specific Aim, Phase 2: Assess the 8‐week acceptability and consumption of 2 selected supplements with nutrient content consistent with Bill and Melinda Gates Foundation (BMGF) guidance among pregnant women in Southern Nepal. Specific Aims hase 3: Community‐Based Randomized Field Trial There is one primary aim and a number of secondary aims for each marginal treatment arm of this trial. Primary aims: 1. To compare the incidence of small‐for‐gestational‐age (SGA) newborn infants born to mothers randomized to receive either a daily balanced protein‐energy nutritional supplement with multiple micronutrients or control during pregnancy. SGA will be defined as &lt;10th centile of birthweight for gestational age standard using InterGrowth 21st criteria (Villar et al., 2014). 2. To compare the growth of live‐born infants among mothers randomized to the two groups during the first 6 months post‐partum. The primary infant growth outcome is Length‐for‐Age Z (LAZ) score using the WHO Child Growth Study criteria (WHO, 2006). Secondary aims: Pregnancy Supplementation 1. To compare the incidence of short‐for‐gestational‐age (ShGA) newborn infants born to mothers randomized to the two groups during pregnancy. ShGA defined as &lt;10th centile of birth length for gestational age standard using InterGrowth 21st criteria. 2. To compare the incidence of small‐for‐gestational‐age (SGA) newborn infants born to mothers randomized to the two groups during pregnancy. SGA defined as &lt;3rd centile of birthweight for gestational age standard using InterGrowth 21st criteria. 3. To compare the incidence of short‐for‐gestational‐age (ShGA) newborn infants born to mothers randomized to the two groups during pregnancy. ShGA defined as &lt;3rd centile of birth length for gestational age standard using InterGrowth 21st criteria. 4. To compare the means and distribution of birth weight, birth length and gestational age (and percent &lt;2500 gm, &lt;37 weeks gestation) in infants born to women randomized to the two groups during pregnancy. 5. To compare the growth through 6 and 12 months of age (LAZ, weight‐for‐age Z (WAZ), weight‐for‐length Z (WLZ) scores) of infants born to women randomized to the two groups during pregnancy. 12 months follow‐up will be available on approximately 2/3rd of infants. 6. To compare the composition of breastmilk and the volume of a 24 hour feeding among women randomized to the two groups during pregnancy. 7. To compare maternal weight gain during pregnancy among women randomized to the two groups during pregnancy. Post‐Partum Supplementation 1. To compare WAZ and WLZ scores through 6 and 12 months of age of infants born to women randomized to receive either a daily balanced protein‐energy nutritional supplement or control during the first 6 months post‐partum. 12 months follow‐up will be available on approximately 2/3rd of infants and women. 2. To compare the composition of breastmilk and the volume of a 24 hour feeding among women randomized to the two groups during the first 6 months post‐partum. 3. To compare the weight and BMI of mothers at 6 and 12 months post‐partum among women randomized to the two groups during the first 6 months post‐partum. 12 months follow‐up will be available on approximately 2/3rd of mothers. Combination of Pregnancy and Post‐Partum Supplementation 1. To compare the impact of combined pregnancy and post‐partum nutritional supplementation with women who received only pregnancy or post‐partum supplementation alone on LAZ, WAZ, and WLZ scores at 6 and 12 months of age among infants born to these mothers. 12 months follow‐up will be available on approximately 2/3rd of infants. Study Design for Phases 1 &amp; 2: A two‐phase, mixed methods approach combining qualitative and quantitative methods for data collection will be used. Phase 1: 11 product types will be introduced to participants in a single‐meal test for their feedback on acceptability. Phase 1 will collect data to describe general preferences across product types and variations. Phase 2: 2 product types identified in Phase 1 will be tested in an 8‐week feeding trial. Each participating woman will experience one selected product type for a total of 8 weeks. Hedonic properties will be assessed at 2 and 8 weeks. Complementary ualitative data will also be collected using in‐depth interviews and focus group discussions during both phases 1 and 2. Setting for all Phases This project will be conducted in a chronically food insecure study site in southern Nepal (Sarlahi District). This site is representative of a region (South Asia) and meets the criteria of having adequate local security conditions and presence of a strong field research site. Study population and sample size estimates Pregnant Women (PW): In Phase 1, a convenience sample of 40 PW will be selected to evaluate 11 product types. In Phase 2, women participating in the home feeding trial (n = 40 for each of two product types, total n=80) will additionally participate in in‐depth interviews. Sample size for in‐depth interviews and focus group discussions is a maximum of 40 women (Kodish et al., 2014; Sandelowski et al., 2000; Bernard, 2006). Community &amp; household Influencers : In Phase 2, we will recruit key influencers who may help to add information on the potential determinants of acceptability and utilization by supplement type. Those individuals may include community leaders, health providers, husbands, in‐laws and health staff. Data Collection: Phases 1 &amp; 2: Phase 1. Identify preferred product types Direct observation of single meal with hedonic testing: During the single meal observation, each participant will receive 1 serving of each product. Acceptability will be assessed based on Likert‐like scoring using hedonic scales of overall liking, appearance, smell, taste and consistency. Focus group discussion: Focus groups (maximum of 40 women) will be conducted following the single meal direct observation. Phase 2. Home‐feeding trial to assess acceptability and at‐home consumption Two product types selected in Phase 1 will be assessed for medium‐term acceptability and utilization through an 8‐week feeding trial. Two measures of adherence will be assessed at each weekly home distribution; adherence in the last 24 hours using direct questioning and adherence using direct sachet/packet count. Hedonic testing: Hedonic testing will be repeated at 2 and 8 weeks (de Graaf et al., 2005). Direct observations of household meals: Direct observations will be used to understand supplement utilization, sharing and general household dietary behaviors (Bernard, 2006). Women will have two 12‐hour home observations. In‐depth interviews: For both products, interviews will be conducted with PW and other household members, community leaders, and health staff. Focus group discussions: Focus groups among PW receiving both products will be conducted at the end of Phase 2. Data analysis, Phases 1 &amp; 2: Adherence data: Adherence by self‐report will be calculated as the percentage of days the supplement was reported to be consumed and mean portion when consumed, and adherence by sachet count will be calculated as total empty packages returned divided by total packages expected to be consumed. Hedonic test data: Product liking, and left over quantities over time will be summarized by product type using means for continuous variables. Qualitative data: All qualitative data will be transcribed and translated into English. Analysis will be ongoing throughout data collection, and conducted by the research team using an exploratory, inductive approach that will draw from Grounded Theory and allow for the analysis of emergent themes (Charmaz, 2014; Ridder et al., 2014; Charmaz, 2006). Data will be systematically coded using Dedoose computer software (Consultants, 2016) (Glesne &amp; Peshkin, 1992). Phase 3: Cluster Randomized Trial Design The design of this study is a community‐based, cluster‐randomized 2x2 factorial trial among women who become pregnant in the study area over a 9 month period. Follow‐up will be through 6 months post‐partum for women and their infants. Study Population The study population for this trial will include all women who become pregnant during a 9‐month period in a set of Palikas in Sarlahi District, Nepal. Newly pregnant women will be identified through a p egnancy surveillance system. Cluster Formation Palikas in Nepal are divided into multiple wards. We will limit participation to high‐yield wards (clusters) that will provide an average of 22.3 (SD = 16.0) eligible live births per ward who can be measured within 72 hours of delivery over the 9 month enrollment period. Intervention Two interventions strategies will be tested in a factorial design in this trial; nutritional supplementation during pregnancy and nutritional supplementation during the first 6 months post‐partum. The intervention product will be a daily fortified balanced protein‐energy nutritional supplement. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the BMGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). Women in clusters allocated to the control groups will receive a standard package of antenatal services and nutritional counseling by study staff. In all four groups, the following antenatal and post‐natal interventions will be offered: ‐ Women will be encouraged to enroll in routine antenatal care at their local health post/center. ‐ A clean birthing kit will be provided consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump. ‐ Women will be encouraged to deliver at a certified birthing facility and participate in the government&apos;s incentive scheme. ‐ Additional nutritional, hygiene, and infant care counseling will be provided by study staff. ‐ If a woman reports not attending ANC and/or not receiving tetanus toxoid or iron‐folic acid supplements, our study staff will provide them. Masking While it will not be possible to mask the participants or the Ward Data Collectors to the treatment assignment, we will attempt to mask the birth and growth assessment teams to the treatment assignments. Randomization Randomization will be done in a transparent manner with involvement of senior study staff and local officials. Geographic clusters (wards) will be assigned a specific number 1 through 72. Identically sized paper slips with numbers 1 through 72 will be prepared and placed in an opaque container. Senior study staff and local officials will draw individual slips from the container in a masked fashion until 18 have been selected. These 18 clusters will constitute treatment group 1. The other 54 clusters will be assigned to treatment groups 2 through 4 using the same process. Next, 4 identically sized paper slips will be prepared, one indicating the active supplementation group in pregnancy only, one the active supplementation group post‐partum only, one the active supplementation group in both periods, and one the control group in both periods. These slips will be placed in the opaque container and the District Public Health Officer will draw one slip at a time in a masked fashion to assign treatment groups 1 to 4. T Biospecimen Sub‐study A random sample of participating women will be selected from each of the 4 groups for inclusion in this sub‐study. Blood will be collected 3 times (baseline, ~34 weeks gestation, and 3‐4 months post‐partum). Breastmilk will be collected twice during lactation, once between months 1 &amp; 2 and again between months 3 &amp; 4. Infant stool will be collected twice during early infancy at the same time a breastmilk collection. Maternal blood will be assessed for hemoglobin and a variety of nutrients. The nutrients to be assessed in breastmilk include vitamins A, E, B6, B12, Riboflavin, Thiamin, Niacin, Choline, Biotin and minerals Iron, Zinc, Copper and Selenium. Macronutrients will include fat, lactose and total protein. The infant intestinal microbiome will be assessed for diversity and specific pathogens. Dietary Intake Sub‐Study A random sample of 60 women in each group during pregnancy and again in the post‐partum groups will be selected to participate in this dietary in ake sub‐study. The purpose is to assess whether there is significant dietary diversion occurring in the supplementation groups compared with controls. We will use daily energy and protein intake as the primary indicators of diversion. A quantitative 24‐hour recall instrument will be used (Sudo et al, 2006; Parajuli et al, 2012; Campbell et al, 2014; Henjum et al, 2015). Sample Size / Power Calculations These calculations assume the nutritional supplementation in pregnancy and post‐partum periods have independent effects on the outcomes of interest. Clearly, outcomes of pregnancy cannot be affected by nutritional supplementation given only after birth, but infant growth may be affected by supplementation during both time periods. Primary Outcomes: Small‐for‐gestational‐age (SGA) is the primary outcome that we have used to drive the sample size calculations. Over a period of 9 months, we expect that clusters will provide an average of 22.3 (SD = 16.2) pregnancy outcome measures. We used Intergrowth21 standards to estimate the overall proportion of SGA (10th percentile) among 14,468 infants in similar clusters in a previous study; 41.3% were SGA ((k=0.107). In the table below, we show the number of clusters needed (in each group) to detect a 22.5% reduction in SGA with 80% and 90% power using the approach described by Hayes/Moulton, 2009. We have chosen a 22.5% reduction as the minimally important reduction for detection with high power as we believe this level of reduction would be compelling from the perspective of policy makers in countries with similar characteristics to southern Nepal. Sample Size Requirements for Primary Outcome Outcome (Number of Clusters in Each Group) 80% Power 90% Power Primary SGA (10th centile) 27 36 We will include 36 clusters per marginal group in order to achieve 90% power to detect a 22.5% reduction in SGA when comparing the treatment groups that receive supplementation during pregnancy versus those that do not. This number of clusters translates to approximately 803 live births per group (# clusters x mean number of births per cluster). Given 36 clusters per group, we have also estimated the detectable difference (reduction) in the pregnancy supplementation group versus those not supplemented during pregnancy for a number of the secondary outcomes with 80% and 90% power in the table below. Detectable Difference in Secondary Outcomes (Marginal Comparisons) Outcome Detectable Difference Between Groups 80% Power 90% Power Secondary ShGA (10th centile)a 24.3% 27.9% SGA (3rd centile)b 29.2% 33.4% ShGA (3rd centile)c 35.9% 40.9% Mean Birth Weight d 75.3 g 87.1 g Mean Birth Length e 3.7 mm 4.3 mm LAZ at 6 months1 0.25 Z scores 0.20 Z Scores WAZ at 6 months2 0.26 Z scores 0.29 Z scores WLZ at 6 months3 0.20 Z scores 0.24 Z scores Maternal Weight Gain in Pregnancy4 418 g 494 g Maternal Weight at 6 months Post‐Partum5 1.16 kg 1.35 kg a ShGA (10th centile expected rate is 30.1% (k=0.135). b SGA (3rd centile) expected rate is 22.1% (k=0.156). c ShGA (3rd centile) expected rate is 14.4% (k=0.138). d Expected mean birth weight is 2708 g (SD=429), (k=0.018). e Expected mean birth length is 47.6 cm (SD=2.2) (k=0.005). 1. Expected mean LAZ at 6 months is ‐1.04 (k=0.251). 2. Expected mean WAZ at 6 months is ‐1.63 (k=0.186). 3. Expected mean WLZ at 6 months is ‐1.23 (k=0.118). 4. Expected mean weight gain in pregnancy is 7.55 kg (SD=3.23 kg), (k=0.027). 5. Expected mean maternal weight at 6 m PP is 44.07 kg (SD=6.21 kg), (k=0.02). While detectable relative differences in ShGA (10th centile) and SGA and ShGA at the 3rd centile will be larger than 20%, at 80% power they remain within a range of plausible outcomes. Increases in continuous measures of birth weight, birth length, Z scores at 6 months, maternal weight gain in pregnancy, and maternal weight at 6 months post‐partum are detectable with high power at even moderate mean changes/differences. Note that the primary outcome for assessing the effect of the post‐partum supplementation is LAZ score at 6 months. Since we are assuming no nteraction between the marginal effects, the detectable difference is 0.20 Z scores with 90% power. Note that the detectable growth secondary outcomes are slightly larger at 0.29 Z scores for WAZ and 0.24 Z scores for WLZ. Biospecimen Composition Sub‐study: We used the breastmilk aim to drive this sample size estimate. 90 persons per group will be required to detect a 0.5 SD increase in breastmilk concentrations with 80% power for those nutrients identified previously based on marginal comparisons. Concentrations for some of these nutrients prior to supplementation were estimated from lactating women in Bangladesh (Hampel et al., 2017). Reported medians and IQRs were converted to means and SDs (Wan et al. 2014) and PASS version 14 (NCSS LLC, Kaysville, UT) was used for sample size calculations. Dietary Intake Sub‐Study: We used two studies conducted among adults in the terai that use quantitative methods to estimate actual intake (Parajuli et al, 2012; Sudo et al, 2006). We used the average of their estimated intake of energy (kcal) and protein (g) and the associate average standard errors for our calculation. As this sub‐study is designed to assess dietary diversion due to the supplement, we used a minimally detectable difference of ‐15% for energy and protein as an indicator that dietary diversion was occurring. Given these parameters and a 20% increase in sample size to account for the clustered design, 60 persons per group will provide over 90% power for energy intake and approximately 85% power for protein intake. Data Analysis, Phase 3 Data analysis will proceed in two phases, an exploratory data analysis phase followed by a confirmatory analysis phase and focuses on the specific aims of this project. The exploratory phase will involve final data cleaning and editing as well as examination of the distributions for all variables and the application of appropriate transformations. We will populate a CONSORT diagram. Next, comparisons will be made between the four treatment groups on a variety of variables at the household and individual levels to assess their comparability. All eligible birth outcomes will be limited to those measured within 72 hours of delivery. Pregnancy Intervention Primary Aim: Data analysis will be by intent to treat. The proportion of babies born SGA (10th centile) will be compared in the two treatment groups using generalized estimating equations (GEE) to account for the clustered study design. An effect size will be estimated as the proportionate change in the intervention group relative to the control group. A 95% confidence interval will be calculated around this effect size estimate that accounts for the correlation within clusters. P‐values will not be used. A secondary, post‐hoc stratification by level of compliance with supplement use will be done within the active treatment group and the proportion SGA will be compared across groups. A dose‐response effect will be estimated by linear regression techniques. Secondary Aims 1, 2, and 3: A similar analysis to that of the primary aim will be done for the outcome ShGA (10th centile), SGA (3rd centile), and ShGA (3rd centile). Secondary Aim 4: Mean birthweight and the distribution of birthweights will be compared by treatment group (supplementation during pregnancy versus not). Means and proportions below 2500 grams will be compared using GEE. A comparison of the full distribution of birthweights between treatment groups will also be done as previous research in this study area has indicated that treatment effects may vary by location on the birthweight distribution. (Katz et al, 2006; Dominici et al, 2006). A similar analysis of birth length will be conducted. A similar analysis will be conducted for the mean and distribution of gestational age and the proportion preterm (&lt;37 weeks gestation). Secondary Aim 5: Mean Length‐for‐Age, Weight‐for‐Age, Weight‐for‐Length, and proportions (&lt;‐2 Z scores) at 6 months of age will be compared by treatment group using GEE. Secondary Aim 6: The nutritional composition of breast ilk collected at 2 time points during the first 6 months following delivery will be compared by treatment group. These assays will be conducted by colleagues at the USDA Center at the University of California‐Davis. A similar analysis for that proposed for continuous anthropometric outcomes will be used. Volume of breastmilk consumed over a 24 hour period will be calculated by the difference in weights of the infant 24 hours apart divided by the specific gravity of breastmilk. Post‐Partum Intervention Primary Aim: Data analysis will be by intent to treat. The mean LAZ score among infants at 6 months of age will be compared in the two treatment groups using GEE to account for the clustered study design. An effect size will be estimated as the proportionate change in the intervention group relative to the control group. A 95% confidence interval will be calculated around this effect size estimate that accounts for the correlation within clusters. P‐values will not be used. A secondary, post‐hoc stratification by level of compliance with supplement use during lactation will be done within the active treatment group and the mean LAZ score will be compared across groups. A dose‐response effect will be estimated by linear regression techniques. Secondary Aim 1: A similar analysis to that of the primary aim will be done for the outcome WAZ and WLZ scores. Secondary Aim 2: The nutritional composition of breastmilk collected at 2 time points during the first 6 months following delivery will be compared by treatment group. A similar analysis for that proposed for continuous anthropometric outcomes will be used. Secondary Aim 3: Weight (and BMI) of mothers at 6 months post‐partum will be compared by treatment group using GEE. An effect size will be estimated as the proportionate change in the intervention group relative to the control group. A 95% confidence interval will be calculated around this effect size estimate that accounts for the correlation within clusters. P‐values will not be used. A secondary, post‐hoc stratification by level of compliance with supplement use during lactation will be done within the active treatment group and the mean weight and BMI will be compared across groups. A dose‐response effect will be estimated by linear regression techniques. Combination of Pregnancy and Post‐Partum Supplementation Secondary Aim 1: The combined effect of both pregnancy and post‐partum supplementation on 6 and 12 month LAZ, WAZ, and WLZ scores will be estimated two ways. First a stratified analysis will be done comparing mean and 95% CI on Z scores among control in both periods with pregnancy alone, post‐partum alone, and both pregnancy and post‐partum supplementation. For significance testing we are allowed 3 orthogonal contrasts and we have chosen the following 3 comparisons to apply tests of significance: ‐ Control in both periods versus post‐partum alone. ‐ Pregnancy alone versus post‐partum alone. ‐ Post‐partum alone versus both pregnancy and post‐partum. The second approach will be to model the effects of the treatment groups using linear regression models that include an interaction term for the combined treatment arm. A test of interaction will be used but we will primarily rely on interpreting the size of the interaction effect relative to the changes in the period‐specific supplementation effects. GEE will be used to adjust for the clustered design. A variety of additional analyses will be conducted to explore the consistency of the main effects of these interventions. Ethical Considerations The project has been approved by Institutional Review Boards (IRBs) at the George Washington University, the Johns Hopkins Bloomberg School of Public Health, and the Nepal Health Research Council. The IRB at the Harvard T.H. Chan School of Public Health have defered to the IRB of record at George Washington University. This trial will be conducted according to Good Clinical Practice (GCP) guidelines (WHO, 2005). An independent in‐country Safety Officer will be appointed from among the faculty at the Institute of Medicine of Tribhuvan University. Adverse Event Reporting Serious Adverse Events: Serious adverse events (SAE) under GCP guidelines include death, a life‐threatening reaction to the supplement or other study procedure, hospitalization, significant or persistent disability or impairment, or a congenital anomaly/birth defect. Other Adverse Events: These include any untoward medical event that occurs in a participant, any unfavorable sign or symptom of disease temporally associated with the provision of the supplement, or any noxious and unintended response to the supplement. Anticipated adverse events include signs/symptoms of allergic reaction to the supplement, preeclampsia, infection during pregnancy, gestational diabetes. Unanticipated adverse events are either unexpected in terms of nature, severity and frequency. An example would include newborn macrosomia (BW&gt;97th centile according to InterGrowth21 standards). All adverse events will be reported to the designated local investigator (Dr. Subarna K. Khatry) for review within 48 hours. If there is a possibility of the event being related to the study, a report will be made to the independent Safety Officer within 24 hours of receipt by the investigator. The Safety Officer will review the file and make a determination regarding attribution to study procedures or the intervention. If the adverse event is considered by the Safety Officer to be minor in severity, it will be logged and a summary of such events will be reported to the DSMB at their next meeting. If the severity of the adverse event is considered to be moderate or severe by the Safety Officer, he/she will indicate to the Principal Investigator that it should be reported to the DSMB and the cognizant IRBs immediately. The PI will then forward all materials together with the Safety Officer&apos;s summary to the DSMB and the IRBs.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01706471/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>336</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Horlenko, O. M.</style></author><author><style face="normal" font="default" size="100%">Polyak, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">O.M. Horlenko, Pediatric with Infectiuos Diseases, Uzhgorod National University, Medical Faculty, Uzhgorod, Ukraine</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biochemical and immunological markers of measles with helminthiasis in the children</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Disease in Childhood</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Disease in Childhood</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A322</style></pages><volume><style face="normal" font="default" size="100%">99</style></volume><keywords><keyword><style face="normal" font="default" size="100%">marker</style></keyword><keyword><style face="normal" font="default" size="100%">iodine</style></keyword><keyword><style face="normal" font="default" size="100%">phosphorus</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">thymol</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">amylase</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 6</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 2</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 10</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">measles</style></keyword><keyword><style face="normal" font="default" size="100%">helminthiasis</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">organization</style></keyword><keyword><style face="normal" font="default" size="100%">parameters</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">Ukraine</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">trichuriasis</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">urine</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">ascariasis</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">immunological parameters</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">mineral metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0003-9888</style></isbn><abstract><style face="normal" font="default" size="100%">Background and aims Duration of Measles in association with Helminthiasis (MwH) in the children is insufficiently studied and requires more research is. Methods We investigated of biochemical and immunological markers in the children with MwH. We observed 87 children (age 3.12 ± 1.24 years) with a primary diagnosis of Measles and associated worm infestation (ascariasis and trichuriasis) on the bases of Regional Infectious Hospital, Uzhgorod, Ukraine. These biochemical and immunological parameters were compared with the dates of control group (Measles without of Helminthiasis). Results MwH children characterised prevalence following parameters: higher alpha -amylase (p &lt; 0.01), glucose (p &lt; 0.001), GGT (p &lt; 0.001) and alkaline phosphatase (p &lt; 0.001). Also dominated indicators of ALT (44,50 ± 8,21 U/L, p &lt; 0.05), AST (64,92 ± 2,83 U/L, p &lt; 0.001) and thymol (5,21 ± 0,29 IU, p &lt; 0.001), on the basis of what we can concluded about the complications of Measles infection by reactive hepatitis. We indeficated increase of level of IL-2 in 5.5 times to the control group (p &lt; 0.001), IL-6 in 25-time (p &lt; 0,001), IL-10 in 1.7 time (p &lt; 0.001). The levels of microelements of blood serum? were lower: iodine (p &lt; 0.001), copper (p &lt; 0.001), zinc (p &lt; 0.001) by our study. Phosphorus level was higher in the group of children with the Measles in association with Helminthiasis (p &lt; 0.001). The mikro elements parameters of urine were lower in the study group: iron (p &lt; 0.001),copper (p &lt; 0.001), zinc (p &lt; 0.001) and iodine (p &lt; 0.001). Level of phosphorus were increased (p &lt; 0.001). Conclusions The dates of our investigation in the children diagnosed with Measles in association with Helminthic infestation presented significant increase of inflammation markers and an imbalance of mineral metabolism.</style></abstract><notes><style face="normal" font="default" size="100%">L71667133&#xD;2014-11-07</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71667133</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/archdischild-2014-307384.889</style></url><url><style face="normal" font="default" size="100%">http://adc.bmj.com/content/99/Suppl_2/A322.2.abstract?sid=0e1cd4ee-7b5b-47b3-b37c-2e94b265b61d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/archdischild-2014-307384.889</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>278</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graziola, F.</style></author><author><style face="normal" font="default" size="100%">Curatolo, P.</style></author><author><style face="normal" font="default" size="100%">Vigevano, F.</style></author><author><style face="normal" font="default" size="100%">Capuano, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">F. Graziola, Child Neurology and Psychiatry Unit, Tor Vergata University- Rome, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biochemical markers of tic disorders in children: A prospective pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Paediatric Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Paediatric Neurology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e217-e218</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><keywords><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">transferrin</style></keyword><keyword><style face="normal" font="default" size="100%">blood cell count</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">Gilles de la Tourette syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">iron chelation</style></keyword><keyword><style face="normal" font="default" size="100%">longitudinal study</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">software</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus infection</style></keyword><keyword><style face="normal" font="default" size="100%">throat culture</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1532-2130</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Chronic tics and Tourette&apos;s syndrome are neurodevelopment disorders characterized by multiple motor and /or vocal tics. It has been hypothesized that genetic factors during the development interact with other environmental factors to establish the disorder. The main aim of our study was to individuate early markers of the onset of tic disorders in a prospective, longitudinal study. Methods: Consecutive pediatric patients attending Movement Disorders Clinic of Bambino Gesù Children&apos;s Hospital were prospectively enrolled in the study. All patients were treatment-naive and received a diagnosis of tics disorders or Tourette syndrome according DMS-5 criteria. Patients with other movement disorders, epilepsy, malabsorptionrelated disorders and other neuropsychiatric disorders were excluded from the study. A comprehensive biochemical and immunological work up (including complete blood count, quantitative immunoglobulins and subclasses, copper, ceruloplasmin, iron, ferritin, transferrin, other immunologicalmarkers as C3, C4) was done; all patients performed throat swab for groupA streptococcal infection. Data were analyzed by MYSTAT software. Results: Seventy-four patients (as expected by disease, 75% males) were recruited for the study. Themean age was 8,23 ± 3,15 years (mean ± SD), the mean time of first visit from the onset of tics was 14,15 ± 11,9 months (mean ± SD), no statistical difference was done between male and female patients. All patients were divided in 5 groups according to the time of our first observation from the onset of tics in five groups: 0-6 months, 7-12 months, 13-18 months, 19-24 months and &gt;24 months. Ferritin and transferrin levels were statistically lower in the group of 0-6 months onset of tics compared to other groups (p &lt; 0,001). No significant comorbid streptococcal infection was found. Conclusions: Our study demonstrated that ferritin and transferrin could be correlated to tics onset in children. In particular lower levels could be a marker of risk to develop tics.</style></abstract><notes><style face="normal" font="default" size="100%">L619068820&#xD;2017-11-08</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L619068820</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ejpn.2017.04.1127</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejpn.2017.04.1127</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>392</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">392</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naha, K.</style></author><author><style face="normal" font="default" size="100%">Saravu, K.</style></author><author><style face="normal" font="default" size="100%">Shastry, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Saravu, Department of Medicine, Kasturba Medical College, Manipal University, Manipal, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blue vitriol poisoning: A 10-year experience in a tertiary care hospital</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Toxicology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Toxicology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">197-201</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">copper sulfate</style></keyword><keyword><style face="normal" font="default" size="100%">dimercaprol</style></keyword><keyword><style face="normal" font="default" size="100%">diuretic agent</style></keyword><keyword><style face="normal" font="default" size="100%">egg white</style></keyword><keyword><style face="normal" font="default" size="100%">mannitol</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">methylene blue</style></keyword><keyword><style face="normal" font="default" size="100%">penicillamine</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin K group</style></keyword><keyword><style face="normal" font="default" size="100%">acute hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">blood transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">blue vitriol intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">blue vitriol poisoning</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">epigastric pain</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">rectum hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">high risk patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">jaundice</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">pallor</style></keyword><keyword><style face="normal" font="default" size="100%">patient identification</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">receiver operating characteristic</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity and specificity</style></keyword><keyword><style face="normal" font="default" size="100%">stomach lavage</style></keyword><keyword><style face="normal" font="default" size="100%">tertiary health care</style></keyword><keyword><style face="normal" font="default" size="100%">upper gastrointestinal bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1556-3650&#xD;1556-9519</style></isbn><abstract><style face="normal" font="default" size="100%">Background and aim. Copper sulphate poisoning, while unusual in the West, is not rare in the Indian subcontinent, and mostly suicidal in intent. Unfortunately, data available on copper sulphate poisoning is limited. This study was planned to identify common presentations and complications of copper sulphate poisoning, and biochemical parameters that predict outcomes in these patients. Materials and methods. A retrospective analysis of 35 patients presenting with copper sulphate poisoning over a period of 10 years (20012010) was performed, based on review of their medical records. Paediatric cases and patients with concomitant poisoning with other substances were excluded. Clinical presentation, laboratory parameters, complications and treatment modalities were studied. Results. Of the 35 cases, 23 were females (65.71%). Mean age was 29.18±10.77 years. Vomiting was the commonest symptom (85.71%) followed by diarrhoea (45.71%), epigastric pain (42.86%) and rectal passage of blood (31.43%). Fourteen (40%) patients had pre-existing psychiatric disease. Medical signs included pallor (37.14%) and icterus (37.14%). Major complications included hemolysis (68.57%), renal failure (51.43%), acute hepatitis (45.71%) and upper gastrointestinal bleed (40%). Mean serum copper at presentation was 104.53±56.67 μg/dL; mean methemoglobin level was 9.59±8.28%. Twenty-seven patients survived yielding a mortality rate of 22.9%. Peak serum aspartate and alanine aminotransferases were significantly lower (223.8±247.3U/L, 66.3±92.2U/L) in survivors compared to non-survivors (489.6±374.0U/L, 192.9±168.7U/L; p =0.03, p &lt;0.01, respectively). Analysis by receiver operating characteristic (ROC) curve showed sensitivities of 100% and 85.7%, and specificities of 73.1% and 69.2%, respectively for peak serum alanine aminotransferase levels greater than 55 U/L, and peak serum aspartate aminotransferase levels greater than 234 U/L in predicting mortality. Conclusion. Copper sulphate is a potent poison that can involve multiple organ systems. Elevated levels of serum aspartate and alanine aminotransferases beyond the aforementioned values can identify patients at greater risk of mortality, allowing for institution of aggressive treatment. © 2012 Informa Healthcare USA, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L364361288&#xD;2012-03-12&#xD;2012-03-13</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L364361288</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3109/15563650.2012.660572</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">22372787</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/15563650.2012.660572</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>445</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">445</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Herndon, D. H.</style></author><author><style face="normal" font="default" size="100%">Wernerman, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Wernerman, Department of Anaesthesia and Intensive Care Medicine, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Brussels 2007 roundtable on metabolism in sepsis and multiple organ failure</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Parenteral and Enteral Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Parenteral and Enteral Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-5</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">corticotropin</style></keyword><keyword><style face="normal" font="default" size="100%">corticotropin releasing factor</style></keyword><keyword><style face="normal" font="default" size="100%">estradiol</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">glutamine</style></keyword><keyword><style face="normal" font="default" size="100%">nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">noradrenalin</style></keyword><keyword><style face="normal" font="default" size="100%">oxandrolone</style></keyword><keyword><style face="normal" font="default" size="100%">protirelin</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">thyroxine</style></keyword><keyword><style face="normal" font="default" size="100%">vasopressin</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style face="normal" font="default" size="100%">burn</style></keyword><keyword><style face="normal" font="default" size="100%">health care organization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">insulin resistance</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">multiple organ failure</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">0148-6071</style></isbn><abstract><style face="normal" font="default" size="100%">At the 2007 International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, a roundtable conference on &quot;Metabolic Support in Sepsis and Multiple Organ Failure&quot; was held. The roundtable was endorsed by the European Society of Intensive Care Medicine, the Society of Critical Care Medicine, the European Society for Clinical Nutrition and Metabolism, and the American Society for Parenteral and Enteral Nutrition. Metabolic support in intensive care has become an exciting topic in recent years, with improved understanding of the effects of compromised mitochondrial function, studies demonstrating outcome benefits of tight glucose control, new insights into the mechanisms behind insulin resistance, recognition of glutamine and antioxidants as key nutrients, and emerging knowledge concerning the interactions between metabolism and endocrinology. Together, these aspects have generated an increased interest in the importance of metabolism in intensive care medicine, reflected in the programs and abstracts at international congresses of the past few years. This roundtable&apos;s participants each gave a presentation within their specific area of expertise, and each was followed by general discussion. Discussions became heated as new concepts and ideas were debated. New data will be discussed in this summary which reveals metabolic and nutrition interventions that could lead to major improvements in clinically relevant outcomes. Copyright © 2008 by the American Society for Parenteral and Enteral Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">L351113843&#xD;2008-02-04</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L351113843</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/014860710803200101</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18165440</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/014860710803200101</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>275</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weber, D. J.</style></author><author><style face="normal" font="default" size="100%">Otter, J. A.</style></author><author><style face="normal" font="default" size="100%">Rutala, W. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.J. Weber, Department of Hospital Epidemiology, University of North Carolina Hospitals, Chapel Hill, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can copper-coated surfaces prevent healthcare-associated infections?</style></title><secondary-title><style face="normal" font="default" size="100%">Infection Control and Hospital Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection control and hospital epidemiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">772-776</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">central venous catheter</style></keyword><keyword><style face="normal" font="default" size="100%">urinary catheter</style></keyword><keyword><style face="normal" font="default" size="100%">ventilator</style></keyword><keyword><style face="normal" font="default" size="100%">carbapenem derivative</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">heavy metal</style></keyword><keyword><style face="normal" font="default" size="100%">hydrogen peroxide</style></keyword><keyword><style face="normal" font="default" size="100%">photosensitizing agent</style></keyword><keyword><style face="normal" font="default" size="100%">reactive oxygen metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter infection</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial colonization</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial transmission</style></keyword><keyword><style face="normal" font="default" size="100%">bactericidal activity</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium contamination</style></keyword><keyword><style face="normal" font="default" size="100%">catheter infection</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile infection</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">cross infection</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">enterococcal infection</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">hand washing</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus infection</style></keyword><keyword><style face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Norovirus</style></keyword><keyword><style face="normal" font="default" size="100%">norovirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">photocatalysis</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">surface property</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">ventilator associated pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">virus transmission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1559-6834&#xD;0899-823X</style></isbn><notes><style face="normal" font="default" size="100%">L617505734&#xD;2017-07-31&#xD;2017-08-02</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L617505734</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1017/ice.2017.90</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/ice.2017.90</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>330</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiang, Y.</style></author><author><style face="normal" font="default" size="100%">Fu, W. C.</style></author><author><style face="normal" font="default" size="100%">Dai, Y. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Y.-K. Dai, Department of Ophthalmology, Ren Ji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Change of trace elements and body comprehensive immune state of patients with viral keratitis</style></title><secondary-title><style face="normal" font="default" size="100%">International Eye Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Eye Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">259-261</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cellular immunity</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte immunity</style></keyword><keyword><style face="normal" font="default" size="100%">herpes zoster</style></keyword><keyword><style face="normal" font="default" size="100%">herpes zoster keratitis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune status</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">virus keratitis</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1672-5123</style></isbn><abstract><style face="normal" font="default" size="100%">AIM: To study and investigate the change situation of trace elements and body comprehensive immune state of patients with viral keratitis. METHODS: Sixty-two patients with viral keratitis in our hospital from December 2011 to February 2014 were selected as observation group, 62 healthy persons with health education at the same time were the control group, then the serum and tear Zn, Cu, cellular immunity and erythrocyte immunity of two groups were compared, and the detection results of observation group with different types and severity degree were compared. RESULTS: The serum and tear Zn of observation group was all lower than that in control group, serum and tear Cu was higher than that in control group, cellular immunity and erythrocyte immunity indexes were all worse than that in control group, the detection results of observation group with mild, moderate and severe infection had significant differences (P&lt;0.05), while the detection results of observation group with herpes simplex keratitis and herpes zoster keratitis had no significant differences (P&gt;0.05). CONCLUSION: The change of trace elements and body comprehensive immune state of patients with viral keratitis are obvious, and the severity degree for the detection levels of keratitis are greater.</style></abstract><notes><style face="normal" font="default" size="100%">L602216247&#xD;2015-02-18&#xD;2015-02-24</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L602216247</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3980/j.issn.1672-5123.2015.2.18</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3980/j.issn.1672-5123.2015.2.18</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">Chinese</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>314</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">314</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, N.</style></author><author><style face="normal" font="default" size="100%">Hinton, A.</style></author><author><style face="normal" font="default" size="100%">Conwell, D. L.</style></author><author><style face="normal" font="default" size="100%">Krishna, S.</style></author><author><style face="normal" font="default" size="100%">Mumtaz, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N. Li, Ohio State University, Wexner Medical Center, Columbus, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization and outcomes of hospitalized patients with wilson&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S915</style></pages><volume><style face="normal" font="default" size="100%">110</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenterology</style></keyword><keyword><style face="normal" font="default" size="100%">college</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">kidney disease</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gender</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">multivariate logistic regression analysis</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">population research</style></keyword><keyword><style face="normal" font="default" size="100%">genetic disorder</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">multivariate analysis</style></keyword><keyword><style face="normal" font="default" size="100%">brain</style></keyword><keyword><style face="normal" font="default" size="100%">race difference</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">rare disease</style></keyword><keyword><style face="normal" font="default" size="100%">ICD-9</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9270</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Big data analytics can be used to better characterize rare diseases. Wilson&apos;s disease (WD) is a rare hereditary disorder characterized by excessive deposition of copper in various organs, predominantly in the liver and the brain. There are no large population studies on patients with WD in the United States. The aim of this study is to examine the inpatient epidemiological characteristics and discharge outcomes of adult patients with WD. Methods: The National Inpatient Sample database was queried from 2006 to 2011 using the ICD-9 code for WD (275.1). Adult patients older than age 18 were included in the database. We compared the demographic characteristics and outcomes of WD patients based on gender, neuropsychiatric and hepatic disorders using univariate and multivariate logistic regression analysis. Results: A total of 9,968 (median age 46.2, age range 18-102, female 54.2%) hospitalizations were identified in patients with WD. WD patients with hepatic disorders were significantly younger than patients with neuropsychiatric disorders (45.2 vs. 50.6 years, p &lt; 0.001). Women were more likely admitted for neuropsychiatric disorders (61.6% vs. 51.3%, p &lt; 0.01), and men for hepatic disorders (39.6% vs. 27.5%, p &lt; 0.001). Compared to other races, white patients with WD were more likely hospitalized for neuropsychiatric than hepatic disorders (79.9% vs. 59.7%, p &lt; 0.0001). The most common reasons for admission were infections (17.0%), neuropsychiatric disorders (13.1%), followed by hepatic disorders (11.7%). The mortality rate for WD was 2.5% (n = 233) for all hospitalizations. On multivariate analysis, predictors for inpatient mortality were renal disorders (OR 5.3, 95% CI 2.6-10.9) and hepatic disorders (OR 2.6, 95% CI 1.3-5.2). Conclusion: We reported the largest description of inpatients with WD in the United States. The most common reason for admission is infection. Gender and racial differences exist. Hepatic and renal disorders are associated with higher in-hospital mortality. These results may have significant implications for future research in WD.</style></abstract><notes><style face="normal" font="default" size="100%">L72132260&#xD;2016-01-15</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72132260</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1038/ajg.2015.277</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/ajg.2015.277</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rose, S. B.</style></author><author><style face="normal" font="default" size="100%">Garrett, S. M.</style></author><author><style face="normal" font="default" size="100%">Stanley, J.</style></author><author><style face="normal" font="default" size="100%">Pullon, S. R. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Primary Health Care and General Practice, University of Otago, Wellington, New Zealand.&#xD;Biostatistical Group, University of Otago, Wellington, New Zealand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chlamydia testing and diagnosis following initiation of long-acting reversible contraception: A retrospective cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Aust N Z J Obstet Gynaecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aust N Z J Obstet Gynaecol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">665-675</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2017/08/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Abortion, Induced/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia Infections/*diagnosis/ethnology</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptives, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic Techniques and Procedures/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Implants</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Long-Acting Reversible Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Oceanic Ancestry Group/statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Period</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia trachomatis</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive implant</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraception</style></keyword><keyword><style face="normal" font="default" size="100%">long-acting reversible contraception</style></keyword><keyword><style face="normal" font="default" size="100%">oral contraception</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0004-8666</style></isbn><accession-num><style face="normal" font="default" size="100%">28832936</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Long-acting reversible contraception (LARC) effectively protects against pregnancy but provides no protection against sexually transmitted infections (STIs). AIM: To compare rates of chlamydia testing and diagnosis for women initiating long-acting versus oral contraception. MATERIALS AND METHODS: Retrospective cohort study involving data collection for 6160 women initiating post-abortion contraception at a large New Zealand regional public hospital abortion clinic (2009-2012), with chlamydia testing data obtained from the local laboratory during two-year follow up. Negative binomial regression modelling examined the effect of contraceptive method on two outcome measures: chlamydia testing and chlamydia diagnosis (adjusting for potential covariates of age, ethnicity, past chlamydia infection, pregnancy history) in year one and two of follow up. RESULTS: Two thousand seven hundred and twenty nine women (44%) received a LARC and 1764 (28.6%) were prescribed oral contraception. Adjusted testing rates differed by contraceptive method only in year one (P &lt; 0.01): with higher rates among copper intrauterine device users (relative risk (RR) 1.2, 95% CI 1.06-1.35), and lower rates for implant users (RR 0.84, 95% CI 0.72-0.99) compared with oral contraceptive users (reference group). No significant differences were observed in chlamydia diagnosis rates by contraceptive method (P &gt; 0.05). Younger age, past chlamydia infection, Maori and Pacific ethnicity were associated with higher rates of chlamydia diagnosis (P &lt; 0.01). CONCLUSIONS: Known STI-related risk factors (age, ethnicity, past infection) but not contraceptive method were independently related to rates of subsequent chlamydia diagnosis. This suggests that increased LARC uptake would not occur at the expense of chlamydia control. Regular screening and risk reduction advice (including condom use) are important chlamydia control measures for at-risk groups.</style></abstract><notes><style face="normal" font="default" size="100%">1479-828x&#xD;Rose, Sally B&#xD;ORCID: http://orcid.org/0000-0002-5626-5142&#xD;Garrett, Susan M&#xD;Stanley, James&#xD;ORCID: http://orcid.org/0000-0002-8572-1047&#xD;Pullon, Susan R H&#xD;Journal Article&#xD;Australia&#xD;Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):665-675. doi: 10.1111/ajo.12685. Epub 2017 Aug 22.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ajo.12685</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>464</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">464</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pan, J. J.</style></author><author><style face="normal" font="default" size="100%">Chu, C. J.</style></author><author><style face="normal" font="default" size="100%">Chang, F. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.-J. Chu, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, No-201, Sec 2, Shih-Pai Road, Taipei 11217, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">The clinical experience of Chinese patients with Wilson&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Hepato-Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hepato-Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">166-169</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">61</style></number><keywords><keyword><style face="normal" font="default" size="100%">aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">cause of death</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Chinese</style></keyword><keyword><style face="normal" font="default" size="100%">chronic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">dysarthria</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Kaplan Meier method</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">survival rate</style></keyword><keyword><style face="normal" font="default" size="100%">tremor</style></keyword><keyword><style face="normal" font="default" size="100%">urine level</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">0172-6390</style></isbn><abstract><style face="normal" font="default" size="100%">Background/Aims: Wilson&apos;s disease has protean presentations. Most patients manifested as either hepatic or neurologic symptoms and signs initially. No study has investigated the predictor of presentation and differences in laboratory tests and survival between patients presented with hepatic or neurological disease so far. Methodology: Forty-one patients with Wilson&apos;s disease were diagnosed between 1981 and 2002 at our hospital. Their clinical features at presentation and laboratory findings were retrospectively collected. Survival was calculated using the Kaplan-Meier analysis. Results: Twelve patients initially presented with hepatic symptoms including chronic hepatitis, complications of cirrhosis, and fulminant hepatic failure. Twenty-nine patients presented with neurological symptoms including tremor, dysarthria, ataxia, and psychiatric diseases. No specific factor identified could predict the initial presentations. Compared to patients with neurological symptoms, patients with hepatic disease had significantly higher serum levels of aminotransferase, ceruloplasmin, copper, and 24-hour urine copper excretion. There was no significant difference in survival between these two groups. Among the patients who died, the most common causes of death were fulminant hepatic failure and complications of cirrhosis. Conclusions: Our results suggested that the overall survival did not differ significantly according to the initial presentations. There was no predictor found that could foretell the clinical course of Wilson&apos;s disease.</style></abstract><notes><style face="normal" font="default" size="100%">L40282656&#xD;2005-03-09</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L40282656</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">15783020</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>460</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thilo-Körner, D. G. S.</style></author><author><style face="normal" font="default" size="100%">Inderst, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.G.S. Thilo-Körner, Facharzt für Innere Medizin, Hämostaseologie, Angiologie, Naturheilverfahren Zellerstr. 9, 91074 Herzogenaurach, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">The clinical significance of the trace element copper</style></title><secondary-title><style face="normal" font="default" size="100%">Arztezeitschrift fur Naturheilverfahren und Regulationsmedizin</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arztezeitschrift fur Naturheilverfahren und Regulationsmedizin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">809-815</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">amyotrophic lateral sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chronic inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Crohn disease</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">dietary intake</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatic fever</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">1614-8339</style></isbn><abstract><style face="normal" font="default" size="100%">Presentation of the pathophysiological significance of the essential trace element copper in chronic inflammations, rheumatic fever, immune system, tumour, vascular wall, liver, intestinal diseases, Alzheimer&apos;s dementia, amyotrophic lateral sclerosis and wound healing. The results of initial serum copper assays (N = 615 patients) from patients in our own hospital are presented. Courses of serum copper are shown in clinical examples (m. Crohn, mammary carcinoma, rheumatoid arthritis, fibromyalgia / chronic pain syndrome, dementia). They underline the necessity of course monitoring so that therapy with trace elements can be controlled in an effective and meaningful manner.</style></abstract><notes><style face="normal" font="default" size="100%">L43066768&#xD;2006-01-31</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L43066768</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">German</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>413</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">413</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shareej, S.</style></author><author><style face="normal" font="default" size="100%">Iqbal, M.</style></author><author><style face="normal" font="default" size="100%">Kumar, K. S.</style></author><author><style face="normal" font="default" size="100%">Ramachandran, T. M.</style></author><author><style face="normal" font="default" size="100%">Varghese, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Shareej, Department of Gastroenterology and Internal Medicine, Medical College Calicut, Kerala, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical spectrum and prognostic factors of acute liver failure in North Kerala</style></title><secondary-title><style face="normal" font="default" size="100%">Indian Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Indian Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A59</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">rodenticide</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">ammonia</style></keyword><keyword><style face="normal" font="default" size="100%">fetoprotein</style></keyword><keyword><style face="normal" font="default" size="100%">marker</style></keyword><keyword><style face="normal" font="default" size="100%">acute liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">Indian</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenterology</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">prothrombin time</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">acute hepatitis A</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">serology</style></keyword><keyword><style face="normal" font="default" size="100%">college</style></keyword><keyword><style face="normal" font="default" size="100%">tertiary care center</style></keyword><keyword><style face="normal" font="default" size="100%">liver biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">Student t test</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">HELLP syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">brain disease</style></keyword><keyword><style face="normal" font="default" size="100%">virus hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">survival</style></keyword><keyword><style face="normal" font="default" size="100%">international normalized ratio</style></keyword><keyword><style face="normal" font="default" size="100%">amplified fragment length polymorphism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0254-8860</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To analyze the demographic profile, etiology and disease characteristics and prognostic variables of ALF presenting to a tertiary care centre. Methods: The details of patients who presented to the department of Gastroenterology and Medicine of CalicutMedical College between January 2010 and July 2010 are collected prospectively in a structured proforma. Routine laboratory tests, hepatitis serology, arterial ammonia, alfa fetoprotein, autoimmune markers and copper profile were done in all. Results: 17 patients were seen during this period. The F:M ratio was 1.1:1 with a mean age of 26.59 with SD of ±9.99 years. 9 (52.9%) patients survived while 8 (47.1%) died. Etiology of ALF was identified in 14 cases such as acute hepatitis A in 7, rat poison injestion in 3, AFLP in1, HELLP syndrome in1, ATT in1 and 1case was diagnosed as sickle disease by postmortem liver biopsy. 9 patient developed features of encephalopathy in first 7days,3during8â€” 14 days, 1 during 14-21 days and 2 during 21-28 days. Total bilirubin level was high in those who died (20.20 with a SD of ±8.915) compared to 9.2±5.308 (P=.008) those who survived. Prothrombin time was prolonged in those who died (mean 40.363 with SD 25.623 t test 3.300 p=.005). Level of AFP at day 1 and 3 indicated better prognosis. Conclusions: The main cause of ALF in our centre is viral hepatitis followed by rat poison. High bilirubin, prothrombin time and INR predicted worse outcome. Higher AFP level showed a better survival chance.</style></abstract><notes><style face="normal" font="default" size="100%">L71905298&#xD;2015-06-12</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71905298</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s12664-010-0063-7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12664-010-0063-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>223</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maitland, K.</style></author><author><style face="normal" font="default" size="100%">Olupot-Olupot, P.</style></author><author><style face="normal" font="default" size="100%">Kiguli, S.</style></author><author><style face="normal" font="default" size="100%">Chagaluka, G.</style></author><author><style face="normal" font="default" size="100%">Alaroker, F.</style></author><author><style face="normal" font="default" size="100%">Opoka, R. O.</style></author><author><style face="normal" font="default" size="100%">Mpoya, A.</style></author><author><style face="normal" font="default" size="100%">Walsh, K.</style></author><author><style face="normal" font="default" size="100%">Engoru, C.</style></author><author><style face="normal" font="default" size="100%">Nteziyaremye, J.</style></author><author><style face="normal" font="default" size="100%">Mallewa, M.</style></author><author><style face="normal" font="default" size="100%">Kennedy, N.</style></author><author><style face="normal" font="default" size="100%">Nakuya, M.</style></author><author><style face="normal" font="default" size="100%">Namayanja, C.</style></author><author><style face="normal" font="default" size="100%">Kayaga, J.</style></author><author><style face="normal" font="default" size="100%">Nabawanuka, E.</style></author><author><style face="normal" font="default" size="100%">Sennyondo, T.</style></author><author><style face="normal" font="default" size="100%">Aromut, D.</style></author><author><style face="normal" font="default" size="100%">Kumwenda, F.</style></author><author><style face="normal" font="default" size="100%">Musika, C. W.</style></author><author><style face="normal" font="default" size="100%">Thomason, M. J.</style></author><author><style face="normal" font="default" size="100%">Bates, I.</style></author><author><style face="normal" font="default" size="100%">von Hensbroek, M. B.</style></author><author><style face="normal" font="default" size="100%">Evans, J. A.</style></author><author><style face="normal" font="default" size="100%">Uyoga, S.</style></author><author><style face="normal" font="default" size="100%">Williams, T. N.</style></author><author><style face="normal" font="default" size="100%">Frost, G.</style></author><author><style face="normal" font="default" size="100%">George, E. C.</style></author><author><style face="normal" font="default" size="100%">Gibb, D. M.</style></author><author><style face="normal" font="default" size="100%">Walker, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Maitland, Division of Medicine, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">The Lancet Global Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Lancet Global Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e1435-e1447</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">ISRCTN84086586</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">C reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin A</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">multivitamin</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">African</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diet supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobinuria</style></keyword><keyword><style face="normal" font="default" size="100%">hospital readmission</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">iron intake</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">mineral supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">sickle cell anemia</style></keyword><keyword><style face="normal" font="default" size="100%">single blind procedure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2214-109X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Severe anaemia is a leading cause of paediatric admission to hospital in Africa; post-discharge outcomes remain poor, with high 6-month mortality (8%) and re-admission (17%). We aimed to investigate post-discharge interventions that might improve outcomes. Methods: Within the two-stratum, open-label, multicentre, factorial randomised TRACT trial, children aged 2 months to 12 years with severe anaemia, defined as haemoglobin of less than 6 g/dL, at admission to hospital (three in Uganda, one in Malawi) were randomly assigned, using sequentially numbered envelopes linked to a second non-sequentially numbered set of allocations stratified by centre and severity, to enhanced nutritional supplementation with iron and folate-containing multivitamin multimineral supplements versus iron and folate alone at treatment doses (usual care), and to co-trimoxazole versus no co-trimoxazole. All interventions were administered orally and were given for 3 months after discharge from hospital. Separately reported randomisations investigated transfusion management. The primary outcome was 180-day mortality. All analyses were done in the intention-to-treat population; follow-up was 180 days. This trial is registered with the International Standard Randomised Controlled Trial registry, ISRCTN84086586, and follow-up is complete. Findings: From Sept 17, 2014, to May 15, 2017, 3983 eligible children were randomly assigned to treatment, and followed up for 180 days. 164 (4%) were lost to follow-up. 1901 (95%) of 1997 assigned multivitamin multimineral supplement, 1911 (96%) of 1986 assigned iron and folate, and 1922 (96%) of 1994 assigned co-trimoxazole started treatment. By day 180, 166 (8%) children in the multivitamin multimineral supplement group versus 169 (9%) children in the iron and folate group had died (hazard ratio [HR] 0·97, 95% CI 0·79–1·21; p=0·81) and 172 (9%) who received co-trimoxazole versus 163 (8%) who did not receive co-trimoxazole had died (HR 1·07, 95% CI 0·86–1·32; p=0·56). We found no evidence of interactions between these randomisations or with transfusion randomisations (p&gt;0·2). By day 180, 489 (24%) children in the multivitamin multimineral supplement group versus 509 (26%) children in the iron and folate group (HR 0·95, 95% CI 0·84–1·07; p=0·40), and 500 (25%) children in the co-trimoxazole group versus 498 (25%) children in the no co-trimoxazole group (1·01, 0·89–1·15; p=0·85) had had one or more serious adverse events. Most serious adverse events were re-admissions, occurring in 692 (17%) children (175 [4%] with at least two re-admissions). Interpretation: Neither enhanced supplementation with multivitamin multimineral supplement versus iron and folate treatment or co-trimoxazole prophylaxis improved 6-month survival. High rates of hospital re-admission suggest that novel interventions are urgently required for severe anaemia, given the burden it places on overstretched health services in Africa. Funding: Medical Research Council and Department for International Development.</style></abstract><notes><style face="normal" font="default" size="100%">L2002898613&#xD;2019-09-20&#xD;2019-10-03</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2002898613</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S2214-109X(19)30345-6</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">31537373</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S2214-109X(19)30345-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>472</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">472</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Connor, C. S.</style></author><author><style face="normal" font="default" size="100%">Lepp, N. W.</style></author><author><style face="normal" font="default" size="100%">Edwards, R.</style></author><author><style face="normal" font="default" size="100%">Sunderland, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N.W. Lepp, School of Biological/Earth Sciences, Liverpool John Moores University, Liverpool, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">The combined use of electrokinetic remediation and phytoremediation to decontaminate metal-polluted soils: A laboratory-scale feasibility study</style></title><secondary-title><style face="normal" font="default" size="100%">Environmental Monitoring and Assessment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Environmental Monitoring and Assessment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">141-158</style></pages><volume><style face="normal" font="default" size="100%">84</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><keywords><keyword><style face="normal" font="default" size="100%">arsenic</style></keyword><keyword><style face="normal" font="default" size="100%">cadmium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">metal</style></keyword><keyword><style face="normal" font="default" size="100%">acidification</style></keyword><keyword><style face="normal" font="default" size="100%">anode</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bioreactor</style></keyword><keyword><style face="normal" font="default" size="100%">cathode</style></keyword><keyword><style face="normal" font="default" size="100%">concentration (parameter)</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Coprinus</style></keyword><keyword><style face="normal" font="default" size="100%">electokinetic remediation</style></keyword><keyword><style face="normal" font="default" size="100%">electric potential</style></keyword><keyword><style face="normal" font="default" size="100%">electrode</style></keyword><keyword><style face="normal" font="default" size="100%">feasibility study</style></keyword><keyword><style face="normal" font="default" size="100%">foliage</style></keyword><keyword><style face="normal" font="default" size="100%">fungus spore</style></keyword><keyword><style face="normal" font="default" size="100%">Fusarium</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">mycosis</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">perennial ryegrass</style></keyword><keyword><style face="normal" font="default" size="100%">pH</style></keyword><keyword><style face="normal" font="default" size="100%">phytoremediation</style></keyword><keyword><style face="normal" font="default" size="100%">plant disease</style></keyword><keyword><style face="normal" font="default" size="100%">plant growth</style></keyword><keyword><style face="normal" font="default" size="100%">sampling</style></keyword><keyword><style face="normal" font="default" size="100%">soil analysis</style></keyword><keyword><style face="normal" font="default" size="100%">soil microflora</style></keyword><keyword><style face="normal" font="default" size="100%">soil pollution</style></keyword><keyword><style face="normal" font="default" size="100%">procedures</style></keyword><keyword><style face="normal" font="default" size="100%">validation process</style></keyword><keyword><style face="normal" font="default" size="100%">waste management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">0167-6369</style></isbn><abstract><style face="normal" font="default" size="100%">The use of a combination of electrokinetic remediation and phytoremediation to decontaminate two metal-polluted soils has been demonstrated in laboratory-scale reactors. One soil was heavily contaminated with copper, the other with cadmium and arsenic (2500 μg g-1 Cu; 300-400 μg g-1 Cd and 230 μg g-1 As, respectively). Test reactors with two separated chambers, each with a capacity of 5.25 kg soil, were constructed, then the respective chambers were filled with either a mixture of the polluted soil and a control topsoil (75:25) or topsoil alone. Reactors were sown with perennial ryegrass (Lolium perenne cv Elka) and a constant voltage of 30 V was applied continually across the soils in each reactor. Soil sampling took place at the start and the end of the test run, whilst plant foliage was sampled after approximately 3 weeks (both reactors) 6 weeks (Cd soil reactor only) and at the conclusion of each test run (98 days Cu soil, 80 days Cd soil). Soil and plant metal concentrations were measured, together with soil pH. Results showed that in both soils there was a significant re-distribution of metals from anode to cathode in the test reactors, coupled with an enhancement of plant Cu uptake in the cathode region for the Cu soil. Patterns of plant Cd uptake were less clear cut and were not as clearly related to the redistribution of Cd measured in the soil. There was significant acidification of soil at the anode in each test reactor, but soil pH in other parts of the reactor changed little during the course of the experiment. Plant growth was affected at the anode, but was not affected in other parts of the reactor. There was no visual evidence of metal toxicity in the ryegrass in either polluted soil. Some effects on soil fungi were apparent, with a stimulation of Fusarium infection of ryegrass in the cathode region of all reactors and the appearance of sporophores of Coprinus in the same location. It is concluded that the combination of the two techniques represents a very promising approach to the decontamination of metal polluted soils that now requires validation in field conditions.</style></abstract><notes><style face="normal" font="default" size="100%">L36503188&#xD;2003-05-06</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L36503188</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1023/A:1022851501118</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">12733815</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1023/A:1022851501118</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muraca, P.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative assessment of chlorine, heat, ozone, and UV light for killing Legionella pneumophila within a model plumbing system</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">447-53</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">1987/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chlorine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Hot Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">*Legionella/drug effects/radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Ozone/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Sanitary Engineering</style></keyword><keyword><style face="normal" font="default" size="100%">*Sterilization</style></keyword><keyword><style face="normal" font="default" size="100%">Ultraviolet Rays</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1987</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0099-2240 (Print)&#xD;0099-2240</style></isbn><accession-num><style face="normal" font="default" size="100%">3566272</style></accession-num><abstract><style face="normal" font="default" size="100%">Nosocomial Legionnaires disease can be acquired by exposure to the organism from the hospital water distribution system. As a result, many hospitals have instituted eradication procedures, including hypercholorination and thermal eradication. We compared the efficacy of ozonation, UV light, hyperchlorination, and heat eradication using a model plumbing system constructed of copper piping, brass spigots, Plexiglas reservoir, electric hot water tank, and a pump. Legionella pneumophila was added to the system at 10(7) CFU/ml. Each method was tested under three conditions; (i) nonturbid water at 25 degrees C, (ii) turbid water at 25 degrees C, and (iii) nonturbid water at 43 degrees C. UV light and heat killed L. pneumophila most rapidly and required minimal maintenance. Both UV light and heat (60 degrees C) produced a 5 log kill in less than 1 h. In contrast, both chlorine and ozone required 5 h of exposure to produce a 5 log decrease. Neither turbidity nor the higher temperature of 43 degrees C impaired the efficacy of any of the disinfectant methods. Surprisingly, higher temperature enhanced the disinfecting efficacy of chlorine. However, higher temperature accelerated the decomposition of the chlorine residual such that an additional 120% volume of chlorine was required. All four methods proved efficacious in eradicating L. pneumophila from a model plumbing system.</style></abstract><notes><style face="normal" font="default" size="100%">Muraca, P&#xD;Stout, J E&#xD;Yu, V L&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;Appl Environ Microbiol. 1987 Feb;53(2):447-53.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC203680</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>397</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">397</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casey, A. L.</style></author><author><style face="normal" font="default" size="100%">Karpanen, T. J.</style></author><author><style face="normal" font="default" size="100%">Adams, D.</style></author><author><style face="normal" font="default" size="100%">Lambert, P. A.</style></author><author><style face="normal" font="default" size="100%">Nightingale, P.</style></author><author><style face="normal" font="default" size="100%">Miruszenko, L.</style></author><author><style face="normal" font="default" size="100%">Elliott, T. S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T.S.J. Elliott, University Hospitals Birmingham, National Health Service Foundation Trust, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">A comparative study to evaluate surface microbial contamination associated with copper-containing and stainless steel pens used by nurses in the critical care unit</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e52-e54</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">2 propanol</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">stainless steel</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter lwoffii</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium isolation</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">health care personnel</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection rate</style></keyword><keyword><style face="normal" font="default" size="100%">devices</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">microbial contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Micrococcus</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nurse</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">Agrobacterium tumefaciens</style></keyword><keyword><style face="normal" font="default" size="100%">room temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Sphingomonas paucimobilis</style></keyword><keyword><style face="normal" font="default" size="100%">storage</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus oralis</style></keyword><keyword><style face="normal" font="default" size="100%">time</style></keyword><keyword><style face="normal" font="default" size="100%">writing</style></keyword><keyword><style face="normal" font="default" size="100%">writing pen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553&#xD;1527-3296</style></isbn><abstract><style face="normal" font="default" size="100%">A clinical study was undertaken to compare the surface microbial contamination associated with pens constructed of either a copper alloy or stainless steel used by nurses on intensive care units. A significantly lower level of microbial contamination was found on the copper alloy pens. Copyright © 2011 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L51467758&#xD;2011-06-14&#xD;2011-10-17</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L51467758</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2010.12.012</style></url><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272359/1-s2.0-S0196655311X00093/1-s2.0-S0196655311001131/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEHQaCXVzLWVhc3QtMSJGMEQCIDjmiqihRxmGIgorGIzvgwQcifPoe0UCmoJWGCCPHQsSAiAm0vw5irPS94z3Pd92%2BMZUPHtA49n7Lr3RzvNwclLP7Cq0AwhtEAIaDDA1OTAwMzU0Njg2NSIM%2FO9r7nOOBUds%2FtjdKpEDXEIoG2eXGz3qh4ni%2Fp3LwCMP9Owpe6dSyd6vYaPAEHL8JZmqZEEqGLIVIkPj6WQDZuVXpjytahPfXjlv1ii8dKq82rFDzbXWFH5%2FcrYsc6Z1h7F4zojDSgyYVFhK0Jaqm5EiJAmhS3wzANBpMs1AQBGJEVIMqebpNDax1QUba98bYN3RTAEe4zDfP7IiKb%2BkyNkXcH4QCxK22Gk2AB7CrHNtM9OCeV4KzMFTiWpIT4m6TgCeFOkeEKyvWHwYrr3WXyX1IlXB3ZlZXj9bbSrcBvOwFN1LvuoPkW3rzrBc%2FJ%2B8ZJeoV15Jt4pUacWxJ8Au6R0iwSZgSiGVHxl1CNY4K53mgkxgOM5sq6B%2FqPv0Qmfb42%2Bg9Qh5VTtSdzAtJ6%2BpHvyk2eHt8iTc0MQTRhfnD54tXd1nCDAZUPSW1lGConOelfliSrG9fu1DEdQPoJ5CLssEbSNN9y9F%2BqJ4EsmQO97PVvytkXZrtbd2A4JxHTLI5dkb4KbZMBqZy9sY6S5E%2BpEMJJo5GGaclyAlc9AJZMQwuavr8wU67AEW9be%2FZvnz8AXpBKP83RFcJJ%2BCqlaDb2xmjSbF8IpyVgKa948AMaSVlw1XPVaRffzxWB3iM%2FOx9MGke3cR1bozGSuNoy2YPVxI9zLvmQNKcOPsaxsrxq8in%2B8YY2nX2WT4nNgJ5AinGYww18wjh7G2auzzjqBCbTVoIeY76D4FJhBbEbppGWovPQkhk9PMS%2FWpvBjjMwF72AjVBEWbZPbUf71%2F2%2FlEpDAvwE3IIcFAyDpDhlr2Q49%2FYKclFzQG4tkMBWqv0JTHKqfN5JdIHySt7F63RbsF8PiRX4mTJMMStAXiZaDrdDoRPUDfvw%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200325T052539Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTY64GSHCFU%2F20200325%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=9209ee4b3eb861bbe5d7656d2b35f7356f8ee40381735879a8a11c900f522fc6&amp;hash=f17e931ae365f2673753ba00b7a1b0c3cf23b9c7b52b187ad2755e33144e47b4&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S0196655311001131&amp;tid=spdf-7f0b6b20-2ad0-450b-87fb-fe9537051623&amp;sid=b6c9ad95419947419618c891c856c8d040eegxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://4208089464/Casey-2011-A comparative study to evaluate sur.pdf</url></pdf-urls></urls><custom5><style face="normal" font="default" size="100%">21664004</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2010.12.012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>387</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">387</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thanapirom, K.</style></author><author><style face="normal" font="default" size="100%">Treeprasertsuk, S.</style></author><author><style face="normal" font="default" size="100%">Komolmit, P.</style></author><author><style face="normal" font="default" size="100%">Kullavanijaya, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Thanapirom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparing long-term outcome of patients with wilson&apos;s disease presenting with acute liver failure versus acute-on-chronic liver failure</style></title><secondary-title><style face="normal" font="default" size="100%">Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S985-S986</style></pages><volume><style face="normal" font="default" size="100%">142</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">chelating agent</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">acute on chronic liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">acute liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">onset age</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">copper metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">chronic liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">survival</style></keyword><keyword><style face="normal" font="default" size="100%">septicemia</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0016-5085</style></isbn><abstract><style face="normal" font="default" size="100%">Background : Wilson&apos; s disease (WD) is an inherited disorder of copper metabolism, leading to hepatic and neuropsychiatric manifestations. The long-term outcome of patients with Wilson&apos;s disease presenting with acute liver failure (ALF) versus those with acute-on-chronic liver failure (ACLF) has not been well documented. We aimed to compare the clinical presentations and long-term outcome after various treatments between patients with ALF versus those with ACLF. Material and methods : We performed a retrospective review of 39 patients with Wilson&apos;s disease, at the King Chulalongkorn Memorial Hospital (KCMH) from January 2003 to September 2011. Primary outcome of this study was liver complications or deaths from any cause. ACLF was defined as an acute hepatic insult in patients with previously diagnosed or undiagnosed chronic liver disease, whereas ALF was defined by an occurrence in the absence of any pre-existing liver disease. Results : Twenty-two of 39 patients (56.4%) presented predominantly with hepatic symptoms with the mean duration of follow-up of 7.7 +/- 8.5 years. Ten of them (45%) presented with ALF, whereas 12 patients (55%) presented with ACLF. Patients with ALF showed a significantly (15.4 +/- 4.5 vs 28.1 +/- 13.0 years; p &lt; 0.05) earlier age of onset of presenting symptoms than those with ACLF. The mean baseline of 24- hour urinary copper in patients with ALF was higher than those found in ACLF (1,645 +/- 1,406 vs 441 +/- 434 mcg/day, respectively). The liver biochemical characteristics, which predicted acute liver failure were the ratios of serum alkaline phosphatase to total bilirubin of &lt;2, and aspatate transaminase to alanine transaminase of &gt;4, were found more often in patients with ALF than those presenting with ACLF without statistical significance ( 30% vs 8.3%; p = 0.29). Fourteen patients (63.6%) improved with supportive care and chelating agents. No significant difference of clinical improvement was found between patients presented with ALF and ACLF (80% vs 50%; p = 0.19). One patient died of gram negative bacterial septicemia. By using the survival analysis, the mean duration time to liver complications or death in patients with ALF was 16.2 +/- 2.3 years which was significantly longer than those with ACLF (8.5 +/- 3.2 years; p = 0.012). Figure1 showed the significantly longer cumulative percent of free period from liver complication or death during a 9-year period in patients with ALF compared to patients with ACLF (80% vs 21%, p = 0.012). Conclusion : Patients with Wilson&apos;s disease presenting with acute-onchronic liver failure manifested symptoms later and had more liver complications than patients with acute liver failure, as well as a lower cumulative free period from liver complication or death. (Table Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L71109045&#xD;2013-07-15</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71109045</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">79</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Norman, W. V.</style></author><author><style face="normal" font="default" size="100%">Chiles, J. L.</style></author><author><style face="normal" font="default" size="100%">Turner, C. A.</style></author><author><style face="normal" font="default" size="100%">Brant, R.</style></author><author><style face="normal" font="default" size="100%">Aslan, A.</style></author><author><style face="normal" font="default" size="100%">Kaczorowski, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Contraception Access Research Team, Women&apos;s Health Research Institute, Vancouver, British Columbia, V6H 1G3, Canada. wendy.norman@ubc.ca</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparing the effectiveness of copper intrauterine devices available in Canada. Is FlexiT non-inferior to NovaT when inserted immediately after first-trimester abortion? Study protocol for a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">147</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">2012/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Abortion, Induced</style></keyword><keyword><style face="normal" font="default" size="100%">British Columbia</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Device Expulsion/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Rate</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy Trimester, First</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy, Unplanned</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy, Unwanted</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 24</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1745-6215</style></isbn><accession-num><style face="normal" font="default" size="100%">22920273</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: We describe the rationale and protocol for a randomized noninferiority controlled trial (RCT) to determine if the Flexi-T380(+) copper intrauterine contraceptive device (IUD) is comparable in terms of effectiveness and expulsion rates to the most common Canadian IUD currently in use, NovaT-200, when placed immediately after a first-trimester abortion. METHODS/DESIGN: Consenting women choosing to use an IUD after an abortion for a pregnancy of less than 12 weeks of gestation will be randomized to device-type groups to receive immediate post-abortion placement of either a Flexi-T380(+) IUD, a device for which no current evidence on expulsion or effectiveness rates is available, or the Nova-T200 IUD, the only other brand of copper IUD available in Canada at the time of study initiation. The primary outcome measure is IUD expulsion rate at 1 year. Secondary outcomes include: pregnancy rate, method continuation rate, complication rates (infection, perforation), and satisfaction with contraceptive method. A non-intervention group of consenting women choosing a range of other post-abortion contraception methods, including no contraception, will be included for comparison of secondary outcomes. Web-based contraception satisfaction questionnaires, clinical records, and government-linked health administrative databases will be used to assess primary and secondary outcomes. DISCUSSION: The RCT design, combined with access to clinical records at all provincial abortion clinics, and to information in provincial single-payer linked administrative health databases, birth registry, and hospital records, offers a unique opportunity to determine if a novel IUD has a comparable expulsion rate to that of the current standard IUD in Canada, in addition to the first opportunity to determine pregnancy rate and method satisfaction at 1 year post-abortion for women choosing a range of post-abortion contraceptive options. We highlight considerations of design, implementation, and evaluation of the first trial to provide rigorous evidence for the effectiveness of current Canadian IUDs when inserted after first-trimester abortion. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01174225.</style></abstract><notes><style face="normal" font="default" size="100%">1745-6215&#xD;Norman, Wendy V&#xD;Chiles, Jessica L&#xD;Turner, Caroline A&#xD;Brant, Rollin&#xD;Aslan, Andra&#xD;Kaczorowski, Janusz&#xD;117684/Canadian Institutes of Health Research/Canada&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Trials. 2012 Aug 24;13:147. doi: 10.1186/1745-6215-13-147.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3495410</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1745-6215-13-147</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of immediate and delayed intrauterine contraceptive device copper T-380A</style></title><secondary-title><style face="normal" font="default" size="100%">International journal of gynaecology and obstetrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International journal of gynaecology and obstetrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">306</style></pages><volume><style face="normal" font="default" size="100%">Conference: 22nd FIGO World Congress of Gynecology and Obstetrics. Brazil. 143</style></volume><number><style face="normal" font="default" size="100%">Supplement 3</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01923140</style></accession-num><abstract><style face="normal" font="default" size="100%">Objectives: To compare the efficacy in terms of contraception, infection rate, expulsion and uterine perforation of immediate and delayed intrauterine contraceptive device copper T‐380A after vaginal delivery and caesarean section. Method: All patients admitted in labour ward in department of obstetrics and Gynecology after 38 complete weeks of pregnancy who underwent spontaneous vaginal delivery or caesarean section were enrolled. Patients were divided in to two groups randomly by lottery method, group A and group B. Intrauterine contraceptive device copper T‐380A was inserted immediately after delivery of placenta {both after spontaneous vertex delivery and caesarean section} in group A, immediate group. For quantitative variables mean standard deviations were calculated, and for qualitative variables frequency and percentages were calculated. Results: Out of 178 patients, expulsion rate of copper T‐380A in group A was 17% (30) and in group B was 10% (17). 18% (32) in group A had infection and 4% (7) in group B had infection. There was no case of uterine perforation in either group. Conclusions: The study concludes that intrauterine contraceptive device copper T‐380A is a safe and effective method of contraception after vaginal delivery and caesarean section. Efficacy in terms of expulsion rate and infection in immediate group is high as compared to delayed group but overall expulsion rate and infection is low and acceptable in both groups. Uterine perforation is minimum in experienced hands.</style></abstract><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01923140/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 624606025</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ijgo.12582</style></electronic-resource-num></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leslie, D. E.</style></author><author><style face="normal" font="default" size="100%">Garland, S. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbiology Department, Royal Women&apos;s Hospital, Melbourne, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of immunofluorescence and culture for the detection of Actinomyces israelii in wearers of intra-uterine contraceptive devices</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">224-8</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">1991/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Actinomyces/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Actinomycosis/*diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Fluorescent Antibody Technique</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/*diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Specimen Handling</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal Smears</style></keyword><keyword><style face="normal" font="default" size="100%">Australia</style></keyword><keyword><style face="normal" font="default" size="100%">*Bacterial And Fungal Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods</style></keyword><keyword><style face="normal" font="default" size="100%">Developed Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Human Volunteers</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Iud</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Unmedicated</style></keyword><keyword><style face="normal" font="default" size="100%">*Laboratory Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">*Laboratory Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">Oceania</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Report</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1991</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-2615 (Print)&#xD;0022-2615</style></isbn><accession-num><style face="normal" font="default" size="100%">1941993</style></accession-num><abstract><style face="normal" font="default" size="100%">A direct immunofluorescence (IF) method was compared with traditional culture methods for the detection of Actinomyces israelii in endocervical and intra-uterine-device (IUD) smears from 124 IUD wearers. Of 11 specimens that gave positive results by IF, only one was positive by culture. Of the 10 patients with positive IF specimens, three (30%) had signs and symptoms suggestive of pelvic infection and no other pathogen was detected. Direct IF of cervical smears offers a simple, relatively cheap method to screen IUD wearers for A. israelii. Clinical management of such cases is discussed.&#xD;An immunofluorescent microscopic method (IF) was compared with conventional culture methods for detection of Actinomyces israelii in smears from the endocervix and IUD of 124 women over a 4-month period at the Royal Women&apos;s Hospital, Melbourne. Genital actinomycosis is a non-contagious, chronic, suppurative infection caused by a slowly growing, filamentous, gram-positive anaerobe, and it can lead to fibrosis, abscess or death. The women, attending the Family Planning, Gynecology or Emergency Departments for termination of contraception, replacement of an IUD or for signs or symptoms of pelvic infection, work plastic or copper IUDs. All were screened for Chlamydia and cervical cytology. Actinomyces cultures were screened for 4 weeks and A. israelii identified by morphology, Gram stain and gas-liquid chromatography. The immunofluorescence method involved pepsin treatment of heat-fixed slides, staining with fluorescein-conjugated antibody to A. israelii types I and II, counter-staining, and examination under fluorescence microscopy. Slides were graded subjectively in comparison with positive and negative controls. 9 (11%) of 82 cervical smears, and 2 (4%) of 49 IUD smears were positive by IF, while only 1 was positive by culture: all from 10 patients. One patient has a positive chlamydia culture, and also symptoms of pelvic infection requiring hospitalization. There were 6 others who had symptoms such as pain and discharge, who were treated with IUD removal and antibiotics. 3 women asymptomatic women merely had their IUDs removed. There were no incidents of severe actinomycosis requiring surgery or prolonged hospital treatment although this infection can in rare case be life-threatening. Management of pelvic actinomycosis was discussed.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Leslie, D E&#xD;Garland, S M&#xD;Comparative Study&#xD;Journal Article&#xD;England&#xD;J Med Microbiol. 1991 Oct;35(4):224-8. doi: 10.1099/00222615-35-4-224.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1099/00222615-35-4-224</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>371</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">371</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sedighi, B.</style></author><author><style face="normal" font="default" size="100%">Ebrahimi, H. A.</style></author><author><style face="normal" font="default" size="100%">Aboothorabi, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B. Sedighi, Department of Neurology, Kerman Medical University, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of serum levels of copper and zinc among patients newly-diagnosed of Multiple Sclerosis (MS) referred to Kerman Shafa hospital during 2007-2009 by a control group of their relatives</style></title><secondary-title><style face="normal" font="default" size="100%">Multiple Sclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Multiple Sclerosis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">671</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">metal</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">Asian</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Epstein Barr virus</style></keyword><keyword><style face="normal" font="default" size="100%">neurologist</style></keyword><keyword><style face="normal" font="default" size="100%">immunity</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">case control study</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system</style></keyword><keyword><style face="normal" font="default" size="100%">demyelinating disease</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">environmental factor</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">hemostasis</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D deficiency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1352-4585</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: MS is a chronic demyelinating disease of central nervous system. Studies have shown that MS is a result of immune reaction of unknown etiology, but there are several factors known to be effective; such as vitamin D deficiency, smoking, previous infection by Epstein-Barr Virus (EBV), contact to metals and living in high prevalence ecological regions. Method: This is a case-control study conducted from October 2007 to January 2009. 58 MS patients who were diagnosed by neurologist based on McDonald criteria were selected as the patient group and 39 healthy people from among their relatives who were paralleled with regard to age and sex were selected as the control group and the serum level of copper and zinc was measured and compared in both groups. Results: There were 48 female and 10 male individuals in patients group and 30 female and 9 male in control group. Both groups were resembled in age and sex. The average serum level of Copper in patients group and the control group were 93.7 - 88.9 micrograms per deciliter respectively and average serum level of Zinc were 36.7 - 40.9 micrograms per deciliter respectively. There was no significant difference between two groups (P =0.459 - 0.249 respectively) also no significant difference was seen in different levels of Copper and Zinc among two groups (P =0.551 - 0.377 respectively). Conclusion: We brought to this theory that if we exclude some distorting factors that play role in the hemostasis of Copper and Zinc, there will be no difference in serum levels of Copper and Zinc in MS patients comparing to the control group that is similar in genetic and environmental factors.</style></abstract><notes><style face="normal" font="default" size="100%">L71184453&#xD;2013-10-11</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71184453</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/1352458513477288</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1352458513477288</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>100</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hall, T. J.</style></author><author><style face="normal" font="default" size="100%">Wren, M. W.</style></author><author><style face="normal" font="default" size="100%">Jeanes, A.</style></author><author><style face="normal" font="default" size="100%">Gant, V. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Remedy Research Ltd., 8 Blenheim Road, London, UK. tonyjhall@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">A comparison of the antibacterial efficacy and cytotoxicity to cultured human skin cells of 7 commercial hand rubs and Xgel, a new copper-based biocidal hand rub</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">322-6</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2009/01/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Cutaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohols/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents, Local/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Culture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/chemistry/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Epithelial Cells/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Hand Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Skin/cytology/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Skin Irritancy Tests</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">19118920</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hand cleanliness is important in hospital infection control, but skin irritation from frequent alcohol-based hand rub use reduces compliance. We have compared a new copper biocide/Aloe vera-based biocidal hand rub (Xgel) with 7 commercially available hand rubs. METHODS: Hand rubs were cultured with human skin cells for 24 hours after which cytotoxicity was assessed using the sulforhodamine B assay. The EN 12054 bacterial suspension test protocol was used to assess biocidal activity of 2 of the least cytotoxic hand rubs (Xgel and Purell). RESULTS: Hand rubs had 50% cytotoxic concentrations ranging from &gt;10% to &lt;0.1% vol/vol. In the EN12054 assay, Xgel reduced colony forming units (CFU) by &gt;10(8) with methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter in 1 minute, whereas Purell only reduced CFU by 10(4) and 10(5), respectively. Purell was ineffective against C difficile spores, whereas Xgel produced a 3 x 10(3) reduction in CFU. CONCLUSION: The hand rubs had a wide range of cytotoxicity values for human skin cells, with Xgel being the least cytotoxic to human skin cells. In the EN 12054 bacterial suspension test, Xgel was more effective than Purell against all organisms tested. It should be noted that these in vitro results may not translate into clinical differences.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Hall, Tony J&#xD;Wren, Michael W D&#xD;Jeanes, Annette&#xD;Gant, Vanya A&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 2009 May;37(4):322-6. doi: 10.1016/j.ajic.2008.09.011. Epub 2008 Dec 31.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2008.09.011</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>285</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spencer, W.</style></author><author><style face="normal" font="default" size="100%">Westermann, G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comprehensive overview of current topics: Infection control, sterilization &amp; decontamination in healthcare, London, 21-22 March 2017</style></title><secondary-title><style face="normal" font="default" size="100%">Zentralsterilisation - Central Service</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zentralsterilisation - Central Service</style></full-title></periodical><pages><style face="normal" font="default" size="100%">86-88</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">decontamination</style></keyword><keyword><style face="normal" font="default" size="100%">dentistry</style></keyword><keyword><style face="normal" font="default" size="100%">endoscope</style></keyword><keyword><style face="normal" font="default" size="100%">England</style></keyword><keyword><style face="normal" font="default" size="100%">hospital department</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">instrument sterilization</style></keyword><keyword><style face="normal" font="default" size="100%">low temperature</style></keyword><keyword><style face="normal" font="default" size="100%">materials management</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Norway</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0942-6086</style></isbn><notes><style face="normal" font="default" size="100%">L616189099&#xD;2017-05-19&#xD;2017-05-31</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L616189099</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>305</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kar Mahapatra, D.</style></author><author><style face="normal" font="default" size="100%">Bharti, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D. Kar Mahapatra, Guru Ghasidas Vishwavidyalaya (A Central University of India), Bilaspur, Chhattisgarh, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Computer assisted rational design and synthesis of some novel 2,4-di-substitued thiazole derivatives and their metal complexes (copper, cobalt, and nickel) as inhibitor of bacterial metabolic enzymes</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">126-127</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><keywords><keyword><style face="normal" font="default" size="100%">thiazole derivative</style></keyword><keyword><style face="normal" font="default" size="100%">metal complex</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cobalt</style></keyword><keyword><style face="normal" font="default" size="100%">nickel</style></keyword><keyword><style face="normal" font="default" size="100%">digestant</style></keyword><keyword><style face="normal" font="default" size="100%">nuclease</style></keyword><keyword><style face="normal" font="default" size="100%">amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">phorbol dibutyrate</style></keyword><keyword><style face="normal" font="default" size="100%">thiazole</style></keyword><keyword><style face="normal" font="default" size="100%">thiosemicarbazide</style></keyword><keyword><style face="normal" font="default" size="100%">nickel complex</style></keyword><keyword><style face="normal" font="default" size="100%">copper complex</style></keyword><keyword><style face="normal" font="default" size="100%">ligand</style></keyword><keyword><style face="normal" font="default" size="100%">transition element</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">Schiff base</style></keyword><keyword><style face="normal" font="default" size="100%">computer</style></keyword><keyword><style face="normal" font="default" size="100%">synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">microbial activity</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">chemical structure</style></keyword><keyword><style face="normal" font="default" size="100%">crystal structure</style></keyword><keyword><style face="normal" font="default" size="100%">analytic method</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">computer model</style></keyword><keyword><style face="normal" font="default" size="100%">drug design</style></keyword><keyword><style face="normal" font="default" size="100%">plasmid</style></keyword><keyword><style face="normal" font="default" size="100%">molecular weight</style></keyword><keyword><style face="normal" font="default" size="100%">gel electrophoresis</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus subtilis</style></keyword><keyword><style face="normal" font="default" size="100%">microorganism</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1201-9712</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Recent clinical reports have highlighted the increasing occurrence of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and other antibiotic-resistant human pathogenic microorganisms. Transition metal complexes of heterocyclic moieties or/with Schiff&apos;s base components have been reported to show promising nucleolytic activity. In an effort to develop newer generation low molecular weight ligands, few thiazole coupled with Schiff&apos;s base and their metal complexes were synthesized and biologically evaluated. Methods &amp; Materials: A novel series of thiazole derivatives were rationally designed by Computer Assisted Drug Design (CADD) approach (VLife Science®). The optimized scaffold was synthesized in multiple steps from thiosemicarbazide and was suitably cyclized to get corresponding active 2,4-di-substitued thiazole derivatives. Metal complexes of thiazoles were further prepared using salts of d-block compounds (copper, nickel and cobalt) as per protocol designed in our laboratory. The modern analytical techniques (UV-Vis, IR, NMR, MS, RS, XRD, AAS, MM, MC) revealed that the results were in full agreement with their assigned chemical structures. All the synthesized compounds were screened for their anti-microbial activity according to standard protocol against bacterial strains (E. coli, MTCC-1687; S. aureus, MTCC-2940; B. subtilis, MTCC-441; and K. pneumonia, MTCC-3040). The nucleolytic activity of compounds and metal complexes were evaluated using gel electrophoresis employing E. coli plasmid pBR322. Results: Among them, para-substituted (halogenated) thiazoles exhibited excellent anti-bacterial activity against E. coli, S. aureus, and K. pneumonia. Nearly all compounds exhibited moderate to high nuclease activity. The copper complexes showed moderate nuclease activity while cobalt and nickel complexes displayed excellent nuclease activity. The in silico docking study performed revealed the binding orientations of these compounds at active site amino acid residues ASN 165 and GLU 40 (PDB ID: 1AHP), amino acid residues TYR 151 and GLY 18 (PDB ID: 2C44) and amino acid residues ARG 73 and ASP 76 (PDB ID: 1K6W) of crystal structure of E. coli metabolic enzymes. Conclusion: From this study, it can be concluded that the novel molecules have tremendous anti-microbial and nuclease activity. This research helps in understanding mechanism of action of thiazole based anti-microbials and it may possibly be used as template for searching potent anti-microbial agents in future.</style></abstract><notes><style face="normal" font="default" size="100%">L72245267&#xD;2016-04-21</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72245267</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ijid.2016.02.314</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijid.2016.02.314</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>479</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">479</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Domej, W.</style></author><author><style face="normal" font="default" size="100%">Krachler, M.</style></author><author><style face="normal" font="default" size="100%">Goessler, W.</style></author><author><style face="normal" font="default" size="100%">Maier, A.</style></author><author><style face="normal" font="default" size="100%">Irgolic, K. J.</style></author><author><style face="normal" font="default" size="100%">Lang, J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W. Domej, Department of Internal Medicine, Karl-Franzens-University, Graz, Austria</style></auth-address><titles><title><style face="normal" font="default" size="100%">Concentrations of copper, zinc, manganese, rubidium, and magnesium in thoracic empyemata and corresponding sera</style></title><secondary-title><style face="normal" font="default" size="100%">Biological Trace Element Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biological Trace Element Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">53-66</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">1-3</style></number><keywords><keyword><style face="normal" font="default" size="100%">C reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">lactate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">rubidium</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">mineral blood level</style></keyword><keyword><style face="normal" font="default" size="100%">pleura effusion</style></keyword><keyword><style face="normal" font="default" size="100%">pleura empyema</style></keyword><keyword><style face="normal" font="default" size="100%">VG Plasma Quad PQ 2 Turbo Plus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><isbn><style face="normal" font="default" size="100%">0163-4984</style></isbn><abstract><style face="normal" font="default" size="100%">In this study, a number of selected trace elements and clinically relevant parameters were compared between thoracic empyemata and the corresponding sera for a better understanding of the trace element distribution between these two compartments. Serumempyema pairs were obtained from 13 patients and quantified for selected and essential trace elements, namely copper (Cu), zinc (Zn), manganese (Mn), rubidium (Rb), and magnesium (Mg), by inductively coupled plasma-mass spectrometry (ICP-MS). In addition, the concentrations of the following clinical laboratory parameters were analyzed by standard methods: total protein, leukocyte count, lactate dehydrogenase, glucose, pH, and the C-reactive protein. Individual concentrations of the elements determined in the empyemata were frequently higher than in pleural effusions of any other benign or malignant condition except for Cu. Serum Cu exceeded the normal range (600-1400 μg/kg) in 6 out of 13 patients (median 1410 μg/kg). In the empyemata, Zn concentrations (median 2000 μg/kg) were characteristically higher than in the sera (median 450 μg/kg) and exceeded the upper limit for serum (1200 μg/kg) in 8 of the 13 patients. Manganese concentrations in the empyemata (median 2.7 μg/kg) were also higher compared to corresponding sera, although they stayed within the limits considered normal for serum of healthy adults (upper limit 2.9 μg/kg). Rubidium was also moderately higher in most empyemata (median 290 μg/kg) and exceeded the upper limit for serum (560 μg/kg) in two patients. The median concentration of the essential element magnesium was higher in the empyemata (23 mg/kg) than in the sera (21 mg/kg). However, all serum Mg concentrations except three remained within the normal range (17-22 mg/kg). Removal of large amounts of empyematous fluid may deprive the body of trace elements and can cause suboptimal or deficient trace element status and homeostasis. Recuperation will be accelerated by compensatory supplementation of trace elements. Therefore, selective medication with adequate trace element compounds in patients with thoracic empyema can be generally recommended for zinc. The other elements need not necessarily be monitored or substituted, because of their stable concentrations in the serum. Rb may have a biological impact, but deficiency symptoms in man are not clearly defined.</style></abstract><notes><style face="normal" font="default" size="100%">L32275888&#xD;2001-04-20</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L32275888</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1385/BTER:78:1-3:53</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">VG Plasma Quad PQ 2 Turbo Plus(VG,United Kingdom)</style></custom3><custom4><style face="normal" font="default" size="100%">VG(United Kingdom)</style></custom4><custom5><style face="normal" font="default" size="100%">11314988</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1385/BTER:78:1-3:53</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>21</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">21</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abbas, M.</style></author><author><style face="normal" font="default" size="100%">Pires, D.</style></author><author><style face="normal" font="default" size="100%">Peters, A.</style></author><author><style face="normal" font="default" size="100%">Morel, C. M.</style></author><author><style face="normal" font="default" size="100%">Hurst, S.</style></author><author><style face="normal" font="default" size="100%">Holmes, A.</style></author><author><style face="normal" font="default" size="100%">Saito, H.</style></author><author><style face="normal" font="default" size="100%">Allegranzi, B.</style></author><author><style face="normal" font="default" size="100%">Lucet, J. C.</style></author><author><style face="normal" font="default" size="100%">Zingg, W.</style></author><author><style face="normal" font="default" size="100%">Harbarth, S.</style></author><author><style face="normal" font="default" size="100%">Pittet, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infection Control Programme, University of Geneva, Hospitals and Faculty of Medicine, WHO Collaborating Centre on Patient Safety (Infection Control and Improving Practices), Geneva, Switzerland. mohamed.abbas@hcuge.ch.&#xD;Infection Control Programme, University of Geneva, Hospitals and Faculty of Medicine, WHO Collaborating Centre on Patient Safety (Infection Control and Improving Practices), Geneva, Switzerland.&#xD;Department of Infectious Diseases, Centro Hospitalar Lisboa Norte and Faculdade de Medicine da Universidade de Lisboa, Lisbon, Portugal.&#xD;Institute for Ethics, History, and the Humanities, University of Geneva Medical School, Geneva, Switzerland.&#xD;Department of Infectious Diseases and the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.&#xD;Infection Prevention and Control Global Unit, Department of Service Delivery and Safety, World Health Organization, 1211, Geneva, Switzerland.&#xD;Infection Control Unit, Bichat-Claude Bernard Hospital (AP-HP), Paris, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Conflicts of interest in infection prevention and control research: no smoke without fire. A narrative review</style></title><secondary-title><style face="normal" font="default" size="100%">Intensive Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Intensive Care Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1679-1690</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">2018/09/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Biomedical Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Conflict of Interest</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Infection Control/economics</style></keyword><keyword><style face="normal" font="default" size="100%">Research Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Support as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Conflicts of interest</style></keyword><keyword><style face="normal" font="default" size="100%">Industry sponsorship</style></keyword><keyword><style face="normal" font="default" size="100%">Infection prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">Integrity</style></keyword><keyword><style face="normal" font="default" size="100%">Public-private partnerships</style></keyword><keyword><style face="normal" font="default" size="100%">Retraction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0342-4642</style></isbn><accession-num><style face="normal" font="default" size="100%">30206643</style></accession-num><abstract><style face="normal" font="default" size="100%">Conflicts of interest (COIs) do occur in healthcare research, yet their impact on research in the field of infection prevention and control (IPC) is unknown. We conducted a narrative review aiming to identify examples of COIs in IPC research. In addition to well-known instances, we conducted PubMed and Google searches to identify and report case studies of COIs in IPC and antimicrobial resistance (AMR), which were chosen arbitrarily following consensus meetings, to illustrate different types of COIs. We also searched the Retraction Watch database and blog to systematically identify retracted IPC and/or infectious disease-related papers. Our review highlights COIs in academic research linked to ties between industry and physicians, journal editors, peer-reviewed journals&apos; choice for publication, and guideline committees participants and authors. It explores how COIs can affect research and could be managed. We also present several selected case studies that involve (1) the chlorhexidine industry and how it has used marketing trials and key opinion leaders to promote off-label use of its products; (2) the copper industry and how reporting of its trials in IPC have furthered their agenda; (3) the influence of a company developing &quot;closed infusion systems&quot; for catheters and how this affects networks in low- and middle-income countries and guideline development; (4) potential perverse incentives hospitals may have in reporting healthcare-associated infection or AMR rates and how government intervention may restrict AMR research for fear of bad publicity and subsequent negative economic consequences. Finally, the analysis of reasons for the retraction of previously published papers highlights the fact that misconduct in research may have other motivations than financial gain, the most visible form of COIs. COIs occur in the field of research in general, and IPC and AMR are no exceptions. Their effects pervade all aspects of the research and publication processes. We believe that, in addition to improvements in management strategies of COIs, increased public funding should be available to decrease researchers&apos; dependency on industry ties. Further research is needed on COIs and their management.</style></abstract><notes><style face="normal" font="default" size="100%">1432-1238&#xD;Abbas, Mohamed&#xD;ORCID: http://orcid.org/0000-0002-7265-1887&#xD;Pires, Daniela&#xD;Peters, Alexandra&#xD;Morel, Chantal M&#xD;Hurst, Samia&#xD;Holmes, Alison&#xD;Saito, Hiroki&#xD;Allegranzi, Benedetta&#xD;Lucet, Jean-Christophe&#xD;Zingg, Walter&#xD;Harbarth, Stephan&#xD;Pittet, Didier&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Intensive Care Med. 2018 Oct;44(10):1679-1690. doi: 10.1007/s00134-018-5361-z. Epub 2018 Sep 11.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00134-018-5361-z</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">82</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharpe, P. A.</style></author><author><style face="normal" font="default" size="100%">Schmidt, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Irwin P. Sharpe &amp; Associates, West Orange, NJ 07052, USA. pas@sharpeassociates.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Control and mitigation of healthcare-acquired infections: designing clinical trials to evaluate new materials and technologies</style></title><secondary-title><style face="normal" font="default" size="100%">Herd</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Herd</style></full-title></periodical><pages><style face="normal" font="default" size="100%">94-115</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/02/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Clinical Trials as Topic/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Facility Design and Construction/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Facility Environment</style></keyword><keyword><style face="normal" font="default" size="100%">Housekeeping, Hospital/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Design</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Fall</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1937-5867 (Print)&#xD;1937-5867</style></isbn><accession-num><style face="normal" font="default" size="100%">22322640</style></accession-num><abstract><style face="normal" font="default" size="100%">Hospitals clean environmental surfaces to lower microbial contamination and reduce the likelihood of transmitting infections. Despite current cleaning and hand hygiene protocols, hospital-acquired infections (HAIs) continue to result in a significant loss of life and cost the U.S. healthcare system an estimated $45 billion annually. Stainless steel and chrome are often selected for hospital touch surfaces for their &quot;clean appearance,&quot; comparatively smooth finish, resistance to standard cleaners, and relative effectiveness for removing visible dirt during normal cleaning. Designers use wood surfaces for aesthetics; plastic surfaces have become increasingly endemic for their relative lower initial cost; and &quot;antimicrobial agents&quot; are being incorporated into a variety of surface finishes.This paper concentrates on environmental surface materials with a history of bactericidal control of infectious agents and focuses on the methods necessary to validate their effectiveness in healthcare situations. Research shows copper-based metals to have innate abilities to kill bacteria in laboratory settings, but their effectiveness in patient care environments has not been adequately investigated. This article presents a research methodology to expand the evidence base from the laboratory to the built environment. For such research to have a meaningful impact on the design/specifying community, it should assess typical levels of environmental pathogens (i.e., surface &quot;cleanliness&quot;) as measured by microbial burden (MB); evaluate the extent to which an intervention with copper-based materials in a randomized clinical trial affects the level of contamination; and correlate how the levels of MB affect the incidence of infections acquired during hospital stays.</style></abstract><notes><style face="normal" font="default" size="100%">Sharpe, Peter A&#xD;Schmidt, Michael G&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;HERD. 2011 Fall;5(1):94-115. doi: 10.1177/193758671100500109.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/193758671100500109</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loo, V. G.</style></author><author><style face="normal" font="default" size="100%">Bertrand, C.</style></author><author><style face="normal" font="default" size="100%">Dixon, C.</style></author><author><style face="normal" font="default" size="100%">Vitye, D.</style></author><author><style face="normal" font="default" size="100%">DeSalis, B.</style></author><author><style face="normal" font="default" size="100%">McLean, A. P.</style></author><author><style face="normal" font="default" size="100%">Brox, A.</style></author><author><style face="normal" font="default" size="100%">Robson, H. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Royal Victoria Hospital, Montreal, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">360-4</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">1996/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Air Pollution, Indoor/*adverse effects/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillosis/complications/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Bone Marrow Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/complications/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital Design and Construction</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunocompromised Host</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">Neutropenia/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Oncology Service, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Ventilation/*standards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1996</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">8805066</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine the incidence of aspergillosis in patients with leukemia or bone marrow transplants during a construction-associated outbreak, and the effect of an environmental control program for Aspergillus. DESIGN: Clinical, microbiological, and pathological records were reviewed retrospectively once the outbreak was appreciated, and prospectively thereafter, to determine the presence or absence of aspergillosis and duration of neutropenia. SETTING: A university tertiary-care center with a single designated hematology-oncology unit. PATIENTS: From January 1988 to September 1993, there were 141 patients with leukemia or bone marrow transplants identified as being neutropenic during 231 admissions to this specialized unit. INTERVENTIONS: Installation of wall-mounted portable high-efficiency particulate air (HEPA)-filter air purifiers, application of copper-8-quinolinolate-formulated paint, replacement of perforated ceiling tiles with nonperforated type, sealing of all windows, replacement of horizontal, dust-accumulating blinds with vinyl, opaque, roller shades, and systematic and regular cleaning of surfaces. RESULTS: Thirty-six cases of nosocomial aspergillosis were diagnosed during this period. The incidence density (ID) in the preconstruction period was 3.18 per 1,000 days at risk. During construction activity-before the implementation of a control strategy-the ID increased dramatically to 9.88 per 1,000 days at risk. With infection control measures implemented and continued construction work, the ID decreased to 2.91 per 1,000 days at risk, comparable to the preconstruction baseline rate. CONCLUSIONS: An environmental control strategy incorporating widely available technology may have played an important role in controlling this outbreak of construction-associated invasive aspergillosis.</style></abstract><notes><style face="normal" font="default" size="100%">Loo, V G&#xD;Bertrand, C&#xD;Dixon, C&#xD;Vitye, D&#xD;DeSalis, B&#xD;McLean, A P&#xD;Brox, A&#xD;Robson, H G&#xD;Journal Article&#xD;United States&#xD;Infect Control Hosp Epidemiol. 1996 Jun;17(6):360-4. doi: 10.1086/647317.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/647317</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>386</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">386</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kandiah, S.</style></author><author><style face="normal" font="default" size="100%">Yassin, M. H.</style></author><author><style face="normal" font="default" size="100%">Hariri, R.</style></author><author><style face="normal" font="default" size="100%">Ferrelli, J.</style></author><author><style face="normal" font="default" size="100%">Fabrizio, M.</style></author><author><style face="normal" font="default" size="100%">Porter, L.</style></author><author><style face="normal" font="default" size="100%">Duda, S.</style></author><author><style face="normal" font="default" size="100%">Stout, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Kandiah, Division of Infectious Diseases, Emory University, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Control of legionella contamination with monochloramine disinfection in a large urban hospital hot water system</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e84</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">monochloramine</style></keyword><keyword><style face="normal" font="default" size="100%">hot water</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">well water</style></keyword><keyword><style face="normal" font="default" size="100%">bleaching agent</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">sensor</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">model</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro study</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">chemical parameters</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">aerosol</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">procedures</style></keyword><keyword><style face="normal" font="default" size="100%">microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><abstract><style face="normal" font="default" size="100%">Issue: Legionella species mainly L. pneumophila is the etiologic agent causing “Legionnaires disease” which is a systemic infection obtained through the aerosolization of contaminated water sources. Multiple outbreaks of Legionnaires disease occurred within hospitals, and extended care facilities due to contaminated water supply with Legionella. Legionella sp is known to create biofilm in plumbing systems making it very difficult to eradicate using current methods. Monochloramine has been found to be effective against Legionella in vitro and against biofilm-associated Legionella in model plumbing systems. Monochloramine disinfection of municipal water supplies has been associated with decreased risk for Legionnaires&apos; disease. However, using monochloramine in hospital water supply has never been evaluated in the USA. We describe our experience with monochloramine disinfection in a 490 bed urban hospital in Pittsburgh, PA implemented after using a copper-silver ionization system for many years. Project: As part of a Legionella control plan, multiple sites in the hospital are tested routinely every month. The cultures obtained using swabs of faucets. Legionella enriched culture were done in our Microbiology laboratory. In 2011, increasing levels of Legionella were found particularly in sensor sinks (recently installed) and in areas with water shut down due to construction and renovation projects. Appropriate flushing procedures and cleaning of the faucets with a bleach-based solution were unsuccessful in eradication of Legionella species despite adequate copper and silver levels. In September of 2011 the hospital consulted and collaborated with the Special Pathogens Lab in Pittsburgh to implement a hospital-based monochloramine delivery system manufactured in Italy by Sanipur. The monochloramine was only applied to the hot water system and the levels of the monochloramine as well as other chemical parameters were monitored closely. Routine Legionella cultures were obtained as well water sample cultures on monthly bases. Results: From January 2011-September 2011, 23 faucets swabs were done monthly with an overall average positivity rate of 33% positivity. Sensor sinks cultures had higher positivity rate of 57%. After monochloramine introduction into the hot water system in September 2011 faucets swabs revealed a positivity rate of 0.00 %. All sensor faucets converted negative after only three weeks of monochloramine installation. Additional water cultures by the Special Pathogens laboratory revealed similar decrease in positive cultures. Lesson Learned: This is the first report of evaluation of monochloramine delivery system for eradication of Legionella within the US health system. This new delivery system allows the use of monochloramine on a small scale. The eradication of Legionella was successful in a surprisingly shorter period than what was anticipated. Monochloramine was very effective in eradicating Legionella from sensor faucets that are particularly problematic. These results suggest that, monochloramine can penetrate biofilm more effectively than the copper-silver ionization system.</style></abstract><notes><style face="normal" font="default" size="100%">L70811609&#xD;2012-07-23</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70811609</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2012.04.149</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2012.04.149</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">153</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Tedesco, L.</style></author><author><style face="normal" font="default" size="100%">Boldin, M.</style></author><author><style face="normal" font="default" size="100%">Hwang, C.</style></author><author><style face="normal" font="default" size="100%">Diven, W. F.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Pittsburgh, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Controlled evaluation of copper-silver ionization in eradicating Legionella pneumophila from a hospital water distribution system</style></title><secondary-title><style face="normal" font="default" size="100%">J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">919-22</style></pages><volume><style face="normal" font="default" size="100%">169</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">1994/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Evaluation Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, Veterans</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Pennsylvania</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-1899 (Print)&#xD;0022-1899</style></isbn><accession-num><style face="normal" font="default" size="100%">8133111</style></accession-num><abstract><style face="normal" font="default" size="100%">A controlled evaluation was made of the efficacy of copper-silver ionization in eradicating Legionella pneumophila from a hospital water supply. Copper-silver ionization units were installed on the hot water recirculation line of one building with water fixtures positive for Legionella species. Another building with the same water supply served as a control. Legionella species persisted within the system when copper and silver concentrations were &lt; 0.3 and &lt; 0.03 ppm, respectively. When copper and silver concentrations were &gt; 0.4 and &gt; 0.04 ppm, respectively, there was a significant decrease in Legionella species colonization, but the percentage of water fixtures positive for organisms was unchanged in the control building. When the ionization unit was inactivated, water fixtures continued to be free of Legionella species for 2 additional months. Copper-silver ionization can eradicate L. pneumophila in a water distribution system. The advantages of copper-silver ionization include relatively low cost, straightforward installation, easy maintenance, nontoxic by-products and the presence of a disinfecting residual.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Z&#xD;Stout, J E&#xD;Tedesco, L&#xD;Boldin, M&#xD;Hwang, C&#xD;Diven, W F&#xD;Yu, V L&#xD;Journal Article&#xD;United States&#xD;J Infect Dis. 1994 Apr;169(4):919-22. doi: 10.1093/infdis/169.4.919.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/169.4.919</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">87</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, Y. E.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Kaohsiung Normal University, Kaohsiung, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Controlling Legionella in hospital drinking water: an evidence-based review of disinfection methods</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">166-73</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/04/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/economics/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Legionellosis/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">21460472</style></accession-num><abstract><style face="normal" font="default" size="100%">Hospital-acquired Legionnaires&apos; disease is directly linked to the presence of Legionella in hospital drinking water. Disinfecting the drinking water system is an effective preventive measure. The efficacy of any disinfection measures should be validated in a stepwise fashion from laboratory assessment to a controlled multiple-hospital evaluation over a prolonged period of time. In this review, we evaluate systemic disinfection methods (copper-silver ionization, chlorine dioxide, monochloramine, ultraviolet light, and hyperchlorination), a focal disinfection method (point-of-use filtration), and short-term disinfection methods in outbreak situations (superheat-and-flush with or without hyperchlorination). The infection control practitioner should take the lead in selection of the disinfection system and the vendor. Formal appraisals by other hospitals with experience of the system under consideration is indicated. Routine performance of surveillance cultures of drinking water to detect Legionella and monitoring of disinfectant concentrations are necessary to ensure long-term efficacy.</style></abstract><notes><style face="normal" font="default" size="100%">1559-6834&#xD;Lin, Yusen E&#xD;Stout, Janet E&#xD;Yu, Victor L&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2011 Feb;32(2):166-73. doi: 10.1086/657934.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/657934</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. S.</style></author><author><style face="normal" font="default" size="100%">Goetz, A. M.</style></author><author><style face="normal" font="default" size="100%">Muder, R. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Special Pathogens Laboratory, Veterans&apos; Affairs Pittsburgh Health Care System, University of Pittsburgh School of Medicine, PA 15240, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Controlling Legionella in hospital water systems: experience with the superheat-and-flush method and copper-silver ionization</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">911-4</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">1999/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/epidemiology/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Heating</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, Veterans</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Ions</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/epidemiology/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance and Engineering, Hospital/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Pennsylvania</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">9872527</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To evaluate the effect of copper-silver ionization on Legionella colonization and nosocomial legionnaires&apos; disease and to compare the efficacy of metal ions versus the superheat-and-flush method of disinfection. DESIGN: Prospective determination over a 36-month period of copper and silver ion concentrations in the recirculating hot-water system, Legionella colonization of the hospital water distribution system, and cases of nosocomial legionnaires&apos; disease. Retrospective comparison of results with the previous 13 years, during which the superheat-and-flush method was used. SETTING: The Pittsburgh Veterans&apos; Affairs Health Care System (University Drive Division) acute-care hospital. INTERVENTION: Three copper-silver ionization systems were installed on the hot-water distribution system in November 1994. RESULTS: The average number of cases of legionnaires&apos; disease per year and the percentage of distal sites positive for Legionella pneumophila for the superheat-and-flush method versus the copper-silver ionization method was six cases with 15% positivity versus two cases with 4% positivity, respectively. The reduction in Legionella colonization after copper-silver ionization was significant (P&lt;.05) compared to the superheat and flush. Mean copper and silver ion concentrations (mg/L) were 0.29 and 0.054 from hot-water tanks, and 0.17 and 0.04 from distal outlets, respectively. CONCLUSIONS: We conclude that a properly maintained and monitored copper-silver ionization system was more effective than the superheat-and-flush method for reducing the recovery of Legionella from the hospital water distribution system.</style></abstract><notes><style face="normal" font="default" size="100%">Stout, J E&#xD;Lin, Y S&#xD;Goetz, A M&#xD;Muder, R R&#xD;Journal Article&#xD;United States&#xD;Infect Control Hosp Epidemiol. 1998 Dec;19(12):911-4.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cloutman-Green, E.</style></author><author><style face="normal" font="default" size="100%">Barbosa, V. L.</style></author><author><style face="normal" font="default" size="100%">Jimenez, D.</style></author><author><style face="normal" font="default" size="100%">Wong, D.</style></author><author><style face="normal" font="default" size="100%">Dunn, H.</style></author><author><style face="normal" font="default" size="100%">Needham, B.</style></author><author><style face="normal" font="default" size="100%">Ciric, L.</style></author><author><style face="normal" font="default" size="100%">Hartley, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Virology, and Infection Prevention Control, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom; Department of Civil, Environmental, and Geomatic Engineering, University College London, London, United Kingdom. Electronic address: elaine.cloutman-green@gosh.nhs.uk.&#xD;Department of Flood and Coastal Risk Management, Environment Agency, Brampton, Cambridgeshire, United Kingdom.&#xD;Department of Civil, Environmental, and Geomatic Engineering, University College London, London, United Kingdom.&#xD;Department of Geography, King&apos;s College London, London, United Kingdom.&#xD;Department of Microbiology, Virology, and Infection Prevention Control, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.&#xD;Department of Estates and Facilities, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Controlling Legionella pneumophila in water systems at reduced hot water temperatures with copper and silver ionization</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">761-766</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2019/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Engineering control</style></keyword><keyword><style face="normal" font="default" size="100%">*Environment</style></keyword><keyword><style face="normal" font="default" size="100%">*Health care</style></keyword><keyword><style face="normal" font="default" size="100%">*Infection prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">*Water management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">30661910</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hospital-acquired Legionnaires&apos; disease is associated with the presence of Legionella pneumophila in hospital water systems. In the United Kingdom, the Department of Health recommends maintaining hot water temperatures &gt;55 degrees C and cold water temperatures &lt;20 degrees C at the point of delivery to prevent proliferation of L pneumophila in water systems. In this study, we evaluated the efficacy of copper and silver ionization to control L pneumophila at deliberately reduced hot water temperatures (43 degrees C) within a newly installed water system in a new building linked to a large health care facility in the United Kingdom. METHODS: One thousand, five hundred ninety-eight water samples were collected between September 2011 and June 2017. Samples were tested using accredited methods for L pneumophila, copper and silver ion levels, and total viable counts. Energy consumption and water usage data were also collected to permit carbon emission calculations. RESULTS: The results of 1,598 routine samples from September 2011 to June 2017, and the recordings of temperatures at outlets in this facility, demonstrated effective (100%) L pneumophila control throughout the study period with an average hot water temperature of 42 degrees C. The energy savings and reduction of carbon emissions were calculated to amount to 33% and 24%, respectively, compared to an equivalent temperature-controlled system. Water system management interventions were required to achieve consistently adequate levels of copper and silver across outlets. CONCLUSIONS: This study demonstrated that it is possible to control L pneumophila independent of temperature when copper and silver ionization is introduced into a new building in conjunction with an appropriately managed water system.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Cloutman-Green, Elaine&#xD;Barbosa, Vera L&#xD;Jimenez, Diego&#xD;Wong, Daniel&#xD;Dunn, Helen&#xD;Needham, Brian&#xD;Ciric, Lena&#xD;Hartley, John C&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 2019 Jul;47(7):761-766. doi: 10.1016/j.ajic.2018.12.005. Epub 2019 Jan 18.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2018.12.005</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kappes, T.</style></author><author><style face="normal" font="default" size="100%">Dominguez, M.</style></author><author><style face="normal" font="default" size="100%">Bello-Toledo, H.</style></author><author><style face="normal" font="default" size="100%">Mella Montecinos, S.</style></author><author><style face="normal" font="default" size="100%">Riedel Molina, G.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Rocha, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Microbiologia Laboratorio de Investigacion en Agentes Antibacterianos, Facultad de Ciencias Biologicas, Universidad de Concepcion, Concepcion, Chile.&#xD;Departamento de Medicina Interna, Facultad de Medicina, Universidad de Concepcion, Concepcion, Chile.&#xD;Unidad de Infectologia, Hospital Regional Dr. Guillermo Grant Benavente, Concepcion, Chile.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Copper activity against multiresistant Gram-positive cocci isolated in Chilean hospitals]</style></title><secondary-title><style face="normal" font="default" size="100%">Rev Chilena Infectol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rev Chilena Infectol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">519-523</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2017/01/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Chile</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/*drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Actividad de cobre sobre cocaceas grampositivas multi-resistentes a los antibioticos aisladas en hospitales chilenos.</style></orig-pub><isbn><style face="normal" font="default" size="100%">0716-1018</style></isbn><accession-num><style face="normal" font="default" size="100%">28112334</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Nosocomial infections caused by multiresistant Gram-positive cocci are a serious problem for public health systems worldwide. The use of copper surfaces in hospital environments has proven to be an effective alternative for the control of various microorganisms, including multiresistant nosocomial pathogens. AIM: To determine the association between antibiotic multiresistance and higher levels of copper tolerance in Gram-positive cocci isolated from Chilean hospitals, which might confer a selective advantage in environments with copper. METHODS: The ionic copper tolerance levels were evaluated using the Mueller Hinton agar dilution method, in S. aureus and Enterococcus spp. strains with different levels of susceptibility to clinically relevant antibiotics. RESULTS: A statistically significant association between higher levels of tolerance to copper ion and multi-resistance to antibiotics in Enterococcus spp. was observed.</style></abstract><notes><style face="normal" font="default" size="100%">0717-6341&#xD;Kappes, Tomas&#xD;Dominguez, Mariana&#xD;Bello-Toledo, Helia&#xD;Mella Montecinos, Sergio&#xD;Riedel Molina, Gisella&#xD;Gonzalez-Rocha, Gerardo&#xD;Journal Article&#xD;Chile&#xD;Rev Chilena Infectol. 2016 Oct;33(5):519-523. doi: 10.4067/S0716-10182016000500005.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4067/s0716-10182016000500005</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">spa</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">44</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hinsa-Leasure, S. M.</style></author><author><style face="normal" font="default" size="100%">Nartey, Q.</style></author><author><style face="normal" font="default" size="100%">Vaverka, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biology, Grinnell College, Grinnell, IA; Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC. Electronic address: hinsa@grinnell.edu.&#xD;Department of Biology, Grinnell College, Grinnell, IA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper alloy surfaces sustain terminal cleaning levels in a rural hospital</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e195-e203</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2016/11/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Load</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospitals, Rural</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Patients&apos; Rooms</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Bacteria burden</style></keyword><keyword><style face="normal" font="default" size="100%">*Built environment</style></keyword><keyword><style face="normal" font="default" size="100%">*Health care-associated infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Infection control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">27692787</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess the ability of copper alloy surfaces to mitigate the bacterial burden associated with commonly touched surfaces in conjunction with daily and terminal cleaning in rural hospital settings. DESIGN: A prospective intention-to-treat trial design was used to evaluate the effectiveness of cooper alloy surfaces and respective controls to augment infection control practices under pragmatic conditions. SETTING: Half of the patient rooms in the medical-surgical suite in a 49-bed rural hospital were outfitted with copper alloy materials. The control rooms maintained traditional plastic, metal, and porcelain surfaces. METHODS: The primary outcome was a comparison of the bacterial burden harbored by 20 surfaces and components associated with control and intervention areas for 12 months. Locations were swabbed regardless of the occupancy status of the patient room. Significance was assessed using nonparametric methods employing the Mann-Whitney U test with significance assessed at P &lt; .05. RESULTS: Components fabricated using copper alloys were found to have significantly lower concentrations of bacteria, at or below levels prescribed, upon completion of terminal cleaning. Vacant rooms were found to harbor significant concentrations of bacteria, whereas those fabricated from copper alloys were found to be at or below those concentrations prescribed subsequent to terminal cleaning. CONCLUSIONS: Copper alloys can significantly decrease the burden harbored on high-touch surfaces, and thus warrant inclusion in an integrated infection control strategy for rural hospitals.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Hinsa-Leasure, Shannon M&#xD;Nartey, Queenster&#xD;Vaverka, Justin&#xD;Schmidt, Michael G&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 2016 Nov 1;44(11):e195-e203. doi: 10.1016/j.ajic.2016.06.033. Epub 2016 Sep 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272359/1-s2.0-S0196655316X00107/1-s2.0-S0196655316307519/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEHQaCXVzLWVhc3QtMSJIMEYCIQDtfhMRpoiY%2FkGWv9z%2BzGAiJBhrZfcb2dN2nMrKRdlUNgIhAIGkgeBqi105w3N4AZ4pspJF93QRS%2B%2FvU5SJNa9Cp6HxKrQDCG0QAhoMMDU5MDAzNTQ2ODY1IgwlxaLwIg8dPSEadgEqkQMzsTI3Dh%2FmSlt3%2BW01kpI2Qjx998fOjuT0SMPsHXEr8MFBpmNPXcZojQvCCSFX715QkK5ud5%2BdDIScoNbxfuix1kCWL%2BZeHWBawfTpZ0VjhxsdTSc96WvW3GPZco7fMZ93N0UYFBmRPjWxFgHqtIHV5ulsf8PfAky0SZrn18NxNez0fEQakf6z0Rtn%2FKy5ZSzTzliuX3SvKqNWIxkb99MMVW09pSw0d698uNWzM2Stc8jE4gv0rip37E04pRzePaAcUgJ%2F1YfcZhGUKTIBle9ogNpxTu1xp7Zb4Ksz9CyVM5BDtokx4YNy3PAdPXNglt29ohJ8L060NZZLc6zPSKwdEVBj96ZLprbQ4%2FPdcQESDnurUaA9aGy9ldiJJAdiSpXf1LxCgaO2THvWyaQ4jHkzrSqbJ4liX1Sfy1YStp%2BEuDutcXTAy9L3HXdP256FOVG7XXb7plQA%2FyIvCQMZNA2%2BOvcUJsqh6cKKBNDm1eNpxAnl%2B0%2B1E5RPiCYQDf9SxrRdAlBI5dJSNNqkmFrFhq%2FrqTCBoevzBTrqAXz4S2zxjZyslZ3MZ0azC7IbEbbIR0barsxdn5CvyFGD6G5YF9mXXURPRSJmgvdQUA41CVpc4J0seYN29bpPjBwhxwba2ION5CWievJJAgK0MHawSlmSyu%2Fi4h7Zx1QC8jQKNHB8AF7PRzGnEAkU3za2xmAkhFIw7n%2BaBzJwql9mw80JAbjOxRzqCgkjKcGQRzVD57BXivAR97YNK2Vkvmc8ygbJwmn9nywCnbtsKnZ3c3a%2FZ1aUArwSmyQId6adkDFIEB1wsmLWDyYHFcxQ%2BNrrDfeQEQNDdlzAiUHKMqNMWM0fZFDLLJpsIg%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200325T052527Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTYU6UYQR7I%2F20200325%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=f06886eeb69c2fa659566b7152ee1b6940931288660cef76614124a02e2bf09b&amp;hash=25b1fbdf4c0b77b6d77dcb1876a590beacd80a2cd2d612a8bee0f61da26b9e08&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S0196655316307519&amp;tid=spdf-825bf5fa-0dd7-403b-afc3-7fe59a095570&amp;sid=b6c9ad95419947419618c891c856c8d040eegxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://3456641625/Hinsa-Leasure-2016-Copper alloy surfaces susta.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2016.06.033</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colin, M.</style></author><author><style face="normal" font="default" size="100%">Klingelschmitt, F.</style></author><author><style face="normal" font="default" size="100%">Charpentier, E.</style></author><author><style face="normal" font="default" size="100%">Josse, J.</style></author><author><style face="normal" font="default" size="100%">Kanagaratnam, L.</style></author><author><style face="normal" font="default" size="100%">De Champs, C.</style></author><author><style face="normal" font="default" size="100%">Gangloff, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biomateriaux et Inflammation en Site Osseux, EA 4691, SFR CAP-Sante, UFR de Pharmacie, Universite de Reims Champagne Ardenne, 51100 Reims, France. marius.colin@univ-reims.fr.&#xD;Biomateriaux et Inflammation en Site Osseux, EA 4691, SFR CAP-Sante, UFR de Pharmacie, Universite de Reims Champagne Ardenne, 51100 Reims, France. flora.klingelschmitt@univ-reims.fr.&#xD;Biomateriaux et Inflammation en Site Osseux, EA 4691, SFR CAP-Sante, UFR de Pharmacie, Universite de Reims Champagne Ardenne, 51100 Reims, France. emilie.charpentier@univ-reims.fr.&#xD;Service de Microbiologie, UFR pharmacie, Universite de Reims Champagne-Ardenne, 51100 Reims, France. emilie.charpentier@univ-reims.fr.&#xD;Biomateriaux et Inflammation en Site Osseux, EA 4691, SFR CAP-Sante, UFR de Pharmacie, Universite de Reims Champagne Ardenne, 51100 Reims, France. jeromejosse18@gmail.com.&#xD;Unite d&apos;aide methodologique, CHU de Reims, 51100 Reims, France. lkanagaratnam@chu-reims.fr.&#xD;Inserm UMR-S 1250 P3Cell, SFR CAP-Sante, Universite de Reims Champagne-Ardenne, 51100 Reims, France. cdechamps@chu-reims.fr.&#xD;Biomateriaux et Inflammation en Site Osseux, EA 4691, SFR CAP-Sante, UFR de Pharmacie, Universite de Reims Champagne Ardenne, 51100 Reims, France. sophie.gangloff@univ-reims.fr.&#xD;Service de Microbiologie, UFR pharmacie, Universite de Reims Champagne-Ardenne, 51100 Reims, France. sophie.gangloff@univ-reims.fr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper Alloy Touch Surfaces in Healthcare Facilities: An Effective Solution to Prevent Bacterial Spreading</style></title><secondary-title><style face="normal" font="default" size="100%">Materials (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Materials (Basel)</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2018/12/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare-associated infections</style></keyword><keyword><style face="normal" font="default" size="100%">long-term care facilities</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1996-1944 (Print)&#xD;1996-1944</style></isbn><accession-num><style face="normal" font="default" size="100%">30563265</style></accession-num><abstract><style face="normal" font="default" size="100%">In the healthcare environment, microorganisms&apos; cross-transmission between inanimate surfaces and patients or healthcare workers can lead to healthcare-associated infections. A recent interest has grown to create antimicrobial copper touch surfaces, in order to counteract microbial spread in the healthcare environment. For the first time, five French long-term care facilities were at 50% fitted with copper alloys door handles and handrails. Related to the environmental bacterial contamination, 1400 samples were carried out on copper and control surfaces over three years after copper installation. In addition, some copper door handles were taken from the different facilities, and their specific activity against methicillin-resistant S. aureus (MRSA) was tested in vitro. In comparison to control surfaces, copper door handles and handrails revealed significantly lower contamination levels. This difference was observed in the five long-term care facilities and it persists through the three years of the study. High and extreme levels of bacterial contamination were less frequent on copper surfaces. Although, the antibacterial activity of copper surfaces against MRSA was lowered after three years of regular use, it was still significant as compared to inert control surfaces. Therefore, copper containing surfaces are promising actors in the non-spreading of environmental bacterial contamination in healthcare facilities.</style></abstract><notes><style face="normal" font="default" size="100%">Colin, Marius&#xD;Klingelschmitt, Flora&#xD;Charpentier, Emilie&#xD;Josse, Jerome&#xD;Kanagaratnam, Lukshe&#xD;De Champs, Christophe&#xD;Orcid: 0000-0002-4375-2080&#xD;Gangloff, Sophie C&#xD;Orcid: 0000-0003-2651-9372&#xD;CIFRE 201411394/Association Nationale de la Recherche et de la Technologie&#xD;D201700373/Region Grand Est&#xD;D201700623/European Regional Development Fund&#xD;Journal Article&#xD;Switzerland&#xD;Materials (Basel). 2018 Dec 6;11(12). pii: ma11122479. doi: 10.3390/ma11122479.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://res.mdpi.com/d_attachment/materials/materials-11-02479/article_deploy/materials-11-02479.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://2118128627/Colin-2018-Copper Alloy Touch Surfaces in Heal.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default" size="100%">PMC6317222</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ma11122479</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harrison, J. J.</style></author><author><style face="normal" font="default" size="100%">Turner, R. J.</style></author><author><style face="normal" font="default" size="100%">Joo, D. A.</style></author><author><style face="normal" font="default" size="100%">Stan, M. A.</style></author><author><style face="normal" font="default" size="100%">Chan, C. S.</style></author><author><style face="normal" font="default" size="100%">Allan, N. D.</style></author><author><style face="normal" font="default" size="100%">Vrionis, H. A.</style></author><author><style face="normal" font="default" size="100%">Olson, M. E.</style></author><author><style face="normal" font="default" size="100%">Ceri, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Sciences, University of Calgary, 2500 University Drive N.W., Calgary, Alberta, Canada T2N 1N4.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper and quaternary ammonium cations exert synergistic bactericidal and antibiofilm activity against Pseudomonas aeruginosa</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2870-81</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2008/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilms/*drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Calorimetry</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Confocal</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/*drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Quaternary Ammonium Compounds/*pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">18519726</style></accession-num><abstract><style face="normal" font="default" size="100%">Biofilms are slimy aggregates of microbes that are likely responsible for many chronic infections as well as for contamination of clinical and industrial environments. Pseudomonas aeruginosa is a prevalent hospital pathogen that is well known for its ability to form biofilms that are recalcitrant to many different antimicrobial treatments. We have devised a high-throughput method for testing combinations of antimicrobials for synergistic activity against biofilms, including those formed by P. aeruginosa. This approach was used to look for changes in biofilm susceptibility to various biocides when these agents were combined with metal ions. This process identified that Cu(2+) works synergistically with quaternary ammonium compounds (QACs; specifically benzalkonium chloride, cetalkonium chloride, cetylpyridinium chloride, myristalkonium chloride, and Polycide) to kill P. aeruginosa biofilms. In some cases, adding Cu(2+) to QACs resulted in a 128-fold decrease in the biofilm minimum bactericidal concentration compared to that for single-agent treatments. In combination, these agents retained broad-spectrum antimicrobial activity that also eradicated biofilms of Escherichia coli, Staphylococcus aureus, Salmonella enterica serovar Cholerasuis, and Pseudomonas fluorescens. To investigate the mechanism of action, isothermal titration calorimetry was used to show that Cu(2+) and QACs do not interact in aqueous solutions, suggesting that each agent exerts microbiological toxicity through independent biochemical routes. Additionally, Cu(2+) and QACs, both alone and in combination, reduced the activity of nitrate reductases, which are enzymes that are important for normal biofilm growth. Collectively, the results of this study indicate that Cu(2+) and QACs are effective combinations of antimicrobials that may be used to kill bacterial biofilms.</style></abstract><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Harrison, Joe J&#xD;Turner, Raymond J&#xD;Joo, Daniel A&#xD;Stan, Michelle A&#xD;Chan, Catherine S&#xD;Allan, Nick D&#xD;Vrionis, Helen A&#xD;Olson, Merle E&#xD;Ceri, Howard&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Antimicrob Agents Chemother. 2008 Aug;52(8):2870-81. doi: 10.1128/AAC.00203-08. Epub 2008 Jun 2.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2493123</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.00203-08</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kusnetsov, J.</style></author><author><style face="normal" font="default" size="100%">Iivanainen, E.</style></author><author><style face="normal" font="default" size="100%">Elomaa, N.</style></author><author><style face="normal" font="default" size="100%">Zacheus, O.</style></author><author><style face="normal" font="default" size="100%">Martikainen, P. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Environmental Microbiology, National Public Health Institute, Kuopio, Finland. jaana.kusnetsov@ktl.fi</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper and silver ions more effective against legionellae than against mycobacteria in a hospital warm water system</style></title><secondary-title><style face="normal" font="default" size="100%">Water Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Water Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4217-25</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">17</style></number><edition><style face="normal" font="default" size="100%">2002/01/17</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control</style></keyword><keyword><style face="normal" font="default" size="100%">Ions</style></keyword><keyword><style face="normal" font="default" size="100%">*Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Waste</style></keyword><keyword><style face="normal" font="default" size="100%">*Mycobacteriaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Population Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Waste Disposal, Fluid/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0043-1354 (Print)&#xD;0043-1354</style></isbn><accession-num><style face="normal" font="default" size="100%">11791852</style></accession-num><abstract><style face="normal" font="default" size="100%">We studied the influence of electrolytically released copper and silver ions on the microbiological quality in a warm water system of a hospital. The concentration of nontuberculous mycobacteria was followed for three, and that of legionellae and other heterotrophic bacteria in the water for four years. The highest concentrations of copper and silver ions were 220 and 68 microg/l, respectively. Silver ion concentration of about 3 microg/l was sufficient to control the growth of legionellae in circulating warm water. The results showed that it is more difficult to eradicate legionellae from taps and showers: these points were colonized by a small number of legionellae after the metal ion concentrations were increased in the circulating water. A regular use of water eradicated legionellae from the shower. One tap was still used irregularly, and this may be a reason why it still contained small concentrations of legionellae also in the last years of the study. Mycobacteria were occasionally isolated from the circulating water and repeatedly from the shower, even when the metal concentrations were high. To control legionella bacteria in warm water systems, silver concentrations of only 3 microg/l are needed if all taps and showers of the system are regularly used. Such low copper and silver concentrations, however, are not efficient against nontuberculous mycobacteria or other heterotrophic bacteria.</style></abstract><notes><style face="normal" font="default" size="100%">Kusnetsov, J&#xD;Iivanainen, E&#xD;Elomaa, N&#xD;Zacheus, O&#xD;Martikainen, P J&#xD;Evaluation Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Water Res. 2001 Dec;35(17):4217-25. doi: 10.1016/s0043-1354(01)00124-5.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0043-1354(01)00124-5</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>45</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">45</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Inkinen, J.</style></author><author><style face="normal" font="default" size="100%">Makinen, R.</style></author><author><style face="normal" font="default" size="100%">Keinanen-Toivola, M. M.</style></author><author><style face="normal" font="default" size="100%">Nordstrom, K.</style></author><author><style face="normal" font="default" size="100%">Ahonen, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Technology, WANDER Nordic Water and Materials Institute, Satakunta University of Applied Sciences, Rauma, Finland.&#xD;Department of Civil Engineering, School of Engineering, Aalto University, Espoo, Finland.&#xD;Department of Biotechnology and Chemical Technology, School of Chemical Technology, Aalto University, Espoo, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper as an antibacterial material in different facilities</style></title><secondary-title><style face="normal" font="default" size="100%">Lett Appl Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lett Appl Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">19-26</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2016/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections/prevention &amp; control/*transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">*antibacterial copper</style></keyword><keyword><style face="normal" font="default" size="100%">*environmental microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">*infection control</style></keyword><keyword><style face="normal" font="default" size="100%">*touch surfaces</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0266-8254</style></isbn><accession-num><style face="normal" font="default" size="100%">27718259</style></accession-num><abstract><style face="normal" font="default" size="100%">The present study was performed in real life settings in different facilities (hospital, kindergarten, retirement home, office building) with copper and copper alloy touch surface products (floor drain lids, toilet flush buttons, door handles, light switches, closet touch surfaces, corridor hand rails, front door handles and toilet support rails) in parallel to reference products. Pure copper surfaces supported lower total bacterial counts (16 +/- 45 vs 105 +/- 430 CFU cm(-2) , n = 214, P &lt; 0.001) and a lower occurrence of Staphylococcus aureus (2.6 vs 14%, n = 157, P &lt; 0.01) and Gram-negatives (21 vs 34%, n = 214, P &lt; 0.05) respectively than did reference surfaces, whereas the occurrence of enterococci (15%, n = 214, P &gt; 0.05) was similar. The studied products could be assigned to three categories according to their bacterial loads as follows (P &lt; 0.001): floor drain lids (300 +/- 730 CFU cm(-2) , n = 32), small area touch surfaces (8.0 +/- 7.1 to 62 +/- 160 CFU cm(-2) , n = 90) and large area touch surfaces (1.1 +/- 1.1 to 1.7 +/- 2.4 CFU cm(-2) , n = 92). In conclusion, copper touch surface products can function as antibacterial materials to reduce the bacterial load, especially on frequently touched small surfaces. SIGNIFICANCE AND IMPACT OF THE STUDY: The efficiency of copper as an antimicrobial material has been noted in laboratory studies and in the hospital environment. The present study further shows that copper exerted an antibacterial effect in different facilities, i.e. in a hospital, a kindergarten, an office building and in a retirement home for the elderly. The study suggests that copper has potential use as an antibacterial material and therefore might serve as a means to lower the incidence of transmission of infectious agents from inanimate surfaces in different facilities, with everyday functions.</style></abstract><notes><style face="normal" font="default" size="100%">1472-765x&#xD;Inkinen, J&#xD;Makinen, R&#xD;Keinanen-Toivola, M M&#xD;Nordstrom, K&#xD;Ahonen, M&#xD;Journal Article&#xD;England&#xD;Lett Appl Microbiol. 2017 Jan;64(1):19-26. doi: 10.1111/lam.12680. Epub 2016 Nov 28.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/lam.12680</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">80</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">[Copper is an important building block in control of antibiotic-resistant bacteria (MRSA)]</style></title><secondary-title><style face="normal" font="default" size="100%">Kinderkrankenschwester</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Kinderkrankenschwester</style></full-title></periodical><pages><style face="normal" font="default" size="100%">254-5</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2012/07/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Antisepsis</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Communicable Disease Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Construction Materials</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*nursing/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital Design and Construction</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Methicillin-Resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections/*nursing/*prevention &amp; control/transmission</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Kupfer ein wichtiger Baustein im Kampf gegen Antibiotika-resistente Bakterien (MRSA).</style></orig-pub><isbn><style face="normal" font="default" size="100%">0723-2276 (Print)&#xD;0723-2276</style></isbn><accession-num><style face="normal" font="default" size="100%">22808678</style></accession-num><notes><style face="normal" font="default" size="100%">Journal Article&#xD;Germany&#xD;Kinderkrankenschwester. 2012 Jun;31(6):254-5.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">ger</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Copper rather than steel surfaces for infection control</style></title><secondary-title><style face="normal" font="default" size="100%">Nurs Stand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nurs Stand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14-15</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2006/09/20</style></edition><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0029-6570</style></isbn><accession-num><style face="normal" font="default" size="100%">28086521</style></accession-num><abstract><style face="normal" font="default" size="100%">The use of stainless steel for work surfaces or door furniture in hospitals is not recommended on the grounds of infection control.</style></abstract><notes><style face="normal" font="default" size="100%">2047-9018&#xD;Journal Article&#xD;England&#xD;Nurs Stand. 2006 Sep 20;21(2):14-15. doi: 10.7748/ns.21.2.14.s21.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7748/ns.21.2.14.s21</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vessey, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Copper Development Association, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper shows its mettle worldwide</style></title><secondary-title><style face="normal" font="default" size="100%">Health Estate</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Health Estate</style></full-title></periodical><pages><style face="normal" font="default" size="100%">59-63</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2012/11/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, Public</style></keyword><keyword><style face="normal" font="default" size="100%">*Internationality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">23140007</style></accession-num><abstract><style face="normal" font="default" size="100%">While MRSA rates in England continue to fall, NHS Trusts are looking for smarter ways to achieve further reductions in infection rates, or to support their &apos;zero-tolerance approaches&apos;, and, according to the Copper Development Association (CDA), the not-for-profit, membership-based organisation which supports and promotes &apos;the correct and efficient use of copper and its alloys&apos;, deployment of antimicrobial copper touch surfaces is being adopted in many hospitals and other healthcare facilities worldwide as &apos;an additional and cost-effective infection control measure&apos;. CDA Director Angela Vessey highlights the benefits, and examines some of the growing number of healthcare installations of &apos;antimicrobial copper&apos; worldwide.</style></abstract><notes><style face="normal" font="default" size="100%">Vessey, Angela&#xD;Journal Article&#xD;England&#xD;Health Estate. 2012 Oct;66(9):59-63.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, M. G.</style></author><author><style face="normal" font="default" size="100%">von Dessauer, B.</style></author><author><style face="normal" font="default" size="100%">Benavente, C.</style></author><author><style face="normal" font="default" size="100%">Benadof, D.</style></author><author><style face="normal" font="default" size="100%">Cifuentes, P.</style></author><author><style face="normal" font="default" size="100%">Elgueta, A.</style></author><author><style face="normal" font="default" size="100%">Duran, C.</style></author><author><style face="normal" font="default" size="100%">Navarrete, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC. Electronic address: schmidtm@musc.edu.&#xD;Pediatric Intensive Care Unit, Hospital de Ninos Roberto del Rio, Santiago, Chile.&#xD;Microbiology Laboratory, Hospital de Ninos Roberto del Rio, Santiago, Chile.&#xD;Infection Control Committee, Hospital de Ninos Roberto del Rio, Santiago, Chile.&#xD;Department of Microbiology, University of Chile, Santiago, Chile.&#xD;School of Public Health, Faculty of Medicine, University of Chile, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper surfaces are associated with significantly lower concentrations of bacteria on selected surfaces within a pediatric intensive care unit</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">203-9</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/11/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Chile</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intensive Care Units, Pediatric</style></keyword><keyword><style face="normal" font="default" size="100%">Tertiary Care Centers</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental burden</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital-associated infection mitigation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">26553403</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Health care-associated infections result in significant patient morbidity and mortality. Although cleaning can remove pathogens present on hospital surfaces, those surfaces may be inadequately cleaned or recontaminated within minutes. Because of copper&apos;s inherent and continuous antimicrobial properties, copper surfaces offer a solution to complement cleaning. The objective of this study was to quantitatively assess the bacterial microbial burden coincident with an assessment of the ability of antimicrobial copper to limit the microbial burden associated with 3 surfaces in a pediatric intensive care unit. METHODS: A pragmatic trial was conducted enrolling 1,012 patients from 2 high acuity care units within a 249-bed tertiary care pediatric hospital over 12 months. The microbial burden was determined from 3 frequently encountered surfaces, regardless of room occupancy, twice monthly, from 16 rooms, 8 outfitted normally and 8 outfitted with antimicrobial copper. RESULTS: Copper surfaces were found to be equivalently antimicrobial in pediatric settings to activities reported for adult medical intensive care units. The log10 reduction to the microbial burden from antimicrobial copper surfaced bed rails was 1.996 (99%). Surprisingly, introduction of copper objects to 8 study rooms was found to suppress the microbial burden recovered from objects assessed in control rooms by log10 of 1.863 (73%). CONCLUSION: Copper surfaces warrant serious consideration when contemplating the introduction of no-touch disinfection technologies for reducing burden to limit acquisition of HAIs.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Schmidt, Michael G&#xD;von Dessauer, Bettina&#xD;Benavente, Carmen&#xD;Benadof, Dona&#xD;Cifuentes, Paulina&#xD;Elgueta, Alicia&#xD;Duran, Claudia&#xD;Navarrete, Maria S&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 2016 Feb;44(2):203-9. doi: 10.1016/j.ajic.2015.09.008. Epub 2015 Nov 6.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2015.09.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>244</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lahiri, J.</style></author><author><style face="normal" font="default" size="100%">Golas, A.</style></author><author><style face="normal" font="default" size="100%">Kurzejewski, J.</style></author><author><style face="normal" font="default" size="100%">Balakrisnan, B.</style></author><author><style face="normal" font="default" size="100%">Caracci, S.</style></author><author><style face="normal" font="default" size="100%">Novak, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Lahiri, Corning Incoporated, Painted Post, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper-containing glass ceramic particles with high microbicidal efficacy against eskape pathogens and non-enveloped viruses</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></full-title></periodical><volume><style face="normal" font="default" size="100%">8</style></volume><keywords><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">glass</style></keyword><keyword><style face="normal" font="default" size="100%">quaternary ammonium derivative</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">ceramics</style></keyword><keyword><style face="normal" font="default" size="100%">comparative effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">environmental temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Feline calicivirus</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human adenovirus 5</style></keyword><keyword><style face="normal" font="default" size="100%">humidity</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infectious agent</style></keyword><keyword><style face="normal" font="default" size="100%">inoculation</style></keyword><keyword><style face="normal" font="default" size="100%">limit of detection</style></keyword><keyword><style face="normal" font="default" size="100%">microorganism</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">survivor</style></keyword><keyword><style face="normal" font="default" size="100%">touch</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Studies suggest that continuously killing antimicrobial surfaces based on copper can reduce bioburden and lower the risk of infection [1]. Copper-containing glass ceramic particles in materials such as architectural wall paint stabilize and release Cu(I) by a slow-release mechanism imparting microbicidal properties to the coated surface [2]. Objectives: Evaluation of the bactericidal efficacy of coated surfaces containing copper-glass ceramic particles against ESKAPE pathogens - leading cause of nosocomial infections, and non-enveloped viruses (Adenovirus 5 and Feline Calicivirus). ComParison with currently available antimicrobial paints containing silver ions and quaternary ammonium compounds (QACs). Methods: Bactericidal efficacy tests including study controls were performed as described in the US EPA&apos;s test for efficacy of copper alloy surfaces as a sanitizer. A 20μL inoculum of test microbes was exposed to coated coupons containing copper-glass ceramic particles for 2 hours at ambient temperature and humidity (23°C; 42% RH). Following the exposure period, coupons were neutralized and assayed for survivors/infectivity. Differences in CFU/PFU counts between control and test coupons were calculated to evaluate efficacy. Results: A 3 log (≥99.9%) reduction in colony counts and or reduction of bacteria down to limit of detection was observed against all six ESKAPE pathogens, Adenovirus 5, and Feline Calicivirus when exposed to coatings containing copper-glass ceramic particles. In contrast, commercially available paints with silver ions did not demonstrate ≥3 log kill when screened against S. aureus under real-use contamination conditions. Conclusion: Copper-containing glass particles in decorative coatings and other high-touch environmental surfaces offer a pragmatic and broadly deployable solution for hospital infection control.</style></abstract><notes><style face="normal" font="default" size="100%">L629610038&#xD;2019-10-22</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L629610038</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s13756-019-0567-6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-019-0567-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gross, T. M.</style></author><author><style face="normal" font="default" size="100%">Lahiri, J.</style></author><author><style face="normal" font="default" size="100%">Golas, A.</style></author><author><style face="normal" font="default" size="100%">Luo, J.</style></author><author><style face="normal" font="default" size="100%">Verrier, F.</style></author><author><style face="normal" font="default" size="100%">Kurzejewski, J. L.</style></author><author><style face="normal" font="default" size="100%">Baker, D. E.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Novak, P. F.</style></author><author><style face="normal" font="default" size="100%">Snyder, M. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Corning Incorporated, Corning, NY, 14831, USA. grosstm@corning.com.&#xD;Corning Incorporated, Corning, NY, 14831, USA. lahirij@corning.com.&#xD;Corning Incorporated, Corning, NY, 14831, USA.&#xD;Argonne National Laboratory, Argonne, IL, 60439, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Copper-containing glass ceramic with high antimicrobial efficacy</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nat Commun</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1979</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Ceramics/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Nanoparticles/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2041-1723</style></isbn><accession-num><style face="normal" font="default" size="100%">31040286</style></accession-num><abstract><style face="normal" font="default" size="100%">Hospital acquired infections (HAIs) and the emergence of antibiotic resistant strains are major threats to human health. Copper is well known for its high antimicrobial efficacy, including the ability to kill superbugs and the notorious ESKAPE group of pathogens. We sought a material that maintains the antimicrobial efficacy of copper while minimizing the downsides - cost, appearance and metallic properties - that limit application. Here we describe a copper-glass ceramic powder as an additive for antimicrobial surfaces; its mechanism is based on the controlled release of copper (I) ions (Cu(1+)) from cuprite nanocrystals that form in situ in the water labile phase of the biphasic glass ceramic. Latex paints containing copper-glass ceramic powder exhibit &gt;/=99.9% reduction in S. aureus, P. aeruginosa, K. aerogenes and E. Coli colony counts when evaluated by the US EPA test method for efficacy of copper-alloy surfaces as sanitizer, approaching that of benchmark metallic copper.</style></abstract><notes><style face="normal" font="default" size="100%">2041-1723&#xD;Gross, Timothy M&#xD;Lahiri, Joydeep&#xD;Golas, Avantika&#xD;Orcid: 0000-0002-5090-429x&#xD;Luo, Jian&#xD;Verrier, Florence&#xD;Kurzejewski, Jackie L&#xD;Baker, David E&#xD;Wang, Jie&#xD;Novak, Paul F&#xD;Snyder, Michael J&#xD;Journal Article&#xD;England&#xD;Nat Commun. 2019 Apr 30;10(1):1979. doi: 10.1038/s41467-019-09946-9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6491652</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41467-019-09946-9</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>246</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ramlingareddy,</style></author><author><style face="normal" font="default" size="100%">Malathi, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ramlingareddy, Department of Biochemistry, FMMCH, Mangalore, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">A correlative study of serum levels of copper, zinc and iron in chronic renal failure patients, before and after hemodialysis</style></title><secondary-title><style face="normal" font="default" size="100%">Indian Journal of Clinical Biochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Indian Journal of Clinical Biochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S80</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">trace metal</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">biochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">dialysate</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hemodialysis</style></keyword><keyword><style face="normal" font="default" size="100%">hepatobiliary disease</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">malignant neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">medical school</style></keyword><keyword><style face="normal" font="default" size="100%">nephrology</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword><keyword><style face="normal" font="default" size="100%">spectrophotometer</style></keyword><keyword><style face="normal" font="default" size="100%">spectroscopy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">0974-0422</style></isbn><abstract><style face="normal" font="default" size="100%">Haemodialysis patients are at risk for essential trace element deficiency and accumulation of toxic trace elements, both of which can affect health. During haemodialysis essential kidney functions, such as the elimination of metabolic waste and water as well as the correction of the electrolyte and acid-base state are replaced by the artificial purification system. Risk for both deficiency and accumulation of trace elements depend on dietary intake, removal by dialysis, composition of the source water used for dialysis and residual kidney function. This study aimed to evaluate the possible alterations in serum copper(Cu), zinc (Zn) and iron (Fe) levels in chronic renal failure patients undergoing before and after hemodialysis. To estimate &amp; correlate serum levels of Copper, Iron and Zinc among clinically diagnosed chronic renal failure patients, before and after hemodialysis It is an observational analytical study, which was collected from Nephrology unit, Medical College Hospital, Clinical Biochemistry Laboratory over a period of 3 months. Total numbers of 30first time clinically diagnosed chronic renal failure patients subjects were included in the study who were considered as (Group-I subjects), (age: 25-70 years) admitted before hemodialysis (n = 30); Thirty (Group-II subjects): Same Group-I subjects will be followed up after hemodialysis (n = 30). Chronic alcoholics, smokers, tobacco chewers, pregnancy, and other systemic illness (infections, malignancy, hepatobiliary diseases, cardiovascular diseases) were excluded from study. Biochemical parameters were analyzed using standard spectrophotometric methods by semiautomated spectrophotometer. Serum copper(Cu), and iron (Fe) levels in group II CRF patients were significantly higher compared to group I CRF patients. But Serum levels of zinc in Group-II are higher compared to Group-1 patients which was non-significant. Present study has observed significant changes in copper, iron and zinc in CRF patients, before and after haemodialysis. Therefore, dialysate trace metal content should be checked regularly. Since both excess and deficiency of trace elements are potentially amenable to therapy, the hypothesis that trace element status influences adverse risk on clinical outcomes appears worthy of investigation.</style></abstract><notes><style face="normal" font="default" size="100%">L626452874&#xD;2019-02-26</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L626452874</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s12291-018-0795-1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12291-018-0795-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fortier, L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Criteria of selection of the means of contraception for the purpose of prevention]</style></title><secondary-title><style face="normal" font="default" size="100%">Union Med Can</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Union Med Can</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1528-35</style></pages><volume><style face="normal" font="default" size="100%">104</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">1975/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Congenital Abnormalities</style></keyword><keyword><style face="normal" font="default" size="100%">Demographic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility</style></keyword><keyword><style face="normal" font="default" size="100%">Infant Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Population</style></keyword><keyword><style face="normal" font="default" size="100%">Population Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy, Unwanted</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Behavior</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1975</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Criteres de selection des modes de contraception dans un but de prevention</style></orig-pub><isbn><style face="normal" font="default" size="100%">0041-6959 (Print)&#xD;0041-6959</style></isbn><accession-num><style face="normal" font="default" size="100%">1220101</style></accession-num><abstract><style face="normal" font="default" size="100%">Contraception, considered as the ultimate in preventive medicine, is discussed from the viewpoint of the child, the mother and society, then methods are compared in this context. Congenital and hereditary disorders have doubled since 1916, while infant mortality from malnutrition and infections has fallen from 24.1 to .6/1000. Unplanned children, such as products of a refused abortion, youngest in a large family, firstborn in a young marriage and illegitimate children, suffer increased risks of mental illness, delinquency and infant mortality, in various studies. Adoption is not the solution since most children in foster care are too old to be desirable for adoption; 33-60% of these have emotional problems. Battered children, a phenomenon discovered by the medical profession in 1961, are often undesired children. In the author&apos;s view, pregnancy, although a natural function, represents consid erable danger to a woman&apos;s health, particularly if she is under 20. As evidence for this view she states that before prenatal care and hospital deliveries were universal, maternal mortality was 4.5%, and it is 10-12% in some developing countries. Socially, an unwanted pregnancy can be disastrous, particularly if a young woman is forced to marry or stop her education. On a societal level, poverty is prepetuated where contraception is not available. In U.S.A. in 1962 50% of families making less than $3000/year had 4 or more children, compared to 25% of those making $10,000 or more. These children have contributed disproportionally to societal costs, e.g., social services and uncontrolled urbanization, even in the U.S. and Canada. The benefit-cost ratio of providing contraception was estimated in England in 1971 as 20/1 to 128/1. The author recommended the specific contraceptive methods: pills especially for adolescents and menopausal women, copper IUD for those who cannot use pills, chemical and barrier methods combined for special cases, vasectomy and abortion where applicable.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Fortier, L&#xD;English Abstract&#xD;Journal Article&#xD;Canada&#xD;Union Med Can. 1975 Oct;104(10):1528-35.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">fre</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">68</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kishida, N.</style></author><author><style face="normal" font="default" size="100%">Simazaki, D.</style></author><author><style face="normal" font="default" size="100%">Kosaka, K.</style></author><author><style face="normal" font="default" size="100%">Kosuge, R.</style></author><author><style face="normal" font="default" size="100%">Akiba, M.</style></author><author><style face="normal" font="default" size="100%">Hayashi, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Public Health.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Current situation and problems associated with inactivation of microorganisms in water using copper]</style></title><secondary-title><style face="normal" font="default" size="100%">Nihon Koshu Eisei Zasshi</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nihon Koshu Eisei Zasshi</style></full-title></periodical><pages><style face="normal" font="default" size="100%">579-85</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2013/10/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0546-1766 (Print)&#xD;0546-1766</style></isbn><accession-num><style face="normal" font="default" size="100%">24125817</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The current situation and problems associated with inactivation of microorganisms in water using copper were elucidated. METHODS: A literature review was conducted regarding the history and mechanisms of inactivation technology using copper, the variety of microorganisms shown to be inactivated by these methods in previous experiments, and the efficacy of such technologies for the inactivation of microorganisms in water. RESULTS: The use of copper for inactivation of microorganisms has a long history. Although the use of copper was discontinued temporarily owing to the advent of antibiotics in the 1930s, the occurrence of antibiotic-resistant bacteria has resulted in the need for different approaches to control pathogenic microorganisms. One such alternative is the use of copper. Although the mechanisms underlying the efficacy of copper inactivation technology have not yet been elucidated in detail, it has been suggested that pathogenic bacteria are inactivated due to the toxicity of copper ions and strong oxidation effects of reactive oxygen species. Copper inactivation technology is effective against many pathogenic microorganisms that pose a risk to public health, such as Legionella pneumophila, Salmonella enterica, and Mycobacterium tuberculosis. In recent years, copper inactivation technology has been used in various water-related devices, especially water supply pipes in buildings. Previous studies have demonstrated that microorganisms can be sufficiently inactivated by copper even at concentrations below that specified in the Water Quality Standard for Drinking Water. However, some previous studies have indicated that the inactivation effect of copper is short-lived. Therefore, the development of techniques to maintain a long-term inactivation effect is a key concern. In addition, it has been reported that the use of copper pipes triggers chlorine decay and results in the formation of chlorine disinfection byproducts. Hence, further studies should aim at assessing the risks and benefits associated with the use of copper. CONCLUSION: Although the practical issues regarding copper inactivation technology are persistent, this method has been demonstrated to be efficacious. Therefore, this technology could be expected to be used in many devices such as water supply systems in hospitals in the near future.</style></abstract><notes><style face="normal" font="default" size="100%">Kishida, Naohiro&#xD;Simazaki, Dai&#xD;Kosaka, Koji&#xD;Kosuge, Ruka&#xD;Akiba, Michihiro&#xD;Hayashi, Kenji&#xD;English Abstract&#xD;Journal Article&#xD;Review&#xD;Japan&#xD;Nihon Koshu Eisei Zasshi. 2013 Sep;60(9):579-85.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">jpn</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>437</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">437</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hall, T. J.</style></author><author><style face="normal" font="default" size="100%">Wren, M. W. D.</style></author><author><style face="normal" font="default" size="100%">Jeanes, A.</style></author><author><style face="normal" font="default" size="100%">Gant, V. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T.J. Hall, Remedy Research Ltd, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decontamination of laundry at low temperature with CuWB50, a novel copper-based biocidal compound</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">478-483</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">biocide</style></keyword><keyword><style face="normal" font="default" size="100%">copper derivative</style></keyword><keyword><style face="normal" font="default" size="100%">detergent</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii</style></keyword><keyword><style face="normal" font="default" size="100%">Acinetobacter calcoaceticus</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium contamination</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">degradation</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">energy cost</style></keyword><keyword><style face="normal" font="default" size="100%">laundry</style></keyword><keyword><style face="normal" font="default" size="100%">low temperature</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Traditional laundry decontamination relies on thermal disinfection that degrades textiles. We investigated the ability of a novel copper-based biocidal compound, CuWB50, to assist in the decontamination of swatches purposely contaminated with Staphylococcus aureus and Acinetobacter during &quot;real-life&quot; low-temperature machine washing with and without 2 commercial detergents. Methods: Contaminated and noncontaminated swatches were attached to ballast sheets and washed in cold water for 15 minutes in an industrial Electrolux machine. We assessed colony-forming units (cfu) on the swatches and in the postwash water. Results: Low-temperature machine washing produced only partial reductions in viable methicillin-resistant Staphylococcus aureus and Acinetobacter calcoaceticus baumannii counts on swatches and resulted in cross contamination of other swatches in the same wash. Washing with CuWB50 alone at high concentration (100 mg/L), however, resulted in superior decontamination compared with water alone, whereas washing with a combination of detergent and CuWB50 at low concentration (5 mg/L) yielded synergistic and complete decontamination of swatches and postwash water. Conclusion: Our results show highly effective laundry decontamination using CuWB50 with detergent at low temperature and are timely both in terms of rising energy costs and textile degradation issues. © 2009 Association for Professionals in Infection Control and Epidemiology, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L50417553&#xD;2009-08-27</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L50417553</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2008.10.033</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">19216003</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2008.10.033</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>279</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lytsy, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B. Lytsy, Department of Clinical Microbiology and Infection Control, Uppsala University Hospital, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decreasing the risk of health-care associated legionellosis requires joint efforts and close collaboration between all relevant functions in a hospital</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></full-title></periodical><volume><style face="normal" font="default" size="100%">6</style></volume><keywords><keyword><style face="normal" font="default" size="100%">hot water</style></keyword><keyword><style face="normal" font="default" size="100%">cold stress</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">filter</style></keyword><keyword><style face="normal" font="default" size="100%">flushing</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">joint</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory infection</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacokinetics</style></keyword><keyword><style face="normal" font="default" size="100%">responsibility</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">social care</style></keyword><keyword><style face="normal" font="default" size="100%">staff</style></keyword><keyword><style face="normal" font="default" size="100%">tooth</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Between 2005 and 2009 15 patients acquired legionellosis from the water system at Uppsala University Hospital (UUH), some fatal. Several control measures has been descibed with more or less effectiveness (1). Objectives: To highlight the importance of a water saftey plan with defined roles, responsibilities and ways of communication between all functions can reduce the risk of health-care associated legionellosis. Methods: During 2010 the hospital adopted the WHO water safety plan which included defining roles, responibilities and ways of communications between all relevant functions (2). A steering group chaired by the chief physicia, engineers, janitors, the clinical microbiology laboratory and infection prevention and control staff met regularly. The water safety plan included monitoring the water system twice yearly and defining action limits. Control measures included weekly flushing of taps, plugging dead ends, point-of-use filters in some wards, adjusting cold and warm water temperatures and replacing plastic waterlines with copper. Clear action plans were set up, documented and followed up in regular meetings. Results: Between the years 2010-2017 three patients acquired legionellosis at UUH and all cases could be clearly explained by all functions of the steering group. The first case in 2012 acquired legionellosis from a dental unit which has been described in a recently published casereport (3). All three cases have been reported to the Swedish Social Care Inspectorate and carefully followed up to prevent new cases. Conclusion: When a clear water safety plan was established at UUH the risk of acquiring legionellosis from the hospital water system dramatically decreased. The decisions to take on preventable actions were shared between all functions with different knowledge in order to control the risks that continuously developed over time.</style></abstract><notes><style face="normal" font="default" size="100%">L619545051&#xD;2017-12-11</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L619545051</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s13756-017-0201-4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-017-0201-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>329</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dhar, R.</style></author><author><style face="normal" font="default" size="100%">Krain, L. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. Dhar, University of Arkansas for Medical Sciences, Little Rock, AR, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dementia and psychosis in cerebellar degeneration</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Geriatric Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S125-S127</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">ziprasidone</style></keyword><keyword><style face="normal" font="default" size="100%">olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">heavy metal</style></keyword><keyword><style face="normal" font="default" size="100%">Hu antibody</style></keyword><keyword><style face="normal" font="default" size="100%">gliadin antibody</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">neuroleptic agent</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellum degeneration</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">gerontopsychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">mental disease</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellum</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellum disease</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">manager</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">cerebellum atrophy</style></keyword><keyword><style face="normal" font="default" size="100%">dysmetria</style></keyword><keyword><style face="normal" font="default" size="100%">spinocerebellar degeneration</style></keyword><keyword><style face="normal" font="default" size="100%">olivopontocerebellar atrophy</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">agitation</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">personality disorder</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">recall</style></keyword><keyword><style face="normal" font="default" size="100%">learning</style></keyword><keyword><style face="normal" font="default" size="100%">velocity</style></keyword><keyword><style face="normal" font="default" size="100%">language</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">modulation</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">rating scale</style></keyword><keyword><style face="normal" font="default" size="100%">processing</style></keyword><keyword><style face="normal" font="default" size="100%">physical disease by body function</style></keyword><keyword><style face="normal" font="default" size="100%">tracheobronchial stent</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">fall risk</style></keyword><keyword><style face="normal" font="default" size="100%">extrapyramidal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">medical care</style></keyword><keyword><style face="normal" font="default" size="100%">feeding</style></keyword><keyword><style face="normal" font="default" size="100%">persecutory delusion</style></keyword><keyword><style face="normal" font="default" size="100%">gait</style></keyword><keyword><style face="normal" font="default" size="100%">psychiatric department</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">hereditary ataxia</style></keyword><keyword><style face="normal" font="default" size="100%">motor performance</style></keyword><keyword><style face="normal" font="default" size="100%">coworker</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">delusion</style></keyword><keyword><style face="normal" font="default" size="100%">paraneoplastic neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">atrophy</style></keyword><keyword><style face="normal" font="default" size="100%">brain stem</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">Caucasian</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">prefrontal cortex</style></keyword><keyword><style face="normal" font="default" size="100%">ataxic gait</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">perception disorder</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">limbic system</style></keyword><keyword><style face="normal" font="default" size="100%">Huntington chorea</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">blinking</style></keyword><keyword><style face="normal" font="default" size="100%">bradykinesia</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">family counseling</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1064-7481</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: The cerebellum has been historically associated with motor function but neuroanatomical and neuropsychological studies suggest it has a role in modulation of cognitive and affective functioning(1-3 ).The cerebellum has connections with nonmotor cortical and subcortical areas including limbic system and the prefrontal cortex(4). The nonmotor functions of cerebellum include coordinating and monitoring errors of thought and hence, symptoms secondary to cerebellar dysfunction have been referred to as “dysmetria of thought”(3). Case reports of cerebellar disease due to multiple etiologies including tumors, hereditary ataxia, olivopontocerebellar atrophy, degenerative cerebellar diseases, infections and strokes may present with variety of cognitive deficits as well as psychiatric symptoms including depression, anxiety, personality changes, or psychotic symptoms. Methods: We report a case of a 67 year old Caucasian male with 16 years of education who presented with cognitive decline and psychotic symptoms. He was diagnosed with schizophrenia by an outside provider due to delusions of persecution and ideas of reference involving his co- workers .He was initiated on ziprasidone. In the next 6 months, there was a rapid decline in his cognitive functioning with with gait instability and falls. He also needed assistance with dressing and feeding predominantly due to incoordination of his movements and also most of his IADLs. His psychotic symptoms escalated, incorporating his wife as well as outpatient provider in his delusional system. Neuropsychological evaluation confirmed severe deficits in domains of language, visual construction, processing speed, executive functioning, wordlist learning and recall, and significant motor impairment.On neurological exam, the patient exhibited bradykinesia reduced blinking rate and cerebellar signs of dysdiadokinesia, past pointing and broad based ataxic gait. CT and MRI showed prominent cerebellar atrophy and moderate brain stem atrophy. Broad differential diagnosis was kept including sporadic olivopontocerebellar atrophy, paraneoplastic cerebellar degeneration and spinocerebellar ataxia and sprue .Work-up including anti-gliadin antibody, anti-hu antibody were negative. Heavy metals including copper and lead and vitamin B12 were within normal range .A literature review on cognitive deficits and psychiatric symptoms in cerebellar disease was performed using the terms cerebellar degeneration “cerebellar atrophy” “psychosis and cerebellum” and “ cognition and cerebellum.” Results: The patient was admitted to acute inpatient psychiatric unit following increased agitation and threatening to hurt his wife driven by his persecutory delusions. He was cross-tapered from ziprasidone to olanzapine. The patient displayed gradual improvement in his agitation and psychotic symptoms and discharged to his family&apos;s care. He has been largely cooperative with his caregivers and medical care on outpatient follow up. A review(5) of 133 cases of diseases associated with cerebellar degeneration spinocerebellar ataxia including the hereditary variant in children and sporadic variants found psychiatric and/or cognitive findings were present in 51% of cases. Most common psychiatric symptoms reported include anxiety and depression. Authors(3)examined 20 consecutive patients, primarily with cerebellar stroke, and described a “cerebellar cognitive affective syndrome” that involved executive, visuospatial, and linguistic dysfunction, accompanied by personality change. “cognitive dysmetria” proposed by authors(6)and also applied to schizophrenia(7) postulates that the fluidity and synchrony of thought, like movement, are normally modulated by the cerebellum and hence, disruption of cortical-thalamic-cerebellar circuit can lead to perceptual disturbances and cognitive dysfunction. A study included a series of 31 patients with degenerative cerebellar diseases, compared with patients with Huntington&apos;s disease and neurologically healthy comparison subjects. Comprehensive psychiatric ev luations, including the SCID for DSM-IV and psychopathology rating scales, were administered and found overall rate of rate of non-cognitive psychiatric disorders was 77% in the patients with degenerative cerebellar diseases, nearly identical to that in the patients with Huntington&apos;s disease and about double that seen in the neurologically healthy subjects(8). Conclusions: Cerebellar disorders including neurodegenerative disorders not only present with motor signs and symptoms but may also result in cognitive as well as psychiatric symptoms. Deficits in cognition include executive functioning as well as impaired verbal fluency and visuospatial impairment. The psychiatric symptoms can be severe enough to warrant hospitalization for safety of patient and others. Antipsychotics may be used judiciously due to existing motor deficits and fall risk and medications with lesser propensity for extrapyramidal side effects should be used. (Figure Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L71814322&#xD;2015-03-18</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71814322</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>307</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">307</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vasudevan, S.</style></author><author><style face="normal" font="default" size="100%">Shalimar,</style></author><author><style face="normal" font="default" size="100%">Kavimandan, A.</style></author><author><style face="normal" font="default" size="100%">Kalra, N.</style></author><author><style face="normal" font="default" size="100%">Nayak, B.</style></author><author><style face="normal" font="default" size="100%">Thakur, B.</style></author><author><style face="normal" font="default" size="100%">Das, P.</style></author><author><style face="normal" font="default" size="100%">Gupta, S. D.</style></author><author><style face="normal" font="default" size="100%">Panda, S. K.</style></author><author><style face="normal" font="default" size="100%">Acharya, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.K. Acharya, Department of Gastroenterology, All India Institute of Medical Sciences, 3(rd) Floor Teaching Block, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Demographic profile, host, disease &amp; viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India</style></title><secondary-title><style face="normal" font="default" size="100%">Indian Journal of Medical Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Indian Journal of Medical Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-340</style></pages><volume><style face="normal" font="default" size="100%">143</style></volume><number><style face="normal" font="default" size="100%">MARCH</style></number><keywords><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">albumin</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">alpha fetoprotein</style></keyword><keyword><style face="normal" font="default" size="100%">alpha2b interferon plus ribavirin</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">colecalciferol</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">granulocyte macrophage colony stimulating factor</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">insulin</style></keyword><keyword><style face="normal" font="default" size="100%">peginterferon alpha2b</style></keyword><keyword><style face="normal" font="default" size="100%">urea</style></keyword><keyword><style face="normal" font="default" size="100%">virus RNA</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">chronic hepatitis C</style></keyword><keyword><style face="normal" font="default" size="100%">compensated liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cytopenia</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">drug substitution</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">echography</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style face="normal" font="default" size="100%">erythema</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal endoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">headache</style></keyword><keyword><style face="normal" font="default" size="100%">hematological parameters</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis C virus genotype 1</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis C virus genotype 3</style></keyword><keyword><style face="normal" font="default" size="100%">host</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">insulin resistance</style></keyword><keyword><style face="normal" font="default" size="100%">liver biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">loss of appetite</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaise</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical procedures</style></keyword><keyword><style face="normal" font="default" size="100%">microbiological parameters</style></keyword><keyword><style face="normal" font="default" size="100%">real time polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">suicidal behavior</style></keyword><keyword><style face="normal" font="default" size="100%">sustained virologic response</style></keyword><keyword><style face="normal" font="default" size="100%">tertiary care center</style></keyword><keyword><style face="normal" font="default" size="100%">transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">virus detection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">0971-5916</style></isbn><abstract><style face="normal" font="default" size="100%">Background &amp; objectives: Standard of care for chronic hepatitis C (CHC) in India is peginterferon and ribavirin (RBV). The response to treatment in real life stetting is unclear. The objectives of this study were to evaluate the demographic profile and assess the virological response and predictors of response in CHC patients. Methods: Consecutive patients with CHC were included in this study. Detailed clinical history, risk factors, and predictive factors of response were noted. Patients were treated with peginterferon α2b (1.5 μg/kg/wk) and RBV (12 mg/kg/day) for 6 to 18 months based on response. Results: A total of 211 patients were included in the analysis, mean age 40.6±12.3 yr, 144 (68%) were males and 71 (34%) had compensated cirrhosis. Commonest risk factor for acquiring CHC was previous transfusion and surgery (51%). Genotype 3 (72%) was most common followed by genotype 1 (23%). Overall sustained virologic response (SVR) was 64 per cent [95% CI 57.1%-70.4%]. The SVR was 66.5 per cent [95% CI 58.34-73.89%] for genotype 3 and 61.2 per cent [95% CI 46.23 to 74.80%] for genotype 1. Non-cirrhotics had better SVR rates compared to cirrhotics (76 vs 41%, P&lt;0.001). On multivariate analysis, BMI ≥23 kg/m2, HOMA-IR ≥2, compliance (≤80%), and fibrosis &gt;2 were predictors of low SVR. Interpretation &amp; conclusions: Genotype 3 was the commonest HCV genotype. The commonest source of infection was previous transfusion and surgery. SVR rates for genotypes 3 were better than genotype 1 patients. Predictors of non-response were high BMI, insulin resistance, significant fibrosis and inadequate compliance.</style></abstract><notes><style face="normal" font="default" size="100%">L610425806&#xD;2016-05-27&#xD;2016-06-06</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L610425806</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.4103/0971-5916.182624</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">27241647</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.4103/0971-5916.182624</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>502</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">502</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fattore, L.</style></author><author><style face="normal" font="default" size="100%">Rosenstein, H. E.</style></author><author><style face="normal" font="default" size="100%">Fine, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L. Fattore, Zoller Dental Clinic, University of Chicago, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dental rehabilitation of the patient with severe caries after radiation therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">258-261</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">carcinoma</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">complete denture</style></keyword><keyword><style face="normal" font="default" size="100%">dental abutment</style></keyword><keyword><style face="normal" font="default" size="100%">dental caries</style></keyword><keyword><style face="normal" font="default" size="100%">denture</style></keyword><keyword><style face="normal" font="default" size="100%">endodontics</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">head and neck tumor</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">larynx tumor</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">overlay denture</style></keyword><keyword><style face="normal" font="default" size="100%">patient care planning</style></keyword><keyword><style face="normal" font="default" size="100%">radiation injury</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">squamous cell carcinoma</style></keyword><keyword><style face="normal" font="default" size="100%">tonsil tumor</style></keyword><keyword><style face="normal" font="default" size="100%">tooth periapical disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1986</style></year></dates><isbn><style face="normal" font="default" size="100%">0275-1879</style></isbn><abstract><style face="normal" font="default" size="100%">Dental management of the patient with severe caries after radiation therapy can be accomplished by the general practitioner in an office setting. Because of the decrease in vascularity that results from radiotherapy, the general practitioner must keep the following points in mind when treating these patients: Extraction of teeth that were in the field of radiotherapy is contraindicated. If there is a question about a possible extraction, consultation should be made with the patient&apos;s radiotherapist and a hospital-trained dentist (preferably, an oral surgeon). Endodontic treatment is the only treatment indicated for pulpally damaged teeth in the field of radiotherapy. When endodontic treatment is done, the following precautions are necessary: all teeth that are an immediate source of infection must be treated first; prophylactic antibiotics should be administered for the duration of treatment&apos;; all endodontic procedures must be administered in an aseptic field of treatment--if a tooth is badly deteriorated as a result of severe caries, a copper band should be used with a rubber dam and no tooth should ever be left &quot;open for drainage&quot; in these patients; temporary fillings should be of sufficient strength to prevent contamination between appointments; tooth-length determination should be done with precision--instrumentation beyond the apex should be avoided; caustic irrigating solutions such as sodium hypochlorite should be avoided--sterile water or sterile saline solution is preferable. For fabrication of prostheses, the general practitioner should be aware that: metallic-oxide impression materials such as zinc-oxide and eugenol should be avoided because of their irritating properties; trismus is common when the masticatory muscles are bilaterally in the field of radiotherapy-therefore, to prevent encroachment on the freeway space for these patients, the vertical dimension of occlusion should be decreased accordingly; monoplane teeth are preferable to cusped teeth for patients with trismus because their border movements are often irregular-monoplane teeth cause less interferences and are easier for the patient to manage; a remount of the overdentures to check the occlusion as well as a careful examination of flange extensions are necessary to prevent tissue ulcerations that could lead to tissue and bony necroses. Cast restorations should be avoided for patients with severe caries after radiation therapy (for example, a cast core and dowel). Prevention of postradiotherapy treatment complications is the primary goal in the management of the patient who has had head and neck cancer. If, however, the patient who has received radiation therapy and as a result has severe caries does come to the general practitioner, a logical and organized treatment plan can be followed that will result in control of the carious disease process and the functional rehabilitation of the patient.</style></abstract><notes><style face="normal" font="default" size="100%">L563010802&#xD;2014-01-13</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L563010802</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24006569</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>395</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">395</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asghari, F. B.</style></author><author><style face="normal" font="default" size="100%">Nikaeen, M.</style></author><author><style face="normal" font="default" size="100%">Hatamzadeh, M.</style></author><author><style face="normal" font="default" size="100%">Dastjerdi, M. V.</style></author><author><style face="normal" font="default" size="100%">Hassanzadeh, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Nikaeen, Department of Environmental Health Engineering, Environment Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detection of Legionella Spp. in water from cooling towers</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Isfahan Medical School</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Isfahan Medical School</style></full-title></periodical><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">195</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">biochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">cooling tower</style></keyword><keyword><style face="normal" font="default" size="100%">health survey</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">pH</style></keyword><keyword><style face="normal" font="default" size="100%">polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">temperature</style></keyword><keyword><style face="normal" font="default" size="100%">turbidity</style></keyword><keyword><style face="normal" font="default" size="100%">water contamination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1735-854X&#xD;1027-7595</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Legionella are Gram negative and non-spore bacteria which are found in various natural and manmade aquatic environments. Legionella can cause legionnaires&apos; disease or Pontiac fever. Inhalation of aerosols from contaminated water sources leads to Legionella infections or legionellosis. Contamination of waters from cooling towers with Legionella was recognized as a major source for legionellosis. Therefore, this study was conducted to survey the Legionella contamination of waters from cooling towers. Methods: A total of 33 water samples were taken from cooling towers. After measuring temperature and pH, the samples were examined for the presence of Legionella in two methods of culture and polymerase chain reaction (PCR). We also evaluated turbidity, iron, magnesium, zinc, and copper content, and heterotrophic bacteria of the samples. Findings: From the 33 cooling towers examined, 15% and 70% of the samples were positive for Legionella by the culture method and nested PCR, respectively. Biochemical tests showed Legionella pneumophila to be the main detected species in contaminated water samples. Conclusion: The results of the study indicated that cooling towers can potentially transmit Legionella infections. Therefore, regular monitoring and application of control measures such as disinfection of waters of cooling towers are needed to minimize human exposure to Legionella, especially in hospital environments with high risk patients.</style></abstract><notes><style face="normal" font="default" size="100%">L373961659&#xD;2014-10-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L373961659</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">Persian</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>233</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gouliouris, T.</style></author><author><style face="normal" font="default" size="100%">Raven, K. E.</style></author><author><style face="normal" font="default" size="100%">Moradigaravand, D.</style></author><author><style face="normal" font="default" size="100%">Ludden, C.</style></author><author><style face="normal" font="default" size="100%">Coll, F.</style></author><author><style face="normal" font="default" size="100%">Blane, B.</style></author><author><style face="normal" font="default" size="100%">Naydenova, P.</style></author><author><style face="normal" font="default" size="100%">Horner, C.</style></author><author><style face="normal" font="default" size="100%">Brown, N. M.</style></author><author><style face="normal" font="default" size="100%">Corander, J.</style></author><author><style face="normal" font="default" size="100%">Limmathurotsakul, D.</style></author><author><style face="normal" font="default" size="100%">Parkhill, J.</style></author><author><style face="normal" font="default" size="100%">Peacock, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Gouliouris, Department of Medicine, University of Cambridge, Cambridge, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Detection of vancomycin-resistant Enterococcus faecium hospital-adapted lineages in municipal wastewater treatment plants indicates widespread distribution and release into the environment</style></title><secondary-title><style face="normal" font="default" size="100%">Genome Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Genome Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">626-634</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">cell surface protein</style></keyword><keyword><style face="normal" font="default" size="100%">chloramphenicol</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">spectinomycin</style></keyword><keyword><style face="normal" font="default" size="100%">tetracycline</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial count</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium detection</style></keyword><keyword><style face="normal" font="default" size="100%">bloodstream infection</style></keyword><keyword><style face="normal" font="default" size="100%">cross-sectional study</style></keyword><keyword><style face="normal" font="default" size="100%">decontamination</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecium</style></keyword><keyword><style face="normal" font="default" size="100%">environmental release</style></keyword><keyword><style face="normal" font="default" size="100%">genetic variability</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">municipal wastewater</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">sewage</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">virulence</style></keyword><keyword><style face="normal" font="default" size="100%">waste water management</style></keyword><keyword><style face="normal" font="default" size="100%">waste water treatment plant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1549-5469&#xD;1088-9051</style></isbn><abstract><style face="normal" font="default" size="100%">Vancomycin-resistant Enterococcus faecium (VREfm) is a leading cause of healthcare-associated infection. Reservoirs of VREfm are largely assumed to be nosocomial although there is a paucity of data on alternative sources. Here, we describe an integrated epidemiological and genomic analysis of E. faecium associated with bloodstream infection and isolated from wastewater. Treated and untreated wastewater from 20 municipal treatment plants in the East of England, United Kingdom was obtained and cultured to isolate E. faecium, ampicillin-resistant E. faecium (AREfm), and VREfm. VREfm was isolated from all 20 treatment plants and was released into the environment by 17/20 plants, the exceptions using terminal ultraviolet light disinfection. Median log10 counts of AREfm and VREfm in untreated wastewater from 10 plants in direct receipt of hospital sewage were significantly higher than 10 plants that were not. We sequenced and compared the genomes of 423 isolates from wastewater with 187 isolates associated with bloodstream infection at five hospitals in the East of England. Among 481 E. faecium isolates belonging to the hospital-adapted clade, we observed genetic intermixing between wastewater and bloodstream infection, with highly related isolates shared between a major teaching hospital in the East of England and 9/20 plants. We detected 28 antibiotic resistance genes in the hospital-adapted clade, of which 23 were represented in bloodstream, hospital sewage, and municipal wastewater isolates. We conclude that our findings are consistent with widespread distribution of hospital-adapted VREfm beyond acute healthcare settings with extensive release of VREfm into the environment in the East of England.</style></abstract><notes><style face="normal" font="default" size="100%">L2001791862&#xD;2019-04-15&#xD;2019-07-05</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2001791862</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1101/gr.232629.117</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">30898881</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1101/gr.232629.117</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>236</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">236</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdelgawad, M. E.</style></author><author><style face="normal" font="default" size="100%">El-mezayen, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.E. Abdelgawad, Biochemistry Division, Chemistry Department, Helwan University, Cairo, Egypt</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of a novel angiogenic score for early detection of hepatocellular carcinoma among high-risk hepatitis c virus patients</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Vascular Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Vascular Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><keywords><keyword><style face="normal" font="default" size="100%">albumin</style></keyword><keyword><style face="normal" font="default" size="100%">alpha fetoprotein</style></keyword><keyword><style face="normal" font="default" size="100%">aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">angiogenic factor</style></keyword><keyword><style face="normal" font="default" size="100%">angiopoietin 2</style></keyword><keyword><style face="normal" font="default" size="100%">biological marker</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">clinical laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic test accuracy study</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatitis C virus</style></keyword><keyword><style face="normal" font="default" size="100%">high risk patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">international normalized ratio</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">liver cell carcinoma</style></keyword><keyword><style face="normal" font="default" size="100%">liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">platelet count</style></keyword><keyword><style face="normal" font="default" size="100%">prediction</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity and specificity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1423-0135</style></isbn><abstract><style face="normal" font="default" size="100%">Hepatocellular carcinoma (HCC) is often diagnosed at advanced stage where effective therapies are lacking. More than 90% of HCC cases develop in chronically inflamed liver as a result of viral hepatitis including virus C and B. The current diagnostic tools for HCC among high risk patients include clinical, laboratory, imaging, and biopsies which have multiple drawbacks and limitations. Therefore, there is an urgent need to identify more sensitive and reliable serum biomarkers for early non-invasive detection of HCC among high risk patients. One of the notable features of HCC is hypervascularity which open the door for using angiogenic markers for HCC early detection; thus, herein we aimed to develop a novel score based on combination of angiogenic factors including angiopoietin 2 (Ang2), copper, nitric oxide (NO) in addition to routine laboratory tests for early prediction of HCC. Ang2 were assayed for HCC group (80 patients), liver cirrhosis group (65 patients), and control group (40 patients) by enzyme-linked immunosorbent assay (ELISA). Copper and nitric oxide were assayed by simple colorimetric method. Data from all groups were retrospectively analyzed including α-fetoprotein (AFP), international normalized ratio (INR), albumin and platelet count, transaminases, and participants age. Areas under receiving operating curve (ROC) were used to develop the score. A novel index named Angio-HCC score = 2.4 [0.45×Ang2 (ng/ml) - 0.01×Cu (mg/dL) + 97×NO (μmol/L) - 9.9×Albumin (g/l) - 0.04×Platelets count [×10]3 l(-1)] was developed. Angio-HCC score produced area under ROC curve of 0.97 for discriminating HCC patients from liver cirrhosis with sensitivity of 89% and specificity of 81% at cutoff 1.5 (i.e., less than 1.5 was considered cirrhosis whereas greater than 1.5 was considered HCC). Angio-HCC score is a novel non-invasive diagnostic tool that could replace AFP in HCC screening and follow up of cirrhotic patients.</style></abstract><notes><style face="normal" font="default" size="100%">L627389168&#xD;2019-05-14</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L627389168</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1159/000499516</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000499516</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tian, Y.</style></author><author><style face="normal" font="default" size="100%">Gong, G. Z.</style></author><author><style face="normal" font="default" size="100%">Yang, X.</style></author><author><style face="normal" font="default" size="100%">Peng, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Liver Disease Research Center, Second Xiangya Hospital of Central South University, Changsha, 410011, China. doctortianyi@qq.com.&#xD;Liver Disease Research Center, Second Xiangya Hospital of Central South University, Changsha, 410011, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and management of fulminant Wilson&apos;s disease: a single center&apos;s experience</style></title><secondary-title><style face="normal" font="default" size="100%">World J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World J Pediatr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">209-14</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2015/06/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatolenticular Degeneration/*diagnosis/mortality/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">decoppering</style></keyword><keyword><style face="normal" font="default" size="100%">dimercaptopropansulfonate sodium</style></keyword><keyword><style face="normal" font="default" size="100%">fulminant hepatic failure</style></keyword><keyword><style face="normal" font="default" size="100%">therapeutic plasma exchange</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">26041495</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Medical therapy is rarely effective in patients with fulminant Wilson&apos;s disease (FWD). Liver transplantation is limited by the lack of donor liver in most patients with FWD at the time of diagnosis. New Wilson&apos;s index, model for end-stage liver disease (MELD) and Child-Pugh score are useful tools for decision-making of liver transplantation; however, none of them is an independent decisive tool. It is worthwhile to explore a more effective and practical therapeutic strategy and reevaluate the prediction systems for patients with FWD. METHODS: Nine patients with FWD associated with hemolytic crisis and fulminant hepatic failure (FHF) were investigated. The clinical presentation, prognostic score and medical therapies of the patients were analyzed. RESULTS: In 7 of the 9 patients with FWD who received the comprehensive therapy of corticosteroid, copper-chelating agent (dimercaptopropansulfonate sodium) and therapeutic plasma exchange (TPE), 6 patients recovered from FHF. The remaining one had been improved through the comprehensive therapy but died of septicemia 51 days later. Two patients with spontaneous bacterial peritonitis (SBP) died from liver failure in three or five hospital days without plasma exchange or chelating therapy. All of the 9 patients with FWD presented with acute hepatic failure, severe jaundice and mild to severe hemolytic anemia. No marked difference in the incidence of severe hemolytic anemia was detected between the survival and deceased groups. However, the incidence and the degree of hepatic encephalopathy (HE) in the non-survival group were higher than those in the survival group. Unlike the deceased group, the survival group had no complications induced by bacterial infection. Compared to new Wilson&apos;s index, Child-Pugh score and MELD score, the variation of prothrombin activity (PTA) between the survival and deceased groups was more evident. CONCLUSION: For patients with FWD, the episode of severe hepatic encephalopathy or/and spontaneous bacterial peritonitis indicates worse prognosis, and PTA is a recommendable predictor. An emergent liver transplantation should be considered for patients whose PTA is below 20%, or for those with severe HE or/and SBP. The comprehensive therapy of corticosteroid, copper-chelating agent and TPE is effective for patients without SBP and whose PTA is higher than 20%.</style></abstract><notes><style face="normal" font="default" size="100%">1867-0687&#xD;Tian, Yi&#xD;Gong, Guo-Zhong&#xD;Yang, Xu&#xD;Peng, Feng&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;World J Pediatr. 2016 May;12(2):209-14. doi: 10.1007/s12519-015-0026-2. Epub 2015 Jun 4.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12519-015-0026-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>405</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Evliyaoʇlu, O.</style></author><author><style face="normal" font="default" size="100%">Kelekc¸i, S.</style></author><author><style face="normal" font="default" size="100%">Başc¸ik, H.</style></author><author><style face="normal" font="default" size="100%">Mete, N.</style></author><author><style face="normal" font="default" size="100%">Gürkan, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">O. Evliyaoʇlu, Departments of Medical Biochemistry, Medical Faculty, Dicle University, Diyarbakir, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Different antioxidant pathways of hospitalized pediatric patients with pandemic influenza A (H1N1)</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">In Vivo</style></full-title></periodical><pages><style face="normal" font="default" size="100%">526</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">ubiquinone</style></keyword><keyword><style face="normal" font="default" size="100%">lipid</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">pandemic influenza</style></keyword><keyword><style face="normal" font="default" size="100%">influenza A</style></keyword><keyword><style face="normal" font="default" size="100%">seasonal influenza</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">child hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalized child</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">nose smear</style></keyword><keyword><style face="normal" font="default" size="100%">Influenza A virus</style></keyword><keyword><style face="normal" font="default" size="100%">assay</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0258-851X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: This study evaluated the relationship of total antioxidant capacity (TAC) and Coenzyme Q (Q10) levels with clinical outcome of hospitalized children with pandemic influenza. Serum copper (Cu) and zinc (Zn) levels were also determined to evaluate the antioxidative enzyme activity changes depending on their cofactor concentrations. Methods: A total of 66 patients, age range 48 days to 14 years, with suspected H1N1 virus infection were hospitalized and nasal swabs were sent to the National Influenza Reference Laboratory for confirmation of pandemic influenza A virus infection (H1N1) by rRT-PCR assay. Results: A total of 28 patients had H1N1 and 38 patients had seasonal influenza. Clinical and/or radiological pneumonia were detected in 24 of HIN 1 patients and 4 patients were exitus. TAC, Q10 and Zn levels were decreased significantly in H1N1 patients compared to those with seasonal influenza. There was no relationship between mortality and biochemical parameters. Serum Cu levels, WBC and the other routine laboratory tests were not changed significantly in patients with H1N1. Conclusion: Our data showed that pathogenesis of pandemic influenza infection had additional different mechanisms of oxidative stress from that of seasonal influenza. Antioxidants which use the lipid pathway or Zn may be the main oxidative factors that take part in the pathophysiology of H1N1.</style></abstract><notes><style face="normal" font="default" size="100%">L70427181&#xD;2011-06-02</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70427181</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>306</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">306</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prasad, P.</style></author><author><style face="normal" font="default" size="100%">Singh, N.</style></author><author><style face="normal" font="default" size="100%">Das, B.</style></author><author><style face="normal" font="default" size="100%">Raisuddin, S.</style></author><author><style face="normal" font="default" size="100%">Dudeja, M.</style></author><author><style face="normal" font="default" size="100%">Rastogi, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Prasad, National Institute of Pathology (ICMR), New Delhi, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential expression of superoxide dismutases in early aborters infected with Chlamydia trachomatis</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">203-204</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><keywords><keyword><style face="normal" font="default" size="100%">superoxide</style></keyword><keyword><style face="normal" font="default" size="100%">copper zinc superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">manganese superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">messenger RNA</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia trachomatis</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">abortion</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">plasmid</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">gynecology</style></keyword><keyword><style face="normal" font="default" size="100%">obstetrics</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">first trimester pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">tissues</style></keyword><keyword><style face="normal" font="default" size="100%">assay</style></keyword><keyword><style face="normal" font="default" size="100%">curettage</style></keyword><keyword><style face="normal" font="default" size="100%">placenta disorder</style></keyword><keyword><style face="normal" font="default" size="100%">scavenging system</style></keyword><keyword><style face="normal" font="default" size="100%">ethics</style></keyword><keyword><style face="normal" font="default" size="100%">real time polymerase chain reaction</style></keyword><keyword><style face="normal" font="default" size="100%">reverse transcription</style></keyword><keyword><style face="normal" font="default" size="100%">spontaneous abortion</style></keyword><keyword><style face="normal" font="default" size="100%">decidua</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1201-9712</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Chlamydia trachomatis (Ct) can infect placenta/ decidua causing Spontaneous Abortion (SA). However, associated pathogenic mechanisms are unknown. Placental oxidative stress has been implicated in pathophysiology of abortion. It was hypothesized that oxidative stress-induced placental dysfunction may be cause of multifactorial/ polygenic etiologies of abortion. Study aimed to evaluate role of Superoxide Dismutases (SODs) in pathophysiology of early abortion by studying expression of Manganese-Superoxide Dismutase (Mn-SOD) and Copper, Zinc- Superoxide Dismutase (Cu, Zn-SOD) in Ct-infected women. Methods &amp; Materials: With hospital ethics permission, Endometrial Curettage Tissue (ECT) was collected from 145 aborters (Sporadic Spontaneous Aborters, SSA and Recurrent Spontaneous Aborters, RSA) presenting with vaginal bleeding/ undergoing incomplete SA in first trimester of pregnancy and 120 aborters undergoing MTP at Department of Obstetrics and Gynaecology, Safdarjung hospital, New Delhi (India). Group I comprised of Ct-infected SSA/ RSA while uninfected induced aborters were included in Group II. PCR assay was performed for diagnosis of Ct cryptic plasmid (200 bp). Qualitative/ quantitative expression of Mn-SOD/ Cu, Zn-SOD mRNA was assessed by Reverse Transcription (RT)-PCR/ Taqman real-time PCR (q-PCR). Results: Infection with Ct was found in Group I (13.7%; n= 20/145) patients, viz.: SSA and RSA (11/85 and 9/60, respectively), whereas none of controls were infected (Group II). Qualitatively, both Mn-SOD (p &lt; 0.0001) and Cu, Zn-SOD (p &lt; 0.05) showed upregulated expression in Group I (Ct-infected SSA/ RSA) versus Group II (control) patients; however, level of Mn-SOD was significantly increased (p &lt; 0.0001) in comparison to Cu, Zn-SOD. Similar findings were obtained by qPCR analysis as there was significant differential expression of transcript level of SODs, viz.: Mn-SOD (p &lt; 0.0001) and Cu, Zn-SOD (p &lt; 0.05) in infected SSA/ RSA patients (Group I). Ct-infected RSA showed elevated Mn-SOD expression (p &lt; 0.001) as compared to infected SSA. However, no significant difference was found in expression of Cu, Zn-SOD between infected patients, viz.: RSA versus SSA. Conclusion: The study suggested that superoxide radical and its scavenging system play important role in maintenance of pregnancy in Ct-infected women. Overall results indicated that both SODs are differentially expressed and Mn-SOD plays greater protective role in Ct-associated early abortion.</style></abstract><notes><style face="normal" font="default" size="100%">L72245420&#xD;2016-04-21</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72245420</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ijid.2016.02.467</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijid.2016.02.467</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, Y. S.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author><author><style face="normal" font="default" size="100%">Vidic, R. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Civil &amp; Environmental Engineering, University of Pittsburgh, PA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disinfection of water distribution systems for Legionella</style></title><secondary-title><style face="normal" font="default" size="100%">Semin Respir Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Semin Respir Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">147-59</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">1998/06/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance and Engineering, Hospital/*standards</style></keyword><keyword><style face="normal" font="default" size="100%">Sanitary Engineering/standards</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0882-0546 (Print)&#xD;0882-0546</style></isbn><accession-num><style face="normal" font="default" size="100%">9643393</style></accession-num><abstract><style face="normal" font="default" size="100%">Hospital-acquired legionnaires&apos; disease arises from the presence of Legionella in hospital water systems. Legionella not only persists in hot water tanks but is also found in the biofilm throughout the entire water distribution system. Conditions within water systems that promote Legionella colonization include water temperature, configuration and age of the hot water tank, physicochemical constituents of the water, plumbing materials, and commensal microflora. Hospital-acquired legionnaires&apos; disease has been prevented by instituting control measures directed at the water distribution system. These include superheat-and-flush, copper/silver ionization, ultraviolet light, instantaneous heating systems, and hyperchlorination. Each of the above disinfection methods has been proven to be effective in the short-term, but long-term efficacy has been difficult due to limitations associated with each method. The complexities of Legionella disinfection, including advantages and disadvantages of each method, are reviewed. A successful Legionella prevention program requires cooperation and communication among hospital administrative personnel, engineers, and infection control staff. Routine environmental surveillance cultures for Legionella are the critical component for successful long-term disinfection. Culture results document the efficacy of the disinfection method and alert the hospital staff to consider Legionella in hospitalized patients with pneumonia.</style></abstract><notes><style face="normal" font="default" size="100%">Lin, Y S&#xD;Stout, J E&#xD;Yu, V L&#xD;Vidic, R D&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Semin Respir Infect. 1998 Jun;13(2):147-59.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>243</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Espadinha, D.</style></author><author><style face="normal" font="default" size="100%">Sobral, R. G.</style></author><author><style face="normal" font="default" size="100%">Mendes, C. I.</style></author><author><style face="normal" font="default" size="100%">Méric, G.</style></author><author><style face="normal" font="default" size="100%">Sheppard, S. K.</style></author><author><style face="normal" font="default" size="100%">Carriço, J. A.</style></author><author><style face="normal" font="default" size="100%">Lencastre, H.</style></author><author><style face="normal" font="default" size="100%">Miragaia, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Miragaia, Laboratory of Bacterial Evolution and Molecular Epidemiology, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distinct phenotypic and genomic signatures underlie contrasting pathogenic potential of staphylococcus epidermidis clonal lineages</style></title><secondary-title><style face="normal" font="default" size="100%">Frontiers in Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Frontiers in Microbiology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">AUG</style></number><keywords><keyword><style face="normal" font="default" size="100%">genetic analyzer</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial polysaccharide</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial protein</style></keyword><keyword><style face="normal" font="default" size="100%">carotenoid</style></keyword><keyword><style face="normal" font="default" size="100%">chloramphenicol</style></keyword><keyword><style face="normal" font="default" size="100%">ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">clindamycin</style></keyword><keyword><style face="normal" font="default" size="100%">collagen</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cotrimoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">dalfopristin plus quinupristin</style></keyword><keyword><style face="normal" font="default" size="100%">erythromycin</style></keyword><keyword><style face="normal" font="default" size="100%">formaldehyde</style></keyword><keyword><style face="normal" font="default" size="100%">fusidic acid</style></keyword><keyword><style face="normal" font="default" size="100%">gentamicin</style></keyword><keyword><style face="normal" font="default" size="100%">linezolid</style></keyword><keyword><style face="normal" font="default" size="100%">P-type Cu+ transporter</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin derivative</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">staphyloxanthin</style></keyword><keyword><style face="normal" font="default" size="100%">tetracycline</style></keyword><keyword><style face="normal" font="default" size="100%">trehalose</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">virulence factor</style></keyword><keyword><style face="normal" font="default" size="100%">adaptation</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant assay</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial cell wall</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial colonization</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial gene</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial growth</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial survival</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial virulence</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium adherence</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium isolation</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">blaI gene</style></keyword><keyword><style face="normal" font="default" size="100%">blaZ gene</style></keyword><keyword><style face="normal" font="default" size="100%">carbohydrate metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">detoxification</style></keyword><keyword><style face="normal" font="default" size="100%">ecological niche</style></keyword><keyword><style face="normal" font="default" size="100%">esaA gene</style></keyword><keyword><style face="normal" font="default" size="100%">esaB gene</style></keyword><keyword><style face="normal" font="default" size="100%">essA gene</style></keyword><keyword><style face="normal" font="default" size="100%">essB gene</style></keyword><keyword><style face="normal" font="default" size="100%">essC gene</style></keyword><keyword><style face="normal" font="default" size="100%">gene identification</style></keyword><keyword><style face="normal" font="default" size="100%">genetic distance</style></keyword><keyword><style face="normal" font="default" size="100%">genetic variability</style></keyword><keyword><style face="normal" font="default" size="100%">genome-wide association study</style></keyword><keyword><style face="normal" font="default" size="100%">genomics</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">growth curve</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">host bacterium interaction</style></keyword><keyword><style face="normal" font="default" size="100%">innate immunity</style></keyword><keyword><style face="normal" font="default" size="100%">lipid metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">minimum inhibitory concentration</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">osmotic stress</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">pH</style></keyword><keyword><style face="normal" font="default" size="100%">phagocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">phylogenetic tree</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Propionibacterium</style></keyword><keyword><style face="normal" font="default" size="100%">protein degradation</style></keyword><keyword><style face="normal" font="default" size="100%">sequence alignment</style></keyword><keyword><style face="normal" font="default" size="100%">single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus epidermidis</style></keyword><keyword><style face="normal" font="default" size="100%">surface charge</style></keyword><keyword><style face="normal" font="default" size="100%">HiSeq 2500</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1664-302X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Staphylococcus epidermidis is a common skin commensal that has emerged as a pathogen in hospitals, mainly related to medical devices-associated infections. Noteworthy, infection rates by S. epidermidis have the tendency to rise steeply in next decades together with medical devices use and immunocompromized population growth. Staphylococcus epidermidis population structure includes two major clonal lineages (A/C and B) that present contrasting pathogenic potentials. To address this distinction and explore the basis of increased pathogenicity of A/C lineage, we performed a detailed comparative analysis using phylogenetic and integrated pangenome-wide-association study (panGWAS) approaches and compared the lineages’s phenotypes in in vitro conditions mimicking carriage and infection. Results: Each S. epidermidis lineage had distinct phenotypic signatures in skin and infection conditions and differed in genomic content. Combination of phenotypic and genotypic data revealed that both lineages were well adapted to skin environmental cues. However, they appear to occupy different skin niches, perform distinct biological functions in the skin and use different mechanisms to complete the same function: lineage B strains showed evidence of specialization to survival in microaerobic and lipid rich environment, characteristic of hair follicle and sebaceous glands; lineage A/C strains showed evidence for adaption to diverse osmotic and pH conditions, potentially allowing them to occupy a broader and more superficial skin niche. In infection conditions, A/C strains had an advantage, having the potential to bind blood-associated host matrix proteins, form biofilms at blood pH, resist antibiotics and macrophage acidity and to produce proteases. These features were observed to be rare in the lineage B strains. PanGWAS analysis produced a catalog of putative S. epidermidis virulence factors and identified an epidemiological molecular marker for the more pathogenic lineage. Conclusion: The prevalence of A/C lineage in infection is probably related to a higher metabolic and genomic versatility that allows rapid adaptation during transition from a commensal to a pathogenic lifestyle. The putative virulence and phenotypic factors associated to A/C lineage constitute a reliable framework for future studies on S. epidermidis pathogenesis and the finding of an epidemiological marker for the more pathogenic lineage is an asset for the management of S. epidermidis infections.</style></abstract><notes><style face="normal" font="default" size="100%">L629171985&#xD;2019-09-12&#xD;2019-09-20</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L629171985</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3389/fmicb.2019.01971</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">HiSeq 2500(Illumina,United States)</style></custom3><custom4><style face="normal" font="default" size="100%">Illumina(United States)</style></custom4><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fmicb.2019.01971</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Briassoulis, G.</style></author><author><style face="normal" font="default" size="100%">Filippou, O.</style></author><author><style face="normal" font="default" size="100%">Hatzi, E.</style></author><author><style face="normal" font="default" size="100%">Papassotiriou, I.</style></author><author><style face="normal" font="default" size="100%">Hatzis, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Intensive Care Unit, University Hospital of Heraklion, Crete, Greece; Pediatric Intensive Care Medicine, Aghia Sophia Children&apos;s Hospital, Athens, Greece. ggbriass@med.uoc.gr</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early enteral administration of immunonutrition in critically ill children: results of a blinded randomized controlled clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">799-807</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">7-8</style></number><edition><style face="normal" font="default" size="100%">2005/06/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antioxidants/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Critical Illness/mortality/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Energy Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Enteral Nutrition/adverse effects/*methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Food, Formulated/*classification</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunocompetence</style></keyword><keyword><style face="normal" font="default" size="100%">Infections/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intensive Care Units, Pediatric</style></keyword><keyword><style face="normal" font="default" size="100%">Length of Stay</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrogen/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-9007 (Print)&#xD;0899-9007</style></isbn><accession-num><style face="normal" font="default" size="100%">15975487</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: In a blinded, prospective, randomized, controlled clinical trial, we compared nitrogen balance (NB), nutritional indices, antioxidant catalysts, and outcome in critically ill children given an immune-enhancing formula (I) or conventional early enteral nutrition (C). METHODS: Fifty patients, 103 +/- 7 months old, with disorders prompting admission to the pediatric intensive care unit, including sepsis, respiratory failure, and severe head injury, were enrolled in the study. Within 12 h of admission, patients were randomized to receive I (n=25) or C (n=25). Caloric intake was aimed at meeting patient&apos;s predicted basal metabolic rate by day 2 and predicted energy expenditure by day 4, irrespective of group assignment. Outcome endpoints and complications were recorded; NB, transthyretin, retinol-binding protein, transferrin, zinc, copper, and metabolic indices were measured on days 1 and 5 and compared with clinical and nutritional characteristics within and between groups. RESULTS: Both diets achieved their initial targets of covering predicted basal metabolic rate by day 2 and predicted energy expenditure by day 4. Twenty four-hour NB became positive in 40% of patients in group C and occurred in 64% of patients in group I by day 5. Only in group I did the mean NB become positive by day 5 (0.07+/-0.07 g/kg versus -0.24+/-0.03 g/kg on day 1, P&lt;0.001) compared with group C in which the mean NB remained negative (-0.06+/-0.04 g/kg versus -0.25+/-0.06 g/kg on day 1, P&lt;0.001). By day 5, nutritional indices and antioxidant catalysts showed a higher increasing trend in group I compared with group C and higher osmolality (P&lt;0.02), sodium (P&lt;0.03), and urea (P&lt;0.04). Diarrhea for group I (P&lt;0.02) and gastric distention for group C (P&lt;0.04) were the most frequently recorded complications. Mortality or length of stay did not differ between groups, but there was a trend for less gastric gram plus isolates (P&lt;0.05) or for Candida species (P&lt;0.04) and nosocomial infections in group I compared with group C. CONCLUSIONS: Although less well tolerated, immunonutrition is a feasible method of early enteral nutrition in the pediatric intensive care unit. It has a favorable effect on nutritional indices and antioxidant catalysts, but not on outcome hard endpoints. Although it poses a higher metabolic burden to the patient, it shows a trend to improve colonization and infection rates. Appropriate modifications for specific age populations might improve its tolerability and benefits among critically ill children.</style></abstract><notes><style face="normal" font="default" size="100%">Briassoulis, George&#xD;Filippou, Olga&#xD;Hatzi, Eugenia&#xD;Papassotiriou, Ioannis&#xD;Hatzis, Tassos&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;United States&#xD;Nutrition. 2005 Jul-Aug;21(7-8):799-807. doi: 10.1016/j.nut.2004.12.006.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nut.2004.12.006</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>467</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">467</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phipatanakul, W.</style></author><author><style face="normal" font="default" size="100%">Cronin, B.</style></author><author><style face="normal" font="default" size="100%">Wood, R. A.</style></author><author><style face="normal" font="default" size="100%">Eggleston, P. A.</style></author><author><style face="normal" font="default" size="100%">Shih, M. C.</style></author><author><style face="normal" font="default" size="100%">Song, L.</style></author><author><style face="normal" font="default" size="100%">Tachdjian, R.</style></author><author><style face="normal" font="default" size="100%">Oettgen, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W. Phipatanakul, Boston Children&apos;s Hospital, Harvard Medical School, Division of Immunology, 300 Longwood Ave., Boston, MA 02115, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect environmental intervention on mouse allergen levels in homes of inner-city Boston children with asthma</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Allergy, Asthma and Immunology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Allergy, Asthma and Immunology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">420-425</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">allergen</style></keyword><keyword><style face="normal" font="default" size="100%">Bla g 1 allergen</style></keyword><keyword><style face="normal" font="default" size="100%">cockroach allergen</style></keyword><keyword><style face="normal" font="default" size="100%">mouse allergen</style></keyword><keyword><style face="normal" font="default" size="100%">Mus m 1 allergen</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bedroom</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">childhood disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">environmental sanitation</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">house dust</style></keyword><keyword><style face="normal" font="default" size="100%">household</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infestation</style></keyword><keyword><style face="normal" font="default" size="100%">integrated pest management</style></keyword><keyword><style face="normal" font="default" size="100%">kitchen</style></keyword><keyword><style face="normal" font="default" size="100%">living room</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">pest control</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">urban area</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">1081-1206</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Recent studies have suggested that mouse allergen exposure and sensitization are common in urban children with asthma. The effectiveness of environmental intervention in reducing mouse allergen exposure has not been established. Objective: To evaluate whether environmental intervention of mouse extermination and cleaning results in a reduction in mouse allergen levels. Methods: Eighteen homes of children with positive mouse allergen skin test results and at least mild persistent asthma in urban Boston, MA, with evidence of mouse infestation or exposure were randomized in a 2:1 ratio (12 intervention and 6 control homes). The intervention homes received an integrated pest management intervention, which consisted of filling holes with copper mesh, vacuuming and cleaning, and using low-toxicity pesticides and traps. Dust samples were collected and analyzed for major mouse allergen (Mus m 1) and cockroach allergen (Bla g 1) at baseline and 1, 3, and 5 months after the intervention was started and compared with control homes. Results: Mouse allergen levels were significantly decreased compared with control homes by the end of the intervention period at month 5 in the kitchen and bedroom (kitchen intervention, 78.8% reduction; control, 319% increase; P = .02; bedroom intervention, 77.3% reduction; control, 358% increase; P &lt; .01; and living room intervention, 67.6% reduction; control, 32% reduction; P = .07). Conclusions: Mouse allergen levels were significantly reduced during a 5-month period using an integrated pest management intervention.</style></abstract><notes><style face="normal" font="default" size="100%">L39077583&#xD;2004-09-05</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L39077583</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/S1081-1206(10)61777-2</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">15104193</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1081-1206(10)61777-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elhag, K. M.</style></author><author><style face="normal" font="default" size="100%">Bahar, A. M.</style></author><author><style face="normal" font="default" size="100%">Mubarak, A. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Faculty of Medicine, Kuwait University, Safat.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effect of a copper intra-uterine contraceptive device on the microbial ecology of the female genital tract</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">245-51</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">1988/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Actinomyces/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Actinomycetaceae/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Actinomycetales Infections/*etiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteroides/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Candida/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genitalia, Female/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/*etiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">*Adnexitis--etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Arab Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">*Bacterial And Fungal Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Biology</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception Termination</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Genital Effects, Female--etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Genitalia</style></keyword><keyword><style face="normal" font="default" size="100%">Genitalia, Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Ingredients And Chemicals</style></keyword><keyword><style face="normal" font="default" size="100%">Inorganic Chemicals</style></keyword><keyword><style face="normal" font="default" size="100%">Insertion</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Kuwait</style></keyword><keyword><style face="normal" font="default" size="100%">Menorrhagia</style></keyword><keyword><style face="normal" font="default" size="100%">Metals</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Tract Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital System</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine Perforation</style></keyword><keyword><style face="normal" font="default" size="100%">*Western Asia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1988</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-2615 (Print)&#xD;0022-2615</style></isbn><accession-num><style face="normal" font="default" size="100%">3357191</style></accession-num><abstract><style face="normal" font="default" size="100%">Bacteria isolated from 108 intra-uterine contraceptive devices (IUCD) removed from patients with pelvic inflammatory disease (PID), haemorrhage, pregnancy and from asymptomatic women, and from the genital tracts of 66 healthy controls not wearing an IUCD, were studied. No significant differences were found in the types of micro-organisms or isolation rates from IUCDs removed from women in the various clinical groups. The isolation rate of anaerobic bacteria from IUCDs removed from asymptomatic wearers was significantly lower than that from controls, with the exception of the isolation rate of actinomyces which was significantly higher in IUCD wearers and A. israelii was recovered only from IUCDs. The isolation rates of the different bacterial species varied with the duration of the device in utero. The presence of a copper IUCD altered the bacterial flora of the female genital tract. The insertion of such a device and the ecological changes that follow play a crucial role in the development of PID.&#xD;The bacterial flora of the cervix and vagina were examined in 108 patients who had copper IUDs removed and in 66 controls at the Maternity Hospital and Maternal Welfare Clinics in Kuwait. The IUDs removed were the Nova-T, Copper 7, and Cu 250. 15 of the women having IUDs removed had pelvic inflammatory disease; 21 had irregular bleeding; 11 had suprapubic pain, vaginal discharge, or uterine perforation; and 51 were asymptomatic. Actinomyces species, particularly Actinomyces israelii, and Arachnia propionica were isolated from 16 of the IUD wearers but only 2 of the controls. Lactobacillus species were isolated from 10 of the IUD wearers and 25 of the controls. Anaerobic cocci were isolated from 13 device wearers and 12 controls. Except for Actinomyces, anaerobic bacteria were isolated from controls more often than from the IUD wearers. Copper is known to have an antibacterial effect on gram-positive anaerobes, and even Actinomyces was absent from IUD wearers who had worn the device less than a year, i.e., during the period of maximum copper release. Moreover, no significant difference was found in the patients in the different clinical groups. The presence of an IUD does promote colonization of the genital tract by Actinomyces. However, other factors must be considered in the development of pelvic inflammatory disease. The creation of an acidic environment by some bacteria, such as Lactobacillus, may promote the growth of some pathogens, while inhibiting the growth of others. Furthermore, the insertion of an IUD breaches the protective barrier of the cervical mucus, and the IUD tail creates a transmission link into the uterus.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Elhag, K M&#xD;Bahar, A M&#xD;Mubarak, A A&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Med Microbiol. 1988 Apr;25(4):245-51. doi: 10.1099/00222615-25-4-245.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1099/00222615-25-4-245</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of Copper on the Healing of Obstetric Wounds</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT03284749</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT03284749</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Communicable Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Surgical Wound Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Wound Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Wounds and Injuries</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01564123</style></accession-num><abstract><style face="normal" font="default" size="100%">This is a double blind randomised controlled pilot study to assess feasibility of copper impregnated wound dressings and maternity pads for the healing of obstetric wounds. All women having a caesarean section or with perineal sutures after a vaginal delivery will be recruited from the antenatal clinic (in case of an elective caesarean section) or from the maternity wards within Croydon Health Services. All women will be given a patient information sheet describing the study prior to consent and will be giving adequate time to read the information before signing the Informed consent. Participants will be followed up via a telephone questionnaire 7, 14 and 30 days after the delivery. Randomisation: After inclusion all participants will be randomised for a wound dressing or maternity pad with (study group) or without copper (control group). The two sets of wound dressings and pads will be marked &quot;A&quot; or &quot;B&quot;. Both the clinician and the participant will be blinded to the randomised group. Only the manufacturer will be aware of which group contains copper. Copper impregnated dressings: As soon as possible, but within 12 hours after primary closure of the caesarean section incision, the randomised study dressing will be applied. The two study dressings were equivalent to the dressing normally used within this Trust, except the foam of one set of dressings was impregnated with 3% copper oxide ions. The two sets of wound dressings were marked &quot;A&quot; and &quot;B&quot; and both the women and clinician were blinded to the randomised group. According to local protocol the wound dressing will be left intact for 7 days following surgery and will be renewed if necessary. Copper impregnated maternity pads As soon as possible, but within 12 hours after suturing, women will be asked to wear the study maternity pads, which will be provided. The two sets of study maternity pads will be equivalent to the currently recommended pads, except that one set of pads will have a thin top layer of non‐woven polyester fibres with 3% copper oxide ions permanently attached to it. Women will be asked to use the pads for 14 days. Patient data, history and physical examination: Demographic data such as age, ethnicity, height and weight will be collected as well as obstetric data and delivery details. Past medical history such as concomitant (chronic) diseases and the use of medications will be obtained. Wound infection will be assessed via a telephone questionnaire after 7, 14 and 30 days after delivery. The data will be stored in a secure room within Trust facilities. All electronic data will be stored within password protected IT system within the Trust, which is only accessible by the clinical and research team. Questionnaire: For the assessment of surgical site infection, the Post Discharge Questionnaire used by the HPC surgical site infection surveillance will be used, which is according to the worldwide used definition of surgical site infection by the CDC. Statistical analysis Statistical analysis will be performed using SPSS version 20.0 or higher. Infection rates in the perineal tear group and the caesarean section group will be analysed seperately. The infection rates in the study group (with copper) will be compared to the control group and possible risk factors for infection will be explored. the Chi‐Square will be used to analyse categorical variables and the T‐test or Mann Whitney‐U test will be used to analyse continuous variables. Multivariable logistic regression will be used to investigate risk factors for development of infection. Sample size calculation Since the effect of copper on infection rates is currently unknown, we will conduct a pilot study for 12 months.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01564123/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Butler, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sentara Healthcare, Norfolk, VA, USA. Electronic address: jpbutler@sentara.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of copper-impregnated composite bed linens and patient gowns on healthcare-associated infection rates in six hospitals</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e130-e134</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2018/05/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacterial Infections/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Bedding and Linens/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">*Clothing</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Transmission, Infectious/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacteria/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">United States/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile</style></keyword><keyword><style face="normal" font="default" size="100%">Copper oxide</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare-associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">Linens</style></keyword><keyword><style face="normal" font="default" size="100%">Medical textiles</style></keyword><keyword><style face="normal" font="default" size="100%">Multidrug-resistant organism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">29803808</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hospital linens and patient gowns are frequently touched and contaminated, and may contribute to endogenous, indirect-contact, and aerosol transmission of nosocomial-related pathogens. Recently Sentara Healthcare adopted biocidal copper oxide-impregnated linens across its hospitals. AIM: To assess whether the replacement of the linens resulted in the reduction of healthcare-associated infection (HCAI). METHODS: Rates of HCAI caused by Clostridium difficile and multidrug-resistant organisms (MDROs) were compared in six Sentara Healthcare hospitals with similar patient demo-graphics (total of 1019 beds) in three parallel periods (90, 180 and 240 days) before and after (periods A1, A2 and A3, and periods B1, B2, and B3, respectively), replacing all the regular non-biocidal linens with the copper oxide-impregnated biocidal linens. FINDINGS: During periods B1, B2, and B3, compared with periods A1, A2 and A3, there were 61.2% (P &lt; 0.05), 41.1% (P &lt; 0.05) and 42.9% (P &lt; 0.01) reductions in HCAI per 10,000 patient-days in hospital caused by C. difficile, respectively; 48.3% (P &gt; 0.05), 36.4% (P &gt; 0.05), and 19.2% (P &gt; 0.05) reductions in HCAI per 1000 patient-days caused by MDROs; and 59.8% (P &lt; 0.01), 39.9% (P &lt; 0.05), and 37.2% (P &lt; 0.05) in the reduction of HCAI per 1000 patient-days caused by C. difficile and MDROs combined. CONCLUSION: The use of biocidal copper oxide-impregnated linens in the six analysed Sentara Healthcare hospitals resulted in significant reduction in both HCAI caused by C. difficile, and the combined metric of C. difficile or MDRO infection. Similar reductions in HCAI caused by MDROs were observed, although these reductions did not reach statistical significance, probably due to very low HCAI rates caused by these pathogens in the study facilities.</style></abstract><notes><style face="normal" font="default" size="100%">1532-2939&#xD;Butler, J P&#xD;Journal Article&#xD;England&#xD;J Hosp Infect. 2018 Nov;100(3):e130-e134. doi: 10.1016/j.jhin.2018.05.013. Epub 2018 May 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272390/1-s2.0-S0195670118X00127/1-s2.0-S0195670118302780/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEIn%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIHNYMQQLyBQz2sE3fbbTD3dQGPsHZcOz90ZaIM%2F%2F9mPyAiASLW0CLvRIDCzLWEvUFAmzOVPbeZRqAvXJ%2BxKFx0QMySq9AwiC%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAIaDDA1OTAwMzU0Njg2NSIMx%2BGVKbpMmc2%2BERI0KpEDhkHnEwLsZO7PneAXGaC5fwF4xSX1QEEoUqUvQNG%2BE3IatLNZoKWlK8335renViBnCNGdPA1b6KOEQ8q6kAHkTq3FSpEgNvS3IpF3qfafgJa0ZPcfNIxAuDQKBGMrxFbkrMx5oG5s7pjJrixQW6bEVEe8esggNkBly31YNAdIT450WADAR3GJV1YAfYTTYaeOciwQ10PO0pwVOM7%2FpswwbFibj9vAuijrzONHO%2BXnCujT04SQr5Dqukaz%2FKGYrbiDScJjUxJQE08HlbMYXwoTun6FiJ%2FxC9ZEZc5YwfiH56SooF5f75B5wYAiRmZO3hcrMdUQWO%2BqeFmbBh76%2FBoAC5PybvYXih1FyJQoJw6C8o%2FuAwWo2E%2BSknBsYF7uhD7sm%2FQ94anWU8LDUdmS8gZoE19eiq81sQPVYLAmboMn88iRyH%2BXU3T5%2F9Nko7xiOPt%2BeNnN4o728nwuQ0Vysca6jCfKNfiFbVDQ3A6s%2Fi7uxd8hxYLkSaTasDGkmyy1WeKXdfNaFKTRExmfO%2Fu9XsfCcK0wo%2Frv8wU67AFg64v86nfJGOJC28K1VwJXh4EtTqEUhSt1KKxVffAuE5aRz4pOS32q8Pik8LSNCek5nXHpmkdfpJdYRY9x99EPCXuqWVke6DYyaiVZeEyfK22uBtqjubeqk9n61MmcTul3aSHp%2BxwoBII08o8IZYd8wNv8%2BDqkgHanat7iuJbIAeRJWGVpvKjeFDbSphFj90UhblFZ6U7%2BEGHmeRTJZxIDiAXqqtDyzQpUxd2j65BYLzZ4TjKnEWlGzHjnV%2BrxRaYAvGwLmGW9uUvR9uIuDhDGY%2FwpHZsFMIvhqrFD%2F9aFPBAoRKiGkTXNIKeVSg%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200326T015714Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTY7TSYMIOH%2F20200326%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=d9c4c4699a9e526c42ce2aaccec96d7eb7c1158ae4af7e85e05378bbbff117e3&amp;hash=17470c544c5bbaddb05ea4587c55247d53d81e3716a4778e7127c763e874606a&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S0195670118302780&amp;tid=spdf-78d4b400-9dfb-4bd6-a36f-2727c54a0e1c&amp;sid=b55cb6f75e12284bca8a0eb9c40a5781e75agxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://4262978819/Butler-2018-Effect of copper-impregnated compo.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2018.05.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marik, P. E.</style></author><author><style face="normal" font="default" size="100%">Shankaran, S.</style></author><author><style face="normal" font="default" size="100%">King, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Norfolk, VA, USA. Electronic address: marikpe@evms.edu.&#xD;Division of Infectious Diseases, Eastern Virginia Medical School, Norfolk, VA, USA; Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, USA.&#xD;Infection Prevention and Control Coordinator, Sentara Norfolk General Hospital, Norfolk, VA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effect of copper-oxide-treated soft and hard surfaces on the incidence of healthcare-associated infections: a two-phase study</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><edition><style face="normal" font="default" size="100%">2020/02/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Catheter-associated urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Central-line-associated bloodstream infection</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">Copper oxide</style></keyword><keyword><style face="normal" font="default" size="100%">Hard surfaces</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare-associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">Soft surfaces</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">32068014</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Copper-oxide-impregnated linens and hard surfaces within the hospital environment have emerged as a novel technology to reduce environmental contamination and thereby potentially reduce the risk of healthcare-associated infections (HCAIs). METHODS: This was a two-phase study. Phase 1 was a prospective, cluster-randomized, cross-over clinical trial in which one pod (eight beds) of our general ICU (GICU) utilized copper-oxide-impregnated linens whereas the other pod (eight beds) used standard hospital linens. Phase 2 was a two-year before-after study, following the relocation of three ICUs into a new ICU tower in which all the hard surfaces were treated with copper oxide (in addition to copper-impregnated linens). HCAIs were recorded using the National Healthcare Safety Network definitions. FINDINGS: A total of 1282 patients were enrolled in phase 1. There was no difference in the rate of HCAI between the patients who received standard compared with copper oxide linen. In phase 2 there was a significant reduction in the number of infections due to Clostridioides difficile (2.4 per 1000 vs 0.7 per 1000 patient-days; incidence rate ratio: 3.3; 95% confidence interval: 1.4-8.7; P = 0.002) but no difference in the rate of central-line-associated bloodstream infections nor of catheter-associated urinary tract infections. CONCLUSION: Copper-oxide-impregnated linens alone had no effect on the rate of HCAI. Our data suggest that copper-oxide-treated hard surfaces reduced the rate of infections due to C. difficile; however, important confounders cannot be excluded.</style></abstract><notes><style face="normal" font="default" size="100%">1532-2939&#xD;Marik, P E&#xD;Shankaran, S&#xD;King, L&#xD;Journal Article&#xD;England&#xD;J Hosp Infect. 2020 Feb 14. pii: S0195-6701(20)30053-0. doi: 10.1016/j.jhin.2020.02.006.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272390/AIP/1-s2.0-S0195670120300530/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEHQaCXVzLWVhc3QtMSJGMEQCIDjmiqihRxmGIgorGIzvgwQcifPoe0UCmoJWGCCPHQsSAiAm0vw5irPS94z3Pd92%2BMZUPHtA49n7Lr3RzvNwclLP7Cq0AwhtEAIaDDA1OTAwMzU0Njg2NSIM%2FO9r7nOOBUds%2FtjdKpEDXEIoG2eXGz3qh4ni%2Fp3LwCMP9Owpe6dSyd6vYaPAEHL8JZmqZEEqGLIVIkPj6WQDZuVXpjytahPfXjlv1ii8dKq82rFDzbXWFH5%2FcrYsc6Z1h7F4zojDSgyYVFhK0Jaqm5EiJAmhS3wzANBpMs1AQBGJEVIMqebpNDax1QUba98bYN3RTAEe4zDfP7IiKb%2BkyNkXcH4QCxK22Gk2AB7CrHNtM9OCeV4KzMFTiWpIT4m6TgCeFOkeEKyvWHwYrr3WXyX1IlXB3ZlZXj9bbSrcBvOwFN1LvuoPkW3rzrBc%2FJ%2B8ZJeoV15Jt4pUacWxJ8Au6R0iwSZgSiGVHxl1CNY4K53mgkxgOM5sq6B%2FqPv0Qmfb42%2Bg9Qh5VTtSdzAtJ6%2BpHvyk2eHt8iTc0MQTRhfnD54tXd1nCDAZUPSW1lGConOelfliSrG9fu1DEdQPoJ5CLssEbSNN9y9F%2BqJ4EsmQO97PVvytkXZrtbd2A4JxHTLI5dkb4KbZMBqZy9sY6S5E%2BpEMJJo5GGaclyAlc9AJZMQwuavr8wU67AEW9be%2FZvnz8AXpBKP83RFcJJ%2BCqlaDb2xmjSbF8IpyVgKa948AMaSVlw1XPVaRffzxWB3iM%2FOx9MGke3cR1bozGSuNoy2YPVxI9zLvmQNKcOPsaxsrxq8in%2B8YY2nX2WT4nNgJ5AinGYww18wjh7G2auzzjqBCbTVoIeY76D4FJhBbEbppGWovPQkhk9PMS%2FWpvBjjMwF72AjVBEWbZPbUf71%2F2%2FlEpDAvwE3IIcFAyDpDhlr2Q49%2FYKclFzQG4tkMBWqv0JTHKqfN5JdIHySt7F63RbsF8PiRX4mTJMMStAXiZaDrdDoRPUDfvw%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200325T052535Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTY64GSHCFU%2F20200325%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=90db13d7c6df67fa66bde501c02c42127ed820f264cd5dd16582d0c32c25ed1a&amp;hash=5fb8d59b067be5d27ada982b6ced7104405f3ffd6b882cc05e7e67a980fe29bd&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S0195670120300530&amp;tid=spdf-2a818f08-adfc-440c-885d-28484cdf8485&amp;sid=b6c9ad95419947419618c891c856c8d040eegxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://1981302850/Marik-2020-The effect of copper-oxide-treated.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2020.02.006</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">60</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adjepong, M.</style></author><author><style face="normal" font="default" size="100%">Agbenorku, P.</style></author><author><style face="normal" font="default" size="100%">Brown, P.</style></author><author><style face="normal" font="default" size="100%">Oduro, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Technology, College of Science, Kwame Nkrumah University of Science &amp; Technology, Kumasi, Ghana.&#xD;Reconstructive Plastic Surgery &amp; Burns Unit, Department of Surgery, Komfo Anokye Teaching Hospital, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science &amp; Technology, Kumasi, Ghana.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effect of dietary intake of antioxidant micronutrients on burn wound healing: a study in a tertiary health institution in a developing country</style></title><secondary-title><style face="normal" font="default" size="100%">Burns Trauma</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Burns Trauma</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><edition><style face="normal" font="default" size="100%">2015/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antioxidants</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary intake</style></keyword><keyword><style face="normal" font="default" size="100%">Micronutrients</style></keyword><keyword><style face="normal" font="default" size="100%">Recovery</style></keyword><keyword><style face="normal" font="default" size="100%">Wound healing</style></keyword><keyword><style face="normal" font="default" size="100%">Wound infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">2321-3868 (Print)&#xD;2321-3868</style></isbn><accession-num><style face="normal" font="default" size="100%">27574658</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Burn injury results in emotional stress affecting dietary intake and antioxidant micronutrient intake, which is known to have effects on recovery outcomes. The study aimed to assess dietary intake of antioxidant micronutrients and recovery outcomes of burn patients. METHODS: Questionnaires were administered to 40 burn patients at Komfo Anokye Teaching Hospital (Ghana) from January 1, 2014 to May 30, 2014. The data taken include anthropometric measurements and dietary assessment. Their nutrient intakes were assessed with the Nutrient Analysis Template. The average intakes were compared to the recommended daily allowance. Assessment of recovery was based on records of wound healing assessments and infection rates from the health practitioners. RESULTS: A cross-sectional study of 40 patients revealed an average total burn surface area (TBSA) of 31.4 %, where 70.0, 35.0, 75.0, 52.5, 12.5 and 32.5 % patients were deficient in vitamins A, C and E, zinc, copper and selenium, respectively and adequate amounts of vitamin C intake were related with significantly better wound healing progress. Positive wound healing outcomes were observed for patients with adequate vitamins A and E and zinc intake. Less infection presented among patients with adequate amount of vitamins A and C and zinc, but this was not observed for patients with adequate vitamin E, copper and selenium. CONCLUSIONS: Most burn patients did not meet their dietary requirements for antioxidant micronutrients and this was due to meals not tailored to suit individual requirements. Adequacy of the antioxidants especially vitamin C resulted in positive wound healing outcomes. Hence, there is need for planned well-balanced meals of high vitamin C.</style></abstract><notes><style face="normal" font="default" size="100%">Adjepong, Mary&#xD;Agbenorku, Pius&#xD;Brown, Patricia&#xD;Oduro, Ibok&#xD;Journal Article&#xD;England&#xD;Burns Trauma. 2015 Aug 12;3:12. doi: 10.1186/s41038-015-0012-x. eCollection 2015.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4963941</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s41038-015-0012-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">59</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yones, D. A.</style></author><author><style face="normal" font="default" size="100%">Galal, L. A.</style></author><author><style face="normal" font="default" size="100%">Abdallah, A. M.</style></author><author><style face="normal" font="default" size="100%">Zaghlol, K. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Parasitology, Faculty of Medicine, Assiut University, Assiut, Egypt.&#xD;Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of enteric parasitic infection on serum trace elements and nutritional status in upper Egyptian children</style></title><secondary-title><style face="normal" font="default" size="100%">Trop Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trop Parasitol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">29-35</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2015/02/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Egypt</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">enteric parasites</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan-Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2229-5070 (Print)&#xD;2229-5070</style></isbn><accession-num><style face="normal" font="default" size="100%">25709950</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Enteric parasitic infections still the cause of major health problems among Egyptian children as they have great morbid effect on their physical and cognitive development. Malnutrition makes children more prone to micronutrient deficiency and subsequently more vulnerable to parasitic infection. The present study aimed to identify the effect of intestinal parasitism on micronutrient serum level and children nutritional status. MATERIALS AND METHODS: A case control study was carried out on children from 1 to 6 years old who were attending the Assiut University Children Hospital outpatient clinic, after parasitological stool examination they were divided into Group 1 (G1, n: 60) positive with enteric parasite and Group 2 (G2, n: 60) age and sex matched and free of parasites. Anthropometric measurements were expressed as weight for age (WFA), height for age (HFA), and weight for height (WFH) parameters. Serum zinc (Zn) and copper (Cu) were determined by atomic absorption spectrophotometer. RESULTS: Intestinal parasitic infection rate was 55.7%; more commonly detected parasites were Giardia lamblia 28%, Cryptosporidium sp. 20%, and polyparasitism 18%. All children (G1 and G2) were underweight (WFA) while 63% of G1 were malnourished, either in the form of wasting (WFH) or stunting (HFA) or both aspects. Stunting and wasting were more dominant among children infected with G. lamblia and Cryptosporidium sp. and most of them were below 2 years old. CONCLUSIONS: Coincident decrease in serum Zn level and an increase of serum Cu was more prominent among G. lamblia and Cryptosporidium sp. patients. G. lamblia and Cryptosporidium sp. were found to be more associated with nonstandard children nutritional status beside to an altered micronutrient level.</style></abstract><notes><style face="normal" font="default" size="100%">Yones, Doaa A&#xD;Galal, Lamia A&#xD;Abdallah, Alameldin M&#xD;Zaghlol, Khaled S&#xD;Journal Article&#xD;India&#xD;Trop Parasitol. 2015 Jan-Jun;5(1):29-35. doi: 10.4103/2229-5070.145581.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4326990</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.4103/2229-5070.145581</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>334</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">334</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lodha, R.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, A.</style></author><author><style face="normal" font="default" size="100%">Singh, V.</style></author><author><style face="normal" font="default" size="100%">Singh, S.</style></author><author><style face="normal" font="default" size="100%">Friis, H.</style></author><author><style face="normal" font="default" size="100%">Faurholt-Jepsen, D.</style></author><author><style face="normal" font="default" size="100%">Bhatnagar, S.</style></author><author><style face="normal" font="default" size="100%">Saini, S.</style></author><author><style face="normal" font="default" size="100%">Kabra, S. K.</style></author><author><style face="normal" font="default" size="100%">Grewal, H. M. S.</style></author><author><style face="normal" font="default" size="100%">Aneja, S.</style></author><author><style face="normal" font="default" size="100%">Arya, T.</style></author><author><style face="normal" font="default" size="100%">Chandra, J.</style></author><author><style face="normal" font="default" size="100%">Dutta, A. K.</style></author><author><style face="normal" font="default" size="100%">Doherty, T. M.</style></author><author><style face="normal" font="default" size="100%">Hesseling, A. C.</style></author><author><style face="normal" font="default" size="100%">Marais, B.</style></author><author><style face="normal" font="default" size="100%">Parashar, D.</style></author><author><style face="normal" font="default" size="100%">Prajapati, S.</style></author><author><style face="normal" font="default" size="100%">Purohit, K.</style></author><author><style face="normal" font="default" size="100%">Saini, D.</style></author><author><style face="normal" font="default" size="100%">Singh, R. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.K. Kabra, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: A randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of clinical nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1287-1297</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">NCT00801606</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">ethambutol</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">isoniazid</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">pyrazinamide</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">rifampicin</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">arm circumference</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">body height</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">caloric intake</style></keyword><keyword><style face="normal" font="default" size="100%">cause of death</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">factorial design</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">intestine perforation</style></keyword><keyword><style face="normal" font="default" size="100%">intrathoracic tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">lung tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medication compliance</style></keyword><keyword><style face="normal" font="default" size="100%">miliary tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistant tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">patient compliance</style></keyword><keyword><style face="normal" font="default" size="100%">protein calorie malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory failure</style></keyword><keyword><style face="normal" font="default" size="100%">rickets</style></keyword><keyword><style face="normal" font="default" size="100%">secondary infection</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword><keyword><style face="normal" font="default" size="100%">sex ratio</style></keyword><keyword><style face="normal" font="default" size="100%">skinfold thickness</style></keyword><keyword><style face="normal" font="default" size="100%">superinfection</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">teaching hospital</style></keyword><keyword><style face="normal" font="default" size="100%">thorax radiography</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1938-3207&#xD;0002-9165</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Micronutrients play an important role in immune function. To our knowledge, there have been no comprehensive studies on the role of micronutrient supplementation in children with tuberculosis. Objective: We assessed the effect of micronutrient supplementation in children treated with antituberculosis therapy (ATT). Design: A randomized, double-blind, placebo-controlled trial that used a 2 X 2 factorial design was undertaken at 2 teaching hospitals in Delhi. Children with newly diagnosed intrathoracic tuberculosis were enrolled, and they received ATT together with daily supplementation for 6 mo with either zinc alone, micronutrients without zinc, micronutrients in combination with zinc, or a placebo. Main outcomes were weight gain and an improvement in a chest X-ray (CXR) lesion assessed at 6 mo of treatment. Results: A total of 403 children were enrolled and randomly assigned. A microbiological diagnosis of tuberculosis was confirmed in 179 children (44.4%). The median (95% CI) increase in weight-for-age z score at 6 mo was not significantly different between subjects who received micronutrients [0.75 (0.66, 0.84)] and those who did not receive micronutrients [0.76 (0.67, 0.85)] and between subjects who received zinc [0.76 (0.68, 0.85)] and those who did not receive zinc [0.75 (0.66, 0.83)]. An improvement in CXR was observed in 285 children, but there was no difference between those receiving zinc and no zinc or between those receiving micronutrients and no micronutrients after 6 mo of ATT. However, children who received micronutrients had a faster gain in height over 6 mo than did those who did not receive micronutrients (height-for-age z score Δ = 0.08; P = 0.014). Conclusions: Micronutrient supplementation did not modify the weight gain or clearance of lesions on CXR in children with intrathoracic tuberculosis. However, micronutrient supplementation during treatment may improve height gain in children with intrathoracic tuberculosis. This trial was registered at clinicaltrials.gov as NCT00801606.</style></abstract><notes><style face="normal" font="default" size="100%">L600258646&#xD;2014-11-04&#xD;2019-10-31</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L600258646</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3945/ajcn.113.082255</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">25332327</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/ajcn.113.082255</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>453</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">453</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, B. A.</style></author><author><style face="normal" font="default" size="100%">McGeer, A.</style></author><author><style face="normal" font="default" size="100%">McArthur, M. A.</style></author><author><style face="normal" font="default" size="100%">Simor, A. E.</style></author><author><style face="normal" font="default" size="100%">Aghdassi, E.</style></author><author><style face="normal" font="default" size="100%">Davis, L.</style></author><author><style face="normal" font="default" size="100%">Allard, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B.A. Liu, Sunnybrook Health Sciences Centre, H479, 2075 Bayview Ave, Toronto, Ont. M4N 3M5, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of multivitamin and mineral supplementation on episodes of infection in nursing home residents: A randomized, placebo-controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Geriatrics Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-42</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">calcium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">iodine</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">mineral</style></keyword><keyword><style face="normal" font="default" size="100%">multivitamin</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">hematologic disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug eruption</style></keyword><keyword><style face="normal" font="default" size="100%">drug use</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">multivariate analysis</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home patient</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">skin infection</style></keyword><keyword><style face="normal" font="default" size="100%">soft tissue infection</style></keyword><keyword><style face="normal" font="default" size="100%">statistical model</style></keyword><keyword><style face="normal" font="default" size="100%">univariate analysis</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-8614&#xD;1532-5415</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To evaluate the effect of vitamin and mineral supplementation on infections in an elderly institutionalized population. DESIGN: Eighteen-month, randomized, placebo-controlled trial. SETTING: Twenty-one long-term care facilities. PARTICIPANTS: Seven hundred sixty-three subjects from 21 long-term care facilities. INTERVENTION: Participants were randomized to receive one multivitamin and mineral supplementation daily or placebo. MEASUREMENTS: The primary outcome was number of infections per subject. Secondary outcomes were antibiotic use and hospitalization rates. Infection control surveillance was conducted over 18 months using standardized criteria. RESULTS: Outcome data from 748 subjects, mean age 85, were included in the intention-to-treat analysis. Using univariate analyses, there was no difference in infectious episodes between the supplemented and placebo groups (3.5 infections per 1,000 resident-days vs 3.8 infections per 1,000 resident-days, odds ratio (OR)=0.92, 95% confidence interval (CI)=0.82-1.03, P=.12). There was a reduction in antibiotic usage in the supplementation group, but this was not significant in the multivariate model. There was no difference in the number of hospital visits. In the multivariate analysis, the effect of multivitamin use on total number of infections was not significant (OR=0.77, 95% CI=0.54-1.1). Subjects without dementia had a greater rate of infections than those with dementia (OR=1.44, 95% CI=1.19-1.76). In post hoc subgroup analysis, subjects without dementia who received supplementation had a significantly lower rate of infections than those who received placebo (relative risk=0.81, 95% CI=0.66-0.99). CONCLUSION: Overall, multivitamin and mineral supplementation does not have a significant effect on the incidence of infections in institutionalized seniors, although the subgroup of residents in long-term care without dementia may benefit from supplementation. Further research is needed to determine its effect in high-risk subgroups within the nursing home population. © 2007, The American Geriatrics Society.</style></abstract><notes><style face="normal" font="default" size="100%">L46046226&#xD;2007-01-29</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L46046226</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1532-5415.2006.01033.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17233683</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2006.01033.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>206</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Norouzy, A.</style></author><author><style face="normal" font="default" size="100%">Khazdoz, M.</style></author><author><style face="normal" font="default" size="100%">Ehsaee, M.</style></author><author><style face="normal" font="default" size="100%">Samini, F.</style></author><author><style face="normal" font="default" size="100%">Nematy, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of oral zinc administration on clinical improvement of severe head trauma patients in ICU: a pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical nutrition.</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical nutrition.</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S32</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*European</style></keyword><keyword><style face="normal" font="default" size="100%">*head injury</style></keyword><keyword><style face="normal" font="default" size="100%">*human</style></keyword><keyword><style face="normal" font="default" size="100%">*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">*patient</style></keyword><keyword><style face="normal" font="default" size="100%">*pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">*society</style></keyword><keyword><style face="normal" font="default" size="100%">*zinc</style></keyword><keyword><style face="normal" font="default" size="100%">Albumin</style></keyword><keyword><style face="normal" font="default" size="100%">Blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Control group</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Injury</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Sequential Organ Failure Assessment Score</style></keyword><keyword><style face="normal" font="default" size="100%">Supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc urine level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01073839</style></accession-num><abstract><style face="normal" font="default" size="100%">Rationale: Plasma level of zinc in trauma patients is related to increased status of inflammation, infection and organ failure. It seems that zinc supplementation in severe head trauma patients may improve the recovery outcomes. Methods: Fifty patients (mean age 32+/‐12 years, 42 male, 8 female) with severe head trauma and GCS between 5 to 8, were assigned to double blind RCT and divided to case and control groups. In case group, 120mg elemental zinc were orally administrated for 15 days. Plasma zinc and copper, leukocyte zinc concentration (only day one for diagnosis of zinc deficiency), 24 hour urinary zinc excretion, SOFA score and albumin were measured on day 1, 7 and 16 of study. Patients were assessed on day 28 for mortality and GCS. Results: See the table. Mortality rate at day 28: was 8 in the case group and 4 in the control group. Conclusion: This study shows a significant improvement in GCS, SOFA and mortality rate after administration of 120 mg of elemental zinc in severe head injury patients.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal: Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01073839/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 71801306</style></custom3></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>210</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slctr,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effect of zinc on sugar control among diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=SLCTR/2008/017</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=SLCTR/2008/017</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01873143</style></accession-num><abstract><style face="normal" font="default" size="100%">INTERVENTION: The diabetic patients will be chosen from patients attending the medical clinics of the Teaching Hospital, Karapitiya 1. Diabetes patients will be stratified by sex, age and duration of treatment and randomly assigned to one of three treatment groups 2. Group A will be supplemented with oral zinc sulfate (22mg of elemental zinc/day) and multivitamin/mineral preparation (vitamin A, Vitamin D3, Vitamin E, magnesium, manganese, copper and selenium) 3. Group B will be supplemented with same preparation but without zinc 4. Group C will be supplemented with placebo and designed as a control group 5.Depending upon the treatment groups, each subject will receive one tablet per day for a period of 4 months 6. A questionnaire on social demography will be administered and 24 hour dietary intake will be recorded 7. Their anthropometry and blood pressure will be recorded 8. Following investigations will be done at the study entry and at the end of the follow‐up Fasting blood sugar a.Post prandial blood sugar b.HbA1c c.Serum creatinine d.Serum zinc e.Urinary zinc f.Urinary creatinine CONDITION: Diabetes Mellitus PRIMARY OUTCOME: Improvement in glycaemic control by multi mineral/vitamin supplementation; SECONDARY OUTCOME: •Improving awareness on proper blood sugar control among diabetes patients ; •Improving awareness on general nutritional status of the diabetes patients INCLUSION CRITERIA: 1. not taking vitamin and/or mineral supplements, thyroid hormones, estrogen or progesterone 2. having no history of a recent surgery or acute infection 3. women, not being pregnant or lactating</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01873143/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>420</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">420</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prado, V.</style></author><author><style face="normal" font="default" size="100%">Durán, C.</style></author><author><style face="normal" font="default" size="100%">Crestto, M.</style></author><author><style face="normal" font="default" size="100%">Gutierrez, A.</style></author><author><style face="normal" font="default" size="100%">Sapiain, P.</style></author><author><style face="normal" font="default" size="100%">Flores, G.</style></author><author><style face="normal" font="default" size="100%">Fabres, H.</style></author><author><style face="normal" font="default" size="100%">Schmidt, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V. Prado, Faculty of Medicine, University of Chile, Santiago, Chile</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of copper contact surfaces in reducing the microbial burden (MB) in the intensive care unit (ICU) of hospital del Cobre, Calama, Chile</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e268</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">Chile</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">microorganism</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">arm</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro study</style></keyword><keyword><style face="normal" font="default" size="100%">desert</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">humidity</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1201-9712</style></isbn><abstract><style face="normal" font="default" size="100%">Background: The environment plays a role as reservoir and transmission of microbes in hospital settings. In vitro studies have demonstrated the microbicidal activity of copper (Cu). We studied the ability of Cu to reduce the MB associated with commonly contact surfaces within an ICU of Hospital del Cobre de Calama, located in a semi-desert area in the north of Chile. Methods: Copperized (Cu) surfaces (bed rails, bed lever, tray tables, chair arms, touch screen monitor stylus, and IV poles) were placed into 3 randomly selected ICU rooms. Three paired rooms were compared by measuring the MB during 18 weeks. The mean(m) MB for each Cu object, determined as colony forming units (cfu)/100cm2 was compared to noncopper rooms. Antimicrobial efficacy of Cu was calculated as the difference in mMB between the Cu and non-Cu objects. The environmental cleaning procedures were equivalent for Cu and non-Cu rooms. The Kruskal- Wallist test for two groups was used. Results: The mMB associated with 594 Cu surfaces from 54 rooms containing Cu was compared against the mMB of equivalent surfaces from 54 non-Cu rooms from an ICU with humidity between 7.2 to 19.7%. Cu was effective in reducing mMB on all 6 surfaces tested (bed rails by 86%, bed lever by 84%, tray tables by 93%, chair arms by 88%, monitor pen by 49%, and IV poles by 89%). Total mMB count in rooms with Cu (2,142 cfu/100cm2) was significantly lower than in rooms without Cu (13,215 cfu/100cm2) p &lt; 0.00001 Staphylococci were the most predominant microorganism isolated. Cu was equivalently effective and significant in reducing the staphylococcal burden associated with the objects, p &lt; 0.00001. MRSA and VRE were never isolated, regardless of the presence of Cu. Gram negatives were infrequently isolated from some surfaces, and Cu reduced the Gram negative burden by 74%-88%. Conclusion: The antimicrobial effect of Cu was evident and significant in this arid region of Chile; reduced the total mMB, mMB of staphylococcal and Gram negative in ICU rooms containing Cu. Further studies regarding the clinical impact of reducing the mMB by Cu objects within the environment of hospitals is warranted.</style></abstract><notes><style face="normal" font="default" size="100%">L70125659&#xD;2010-05-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70125659</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ijid.2010.02.2083</style></url><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272991/1-s2.0-S1201971210X00030/1-s2.0-S1201971210021235/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEHUaCXVzLWVhc3QtMSJHMEUCIBPixEp7nvfPD4D%2BVSUVtDlBy7Rp%2BrweBPHII%2BOIwWXNAiEAjklEnnxr5IPYz%2Fylg3HhHk9lSgXUX%2Bi7fN%2BMyoEZAP0qtAMIbhACGgwwNTkwMDM1NDY4NjUiDJXZF0KonQuYnihk9SqRAzqCMgMA6t%2BPL9wvgX46ZSwP%2BOgjKneFaFo%2BfU4C7qKeLTWBx5yRyCdYqoEqTP%2Ba8WNL8jFHu%2BTR0tEhxrcSbSnONnxk1uFC4pBAPUUu1H1zz1zOkx9c66gZAEyDJ6OESP9qFatV0cYiGoo1b2Qu2lcUDln5r8%2FOh2VrtZeXrmfXCU1PH4yPCTLj70LjBAy85i10EaAkkS3illE5u4GHGpkVVRZHAwvgNXxt8dWgL1JKlFMJ1SxmVEbuDEPK7HDVYImfT2YMuIw8bQBZs8VhrrtFbyNbGc%2FeTrXqh2wKylnMgF0eMPNsepNVQKMtE6HE6TR8PFBYNcZABexuhHk%2Fi3MF%2Fzfxm1S6DGcffBHWc7c3pya0V4n7hpSB4XazZ%2BiBHxhHEHtSThbAaMUxF3vCrHwAjX0ArV8DaPwmQBF5AIgkGMrtoy3IG64q4NQyVJRswlGIFpv%2BDbi6ke3sFO0YSPRj%2B55Z0aXlQ4vOFqHRy79dsuNWgPXL6nmXfhKCvvpBtgi2kuMtdNvfEzjZ6FLBdHVCMJHB6%2FMFOusBGT6Q2h%2Fv%2ByKccdpao28p1MRHwInrK7fRnvD2CFvH1vn67EnnwLVVPiYg6v5%2Ftchqg1s4SmDWoMYA1e0tnZzQ0RRGYPfdQcIdzOMzLNL9M1vAOngdC3a3F7Wa%2FUaXAyKq8n0bdsvycnmYIYkG5dRzJaFwMFuzeib4s%2By6g%2BWImDLg4eFT0MT7R%2Br8jvzp39SE1QrqXf4BsjIKMFpQBGssfuWbvJYpTw6kmwUXcBOM5VnTFg3QOeRUZ1j5J8tRBHLoXBIM3klVK5yJjIXURADL3SppmU%2BzdDSZNeXq%2BIz1NH0e8V8Qa2SqJZlEiQ%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200325T052542Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTYXIYRFGSZ%2F20200325%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=786d739929c6c049dc55120d5c71854f3a2d3da960de79e4ca4e56f874a3750e&amp;hash=5574492b816e641a822e30a37e99331a0e48aa217f0de041d18df613b09b6280&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S1201971210021235&amp;tid=spdf-15f2091c-5057-4dc3-ab55-dc9c23844a77&amp;sid=b6c9ad95419947419618c891c856c8d040eegxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://3104073789/Prado-2010-Effectiveness of copper contact sur.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijid.2010.02.2083</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>354</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Young, L.</style></author><author><style face="normal" font="default" size="100%">Sheets, D.</style></author><author><style face="normal" font="default" size="100%">Paul, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L. Young, School of Nursing, University of Victoria, BC, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of physical activity interventions with healthy older women: A systematic review protocol</style></title><secondary-title><style face="normal" font="default" size="100%">JBI Database of Systematic Reviews and Implementation Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JBI Database of Systematic Reviews and Implementation Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">77-87</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">aerobic capacity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood pressure</style></keyword><keyword><style face="normal" font="default" size="100%">body composition</style></keyword><keyword><style face="normal" font="default" size="100%">body fat</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">cardiopulmonary function</style></keyword><keyword><style face="normal" font="default" size="100%">endurance training</style></keyword><keyword><style face="normal" font="default" size="100%">heart rate</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">muscle strength</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">physical activity</style></keyword><keyword><style face="normal" font="default" size="100%">pulse rate</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">stretching exercise</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">waist circumference</style></keyword><keyword><style face="normal" font="default" size="100%">waist hip ratio</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">2202-4433</style></isbn><abstract><style face="normal" font="default" size="100%">Review question/objective The objective of this review is to assess the effectiveness of trace element supplementation on clinically meaningful outcomes following severe burn injury in children and adults. More specifically, the objectives are to assess the effectiveness of selenium, copper and zinc supplementation on mortality, length of intensive care unit (ICU) hospital stay, wound healing and infection rates (wound and nosocomial) in patients who have sustained a severe burn injury. Inclusion criteria Types of participation This review will consider studies that include children (2-18 years of age) and adults (≥ 18 years of age) who have sustained a severe burn injury (defined as burn injury ≥ 10% Total Body Surface Area (TBSA) in children and ≥ 15% TBSA in adults) and been admitted to an ICU, Burns ICU (BICU), or burns unit for surgical management of their injury. Studies that include patients with significant multi-trauma in addition to burn injury will be excluded. Types of intervention(s)/phenomena of interest This review will consider studies that evaluate enteral or parenteral supplementation of selenium, copper and zinc, either alone or combined and compared to placebo or regular treatment. Intervention and comparison groups will have received standard nutrition intervention including enteral or parenteral nutrition and multi-vitamin supplements. Studies that include trace element supplementation in combination with other predefined nutrient supplementations will be considered for inclusion. Types of outcomes This review will consider studies that include one of the following outcome measures: 1) cardiorespiratory (e.g. pulse, heart rate, blood pressure, aerobic capacity); 2) body composition (e.g. BMI, waist circumference, hip/waist ratio, % body fat); 3) flexibility (e.g. stretching, balance); and 4) muscular strength and endurance (e.g. grip strength, walking speed).</style></abstract><notes><style face="normal" font="default" size="100%">L370472363&#xD;2013-12-21&#xD;2013-12-27</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L370472363</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.11124/jbisrir-2013-794</style></url><url><style face="normal" font="default" size="100%">http://www.joannabriggslibrary.org/jbilibrary/index.php/jbisrir/article/Download/794/1692</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.11124/jbisrir-2013-794</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>353</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">353</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kurmis, R.</style></author><author><style face="normal" font="default" size="100%">Aromataris, E.</style></author><author><style face="normal" font="default" size="100%">Greenwood, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. Kurmis, The Joanna Briggs Institute, School of Translational Health Science, The University of Adelaide, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effectiveness of trace element supplementation following severe burn injury: A systematic review protocol</style></title><secondary-title><style face="normal" font="default" size="100%">JBI Database of Systematic Reviews and Implementation Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JBI Database of Systematic Reviews and Implementation Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">44-53</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">burn</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection rate</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">intervention study</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">2202-4433</style></isbn><abstract><style face="normal" font="default" size="100%">Review question/objective The objective of this review is to assess the effectiveness of trace element supplementation on clinically meaningful outcomes following severe burn injury in children and adults. More specifically, the objectives are to assess the effectiveness of selenium, copper and zinc supplementation on mortality, length of intensive care unit (ICU) hospital stay, wound healing and infection rates (wound and nosocomial) in patients who have sustained a severe burn injury. Inclusion criteria Types of participation This review will consider studies that include children (2-18 years of age) and adults (≥ 18 years of age) who have sustained a severe burn injury (defined as burn injury ≥ 10% Total Body Surface Area (TBSA) in children and ≥ 15% TBSA in adults) and been admitted to an ICU, Burns ICU (BICU), or burns unit for surgical management of their injury. Studies that include patients with significant multi-trauma in addition to burn injury will be excluded. Types of intervention(s)/phenomena of interest This review will consider studies that evaluate enteral or parenteral supplementation of selenium, copper and zinc, either alone or combined and compared to placebo or regular treatment. Intervention and comparison groups will have received standard nutrition intervention including enteral or parenteral nutrition and multi-vitamin supplements. Studies that include trace element supplementation in combination with other predefined nutrient supplementations will be considered for inclusion. Types of outcomes This review will consider studies that include the following outcome measures: mortality; length of ICU/ hospital stay; rate of wound healing (time to first donor site healing or time to wound closure); complications (e.g. wound infection, hospital acquired pneumonia). Secondary outcome measures: tissue (measured from skin biopsies) and plasma (measured via blood sampling) selenium, copper and zinc levels.</style></abstract><notes><style face="normal" font="default" size="100%">L370472360&#xD;2013-12-21&#xD;2013-12-27</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L370472360</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.11124/jbisrir-2013-1134</style></url><url><style face="normal" font="default" size="100%">http://www.joannabriggslibrary.org/jbilibrary/index.php/jbisrir/article/Download/1134/1686</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.11124/jbisrir-2013-1134</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">38</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hofmeyr, G. J.</style></author><author><style face="normal" font="default" size="100%">Singata-Madliki, M.</style></author><author><style face="normal" font="default" size="100%">Lawrie, T. A.</style></author><author><style face="normal" font="default" size="100%">Bergel, E.</style></author><author><style face="normal" font="default" size="100%">Temmerman, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Effective Care Research Unit, Eastern Cape Department of Health/Universities of the Witwatersrand, Walter Sisulu and Fort Hare, South Africa.&#xD;Royal United Hospital, Bath, UK.&#xD;International Centre for Reproductive Health, Ghent University, Ghent, Belgium.&#xD;Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">J Fam Plann Reprod Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Fam Plann Reprod Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">175-180</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2017/04/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">DMPA, IUD, HIV, medroxyprogesterone acetate, randomised</style></keyword><keyword><style face="normal" font="default" size="100%">hormonal contraception</style></keyword><keyword><style face="normal" font="default" size="100%">health and HIV Outcomes (ECHO) consortium that is undertaking a multicentre</style></keyword><keyword><style face="normal" font="default" size="100%">randomised trial of contraceptive methods and HIV acquisition.</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-1893</style></isbn><accession-num><style face="normal" font="default" size="100%">28381443</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Evidence from observational studies suggests an increased risk of HIV acquisition among women using depot medroxyprogesterone acetate (DMPA) contraception. METHODS: Within the context of a South African programme to increase women&apos;s access to the intrauterine contraceptive device (IUD), we conducted a pragmatic, open-label, parallel-arm, randomised controlled trial (RCT) of the IUD versus injectable progestogen contraception (IPC) at two South African hospitals. The primary outcome was pregnancy; secondary outcomes included HIV acquisition. Consenting women attending termination of pregnancy services were randomised after pregnancy termination between July 2009 and November 2012. Condoms were promoted for the prevention of sexually transmitted infections. Voluntary HIV testing was offered at baseline and at 12 or more months later. Findings on HIV acquisition are reported in this article. RESULTS: HIV acquisition data were available for 1290 initially HIV-negative women who underwent a final study interview at a median of 20 months after randomisation to IPC or an IUD. Baseline group characteristics were comparable. In the IPC group, 545/656 (83%) of participants received DMPA, 96 (15%) received injectable norethisterone enanthate, 14 (2%) received the IUD and one received oral contraception. In the IUD group 609 (96%) received the IUD, 20 (3%) received IPC and 5 (1%) had missing data. According to intention-to-treat analysis, HIV acquisition occurred in 20/656 (3.0%) women in the IPC arm and 22/634 (3.5%) women in the IUD arm (IPC vs IUD, risk ratio 0.88; 95% confidence interval 0.48-1.59; p=0.7). CONCLUSIONS: This sub-study was underpowered to rule out moderate differences in HIV risk, but confirms the feasibility of randomised trial methodology to address this question. Larger RCTs are needed to determine the relative risks of various contraceptive methods on HIV acquisition with greater precision. TRIAL REGISTRATION NUMBER: Pan African Clinical Trials Registry number PACTR201409000880157 (04-09-2014).</style></abstract><notes><style face="normal" font="default" size="100%">2045-2098&#xD;Hofmeyr, G Justus&#xD;Singata-Madliki, Mandisa&#xD;Lawrie, Theresa A&#xD;ORCID: http://orcid.org/0000-0002-5500-8590&#xD;Bergel, Eduardo&#xD;Temmerman, Marleen&#xD;Journal Article&#xD;England&#xD;J Fam Plann Reprod Health Care. 2017 Jul;43(3):175-180. doi: 10.1136/jfprhc-2016-101607. Epub 2017 Apr 5.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5537534</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/jfprhc-2016-101607</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>404</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">404</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aquilani, R.</style></author><author><style face="normal" font="default" size="100%">Zuccarelli, G. C.</style></author><author><style face="normal" font="default" size="100%">Dioguardi, F. S.</style></author><author><style face="normal" font="default" size="100%">Baiardi, P.</style></author><author><style face="normal" font="default" size="100%">Frustaglia, A.</style></author><author><style face="normal" font="default" size="100%">Rutili, C.</style></author><author><style face="normal" font="default" size="100%">Comi, E.</style></author><author><style face="normal" font="default" size="100%">Catani, M.</style></author><author><style face="normal" font="default" size="100%">Iadarola, P.</style></author><author><style face="normal" font="default" size="100%">Viglio, S.</style></author><author><style face="normal" font="default" size="100%">Barbieri, A.</style></author><author><style face="normal" font="default" size="100%">D&apos;Agostino, L.</style></author><author><style face="normal" font="default" size="100%">Verri, M.</style></author><author><style face="normal" font="default" size="100%">Pasini, E.</style></author><author><style face="normal" font="default" size="100%">Boschi, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">F. Boschi, Dipartimento di Farmacologia Sperimentale ed Applicata, Università degli Studi di Pavia, Viale Taramelli, 14, I-27100 Pavia, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of oral amino acid supplementation on long-term-care-acquired infections in elderly patients</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Gerontology and Geriatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Gerontology and Geriatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e123-e128</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">albumin</style></keyword><keyword><style face="normal" font="default" size="100%">amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">amoxicillin plus clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">C reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">calcium</style></keyword><keyword><style face="normal" font="default" size="100%">cephalosporin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cysteine</style></keyword><keyword><style face="normal" font="default" size="100%">essential amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">histidine</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">isoleucine</style></keyword><keyword><style face="normal" font="default" size="100%">leucine</style></keyword><keyword><style face="normal" font="default" size="100%">levofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">lysine</style></keyword><keyword><style face="normal" font="default" size="100%">methionine</style></keyword><keyword><style face="normal" font="default" size="100%">phenylalanine</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">sodium</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">threonine</style></keyword><keyword><style face="normal" font="default" size="100%">tryptophan</style></keyword><keyword><style face="normal" font="default" size="100%">tyrosine</style></keyword><keyword><style face="normal" font="default" size="100%">valine</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">albumin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">caloric intake</style></keyword><keyword><style face="normal" font="default" size="100%">carbohydrate intake</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diet supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">fat intake</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal infection</style></keyword><keyword><style face="normal" font="default" size="100%">geriatric patient</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional support</style></keyword><keyword><style face="normal" font="default" size="100%">population risk</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">protein intake</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">risk reduction</style></keyword><keyword><style face="normal" font="default" size="100%">single blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">wound infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0167-4943</style></isbn><abstract><style face="normal" font="default" size="100%">The very high general infection rate (IRI) observed in our Geriatric Intensive Rehabilitation Center (GIRC) led us to investigate whether patient supplementation with essential amino acids (EAAs), modulators of immuno-competence, could reduce IRI. Eighty elderly patients admitted to our GIRC (n= 40; age 79.5 ± 7.71; male/female 14/26) or placebo (n= 40; age 82.13 ± 6.15; male/female 13/27) were allocated to an 8. g/day oral EAAs group and were surveyed for infections (&gt;48. h from admission) over the first month of their hospital stay. The IRI was 67% for the entire population of patients, 82.5% (33/40 patients) in the placebo group and 52% (21/40 patients) in the EAA group (p&lt; 0.02). When patients were divided into infection group (IG) and without-infection group (WIG), independently of post randomization allocation, the WIG had higher levels of serum albumin (p&lt; 0.001), blood hemoglobin (Hb) concentration (p= 0.01), dietary protein (p= 0.008) calorie intakes (p= 0.05) but lower serum C-reactive protein (CRP) (p&lt; 0.001). The factor of CRP &gt; 0.8. mg/dl and Hb ≤ 12 in females, ≤13 in males was associated 4 times and 3.6 times risk of infection, respectively, by sex. EAAs supplementation may lower the risk of infection by 30% in the rehabilitative elderly population. CRP and blood hemoglobin levels can be considered risk markers of future infection. © 2010 Elsevier Ireland Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">L51102410&#xD;2010-10-13&#xD;2011-04-11</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L51102410</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.archger.2010.09.005</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20934757</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.archger.2010.09.005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kanat-Pektas, M.</style></author><author><style face="normal" font="default" size="100%">Ozat, M.</style></author><author><style face="normal" font="default" size="100%">Gungor, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Family Planning, Dr Zekai Tahir Burak Women Health Education and Research Hospital, Ankara, Turkey. minekanat@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effects of TCu-380A on cervicovaginal flora</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Gynecol Obstet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arch Gynecol Obstet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">429-32</style></pages><volume><style face="normal" font="default" size="100%">277</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2007/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria, Aerobic/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria, Anaerobic/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Cervix Uteri/metabolism/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Infection/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Assessment</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Vagina/metabolism/*microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0932-0067 (Print)&#xD;0932-0067</style></isbn><accession-num><style face="normal" font="default" size="100%">17972087</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: This study aims to identify the alterations in cervicovaginal flora after insertion of TCu 380A which is a popular type of copper IUD. STUDY DESIGN: Among the women who visited the Department of Family Planning in our hospital during 1 month, 100 subjects who preferred IUDs for contraception and who had no history of local or systemic antibiotic use were considered eligible candidates. RESULTS: Anaerobic colonies, especially Gram-positive cocci and Gram-negative bacilli were isolated at significantly higher rates after the insertion of TCu-380A. Aerobic colonies were isolated relatively less. CONCLUSIONS: It can be suggested that copper IUD causes the predominance of anaerobic species in the cervicovaginal flora, which is consistent with the literature. This clinically insignificant condition can be attributed to the copper content or threads of the IUDs. Yet there is no evidence that the prevalance of pelvic infections is influenced by the use of IUDs.</style></abstract><notes><style face="normal" font="default" size="100%">Kanat-Pektas, Mine&#xD;Ozat, Mustafa&#xD;Gungor, Tayfun&#xD;Controlled Clinical Trial&#xD;Journal Article&#xD;Germany&#xD;Arch Gynecol Obstet. 2008 May;277(5):429-32. doi: 10.1007/s00404-007-0496-0. Epub 2007 Oct 31.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00404-007-0496-0</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">49</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hofmeyr, G. J.</style></author><author><style face="normal" font="default" size="100%">Singata-Madliki, M.</style></author><author><style face="normal" font="default" size="100%">Lawrie, T. A.</style></author><author><style face="normal" font="default" size="100%">Bergel, E.</style></author><author><style face="normal" font="default" size="100%">Temmerman, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Effective Care Research Unit, Eastern Cape Department of Health/Universities of the Witwatersrand, Walter Sisulu and Fort Hare, Mthatha, Eastern Cape, South Africa.&#xD;Effective Care Research Unit, Eastern Cape Department of Health/Universities of the Witwatersrand, Walter Sisulu and Fort Hare, Mthatha, Eastern Cape, South Africa. tess@lawrie.com.&#xD;Royal United Hospital, Bath, UK. tess@lawrie.com.&#xD;Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.&#xD;Reproductive Health and Research, World Health Organization, Geneva, Switzerland.&#xD;International Centre for Reproductive Health, Ghent University, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Reprod Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Reprod Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">42</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">2016/04/20</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Abdominal Pain/chemically induced/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Abortion, Legal</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Back Pain/chemically induced/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception Behavior/ethnology</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Agents, Female/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Implants/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Early Termination of Clinical Trials</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Lost to Follow-Up</style></keyword><keyword><style face="normal" font="default" size="100%">Medroxyprogesterone Acetate/administration &amp; dosage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Norethindrone/administration &amp; dosage/adverse effects/analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default" size="100%">Postoperative Period</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Rate/ethnology</style></keyword><keyword><style face="normal" font="default" size="100%">Progestins/administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">South Africa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Dmpa</style></keyword><keyword><style face="normal" font="default" size="100%">Iud</style></keyword><keyword><style face="normal" font="default" size="100%">Random</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 18</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-4755</style></isbn><accession-num><style face="normal" font="default" size="100%">27091008</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The copper intrauterine device (IUD) is under-utilised in South Africa, where injectable progestin contraception (IPC) dominates contraception usage. There is a lack of robust comparative data on these contraceptive options to inform policy, programs, clinical counseling, and women&apos;s choices. METHODS: Within the context of a South African program to increase women&apos;s access to the IUD, we conducted a pragmatic, open-label, parallel-arm, randomised controlled trial of the IUD versus IPC at two South African hospitals. The target sample size was 7,000 women and the randomisation ratio was 1:1. The random sequence was computer-generated and group allocation was concealed in sealed, opaque, consecutively-numbered envelopes. Counselled, consenting women attending termination of pregnancy services were randomly assigned to IUD or IPC immediately post-termination. Condoms were promoted for the prevention of sexually-transmitted infections. The primary outcome was pregnancy; secondary outcomes were discontinuation, side-effects, and HIV acquisition and disease progression. Pregnancy and discontinuation outcomes are reported here. RESULTS: The trial closed early with 2,493 participants randomised (IUD = 1,247, IPC = 1,246), due to international concerns regarding a possible association between IPC and HIV acquisition. Median follow-up was 20 months; 982 and 1000 participants were followed up in the IUD and IPC groups, respectively. Baseline group characteristics were comparable. Pregnancy occurred significantly less frequently among women allocated to the IUD than IPC: 56/971 (5.8%) versus 83/992 (8.4%), respectively; risk ratio (RR) 0.69, 95% confidence interval (CI) 0.50 to 0.96; P = 0.025. There were more protocol violations in the IUD group; however, discontinuation rates were similar between IUD and IPC groups (141/855 [16.5%] and 143/974 [14.7%], respectively). Women in the IUD group were more likely to discontinue contraceptive use due to abdominal pain or backache and non-specific symptoms, and those in the IPC group due to oligo- or amenorhoea and lack of sexual activity. CONCLUSIONS: The IUD was significantly more effective in preventing pregnancy than IPC. Efforts to expand contraception options and improve access to the IUD in settings where it is under-utilised are worthwhile. This trial shows that randomising long-acting, reversible contraceptives is feasible. TRIAL REGISTRATION: Pan African Clinical Trials Registry number PACTR201409000880157 (04-09-2014).</style></abstract><notes><style face="normal" font="default" size="100%">1742-4755&#xD;Hofmeyr, G Justus&#xD;Singata-Madliki, Mandisa&#xD;Lawrie, Theresa A&#xD;Bergel, Eduardo&#xD;Temmerman, Marleen&#xD;Comparative Study&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Reprod Health. 2016 Apr 18;13:42. doi: 10.1186/s12978-016-0153-9.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4835872</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12978-016-0153-9</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>319</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">319</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chyderiotis, S.</style></author><author><style face="normal" font="default" size="100%">Legeay, C.</style></author><author><style face="normal" font="default" size="100%">Verjat-Trannoy, D.</style></author><author><style face="normal" font="default" size="100%">Le Gallou, F.</style></author><author><style face="normal" font="default" size="100%">Astagneau, P.</style></author><author><style face="normal" font="default" size="100%">Lepelletier, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Legeay, Unité De Prévention Et De Lutte Contre Les Infections Nosocomiales, CHU D&apos;Angers, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of copper surfaces in the healthcare environment: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">stainless steel</style></keyword><keyword><style face="normal" font="default" size="100%">polyvinylchloride</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro study</style></keyword><keyword><style face="normal" font="default" size="100%">in vivo study</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">language</style></keyword><keyword><style face="normal" font="default" size="100%">Medline</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">study design</style></keyword><keyword><style face="normal" font="default" size="100%">skill</style></keyword><keyword><style face="normal" font="default" size="100%">reading</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">flora</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial load</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: To this date, the efficacy of copper in environmental surfaces surrounding patients to decrease bacterial load and ultimately healthcare-associated infections remains controversial. Objectives: To determine the potential of copper surfaces to help fight against infection risk in healthcare settings, we conducted a systematic review. Methods: A PubMed and Nosobase (French database on infection control) search was performed by two investigators with the following key words: Copper; Surface; Anti-infective; Antimicrobial; Activity. Both in vitro and in vivo studies were included, studies assessing the effects of copper outside of hospital surfaces were excluded (water, air). English, French and Spanish languages were included based on investigators&apos; skills. Studies encountered on Nosobase and published in non-indexed reviews were excluded. Results: A total of 3,289 articles were retrieved with those keywords. Based on titles and after reading abstracts and articles, the investigators selected 34 articles including 24 in vitro studies and 10 in vivo (on-site environmental or clinical) studies. In vitro studies mostly demonstrated a broad-spectrum activity of copper with a significant decrease of antimicrobial load on copper surfaces compared to control surfaces (mainly stainless steel and PVC). In vivo studies assessed the total flora reduction as the main outcome with an important decrease on most copper surfaces compared to controls. An important heterogeneity in the design and the results of these studies was observed, making extrapolations to a clinical impact of copper surfaces difficult. One study in particular assessed the nosocomial infections and/or colonisation with MRSA or VRE as the outcome after introducing 6 copper objects in ICU rooms using a randomized controlled trial. The authors observed a 50% decrease in healthcare-associated infections, although several methodological issues could be addressed regarding the study design. Conclusion: Although copper surfaces gained much interest during the past few years, there is a lack of clinical studies to demonstrate a significant effect on patient outcome. Cost-effectiveness studies should also be conducted before concluding on the benefits of copper surfaced equipment for healthcare settings.</style></abstract><notes><style face="normal" font="default" size="100%">L72038986&#xD;2015-10-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72038986</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">73</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, C. H.</style></author><author><style face="normal" font="default" size="100%">Lin, L. C.</style></author><author><style face="normal" font="default" size="100%">Chang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Liu, C. E.</style></author><author><style face="normal" font="default" size="100%">Soon, M. S.</style></author><author><style face="normal" font="default" size="100%">Huang, C. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Changhua Christian Hospital, Chinese Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of copper-silver ionization for controlling fungal colonization in water distribution systems</style></title><secondary-title><style face="normal" font="default" size="100%">J Water Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Water Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">277-80</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2013/05/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Fungi/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply/*standards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1477-8920 (Print)&#xD;1477-8920</style></isbn><accession-num><style face="normal" font="default" size="100%">23708575</style></accession-num><abstract><style face="normal" font="default" size="100%">The purpose of this study was to identify the prevalence of fungal colonization in water systems and to evaluate the effect of decreasing fungal colonization by a copper-silver ionization system. Environmental samples were collected for fungal culture prospectively during a 1-year period (2011-2012) at the study hospital. A total of 392 water samples were examined from five buildings on March 1, 2011 and February 29, 2012. Fungi were isolated in 13 (3.4%) of 392 water samples from five buildings. The prevalence of fungal colonization in buildings was decreased from 4.76% (9/189) to 1.97% (4/203), a reduction of more than 40%, in pre-ionization and post-ionization treatment (p &lt; 0.001). Thirteen (3.4%) of 392 water samples yielded fungi including Fusarium species (n = 7), Penicillium species (n = 2), Scedosporium species (n = 2), Aspergillus species (n = 1), and one unidentifiable mold. The number of isolated Fusarium species in ionized water samples (0.5% (1/203)) was statistically lower than those in nonionized (3.2% (6/189)) (p = 0.003). Our finding may determine if this ionization method can be applied for control of waterborne fungi colonization in hospital water systems.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Chang-Hua&#xD;Lin, Li-Chen&#xD;Chang, Yu-Jun&#xD;Liu, Chun-Eng&#xD;Soon, Maw-Soan&#xD;Huang, Ching-Shan&#xD;Journal Article&#xD;England&#xD;J Water Health. 2013 Jun;11(2):277-80. doi: 10.2166/wh.2013.139.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2166/wh.2013.139</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">94</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shih, H. Y.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Institute of Environmental Education, National Kaohsiung Normal University, 62 Shen-chong Rd, Yanchao, Kaohsiung, Taiwan 824.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of copper-silver ionization in controlling biofilm- and plankton-associated waterborne pathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2032-5</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2010/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acinetobacter baumannii/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilms/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Ions/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Stenotrophomonas maltophilia/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0099-2240</style></isbn><accession-num><style face="normal" font="default" size="100%">20080997</style></accession-num><abstract><style face="normal" font="default" size="100%">The study was to determine the efficacy of copper-silver ionization against the formation of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii in biofilms and planktonic phases. At concentrations below the EPA limits, ionization has potential to control the three waterborne pathogens, in addition to Legionella, in hospital water systems for nosocomial infection control.</style></abstract><notes><style face="normal" font="default" size="100%">1098-5336&#xD;Shih, Hsiu-Yun&#xD;Lin, Yusen E&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Appl Environ Microbiol. 2010 Mar;76(6):2032-5. doi: 10.1128/AEM.02174-09. Epub 2010 Jan 15.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2838026</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aem.02174-09</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, Y.</style></author><author><style face="normal" font="default" size="100%">Lu, C. J.</style></author><author><style face="normal" font="default" size="100%">Chien, K. L.</style></author><author><style face="normal" font="default" size="100%">Chen, S. T.</style></author><author><style face="normal" font="default" size="100%">Chen, R. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Y. Sun, Department of Neurology, En Chu Kong Hospital, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of Multivitamin Supplementation Containing Vitamins B6 and B12 and Folic Acid as Adjunctive Treatment with a Cholinesterase Inhibitor in Alzheimer&apos;s Disease: A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study in Taiwanese Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2204-2214</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">calcium carbonate</style></keyword><keyword><style face="normal" font="default" size="100%">cholinesterase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">colecalciferol</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">donepezil</style></keyword><keyword><style face="normal" font="default" size="100%">ferrous ion</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">homocysteine</style></keyword><keyword><style face="normal" font="default" size="100%">iodine</style></keyword><keyword><style face="normal" font="default" size="100%">mecobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">multivitamin</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinamide</style></keyword><keyword><style face="normal" font="default" size="100%">pantothenate calcium</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine mononitrate</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">abnormal laboratory result</style></keyword><keyword><style face="normal" font="default" size="100%">add on therapy</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer disease</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">caregiver</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">coughing</style></keyword><keyword><style face="normal" font="default" size="100%">daily life activity</style></keyword><keyword><style face="normal" font="default" size="100%">delirium</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">dizziness</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">drug tolerability</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">interview</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">muscle cramp</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">neuralgia</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">scoring system</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">stomach discomfort</style></keyword><keyword><style face="normal" font="default" size="100%">Taiwan</style></keyword><keyword><style face="normal" font="default" size="100%">thorax pain</style></keyword><keyword><style face="normal" font="default" size="100%">treatment duration</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified side effect</style></keyword><keyword><style face="normal" font="default" size="100%">upper respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vital sign</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">0149-2918&#xD;1879-114X</style></isbn><abstract><style face="normal" font="default" size="100%">Background. Elevated serum homocysteine levels have been associated with the development of Alzheimer&apos;s dementia (AD). The combined use of a mecobalamin capsule preparation, which contains vitamin B12 0.5 mg with an active methyl base, and an over-the-counter nutritional supplement that contains folic acid 1 mg and pyridoxine hyperchloride 5 mg may be effective as a homocysteine-lowering vitamin regimen. Objective. The aim of this study was to determine whether oral multivitamin supplementation containing vitamins B6 and B12 and folic acid would improve cognitive function and reduce serum homocysteine levels in patients with mild to moderate AD. Methods. This randomized, double-blind, placebocontrolled trial was conducted at En Chu Kong Hospital, Taipei, Taiwan. Male and female patients aged &gt;50 years with mild to moderate AD and normal folic acid and vitamin B12 concentrations were enrolled. All patients received treatment with an acetylcholinesterase inhibitor and were randomized to receive add-on mecobalamin (B12) 500 mg + multivitamin supplement, or placebos, PO QD for 26 weeks. The multivitamin contained pyridoxine (B6) 5 mg, folic acid 1 mg, and other vitamins and iron. Serum homocysteine level was measured and cognitive tests were conducted at baseline and after 26 weeks. The primary efficacy outcome was change in cognition, measured as the change in score from baseline to week 26 on the Alzheimer&apos;s Disease Assessment Scale 11-item Cognition subscale. Secondary efficacy outcomes included changes in function in performance of activities of daily living (ADLs) and concentrations of homocysteine, B12, and folic acid. Tolerability was assessed by comparing the 2 study groups with respect to physical examination findings, including changes in vital signs, laboratory test abnormalities, concomitant medication use, and compliance of study medication was assessed using an interview with the patient&apos;s caregiver, as well as the monitoring of adverse events (AEs) throughout the study. Results. Eighty-nine patients (45 men, 44 women; all Taiwanese; mean [SD] age, 75 [7.3] years) were enrolled and randomized. Overall, there were no significant differences in cognition or ADL function scores between the 2 groups. At week 26, the mean (SD) between-group difference in serum homocysteine concentration versus placebo was -2.25 (2.85) μmol/L (P = 0.008), and the mean serum concentrations of vitamin B12 and folic acid were significantly higher (but within normal range) in the multivitamin group compared with placebo (., +536.9 [694.4] pg/mL [P &lt; 0.001] and +13.84 ng/mL [11.17] [P = 0.012] at 26 weeks, respectively). The 2 most common AEs were muscle pain (11.1% and 6.8%) and insomnia (8.9% and 9.1%) in the multivitamin and placebo groups, respectively. Conclusions. In this population of patients with mild to moderate AD in Taiwan, a multivitamin supplement containing vitamins B6 and B12 and folic acid for 26 weeks decreased homocysteine concentrations. No statistically significant beneficial effects on cognition or ADL function were found between multivitamin and placebo at 26 weeks. (Clin Ther. 2007;29: 2204-2214). © 2007 Excerpta Medica, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L350138567&#xD;2007-12-07</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L350138567</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.clinthera.2007.10.012</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18042476</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.clinthera.2007.10.012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>301</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, W. K.</style></author><author><style face="normal" font="default" size="100%">Kim, J. M.</style></author><author><style face="normal" font="default" size="100%">Kim, G. W.</style></author><author><style face="normal" font="default" size="100%">Kim, B. S.</style></author><author><style face="normal" font="default" size="100%">Ko, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W.-K. Lee, Department of Dermatology, School of Medicine, Pusan National University Hospital, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of oral zinc sulphate for molluscum contagiosum</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Academy of Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Academy of Dermatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">AB162</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">zinc sulfate</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulating agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">molluscum contagiosum</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">dermatology</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">atopy</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword><keyword><style face="normal" font="default" size="100%">liver function test</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">maximum permissible dose</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">university</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">skin disease</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">mucosa</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">0190-9622</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Molluscum contagiosum (MC) is a common and benign contagious viral infection of the skin and mucous membrane that primarily affects children. Spontaneous resolution may occur, but often it takes a prolonged period of months to years and the infection can take up to 4 years to resolve. Zinc has an important effect on the immune system and it has been used as an immunomodulator to treat a variety of skin disorders. Objective: To assess whether oral zinc is effective in treating patients with MC. Methods: Fifty nine MC patients were included at Pusan University Yangsan Hospital between July 2012 and July 2014. Twenty seven (45.8%) patients had past history of atopic disease. The patients were treated with oral zinc sulfate (10 mg/kg to a maximum dose of 600 mg/day) for up to 6 months. Serum zinc and copper level, renal and liver function tests were measured at the beginning (baseline) and completion of the trial. Results: Complete clearance of MC was observed in 47.5% (28/59) of the patients and partial clearance, defined as clearance of 50-99%, in 25.4% (15/59). The mean duration to reach complete clearance was 15.9 weeks. Patients with atopic disease showed higher complete clearance compared to nonatopic disease (56% vs 43%). The response to treatment was not related to the increment in serum zinc level as only 3 patients showed the increment. No serious side effects were reported apart from nausea (1%), mild abdominal pain (1%) and constipation (3%). Conclusion: Our findings suggest that oral zinc sulfate is worth considering as a therapeutic option for the treatment of MC, particularly for generalized lesions and uncooperative patients. Oral zinc sulfate is an effective option lacking significant side effects.</style></abstract><notes><style face="normal" font="default" size="100%">L72275633&#xD;2016-05-31</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72275633</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. E.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. C.</style></author><author><style face="normal" font="default" size="100%">Huang, W. K.</style></author><author><style face="normal" font="default" size="100%">Shih, H. Y.</style></author><author><style face="normal" font="default" size="100%">Wann, S. R.</style></author><author><style face="normal" font="default" size="100%">Lee, S. S.</style></author><author><style face="normal" font="default" size="100%">Tsai, H. C.</style></author><author><style face="normal" font="default" size="100%">Li, C. H.</style></author><author><style face="normal" font="default" size="100%">Chao, H. L.</style></author><author><style face="normal" font="default" size="100%">Ke, C. M.</style></author><author><style face="normal" font="default" size="100%">Lu, H. H.</style></author><author><style face="normal" font="default" size="100%">Chang, C. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of point-of-entry copper--silver ionisation system in eradicating Legionella pneumophila in a tropical tertiary care hospital: implications for hospitals contaminated with Legionella in both hot and cold water</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">152-8</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2008/01/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Academic Medical Centers</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiological Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*instrumentation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Ions</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/*growth &amp; development/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">Taiwan/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/*instrumentation/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701 (Print)&#xD;0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">18192074</style></accession-num><abstract><style face="normal" font="default" size="100%">A medical centre in Southern Taiwan experienced an outbreak of nosocomial Legionnaires&apos; disease, with the water distribution system thought to be the source of the infection. Even after two superheats and flush, the rate of Legionella positivity in distal sites in hospital wards and intensive care units (ICUs) was 14% and 66%, respectively. Copper-silver ionisation was therefore implemented in an attempt to control Legionella colonisation in both hot- and cold-water systems. Environmental cultures and ion concentration testing were performed to evaluate the efficacy of ionisation. When the system was activated, no significant change in rate of Legionella positivity in the hospital wards (20% vs baseline of 30%) and ICUs (28% vs baseline of 34%) of the test buildings over a three-month period was found, although all Legionella positivity rates were below 30%, an arbitrary target for Legionnaires&apos; disease prevention. When ion concentrations were increased from month 4 to month 7, however, the rate of Legionella positivity decreased significantly to 5% (mean) in hospital wards (P=0.037) and 16% (mean) in ICUs (P=0.037). Legionella positivity was further reduced to 0% in hospital wards and 5% (mean) in ICUs while 50% sites were still positive for Legionella in a control building. Although Legionella was not completely eradicated during the study period, no culture- or urine-confirmed hospital-acquired Legionnaires&apos; disease was reported. Ionisation was effective in controlling Legionella for both hot and cold water, and may be an attractive alternative as a point-of-entry systematic disinfection solution for Legionella.</style></abstract><notes><style face="normal" font="default" size="100%">Chen, Y S&#xD;Lin, Y E&#xD;Liu, Y-C&#xD;Huang, W K&#xD;Shih, H Y&#xD;Wann, S R&#xD;Lee, S S&#xD;Tsai, H C&#xD;Li, C H&#xD;Chao, H L&#xD;Ke, C M&#xD;Lu, H H&#xD;Chang, C L&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2008 Feb;68(2):152-8. doi: 10.1016/j.jhin.2007.10.020. Epub 2008 Jan 14.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2007.10.020</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. E.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. C.</style></author><author><style face="normal" font="default" size="100%">Huang, W. K.</style></author><author><style face="normal" font="default" size="100%">Shih, H. Y.</style></author><author><style face="normal" font="default" size="100%">Wann, S. R.</style></author><author><style face="normal" font="default" size="100%">Lee, S. S.</style></author><author><style face="normal" font="default" size="100%">Tsai, H. C.</style></author><author><style face="normal" font="default" size="100%">Li, C. H.</style></author><author><style face="normal" font="default" size="100%">Chao, H. L.</style></author><author><style face="normal" font="default" size="100%">Ke, C. M.</style></author><author><style face="normal" font="default" size="100%">Lu, H. H.</style></author><author><style face="normal" font="default" size="100%">Chang, C. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Y.E. Lin, National Kaohsiung Normal University, Kaohsiung, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of point-of-entry copper-silver ionisation system in eradicating Legionella pneumophila in a tropical tertiary care hospital: implications for hospitals contaminated with Legionella in both hot and cold water</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">152-158</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">hot water</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium contamination</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital department</style></keyword><keyword><style face="normal" font="default" size="100%">hospital hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">tertiary health care</style></keyword><keyword><style face="normal" font="default" size="100%">urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">water contamination</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><abstract><style face="normal" font="default" size="100%">A medical centre in Southern Taiwan experienced an outbreak of nosocomial Legionnaires&apos; disease, with the water distribution system thought to be the source of the infection. Even after two superheats and flush, the rate of Legionella positivity in distal sites in hospital wards and intensive care units (ICUs) was 14% and 66%, respectively. Copper-silver ionisation was therefore implemented in an attempt to control Legionella colonisation in both hot- and cold-water systems. Environmental cultures and ion concentration testing were performed to evaluate the efficacy of ionisation. When the system was activated, no significant change in rate of Legionella positivity in the hospital wards (20% vs baseline of 30%) and ICUs (28% vs baseline of 34%) of the test buildings over a three-month period was found, although all Legionella positivity rates were below 30%, an arbitrary target for Legionnaires&apos; disease prevention. When ion concentrations were increased from month 4 to month 7, however, the rate of Legionella positivity decreased significantly to 5% (mean) in hospital wards (P = 0.037) and 16% (mean) in ICUs (P = 0.037). Legionella positivity was further reduced to 0% in hospital wards and 5% (mean) in ICUs while 50% sites were still positive for Legionella in a control building. Although Legionella was not completely eradicated during the study period, no culture- or urine-confirmed hospital-acquired Legionnaires&apos; disease was reported. Ionisation was effective in controlling Legionella for both hot and cold water, and may be an attractive alternative as a point-of-entry systematic disinfection solution for Legionella. © 2007 The Hospital Infection Society.</style></abstract><notes><style face="normal" font="default" size="100%">L50037171&#xD;2008-02-28</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L50037171</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jhin.2007.10.020</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18192074</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2007.10.020</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Esolen, L. M.</style></author><author><style face="normal" font="default" size="100%">Thakur, L.</style></author><author><style face="normal" font="default" size="100%">Layon, A. J.</style></author><author><style face="normal" font="default" size="100%">Fuller, T. A.</style></author><author><style face="normal" font="default" size="100%">Harrington, D. J.</style></author><author><style face="normal" font="default" size="100%">Jha, K.</style></author><author><style face="normal" font="default" size="100%">Kariyawasam, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection Prevention and Control, The Geisinger Medical Center, Danville, PA. Electronic address: lmesolen@icloud.com.&#xD;Department of Critical Care Medicine, The Geisinger Medical Center, Danville, PA.&#xD;Aionx Inc., Hershey, PA.&#xD;Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, PA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The efficacy of self-disinfecting bedrail covers in an intensive care unit</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">417-419</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2017/11/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Beds</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfectants</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Fomites</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intensive Care Units</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental decontamination</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital-acquired infection</style></keyword><keyword><style face="normal" font="default" size="100%">*Silver copper surfaces</style></keyword><keyword><style face="normal" font="default" size="100%">*Surface</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">29162291</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hospital surfaces are considered important vectors in the spread of nosocomial pathogens. This study evaluated microbial counts on novel antimicrobial bedrail covers over a 2-week period in a critical care environment. METHODS: Disposable bedrail covers (Aionx Inc, Hershey, PA) made of a copper and silver polymer and capable of conducting an imperceptible surface potential, were installed in a case-control manner on a series of occupied intensive care unit beds. Seventeen bedrails were covered with the study bedrail surface, and 17 were left uncovered. Two hundred seventy-two microbial surface cultures were obtained from both study and control bedrails and analyzed for microbial growth by bacterial enumeration and speciation. RESULTS: The bedrails covered with the study surface demonstrated &gt;80% average decrease in colony forming units across the study period of 15 days. CONCLUSIONS: These novel, detachable bedrail covers successfully demonstrated significant bacterial count reduction in an intensive care unit setting. This may have implications for acquisition of hospital-acquired infections.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Esolen, Lisa M&#xD;Thakur, Lokendra&#xD;Layon, Abraham J&#xD;Fuller, Thomas A&#xD;Harrington, Deni-Jo&#xD;Jha, Kunal&#xD;Kariyawasam, Subhashinie&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 2018 Apr;46(4):417-419. doi: 10.1016/j.ajic.2017.09.026. Epub 2017 Nov 20.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2017.09.026</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mietzner, S.</style></author><author><style face="normal" font="default" size="100%">Schwille, R. C.</style></author><author><style face="normal" font="default" size="100%">Farley, A.</style></author><author><style face="normal" font="default" size="100%">Wald, E. R.</style></author><author><style face="normal" font="default" size="100%">Ge, J. H.</style></author><author><style face="normal" font="default" size="100%">States, S. J.</style></author><author><style face="normal" font="default" size="100%">Libert, T.</style></author><author><style face="normal" font="default" size="100%">Wadowsky, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children&apos;s Hospital of Pittsburgh, PA 15213, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of thermal treatment and copper-silver ionization for controlling Legionella pneumophila in high-volume hot water plumbing systems in hospitals</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">452-7</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">1998/01/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Electrodes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Ions</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance and Engineering, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Pennsylvania</style></keyword><keyword><style face="normal" font="default" size="100%">*Sanitary Engineering</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1997</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553 (Print)&#xD;0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">9437482</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Thermal treatment and copper-silver ionization are often used for controlling Legionella pneumophila in high-volume hospital plumbing systems, although the comparative efficacies of these measures in high-volume systems are unknown. METHODS: Thermal treatment of a hot water circuit was accomplished by flushing hot water (&gt; 60 degrees C) through distal fixtures for 10 minutes. Copper-silver ionization was conducted in three circuits by installing units into return lines immediately upstream from hot water tanks. Recovery rates of L. pneumophila were monitored by culturing swab samples from faucets. Concentrations of copper and silver in water samples were determined by atomic absorption spectrophotometry. RESULTS: Four heat-flush treatments failed to provide long-term control of L. pneumophila. In contrast, ionization treatment reduced the rate of recovery of L. pneumophila from 108 faucets from 72% to 2% within 1 month and maintained effective control for at least 22 months. Only three samples (1.9%) of hot water from faucets exceeded Environmental Protection Agency standards for silver, and none exceeded the standards for copper. Of 24 samples obtained from hot water tanks, 42% and 50% exceeded the silver and copper standards, respectively. CONCLUSIONS: Copper-silver ionization effectively controls L. pneumophila in high-volume plumbing systems and is superior to thermal treatment; however, high concentrations of copper and silver can accumulate at the bottom of hot water tanks.</style></abstract><notes><style face="normal" font="default" size="100%">Mietzner, S&#xD;Schwille, R C&#xD;Farley, A&#xD;Wald, E R&#xD;Ge, J H&#xD;States, S J&#xD;Libert, T&#xD;Wadowsky, R M&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Infect Control. 1997 Dec;25(6):452-7. doi: 10.1016/s0196-6553(97)90066-3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0196-6553(97)90066-3</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">76</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kinnevey, P. M.</style></author><author><style face="normal" font="default" size="100%">Shore, A. C.</style></author><author><style face="normal" font="default" size="100%">Brennan, G. I.</style></author><author><style face="normal" font="default" size="100%">Sullivan, D. J.</style></author><author><style face="normal" font="default" size="100%">Ehricht, R.</style></author><author><style face="normal" font="default" size="100%">Monecke, S.</style></author><author><style face="normal" font="default" size="100%">Slickers, P.</style></author><author><style face="normal" font="default" size="100%">Coleman, D. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbiology Research Unit, Dublin Dental University Hospital, University of Dublin, Trinity College Dublin, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emergence of sequence type 779 methicillin-resistant Staphylococcus aureus harboring a novel pseudo staphylococcal cassette chromosome mec (SCCmec)-SCC-SCCCRISPR composite element in Irish hospitals</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Agents Chemother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">524-31</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2012/11/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Proteins/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Chromosome Mapping</style></keyword><keyword><style face="normal" font="default" size="100%">*Chromosomes, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Coagulase/deficiency/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*drug therapy/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Inverted Repeat Sequences</style></keyword><keyword><style face="normal" font="default" size="100%">Ireland</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/drug effects/*genetics/isolation &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">purification</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Sequence Analysis, DNA</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections/*drug therapy/microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0066-4804</style></isbn><accession-num><style face="normal" font="default" size="100%">23147725</style></accession-num><abstract><style face="normal" font="default" size="100%">Methicillin-resistant Staphylococcus aureus (MRSA) has been a major cause of nosocomial infection in Irish hospitals for 4 decades, and replacement of predominant MRSA clones has occurred several times. An MRSA isolate recovered in 2006 as part of a larger study of sporadic MRSA exhibited a rare spa (t878) and multilocus sequence (ST779) type and was nontypeable by PCR- and DNA microarray-based staphylococcal cassette chromosome mec (SCCmec) element typing. Whole-genome sequencing revealed the presence of a novel 51-kb composite island (CI) element with three distinct domains, each flanked by direct repeat and inverted repeat sequences, including (i) a pseudo SCCmec element (16.3 kb) carrying mecA with a novel mec class region, a fusidic acid resistance gene (fusC), and two copper resistance genes (copB and copC) but lacking ccr genes; (ii) an SCC element (17.5 kb) carrying a novel ccrAB4 allele; and (iii) an SCC element (17.4 kb) carrying a novel ccrC allele and a clustered regularly interspaced short palindromic repeat (CRISPR) region. The novel CI was subsequently identified by PCR in an additional 13 t878/ST779 MRSA isolates, six from bloodstream infections, recovered between 2006 and 2011 in 11 hospitals. Analysis of open reading frames (ORFs) carried by the CI showed amino acid sequence similarity of 44 to 100% to ORFs from S. aureus and coagulase-negative staphylococci (CoNS). These findings provide further evidence of genetic transfer between S. aureus and CoNS and show how this contributes to the emergence of novel SCCmec elements and MRSA strains. Ongoing surveillance of this MRSA strain is warranted and will require updating of currently used SCCmec typing methods.</style></abstract><notes><style face="normal" font="default" size="100%">1098-6596&#xD;Kinnevey, Peter M&#xD;Shore, Anna C&#xD;Brennan, Grainne I&#xD;Sullivan, Derek J&#xD;Ehricht, Ralf&#xD;Monecke, Stefan&#xD;Slickers, Peter&#xD;Coleman, David C&#xD;Journal Article&#xD;United States&#xD;Antimicrob Agents Chemother. 2013 Jan;57(1):524-31. doi: 10.1128/AAC.01689-12. Epub 2012 Nov 12.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3535981</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aac.01689-12</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>384</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">384</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aurass, P.</style></author><author><style face="normal" font="default" size="100%">Prager, R.</style></author><author><style face="normal" font="default" size="100%">Flieger, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Aurass, Department of Bacterial Infections, Robert Koch Institute, Wernigerode, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Entry of EHEC/EAEC O104:H4 into the VBNC state and its resuscitation upon stress relief</style></title><secondary-title><style face="normal" font="default" size="100%">Zoonoses and Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zoonoses and Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">15-16</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper ion</style></keyword><keyword><style face="normal" font="default" size="100%">tap water</style></keyword><keyword><style face="normal" font="default" size="100%">resuscitation</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli infection</style></keyword><keyword><style face="normal" font="default" size="100%">Shiga toxin producing Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">gene</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">uremia</style></keyword><keyword><style face="normal" font="default" size="100%">chelation</style></keyword><keyword><style face="normal" font="default" size="100%">fitness</style></keyword><keyword><style face="normal" font="default" size="100%">virulence</style></keyword><keyword><style face="normal" font="default" size="100%">microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">bloody diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">microenvironment</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial spore</style></keyword><keyword><style face="normal" font="default" size="100%">staining</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient</style></keyword><keyword><style face="normal" font="default" size="100%">enteroaggregative Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">marker gene</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenicity</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1863-1959</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction and Objectives: Various non-spore forming bacteria including Escherichia coli, enter a dormant-like state, the viable but nonculturable (VBNC) state, characterised by the presence of viable cells but the inability to grow on routine laboratory media. Upon resuscitation, these VBNC cells recover both culturability and pathogenicity. In 2011, a large outbreak involving more than 3000 cases of bloody diarrhea and haemolytic uremic syndrome (HUS) was caused by an E. coli O104:H4 strain expressing genes characteristic of both enterohaemorrhagic (EHEC) and enteroaggregative E. coli (EAEC). The ability of the outbreak strain to enter the VBNC state may have complicated its detection in the suspected sources. In this paper, we investigated the ability of the outbreak strain to enter and subsequently recover from the VBNC state. Results: We found that in a nutrient-poor microenvironment, various stresses such as toxic concentrations of copper ions or certain types of tap water are able to render the bacteria unculturable within a few days. Without copper ion stress, the majority of cells remained culturable for at least 40 days. Incubation with the stressors at 23°C compared to 4°C hastened this observed loss of culturability. The integrity of a considerable fraction of copper ion- and tap water onestressed bacteria was demonstrated by live/dead staining and microscopy. Relieving copper-ion stress by copper-ion chelation facilitated resuscitation of these bacteria while preserving their fitness, major virulence gene markers (stx2, aggR, aggA genes) and specific phenotypes (ESBL resistance, autoaggregation typical for EAEC strains).</style></abstract><notes><style face="normal" font="default" size="100%">L70928810&#xD;2012-11-29</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70928810</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>492</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">492</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rutala, W. A.</style></author><author><style face="normal" font="default" size="100%">Weber, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">W.A. Rutala</style></auth-address><titles><title><style face="normal" font="default" size="100%">Environmental interventions to control nosocomial infections</style></title><secondary-title><style face="normal" font="default" size="100%">Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">442-443</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">paint</style></keyword><keyword><style face="normal" font="default" size="100%">cross infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital design</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">methodology</style></keyword><keyword><style face="normal" font="default" size="100%">note</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year></dates><isbn><style face="normal" font="default" size="100%">0899-823X</style></isbn><notes><style face="normal" font="default" size="100%">L125120455&#xD;1995-12-28</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L125120455</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">7594389</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duffy, R. E.</style></author><author><style face="normal" font="default" size="100%">Brown, S. E.</style></author><author><style face="normal" font="default" size="100%">Caldwell, K. L.</style></author><author><style face="normal" font="default" size="100%">Lubniewski, A.</style></author><author><style face="normal" font="default" size="100%">Anderson, N.</style></author><author><style face="normal" font="default" size="100%">Edelhauser, H.</style></author><author><style face="normal" font="default" size="100%">Holley, G.</style></author><author><style face="normal" font="default" size="100%">Tess, A.</style></author><author><style face="normal" font="default" size="100%">Divan, H.</style></author><author><style face="normal" font="default" size="100%">Helmy, M.</style></author><author><style face="normal" font="default" size="100%">Arduino, M.</style></author><author><style face="normal" font="default" size="100%">Jarvis, W. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CDC, Hospital Infections Program, Atlanta, GA 30333, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An epidemic of corneal destruction caused by plasma gas sterilization. The Toxic Cell Destruction Syndrome Investigative Team</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Arch Ophthalmol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1167-76</style></pages><volume><style face="normal" font="default" size="100%">118</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2000/09/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Corneal Edema/*chemically induced/*epidemiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Endothelium, Corneal/*drug effects/pathology/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">*Equipment Contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Georgia/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lens Implantation, Intraocular</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Phacoemulsification/*instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Rabbits</style></keyword><keyword><style face="normal" font="default" size="100%">Sterilization/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0003-9950 (Print)&#xD;0003-9950</style></isbn><accession-num><style face="normal" font="default" size="100%">10980761</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Toxic endothelial cell destruction (TECD) syndrome after intraocular ophthalmic surgery is rare and can result from exposure to a variety of toxins. During January 8 to 14, 1998, 6 patients developed TECD with corneal edema associated with unreactive or dilated pupils at Hospital A. METHODS: A case patient was any Hospital A patient with TECD within 24 hours after surgery during January 5 to 14, 1998 (epidemic period). A control was any hospital A ophthalmic surgery patient without TECD during the epidemic period. The medical records of hospital A ophthalmology surgery patients during the pre-epidemic (ie, September 1, 1997-January 4, 1998) and epidemic periods were reviewed. Inductively coupled plasma atomic emission spectrometry was used to detect trace inorganic elements on sterilized surgical instruments. Cannulated surgical instruments and laboratory rinsates were perfused directly to the corneal endothelium of isolated rabbit and human corneas. Corneal endothelial ultrastructure and swelling were assessed. RESULTS: The rate of TECD at hospital A was higher during the epidemic than pre-epidemic period (6/12 vs 0/118, P&lt;.001). The only change during the periods was the introduction, on November 5, 1997, of a new sterilization method, AbTox Plazlyte, for sterilization of ophthalmic surgery instruments. Findings from spectrometry revealed that copper and zinc residues were higher in instruments sterilized with Plazlyte than in those sterilized with ethylene oxide (median copper value, 7.64 mg/L vs 0.14 mg/L, respectively, P =.02; median zinc value, 5.90 mg/L vs 1.35 mg/L, respectively, P =.2). Corneal endothelial perfusion of Plazlyte sterilized-instrument rinsates or laboratory solution with copper and zinc produced irreversible damage, similar to toxic corneal endothelial destruction, to rabbit and human corneas. CONCLUSION: A new sterilization method degraded brass to copper and zinc on cannulated surgical instruments resulting in TECD of the cornea. Arch Ophthalmol. 2000;118:1167-1176</style></abstract><notes><style face="normal" font="default" size="100%">Duffy, R E&#xD;Brown, S E&#xD;Caldwell, K L&#xD;Lubniewski, A&#xD;Anderson, N&#xD;Edelhauser, H&#xD;Holley, G&#xD;Tess, A&#xD;Divan, H&#xD;Helmy, M&#xD;Arduino, M&#xD;Jarvis, W R&#xD;EY00933/EY/NEI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;Arch Ophthalmol. 2000 Sep;118(9):1167-76. doi: 10.1001/archopht.118.9.1167.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archopht.118.9.1167</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>485</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">485</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mietzner, S.</style></author><author><style face="normal" font="default" size="100%">Schwille, R. C.</style></author><author><style face="normal" font="default" size="100%">Farley, A.</style></author><author><style face="normal" font="default" size="100%">Wald, E. R.</style></author><author><style face="normal" font="default" size="100%">Ge, J. H.</style></author><author><style face="normal" font="default" size="100%">States, S. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Erratum: Efficacy of thermal treatment and copper-silver ionization for controlling Legionella pneumonia in high-volume hot water plumbing systems in hospitals (American Journal of Infection Control (1997) 25 (452-457))</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">112</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">erratum</style></keyword><keyword><style face="normal" font="default" size="100%">error</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><notes><style face="normal" font="default" size="100%">L28194422&#xD;1998-06-05</style></notes><work-type><style face="normal" font="default" size="100%">Erratum</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L28194422</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naik, P.</style></author><author><style face="normal" font="default" size="100%">Fernandez, J. C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of &apos;tetralin and Copper Oleate&apos; Combination As a Potent Pediculicide</style></title><secondary-title><style face="normal" font="default" size="100%">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">449-454</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">1979/11/01</style></edition><dates><year><style face="normal" font="default" size="100%">1979</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0378-6323</style></isbn><accession-num><style face="normal" font="default" size="100%">28223582</style></accession-num><abstract><style face="normal" font="default" size="100%">A clinical investigation with a pediculicide preparation containing tetralin + copper oleate as active ingredients was conducted and its therapeutic effect was compared with a preparation containing benzyl benzoate + DDT The study was conducted on 50 patients with pediculosis capitis/corporis/pubis; in a skin out patient department of public hospital in Bombay. They were grouped into two groups of 25 patients each. In each group, 21 hadpediculosisca pitis, 3 had pediculosis corporis and one had pediculosis publs. Preparation containing tetralin + copper oleate was effective in all the patients and one application was enough in majority of patients to kill both lice and nits. However 4 patients (i.e. 16%) showed recurrence within 7 days of stopping treatment, which was probably due to reinfection as they were found to be cured on 7th day&apos;s examination. Medication containing benzyl benzoate + DDT was also effective in all cases but more than one application was necessary in majority of patients. Hence the duration of therapy was prolonged. Recurrence was noted in 8 patients within a week (i.e. 32%) after stopping treatment. The chief advantage of preparation containing tetralin + copper oleate lies in its comparative effectiveness from a treatment of only 15 minutes duration. It was interesting enough to find this preparation effective in pediculosis with mild secondary infection without the use of antibiotics or chemodierapeutic agent like sulphonamides, in contrast to preparation containing benzyl benzoate + DDT which by itself had no beneficial effect in presence of secondary infection. However, a clinical trial on larger number of cases is necessary for confirmation.</style></abstract><notes><style face="normal" font="default" size="100%">0973-3922&#xD;Naik, Pushpa&#xD;Fernandez, J C&#xD;Journal Article&#xD;India&#xD;Indian J Dermatol Venereol Leprol. 1979 Nov-Dec;45(6):449-454.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>327</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tseng, Y. R.</style></author><author><style face="normal" font="default" size="100%">Cho, T. L.</style></author><author><style face="normal" font="default" size="100%">Li, K. C.</style></author><author><style face="normal" font="default" size="100%">Lin, H. S.</style></author><author><style face="normal" font="default" size="100%">Hwang, K. P.</style></author><author><style face="normal" font="default" size="100%">Tien, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Y.-R. Tseng, Department of Laboratory Medicine, Department of Medical Laboratory Science and Biotechnology, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of a chlorine dioxide water treatment system to control legionella species in a hospital water system</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Microbiology, Immunology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Microbiology, Immunology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S137</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">chlorine dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">ozone</style></keyword><keyword><style face="normal" font="default" size="100%">ion</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">water treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">health care associated pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">Taiwan</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">filter</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">machine</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1684-1182</style></isbn><abstract><style face="normal" font="default" size="100%">Purpose: The contamination of the water supply system by Legionella, so often results in health care associated pneumonia events. In order to exclude the pathogens in the water supply system, often used in medical institutions of copper and silver ions exchange, chlorine dioxide, ozone or single filters and other disinfection methods. With expert recommendations, reference literature, and take into some issues such as hospital facilities and the building position, we use chlorine dioxide disinfection methods for water disinfection in hospitals. Methods: We monitored the Legionella colonies in the chilled water system. A medical center in central Taiwan since January 2013, in hospital water systems began to routinely monitor growing concentration of Legionella. In April of 2013 began the installation of chlorine dioxide produced machines system, maintaining the concentration of chlorine dioxide in hospital water systems. Water samples were collected for Legionella enumeration by a standardized culture method. Routine environmental cultures were performed to evaluate the efficacy. Results: From January 2013 the detection rate was 20%, by 2014 to July, had 16 consecutive months with no detectable Legionella. Conclusions: According to our monitoring results indicate that chlorine dioxide disinfection method used in chilled water system of hospital had the effectiveness of control Legionella. By treatment using ClO2, we could control Legionella colonization rate in the test building.</style></abstract><notes><style face="normal" font="default" size="100%">L72082667&#xD;2015-11-27</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72082667</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duda, S.</style></author><author><style face="normal" font="default" size="100%">Kandiah, S.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Baron, J. L.</style></author><author><style face="normal" font="default" size="100%">Yassin, M.</style></author><author><style face="normal" font="default" size="100%">Fabrizio, M.</style></author><author><style face="normal" font="default" size="100%">Ferrelli, J.</style></author><author><style face="normal" font="default" size="100%">Hariri, R.</style></author><author><style face="normal" font="default" size="100%">Wagener, M. M.</style></author><author><style face="normal" font="default" size="100%">Goepfert, J.</style></author><author><style face="normal" font="default" size="100%">Bond, J.</style></author><author><style face="normal" font="default" size="100%">Hannigan, J.</style></author><author><style face="normal" font="default" size="100%">Rogers, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Special Pathogens Laboratory, Pittsburgh, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of a new monochloramine generation system for controlling Legionella in building hot water systems</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1356-63</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2014/10/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acinetobacter/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Chloramines/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hot Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/*drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Stenotrophomonas maltophilia/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Tertiary Care Centers</style></keyword><keyword><style face="normal" font="default" size="100%">Water/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">25333430</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To evaluate the efficacy of a new monochloramine generation system for control of Legionella in a hospital hot water distribution system. SETTING: A 495-bed tertiary care hospital in Pittsburgh, Pennsylvania. The hospital has 12 floors covering approximately 78,000 m(2). METHODS: The hospital hot water system was monitored for a total of 29 months, including a 5-month baseline sampling period prior to installation of the monochloramine system and 24 months of surveillance after system installation (postdisinfection period). Water samples were collected for microbiological analysis (Legionella species, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter species, nitrifying bacteria, heterotrophic plate count [HPC] bacteria, and nontuberculous mycobacteria). Chemical parameters monitored during the investigation included monochloramine, chlorine (free and total), nitrate, nitrite, total ammonia, copper, silver, lead, and pH. RESULTS: A significant reduction in Legionella distal site positivity was observed between the pre- and postdisinfection periods, with positivity decreasing from an average of 53% (baseline) to an average of 9% after monochloramine application (P&lt;0.5]). Although geometric mean HPC concentrations decreased by approximately 2 log colony-forming units per milliliter during monochloramine treatment, we did not observe significant changes in other microbial populations. CONCLUSIONS: This is the first evaluation in the United States of a commercially available monochloramine system installed on a hospital hot water system for Legionella disinfection, and it demonstrated a significant reduction in Legionella colonization. Significant increases in microbial populations or other negative effects previously associated with monochloramine use in large municipal cold water systems were not observed.</style></abstract><notes><style face="normal" font="default" size="100%">1559-6834&#xD;Duda, Scott&#xD;Kandiah, Sheena&#xD;Stout, Janet E&#xD;Baron, Julianne L&#xD;Yassin, Mohamed&#xD;Fabrizio, Marie&#xD;Ferrelli, Juliet&#xD;Hariri, Rahman&#xD;Wagener, Marilyn M&#xD;Goepfert, John&#xD;Bond, James&#xD;Hannigan, Joseph&#xD;Rogers, Denzil&#xD;Evaluation Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2014 Nov;35(11):1356-63. doi: 10.1086/678418. Epub 2014 Sep 19.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/678418</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>218</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eichenlaub, M.</style></author><author><style face="normal" font="default" size="100%">Astheimer, K.</style></author><author><style face="normal" font="default" size="100%">Minners, J.</style></author><author><style face="normal" font="default" size="100%">Blum, T.</style></author><author><style face="normal" font="default" size="100%">Restle, C.</style></author><author><style face="normal" font="default" size="100%">Maring, C.</style></author><author><style face="normal" font="default" size="100%">Schweitzer, S.</style></author><author><style face="normal" font="default" size="100%">Thiel, U.</style></author><author><style face="normal" font="default" size="100%">Neumann, F. J.</style></author><author><style face="normal" font="default" size="100%">Arentz, T.</style></author><author><style face="normal" font="default" size="100%">Lehrmann, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Eichenlaub, University Heart Center Freiburg–Bad Krozingen, Suedring 15, Bad Krozingen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of a new ultralow-dose radiation protocol for electrophysiological device implantation: A near-zero fluoroscopy approach for device implantation</style></title><secondary-title><style face="normal" font="default" size="100%">Heart Rhythm</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Heart Rhythm</style></full-title></periodical><pages><style face="normal" font="default" size="100%">90-97</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">angiography device</style></keyword><keyword><style face="normal" font="default" size="100%">Artis zee angiography system</style></keyword><keyword><style face="normal" font="default" size="100%">cardiac resynchronization therapy device</style></keyword><keyword><style face="normal" font="default" size="100%">dual chamber implantable cardioverter defibrillator</style></keyword><keyword><style face="normal" font="default" size="100%">dual chamber pacemaker</style></keyword><keyword><style face="normal" font="default" size="100%">single chamber implantable cardioverter defibrillator</style></keyword><keyword><style face="normal" font="default" size="100%">single chamber pacemaker</style></keyword><keyword><style face="normal" font="default" size="100%">X ray system</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">artificial heart pacemaker failure</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">cardiac resynchronization therapy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical protocol</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fluoroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">image processing</style></keyword><keyword><style face="normal" font="default" size="100%">implantation</style></keyword><keyword><style face="normal" font="default" size="100%">lead dislocation</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">pneumothorax</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">radiation dose</style></keyword><keyword><style face="normal" font="default" size="100%">radiation exposure</style></keyword><keyword><style face="normal" font="default" size="100%">radiation safety</style></keyword><keyword><style face="normal" font="default" size="100%">sex difference</style></keyword><keyword><style face="normal" font="default" size="100%">wound infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1556-3871&#xD;1547-5271</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Radiation is one of the main hazards of electrophysiological device implantation, and insertion of cardiac resynchronization therapy (CRT) devices in particular is associated with high radiation doses. Objective: The purpose of this study was to evaluate the impact of a new ultralow-dose radiation protocol on radiation doses, success rate, and safety of electrophysiological device implantations. Methods: In 2018, we established a new ultralow-dose radiation protocol (reduced pulse width, increased thickness of minimum copper filters, reduced detector entrance dose, reduced pulse rate, optimized image postprocessing settings) for de novo device implantation at our hospital. A total of 1173 patients (11% single-chamber devices, 69% dual-chamber devices, 20% CRT devices) were analyzed. Five hundred twelve patients (44%) in the ultralow-dose group were compared to 661 patients (66%) treated during 2017 with a conventional low-dose protocol. Results: With the ultralow-dose radiation protocol, effective doses could be reduced by 59% (median 0.25 [interquartile range: 0.11–0.63] vs median 0.10 [interquartile range: 0.03–0.28] mSv; P &lt;.0001) per procedure without a significant change in procedure time (P =.5). This dose reduction could be achieved without decreasing procedure success (P = 1) or increasing complication rate (P =.8). Male gender, higher body mass index, increased procedure and fluoroscopy times, and use of the conventional radiation protocol were independent predictors of higher radiation doses in multivariate regression analysis. Conclusion: By establishing a new ultralow-dose radiation protocol, we could significantly decrease radiation exposure, reaching the lowest radiation doses for electrophysiological device implantation reported to date.</style></abstract><notes><style face="normal" font="default" size="100%">L2002795682&#xD;2019-09-11&#xD;2020-01-14</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2002795682</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.hrthm.2019.07.031</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Artis zee angiography system(Siemens Healthcare,Germany)</style></custom3><custom4><style face="normal" font="default" size="100%">Siemens(Germany)&#xD;Siemens Healthcare(Germany)</style></custom4><custom5><style face="normal" font="default" size="100%">31494091</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.hrthm.2019.07.031</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>505</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harris, T. M.</style></author><author><style face="normal" font="default" size="100%">Krishnan Raman, T.</style></author><author><style face="normal" font="default" size="100%">Richards, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Div. Pulmon. Dis., Dept. Med., Albany Med. Coll., Albany, N.Y. 12208</style></auth-address><titles><title><style face="normal" font="default" size="100%">An evaluation of bacterial contamination of ventilator humidifying systems</style></title><secondary-title><style face="normal" font="default" size="100%">CHEST</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">CHEST</style></full-title></periodical><pages><style face="normal" font="default" size="100%">922-925</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">airborne infection</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">methodology</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory care</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1973</style></year></dates><isbn><style face="normal" font="default" size="100%">0012-3692</style></isbn><abstract><style face="normal" font="default" size="100%">The hazard of various humidifying systems as a potential source of bacterial contamination has been stressed because of the increased use of mechanical ventilators in the management of respiratory failure. During the last three years, 1,257 patients required total ventilatory support at the Albany Medical Center Hospital. This study was undertaken to determine the potential role of the humidifying systems as a source of contamination of the patient tubing interface and to evaluate whether accepted techniques of equipment handling were sufficient. This also gave the opportunity to compare the incidence of contamination of the different ventilators in use, and to observe the spectrum of bacterial flora in this hospital. A series of 287 matched cultures of ventilator humidifying systems and the patient interface tubing taken at random over a 3 yr period were evaluated. Bacteriologic contamination of tubing and humidifying systems occurred as independent and separate events, although the incidence of contamination of tubing was significantly higher. Copper mesh air filtering placed in the humidification assembly had the lowest rate of contamination while ultrasonic humidifiers had the highest. The distribution of the bacteriologic population was unusual. Further improvement of &apos;accepted techniques&apos; to monitor and avoid bacteriologic equipment contamination are necessary.</style></abstract><notes><style face="normal" font="default" size="100%">L4144656&#xD;1974-01-01</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L4144656</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1378/chest.63.6.922</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">4197164</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1378/chest.63.6.922</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ojeil, M.</style></author><author><style face="normal" font="default" size="100%">Jermann, C.</style></author><author><style face="normal" font="default" size="100%">Holah, J.</style></author><author><style face="normal" font="default" size="100%">Denyer, S. P.</style></author><author><style face="normal" font="default" size="100%">Maillard, J. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of new in vitro efficacy test for antimicrobial surface activity reflecting UK hospital conditions</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">274-81</style></pages><volume><style face="normal" font="default" size="100%">85</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2013/10/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Load</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiological Techniques/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial surfaces</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial aerosols</style></keyword><keyword><style face="normal" font="default" size="100%">Relative humidity</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">24091310</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Antimicrobial surfaces aim to reduce microbial bioburden and improve hygiene. The current antimicrobial surface efficacy test (ISO22196) is an initial screening test but its conditions, high temperature (37 degrees C) and relative humidity (RH) (100%) bear little relationship to in-use conditions. AIM: To develop an antimicrobial surface efficacy test providing a realistic second-tier test, simulating in-use conditions. METHODS: Surface relative humidity, temperature and soiling were measured over one year at a UK hospital, enabling realistic parameters to be set for our surface efficacy test. A nebulizer, connected to a cascade impactor, aerosolized and uniformly deposited a Staphylococcus aureus suspension over test copper alloys and control stainless steel surfaces. Bacteria were enumerated following nebulization, and after a range of contact times, under [20 degrees C, 50% RH] and [20 degrees C, 40% RH] parameters reflecting in-use conditions; [37 degrees C, 100% RH] was employed to reflect conditions used in ISO22196. FINDINGS: All copper alloys produced a &gt;4 log10 reduction after 24h under all conditions tested. Copper alloys were more effective at [37 degrees C, 100% RH] showing a &gt;4 log10 reduction after 30 min than at in-use conditions [20 degrees C, 50% RH and 20 degrees C, 40% RH], for which 60 min was required to achieve the same level of kill, for most but not all alloys. CONCLUSION: The use of the nebulizer to deposit bacterial inocula on surfaces showed little variability in results. Our method was more discriminatory than the ISO22196 enabling distinction between the bactericidal surface activity, which allows for a more rigorous selection of antimicrobial surfaces for potential use in healthcare settings.</style></abstract><notes><style face="normal" font="default" size="100%">1532-2939&#xD;Ojeil, M&#xD;Jermann, C&#xD;Holah, J&#xD;Denyer, S P&#xD;Maillard, J-Y&#xD;Evaluation Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2013 Dec;85(4):274-81. doi: 10.1016/j.jhin.2013.08.007. Epub 2013 Sep 18.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2013.08.007</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>340</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">340</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kambali, M. M.</style></author><author><style face="normal" font="default" size="100%">Naim, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.M. Kambali, Pusat Darah Negara, Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of non-invasive haemoglobinometer for haemoglobin screening of blood donors, national blood centre, Malaysia</style></title><secondary-title><style face="normal" font="default" size="100%">Vox Sanguinis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Vox Sanguinis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">81-82</style></pages><volume><style face="normal" font="default" size="100%">107</style></volume><keywords><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">copper sulfate</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">blood donor</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">Malaysia</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">blood transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">hematology</style></keyword><keyword><style face="normal" font="default" size="100%">organization</style></keyword><keyword><style face="normal" font="default" size="100%">donor</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">fear</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">venous blood</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">capillary blood</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">visual system</style></keyword><keyword><style face="normal" font="default" size="100%">clip</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">non invasive procedure</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">standard</style></keyword><keyword><style face="normal" font="default" size="100%">biosafety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0042-9007</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Pre-donation haemoglobin (Hb) screening is done to safeguard the blood donor by preventing anaemic donors from donating and to ensure the quality of the collected blood unit. Hemocue and Copper Sulphate methods are routinely used for this purpose; however there are risks of infection, fear that can lead to post donation adverse reactions and consequently reduce return donor rate. The use of a non-invasive haemoglobinometer is safe as there is no biohazard risk and should allay fear among donors, with a subsequent increase in donor recruitment. Aims: To evaluate a non-invasive haemoglobinometer for haemoglobin screening of blood donors in the National Blood Centre, Malaysia. Methods: The number of participants in this study was 217 blood donors who presented themselves for blood donation at the National Blood Centre, Kuala Lumpur, Malaysia from 1 July to 31 December 2013. Each blood donor&apos;s Hb was determined using a non-invasive finger-clip probe haemoglobinometer using Haemospect (MBR Optical Systems GmbH &amp; Co. KG, Wuppertal, Germany) as per manufacturers&apos; instruction, followed by fingerprick capillary blood test using Hemocue 301 (Hemo-cue AB, Angelholm, Sweden) and subsequently a venous blood test done in the laboratory using Beckman Coulter LH750 (Beckman Coulter Inc., Brea, CA, USA). The venous test result was used as the reference standard. Results: Hb tests were carried out on 217 donors; 99 male and 118 female. There were 197 with an acceptable Hb (Hb &gt; 12.5 g/dl) as determined by venous sample testing in the laboratory using Beckman Coulter. Bland Altman analysis of Haemospect and Beckman Coulter showed a bias of 0.17 g/dl, standard deviation of differences (SDD) of 1.32% and 95% limits of agreement from-2.46 to 2.81. Comparison of Hemocue and Beckman Coulter showed a bias of-0.23 g/dl, SDD of 0.66% and 95% limits of agreement from-1.54 to 1.08. HemoCue was found to be the most sensitive technique (sensitivity 100.0%) while Haemospect sensitivity was 92.9% (7.1% acceptable donors were falsely deferred). However, Haemospect specificity (30%) was twice that of Hemocue (15%). This means that Haemospect is more accurate in determining unacceptable donors, compared to Hemocue. Summary/Conclusions: Based on our results, the performance of Haemospect is comparable to Hemocue. In the blood donation setting, deferring low Hb donors is more important than falsely deferring acceptable donors, as in so doing, the health of the donor is safeguarded. Even though Haemospect found only 92.9% of donors acceptable for donation, when compared to Hemocue which found 100% suitable, it prevented 30% of low Hb donors from donation while Hemocue only prevented 15%. Given the benefits of a non-invasive method, we suggest that it can be used as the first line pre-donation Hb screening method. When a donor fails the Haemospect test, the Hb test should be determined again, using Hemocue to prevent false deferrals.</style></abstract><notes><style face="normal" font="default" size="100%">L71501162&#xD;2014-06-26</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71501162</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/vox.12155</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/vox.12155</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moussa, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynecology, Alazhar School of Medicine, Cairo, Egypt. amoussa77@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of postabortion IUD insertion in Egyptian women</style></title><secondary-title><style face="normal" font="default" size="100%">Contraception</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contraception</style></full-title></periodical><pages><style face="normal" font="default" size="100%">315-7</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2001/10/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Abortion, Spontaneous</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Aftercare</style></keyword><keyword><style face="normal" font="default" size="100%">Egypt</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Device Expulsion</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine Hemorrhage/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0010-7824 (Print)&#xD;0010-7824</style></isbn><accession-num><style face="normal" font="default" size="100%">11672553</style></accession-num><abstract><style face="normal" font="default" size="100%">This study was carried out at Alhussein University Hospital and Elmonera General Hospital to assess the safety and efficacy of intrauterine device (IUD) insertion immediately after spontaneous abortion compared with insertion 2 weeks after abortion. One hundred women between ages 18 and 40 years were recruited from those admitted via the emergency room with first trimester spontaneous abortion. All women were counseled about a method of contraception, particularly copper T-380, and divided into two groups: Group I, which included 69 women who preferred immediate IUD insertion, and Group II, which included 31 women who asked for late IUD insertion 2 weeks after an abortion. All women were followed at 2, 6, and 10 weeks after insertion of IUDs. Bleeding patterns were comparable in both groups. Mild bleeding occurred in 9.2% and 16% in Groups I and II, respectively; moderate bleeding occurred in 80% and 64%, respectively, and severe bleeding was observed in 10.8% and 20%, respectively. This was not significant. Expulsion rate was 4.5% and 3.4% in Groups I and II, respectively, which was also not significant. There were no cases of perforation or pelvic infections. This study showed that insertion of an IUD immediately after a spontaneous abortion is safe and could be offered to those who have had an abortion and who ask for a method of contraception.</style></abstract><notes><style face="normal" font="default" size="100%">Moussa, A&#xD;Journal Article&#xD;United States&#xD;Contraception. 2001 Jun;63(6):315-7. doi: 10.1016/s0010-7824(01)00206-2.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0010-7824(01)00206-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Al-Samarrai, A. H.</style></author><author><style face="normal" font="default" size="100%">Adaay, M. H.</style></author><author><style face="normal" font="default" size="100%">Al-Tikriti, K. A.</style></author><author><style face="normal" font="default" size="100%">Al-Anzy, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, College of Medicine, University of Tikrit, Tikrit, Iraq.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of some essential element levels in thalassemia major patients in Mosul district, Iraq</style></title><secondary-title><style face="normal" font="default" size="100%">Saudi Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Saudi Med J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">94-7</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2008/01/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Iraq</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Trace Elements/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/blood</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Thalassemia/*blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0379-5284 (Print)&#xD;0379-5284</style></isbn><accession-num><style face="normal" font="default" size="100%">18176681</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To evaluate the levels of some essential elements in thalassemic patients in Mosul, Iraq. METHODS: One hundred and five thalassemic blood transfusion dependent children, 2.5-18 years of age attending Ibn-Al-Atheer teaching hospital in Mosul City, Iraq, during 2005, were used in this study. Fifty-four healthy subjects served as a control group. Patients were allocated in a non-randomized prospective cross-sectional hospital based study. Essential elements levels were estimated. The mean, standard deviation, correlation coefficient, and z-test were used. P-values &lt;0.05 were considered statistically significant. RESULTS: Low serum zinc, and magnesium, and high serum copper, and potassium levels were found among the 105 thalassemic patients compared to the 54 controls. Levels of calcium, phosphate, and sodium were within normal limits. CONCLUSION: Fluctuations in the essential elements levels seem to be related to the different complications associated with the disease. Zinc deficiency may be attributed to hyperzincuria resulted from the release of Zn from hemolyzed red cells. Hypercupremia occurs in acute and chronic infections and hemochromatosis, which is a principal complication of thalassemia. Increased Na levels may be due to renal damage. Hypomagnesemia may occur due to hypoparathyroidism.</style></abstract><notes><style face="normal" font="default" size="100%">Al-Samarrai, Abdulmunaim H&#xD;Adaay, Mohaisen H&#xD;Al-Tikriti, Khudhair A&#xD;Al-Anzy, Muayed M&#xD;Journal Article&#xD;Saudi Arabia&#xD;Saudi Med J. 2008 Jan;29(1):94-7.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>414</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">414</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karpanen, T. J.</style></author><author><style face="normal" font="default" size="100%">Casey, A. L.</style></author><author><style face="normal" font="default" size="100%">Lambert, P. A.</style></author><author><style face="normal" font="default" size="100%">Cookson, B. D.</style></author><author><style face="normal" font="default" size="100%">Nightingale, P.</style></author><author><style face="normal" font="default" size="100%">Miruszenko, L.</style></author><author><style face="normal" font="default" size="100%">Elliott, T. S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T.J. Karpanen, University Hospitals, Birmingham NHS Foundation Trust, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">An evaluation of the antimicrobial properties of healthcare fomites (furnishings and equipment) made of copper alloys</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S34</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><keywords><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">fomite</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">microorganism</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">pathogen load</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">health care personnel</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Pathogens, such as meticillin resistant Staphylococcus aureus colonise the healthcare environment and survive on surfaces for extended periods. Following cleaning, the surfaces become re-contaminated rapidly due to lack of residual antimicrobial activity of many cleaning agents. Furthermore, the hands of the healthcare workers become readily contaminated with pathogens,when touching surfaces or patients. The use of copper, which has demonstrated continuous antimicrobial activity, may therefore play a part in reducing healthcare-associated infections. Aims/Objectives: The aim of this study was to evaluate the antimicrobial efficacy of copper alloys in the clinical environment. Methods: An acute medical ward at a University Hospital was fitted with copper alloy furnishings and equipment, including door push plates; door pull handles; door lever handles; grab rails; tap handles; dressing trolleys; commodes; patient&apos;s overbed tables; toilet seats; toilet flush lever handles; light switches and sockets. The surfaces of the items were sampled once weekly for three months by swabbing. The total aerobic colony counts were determined and the number of microorganisms on the copper alloy surfaces were compared against the number on equivalent standard items on the same ward. Results: There was a significant reduction in the number of microorganisms on copper alloy: door pull handles (p &lt; 0.0001), door push plates (p = 0.0003), tap handles (p = 0.0004), toilet flush lever handles (p = 0.035), patient over-bed tables [p = 0.004 (brass), p = 0.001 (copper sprayed)], dressing trolley (p = 0.042) and sockets (p = 0.047). For all the other copper alloy items, there were nonsignificant reductions in microbial load compared to standard items. Conclusions: On a busy medical ward, copper alloy frequent-touch surfaces were associated with a lower microbial load than standard equivalent items. Copper surfaces may therefore, be a valuable tool in preventing healthcare-associated infection.</style></abstract><notes><style face="normal" font="default" size="100%">L70386677&#xD;2011-04-16</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70386677</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>271</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knoblauch, A. M.</style></author><author><style face="normal" font="default" size="100%">Divall, M. J.</style></author><author><style face="normal" font="default" size="100%">Owuor, M.</style></author><author><style face="normal" font="default" size="100%">Nduna, K.</style></author><author><style face="normal" font="default" size="100%">Ng&apos;uni, H.</style></author><author><style face="normal" font="default" size="100%">Musunka, G.</style></author><author><style face="normal" font="default" size="100%">Pascall, A.</style></author><author><style face="normal" font="default" size="100%">Utzinger, J.</style></author><author><style face="normal" font="default" size="100%">Winkler, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.M. Knoblauch, Swiss Tropical and Public Health Institute, P.O. Box, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Experience and lessons from health impact assessment guiding prevention and control of HIV/AIDS in a copper mine project, northwestern Zambia</style></title><secondary-title><style face="normal" font="default" size="100%">Infectious Diseases of Poverty</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infectious Diseases of Poverty</style></full-title></periodical><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">acquired immune deficiency syndrome nursing</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">community care</style></keyword><keyword><style face="normal" font="default" size="100%">condom distribution</style></keyword><keyword><style face="normal" font="default" size="100%">condom use</style></keyword><keyword><style face="normal" font="default" size="100%">counseling</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">health education</style></keyword><keyword><style face="normal" font="default" size="100%">health hazard</style></keyword><keyword><style face="normal" font="default" size="100%">health impact assessment</style></keyword><keyword><style face="normal" font="default" size="100%">HIV test</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">public health campaign</style></keyword><keyword><style face="normal" font="default" size="100%">sexually transmitted disease</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword><keyword><style face="normal" font="default" size="100%">Zambia</style></keyword><keyword><style face="normal" font="default" size="100%">Alere Determine HIV-1/2</style></keyword><keyword><style face="normal" font="default" size="100%">UniGold HIV</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">2049-9957</style></isbn><abstract><style face="normal" font="default" size="100%">Background: To avoid or mitigate potential project-related adverse health effects, the Trident copper project in Kalumbila, northwestern Zambia, commissioned a health impact assessment. HIV was identified a priority health issue based on the local vulnerability to HIV transmission and experience from other mining projects in Africa. Hence, an HIV/AIDS management plan was developed, including community and workplace interventions, with HIV testing and counselling (HTC) being one of the key components. We present trends in HTC data over a 4-year period. Methods: In 13 communities affected by the Trident project, HTC was implemented from 2012 onwards, using rapid diagnostic tests, accompanied by pre- and post-test counselling through trained personnel. In addition, HTC was initiated in the project workforce in 2013, coinciding with the launch of the mine development. HTC uptake and HIV positivity rates were assessed in the study population and linked to demographic factors using regression analysis. Results: In total, 11,638 community members and 5564 workers have taken up HTC with an increase over time. The HIV positivity rate in the community was 3.0% in 2012 and 3.4% in 2015, while positivity rate in the workforce was 5.2% in 2013 and 4.3% in 2015. Females showed a significantly higher odds of having a positive test result than males (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.55-2.50 among women in the community and OR = 2.90, 95% CI: 1.74-4.84 among women in the workforce). HTC users in the 35-49 years age group were most affected by HIV, with an average positivity rate of 6.6% in the community sample and 7.9% in the workforce sample. These study groups had 4.50 and 4.95 higher odds of being positive, respectively, compared to their younger counterparts (15-24 years). Conclusions: While HTC uptake increased five-fold in the community and almost three-fold in the workplace, the HIV positivity rates were insignificantly higher in 2015 compared to 2012. Our data can be used alongside other surveillance data to track HIV transmission in this specific context. Guided by the health impact assessment, the HIV prevention and control programme was readily adapted to the current setting through the identification of socioeconomic and environmental determinants of health.</style></abstract><notes><style face="normal" font="default" size="100%">L617088063&#xD;2017-07-11&#xD;2017-07-13</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L617088063</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s40249-017-0320-4</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">Alere Determine HIV-1/2&#xD;UniGold HIV(Trinity Biotech,Ireland)</style></custom3><custom4><style face="normal" font="default" size="100%">Trinity Biotech(Ireland)</style></custom4><custom5><style face="normal" font="default" size="100%">28673329</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s40249-017-0320-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Special Pathogens Laboratory, Veterans Affairs Medical Center, Pittsburg, Pennsylvania 15240, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Experiences of the first 16 hospitals using copper-silver ionization for Legionella control: implications for the evaluation of other disinfection modalities</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">563-8</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">2003/08/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Centers for Disease Control and Prevention, U.S.</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Evaluation Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/etiology/*prevention &amp; control/transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance and Engineering, Hospital/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/*methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">12940575</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND OBJECTIVES: Hospital-acquired legionnaires&apos; disease can be prevented by disinfection of hospital water systems. This study assessed the long-term efficacy of copper-silver ionization as a disinfection method in controlling Legionella in hospital water systems and reducing the incidence of hospital-acquired legionnaires&apos; disease. A standardized, evidence-based approach to assist hospitals with decision making concerning the possible purchase of a disinfection system is presented. DESIGN: The first 16 hospitals to install copper-silver ionization systems for Legionella disinfection were surveyed. Surveys conducted in 1995 and 2000 documented the experiences of the hospitals with maintenance of the system, contamination of water with Legionella, and occurrence of hospital-acquired legionnaires&apos; disease. All were acute care hospitals with a mean of 435 beds. RESULTS: All 16 hospitals reported cases of hospital-acquired legionnaires&apos; disease prior to installing the copper-silver ionization system. Seventy-five percent had previously attempted other disinfection methods including superheat and flush, ultraviolet light, and hyperchlorination. By 2000, the ionization systems had been operational from 5 to 11 years. Prior to installation, 47% of the hospitals reported that more than 30% of distal water sites yielded Legionella. In 1995, after installation, 50% of the hospitals reported 0% positivity, and 43% still reported 0% in 2000. Moreover, no cases of hospital-acquired legionnaires&apos; disease have occurred in any hospital since 1995. CONCLUSIONS: This study represents the final step in a proposed 4-step evaluation process of disinfection systems that includes (1) demonstrated efficacy of Legionella eradication in vitro using laboratory assays, (2) anecdotal experiences in preventing legionnaires&apos; disease in individual hospitals, (3) controlled studies in individual hospitals, and (4) validation in confirmatory reports from multiple hospitals during a prolonged time (5 to 11 years in this study). Copper-silver ionization is now the only disinfection modality to have fulfilled all four evaluation criteria.</style></abstract><notes><style face="normal" font="default" size="100%">Stout, Janet E&#xD;Yu, Victor L&#xD;Journal Article&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2003 Aug;24(8):563-8. doi: 10.1086/502251.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/502251</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>504</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">504</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kullander, S.</style></author><author><style face="normal" font="default" size="100%">Kallen, B.</style></author><author><style face="normal" font="default" size="100%">Sandahl, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. Obstet. Gynaecol., Malmo Gen. Hosp., Malmo</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exposure to drugs and other possibly harmful factors during the first trimester of pregnancy. Comparison of two prospective studies performed in Sweden 10 years apart</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Obstetricia et Gynecologica Scandinavica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Obstetricia et Gynecologica Scandinavica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-405</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">analgesic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antiemetic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antihistaminic agent</style></keyword><keyword><style face="normal" font="default" size="100%">antiinflammatory agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">hormone</style></keyword><keyword><style face="normal" font="default" size="100%">oral contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">psychedelic agent</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">congenital malformation</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">fetus</style></keyword><keyword><style face="normal" font="default" size="100%">gestational age</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">radiation injury</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword><keyword><style face="normal" font="default" size="100%">spontaneous abortion</style></keyword><keyword><style face="normal" font="default" size="100%">tobacco</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1976</style></year></dates><isbn><style face="normal" font="default" size="100%">0001-6349</style></isbn><abstract><style face="normal" font="default" size="100%">474 women in mid pregnancy interviewed at ten different hospitals in Sweden, were questioned on a number of social and medical items: e.g., drug use, contraceptive technique used before pregnancy, exposure to possibly deleterious factors in the environment. The study, compared with a similar study made ten years earlier in Sweden, showed little or no difference in the use of iron and/or vitamin preparations, analgesic drugs, antibiotics, or endocrine drugs; but a drastic reduction is noted in the use of psychotropic drugs and of antihistaminic drugs. A marked decrease in frequency of first trimester X ray exposures can be found, but no marked changes in smoking habits. Appr. 18% of the women used contraceptive pills within 6 months of becoming pregnant 3 had used them during early pregnancy. About 4% (18 women) had used IUD one became pregnant with a Cu IUD (intra uterine device inpregnated with copper). This type of study can provide some information on the prevalence of relatively common factors, but it must be considerably extended in order to permit an analysis of rare events, e.g., use of most drugs.</style></abstract><notes><style face="normal" font="default" size="100%">L7216347&#xD;1977-01-01</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L7216347</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">11632</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Volling, C.</style></author><author><style face="normal" font="default" size="100%">Anceva-Sami, S.</style></author><author><style face="normal" font="default" size="100%">Boyd, D.</style></author><author><style face="normal" font="default" size="100%">Coleman, B.</style></author><author><style face="normal" font="default" size="100%">Downing, M.</style></author><author><style face="normal" font="default" size="100%">Hota, S.</style></author><author><style face="normal" font="default" size="100%">Jamal, A.</style></author><author><style face="normal" font="default" size="100%">Johnstone, J.</style></author><author><style face="normal" font="default" size="100%">Katz, K.</style></author><author><style face="normal" font="default" size="100%">Leis, J.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Factors associated with aerosolization of gammaproteobacteria from intensive care unit (ICU) sinks in a randomized trial of Copper alloy vs. standard chrome sink drains</style></title><secondary-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S440‐</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*Gammaproteobacteria</style></keyword><keyword><style face="normal" font="default" size="100%">*aerosol</style></keyword><keyword><style face="normal" font="default" size="100%">*intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Air sampling</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial growth</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">Binomial distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Cotton</style></keyword><keyword><style face="normal" font="default" size="100%">Drain</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Effect size</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Human cell</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">Patient risk</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02076068</style></accession-num><abstract><style face="normal" font="default" size="100%">Background. Hospital wastewater environments are recognized as reservoirs for multi‐drug‐resistant bacteria, and sink drains in ICUs have been implicated in numerous outbreaks. The mechanism of pathogen transmission to patients, and the best approach to risk mitigation remains unclear. We tested a new copper alloy sink drain for its effect on detection of gammaproteobacteria in sink drains and adjacent aerosols. Methods. We randomized 90 sinks in 76 ICU rooms/bedspaces in 7 ICUs to new standard chrome or copper alloy drains. We sampled sinks on 4 occasions over 4 months. Drain tailpieces were sampled using cotton swabs of 140 cm2 of the interior surface, inserted into 1mL of Dey‐Engley neutralizing broth, and cultured semi‐quantitatively for gammaproteobacteria on Mac3CV. 850L samples of air adjacent to sinks were obtained by impaction onto Mac3CV. Faucet swabs were also cultured. Multivariable analysis adjusting for factors associated with growth in air and drains used conditional logistic regression, GEE with an exchangeable correlation matrix, a robust estimate of variance, negative binomial distribution and log link function. Results. Gammaproteobacteria were detected in 247/424 (58%) tailpiece swabs, 137/456 (30%) air samples, and 31/456 (7%) faucet swabs. In multivariable analysis, growth was less likely from air adjacent to sinks with copper vs. chrome drains [IRR 0.50 (95% CI 0.35, 0.73), P &lt; 0.0001], with reduced effect size observed when drain growth was included in the model [IRR 0.64 (95% CI 0.43, 0.94)], P = 0.025]. Growth in air was more likely when drain growth was 1‐899 cfu/cm2 [IRR 2.38 (95% CI 1.46, 3.88), P = 0.001] or â‰¥900 cfu/cm2 [IRR 3.55 (95% CI 1.87, 6.86), P &lt; 0.001] vs. no growth. Tailpiece swab growth was more likely if rooms were occupied compared with empty [IRR 1.85 (95% CI 1.25, 2.76), P = 0.002], and less likely from copper drains compared with swabs from chrome drains [IRR 0.51 (95% CI 0.47, 0.75), P â‰¤ 0.001]. Conclusion. Sinks with new copper drains are less likely to have detectable gammaproteobacteria in adjacent air when compared with standard chrome drains, and results suggest this is mediated through reduced bacterial growth in the drains. Ongoing study is needed to determine whether this influences patient risk for hospital‐acquired infection.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal: Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02076068/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 630694210</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofz360.1087</style></electronic-resource-num></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>412</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">412</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Köstü, M.</style></author><author><style face="normal" font="default" size="100%">Aktar, F.</style></author><author><style face="normal" font="default" size="100%">Kirimi, E.</style></author><author><style face="normal" font="default" size="100%">Ozkol, H.</style></author><author><style face="normal" font="default" size="100%">Tuluce, Y.</style></author><author><style face="normal" font="default" size="100%">Akdeniz, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Köstü, Yuzuncu Yil University, Faculty of Medicine, Department of Neonatology, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fairly successful treatment of a patient with sulfur metabolism disorder and a new look to molybdenum metabolism</style></title><secondary-title><style face="normal" font="default" size="100%">Early Human Development</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Early Human Development</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S37</style></pages><volume><style face="normal" font="default" size="100%">86</style></volume><keywords><keyword><style face="normal" font="default" size="100%">molybdenum</style></keyword><keyword><style face="normal" font="default" size="100%">sulfur</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">biperiden</style></keyword><keyword><style face="normal" font="default" size="100%">vigabatrin</style></keyword><keyword><style face="normal" font="default" size="100%">clonazepam</style></keyword><keyword><style face="normal" font="default" size="100%">sulfite oxidase</style></keyword><keyword><style face="normal" font="default" size="100%">acetylcysteine</style></keyword><keyword><style face="normal" font="default" size="100%">phenobarbital</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">gluconate copper</style></keyword><keyword><style face="normal" font="default" size="100%">mineral</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic disorder</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">health care organization</style></keyword><keyword><style face="normal" font="default" size="100%">convulsion</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">copper deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">motor dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">copper metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">skill</style></keyword><keyword><style face="normal" font="default" size="100%">hypoxia</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">neonatology</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">muscle hypotonia</style></keyword><keyword><style face="normal" font="default" size="100%">body fat</style></keyword><keyword><style face="normal" font="default" size="100%">hypothermia</style></keyword><keyword><style face="normal" font="default" size="100%">amylase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">lung infection</style></keyword><keyword><style face="normal" font="default" size="100%">wheezing</style></keyword><keyword><style face="normal" font="default" size="100%">metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">diet</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient department</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system</style></keyword><keyword><style face="normal" font="default" size="100%">nervous system malformation</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0378-3782</style></isbn><abstract><style face="normal" font="default" size="100%">Aim: In this case report we present a new therapeutic approach for sulfur metabolism disorders: isolated sulphite oxidase deficiency and molybdenum cofactor deficiency. Case presentation In our neonatology clinic we followed an infant with isolated sulphite oxidase deficiency. We realized that although serum copper of our patient was twice the control value, he had copper deficiency findings: hypotonia, increased body fat mass, hypothermia, decreased serum amylase levels, and intractable convulsions. After the institution of copper gluconate therapy (2 mg/day), his convulsions stopped. We had to administer biperiden for extrapyramidal movement disorder probably caused by secondary manganese toxicity. For complete control of convulsions we had to add phenobarbital, vigabatrin and clonazepam to his drug regimen. He regained some of his psychosocial skills but repeated neurological decompensations secondary to lung infections and wheezing episodes caused loss of these skills again each time. Adding N-acetylcysteine to his drug regimen effectively prevented these metabolic decompensations. We tried every effort to avoid sulfur metabolites from our drug regimen and diet to prevent acute decompensations. He is now8 months old and free of major convulsive episodes but his extrapyramidal movement disorder continues in a decreased intensity. He is followed-up at the outpatient clinic. Conclusion: Our interventions have shown us that sulfur, molybdenum and copper metabolisms are closely interrelated and although there are complex interactions etiopathogenesis of sulfur metabolism disorders can be explained by the impairment of metabolisms of minerals more than molybdenum: copper and manganese. Our results showed us that central nervous system abnormalities of these disorders seem to be the result of severe secondary copper deficiency which causes global cellular hypoxia in the metabolism. Copper, biperiden, phenobarbital, vigabatrin, clonazepam and N-acetylcysteine were relatively effective for the prevention of acute neurological decompensations. Unfortunately we had begun copper therapy to our patient after 3-4 weeks of intractable convulsions. If our therapy protocol can be instituted in early periods of sulfur metabolism disorders, better neurological results should be possible. Lastly all clinical and laboratory results of this therapeutic intervention and review of the literature data about sulfur, molybdenum and copper metabolisms had let us think that copper should have a direct role in the function of molybdoenzymes.</style></abstract><notes><style face="normal" font="default" size="100%">L70309624&#xD;2010-12-10</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70309624</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.earlhumdev.2010.09.101</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.earlhumdev.2010.09.101</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>337</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">337</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Collyer, E.</style></author><author><style face="normal" font="default" size="100%">Kay, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Collyer, Cleveland Clinic Children&apos;s, Cleveland, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fluoxetine-induced transaminitis in an adolescent patient</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S469</style></pages><volume><style face="normal" font="default" size="100%">109</style></volume><keywords><keyword><style face="normal" font="default" size="100%">fluoxetine</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">cytochrome P450</style></keyword><keyword><style face="normal" font="default" size="100%">cytochrome</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">paracetamol</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrion antibody</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">alpha 1 antitrypsin</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertransaminasemia</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">college</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenterology</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">parameters</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">irritable colon</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">psychiatric diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">hepatomegaly</style></keyword><keyword><style face="normal" font="default" size="100%">jaundice</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">examination</style></keyword><keyword><style face="normal" font="default" size="100%">toxic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">drug toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">liver biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis virus</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">travel</style></keyword><keyword><style face="normal" font="default" size="100%">urine</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">appendectomy</style></keyword><keyword><style face="normal" font="default" size="100%">patient history of cholecystectomy</style></keyword><keyword><style face="normal" font="default" size="100%">soft contact lens</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0002-9270</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Fluoxetine (FLX) is a commonly prescribed medication in children used for many psychiatric diagnoses. Reported adverse gastrointestinal effects of fluoxetine include nausea, vomiting, and abdominal pain. Hepatitis is a rare but potentially serious adverse effect of FLX reported in the adult literature. Case Report: A 15-year-old male with history of irritable bowel syndrome and prior cholecystectomy and appendectomy presented to PCP for anxiety and behavioral difficulties. He was started on FLX 20 mg PO daily. After 3 weeks, dose was increased to 40 mg daily. One week after increasing the dose, he presented to emergency department with 2-day history of severe nonradiating right upper quadrant (RUQ) abdominal pain and worsening of baseline diarrhea. He was afebrile and had no travel or risks for hepatitis viruses. On examination, no jaundice, but + marked tenderness in the RUQ without hepatomegaly. The remainder of exam was normal. Liver US was normal. Lab evaluation revealed ALT of 454 U/L, AST 394 U/L, total bilirubin 1.6 mg/dL, and alkaline phosphatase of 153 U/L. One year prior, all laboratory parameters were normal. The remainder of the work-up for acute transaminitis including hepatitis panel, EBV, CMV, ceruloplasmin, 24-hour urine copper determination, celiac screening, acetaminophen level, serum alpha-1 antitrypsin, serum CK, anti-LKM antibodies, and anti-mitochondrial antibodies were negative. He was admitted to the hospital for 2 days for work-up, pain control, and monitoring. Due to suspicion of drug-induced liver injury (DILI), FLX was discontinued. He had marked improvement of his RUQ abdominal pain within 1 week of discharge. His AST, ALT, and total bilirubin normalized completely after 3 months. Discussion: Though this adverse drug reaction has been reported in adults previously, there are no reports of this complication in pediatric patients to date. FLX is metabolized in the liver via the cytochrome P450 system. The definitive mechanism by which FLX exerts hepatotoxic effects is unknown; however, lab abnormalities suggest a hepatocellular type of injury. Management of DILI includes early recognition of drug toxicity and withdrawal of the offending agent. When stopping any agent suspected of causing DILI, patients should be followed with serial laboratory monitoring until laboratory parameters normalize. Though DILI is a clinical diagnosis, in rare cases, liver biopsy may be indicated if the cause of hepatitis cannot be elucidated. Conclusion: Clinicians should be aware of this rare but potentially serious adverse reaction. With an estimated 24.4 million FLX prescriptions in 2011, this adverse effect should be considered in patients with similar symptoms recently started on FLX.</style></abstract><notes><style face="normal" font="default" size="100%">L71750488&#xD;2015-02-03</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71750488</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1038/ajg.2014.279</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/ajg.2014.279</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rohr, U.</style></author><author><style face="normal" font="default" size="100%">Senger, M.</style></author><author><style face="normal" font="default" size="100%">Selenka, F.</style></author><author><style face="normal" font="default" size="100%">Turley, R.</style></author><author><style face="normal" font="default" size="100%">Wilhelm, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut fur Hygiene und Mikrobiologie, Abteilung fur Hygiene, Sozial- und Umweltmedizin, RuhrUniversitat Bochum, Universitatsstr. 44801 Bochum, Germany. rohr@hygiene.ruhr-uni-bochum.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Four years of experience with silver-copper ionization for control of legionella in a german university hospital hot water plumbing system</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1507-11</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">1999/12/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chlorine/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Dose-Response Relationship, Drug</style></keyword><keyword><style face="normal" font="default" size="100%">Germany</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, University</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">10585804</style></accession-num><abstract><style face="normal" font="default" size="100%">Silver-copper ionization was used for controlling Legionella distribution in a German university hospital hot water plumbing system for 4 years. In the beginning, silver concentrations were not allowed to exceed 10 microg/L because of drinking water regulation limits in Germany. Water samples were monitored for Legionella counts, temperature, and silver and copper concentrations. A significant (P&lt;.001) 3.8-log reduction of Legionella counts, from 40, 000 cfu/L to 7 cfu/L, was found during the first year with silver-copper ionization. Nevertheless, the long-term efficacy of silver concentrations &lt;10 ,++microg/L was not sufficient. Legionella counts increased to 10,000 cfu/L during the third year. During the fourth year, we studied the influence of higher silver concentrations on Legionella distribution. With an average silver level of 30 microg/L, only a 1.3-log reduction in Legionella, to 500 cfu/L, was achieved. The effect was not significant (P=.071); therefore, it must be considered that Legionella developed a tolerance to silver ions.</style></abstract><notes><style face="normal" font="default" size="100%">Rohr, U&#xD;Senger, M&#xD;Selenka, F&#xD;Turley, R&#xD;Wilhelm, M&#xD;Comparative Study&#xD;Journal Article&#xD;United States&#xD;Clin Infect Dis. 1999 Dec;29(6):1507-11. doi: 10.1086/313512.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/313512</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>473</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">473</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pérez Lucas, R.</style></author><author><style face="normal" font="default" size="100%">Salamanca Ballesteros, A.</style></author><author><style face="normal" font="default" size="100%">Marchal Corrales, G.</style></author><author><style face="normal" font="default" size="100%">Barranco Castillo, E.</style></author><author><style face="normal" font="default" size="100%">Picazos Vicente, P.</style></author><author><style face="normal" font="default" size="100%">Clavero Salvador, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. Pérez Lucas, Servicio de Obst. y Gine, Hospital Clínico San Cecilio, Av/ Madrid s/n, 18012 Granada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Frequency of actinomyces colonization in non symptomatic carriers of intrauterine devices</style></title><secondary-title><style face="normal" font="default" size="100%">Revista Iberoamericana de Fertilidad y Reproduccion Humana</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista Iberoamericana de Fertilidad y Reproduccion Humana</style></full-title></periodical><pages><style face="normal" font="default" size="100%">357-361</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">amoxicillin plus clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">Actinomyces israelii</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial colonization</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">consultation</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cytopathology</style></keyword><keyword><style face="normal" font="default" size="100%">device removal</style></keyword><keyword><style face="normal" font="default" size="100%">family planning</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">frequency analysis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">metritis</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">Spain</style></keyword><keyword><style face="normal" font="default" size="100%">symptomatology</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><isbn><style face="normal" font="default" size="100%">1132-0249</style></isbn><abstract><style face="normal" font="default" size="100%">Objetive: To analize the frequency and risks factors for the infection by Actinomyces Israelii in carriers of different types of Intrauterine Devices. Material and methods: The poblation of study to include a total of 1295 women that responded for first time to the family planning consultation in the Hospital Universitario San Cecilio of Granada and they performed 9448 revisions, in the period between October 1992 and September1997, among the ones they were inserted a total of 1513 IUDs. We will carry out a descriptive study of the 131 cases of IUDs carriers in whose cytologies were notified the infection sign presence by Actinomyces Israelii and they didn&apos;t have symptoms, considering the type of the IUD, time of insertion, cultivation of the sames after extraction, treatment the ones that were submitted and control cytology after treatment. Results: In our medium the incidence of Actinomyces infection in IUDs carriers is 10% of which, the 56.6% they were carrier more than 5 years. In the 55.7% of the cases, the model of IUD more associate to positive cytology went of high load of copper and the continued conduct after the detection went the use of antibiotic treatment, control cytology and retreat of the IUD if the infection signs persisted. Conclusions:The presence of Actinomyces in the control cytology in IUDs carriers involved the adoption of a therapeutic attitude, in general antibiotics and/or retreat of the device. We didn&apos;t have important complications in this group of women and almost the half of the same would continue utilizing the IUD after the healing.</style></abstract><notes><style face="normal" font="default" size="100%">L36131395&#xD;2003-02-04</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L36131395</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">Spanish</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>325</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Farkas, A. H.</style></author><author><style face="normal" font="default" size="100%">Kraemer, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.H. Farkas, UPMC, Pittsburgh, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gastric bypass... the start of a chain reaction</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S399</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><keywords><keyword><style face="normal" font="default" size="100%">smooth muscle antibody</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">recreational drug</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">gastric bypass surgery</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">internal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">bypass surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">ascites</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol consumption</style></keyword><keyword><style face="normal" font="default" size="100%">leg edema</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">procedures</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol liver cirrhosis</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis A</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">slit lamp</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">fatty liver</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">memory</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol blood level</style></keyword><keyword><style face="normal" font="default" size="100%">drinking behavior</style></keyword><keyword><style face="normal" font="default" size="100%">gastric band</style></keyword><keyword><style face="normal" font="default" size="100%">family history</style></keyword><keyword><style face="normal" font="default" size="100%">leg swelling</style></keyword><keyword><style face="normal" font="default" size="100%">drug use</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">drinking</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVE #1: Recognize the risk of alcohol use disorders (AUD) after gastric bypass surgery LEARNING OBJECTIVE #2: Assess other etiologies for cirrhosis in patients with AUD CASE: A 36 year-old woman with Roux-en-Y gastric bypass 7 years ago presented with worsening ascites and leg edema. She did well after gastric bypass until 1 year ago when she started drinking heavily, progressing to “one-fifth” hard liquor daily. She stopped alcohol use completely 8 months ago after she was diagnosed with Wernicke/Korsak off syndrome. One month ago, she presented to an outside hospital with new ascites. Outside work-up revealed a CTscan with hepatic steatosis and cirrhosis, AST 41 IU/L, ALT 15 IU/ L, negative hepatitis A, B, and C titers, and negative mitochondrial and anti-smooth muscle antibodies. She was diagnosed with alcoholic cirrhosis. Upon presentation to our service, she reported increasing abdominal and leg swelling. Family history included a niece with Wilson&apos;s disease. Our exam revealed ascites, pitting leg edema, and poor shortterm memory. She did not have Kayser-Fleischer rings but no slit-lamp exam was done. A diagnosis of Wilson&apos;s disease was confirmed by laboratory evaluation: ceruloplasmin 13.2 mg/dL (normal 22-58 mg/dL) and 24-h urinary copper 139 ug (normal 20-65 ug). DISCUSSION: With over 1/3 of the US population qualifying as obese1, more patients are being considered for gastric bypass surgery. Evidence suggests that AUD increase after gastric bypass surgery, specifically Roux-en-Y procedures. A prospective cohort study of 1945 adults undergoing gastric bypass surgery found the prevalence of AUD was significantly higher in the second postoperative year (9.6 %) compared to the year prior to surgery (7.6 %, p=0.01)2. Patients who were male, younger, smokers, had regular use of alcohol prior to surgery or prior recreational drug use, had lower sense of belonging, or had Roux-en-Y compared to gastric band procedures were more likely to developAUD. A recent study found that 7 % of patients at year 1 and 6 % of patients at year 2 develop new high risk drinking behaviors following gastric bypass; however the overall rate of AUD was unchanged from baseline3. Gastric bypass, particularly Roux-en-Y, alters alcohol metabolism resulting in higher blood alcohol concentrations and longer time to return to sobriety4-5. This may place patients at risk for developing AUD. While patients are screened for AUD prior to undergoing gastric bypass, it is important to provide education to patients regarding changes in alcohol metabolism after bypass and to continue screening these patients for AUD as they may represent a high risk group. This case also illustrates the importance of assessing for other etiologies of cirrhosis, even in patients with known AUD. In our patient, the relatively brief (&lt;6 months) period of reported heavy alcohol use should have raised suspicion for an additional etiology. Ultimately, she was diagnosed with Wilson&apos;s disease. While her elevated AST/ALT ratio was considered evidence of alcoholic cirrhosis, this ratio is also elevated in Wilson&apos;s disease, particularly in patients with acute liver failure6. In individuals under 40 years-old, Wilson&apos;s disease should be considered as it tends to present at younger ages7. In this patient, the interaction of AUD and Wilson&apos;s disease possibly led to a more accelerated course to cirrhosis. Further, Wilson&apos;s disease may have contributed substantially to her cognitive impairment, which was initially thought to be secondary to gastric bypass-related nutritional deficiencies and AUD.</style></abstract><notes><style face="normal" font="default" size="100%">L71878262&#xD;2015-05-13</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71878262</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, N.</style></author><author><style face="normal" font="default" size="100%">Paknikar, K. M.</style></author><author><style face="normal" font="default" size="100%">Rajwade, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nanobioscience Group, Agharkar Research Institute, G. G. Agarkar Road, Pune, 411 004, Maharashtra, India; Savitribai Phule Pune University, Ganeshkind Road, Pune, 41107, Maharashtra, India.&#xD;Nanobioscience Group, Agharkar Research Institute, G. G. Agarkar Road, Pune, 411 004, Maharashtra, India; Savitribai Phule Pune University, Ganeshkind Road, Pune, 41107, Maharashtra, India. Electronic address: kpaknikar@gmail.com.&#xD;Nanobioscience Group, Agharkar Research Institute, G. G. Agarkar Road, Pune, 411 004, Maharashtra, India; Savitribai Phule Pune University, Ganeshkind Road, Pune, 41107, Maharashtra, India. Electronic address: jrajwade@aripune.org.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gene expression is influenced due to &apos;nano&apos; and &apos;ionic&apos; copper in pre-formed Pseudomonas aeruginosa biofilms</style></title><secondary-title><style face="normal" font="default" size="100%">Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Environ Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">367-375</style></pages><volume><style face="normal" font="default" size="100%">175</style></volume><edition><style face="normal" font="default" size="100%">2019/06/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilms/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Metal Nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Biofilms</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper ions</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">*Gene expression profile</style></keyword><keyword><style face="normal" font="default" size="100%">*Pseudomonas aeruginosa</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0013-9351</style></isbn><accession-num><style face="normal" font="default" size="100%">31153105</style></accession-num><abstract><style face="normal" font="default" size="100%">Today, researchers across the globe suggest the use of antimicrobial coatings containing copper nanoparticles (CuNPs) complementing the traditional protocols to prevent hospital-acquired infections (HAIs). Since Pseudomonas aeruginosa is one of the commonest opportunistic pathogens, we assessed the anti-biofilm activity of CuNPs in P. aeruginosa MTCC 3541 and compared it with Cu(2+) (copper sulphate) since the latter continues to be used as an antimicrobial-of-choice in food industries, agriculture and water treatment. In this study, we synthesized and characterized stable poly-acrylic acid (PAA) coated CuNPs with a size of 66-150nm and zeta potential -13 mV. Pseudomonas aeruginosa MTCC 3541 biofilms were highly resistant to both CuNPs and Cu(2+) (minimum biofilm inhibitory concentration, MBIC 300 and&gt;600mug/mL respectively). Scanning electron microscopy revealed alterations in cell morphology upon treatment with CuNPs. A closer analysis of the biofilm-specific gene expression (qRT-PCR) revealed that CuNPs downregulated the genes involved in biofilm matrix formation, motility, efflux, membrane lipoprotein synthesis and DNA replication. Both, CuNPs and Cu(2+) up regulated copper resistance and biofilm dispersion genes. Copper did not affect the bacterial communication system as evidenced by downregulation of the negative regulator of quorum sensing. The gene expression analysis reveals multiple cellular targets for CuNPs and ionic Cu. The present study highlights the fact that CuNPs affect the membrane functions adversely damaging the cell surface. In pre-formed biofilms, CuNPs were more toxic and displayed distinct responses attributable due to &apos;nano&apos; and &apos;ionic&apos; copper. Our findings thus support the use of CuNPs for curbing HAIs.</style></abstract><notes><style face="normal" font="default" size="100%">1096-0953&#xD;Singh, Nimisha&#xD;Paknikar, Kishore M&#xD;Rajwade, Jyutika&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;Environ Res. 2019 Aug;175:367-375. doi: 10.1016/j.envres.2019.05.034. Epub 2019 May 23.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.envres.2019.05.034</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>333</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stoesser, N.</style></author><author><style face="normal" font="default" size="100%">Giess, A.</style></author><author><style face="normal" font="default" size="100%">Batty, E. M.</style></author><author><style face="normal" font="default" size="100%">Sheppard, A. E.</style></author><author><style face="normal" font="default" size="100%">Walker, A. S.</style></author><author><style face="normal" font="default" size="100%">Wilson, D. J.</style></author><author><style face="normal" font="default" size="100%">Didelot, X.</style></author><author><style face="normal" font="default" size="100%">Bashir, A.</style></author><author><style face="normal" font="default" size="100%">Sebra, R.</style></author><author><style face="normal" font="default" size="100%">Kasarskis, A.</style></author><author><style face="normal" font="default" size="100%">Sthapit, B.</style></author><author><style face="normal" font="default" size="100%">Shakya, M.</style></author><author><style face="normal" font="default" size="100%">Kelly, D.</style></author><author><style face="normal" font="default" size="100%">Pollard, A. J.</style></author><author><style face="normal" font="default" size="100%">Peto, T. E. A.</style></author><author><style face="normal" font="default" size="100%">Crook, D. W.</style></author><author><style face="normal" font="default" size="100%">Donnelly, P.</style></author><author><style face="normal" font="default" size="100%">Thorson, S.</style></author><author><style face="normal" font="default" size="100%">Amatya, P.</style></author><author><style face="normal" font="default" size="100%">Joshi, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N. Stoesser, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae isolates from neonatal infections in a Nepali hospital characterizes the extent of community- Versus hospital- associated transmission in an endemic setting</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7347-7357</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">arsenic</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">kanamycin</style></keyword><keyword><style face="normal" font="default" size="100%">mercury</style></keyword><keyword><style face="normal" font="default" size="100%">neomycin</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">streptomycin</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial mutation</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium isolate</style></keyword><keyword><style face="normal" font="default" size="100%">blood culture</style></keyword><keyword><style face="normal" font="default" size="100%">bloodstream infection</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">community acquired infection</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacter cloacae</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">genetic procedures</style></keyword><keyword><style face="normal" font="default" size="100%">hospital building</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella oxytoca</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Nepal</style></keyword><keyword><style face="normal" font="default" size="100%">newborn</style></keyword><keyword><style face="normal" font="default" size="100%">newborn infection</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">phylogenetic tree</style></keyword><keyword><style face="normal" font="default" size="100%">plasmid</style></keyword><keyword><style face="normal" font="default" size="100%">whole genome sequencing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1098-6596&#xD;0066-4804</style></isbn><abstract><style face="normal" font="default" size="100%">NDM-producing Klebsiella pneumoniae strains represent major clinical and infection control challenges, particularly in re-source- limited settings with high rates of antimicrobial resistance. Determining whether transmission occurs at a gene, plasmid, or bacterial strain level and within hospital and/or the community has implications for monitoring and controlling spread. Whole-genome sequencing (WGS) is the highest-resolution typing method available for transmission epidemiology. We sequenced carbapenem-resistant K. pneumoniae isolates from 26 individuals involved in several infection case clusters in a Nepali neonatal unit and 68 other clinical Gram-negative isolates from a similar time frame, using Illumina and PacBio technologies. Within-outbreak chromosomal and closed-plasmid structures were generated and used as data set-specific references. Three temporally separated case clusters were caused by a single NDM K. pneumoniae strain with a conserved set of four plasmids, one being a 304,526-bp plasmid carrying blaNDM-1. The plasmids contained a large number of antimicrobial/heavy metal resistance and plasmid maintenance genes, which may have explained their persistence. No obvious environmental/human reservoir was found. There was no evidence of transmission of outbreak plasmids to other Gram-negative clinical isolates, although blaNDM variants were present in other isolates in different genetic contexts. WGS can effectively define complex antimicrobial resistance epidemiology. Wider sampling frames are required to contextualize outbreaks. Infection control may be effective in terminating outbreaks caused by particular strains, even in areas with widespread resistance, although this study could not demonstrate evidence supporting specific interventions. Larger, detailed studies are needed to characterize resistance genes, vectors, and host strains involved in disease, to enable effective intervention.</style></abstract><notes><style face="normal" font="default" size="100%">L600572749&#xD;2014-12-05&#xD;2014-12-08</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L600572749</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1128/AAC.03900-14</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">25267672</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.03900-14</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>292</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pop, T. L.</style></author><author><style face="normal" font="default" size="100%">Stefanescu, A.</style></author><author><style face="normal" font="default" size="100%">Grama, A.</style></author><author><style face="normal" font="default" size="100%">Cainap, S.</style></author><author><style face="normal" font="default" size="100%">Andreica, M.</style></author><author><style face="normal" font="default" size="100%">Bizo, A.</style></author><author><style face="normal" font="default" size="100%">Miu, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T.L. Pop, 2nd Pediatric Clinic, University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Cluj, Romania</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hemolytic anemia with acute liver failure in Wilson&apos;s disease in children</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pediatric Gastroenterology and Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pediatric Gastroenterology and Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S346-S347</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><keywords><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease protein</style></keyword><keyword><style face="normal" font="default" size="100%">acute disease</style></keyword><keyword><style face="normal" font="default" size="100%">acute hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">acute liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">adolescence</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">chronic liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical feature</style></keyword><keyword><style face="normal" font="default" size="100%">clinical laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">consensus development</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">emergency</style></keyword><keyword><style face="normal" font="default" size="100%">excretion</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">gene inactivation</style></keyword><keyword><style face="normal" font="default" size="100%">gene mutation</style></keyword><keyword><style face="normal" font="default" size="100%">genetic screening</style></keyword><keyword><style face="normal" font="default" size="100%">girl</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">heterozygosity</style></keyword><keyword><style face="normal" font="default" size="100%">homozygosity</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">liver transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nervous system</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">rest</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1536-4801</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Wilson&apos;s disease is an autosomal, recessive, inherited disorder of copper metabolism with different clinical forms in children: liver, neurological, and rarely, non-immune hemolytic anemia with acute liver failure, but with more severe prognosis. Objective: The aim of our study was to analyze the clinical, laboratory and evolution in children with hemolytic anemia and acute liver failure as presented in the form of Wilson&apos;s disease. Material and Methods: We retrospectively analyzed data from 47 children with Wilson&apos;s disease diagnosed or followed-up in our unit during the last 10 years. The diagnosis was done using clinical features, copper metabolism tests and genetic testing, following the up-to-date Wilson&apos;s disease guidelines. Data were analyzed comparing the patients with acute liver failure and non-immune hemolytic anemia to the patients with other clinical manifestations (acute or chronic liver disease, neurologic disease) for the hepatic parameters, copper metabolism, genetic mutations, treatment and disease evolution. Results: Wilson&apos;s disease was diagnosed in 47 children (26 males, with age between 5 years and 18 years 1 month). Hemolytic anemia with acute liver failure was present at onset in 7 patients (16.27%) and four years after the diagnosis in one non-compliant patient. The other clinical manifestations at presentation were liver disease in 37 patients (78.72%, three of them with autoimmune features and one as acute hepatitis), neurologic in two patients (4.25%) and by screening as a relative of an index case in one patient (2.13%). Molecular analysis of the ATP7B gene revealed the presence of a Wilson&apos;s disease characteristic mutation in 43 patients in homozygous or compound heterozygous status (91.49%). All patients with hemolytic anemia and acute liver failure were girls, with a mean age of 14.95 years (compared with 11.86 years for the rest of the patients), with lower serum ceruloplasmin level (7.98 mg/dL compared with 11.15 mg/dL), higher 24h-urinary copper excretion (2136.4 mcg/24 h compared to 419.46 mcg/24 h). Two of those 8 patients with hemolytic anemia and acute liver failure had fatal evolution (compared with one in the rest of the patients), two received emergency liver transplantation and four received medical treatment with good evolution. Conclusions: The majority of children with Wilson&apos;s disease in our population presented with hepatic manifestations. Hemolytic anemia with acute liver failure was a relatively rare form of onset in our Wilson&apos;s disease patients, frequent in girls, during adolescence, with lower ceruloplasmin level and higher urinary copper excretion and with a severe prognosis in severe cases if emergency liver transplantation was not possible.</style></abstract><notes><style face="normal" font="default" size="100%">L612891797&#xD;2016-11-10</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L612891797</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/01.mpg.0000503536.79797.66</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/01.mpg.0000503536.79797.66</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">48</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leyland, N. S.</style></author><author><style face="normal" font="default" size="100%">Podporska-Carroll, J.</style></author><author><style face="normal" font="default" size="100%">Browne, J.</style></author><author><style face="normal" font="default" size="100%">Hinder, S. J.</style></author><author><style face="normal" font="default" size="100%">Quilty, B.</style></author><author><style face="normal" font="default" size="100%">Pillai, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kastus Technologies, 5 Fitzwilliam Square East, Dublin 2, Ireland.&#xD;Centre for Research in Engineering Surface Technology (CREST), DIT FOCAS Institute, Kevin St, Dublin 8, Ireland.&#xD;The Surface Analysis Laboratory, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.&#xD;School of Biotechnology, Dublin City University, Dublin 9, Ireland.&#xD;Nanotechnology Research Group, Department of Environmental Sciences, Institute of Technology Sligo, Ireland.&#xD;Centre for Precision Engineering, Materials and Manufacturing Research (PEM), Institute of Technology Sligo, Sligo, Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Highly Efficient F, Cu doped TiO2 anti-bacterial visible light active photocatalytic coatings to combat hospital-acquired infections</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title></periodical><pages><style face="normal" font="default" size="100%">24770</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><edition><style face="normal" font="default" size="100%">2016/04/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Catalysis</style></keyword><keyword><style face="normal" font="default" size="100%">Coated Materials, Biocompatible/*chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Fluorides/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Light</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Photoelectron Spectroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">*Titanium/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">X-Ray Diffraction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322</style></isbn><accession-num><style face="normal" font="default" size="100%">27098010</style></accession-num><abstract><style face="normal" font="default" size="100%">Bacterial infections are a major threat to the health of patients in healthcare facilities including hospitals. One of the major causes of patient morbidity is infection with Staphylococcus aureus. One of the the most dominant nosocomial bacteria, Methicillin Resistant Staphylococcus aureus (MRSA) have been reported to survive on hospital surfaces (e.g. privacy window glasses) for up to 5 months. None of the current anti-bacterial technology is efficient in eliminating Staphylococcus aureus. A novel transparent, immobilised and superhydrophilic coating of titanium dioxide, co-doped with fluorine and copper has been prepared on float glass substrates. Antibacterial activity has demonstrated (by using Staphylococcus aureus), resulting from a combination of visible light activated (VLA) photocatalysis and copper ion toxicity. Co-doping with copper and fluorine has been shown to improve the performance of the coating, relative to a purely fluorine-doped VLA photocatalyst. Reductions in bacterial population of log10 = 4.2 under visible light irradiation and log10 = 1.8 in darkness have been achieved, compared with log10 = 1.8 under visible light irradiation and no activity, for a purely fluorine-doped titania. Generation of reactive oxygen species from the photocatalytic coatings is the major factor that significantly reduces the bacterial growth on the glass surfaces.</style></abstract><notes><style face="normal" font="default" size="100%">2045-2322&#xD;Leyland, Nigel S&#xD;Podporska-Carroll, Joanna&#xD;Browne, John&#xD;Hinder, Steven J&#xD;Quilty, Brid&#xD;Pillai, Suresh C&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Sci Rep. 2016 Apr 21;6:24770. doi: 10.1038/srep24770.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4838873</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/srep24770</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>396</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">396</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dancer, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.J. Dancer, Department of Microbiology, Hairmyres Hospital, Eaglesham Road, East Kilbride G75 8RG, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hospital cleaning in the 21st century</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1473-1481</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">biocide</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">detergent</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">silver nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">titanium</style></keyword><keyword><style face="normal" font="default" size="100%">titanium dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">triclosan</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">disease carrier</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">drug coating</style></keyword><keyword><style face="normal" font="default" size="100%">epidemic</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">hospital building</style></keyword><keyword><style face="normal" font="default" size="100%">hospital cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">hospital equipment</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital personnel</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">nursing staff</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">responsibility</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">soil</style></keyword><keyword><style face="normal" font="default" size="100%">staff training</style></keyword><keyword><style face="normal" font="default" size="100%">surface property</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0934-9723&#xD;1435-4373</style></isbn><abstract><style face="normal" font="default" size="100%">More evidence is emerging on the importance of the clinical environment in encouraging hospital infection. This review considers the role of cleaning as an effective means to control infection. It describes the location of pathogen reservoirs and methods for evaluating hospitals&apos; cleanliness. Novel biocides, antimicrobial coatings and equipment are available, many of which have not been assessed against patient outcome. Cleaning practices should be tailored to clinical risk, given the wide-ranging surfaces, equipment and building design. There is confusion between nursing and domestic personnel over the allocation of cleaning responsibilities and neither may receive sufficient training and/or time to complete their duties. Since less labourious practices for dirt removal are always attractive, there is a danger that traditional cleaning methods are forgotten or ignored. Few studies have examined detergent-based regimens or modelled these against infection risk for different patient categories. Fear of infection encourages the use of powerful disinfectants for the elimination of real or imagined pathogens in hospitals. Not only do these agents offer false assurance against contamination, their disinfection potential cannot be achieved without the prior removal of organic soil. Detergent-based cleaning is cheaper than using disinfectants and much less toxic. Hospital cleaning in the 21st century deserves further investigation for routine and outbreak practices. © 2011 Springer-Verlag.</style></abstract><notes><style face="normal" font="default" size="100%">L363103985&#xD;2011-12-23&#xD;2012-01-17</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L363103985</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s10096-011-1250-x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">21499954</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10096-011-1250-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>224</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">224</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kessler, M.</style></author><author><style face="normal" font="default" size="100%">Osman, F.</style></author><author><style face="normal" font="default" size="100%">Pop-Vicas, A. E.</style></author><author><style face="normal" font="default" size="100%">Safdar, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Kessler, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hospital-Acquired Legionella Center. A Case-control Study of Risk Factors</style></title><secondary-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S847-S848</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antigen</style></keyword><keyword><style face="normal" font="default" size="100%">steroid</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">case control study</style></keyword><keyword><style face="normal" font="default" size="100%">chlorination</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">documentation</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">filter</style></keyword><keyword><style face="normal" font="default" size="100%">high risk population</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">molecular typing</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">pulsed field gel electrophoresis</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">smoking</style></keyword><keyword><style face="normal" font="default" size="100%">univariate analysis</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword><keyword><style face="normal" font="default" size="100%">water flow</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">2328-8957</style></isbn><abstract><style face="normal" font="default" size="100%">Background. An outbreak of hospital-acquired Legionella pneumonia, associated with potable water contamination, occurred at our university hospital in November of 2018, despite a longstanding copper-silver ionization system. We conducted a case- control study to examine risk factors for Legionella pneumonia. Methods. We matched controls to cases by dates of admission, hospital ward, and admitting service, in a 4:1 ratio. We reviewed patient charts for potential risk factors and exposures, and summarized demographic information using descriptive analyses. Univariate and multiple logistic regression analyses were also performed. We used pulsed-field gel electrophoresis for molecular typing of isolates from patient respira -Results. We identified 13 cases of nosocomial legionella pneumonia over a one- month period (Figure 1), with 8 males, 5 females, and a mean age of 63 years. The average time to diagnosis was 19 days following admission. Six patients were trans-plant recipients - two had solid organ, and six had bone marrow transplant. Urinary Legionella antigen was positive in all cases. Table 1 shows predictors for pneumonia in univariate analyses. Current smoking (OR = 7.5, 95% CI [1.11 - 50.84], p = 0.03], pre-admission steroid prescription (OR = 6.5, 95% CI [1.65 - 26.20], p = 0.008], documentation of shower (OR = 6.2, 95% CI [1.54 - 25.82], p = 0.01], and number of showers prior to hyper-chlorination (OR = 1.45, 95% CI [1.03 - 2.04], p = 0.03] were significant risk factors on univariate analysis. The multiple regression model was also significant (P &lt; 0.001) with all of the above-identified predictors (Table 2). Molecular typing found Legionella strains from patient respiratory samples and water samples to be identical. Multiple interventions, including restriction of show-ering, hyper-chlorination, and optimization of water flow through the copper-silver ionization system were implemented, and were successful in mitigating the outbreak. Conclusion. We found showering to be a modifiable risk factor for Legionella pneumonia in this outbreak. Interventions to reduce this risk might include point of use filters in showers in high-risk populations. (Figure Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L630693647&#xD;2020-01-31</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L630693647</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/ofid/ofz360.2129</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofz360.2129</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Apewokin, S.</style></author><author><style face="normal" font="default" size="100%">Lee, J. Y.</style></author><author><style face="normal" font="default" size="100%">Goodwin, J. A.</style></author><author><style face="normal" font="default" size="100%">McKelvey, K. D.</style></author><author><style face="normal" font="default" size="100%">Stephens, O. W.</style></author><author><style face="normal" font="default" size="100%">Zhou, D.</style></author><author><style face="normal" font="default" size="100%">Coleman, E. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infectious Diseases, University of Cincinnati, 231 Albert Sabin Way, MSB 6153B, Cincinnati, OH, USA. senukobla@yahoo.com.&#xD;Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.&#xD;Medical Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.&#xD;Department of Genetics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.&#xD;Genomics Core Laboratory, Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.&#xD;Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Host genetic susceptibility to Clostridium difficile infections in patients undergoing autologous stem cell transplantation: a genome-wide association study</style></title><secondary-title><style face="normal" font="default" size="100%">Support Care Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Support Care Cancer</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3127-3134</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2018/03/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Clostridium Infections/*genetics/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genetic Predisposition to Disease/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hematopoietic Stem Cell Transplantation/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Transplantation Conditioning/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Transplantation, Autologous/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile</style></keyword><keyword><style face="normal" font="default" size="100%">Genome wide association study</style></keyword><keyword><style face="normal" font="default" size="100%">Pathophysiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stem cell transplantation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0941-4355</style></isbn><accession-num><style face="normal" font="default" size="100%">29594489</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clostridium difficile infection (CDI) is the most common hospital-acquired infection. Unfortunately, genes that identify CDI-susceptible patients have not been well described. We performed a genome-wide association study (GWAS) to determine genetic variants associated with the development of CDI. METHODS: A cohort study of Caucasian patients undergoing autologous stem cell transplantation for multiple myeloma was performed. Patients were genotyped using Illumina(R) Whole Genome Genotyping Infinium chemistry. We then compared CDI-positive to CDI-negative patients using logistic regression for baseline clinical factors and false discovery rate (FDR) for genetic factors [single nucleotide polymorphisms (SNPs)]. SNPs associated with CDI at FDR of p &lt; 0.01 were then incorporated into a logistic regression model combining clinical and genetic factors. RESULTS: Of the 646 patients analyzed (59.7% male), 57 patients were tested CDI positive (cases) and were compared to 589 patients who were tested negative (controls). Hemoglobin, albumin, and hematocrit were lower for cases (p &lt; 0.05). Eight SNPs on five genes (FLJ16171, GORASP2, RLBP1L1, ASPH, ATP7B) were associated with CDI at FDR p &lt; 0.01. In the combined clinical and genetic model, low albumin and three genes RLBP1L1, ASPH, and ATP7B were associated with CDI. CONCLUSION: Low serum albumin and genes RLBP1L1 and ASPH located on chromosome 8 and ATP7B on chromosome 13 were associated with CDI. Of particular interest is ATP7B given its copper modulatory role and the sporicidal properties of copper against Clostridium difficile.</style></abstract><notes><style face="normal" font="default" size="100%">1433-7339&#xD;Apewokin, Senu&#xD;ORCID: http://orcid.org/0000-0002-3915-5814&#xD;Lee, Jeannette Y&#xD;Goodwin, Julia A&#xD;McKelvey, Kent D&#xD;Stephens, Owen W&#xD;Zhou, Daohong&#xD;Coleman, Elizabeth Ann&#xD;5 RC2NR011945/National Institutes of Health&#xD;#1UL1RR029884/Translation research Institute at UAMS&#xD;Journal Article&#xD;Germany&#xD;Support Care Cancer. 2018 Sep;26(9):3127-3134. doi: 10.1007/s00520-018-4173-6. Epub 2018 Mar 28.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00520-018-4173-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>266</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aly, H.</style></author><author><style face="normal" font="default" size="100%">El Garhy, I.</style></author><author><style face="normal" font="default" size="100%">Hamdy, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H. Aly, Al-Hussein University Hospital, Department of Obstetrics and Gynecology, Cairo, Egypt</style></auth-address><titles><title><style face="normal" font="default" size="100%">How Egyptian culture of gender power imbalance may shape copper intrauterine device sexual acceptability</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Sexual Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Sexual Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e391</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">condom</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">counseling</style></keyword><keyword><style face="normal" font="default" size="100%">domestic violence</style></keyword><keyword><style face="normal" font="default" size="100%">dyspareunia</style></keyword><keyword><style face="normal" font="default" size="100%">Egypt</style></keyword><keyword><style face="normal" font="default" size="100%">Egyptian</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Female Sexual Function Index</style></keyword><keyword><style face="normal" font="default" size="100%">gender</style></keyword><keyword><style face="normal" font="default" size="100%">genital tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">information processing</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">malpractice</style></keyword><keyword><style face="normal" font="default" size="100%">married person</style></keyword><keyword><style face="normal" font="default" size="100%">pelvic pain</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">psychological aspect</style></keyword><keyword><style face="normal" font="default" size="100%">public sector</style></keyword><keyword><style face="normal" font="default" size="100%">questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">rural area</style></keyword><keyword><style face="normal" font="default" size="100%">sexuality</style></keyword><keyword><style face="normal" font="default" size="100%">sexually transmitted disease</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword><keyword><style face="normal" font="default" size="100%">urban area</style></keyword><keyword><style face="normal" font="default" size="100%">vagina discharge</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1743-6109</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To assess the effects of reduced women&apos;s sexual empowerment in Egyptian culture on their acceptability, compliance and convenience with copper IUD. Methods: A total of 136 women who had used copper IUD 380A from one day to ten years, were referred to Al Hussein University Hospital and consented to participate in this study. Data collection was obtained over a period of six months, via questionnaire on variables that could influence both contraceptive choice and sexual outcome. Which includes socio-demographic characteristics, domestic violence, content of the counselling dialogue,partners&apos; involvement, sexually transmitted infections (STIs) screening, side effects of IUD and its sexual impact. Neither Female Sexual Function Index (FSFI) nor psychologic factors were documented in this study. Results: All Participants were married. Of 136 women, 65 (47.8%) were educated and 71 (52.2%) were non-educated. The women&apos;s residences were 44 in rural areas (32%) and 92(68%) in urban areas. All were unwilling to talk about domestic violence but two cases were documented. 44 Women (32 %) reported prolonged heavy bleeding and spotting. 67 Women (49%) suffered from pelvic pain, dyspareunia and vaginal discharge. Their partners refused to use condoms or to share with them medications for genital infections. Strings poke their partners were felt in 20 cases (14.7%). 32 Women (23.5%) reported positive impact on sexuality by being in control over pregnancy. 85 Women (62.5%) reported negative impact on sexuality (abstinence, dyspareunia, strings poking partners) and requested removal of IUDs, of them 22 (25.8 %) had malpositioned IUDs and 7(8%) had pregnancies with IUDs. 19 Women (14%) reported no change on sexuality. No STIs screening was performed. Only 30 cases (22 %) received counselling for IUDs, 20 of them (66.6%) had poor dialogues. Sexual criteria and partner involvement were not included in the counseling. 6 Women (4.4 %) requested removal of IUDs only for worship. Conclusion: Sexuality was not of interest to most Egyptian women seeking contraception. Therefore, sexual criteria and partners&apos; involvement should be integrated into contraceptive counselling protocol to ensure safe, satisfactory sex and contraception. Many efforts are needed to stop malpractice of IUDs in Egypt (poor training &amp; flawed system). Implementing screening program for STIs is recommended. Provision of up to date medications for bleeding and pain and governmental support to ensure the availability of hormonal IUDs in the public sectors are essential. Finally, patient-partner-doctor relationship will continue to be influenced by the cultural norms and diversity. So that, the more the women are socially and sexually empowered, the more they are aware of their rights and more likely to use the contraceptive they wish.</style></abstract><notes><style face="normal" font="default" size="100%">L620190846&#xD;2018-01-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L620190846</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">89</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Freitas, A. R.</style></author><author><style face="normal" font="default" size="100%">Coque, T. M.</style></author><author><style face="normal" font="default" size="100%">Novais, C.</style></author><author><style face="normal" font="default" size="100%">Hammerum, A. M.</style></author><author><style face="normal" font="default" size="100%">Lester, C. H.</style></author><author><style face="normal" font="default" size="100%">Zervos, M. J.</style></author><author><style face="normal" font="default" size="100%">Donabedian, S.</style></author><author><style face="normal" font="default" size="100%">Jensen, L. B.</style></author><author><style face="normal" font="default" size="100%">Francia, M. V.</style></author><author><style face="normal" font="default" size="100%">Baquero, F.</style></author><author><style face="normal" font="default" size="100%">Peixe, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">REQUIMTE, Laboratorio de Microbiologia, Faculdade de Farmacia, Universidade do Porto, Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Human and swine hosts share vancomycin-resistant Enterococcus faecium CC17 and CC5 and Enterococcus faecalis CC2 clonal clusters harboring Tn1546 on indistinguishable plasmids</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">925-31</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2011/01/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Typing Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Transposable Elements</style></keyword><keyword><style face="normal" font="default" size="100%">DNA, Bacterial/*genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecalis/*classification/drug effects/genetics/isolation &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">purification</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecium/*classification/drug effects/genetics/isolation &amp;</style></keyword><keyword><style face="normal" font="default" size="100%">purification</style></keyword><keyword><style face="normal" font="default" size="100%">European Union</style></keyword><keyword><style face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacterial Infections/*microbiology/*veterinary</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Typing</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmids</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Swine Diseases/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">*Vancomycin Resistance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0095-1137</style></isbn><accession-num><style face="normal" font="default" size="100%">21227995</style></accession-num><abstract><style face="normal" font="default" size="100%">VRE isolates from pigs (n = 29) and healthy persons (n = 12) recovered during wide surveillance studies performed in Portugal, Denmark, Spain, Switzerland, and the United States (1995 to 2008) were compared with outbreak/prevalent VRE clinical strains (n = 190; 23 countries; 1986 to 2009). Thirty clonally related Enterococcus faecium clonal complex 5 (CC5) isolates (17 sequence type 6 [ST6], 6 ST5, 5 ST185, 1 ST147, and 1 ST493) were obtained from feces of swine and healthy humans. This collection included isolates widespread among pigs of European Union (EU) countries since the mid-1990s. Each ST comprised isolates showing similar pulsed-field gel electrophoresis (PFGE) patterns (&lt;/=6 bands difference; &gt;82% similarity). Some CC5 PFGE subtype strains from swine were indistinguishable from hospital vancomycin-resistant enterococci (VRE) causing infections. A truncated variant of Tn1546 (encoding resistance to vancomycin) and tcrB (coding for resistance to copper) were consistently located on 150- to 190-kb plasmids (rep(pLG1)). E. faecium CC17 (ST132) isolates from pig manure and two clinical samples showed identical PFGE profiles and contained a 60-kb mosaic plasmid (rep(Inc18) plus rep(pRUM)) carrying diverse Tn1546-IS1216 variants. The only Enterococcus faecalis isolate obtained from pigs (CC2-ST6) corresponded to a multidrug-resistant clone widely disseminated in hospitals in Italy, Portugal, and Spain, and both animal and human isolates harbored an indistinguishable 100-kb mosaic plasmid (rep(pRE25) plus rep(pCF10)) containing the whole Tn1546 backbone. The results indicate a current intra- and international spread of E. faecium and E. faecalis clones and their plasmids among swine and humans.</style></abstract><notes><style face="normal" font="default" size="100%">1098-660x&#xD;Freitas, Ana R&#xD;Coque, Teresa M&#xD;Novais, Carla&#xD;Hammerum, Anette M&#xD;Lester, Camilla H&#xD;Zervos, Marcus J&#xD;Donabedian, Susan&#xD;Jensen, Lars B&#xD;Francia, Maria Victoria&#xD;Baquero, Fernando&#xD;Peixe, Luisa&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Clin Microbiol. 2011 Mar;49(3):925-31. doi: 10.1128/JCM.01750-10. Epub 2011 Jan 12.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3067689</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/jcm.01750-10</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Borneff, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">[Hygiene problems in dental practice with special attention to dental units]</style></title><secondary-title><style face="normal" font="default" size="100%">Zentralbl Bakteriol Mikrobiol Hyg B</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zentralbl Bakteriol Mikrobiol Hyg B</style></full-title></periodical><pages><style face="normal" font="default" size="100%">130-52</style></pages><volume><style face="normal" font="default" size="100%">183</style></volume><number><style face="normal" font="default" size="100%">2-3</style></number><edition><style face="normal" font="default" size="100%">1986/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Dental Equipment</style></keyword><keyword><style face="normal" font="default" size="100%">*Dental Offices</style></keyword><keyword><style face="normal" font="default" size="100%">Enterobacteriaceae/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Water/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply/*standards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1986</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Hygiene-Probleme in der zahnarztlichen Praxis unter besonderer Berucksichtigung der Dentaleinheiten.</style></orig-pub><isbn><style face="normal" font="default" size="100%">0932-6073 (Print)&#xD;0932-6073</style></isbn><accession-num><style face="normal" font="default" size="100%">3107265</style></accession-num><abstract><style face="normal" font="default" size="100%">Within a scope of an investigation concerning hygiene-problems in dental practice a longitudinal study was carried out in 20 dental offices with 53 units. In order to guarantee equal experimental conditions and to eliminate variations caused by changing water flow during the day, we took the samples before office hours alternating mondays, tuesdays and wednesdays. Those samples gathered from all handpieces (n = 530) and the drinking water faucets (n = 200) were examined according to the &quot;Trinkwasser-Verordnung&quot; (1986), diagnostics were supplemented concerning special groups of bacteria (see also Table 1). Analyses of copper, zinc and iron were done once during the study. Selecting certain sampling spots (see also Table 2) the surface contamination of the units and the surroundings was examined using the &quot;Rodac&quot;-method (n = 4800). The results of the study may be summarized as follows: The investigation concerning the surface contamination showed under qualitative and quantitative aspects (see also Fig. 10) constant contaminations on the patients&apos; head- and armrests, the operating lamp, cuspidor-bowl and hand-wash-basin. In samples taken from the water system of dental units potentially pathogenic bacteria were isolated in 71%, in first place Ps. aeruginosa, followed by Ps. acidovorans and other species of this group. Legionella species occurred sporadically in the units and potable water of 8 offices. On the base of the total germ count (22 degrees C and 37 degrees C) the diagnosis &quot;drinking-water quality&quot; was possible only in 31%. The longitudinal investigation showed, that the contamination of the water system follows different progressive forms regarding extent and quality (see also Fig. 7). Relating to these results in the first step the development of a theoretical model concerning the different influencing factors (quality of water tubes and other devices, variation of temperature, quality of potable water and the effect of ionic exchangers, indirect contamination by patients and dental staff, nature of dental treatment, utilization frequency of the direct handpieces) appears to be necessary. Thus the contamination has to be understood as a developing process determined by specific promotors and catalyzers; in the second step the evaluation of adequate bactericidal and virucidal decontamination procedures fitting into the daily practical needs of dental offices should follow.</style></abstract><notes><style face="normal" font="default" size="100%">Borneff, M&#xD;English Abstract&#xD;Journal Article&#xD;Germany&#xD;Zentralbl Bakteriol Mikrobiol Hyg B. 1986 Dec;183(2-3):130-52.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">ger</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>145</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burhanoglu, M.</style></author><author><style face="normal" font="default" size="100%">Tutuncuoglu, S.</style></author><author><style face="normal" font="default" size="100%">Coker, C.</style></author><author><style face="normal" font="default" size="100%">Tekgul, H.</style></author><author><style face="normal" font="default" size="100%">Ozgur, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paediatrics Department, Ege University Hospital, Bornova Izmir, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypozincaemia in febrile convulsion</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur J Pediatr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">498-501</style></pages><volume><style face="normal" font="default" size="100%">155</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">1996/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Blood-Brain Barrier/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Meningitis, Bacterial/blood/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Meningitis, Viral/blood/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Receptors, N-Methyl-D-Aspartate/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Seizures, Febrile/blood/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Trace Elements/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*deficiency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1996</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0340-6199 (Print)&#xD;0340-6199</style></isbn><accession-num><style face="normal" font="default" size="100%">8789769</style></accession-num><abstract><style face="normal" font="default" size="100%">UNLABELLED: To understand further the role role of trace elements in pathogenesis of febrile convulsions, serum zinc (Zn), copper (Cu), magnesium (Mg) and CSF An, Cu, Mg and protein levels were measured by spectrometry in patients with febrile convulsion (n = 19), bacterial meningitis (n = 9), viral CNS infection (n = 16) and in the control group (n = 10) which consisted of children with signs of meningeal irritation due to upper respiratory tract infection but normal CSF findings. Samples were obtained within 6 h after admission to hospital. Mean serum and CSF Zn levels in the febrile convulsion group were significantly lower than in the other groups (for serum Zn: 0.66 +/- 0.03 mg/1 vs 0.98 +/- 0.07 mg/1, 1.06 +/- 0.08 mg/1, 1.05 +/- 0.09 mg/1 P &lt; 0.05; for CSF Zn: 22.96 +/- 1.62 micrograms/1 vs 75.47 +/- 6.9 micrograms/1, 50.32 +/- 5.235 micrograms/1, 39.85 +/- 2.81 micrograms/1 P &lt; 0.05). A linear relationship was established between serum Zn and CSF Zn levels (P &lt; 0.001). Mean CSF Zn, Cu and protein levels in the bacterial meningitis group were significantly higher than in the other groups (for CSF Cu 63.94 +/- 6.33 micrograms/1 vs 38.77 +/- 2.70 micrograms/1, 35.84 +/- 3.48 micrograms/1, 33.86 +/- 2.88 micrograms/1 P &lt; 0.05; for CSF protein 0.80 +/- 0.12 g/1 vs 0.22 +/- 0.02 g/1, 0.53 +/- 0.08 g/1, 0.19 +/- 0.01 g/1 P &lt; 0.05). In children with meningitis, the elevation of the mean CSF Zn and Cu levels may result from the breakdown of the blood-brain barrier and subsequent leakage of trace elements and protein from serum to CSF. There was no significant difference between the four groups in terms of mean serum Mg and mean CSF Mg levels. CONCLUSION: Serum and CSF Zn levels are decreased in children with febrile seizures. Zinc deprivation may play a role in the pathogenesis of febrile seizures.</style></abstract><notes><style face="normal" font="default" size="100%">Burhanoglu, M&#xD;Tutuncuoglu, S&#xD;Coker, C&#xD;Tekgul, H&#xD;Ozgur, T&#xD;Journal Article&#xD;Germany&#xD;Eur J Pediatr. 1996 Jun;155(6):498-501. doi: 10.1007/bf01955189.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/bf01955189</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>388</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">388</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kanekar, S.</style></author><author><style face="normal" font="default" size="100%">Agarwal, A.</style></author><author><style face="normal" font="default" size="100%">Maller, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Kanekar, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Imaging of myelopathy</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Roentgenology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Roentgenology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">198</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">contrast medium</style></keyword><keyword><style face="normal" font="default" size="100%">gadolinium</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">spinal cord disease</style></keyword><keyword><style face="normal" font="default" size="100%">X ray</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">imaging</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">spinal cord</style></keyword><keyword><style face="normal" font="default" size="100%">spine</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">radiodiagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">acute disseminated encephalomyelitis</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">spinocerebellar degeneration</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">leukodystrophy</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrovascular accident</style></keyword><keyword><style face="normal" font="default" size="100%">myelooptic neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">sarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">kidney function</style></keyword><keyword><style face="normal" font="default" size="100%">myelitis</style></keyword><keyword><style face="normal" font="default" size="100%">motor neuron disease</style></keyword><keyword><style face="normal" font="default" size="100%">congenital blood vessel malformation</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">copper deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">vertebral canal</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">radiologist</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrospinal fluid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0361-803X</style></isbn><abstract><style face="normal" font="default" size="100%">Background Information: Hyperintensity of the myelopathic spinal cord either focal or diffuse is challenging for the radiologist to negotiate. This is mainly due to its nonspecific appearance and multiple causes. A thoughtful approach is required to make specific diagnosis or limit the differential diagnosis and guide the referring physician. Educational Goals/Teaching Points: In this exhibit we give an algorithmic approach to acute as well as chronic myelopathy with to assist in arriving at the specific diagnosis. Key Anatomic/Physiologic Issues and Imaging Findings/Techniques: We retrospectively studied 173 patients from our PACS system who had clinical and radiologic diagnosis of myelopathy. All the patients underwent routine MRI of the spine. A total of 169 patients also had gadolinium-enhanced sagittal and axial T1-weighted imaging. Four patients did not receive contrast material due to poor renal function. All studies were read by two neuroradiologists. These findings were correlated with the clinical findings, biochemical, and CSF analysis. Of the 169, 161 patients had a follow-up MRI that was compared with prior scans for stability, progression, or resolution of the abnormality. For the purpose of this exhibit and better understanding of the disease process we categorized our data into following categories: infection (chronic and acute), inflammatory (multiple sclerosis, acute disseminated encephalomyelitis, Devic syndrome, acute transverse myelitis, and sarcoidosis), hereditary (spinocerebellar degeneration, motor neuron disease, leukodystrophy, and distal axonopathies), compressive (trauma, neoplastic, and nonneoplastic), vascular (stroke, Hg, vascular malformations), and metabolic or toxic (nutritional deficiency of vitamin B12, folate, copper, deficiency). Conclusion: Pattern of distribution, anatomic location of the spinal cord hyperintensity, and the corroborative finds within and outside the spinal canal are very helpful in evaluation of patients with myelopathy. Clinical history, laboratory, and CSF analysis are equally important in coming to an appropriate diagnosis. 3. In this exhibit we give an algorithmic approach to acute as well as chronic myelopathy.</style></abstract><notes><style face="normal" font="default" size="100%">L71321099&#xD;2014-02-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71321099</style></url><url><style face="normal" font="default" size="100%">http://www.ajronline.org/doi/full/10.2214/ajr.198.5_supplement.ajronline_198_5_supplement_035</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">4</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">N&apos;Guessan, E.</style></author><author><style face="normal" font="default" size="100%">Gbeli, F.</style></author><author><style face="normal" font="default" size="100%">Dia, J. M.</style></author><author><style face="normal" font="default" size="100%">Guie, P.</style></author><author><style face="normal" font="default" size="100%">Roseline, N. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynecology, University Hospital of Treichville, 01 BP V3 Abidjan 01, Abidjan, Cote d&apos;Ivoire.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immediate Postpartum Intrauterine Device in HIV-Infected Women: Experience from a Tertiary Care Center in Cote d&apos;Ivoire</style></title><secondary-title><style face="normal" font="default" size="100%">J Obstet Gynaecol India</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Obstet Gynaecol India</style></full-title></periodical><pages><style face="normal" font="default" size="100%">64-68</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/02/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">AIDS infection</style></keyword><keyword><style face="normal" font="default" size="100%">Complications</style></keyword><keyword><style face="normal" font="default" size="100%">Copper IUD</style></keyword><keyword><style face="normal" font="default" size="100%">Hiv</style></keyword><keyword><style face="normal" font="default" size="100%">Ppiud</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0971-9202 (Print)&#xD;0975-6434</style></isbn><accession-num><style face="normal" font="default" size="100%">32030008</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Immediate postpartum intrauterine device (PPIUD) is a good solution for reducing low contraceptive coverage in developing countries. However, its use in HIV-infected women is poorly documented. The objective of this study was to assess whether the risk of PPIUD complications was higher in HIV-infected women. Methods: A retrospective cohort study compared 64 HIV-infected women to 128 HIV-negative women who had had a PPIUD at the University Hospital of Treichville between January 2016 and March 2017, with a match at the insertion time of the PPIUD. The complications considered were pelvic pain, metrorrhagia and genital infections. Chi-squared test and relative risk were used to investigate the association between HIV infection and PPIUD complications. Results: HIV-infected patients had an average age of 33.1 years, and 85.9% of them were on antiretroviral therapy. PPIUD was inserted during cesarean section in 66.1% of cases. There was no significant association between HIV infection and PPIUD complications (RR = 0.7, 95% CI [0.4-1.3], p = 0.3). The risk of genital infections was not increased in HIV-infected women (RR = 0.6 [0.1-2.7], p = 0.7). Conclusion: HIV infection does not increase the risk of PPIUD complications. This effective contraceptive strategy can be offered to HIV-infected women. It is therefore necessary to strengthen the training of maternity staff in the installation of PPIUD.</style></abstract><notes><style face="normal" font="default" size="100%">N&apos;guessan, Edouard&#xD;Orcid: 0000-0002-8347-3107&#xD;Gbeli, Franck&#xD;Dia, Jean-Marc&#xD;Guie, Privat&#xD;Roseline, Nguessan Kouame&#xD;Journal Article&#xD;India&#xD;J Obstet Gynaecol India. 2020 Feb;70(1):64-68. doi: 10.1007/s13224-019-01268-6. Epub 2019 Oct 18.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6982613</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s13224-019-01268-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>270</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Braden, A.</style></author><author><style face="normal" font="default" size="100%">Roach, L.</style></author><author><style face="normal" font="default" size="100%">Stehle, J.</style></author><author><style face="normal" font="default" size="100%">Anderson, A.</style></author><author><style face="normal" font="default" size="100%">Bischoff, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Braden, Infection Prevention, Wake Forest Baptist Medical Center, Winston Salem, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of a copper-infused countertop material on the bacterial surface burden: results of a field and laboratory study</style></title><secondary-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S189</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><keywords><keyword><style face="normal" font="default" size="100%">agar</style></keyword><keyword><style face="normal" font="default" size="100%">bleaching agent</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial load</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">neurological intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">surgical intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">touch</style></keyword><keyword><style face="normal" font="default" size="100%">workload</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">2328-8957</style></isbn><abstract><style face="normal" font="default" size="100%">Background. Antimicrobial surfaces have become a promising technology of integrating additional safeguards into hospitals&apos; fight against Healthcare Associated Infections (HAIs). This study assesses the potential benefits of copper-infused countertops compared with standard, laminated surfaces. Methods. The efficacy of a novel surface material in reducing the bacterial load was tested in a Neuro ICU (copper surface, intervention) and a Surgical ICU (laminated surface, control) during routine care (field test). Surfaces were cleaned following standard hospital protocol. After bleach cleaning of 5 high touch areas, pre-moistened swab samples were taken immediately, at 2 hours, and at 4 hours, for a total of 680 surface samples in 46 patient rooms. After incubation on blood agar plates, colony forming units (CFU) were documented. In a separate laboratory test, copper and laminated surfaces were inoculated with S. Aureus and the bacterial load was measured as described. Pre-treatment of the copper counter top followed manufacturer recommendation (light buffing with 365 grit sandpaper every 24 hours) or hospital-approved disinfection policy. Count numbers at the different time points for the surfaces were analyzed. Results. In the field test, no statistically significant differences in bacterial surface burden were noted between the intervention and control unit at the three time points (RR = 1.6 (0.5-5.0); P = 0.4210). In the lab test, significant reductions in CFU across all surfaces were observed after 2 hours (&gt;50%; P &lt; 0.05). Light buffing led to the highest reduction in CFU (&gt;99%; P &lt; 0.05). After 4 hours the laminated surface showed further significant reduction (&gt;93%;P &lt; 0.05). However, CFU on the copper surface treated with standard disinfectant did not change (P &lt; 0.05). Conclusion. The copper surface significantly reduces the bacterial burden if reactivated by light buffing with sandpaper in a lab test. Not following manufacturer recommendation will lead to similar (field) or even higher bacterial burden (lab) compared with standard laminated surfaces. Before implementation, considerations should be given to the increased workload due to daily surface reactivation, the potential of fine particle exposure, and the higher product costs.</style></abstract><notes><style face="normal" font="default" size="100%">L628003440&#xD;2019-06-13</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L628003440</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/ofid/ofx163.353</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofx163.353</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>362</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">362</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miller, N.</style></author><author><style face="normal" font="default" size="100%">Miller, M.</style></author><author><style face="normal" font="default" size="100%">Hill, L. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L.T. Hill, Division of Critical Care, Department of Surgery, University of Cape Town, South Africa</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of antioxidant supplementation on clinical outcomes in the critically ill: A meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Southern African Journal of Critical Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Southern African Journal of Critical Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-26</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylcysteine</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection complication</style></keyword><keyword><style face="normal" font="default" size="100%">infectious complication</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">treatment outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1562-8264</style></isbn><abstract><style face="normal" font="default" size="100%">Background. Critical illness is associated with increased oxidative stress that can influence outcome. Many studies have investigated the effects of exogenous antioxidant supplementation, without showing significance owing to the small patient populations. Methodology. A systematic review and meta-analysis of the English literature was performed to determine the effect of antioxidant micronutrient supplementation on clinically important outcomes in the critically ill. Pubmed, Google Scholar and Science Direct electronic databases were searched for papers published between January 1990 and June 2010. Selection criteria. Randomised controlled trials were selected for inclusion if they investigated the effects of antioxidant supplementation in the critically ill and reported on clinically significant endpoints. Data collection and analysis. The data were analysed using a random effects model in Comprehensive Meta-analysis Version 2 (Biostat, USA) to obtain the odds ratio (OR) with a 95% confidence interval (CI) and statistical significance of p&lt;0.05. Results. Twelve studies met the inclusion criteria. Selenium supplementation was associated with a trend towards decreased mortality (OR=0.717, p=0.106, CI 0.48 - 1.07). Mixed antioxidant supplementation was associated with reduced hospital length of stay (OR= 0.710, p=0.002, CI 0.57 - 0.83), reduced infectious complications (OR=0.494, p=0.024, CI 0.28 - 0.98) and reduced mechanical ventilation (OR=0.259, p=0.023, CI 0.08 - 0.83). Conclusion. A combination of antioxidant micronutrients might be associated with improved clinical outcome in the critically ill.</style></abstract><notes><style face="normal" font="default" size="100%">L369522984&#xD;2013-08-16&#xD;2013-08-26</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L369522984</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.7196/SAJCC.149</style></url><url><style face="normal" font="default" size="100%">http://www.journals.co.za/WebZ/images/ejour/m_sajcc/m_sajcc_v29_n1_a5.pdf?sessionid=01-51363-612777930&amp;format=F</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7196/SAJCC.149</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mohamed, K. I. A.</style></author><author><style face="normal" font="default" size="100%">Al-Wattar, W. M. A.</style></author><author><style face="normal" font="default" size="100%">Taha, G. I.</style></author><author><style face="normal" font="default" size="100%">Ali, S. H. M.</style></author><author><style face="normal" font="default" size="100%">Abu-Al-Ess, H. Q. M.</style></author><author><style face="normal" font="default" size="100%">Al-Fukhar, S. A.</style></author><author><style face="normal" font="default" size="100%">Mousa, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K.I.A. Mohamed, Clinical Communicable Diseases Research, College of Medicine, University of Baghdad, Baghdad, Iraq</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of brucellosis on interleukin-23 level, acid phosphates and some other trace elements</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pure and Applied Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pure and Applied Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2011-2016</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">acid phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">cuprous ion</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin 23</style></keyword><keyword><style face="normal" font="default" size="100%">phosphate</style></keyword><keyword><style face="normal" font="default" size="100%">rose bengal</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc ion</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">age</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">blood sampling</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella</style></keyword><keyword><style face="normal" font="default" size="100%">brucellosis</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">teaching hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">2581-690X&#xD;0973-7510</style></isbn><abstract><style face="normal" font="default" size="100%">The study was carried out during a period of February 2017-July 2018 for the detection of brucellosis in 128 suspected patients with age group range from 17-69 years, who attended to Baghdad teaching hospitals, that had been examined and defined as suspected cases by specialized physician with the recording of clinical manifestation. The diagnosis done by Rose Bengal test (RBT) method, a blood sample was taken from each patients as well as other 30 healthy control matching in age and gender. The study included measurement of the concentration of Interleukin-23, activity of Acidphosphatase, Copper and Zinc in sera of patients and healthy control. The result indicated that Rose Bengal test positive in 18 cases, 12 with a titer of 1:160 and 6 cases with a titer of 1:320. The Level of IL-23, Acid phosphatase increased significantly, with no statistical difference in copper and zinc concentration in both interval ages of patients sera in comparison with healthy control.</style></abstract><notes><style face="normal" font="default" size="100%">L625793690&#xD;2019-01-11</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L625793690</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.22207/JPAM.12.4.37</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.22207/JPAM.12.4.37</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedro-Botet, M. L.</style></author><author><style face="normal" font="default" size="100%">Sanchez, I.</style></author><author><style face="normal" font="default" size="100%">Sabria, M.</style></author><author><style face="normal" font="default" size="100%">Sopena, N.</style></author><author><style face="normal" font="default" size="100%">Mateu, L.</style></author><author><style face="normal" font="default" size="100%">Garcia-Nunez, M.</style></author><author><style face="normal" font="default" size="100%">Rey-Joly, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Unit, Hospital Germans Trias i Pujol of Badalona, Autonomous University of Barcelona, Barcelona, Spain. mlpbotet.germanstrias@gencat.net</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of copper and silver ionization on fungal colonization of the water supply in health care centers: implications for immunocompromised patients</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">84-6</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2007/06/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Fungi/*drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Immunocompromised Host</style></keyword><keyword><style face="normal" font="default" size="100%">Ions/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/chemistry/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply/*analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">17554706</style></accession-num><abstract><style face="normal" font="default" size="100%">Copper and silver ionization is a well-recognized disinfection method to control Legionella species in water distribution systems in hospitals. These systems may also serve as a potential indoor reservoir for fungi. The prevalence of fungi was significantly lower in ionized than in nonionized water samples from health care facilities. The clinical consequences of this finding require further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Pedro-Botet, Maria Luisa&#xD;Sanchez, Inma&#xD;Sabria, Miquel&#xD;Sopena, Nieves&#xD;Mateu, Lourdes&#xD;Garcia-Nunez, Marian&#xD;Rey-Joly, Celestino&#xD;Journal Article&#xD;United States&#xD;Clin Infect Dis. 2007 Jul 1;45(1):84-6. doi: 10.1086/518584. Epub 2007 May 23.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/518584</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arendsen, L.</style></author><author><style face="normal" font="default" size="100%">Thakar, R.</style></author><author><style face="normal" font="default" size="100%">Sultan, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of copper impregnated wound dressings on surgical site infection following caesarean section: a double blind randomised controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">European journal of obstetrics gynecology and reproductive biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European journal of obstetrics gynecology and reproductive biology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e171‐</style></pages><volume><style face="normal" font="default" size="100%">234</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*cesarean section</style></keyword><keyword><style face="normal" font="default" size="100%">*surgical infection</style></keyword><keyword><style face="normal" font="default" size="100%">*wound dressing</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Body mass</style></keyword><keyword><style face="normal" font="default" size="100%">Chi square test</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency</style></keyword><keyword><style face="normal" font="default" size="100%">England</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Infection rate</style></keyword><keyword><style face="normal" font="default" size="100%">Major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">Practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Public health</style></keyword><keyword><style face="normal" font="default" size="100%">Questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">Telephone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01787183</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction: Copper has been known for its antimicrobial effect for centuries. Surgical site infection (SSI) rate following caesarean section (CS) is increasing and treatment is becoming more challenging due to rising rate of antibiotic resistance. Objective: The aim of this study was to investigate the impact of copper impregnated wound dressings on the SSI rate following CS. Methods: A double blind randomised controlled study was performed adhering to CONSORT guidelines. Dressing impregnated with 3% copper oxide ions and placebo were used in the interventional arm and control arm of the study respectively. SSI was assessed via a telephone questionnaire 7, 14 and 30 days post‐partum. The validated Post Discharge Questionnaire used by the Public Health England for SSI surveillance was used. Chi‐square test was used to compare categorical data and t‐test was used to analyse continuous data. Discussion and conclusions: From 14 January 2016 to 8 May 2017, 324 women were recruited. Follow up rate was a 100%. Mean age was 33 (SD ± 6) years, mean BMI 28.2 (SD ± 6.1), mean gestation 39 (±1.6 SD) weeks. There was no significant difference in participants’ characteristics between the intervention and control group. In total 77 (24.4%) developed SSI. There was a significant 38.4% reduction in overall SSI rate (18.6% vs. 30.2%, p = 0.017) and an 80.3% significant reduction in organ/space infections (2.6% vs. 13.2%, p = 0.002) in the intervention group. There was no difference in SSI rates between elective and emergency CS. This is the first study to demonstrate a significant reduction in SSI rates following CS with the use of copper impregnated wound dressings. The high SSI rate confirms the importance of new strategies to reduce the infection rate. Copper is a potential potent natural remedy which could reduce hospital acquired infections without the use of antibiotics and its associated risks of antibiotic resistance.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal: Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01787183/full</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 2001485555</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejogrb.2018.08.534</style></electronic-resource-num></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">91</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abou-Shady, O.</style></author><author><style face="normal" font="default" size="100%">El Raziky, M. S.</style></author><author><style face="normal" font="default" size="100%">Zaki, M. M.</style></author><author><style face="normal" font="default" size="100%">Mohamed, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Parasitology, Cairo University, Giza, Egypt.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of Giardia lamblia on growth, serum levels of zinc, copper, and iron in Egyptian children</style></title><secondary-title><style face="normal" font="default" size="100%">Biol Trace Elem Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biol Trace Elem Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-6</style></pages><volume><style face="normal" font="default" size="100%">140</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2010/03/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Egypt</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal Diseases/diagnosis/etiology/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Giardia lamblia/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Giardiasis/*blood/complications/diagnosis/*parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Growth/*physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Iron/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0163-4984</style></isbn><accession-num><style face="normal" font="default" size="100%">20340051</style></accession-num><abstract><style face="normal" font="default" size="100%">The aim of this study is to evaluate the serological levels of zinc, copper and iron in Giardia lamblia-infected children and to study the effect of giardiasis on their weight compared to controls. We studied 30 children, 1-10 years old, who attended the outpatient clinics of Cairo University Pediatric Hospital, with gastrointestinal complaints and diagnosed as having giardiasis by stools examination, they were enrolled as a study group. The control group consisted of 30 age- and sex-matched healthy children, free of gastrointestinal complaints and free of giardiasis. Serological levels of zinc, copper, and iron were measured by atomic absorption spectrophotometer. The infected group had significantly lower weight, serum iron, and zinc than controls (P = 0.035, &lt;0.001, and &lt;0.001 respectively) and 63.3% of patients infected with giardiasis were 1-5 years old. In the infected cases, 60% suffered from of abdominal pain, 50% from weight loss, and 40% had intermittent diarrhea. Infected cases with weight percentiles below the fifth had significantly lower serum iron than those with normal percentiles (&gt;5th). In conclusion, most giardiasis-infected children were between 1 and 5 years, with significant affection of weight, abdominal pain, and/or intermittent diarrhea. Serum zinc and iron levels were significantly decreased in the infected group compared to control (P &lt; 0.001).</style></abstract><notes><style face="normal" font="default" size="100%">1559-0720&#xD;Abou-Shady, Omaima&#xD;El Raziky, Mona S&#xD;Zaki, Mayssa Mohamed&#xD;Mohamed, Reham Kamal&#xD;Journal Article&#xD;United States&#xD;Biol Trace Elem Res. 2011 Apr;140(1):1-6. doi: 10.1007/s12011-010-8673-6. Epub 2010 Mar 26.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12011-010-8673-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>209</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Isrctn,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of zinc supplementation in low birth weight infants on severe morbidity and zinc status: a randomised controlled trial (India)</style></title><secondary-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN85633178</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN85633178</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01799773</style></accession-num><abstract><style face="normal" font="default" size="100%">INTERVENTION: 2000 infants in total: Infants in the intervention group will receive one Recommended Daily Allowance (RDA) of elemental zinc (5 mg elemental zinc per day in infants aged 14 days to 6 months and 10 mg per day for infants older than six months) daily for a period of one year compared to placebo (plain glucose) in the control group for a period of 12 months. CONDITION: Low Birth Weight (LBW) ; Neonatal Diseases ; Low birth weight PRIMARY OUTCOME: 1. Hospitalisations, measured at three monthly intervals; 2. Healthcare provider visits, measured at three monthly intervals; 3. Diarrhoea and Acute Respiratory Infection (ARI) morbidity, measured at three monthly intervals; 4. Mortality, death identified at regular home visits; 5. Proportion of stunted and under weight children, measured at three monthly visits; 6. Plasma zinc, copper and iron, measured at baseline and end of study SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Infants aged 14 to 28 days born after 37 weeks of gestation and weighing less than or equal to 2.5 kg at birth (less than 10th percentile of the National Center for Health Statistics [NCHS] median birth weight) 2. Either sex 3. Resides within 7 km of the hospital</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01799773/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>212</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: a Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT00272142</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT00272142</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Birth Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02015549</style></accession-num><abstract><style face="normal" font="default" size="100%">A double blind, randomized, placebo controlled trial is being conducted in which the unit of randomization is 14‐28 days old infants. Infants in the intervention group receive 1 RDA of elemental zinc compared to placebo in the control group, from the day of enrollment till 12 months of age. Infants for enrollment are being identified through daily screening of newborns in two hospitals. Eligible infants are visited at home for enrollment when aged 14‐28 days. The mother is trained in supplement administration. A total of 2000 infants will be enrolled. Infants in the intervention group are being administered a dispersible tablet daily containing 1 RDA of elemental zinc (5 mg elemental zinc per day in infants aged 14 days to 6 months and 10 mg per day for infants older than 6 months) daily till 12 months of age. The placebo contains plain glucose but is similar in taste, color and consistency to the zinc tablet. The tablets are packaged in strips containing 15 tablets each. Monthly supplies of the supplement are given to the caregiver to be kept at home. The supplement is administered by the caregiver (usually the mother) herself and the method of administration is taught at the time of enrollment. At the end of every four weeks the monitor collects the strips for the previous month and records the supplement intake for the previous month by examining the strips and querying the caregiver. Three monthly morbidity visits are conducted by a field investigator to obtain information on the hospitalizations and their causes in the last 3 months, healthcare provider visits in the last 1 month, illnesses for which these were made and severity of these illnesses, diarrhea and respiratory morbidity in the previous 24 hours, week and month. If the infant has been hospitalized in the last 3 months, a hospitalization form is filled to ascertain the reason for hospitalization. In case of deaths, an interview is conducted with the caregiver and a verbal autopsy form is filled. Blood specimens for estimation of plasma zinc, copper and ferritin are being obtained in 15% randomly selected children at baseline and at end study. Weights and lengths are being obtained in a subset of children at birth, 3, 6, 9 and 12 months.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02015549/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">IMPACT STUDY: investigating Microbial Pathogen Activity of Copper Textiles</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT02627092</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT02627092</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Critical Illness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01598975</style></accession-num><abstract><style face="normal" font="default" size="100%">The purpose of this study is to assess the impact of copper linens on hospital acquired infections and drug resistant bacteria.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01598975/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Demirjian, A.</style></author><author><style face="normal" font="default" size="100%">Lucas, C. E.</style></author><author><style face="normal" font="default" size="100%">Garrison, L. E.</style></author><author><style face="normal" font="default" size="100%">Kozak-Muiznieks, N. A.</style></author><author><style face="normal" font="default" size="100%">States, S.</style></author><author><style face="normal" font="default" size="100%">Brown, E. W.</style></author><author><style face="normal" font="default" size="100%">Wortham, J. M.</style></author><author><style face="normal" font="default" size="100%">Beaudoin, A.</style></author><author><style face="normal" font="default" size="100%">Casey, M. L.</style></author><author><style face="normal" font="default" size="100%">Marriott, C.</style></author><author><style face="normal" font="default" size="100%">Ludwig, A. M.</style></author><author><style face="normal" font="default" size="100%">Sonel, A. F.</style></author><author><style face="normal" font="default" size="100%">Muder, R. R.</style></author><author><style face="normal" font="default" size="100%">Hicks, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Epidemic Intelligence Service Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.&#xD;Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.&#xD;Pittsburgh Water and Sewer Authority.&#xD;Epidemic Intelligence Service Pennsylvania Department of Health, Harrisburg.&#xD;Allegheny County Health Department.&#xD;Pennsylvania Department of Health, Pittsburgh.&#xD;Epidemic Intelligence Service VA Office of Public Health Surveillance and Research, Palo Alto, California.&#xD;VA Pittsburgh Healthcare System School of Medicine, University of Pittsburgh, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The importance of clinical surveillance in detecting legionnaires&apos; disease outbreaks: a large outbreak in a hospital with a Legionella disinfection system-Pennsylvania, 2011-2012</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1596-602</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2015/02/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/diagnosis/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Epidemiological Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/diagnosis/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pennsylvania/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Tertiary Care Centers</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; disease</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectants</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare-acquired infection</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">25722201</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Healthcare-associated Legionnaires&apos; disease (LD) is a preventable pneumonia with a 30% case fatality rate. The Centers for Disease Control and Prevention guidelines recommend a high index of suspicion for the diagnosis of healthcare-associated LD. We characterized an outbreak and evaluated contributing factors in a hospital using copper-silver ionization for prevention of Legionella growth in water. METHODS: Through medical records review at a large, urban tertiary care hospital in November 2012, we identified patients diagnosed with LD during 2011-2012. Laboratory-confirmed cases were categorized as definite, probable, and not healthcare associated based on time spent in the hospital during the incubation period. We performed an environmental assessment of the hospital, including collection of samples for Legionella culture. Clinical and environmental isolates were compared by genotyping. Copper and silver ion concentrations were measured in 11 water samples. RESULTS: We identified 5 definite and 17 probable healthcare-associated LD cases; 6 case patients died. Of 25 locations (mostly potable water) where environmental samples were obtained for Legionella-specific culture, all but 2 showed Legionella growth; 11 isolates were identical to 3 clinical isolates by sequence-based typing. Mean copper and silver concentrations were at or above the manufacturer&apos;s recommended target for Legionella control. Despite this, all samples where copper and silver concentrations were tested showed Legionella growth. CONCLUSIONS: This outbreak was linked to the hospital&apos;s potable water system and highlights the importance of maintaining a high index of suspicion for healthcare-associated LD, even in the setting of a long-term disinfection program.</style></abstract><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Demirjian, Alicia&#xD;Lucas, Claressa E&#xD;Garrison, Laurel E&#xD;Kozak-Muiznieks, Natalia A&#xD;States, Stanley&#xD;Brown, Ellen W&#xD;Wortham, Jonathan M&#xD;Beaudoin, Amanda&#xD;Casey, Megan L&#xD;Marriott, Chandra&#xD;Ludwig, Alison M&#xD;Sonel, Ali F&#xD;Muder, Robert R&#xD;Hicks, Lauri A&#xD;Journal Article&#xD;United States&#xD;Clin Infect Dis. 2015 Jun 1;60(11):1596-602. doi: 10.1093/cid/civ153. Epub 2015 Feb 25.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/civ153</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palza, H.</style></author><author><style face="normal" font="default" size="100%">Nunez, M.</style></author><author><style face="normal" font="default" size="100%">Bastias, R.</style></author><author><style face="normal" font="default" size="100%">Delgado, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Ingenieria Quimica y Biotecnologia, Facultad de Ciencias Fisicas y Matematicas, Universidad de Chile, Santiago, Chile. Electronic address: hpalza@ing.uchile.cl.&#xD;Laboratorio de Microbiologia, Instituto de Biologia, Facultad de Ciencias, Pontificia Universidad Catolica de Valparaiso, Valparaiso, Chile.&#xD;Universidad Bernardo OHiggins, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In situ antimicrobial behavior of materials with copper-based additives in a hospital environment</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Antimicrob Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Antimicrob Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">912-917</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2018/02/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/drug therapy/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment and Supplies, Hospital/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Metal Nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">*Nanocomposites</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">In situ antimicrobial tests</style></keyword><keyword><style face="normal" font="default" size="100%">Infection controls</style></keyword><keyword><style face="normal" font="default" size="100%">Polymer composites</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0924-8579</style></isbn><accession-num><style face="normal" font="default" size="100%">29471024</style></accession-num><abstract><style face="normal" font="default" size="100%">Copper and its alloys are effective antimicrobial surface materials in the laboratory and in clinical trials. Copper has been used in the healthcare setting to reduce environmental contamination, and thus prevent healthcare-associated infections, complementing traditional protocols. The addition of copper nanoparticles to polymer/plastic matrices can also produce antimicrobial materials, as confirmed under laboratory conditions. However, there is a lack of studies validating the antimicrobial effects of these nanocomposite materials in clinical trials. To satisfy this issue, plastic waiting room chairs with embedded metal copper nanoparticles, and metal hospital IV pools coated with an organic paint with nanostructured zeolite/copper particles were produced and tested in a hospital environment. These prototypes were sampled once weekly for 10 weeks and the viable microorganisms were analysed and compared with the copper-free materials. In the waiting rooms, chairs with copper reduced by around 73% the total viable microorganisms present, showing activity regardless of the microorganism tested. Although there were only low levels of microorganisms in the IV pools installed in operating rooms because of rigorous hygiene protocols, samples with copper presented lower total viable microorganisms than unfilled materials. Some results did not have statistical significance because of the low load of microorganisms; however, during at least three weeks the IV pools with copper had reduced levels of microorganisms by a statistically significant 50%. These findings show for the first time the feasibility of utilizing the antimicrobial property of copper by adding nanosized fillers to other materials in a hospital environment.</style></abstract><notes><style face="normal" font="default" size="100%">1872-7913&#xD;Palza, Humberto&#xD;Nunez, Mauricio&#xD;Bastias, Roberto&#xD;Delgado, Katherine&#xD;Journal Article&#xD;Netherlands&#xD;Int J Antimicrob Agents. 2018 Jun;51(6):912-917. doi: 10.1016/j.ijantimicag.2018.02.007. Epub 2018 Feb 19.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijantimicag.2018.02.007</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, H. I.</style></author><author><style face="normal" font="default" size="100%">Shih, H. Y.</style></author><author><style face="normal" font="default" size="100%">Lee, C. M.</style></author><author><style face="normal" font="default" size="100%">Yang, T. C.</style></author><author><style face="normal" font="default" size="100%">Lay, J. J.</style></author><author><style face="normal" font="default" size="100%">Lin, Y. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Institute of Environmental Education, National Kaohsiung Normal University, 62 Shen-Chong Road, Yanchao, Kaohsiung 824, Taiwan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro efficacy of copper and silver ions in eradicating Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter baumannii: implications for on-site disinfection for hospital infection control</style></title><secondary-title><style face="normal" font="default" size="100%">Water Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Water Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">73-80</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">2007/07/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Aerobic Bacteria/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Pollutants</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0043-1354 (Print)&#xD;0043-1354</style></isbn><accession-num><style face="normal" font="default" size="100%">17655912</style></accession-num><abstract><style face="normal" font="default" size="100%">Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter baumannii are major opportunistic waterborne pathogens causing hospital-acquired infections. Copper-silver ionization has been shown to be effective in controlling Legionella colonization in hospital water systems. The objective was to determine the efficacy of copper and silver ions alone and in combination in eradicating P. aeruginosa, S. maltophilia and A. baumannii at the concentration applied to Legionella control. Kill curve experiments and mathematical modeling were conducted at copper and silver ion concentrations of 0.1, 0.2, 0.4, 0.8 and 0.01, 0.02, 0.04, 0.08 mg/L, respectively. The combinations of copper and silver ions were tested at concentrations of 0.2/0.02 and 0.4/0.04 mg/L, respectively. Initial organism concentration was ca. of 3 x 10(6)cfu/mL, and viability of the test organisms was assessed at predetermined time intervals. Samples (0.1 mL) withdrawn were mixed with 10 microL neutralizer solution immediately, serially diluted and plated in duplicate onto blood agar plates. The culture plates were incubated for 48 h at 37 degrees C and enumerated for the cfu (detection limit 10 cfu/mL). The results showed all copper ion concentrations tested (0.1-0.8 mg/L) achieved more than 99.999% reduction of P. aeruginosa which appears to be more susceptible to copper ions than S. maltophilia and A. baumannii. Silver ions concentration of 0.08 mg/L achieved more than 99.999% reduction of P. aeruginosa, S. maltophilia and A. baumannii in 6, 12 and 96 h, respectively. Combination of copper and silver ions exhibited a synergistic effect against P. aeruginosa and A. baumannii while the combination exhibited an antagonistic effect against S. maltophilia. Ionization may have a potential to eradicate P. aeruginosa, S. maltophilia and A. baumannii from hospital water systems.</style></abstract><notes><style face="normal" font="default" size="100%">Huang, Hsin-I&#xD;Shih, Hsiu-Yun&#xD;Lee, Chien-Ming&#xD;Yang, Thomas C&#xD;Lay, Jiunn-Jyi&#xD;Lin, Yusen E&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Water Res. 2008 Jan;42(1-2):73-80. doi: 10.1016/j.watres.2007.07.003. Epub 2007 Jul 12.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.watres.2007.07.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>262</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Faranna, M.</style></author><author><style face="normal" font="default" size="100%">Pesado, A.</style></author><author><style face="normal" font="default" size="100%">Rombola, G.</style></author><author><style face="normal" font="default" size="100%">Améstica, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Faranna, Hospital Santojanni, Pilar, Argentina</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increasing the use of long acting reversible contraceptions in public hospital in Argentina</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Contraception and Reproductive Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Contraception and Reproductive Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">83</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><keywords><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">abortion</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">amenorrhea</style></keyword><keyword><style face="normal" font="default" size="100%">Argentina</style></keyword><keyword><style face="normal" font="default" size="100%">basic needs</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">childbirth</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">counseling</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">family planning</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gynecologist</style></keyword><keyword><style face="normal" font="default" size="100%">height</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">implant</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">levonorgestrel releasing intrauterine system</style></keyword><keyword><style face="normal" font="default" size="100%">long-acting reversible contraception</style></keyword><keyword><style face="normal" font="default" size="100%">lowest income group</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">multicenter study</style></keyword><keyword><style face="normal" font="default" size="100%">multipara</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">public hospital</style></keyword><keyword><style face="normal" font="default" size="100%">satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1473-0782</style></isbn><abstract><style face="normal" font="default" size="100%">Context: Long-acting reversible contraceptive methods (LARCs) offer women the option of safe, effectiveness, reversible contraception and requires no action from the user once inserted. Objectives: The aim of the study was to determine demographic profile, factors that influenced women to choose a long acting reversible contraception method, (LARCS), side effects and reasons for discontinuation. Design and methods: We undertook a descriptive, multicenter study involving 293 women in fertile age, including the use of implant, Cu-IUD, LNG-IUS, as a contraceptive method, in a Family Planning Public Hospital in CABA, Argentina. Patients: Study participants were women in fertile age from 14 to 46 years of any nationality, willingness to change or start a new method of contraception, the ability to give signed consent. Data of filiation, weight/height, parity and date of last childbirth or abortion, reasons for choice, side effects, satisfaction and reasons for discontinuation were evaluated from 2015 to 2016 followed up for 6 and 12 month after placement. Main Outcome Measure: 760 patients asked for a contraceptive method. After counseling, subdermal implants were inserted in 76% (n=224) of (n=293), 11% (n=33) out of (n=293) patients chose the Cu-IUD, LNG-IUS were inserted in 13% (n=37) cases of (n=293). Effectiveness, safety and long-acting protection were some of the reasons why 98% of the participants chose them. The recent date of an obstetrical event delivery or recent abortion were decisive in choosing the contraceptive implant. Most of them had one or more children, 152 cases 52% (n=293), 22% (n=66) of the cases were multiparous and low-income, with unsatisfied basic needs, and a great need to plan their pregnancies. The average age was 31 years. Results: Once implants were inserted, we could follow 77 patients: amenorrhea was the main change in their cycle reported in 38% (n=29), extended bleeding in 9% (n=7). Nine percent of them (n=7) had frequent bleeding and 17% of the patients (n=13) presented normal cycle. Three cases of subdermal implants users came for removal: one because of an infection in the place of insertion, one was hysterectomised because of HSIL, one changed her sexual desire. None of them got pregnant. Conclusions: Gynecologists must provide good information for the choice of the birth control methods. Implant should be promoted as a first choice in Public Health, because of its high effectiveness, acceptable and cost-effective. With an adequate counseling, explaining changes in bleeding patterns, we avoid premature discontinuation of the implant.</style></abstract><notes><style face="normal" font="default" size="100%">L621903051&#xD;2018-05-02</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L621903051</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1080/13625187.2018.1442911</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/13625187.2018.1442911</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lewis, S. M.</style></author><author><style face="normal" font="default" size="100%">Stott, G. J.</style></author><author><style face="normal" font="default" size="100%">Wynn, K. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An inexpensive and reliable new haemoglobin colour scale for assessing anaemia</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Pathol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21-4</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1998/05/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anemia/blood/*diagnosis/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Donors</style></keyword><keyword><style face="normal" font="default" size="100%">Color</style></keyword><keyword><style face="normal" font="default" size="100%">Costs and Cost Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobinometry/economics/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Rural Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0021-9746 (Print)&#xD;0021-9746</style></isbn><accession-num><style face="normal" font="default" size="100%">9577366</style></accession-num><abstract><style face="normal" font="default" size="100%">AIM: To describe a new inexpensive method (the WHO Colour Scale) for estimating haemoglobin concentration from a drop of blood by means of a colour scale, and to compare its reliability with a standard laboratory method of measuring haemoglobin, and its clinical usefulness in field trials. METHODS: The new colour scale method was used to measure haemoglobin concentration in 1213 random venous blood samples from routine work in four laboratories (one each in the UK, South Africa, Thailand, and Switzerland). Limited field trials of the method for assessing clinical usefulness were done in a rural hospital (in South Africa) staffed by nurses, at two blood donor sessions (one each in South Africa and Thailand), and by nonlaboratory personnel in malaria clinics (in Thailand), following training and a short practice session. RESULTS: In the laboratory based comparability study the presence of anaemia was reliably detected using the new method with 91% sensitivity and 86% specificity. Clinically relevant levels of anaemia (mild to moderate, pronounced, and severe) were graded and serious anaemia (&lt; 8 g/dl) was identified with an efficiency of 89%. The clinical trials showed the ease and reliability with which the colour scale could be used by non-laboratory persons after brief training. The blood donor trials showed it to be at least as reliable as the copper sulphate method with the advantage of being more convenient. CONCLUSIONS: The preliminary studies have shown that the WHO Colour Scale is a reliable screening method for detecting anaemia, especially for diagnosing serious anaemia. Following a brief training session health workers found it simple to use and, at a cost of about 1/10th that for traditional photometric analysis, it should be of value in &quot;countries in need&quot; for primary health centres, obstetrical management, paediatric clinics, tropical disease control programmes, blood transfusion donor selection, as well as for industrial health checks and epidemiological studies.</style></abstract><notes><style face="normal" font="default" size="100%">Lewis, S M&#xD;Stott, G J&#xD;Wynn, K J&#xD;Clinical Trial&#xD;Journal Article&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Clin Pathol. 1998 Jan;51(1):21-4. doi: 10.1136/jcp.51.1.21.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC500425</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/jcp.51.1.21</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>297</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Capuano, A.</style></author><author><style face="normal" font="default" size="100%">Nicita, F.</style></author><author><style face="normal" font="default" size="100%">Angeloni, M.</style></author><author><style face="normal" font="default" size="100%">Vigevano, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Capuano, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">The inflammatory burden of tic onset in a paediatric cohort: A preliminary study</style></title><secondary-title><style face="normal" font="default" size="100%">Movement Disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Movement Disorders</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S310</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><keywords><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin</style></keyword><keyword><style face="normal" font="default" size="100%">transferrin</style></keyword><keyword><style face="normal" font="default" size="100%">analysis of variance</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">gene inactivation</style></keyword><keyword><style face="normal" font="default" size="100%">group A streptococcal infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">linear regression analysis</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">population based case control study</style></keyword><keyword><style face="normal" font="default" size="100%">school child</style></keyword><keyword><style face="normal" font="default" size="100%">symptom</style></keyword><keyword><style face="normal" font="default" size="100%">tampon</style></keyword><keyword><style face="normal" font="default" size="100%">throat</style></keyword><keyword><style face="normal" font="default" size="100%">tic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1531-8257</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To evaluate the role of inflammatory triggering factors in the onset of tics and Tourette syndrome in a prospective cohort of paediatric population. Background: Chronic tics and Tourette&apos;s syndrome are a neurodevelopment disorders. It has been hypothesised that genetic factors during the development interact with other environmental factors to established the disorder. A great emphasis has been placed on immunological factors. Methods: Paediatric patients attending Movement Disorders Clinic of Bambino Gesù Children&apos;s Hospital were prospectively enrolled in the study. Only patients with an onset of tics less than 6 months and with an history longer than 3 months were included. The patients underwent an extensive clinical, biochemical evaluation. A comprehensive biochemical and immunological work up was performed. All patients performed throat tampon for group A streptococcal infection. Control group was constituted by age -matched healthy children. Patients were clinically evaluated after 6, 9 and 12 months of follow-up. Analysis of variance (ANOVA) was used to compare the the groups; logistic and linear regression was applied to identify variables associated to tic disorders progression. Results: Forty-five patients with relatively recent onset of tics and 20 age matched controls were recruited for the study. The mean age was 9,45+/-5,6 (mean+/-SD), 75% were males and 25% females in both groups. Children with tics had an onset of symptoms of 4,5 months (mean). Thirty children had an associated comorbid condition. We did not find any statistically difference between patients and controls for blood count cells, haemoglobin, total amount of immunoglobulins. Analysis of ferritin, transferrin revealed a statistically higher levels in the patients group compared to controls (p&lt;0.01), while a significant lower levels of non ceruloplasmin copper was found in the patients group. Levels of transferrin and ferritin were found statistically related (linear regression p&lt;0,01) to initial severity of tics. Follow-up revealed that severity of progression of tic disorders was related to higher initial levels transferrin and ferritin (p&lt;0,05), as well as a lower levels of non ceruloplasmin copper (p&lt;0,05). Conclusions: Our preliminary study demonstrates that immunological as well as inflammatory factors may play a role in triggering tics onset in young population.</style></abstract><notes><style face="normal" font="default" size="100%">L612038612&#xD;2016-09-13</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L612038612</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/mds.26688</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mds.26688</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>328</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, J. T.</style></author><author><style face="normal" font="default" size="100%">Yang, J. L.</style></author><author><style face="normal" font="default" size="100%">Lin, C. Y.</style></author><author><style face="normal" font="default" size="100%">Shen, N. J.</style></author><author><style face="normal" font="default" size="100%">Lin, J.</style></author><author><style face="normal" font="default" size="100%">Chen, M. L.</style></author><author><style face="normal" font="default" size="100%">Sheng, W. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.-T. Lee, National Taiwan University Hospital, Yun- Lin Branch, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrating different measures to contain legionella in the healthcare associated environment: A single institute&apos;s experience</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Microbiology, Immunology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Microbiology, Immunology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S164</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">hypochlorite sodium</style></keyword><keyword><style face="normal" font="default" size="100%">chlorine dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">pipeline</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">serotype</style></keyword><keyword><style face="normal" font="default" size="100%">cooling tower</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">pump</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">serotyping</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">disease control</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">immunocompromised patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">temperature</style></keyword><keyword><style face="normal" font="default" size="100%">heat</style></keyword><keyword><style face="normal" font="default" size="100%">heating</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1684-1182</style></isbn><abstract><style face="normal" font="default" size="100%">Purpose: We described the successful experience of using different measures of containing Legionella in our hospital. Methods: We adopted recommendations from Centers for Disease Control and performed water supply surveillance twice each year. The sampled water was sent for screening for Legionella including isolation and serotyping. Results: Our hospital divided into two divisions, a 600-bed 12- to 30-year-old building complex and a 150-bed 6-year-old green building. The old division was equipped with copper-silver alloy at the upstream of water supply system. The new division saved energy using a heat pump with a peaked temperature of no more than 60°C. We performed water surveillance from the reservoir, cooling tower and the pipelines ends in the wards of immunocompromised patients. The water from the new division was positive for Legionella serotype 2-14 (pipeline ends) in May 2013 and serotype 1 (cooling tower) in November 2013. After failing to contain the bacteria by heating, avoiding still water and disinfection of the pipeline ends, we set up a chlorine dioxide pump at the source and achieved continued containment. The water from the old division was positive for Legionella serotype 1 (pipeline ends) in September 2013. We successfully contained the bacteria by shock hyperchlorination (sodium hypochlorite 50 ppm) and disinfection of the pipeline ends. There was no confirmed case of Legionnaires&apos; disease in our hospital. Conclusions: We integrated different measures to contain Legionella in our hospital with continued success.</style></abstract><notes><style face="normal" font="default" size="100%">L72082756&#xD;2015-11-27</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72082756</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Z.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Boldin, M.</style></author><author><style face="normal" font="default" size="100%">Rugh, J.</style></author><author><style face="normal" font="default" size="100%">Diven, W. F.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Pittsburgh, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intermittent use of copper-silver ionization for Legionella control in water distribution systems: a potential option in buildings housing individuals at low risk of infection</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">138-40</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1998/02/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biofilms</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Legionellosis/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838 (Print)&#xD;1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">9455522</style></accession-num><abstract><style face="normal" font="default" size="100%">One copper-silver ionization system was sequentially installed onto the hot-water recirculation lines of two hospital buildings colonized with Legionella pneumophila, serogroup 1. A third building with the same water supply and also colonized with Legionella served as a control. Four weeks after activation of the system, distal site positivity for Legionella in the first test building dropped to zero. After operating for 16 weeks, the system was disconnected and installed onto the second test building. Twelve weeks of disinfection reduced the distal site positivity for Legionella in the second test building to zero. Legionella recolonization did not occur in the first test building for 6-12 weeks and in the second test building for 8-12 weeks after inactivation of the system. The control building remained Legionella-positive throughout the experimental period. A significantly higher copper concentration was found in the biofilm taken from a sampling device than in that from water. This is likely to be the reason that the copper-silver ionization system had the residual effect of preventing early recolonization. Our study raises the possibility that one copper-silver unit could be rotated among several buildings to maintain a Legionella-free environment. Such an approach may be cost-effective for buildings housing individuals at low risk for contracting legionnaires&apos; disease.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Z&#xD;Stout, J E&#xD;Boldin, M&#xD;Rugh, J&#xD;Diven, W F&#xD;Yu, V L&#xD;Journal Article&#xD;United States&#xD;Clin Infect Dis. 1998 Jan;26(1):138-40. doi: 10.1086/516283.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/516283</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">52</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kakaire, O.</style></author><author><style face="normal" font="default" size="100%">Byamugisha, J. K.</style></author><author><style face="normal" font="default" size="100%">Tumwesigye, N. M.</style></author><author><style face="normal" font="default" size="100%">Gemzell-Danielsson, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynaecology and School of Public Health, Makerere University College of Health Sciences, Old Mulago Hill Kampala, Uganda; and the Division of Obstetrics and Gynaecology, Department of Women&apos;s and Children&apos;s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrauterine Contraception Among Women Living With Human Immunodeficiency Virus: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Obstet Gynecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obstet Gynecol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">928-34</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2015/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Agents, Female/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*HIV Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Levonorgestrel/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Compliance/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0029-7844</style></isbn><accession-num><style face="normal" font="default" size="100%">26444127</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare discontinuation rates of the levonorgestrel and copper intrauterine devices (IUDs) among women with human immunodeficiency virus. METHODS: A double-masked randomized trial was conducted at Mulago Hospital, Uganda. Women received either a copper or levonorgestrel IUD. The primary outcome was discontinuation of intrauterine contraception within 1 year of placement. The secondary outcomes were incidence of side effects and severe adverse events. To discern a difference of 10% from a copper IUD discontinuation rate of 18%, power of 80%, and 95% confidence interval (CI), a sample size of 351 per arm was estimated. Analysis of the primary outcome was by intension-to-treat principle. RESULTS: From September 2013 to December 2014, 979 were screened and 703 randomized as follows: 349 to the copper group and 354 to the levonorgestrel group. In total, 8.6% (29/338) women in the copper group compared with 8.1% (27/334) in the levonorgestrel group discontinued intrauterine conception within 1 year of placement (incidence rate ratio 1.1 [95% CI 0.64-1.96]). Overall, the incidence of heavy bleeding was higher in the copper group (37% [125/338]) than in the levonorgestrel group (19.5% [65/334]). However, the incidence of amenorrhea, which occurred in 3.3% (11/338) of women, was lower in the copper group than the 19.8% (66/334) of women who reported amenorrhea in the levonorgestrel group. CONCLUSION: There was no difference in discontinuation rates between the copper and levonorgestrel devices. Women in the levonorgestrel group had reduced incidence of heavy bleeding and a higher incidence of amenorrhea compared with those in the copper group. CLINICAL TRIAL REGISTRATION: Pan African Clinical Trial Registry, www.pactr.org, PACTR 201308000561212. LEVEL OF EVIDENCE: I.</style></abstract><notes><style face="normal" font="default" size="100%">1873-233x&#xD;Kakaire, Othman&#xD;Byamugisha, Josaphat Kayogoza&#xD;Tumwesigye, Nazarius Mbona&#xD;Gemzell-Danielsson, Kristina&#xD;5R24TW008886/TW/FIC NIH HHS/United States&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;Obstet Gynecol. 2015 Nov;126(5):928-34. doi: 10.1097/AOG.0000000000001087.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/aog.0000000000001087</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>361</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">361</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ravi, A.</style></author><author><style face="normal" font="default" size="100%">Rubin, S.</style></author><author><style face="normal" font="default" size="100%">Waltermaurer, E.</style></author><author><style face="normal" font="default" size="100%">Miller, N.</style></author><author><style face="normal" font="default" size="100%">Prine, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Ravi, Beth Israel, New York, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrauterine contraception during the first 6 months: A comparison between adolescents and non-adolescents&apos; clinical concerns, continuation and infection</style></title><secondary-title><style face="normal" font="default" size="100%">Contraception</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contraception</style></full-title></periodical><pages><style face="normal" font="default" size="100%">314</style></pages><volume><style face="normal" font="default" size="100%">88</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">levonorgestrel</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">reproductive health</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia</style></keyword><keyword><style face="normal" font="default" size="100%">sexually transmitted disease</style></keyword><keyword><style face="normal" font="default" size="100%">devices</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">general practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">health center</style></keyword><keyword><style face="normal" font="default" size="100%">groups by age</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0010-7824</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: Intrauterine contraception (IUD) is among the most effective reversible contraceptives, yet is underutilized. Reasons for underuse include clinicians&apos; concerns that, as compared to non-adolescents, adolescents who use IUDs are more likely to (1) require post-insertion clinical attention, (2) prematurely discontinue IUD use, and/or (3) acquire sexually transmitted infections (STIs) including PID. We sought to determine if there is a significant difference in the post-IUD insertion experience of adolescents vs. non-adolescents with regard to these issues. Method: Retrospective chart review of women up to 35 years old with IUDs inserted in 2011 at a NYC Federally Qualified Health Center network of 13 family physician staffed clinical sites. Women were followed six-months post-insertion or until device was discontinued, whichever occurred first. We compared adolescents (women not yet 21years at insertion visit) to nonadolescents on our variables of interest. Results: Six hundred eighty-four women (182/adolescents, 502/nonadolescent) had IUDs inserted (73% levonorgestrel and 27% Copper-T, no significant difference by age). In the 6 months post-insertion, 331 women (113/adolescents, 218/non-adolescents) had at least one followup clinical contact. The most frequent IUD related concerns for both age groups were bleeding changes and pelvic/abdominal pain. Adolescents made an average of 3.7 visits, non-adolescents made 2.7. Among adolescents with follow-up visits, 16% (n=18) had removals, 8% (n=9) expelled and 5% (n=6) were diagnosed with Chlamydia. Among non-adolescents, 17% (n=37) had removals, 5% (n=11) expelled and 2% had Chlamydia (n=3) or PID (n=1). Conclusions: During the 6-month post-IUD insertion, these urban adolescents as compared to non-adolescents were more likely to make an IUD-related follow-up visit; however, clinical concerns and removal rates are similar. While adolescents&apos; expulsion and STI rates are slightly higher than non-adolescents, the overall rates are relatively low. These results may reassure providers about the safety of inserting IUDs in urban adolescents.</style></abstract><notes><style face="normal" font="default" size="100%">L71163053&#xD;2013-09-16</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71163053</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.contraception.2013.04.039</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.contraception.2013.04.039</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kaufman, D. W.</style></author><author><style face="normal" font="default" size="100%">Shapiro, S.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, L.</style></author><author><style face="normal" font="default" size="100%">Monson, R. R.</style></author><author><style face="normal" font="default" size="100%">Miettinen, O. S.</style></author><author><style face="normal" font="default" size="100%">Stolley, P. D.</style></author><author><style face="normal" font="default" size="100%">Slone, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Intrauterine contraceptive device use and pelvic inflammatory disease</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Obstet Gynecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Obstet Gynecol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">159-62</style></pages><volume><style face="normal" font="default" size="100%">136</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">1980/01/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Acceptor Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">*Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Demographic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility Measurements</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Iud, Copper Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">Iud, Unmedicated</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Parity</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Population</style></keyword><keyword><style face="normal" font="default" size="100%">Population Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Population Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1980</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9378 (Print)&#xD;0002-9378</style></isbn><accession-num><style face="normal" font="default" size="100%">7352496</style></accession-num><abstract><style face="normal" font="default" size="100%">We examined the relationship between use of IUD&apos;s and PID, based on 44 women who were admitted to hospitals with first episodes of PID and 259 hospital control subjects. All the women used either IUD&apos;s or oral contraceptives. The age-adjusted relative risk for those using IUD&apos;s at the time of admission was 6.5 (95% confidence interval, 3.2 to 13.0). The association remained when several variables, and particularly parity, were taken into account. There was a suggestion that users who had had an IUD in place for at least 5 years had a higher risk of PID than did users of shorter duration. The data also suggest that copper-containing IUD&apos;s may be safer than other devices.&#xD;The relationship between the use of IUDs and pelvic inflammatory disease (PID) was examined, based on 44 women who were admitted to hospitals with 1st episodes of PID and 259 hospital control subjects. The age-adjusted relative risk estimate was 6.5, and the lower boundary of the 95% confidence interval was 3.2. When religion, ethnic group, marital status, years of education, and family income were separately considered, the findings were not materially changed. Simultaneous adjustment for age and 4 levels of parity increased the relative risk estimate to 7.9. The age-adjusted relative risk estimate for those who had used IUDs continuously for at least 5 years was 12.9 compared with an estimate of 5.7 for those who used IUDs for less than 5 years. The data also suggest that IUDs containing copper may be safer than other types of IUDs. The study suggests that women using IUDs have a rate of hospital admission for PID that is about 7 times greater than the rate among oral contraceptive users.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Kaufman, D W&#xD;Shapiro, S&#xD;Rosenberg, L&#xD;Monson, R R&#xD;Miettinen, O S&#xD;Stolley, P D&#xD;Slone, D&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;Am J Obstet Gynecol. 1980 Jan 15;136(2):159-62. doi: 10.1016/0002-9378(80)90589-x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/0002-9378(80)90589-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>390</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">390</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossiter, B.</style></author><author><style face="normal" font="default" size="100%">Gold, M. A.</style></author><author><style face="normal" font="default" size="100%">Super, D.</style></author><author><style face="normal" font="default" size="100%">Stager, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B. Rossiter, University of Pittsburgh, School of Medicine, Cleveland, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intrauterine device use among urban teens from 2000-2010: A descriptive study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pediatric and Adolescent Gynecology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pediatric and Adolescent Gynecology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e52-e53</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">liquefied natural gas</style></keyword><keyword><style face="normal" font="default" size="100%">levonorgestrel</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">clinical research</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">gynecology</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">pelvis pain syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">pelvic inflammatory disease</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">Hispanic</style></keyword><keyword><style face="normal" font="default" size="100%">dyspareunia</style></keyword><keyword><style face="normal" font="default" size="100%">vagina bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">sexually transmitted disease</style></keyword><keyword><style face="normal" font="default" size="100%">chi square test</style></keyword><keyword><style face="normal" font="default" size="100%">electronic medical record</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">parity</style></keyword><keyword><style face="normal" font="default" size="100%">gravity</style></keyword><keyword><style face="normal" font="default" size="100%">marriage</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">infertility</style></keyword><keyword><style face="normal" font="default" size="100%">nurse practitioner</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">Fisher exact test</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1083-3188</style></isbn><abstract><style face="normal" font="default" size="100%">Background: IUDs are a highly effective, safe, long-acting, and rapidly reversible method of contraception. A misconception remains that IUDs should not be offered to adolescents due to an increased risk of sexually transmitted infections (STI) or pelvic inflammatory disease (PID), and therefore later risk of infertility. Our aim was to perform a retrospective study of adolescent IUD users over a 10-year period, describing the characteristics of IUD use among this population. Methods: A total of 108 electronic medical records were reviewed of patients aged 15-21 years of age who had either a levonorgestrel-releasing IUD (LNG-IUD) 01- Copper IUD (Cu-IUD) inserted in the last 10 years in a gynecology clinic. Data extracted included: age at IUD insertion, race, marital status, gravity and parity, type of provider who inserted IUD, type of IUD, history of previous STI or PID, STI screening 7 days prior to insertion, subsequent STIs or PIDs post IUD insertion, complications post insertion, non immediate expulsions (&gt; 72 hours post insertion), pregnancies, as well as date and reason for IUD removal. Datawas analyzed using SPSS (Window version 17) with Chi-square test, and Fisher&apos;s exact test. Results: Adolescent IUD users had a mean age of 19.8 ± 1.6 years, with a racial/ethnic distribution of White (41.7%), Black (24.1%), Hispanic (29.6%). Most (73.1%) were single and non-nulliparous (97.2%) with 53.7% having 1 living child, 29.6% having 2 children. Most IUDs were inserted by physicians (75.0%) compared to nurse practitioners (18.5%), and the majority were Cu-IUDs (75.0%). Thirty percent (N=&lt;33) were screened for an STI within 7 days before insertion and one patient (3%) had a positive result. In the post-insertion period, 9.3% (N=10) had an STI documented with none occurring in the first 20 days. Three patients (2.8%) had PID diagnosed post insertion with none occurring in the first 20 days. Overall, 57.4% reported a complication post-insertion. Pelvic pain (26.9%) was the most common complication followed by bleeding (25.9%), other (20.4%), cannot find IUD string (12.0%), dyspareunia (8.3%), and UTI (5,6%). Pelvic pain was reported more frequently with the Cu-IUD in comparison to the LNG-IUD (p= 0.029). There were no pregnancies noted during the insertion period. Non-immediate expulsions were reported by 9,3% (N=10) with 2 occurring within 2 months, 4 within 6 months, and 6 occurring greater than 7 months post insertion. The mean length of time to expulsion was 254.2 ± 203.5 days. Removals were seen among 33.3% (N=36) with a mean length of 575.9 ± 483.5 days before removal. The most common reasons for removal were discomfort (12%), vaginal bleeding (10.2%), and desired pregnancy (7.4%). Of the 108 adolescents, 47.2% (N=51) had their IUD still in place at the end of the study period. Conclusions: Pelvic pain was the most common complication and was reported significantly more frequently with the Cu-IUD. Discomfort was the most common reason for early termination. There were no pregnancies during the insertion period while 9.3% had a STI and 2.8% had a PID. Further research should include comparing these results with an adult population and/or with a nulliparous teen population.</style></abstract><notes><style face="normal" font="default" size="100%">L70725607&#xD;2012-05-16</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70725607</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>448</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">448</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cachafeiro, S. P.</style></author><author><style face="normal" font="default" size="100%">Naveira, I. M.</style></author><author><style face="normal" font="default" size="100%">García, I. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.P. Cachafeiro, Galician Agency for Health Technology Assessment, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is copper-silver ionisation safe and effective in controlling legionella?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">209-216</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">tap water</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Cochrane Library</style></keyword><keyword><style face="normal" font="default" size="100%">decolorization</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">economic evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Embase</style></keyword><keyword><style face="normal" font="default" size="100%">high temperature</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">information retrieval</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">legionnaire disease</style></keyword><keyword><style face="normal" font="default" size="100%">Medline</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">water contamination</style></keyword><keyword><style face="normal" font="default" size="100%">water supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><abstract><style face="normal" font="default" size="100%">Copper-silver ionisation is gaining popularity worldwide as a water disinfection method. We review the literature that supports the effectiveness and safety of the copper-silver ionisation pertaining to legionella control in water distribution systems. A search between January 1997 and January 2007 was conducted in relevant health databases: Medline, Embase, NHS CRD, Cochrane Library Plus, Web of Knowledge, IME (Spanish Medical Index) and IBECS (Health Sciences Bibliographic Index). Ten published studies were selected according to inclusion and exclusion criteria previously established; most of these were experimental. Legionella levels decrease with the application of any of the procedures used in these studies and the procedures can be combined to obtain better outcomes. No studies containing an economic evaluation were found. We conclude that copper-silver ionisation is an effective method to control legionella, bearing in mind that eradication cannot be achieved by any method in isolation. Maintaining high temperatures in the water system can maximise effectiveness of the method. Copper-silver appears to be safe, as long as ion levels are monitored and kept within international recommended levels. More studies with concurrent control group, long follow-up and economic evaluation are required to properly assess this procedure. © 2007 The Hospital Infection Society.</style></abstract><notes><style face="normal" font="default" size="100%">L350028513&#xD;2007-12-19</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L350028513</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jhin.2007.07.017</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17904690</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2007.07.017</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Biggs, M. A.</style></author><author><style face="normal" font="default" size="100%">Harper, C.</style></author><author><style face="normal" font="default" size="100%">Kaller, S.</style></author><author><style face="normal" font="default" size="100%">Mays, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.A. Biggs, University of California, San Francisco, Oakland, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">&quot;it takes the stars aligning&quot;: Challenges to providing the copper IUD as emergency contraception (EC) and same-day IUD visits in community health care settings</style></title><secondary-title><style face="normal" font="default" size="100%">Contraception</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contraception</style></full-title></periodical><pages><style face="normal" font="default" size="100%">418</style></pages><volume><style face="normal" font="default" size="100%">94</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">California</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia</style></keyword><keyword><style face="normal" font="default" size="100%">community care</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">emergency contraception</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gonorrhea</style></keyword><keyword><style face="normal" font="default" size="100%">health center</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy test</style></keyword><keyword><style face="normal" font="default" size="100%">staff</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1879-0518</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: We aimed to assess the extent to which community health centers (CHCs) are equipped to offer the IUD as emergency contraception (EC) and same-day IUD placements and to identify barriers to provision of these birth control options. Methods: We surveyed clinicians and staff from 11 CHC sites in the San Francisco Bay Area and interviewed 20 clinicians working in Bay Area CHCs. Results: Among 97 survey respondents (28 clinicians and 69 staff), 40% indicated that in the past 3 years, IUD as EC provision had increased somewhat or very much in their practice, 17% reported that most patients can get an IUD the same day as one is requested, 66% of clinicians reported they had ever placed the IUD and 19% reported they had ever placed an IUD as EC. The most common barriers to same-day IUD placement were the need for pregnancy (37%) and chlamydia/ gonorrhea testing (24%), insufficient time within one visit (31%), the need to wait for pregnancy test results (30%) and the patient&apos;s need for more time to decide (19%). Qualitative findings indicated that scheduling challenges, pressures to see a certain number of patients a day and unavailability of trained clinicians onsite further contributed to challenges to providing this form of EC. Conclusions: Although access to the IUD as EC and same-day IUD placements appear to be increasing within the CHCs surveyed, significant barriers to provision persist. Clinic policies may need to address a variety of system- and provider-level barriers to better meet the needs of patients and expand access to this form of EC.</style></abstract><notes><style face="normal" font="default" size="100%">L614782026&#xD;2017-03-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L614782026</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.contraception.2016.07.131</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.contraception.2016.07.131</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarez Pelayo, J.</style></author><author><style face="normal" font="default" size="100%">Borbolla Sala, M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ginecoobstetra del Hospital General de Zona II C/M.F. en Cardenas Tabasco del IMSS.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[IUD insertion during cesarean section and its most frequent complications]</style></title><secondary-title><style face="normal" font="default" size="100%">Ginecol Obstet Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ginecol Obstet Mex</style></full-title></periodical><pages><style face="normal" font="default" size="100%">330-5</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><edition><style face="normal" font="default" size="100%">1994/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Cesarean Section</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infections/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pain/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Postpartum Period</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine Hemorrhage/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Americas</style></keyword><keyword><style face="normal" font="default" size="100%">Cesarean Section</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Insertion</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Latin America</style></keyword><keyword><style face="normal" font="default" size="100%">Mexico</style></keyword><keyword><style face="normal" font="default" size="100%">North America</style></keyword><keyword><style face="normal" font="default" size="100%">Obstetrical Surgery</style></keyword><keyword><style face="normal" font="default" size="100%">*Postcesarean Section</style></keyword><keyword><style face="normal" font="default" size="100%">*Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">DIU transcesarea y sus complicaciones mas frecuentes.</style></orig-pub><isbn><style face="normal" font="default" size="100%">0300-9041 (Print)&#xD;0300-9041</style></isbn><accession-num><style face="normal" font="default" size="100%">7821830</style></accession-num><abstract><style face="normal" font="default" size="100%">A prospective and cooperative study was done in 152 patients that were submitted to cesarean section. Seventy eight patients received intrauterine device (IUD) T CU 220 during cesarean section, and the other 74 patients only got the cesarean section without IUD. The events that were analyzed during the puerperium were pain, bleeding and infection. We didn&apos;t find any difference in the results between both groups, these were analyzed with the help of the square chi (X2). These results suggest that with an adequate selection of the patients, the insertion of the IUD during the cesarean section is a secure and helpful method for the fertility control for patients with high risk of reproduction.&#xD;78 women were fitted with copper T 220 IUDs during cesarean deliveries at a Mexican Institute of Social Security hospital in Cardenas, Tabasco, between August 1991 and December 1992 in a study of the suitability of IUD insertion during cesareans. A control group consisted of 74 women undergoing cesarean deliveries who did not have IUDs inserted. The average age was 20.6 years for IUD acceptors and 24.9 years for controls. The average number of pregnancies including the current one was 1.3 for the IUD group and 3.2 for the control group. Average gestational age at the time of delivery was 38.5 weeks for the IUD group and 40.1 weeks for the control group. The indication for cesarean was fetopelvic disproportion for 51.2% of the IUD group and 40.5% of controls. The volume of bleeding was normal for 98.7% of IUD acceptors and all in the control group. The IUD was vaginally removed two hours postpartum in the one IUD acceptor with postpartum hemorrhage. The average duration of bleeding was 23.8 days for the IUD group and 22.0 days for the control group. Pain during the postpartum period was described as light for 91.0% and moderate for 9.0% in the IUD group and as light for 93.2% and moderate for 6.8% in the control group. Four cases of endometritis (5.1%) were observed in the IUD group. Three cases of endometritis and one of abscess of the abdominal incision were observed in the control group, for an overall infection rate of 5.4%. One IUD expulsion occurred on the fifteenth postpartum day, for a rate of 1.28%. The strings could be seen in only 21.7% of cases at the six-week check-up. The IUD was visualized by X-ray for 71.7% at the control visit. IUD insertion did not significantly increase postoperative pain, hospital stay, the volume or duration of bleeding, or frequency of infection. The results suggest that IUD insertion during cesarean is a safe and effective method of fertility control for patients at high reproductive risk.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Alvarez Pelayo, J&#xD;Borbolla Sala, M E&#xD;Comparative Study&#xD;Journal Article&#xD;Mexico&#xD;Ginecol Obstet Mex. 1994 Nov;62:330-5.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">spa</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>311</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vicol, L. A.</style></author><author><style face="normal" font="default" size="100%">Hornsberger, A.</style></author><author><style face="normal" font="default" size="100%">Pick, N.</style></author><author><style face="normal" font="default" size="100%">Van Schalkwyk, J.</style></author><author><style face="normal" font="default" size="100%">Bloomenthal, D.</style></author><author><style face="normal" font="default" size="100%">Christilaw, J.</style></author><author><style face="normal" font="default" size="100%">Money, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">L.A. Vicol, Oak Tree Clinic, BCWH,PHSA, Vancouver, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">IUD use in HIV-positive women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the International AIDS Society</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the International AIDS Society</style></full-title></periodical><pages><style face="normal" font="default" size="100%">92</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><keywords><keyword><style face="normal" font="default" size="100%">CD4 antigen</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">estrogen</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">clinical evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">menorrhagia</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">virus load</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">tree</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine device expulsion</style></keyword><keyword><style face="normal" font="default" size="100%">devices</style></keyword><keyword><style face="normal" font="default" size="100%">oak</style></keyword><keyword><style face="normal" font="default" size="100%">hysteroscopy</style></keyword><keyword><style face="normal" font="default" size="100%">sexual intercourse</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">planning</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1758-2652</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Eighty percent of HIV-positive (HIV+) women are of childbearing age, therefore access to effective, safe contraception is essential. Generally, intrauterine device (IUD) provide safe, effective contraception but historically, IUDs were contraindicated in HIV+ women due to concerns regarding infection. Data in HIV+women are scarce. The goal was to assess rate of complications for IUS insertion in HIV+ women. Methods: IUDs insertions in HIV+ women were offered at Oak Tree Clinic (the provincial referral centre for HIV+ women and children) since 2009, following strict clinical evaluations for eligibility. Criteria used for insertion were: not planning a pregnancy for at least one year; requesting a reversible contraceptive, wanted/needed to avoid oestrogen-based methods and CD4&gt;150. STD screening was done in all cases. Demographic information collected included: age, CD4, ARV at insertion and purpose of IUD (contraception vs. cycle control). Results: Data was reviewed from 44 sequential women given IUDs from 2009 to 2014 with ages 17- 48. CD4 count 160-1230 (median 590); 32/44 (73%) had viral loads &lt;40 c/ml, 9 women had detectable VL between 89-126,908 c/ml. 7 were not on ARV therapy. 2 were on ARV but struggled with adherence and were detectable. 3/44 had a copper IUD. 40/44 had a hormonal IUD. 1 had a hormonal followed by a copper IUD. 3 IUDs were inserted for menorrhagia. 1 IUD was for combined therapeutic and contraceptive purposes. 5 requested the hormonal IUD removed not related to reproductive plans. 1 refused reinsertion when the expired hormonal IUD was removed. Complications included four IUD expulsions (9%) (three spontaneous; one partial within the cervix). The rate of expulsion in general population is 6%. One IUD was removed by hysteroscopy due to upward migration of strings and myometrial embedment. One IUD accidentally pulled out during intercourse and required emergent reinsertion of a new device. No IUD related infections or other serious complications occurred, regardless of CD4 count. Conclusions: In this small series of HIV+ women, IUDs were safe and well tolerated. This method of contraception should remain an option for HIV+ women if close follow up of short and long term complications can be followed.</style></abstract><notes><style face="normal" font="default" size="100%">L72112889&#xD;2015-12-16</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72112889</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.7448/IAS.18.5.20426</style></url><url><style face="normal" font="default" size="100%">http://www.jiasociety.org/index.php/jias/article/view/20479/pdf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7448/IAS.18.5.20426</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hepburn, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">IUDs: current perspectives</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Ther (Seaforth)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Ther (Seaforth)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">49-55</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">1994/10/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Abortion, Septic</style></keyword><keyword><style face="normal" font="default" size="100%">Ambulatory Care Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Counseling</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">Health Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Organization and Administration</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy, Ectopic</style></keyword><keyword><style face="normal" font="default" size="100%">*Uterine Perforation</style></keyword><keyword><style face="normal" font="default" size="100%">Clinic Activities</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--beneficial effects</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--beneficial effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Iud--beneficial effects</style></keyword><keyword><style face="normal" font="default" size="100%">Iud--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Perforations</style></keyword><keyword><style face="normal" font="default" size="100%">Program Activities</style></keyword><keyword><style face="normal" font="default" size="100%">Programs</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Tract Infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0311-905X (Print)&#xD;0311-905x</style></isbn><accession-num><style face="normal" font="default" size="100%">12319352</style></accession-num><abstract><style face="normal" font="default" size="100%">Intrauterine devices (IUDs) have been under much adverse media publicity and many product liability lawsuits have been filed since the mid-1970s, when reports of the association of the Dalkon Shield with septic abortion and pelvic inflammatory disease (PID) surfaced. Yet, worldwide, it is estimated that 70 million women are using IUDs (50 million in China). In Scandinavia they are the most popular form of contraception. An international meeting on the current status of IUDs in New York in 1992 concluded that the IUD is a safe and excellent method of contraception for many women. The newest devices, such as Copper TCu380A and the Multiload Cu375, are the most effective. The risk of PID compared with women using no contraception is elevated by a factor of 7.02 only within the first 20 days after IUD insertion. In Norway, where around 40% of women use IUDs, there has been no increase in subfertility rates compared with the US and UK. A large WHO multicenter study in 1989 found that IUD users were 50% less likely to experience ectopic pregnancy than women using no contraception (90% with Copper TCu 380A). The risk of spontaneous abortion is more than doubled and the risks of preterm delivery increased 10-13% with an IUD in situ; therefore, IUDs should be removed as soon as pregnancy is confirmed. If uterine perforation by the device is suspected, it should be located by ultrasound or x-ray and promptly removed. After contraceptive counselling, even experienced general practitioners can insert IUDs at any time during the menstrual cycle, after induced abortion, or complete spontaneous abortion. Heavy menstrual loss or dysmenorrhea are the most common reasons for removing IUDs. Partial or complete IUD expulsion by uterine contractions is most likely during the first 3 months after insertion. Infection should be suspected in any user who develops pelvic pain.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Hepburn, S&#xD;Journal Article&#xD;Australia&#xD;Curr Ther (Seaforth). 1994 Oct;35(10):49-55.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>310</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">310</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garg, R.</style></author><author><style face="normal" font="default" size="100%">Verma, U.</style></author><author><style face="normal" font="default" size="100%">Agrawal, P.</style></author><author><style face="normal" font="default" size="100%">Singh, R.</style></author><author><style face="normal" font="default" size="100%">Rani, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">R. Garg, Department of Obstetrics and Gynecology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Knowledge and attitude of emergency contraception among medical undergraduate students in Northern India</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of SAFOG</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of SAFOG</style></full-title></periodical><pages><style face="normal" font="default" size="100%">25-28</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">estrogen</style></keyword><keyword><style face="normal" font="default" size="100%">progesterone</style></keyword><keyword><style face="normal" font="default" size="100%">acquired immune deficiency syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">attitude to health</style></keyword><keyword><style face="normal" font="default" size="100%">cross-sectional study</style></keyword><keyword><style face="normal" font="default" size="100%">emergency contraception</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fertility</style></keyword><keyword><style face="normal" font="default" size="100%">health care cost</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">interpersonal communication</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">paramedical personnel</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">single drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">structured questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">undergraduate student</style></keyword><keyword><style face="normal" font="default" size="100%">unprotected sex</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">0975-1920&#xD;0974-8938</style></isbn><abstract><style face="normal" font="default" size="100%">Knowledge, awareness and accessibility of emergency contraception (EC) is still lacking. Medical students are the pillars of the future healthcare system. If their knowledge is lacking, we can think that what would be the awareness of the rest of the country. In India, knowledge and awareness of undergraduate students are not been adequately studied till now. Keeping this in mind, the present study aims to assess the knowledge, attitude and practice of EC among medical undergraduate students. Objective: To assess the knowledge, attitude and practice of EC among medical undergraduate students. Materials and methods: This is a cross-sectional study conducted among medical Interns of SN Medical College, Agra. One hundred and fifty students were randomly selected at a general meeting in the campus after a written and informed consent. A predesigned and structured questionnaire was used for collecting information and was completed by the students. Results: The mean age of the respondents was 24 years. Out of which 40% were females and 60% were males. Only, 34.6% said that ECs should be taken after missed pills. Only 40% indicated use of EC after condom breakage and about more than two-third (72%) said it should be used after rape. Knowledge regarding correct time for taking emergency contraceptive pill (ECP) after unprotected sex was present in 118 (78%). A total of 68.7% did not know that ECs were more effective the sooner they were taken. A total of 70 (44.5%) incorrectly said that they were equally effective as traditional methods of contraception. A total of 30% had no knowledge of its mechanism of action about 5% students were not aware of the doses of EC required. Only two-third students were aware of the fact that high dose of E+P is a method of EC. And, only 70% correctly defined timeframe of use of copper intrauterine contraceptive devices (IUCDs). Seventy-four percent students said that apart from formal education, media and internet helped them know about EC. Twenty-six percent additionally said that communication with friends added to their knowledge of ECs. Only, 54 (36%) were aware of the fact that ECs are available free of cost at government hospital. Regarding attitude questions about one-third had the wrong concept that ECs use will leads to more promiscuity, ultimately leading to increased incidence of sexually transmitted diseases (STDs) and even human immunodeficiency virus/infection and acquired immune deficiency syndrome (HIV/AIDS). Seventy-two percent believed that some women will use it more frequently instead of regular contraception. About one half students believed that it may result in complication in future pregnancies or have a negative impact on fertility. About 30% did not want to use ECPs for fear of side effects. Only two-third of participants will recommend to friend/relative in case of need. One hundred and eight (72%) discourage its distribution by paramedical staff. Seventy-two percent said that they should be available without prescription. Thirty-two (22%) did not want to use ECP for fear of side effects. There is a need to improve both education and attitude to use EC with emphasis on available methods and correct timing of use. Therefore, emphasis should be given to contraception in medical teaching. Educating medical community will be at large benefit to the population as a whole. Emergency contraceptives should be easily accessible in hospitals and pharmacies with reduced costs.</style></abstract><notes><style face="normal" font="default" size="100%">L622143412&#xD;2018-05-21&#xD;2018-05-25</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L622143412</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.5005/jp-journals-10006-1380</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5005/jp-journals-10006-1380</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, A.</style></author><author><style face="normal" font="default" size="100%">Lee, A.</style></author><author><style face="normal" font="default" size="100%">McCabe, E.</style></author><author><style face="normal" font="default" size="100%">Jani, S.</style></author><author><style face="normal" font="default" size="100%">Gonzalez, A.</style></author><author><style face="normal" font="default" size="100%">Demissie, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Knowledge And Attitudes Towards Contraceptives Among Adolescents And Young Adults</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Adolescent Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Adolescent Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S122-S123</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">oral contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">African American</style></keyword><keyword><style face="normal" font="default" size="100%">awareness</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive patch</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">counseling</style></keyword><keyword><style face="normal" font="default" size="100%">emergency contraception</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">female condom</style></keyword><keyword><style face="normal" font="default" size="100%">Hispanic</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">injection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">pill</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">sexual health</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword><keyword><style face="normal" font="default" size="100%">vagina ring</style></keyword><keyword><style face="normal" font="default" size="100%">young adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1879-1972&#xD;1054-139X</style></isbn><abstract><style face="normal" font="default" size="100%">Purpose: The American College of Obstetrics and Gynecology (ACOG) recommends intrauterine devices (IUDs) as first-line contraceptive choices for parous and nulliparous adolescents. The American Academy of Pediatrics (AAP) endorses the use of IUDs as contraception to parous adolescents and those who consistently protect themselves against sexually transmitted infections. The Society for Adolescent Health and Medicine (SAHM) supports equal access for all women to the full range of contraception, including long-acting reversible contraceptives (LARCs). Research reveals young women have limited knowledge and access to IUDs. Although the copper IUD can function as emergency contraception (EC), its use as such remains limited. Male partners can influence contraceptive decisions, making it important to understand their perspectives. Perceived knowledge about IUDs among young men is lower than their objective knowledge, with increased disparities existing among minority populations. This study aims to understand baseline contraceptive knowledge and attitudes of adolescents, allowing providers to improve sexual health education and overcome barriers faced by patients when choosing contraceptives. Methods: Subjects were recruited at Staten Island University Hospital’s adolescent clinic. Participants completed an anonymous survey that assessed their knowledge and attitude towards different methods of contraception, with an emphasis on the IUD. Participants were males and females, aged 13-21. Results: Completed surveys totaled 130 (99 females/31 males). Demographically, 17.6% identified as White, 31.3% as Black/African-American, 30.5% as Latino/Hispanic, 3% as Asian, and 14.5% as other. When assessing awareness, percentage awareness per method was: male condoms (100%); oral contraceptive pills (OCPs) (92.2%); female condoms (89.9%); IUDs (66.7%); hormonal implants (63.3%); hormonal injections (76.2%); vaginal rings (72.1%); and contraceptive patches (64.8%). 80.1% of participants were sexually active. 69.5% stated they/their partner were currently using a contraceptive method. Of those using birth control, 71% used condoms, 38% used OCPs, while only 2.6% used IUDs. 56.6% of females and 10.1% of males had heard of IUDs. 60.5% of sexually active participants had heard of IUDs. Despite having heard of IUDs, both male and female participants lacked knowledge regarding specific IUD facts, whether or not they were sexually active. 78.7% of respondents were satisfied with their method of birth control, yet 22.7% had used EC in the past; only 6.4% who had used EC knew the copper IUD could be used for EC. Conclusions: Barriers continue to exist for adolescents and young adults when it comes to contraception, which include access, awareness, and knowledge. This study shows that despite awareness of the IUD, adequate knowledge lacks among adolescents and young adults regarding its utility. The results of this study highlight the need for comprehensive education initiatives. For example, a significant percentage of participants stated they required EC despite satisfaction with their birth control method and a large percentage of participants were unaware that the IUD could also be used as a form of EC. These discrepancies highlight the importance of further comprehensive contraceptive education for adolescent and young adult patients. Enhanced contraceptive options counseling can help providers ensure that their patients make well-informed decisions about contraceptive methods, thus improving their quality of life. Sources of Support: None</style></abstract><notes><style face="normal" font="default" size="100%">L2001444589&#xD;2019-01-11</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2001444589</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jadohealth.2018.10.257</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jadohealth.2018.10.257</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">70</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fusi-Ngwa, C. K.</style></author><author><style face="normal" font="default" size="100%">Payne, V. K.</style></author><author><style face="normal" font="default" size="100%">Asakizi, A. N.</style></author><author><style face="normal" font="default" size="100%">Katte, B. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Animal Biology, Faculty of Science, University of Dschang, West Region, Cameroon. fncathkesah@yahoo.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Knowledge and practice of family planning in Dschang municipality, Cameroon</style></title><secondary-title><style face="normal" font="default" size="100%">Afr J Reprod Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Afr J Reprod Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">137-48</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2013/09/28</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cameroon/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chi-Square Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Agents/adverse effects/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Knowledge, Attitudes, Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Interviews as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Sexually Transmitted Diseases/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1118-4841 (Print)&#xD;1118-4841</style></isbn><accession-num><style face="normal" font="default" size="100%">24069743</style></accession-num><abstract><style face="normal" font="default" size="100%">This study was conducted to examine factors which influence contraception in order to ameliorate services. For 12 consecutive months, 706 consenting women on fertility control presenting at the Dschang District Hospital, Cameroon were interviewed and cervical/blood samples collected for analysis. Study respondents were aged 15-50 years (mean 33.61 +/- 6.29 years). Levonorgestrel implants (46.7%) and medroxyprogesterone injections (27.6%) were cost effective over the intrauterine copper device (9.5%), Norgestrel (7.8%), Norethisterone enanthate (6.7%), male condoms (6.4%), Progestin only pills (1.4%) and spermicides (1.1%). Lack of expertise precluded tubal ligation or implants and vasectomy. Stigmatization, male rejection, giving or taking methods without adequate laboratory services or regular health checks and failure to recognize or report adverse reproductive health changes impacted on contraception. Genital infections were identified in 33.7% respondents, vaginal candidiasis 20%, bacterial vaginosis 19%, HIV/AIDS 90%, chlamydia 6% and &lt; 2% other traditional venereal diseases. Sensitization, education, improved diagnostics and attitude change were adopted.</style></abstract><notes><style face="normal" font="default" size="100%">Fusi-Ngwa, Catherine K&#xD;Payne, Vincent K&#xD;Asakizi, Augustine N&#xD;Katte, Bridget F&#xD;Journal Article&#xD;Nigeria&#xD;Afr J Reprod Health. 2013 Mar;17(1):137-48.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Brennen, C.</style></author><author><style face="normal" font="default" size="100%">Muder, R. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Special Pathogens Laboratory, VA Pittsburgh Health Care System, Pennsylvania 15240, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Legionnaires&apos; disease in a newly constructed long-term care facility</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Am Geriatr Soc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1589-92</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2000/12/29</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/diagnosis/*etiology/mortality/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Electrophoresis, Gel, Pulsed-Field</style></keyword><keyword><style face="normal" font="default" size="100%">Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default" size="100%">*Facility Design and Construction</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/classification/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/diagnosis/*etiology/mortality/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Pennsylvania</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Serotyping</style></keyword><keyword><style face="normal" font="default" size="100%">*Skilled Nursing Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">United States Department of Veterans Affairs</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-8614 (Print)&#xD;0002-8614</style></isbn><accession-num><style face="normal" font="default" size="100%">11129747</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To determine whether a newly-constructed long-term care facility would become colonized with Legionella and whether Legionnaires&apos; disease would occur in residents of this new facility. DESIGN: Prospective environmental surveillance of the hospital&apos;s water distribution system for the presence of Legionella pneumophila during construction. Utilization of diagnostic tests for Legionnaires&apos; disease in cases of nosocomial pneumonia. SETTING: The Pittsburgh VA Health Care System, Aspinwall Division, a two-building 400-bed complex. PARTICIPANTS: Six patients who acquired Legionnaires&apos; disease while in the facility. INTERVENTION: Installation of copper-silver ionization systems. MEASUREMENTS: Isolation of L. pneumophila from potable water and the occurrence of Legionnaires&apos; disease. RESULTS: L. pneumophila serogroup 1 was recovered from the water distribution system within 1 month of operation; 74% (61/82) of distal sites were positive during construction. In the first 2 years of occupancy, six cases of legionellosis were diagnosed. Both clinical isolates of L. pneumophila were identical to environmental isolates by pulsed field gel electrophoresis (PFGE). Copper-silver ionization systems were installed to control Legionella in the water system. CONCLUSIONS: We conclude that long-term care residents are at risk for acquiring nosocomial Legionnaires&apos; disease in the presence of a colonized water system, even in a newly constructed building.</style></abstract><notes><style face="normal" font="default" size="100%">Stout, J E&#xD;Brennen, C&#xD;Muder, R R&#xD;Journal Article&#xD;United States&#xD;J Am Geriatr Soc. 2000 Dec;48(12):1589-92. doi: 10.1111/j.1532-5415.2000.tb03868.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1532-5415.2000.tb03868.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knobloch, J. K.</style></author><author><style face="normal" font="default" size="100%">Tofern, S.</style></author><author><style face="normal" font="default" size="100%">Kunz, W.</style></author><author><style face="normal" font="default" size="100%">Schutze, S.</style></author><author><style face="normal" font="default" size="100%">Riecke, M.</style></author><author><style face="normal" font="default" size="100%">Solbach, W.</style></author><author><style face="normal" font="default" size="100%">Wuske, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Medical Center Hamburg-Eppendorf, Institute for Medical Microbiology, Virology and Hygiene, Department of Hospital Hygiene, Hamburg, Germany.&#xD;German Center for Infection Research, Partner site Hamburg-Lubeck-Borstel, Germany.&#xD;University Hospital of Schleswig-Holstein, Campus Lubeck, Clinic for Medical Microbiology and Infectiology, Lubeck, Germany.&#xD;Dragerwerk AG &amp; Co. KGaA, Lubeck, Germany.&#xD;University Lubeck, Center for Infection and Inflammation Research (ZIEL), Lubeck, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">&quot;Life-like&quot; assessment of antimicrobial surfaces by a new touch transfer assay displays strong superiority of a copper alloy compared to silver containing surfaces</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0187442</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2017/11/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><accession-num><style face="normal" font="default" size="100%">29135999</style></accession-num><abstract><style face="normal" font="default" size="100%">Transmission of bacteria from inanimate surfaces in healthcare associated environments is an important source of hospital acquired infections. A number of commercially available medical devices promise to fulfill antibacterial activity to reduce environmental contamination. In this study we developed a touch transfer assay modeling fingerprint transmission to investigate the antibacterial activity of surfaces, with confirmed antibacterial activity by a modified ISO 22196 (JIS Z 2801) assay to test such surfaces under more realistic conditions. Bacteria were taken up from a dry standardized primary contaminated surface (PCS) with disinfected fingers or fingers covered with sterile and moistened cotton gloves. Subsequently, bacteria were transferred by pressing on secondary contaminated surfaces (SCS) with or without potential antibacterial activity and the relative reduction rate was determined after 24 h. A stable transmission rate between PCS and SCS was observed using moistened sterile gloves. A copper containing alloy displayed at least a tenfold reduction of the bacterial load consistently reaching less than 2.5 cfu/cm2. In contrast, no significant reduction of bacterial contamination by silver containing surfaces and matured pure silver was observed in the touch transfer assay. With the touch transfer assay we successfully established a new reproducible method modeling cross contamination. Using the new method we were able to demonstrate that several surfaces with confirmed antimicrobial activity in a modified ISO 22196 (JIS Z 2801) assay lacked effectiveness under defined ambient conditions. This data indicate that liquid based assays like the ISO 22196 should be critically reviewed before claiming antibacterial activity for surfaces in the setting of contamination of dry surfaces by contact to the human skin. We suggest the newly developed touch transfer assay as a new additional tool for the assessment of potential antimicrobial surfaces prior utilization in hospital environments.</style></abstract><notes><style face="normal" font="default" size="100%">1932-6203&#xD;Knobloch, Johannes Karl-Mark&#xD;ORCID: http://orcid.org/0000-0002-2591-6387&#xD;Tofern, Sabrina&#xD;Kunz, Wladimir&#xD;Schutze, Sara&#xD;Riecke, Michael&#xD;Solbach, Werner&#xD;Wuske, Thomas&#xD;Comparative Study&#xD;Journal Article&#xD;United States&#xD;PLoS One. 2017 Nov 14;12(11):e0187442. doi: 10.1371/journal.pone.0187442. eCollection 2017.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5685567</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0187442</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>234</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tariq, S.</style></author><author><style face="normal" font="default" size="100%">Conway, U.</style></author><author><style face="normal" font="default" size="100%">Tariq, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Tariq, University Hospital Galway, Galway City, Ireland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Listeriois with non specific symptoms: A dilemma</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Obstetrics Gynecology and Reproductive Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European journal of obstetrics gynecology and reproductive biology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e218-e219</style></pages><volume><style face="normal" font="default" size="100%">234</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">levothyroxine sodium</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil cytoplasmic antibody</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinamide adenine dinucleotide</style></keyword><keyword><style face="normal" font="default" size="100%">parietal cell antibody</style></keyword><keyword><style face="normal" font="default" size="100%">vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal pain</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase level</style></keyword><keyword><style face="normal" font="default" size="100%">blood culture</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">clinician</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fetus</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">food poisoning</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">hypothyroidism</style></keyword><keyword><style face="normal" font="default" size="100%">listeriosis</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">loss of appetite</style></keyword><keyword><style face="normal" font="default" size="100%">meconium</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">nausea</style></keyword><keyword><style face="normal" font="default" size="100%">placenta</style></keyword><keyword><style face="normal" font="default" size="100%">pregnant woman</style></keyword><keyword><style face="normal" font="default" size="100%">premature labor</style></keyword><keyword><style face="normal" font="default" size="100%">primigravida</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract disease</style></keyword><keyword><style face="normal" font="default" size="100%">vaginal delivery</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1872-7654&#xD;0301-2115</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Listeriosis is a rare infection, but is 20 times more common in pregnancy. Should be considered in pregnant women who present with non specific symptoms. It can present as a dilemma? To clinicians as there are no data to guide the management of an exposed, afebrile pregnant woman with mild symptoms that do not strongly suggest Listeriosis? Objective: As preventive measure, foods with a high risk of contamination with Listeria should be discussed at booking visit. Methods: A case of a 37 year old with average BMI in her second IVF pregnancy. Her first pregnancy was uneventful and resulted in a spontaneous vaginal delivery. She had a background medical history of Hypothyroidism well controlled with Eltroxin. At 29 weeks gestation, the patient presented to the maternity assessment unit of a different hospital with nausea 5/7, feeling hot, abdominal pain score 3/10, no appetite, vomiting 2 episodes 2/7 ago, no diarrhoea, no urinary symptoms, urinalysis showed 1+ protein. Her IMEWS were 0. She had URTI 2/52 ago and had Pertusis vaccine 1/52 ago. She had no temperature or sick contacts and her abdominal exam was NAD. FBC, CRP and liver screen (ANA, ANCA, SMA, AMA, LKM-1, Anti-Parietal cell antibodies?) were normal. Raised AST, ALT, Alpha 1 anti trysin and plasma/serum Copper with low IgG. At 30 + 3 weeks presented with preterm labour, NRCTG and pyrexia of 38.7 C. Septic screening done, started on broad spectrum antibiotics and had an EMCS which showed meconium stained liquor. Blood culture and placental swabs grew Listeria monocytogenes. Had devastating effects on fetus. Discussion and conclusions: IMEWS 0 does not mean there is no problem. Reduce dismissive attitude to vague symptoms. Treat patient, not overcomplicated blood tests. EDUCATE: Discuss food-borne diseases and its implications in pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">L2001485348&#xD;2019-02-22</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2001485348</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ejogrb.2018.08.117</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejogrb.2018.08.117</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Litigation avoided when screening, follow-up used</style></title><secondary-title><style face="normal" font="default" size="100%">Contracept Technol Update</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contracept Technol Update</style></full-title></periodical><pages><style face="normal" font="default" size="100%">61-4</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">1995/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ambulatory Care Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Americas</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Counseling</style></keyword><keyword><style face="normal" font="default" size="100%">Developed Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">Health Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">*Jurisprudence</style></keyword><keyword><style face="normal" font="default" size="100%">North America</style></keyword><keyword><style face="normal" font="default" size="100%">Organization and Administration</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Sexually Transmitted Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">Clinic Activities</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--legal aspects</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--legal aspects</style></keyword><keyword><style face="normal" font="default" size="100%">*Litigation</style></keyword><keyword><style face="normal" font="default" size="100%">Northern America</style></keyword><keyword><style face="normal" font="default" size="100%">Program Activities</style></keyword><keyword><style face="normal" font="default" size="100%">Programs</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Tract Infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0274-726X (Print)&#xD;0274-726x</style></isbn><accession-num><style face="normal" font="default" size="100%">12319643</style></accession-num><abstract><style face="normal" font="default" size="100%">GynoPharma Inc. recommends that its copper T380A IUD be used only among women who have had at least one child. Several studies conducted in Europe and New Zealand, however, have demonstrated that nulliparous women tolerate the device as well as parous women. At three years, there was no difference in the termination rates, including expulsion, between two groups of women studied in Belgium. The studies indicate that a woman&apos;s childbearing status does not influence whether she will successfully use an IUD; rather nulliparous women tend to be younger, and younger women tend to have multiple partners. Women with multiple partners tend to contract sexually transmitted diseases (STD) more often than monogamous women, STDs can lead to pelvic inflammatory disease (PID), and PID can lead to infertility. Careful subject screening, recommendation of IUD use only to appropriate acceptors, and post-insertion follow-up are therefore necessary to both provide the highest level of reproductive health to the IUD user and avoid client-provider litigation should problems arise from IUD use. IUD use should be accepted by the nulliparous woman only when she is in a mutually monogamous sexual relationship devoid of STDs. IUD-related legal cases are rare, with all identified adverse judgements in physician malpractice claims related to post-insertion treatment.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Journal Article&#xD;United States&#xD;Contracept Technol Update. 1995 May;16(5):61-4.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>350</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">350</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gündoğan, K.</style></author><author><style face="normal" font="default" size="100%">Bayram, A.</style></author><author><style face="normal" font="default" size="100%">Alp, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Gündoğan, Erciyes Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Yoğun Bakım Bilim Dalı, Kayseri, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Malnutrition in intensive care units: An important risk factor for intensive care unit-acquired infections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medical and Surgical Intensive Care Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical and Surgical Intensive Care Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">36-42</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">2 oxo 4 thiazolidinecarboxylic acid</style></keyword><keyword><style face="normal" font="default" size="100%">acetylcysteine</style></keyword><keyword><style face="normal" font="default" size="100%">arginine</style></keyword><keyword><style face="normal" font="default" size="100%">cysteine</style></keyword><keyword><style face="normal" font="default" size="100%">glutamine</style></keyword><keyword><style face="normal" font="default" size="100%">methionine</style></keyword><keyword><style face="normal" font="default" size="100%">omega 3 fatty acid</style></keyword><keyword><style face="normal" font="default" size="100%">prebiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">sulfur amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">synbiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal infection</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">catheter infection</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">disease predisposition</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug mechanism</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">dysphagia</style></keyword><keyword><style face="normal" font="default" size="100%">enteric feeding</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunonutrition</style></keyword><keyword><style face="normal" font="default" size="100%">infection risk</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit acquired infection</style></keyword><keyword><style face="normal" font="default" size="100%">malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">protein degradation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">social status</style></keyword><keyword><style face="normal" font="default" size="100%">stress</style></keyword><keyword><style face="normal" font="default" size="100%">taste disorder</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1309-6222&#xD;1309-1689</style></isbn><abstract><style face="normal" font="default" size="100%">Intensive care units have the highest prevalence of nosocomial infections in hospitals. Good nutritional support is essential to prevent nosocomial infections. However, malnutrition is a common and important problem in intensive care units, especially in developing countries. For the prevention of malnutrition, a team approach is needed. Immunonutrition is nutrition that affects the immune response in various ways and increases the strength of the immune system. Pharmaconutrition is the administration of immunonutrients over the daily recommended doses that act like pharmacological agents and drugs. The major immunonutrients are glutamine, arginine, omega-3 fatty acids, nucleotides, antioxidants (selenium, vitamin E, vitamin C, zinc, copper, and N-acetyl cysteine), probiotics, prebiotics, and synbiotics. The aim of this review is to highlight the pathophysiology and role of malnutrition in intensive care unit-acquired infections (ICU-AIs) and the use of immunonutrients to prevent ICU-AIs</style></abstract><notes><style face="normal" font="default" size="100%">L602267903&#xD;2015-02-20&#xD;2015-02-24</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L602267903</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.5152/dcbybd.2014.591</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5152/dcbybd.2014.591</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English&#xD;Turkish</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">84</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Warnes, S. L.</style></author><author><style face="normal" font="default" size="100%">Keevil, C. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Healthcare Unit, School of Biological Sciences, Life Sciences Building 85, University of Southampton, Highfield, Southampton SO17 1BJ, UK. s.l.warnes@soton.ac.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mechanism of copper surface toxicity in vancomycin-resistant enterococci following wet or dry surface contact</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6049-59</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">17</style></number><edition><style face="normal" font="default" size="100%">2011/07/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecalis/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus faecium/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fomites/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Vancomycin Resistance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0099-2240</style></isbn><accession-num><style face="normal" font="default" size="100%">21742916</style></accession-num><abstract><style face="normal" font="default" size="100%">Contaminated touch surfaces have been implicated in the spread of hospital-acquired infections, and the use of biocidal surfaces could help to reduce this cross-contamination. In a previous study we reported the death of aqueous inocula of pathogenic Enterococcus faecalis or Enterococcus faecium isolates, simulating fomite surface contamination, in 1 h on copper alloys, compared to survival for months on stainless steel. In our current study we observed an even faster kill of over a 6-log reduction of viable enterococci in less than 10 min on copper alloys with a &quot;dry&quot; inoculum equivalent to touch contamination. We investigated the effect of copper(I) and copper(II) chelation and the quenching of reactive oxygen species on cell viability assessed by culture and their effects on genomic DNA, membrane potential, and respiration in situ on metal surfaces. We propose that copper surface toxicity for enterococci involves the direct or indirect action of released copper ionic species and the generation of superoxide, resulting in arrested respiration and DNA breakdown as the first stages of cell death. The generation of hydroxyl radicals by the Fenton reaction does not appear to be the dominant instrument of DNA damage. The bacterial membrane potential is unaffected in the early stages of wet and dry surface contact, suggesting that the membrane is not compromised until after cell death. These results also highlight the importance of correct surface cleaning protocols to perpetuate copper ion release and prevent the chelation of ions by contaminants, which could reduce the efficacy of the surface.</style></abstract><notes><style face="normal" font="default" size="100%">1098-5336&#xD;Warnes, S L&#xD;Keevil, C W&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Appl Environ Microbiol. 2011 Sep;77(17):6049-59. doi: 10.1128/AEM.00597-11. Epub 2011 Jul 8.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3165410</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aem.00597-11</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>398</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">398</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benedict, M.</style></author><author><style face="normal" font="default" size="100%">Dimitri, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Benedict, Vitebsk State Medical University, Belarus</style></auth-address><titles><title><style face="normal" font="default" size="100%">Meningococcal disease, septic shock, nitroside and oxidative stress</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Medical Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Medical Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">50</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><keywords><keyword><style face="normal" font="default" size="100%">nitrite</style></keyword><keyword><style face="normal" font="default" size="100%">nitrate</style></keyword><keyword><style face="normal" font="default" size="100%">nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">cytokine</style></keyword><keyword><style face="normal" font="default" size="100%">alkadiene</style></keyword><keyword><style face="normal" font="default" size="100%">malonaldehyde</style></keyword><keyword><style face="normal" font="default" size="100%">pentoxifylline</style></keyword><keyword><style face="normal" font="default" size="100%">cysteine</style></keyword><keyword><style face="normal" font="default" size="100%">thiol group</style></keyword><keyword><style face="normal" font="default" size="100%">ammonia</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">copper sulfate</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">student</style></keyword><keyword><style face="normal" font="default" size="100%">scientist</style></keyword><keyword><style face="normal" font="default" size="100%">meningococcosis</style></keyword><keyword><style face="normal" font="default" size="100%">plasma</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">donor</style></keyword><keyword><style face="normal" font="default" size="100%">conjugate</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">blood transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">anaerobic bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">photometry</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0949-2321</style></isbn><abstract><style face="normal" font="default" size="100%">Introuduction: Among the infectious lesions of the central nervous system, a central role is occupied by various aerobic and anaerobic bacteria. Mortality reaches 60% in patients with development of generalized forms of meningococcal infection complicated by the development of septic shock. Key role in the pathogenesis of septic shock belongs molecule nitric oxide (NO). Concerning that the main triggering triggers of synthesis of NO is a cytokine, it was offered a whole pathogenetic anti cytokine treatment strategy. It was found that nitric oxide reacts with the SH-groups of cysteine, forming Snitrosothiols. Methods: A group of 6 patients were diagnosed with meningococcal disease complicated with septic shock based on their complaints, medical history &amp; clinical and laboratory data. Control group consisted of 10 healthy blood transfusion donors. Additionally, work has been used in biochemical methods to determine the level of nitrite / nitrate, malondialdehyde, diene conjugates and total antioxidant activity of plasma. The level of nitrite / nitrate was determined by the method based on the restoration of nitrate to nitrite with zinc dust in alkaline medium in the presence of ammonia complex of copper sulfate, followed by photometry technique Solodkova. The level of malondialdehyde in plasma was determined using Andreeva method. The level of diene conjugates in plasma were obtained from Gavrilov method. Total antioxidant activity of blood plasma was obtained by the Klebanov method. Results: On the 1st day the patients had a plasma concentration of 38,6 ± 9,94 mmol/l which reduced in the 3rd day thus significantly keeping it higher than the donors. Conclusion: In shock during meningococcal infection, there&apos;s a hyperproduction of nitric oxide molecules (increase of nitrite / nitrate plasma) till 7 days from the day of occurrence, which needs pentoxifylline. In patients with meningococcal disease, complicated with secondary shock there&apos;s increase in MD, reducing CAAP.</style></abstract><notes><style face="normal" font="default" size="100%">L71294462&#xD;2014-01-24</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71294462</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doh, A. S.</style></author><author><style face="normal" font="default" size="100%">Ndom, P.</style></author><author><style face="normal" font="default" size="100%">Awasum, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.S. Doh, Dept. of Obstetrics and Gynaecology, CHU, Yaounde, Cameroon</style></auth-address><titles><title><style face="normal" font="default" size="100%">Menstrual pattern of wearers of IUDs: A comparative study of the TCU380A and the TCU200 in Yaounde, Cameroon</style></title><secondary-title><style face="normal" font="default" size="100%">Italian Journal of Gynaecology and Obstetrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Italian Journal of Gynaecology and Obstetrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">19-23</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">Cameroon</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">comparative study</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">developing country</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">female sterilization</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human experiment</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">menstrual cycle</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year></dates><isbn><style face="normal" font="default" size="100%">2385-0868&#xD;1121-8339</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: The search for better contraceptives continues. The intrauterine device (IUD) is one of the most widely used contraceptives in developing countries. One of the commonest reasons for discontinuation is bleeding disorders. We assessed menstrual patterns of wearers of the TCU200 and TCU380A. Methods: We enrolled 277 women in a study at the University Teaching Hospital (CHU), Yaounde, over a 27-month period starting June 1986. We compared two copper-bearing devices (the TCU200 and the newly introduced TCU380A). The women were randomly allocated into the two groups and were followed up for at least a year. Results: We compared the menstrual patterns in addition to other variables over the study period and found no significant differences between the two groups (P 0.05). Conclusion: The lack of differences in the menstrual patterns may be partly due to the relatively large loss to follow-up in this study. Even so, the life span of the TCU380A is virtually double that of the TCU200. It should therefore be a better option for women who want to space their children at long intervals or are not quite ready for sterilization though they want no more children.</style></abstract><notes><style face="normal" font="default" size="100%">L25023716&#xD;1995-01-24</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L25023716</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>381</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">381</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bleichert, P.</style></author><author><style face="normal" font="default" size="100%">Espirito Santo, C.</style></author><author><style face="normal" font="default" size="100%">Grass, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Bleichert, Institut für Mikrobiologie der Bundeswehr, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Metallic copper surfaces efficiently inactivate bacterial biothreat agents</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Medical Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Medical Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">30-31</style></pages><volume><style face="normal" font="default" size="100%">302</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">stainless steel</style></keyword><keyword><style face="normal" font="default" size="100%">membrane lipid</style></keyword><keyword><style face="normal" font="default" size="100%">hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">microorganism</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">species</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">environmental protection</style></keyword><keyword><style face="normal" font="default" size="100%">Burkholderia mallei</style></keyword><keyword><style face="normal" font="default" size="100%">Burkholderia pseudomallei</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">membrane</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella melitensis</style></keyword><keyword><style face="normal" font="default" size="100%">Francisella tularensis</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">kinetics</style></keyword><keyword><style face="normal" font="default" size="100%">Yersinia pestis</style></keyword><keyword><style face="normal" font="default" size="100%">staining</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">solid</style></keyword><keyword><style face="normal" font="default" size="100%">fomite</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1438-4221</style></isbn><abstract><style face="normal" font="default" size="100%">Currently, there is increasing interest in metallic copper (Cu) surfaces due to their inherent antimicrobial properties recently demonstrated to diminish surface related contamination. Dry metallic Cu surfaces demonstrated their hygiene improving potential both in laboratory studies and hospital trials, by rapid inactivation of a wide variety of microorganisms. Due to this property metallic copper is the first solid material to be declared antimicrobial in 2008 by theUS Environmental Protection Agency (EPA). The mechanism by which microbes are killed by dry metallic Cu surfaces is currently discussed controversially. Nonetheless, most microbes exposed to metallic Cu surfaces are inactivated within minutes by a quick and sharp Cu-overload shock in a process termed “contact-killing”. Bacterial species able to evade the host immune system are among the most serious lethal microbial challenges to human health. This group of pathogens comprises biothreat species classified by the Centers for Disease and Control and Prevention (CDC) as bacterial select agents with the potential to be misused for bioterrorist purposes. Here, we investigated the effectiveness of metallic Cu surface mediated “contact-killing” against various biothreat bacteria that cause high morbidity and mortally rates in humans (Brucella melitensis, Burkholderia mallei, Burkholderia pseudomallei, Francisella tularensis tularensis and Yersinia pestis). The pathogens&apos; inactivation kinetics validated rapid inactivation in the minute ranges on dry metallic Cu. In contrast, stainless steel control surfaces were not antimicrobial. Further, we demonstrated by LIVE/DEAD®-staining the ability of metallic Cu surfaces to disrupt the membrane integrity of exposed bacteria. Investigations on potential additional sensitive cellular targets such as membrane lipids and proteins as well as genomic material are on-going. Finally, we showed that “contactkilling” did not induce the potentially infectious viable-but-not-culturable state (VBNC) in the bacteria investigated. Taken together, these results can be expected to open the path to new strategies aimed at preventing surfacemediated spread of bacterial biothreat agents using metallic Cu as additional hygiene improving instruments and also to aid in the struggle against nosocomial- and other fomite-mediated infections.</style></abstract><notes><style face="normal" font="default" size="100%">L70937935&#xD;2012-12-14</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70937935</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ijmm.2012.08.002</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijmm.2012.08.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agarwal, K.</style></author><author><style face="normal" font="default" size="100%">Sharma, U.</style></author><author><style face="normal" font="default" size="100%">Acharya, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynaecology, SMS Medical College, Jaipur, India. aranag@rediffmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microbial and cytopathological study of intrauterine contraceptive device users</style></title><secondary-title><style face="normal" font="default" size="100%">Indian J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Indian J Med Sci</style></full-title></periodical><pages><style face="normal" font="default" size="100%">394-9</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2004/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine Cervical Diseases/*microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Uterus/microbiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal Smears</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0019-5359 (Print)&#xD;0019-5359</style></isbn><accession-num><style face="normal" font="default" size="100%">15470281</style></accession-num><abstract><style face="normal" font="default" size="100%">CONTEXT: Intrauterine contraceptive device (IUCD) is a commonly used birth-spacing method which is fitted into maternal system. Clinical, microbial and cytopathological monitoring of women using these devices are important for ascertaining their side effects, risk of genital tract infection and carcinogenic potential. AIMS: To study clinical, microbial and cytopathological changes in IUCD users in a tertiary care hospital. DESIGN: Prospective analytic. SETTING: Tertiary hospital. MATERIAL AND METHODS: women visiting Family Planning clinic for follow up (IUCD users, n=100) or for IUCD insertion (controls, n=50) were enrolled in the study. Each subject underwent detailed history, general physical, systemic, and per local examination. Vaginal discharge was subjected to pH testing, KOH and wet mount examination, gram staining, and for culture and sensitivity. Bacterial vaginosis was defined using Nugent criteria. Cervical smears were examined and reported as per Bethesda system. STATISTICAL ANALYSIS: The information was entered into Microsoft Excel spreadsheet. The results were analyzed using EPI Info version-6 and Stata statistical software version 7 packages. Two-tailed t-test, chi2 test with Yates correction and two-tailed Fisher Exact tests were applied. RESULTS: Most women used CuT 200 (92%). Median duration of use was 2 years. Chief complaints of IUCD users included backache (54%), vaginal discharge (46%), pain lower abdomen (34%), dyspareunia (22%), menorrhagia (18%) and dysmenorrhea (14%). Mean hemoglobin was lower in IUCD users than controls (11.2+/-1.7 versus 11.9+/-1.8 g/dL, p 0.02). Proportion of women with anemia was higher in IUCD users than in controls (29% versus 16%, p 0.12). Cervical erosion was significantly increased in study group as compared the controls (20% versus 0%, p=0.00) whereas only insignificant increase in vaginitis (6% versus 0%, p=0.17). Trichomonas vaginalis and fungal hyphae positivity and gram stain findings and bacterial vaginosis rate were not significantly different in two groups. Vaginal discharge bacterial culture revealed comparable results in two groups. Cytological findings were predominantly inflammatory. None of cases revealed Actinomycosis infection. High-grade squamous intraepithelial lesion (n=2) and low grade squamous intraepithelial lesion (n=1) cytological finding were present in IUCD users compared to none in controls. None of the cases had any malignant transformation. CONCLUSION: IUCD use results in lower hemoglobin concentration and cervical erosion. Women using IUCD requires a regular follow up, clinical examination, counseling and further investigation if required.</style></abstract><notes><style face="normal" font="default" size="100%">Agarwal, Krishna&#xD;Sharma, Usha&#xD;Acharya, Veena&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;India&#xD;Indian J Med Sci. 2004 Sep;58(9):394-9.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">27</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stuken, A.</style></author><author><style face="normal" font="default" size="100%">Haverkamp, T. H. A.</style></author><author><style face="normal" font="default" size="100%">Dirven, Haam</style></author><author><style face="normal" font="default" size="100%">Gilfillan, G. D.</style></author><author><style face="normal" font="default" size="100%">Leithaug, M.</style></author><author><style face="normal" font="default" size="100%">Lund, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. Zoonotic, Food and Waterborne Infections , Norwegian Institute of Public Health , Oslo , Norway.&#xD;Centre for Ecological and Evolutionary Synthesis (CEES), Department of Biosciences , University of Oslo , Blindern, Oslo , Norway.&#xD;Dept. Toxicology and Risk Assessment , Norwegian Institute of Public Health , Oslo , Norway.&#xD;Dept. Medical Genetics , Oslo University Hospital and University of Oslo , Oslo , Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microbial Community Composition of Tap Water and Biofilms Treated with or without Copper-Silver Ionization</style></title><secondary-title><style face="normal" font="default" size="100%">Environ Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Environ Sci Technol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3354-3364</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2018/02/21</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biofilms</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Drinking Water</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Purification</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 20</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0013-936x</style></isbn><accession-num><style face="normal" font="default" size="100%">29461810</style></accession-num><abstract><style face="normal" font="default" size="100%">Copper-silver ionization (CSI) is an in-house water disinfection method primarily installed to eradicate Legionella bacteria from drinking water distribution systems (DWDS). Its effect on the abundance of culturable Legionella and Legionella infections has been documented in several studies. However, the effect of CSI on other bacteria in DWDS is largely unknown. To investigate these effects, we characterized drinking water and biofilm communities in a hospital using CSI, in a neighboring building without CSI, and in treated drinking water at the local water treatment plant. We used 16S rDNA amplicon sequencing and Legionella culturing. The sequencing results revealed three distinct water groups: (1) cold-water samples (no CSI), (2) warm-water samples at the research institute (no CSI), and (3) warm-water samples at the hospital (after CSI; ANOSIM, p &lt; 0.001). Differences between the biofilm communities exposed and not exposed to CSI were less clear (ANOSIM, p = 0.022). No Legionella were cultured, but limited numbers of Legionella sequences were recovered from all 25 water samples (0.2-1.4% relative abundance). The clustering pattern indicated local selection of Legionella types (Kruskal-Wallis, p &lt; 0.001). Furthermore, one unclassified Betaproteobacteria OTU was highly enriched in CSI-treated warm water samples at the hospital (Kruskal-Wallis, p &lt; 0.001).</style></abstract><notes><style face="normal" font="default" size="100%">1520-5851&#xD;Stuken, Anke&#xD;Orcid: 0000-0002-7553-9524&#xD;Haverkamp, Thomas H A&#xD;Dirven, Hubert A A M&#xD;Gilfillan, Gregor D&#xD;Leithaug, Magnus&#xD;Lund, Vidar&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Environ Sci Technol. 2018 Mar 20;52(6):3354-3364. doi: 10.1021/acs.est.7b05963. Epub 2018 Feb 28.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acs.est.7b05963</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>282</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gernand, A. D.</style></author><author><style face="normal" font="default" size="100%">Aguree, S.</style></author><author><style face="normal" font="default" size="100%">Pobee, R.</style></author><author><style face="normal" font="default" size="100%">Murray-Kolb, L. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.D. Gernand, Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Micronutrient deficiencies in Ghanaian women before pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">FASEB Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FASEB Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">transferrin</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">attention</style></keyword><keyword><style face="normal" font="default" size="100%">blood pressure monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">copper deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">development</style></keyword><keyword><style face="normal" font="default" size="100%">drug combination</style></keyword><keyword><style face="normal" font="default" size="100%">electricity</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style face="normal" font="default" size="100%">expectation</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">flame</style></keyword><keyword><style face="normal" font="default" size="100%">food insecurity</style></keyword><keyword><style face="normal" font="default" size="100%">Ghana</style></keyword><keyword><style face="normal" font="default" size="100%">Ghanaian</style></keyword><keyword><style face="normal" font="default" size="100%">height</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">household</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">iron binding capacity</style></keyword><keyword><style face="normal" font="default" size="100%">iron chelation</style></keyword><keyword><style face="normal" font="default" size="100%">iron deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">malaria</style></keyword><keyword><style face="normal" font="default" size="100%">middle income country</style></keyword><keyword><style face="normal" font="default" size="100%">mobile phone</style></keyword><keyword><style face="normal" font="default" size="100%">night blindness</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">plasma</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy outcome</style></keyword><keyword><style face="normal" font="default" size="100%">progeny</style></keyword><keyword><style face="normal" font="default" size="100%">retinol deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">rural area</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">ultra performance liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">venous blood</style></keyword><keyword><style face="normal" font="default" size="100%">zinc deficiency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1530-6860</style></isbn><abstract><style face="normal" font="default" size="100%">Micronutrient deficiencies have received little attention compared to other global health issues, in spite of their extreme importance for reproductive outcomes. Pregnancy increases nutritional demands due to rapid physiological changes and requirements by the growing placenta and fetus. Inadequate stores or intake of micronutrients during pregnancy can have adverse effects on maternal and child health. Except for folate, little is known about the effects of deficiencies existing before pregnancy. Women in low- and middle-income countries may enter pregnancy with multiple micronutrient deficiencies which could have irreversible effects on pregnancy outcomes by affecting critical developmental processes that begin very early in gestation. We aimed to examine micronutrient status and overall health in 100 prepregnant women living in Asesewa, Ghana (a semi-rural area). Women were eligible if they reported an expectation to become pregnant within the next 6 months. Enrolled women participated in one visit at the regional hospital where they self-reported health history and socio-demographic characteristics and we measured blood pressure, height, weight, and hemoglobin. We collected an 8 mL venous blood sample. Serum and plasma were shipped to Penn State for analysis. Markers of iron status (iron, ferritin, total iron-binding capacity) were measured in serum by ELISA and transferrin saturation (TSAT) was calculated. Zinc and copper were measured in plasma by flame atomic absorption spectrophotometry. Retinol was measured in serum by ultra-high performance liquid chromatography. Women had a mean (SD) age of 26.5 (5.1) years, 10.2 (2.8) years of school, and BMI of 25.4 (5.3) kg/m2. Almost all women reported being in a committed relationship (96%) and 40% of women reported no previous pregnancies. Fifty-four percent had a history of malaria, 15% reported previous night blindness, and only 2 women reported taking micronutrient supplements. Most women reported use of a latrine shared among more than one household and, over 90% of women had electricity and a mobile phone in their household. Twenty percent of households had food insecurity in the past month. For nutritional status, 39% of women were overweight or obese and 34% were anemic. Iron deficiency was seen in 10% (ferritin &lt;12 μg/L and TSAT&lt;16%) of the women, zinc deficiency in 15% (&lt;70 μg/dL), copper deficiency in 9% (&lt;80 μg/dL), and vitamin A deficiency in 7% (retinol &lt;20 μg/dL). Forty-one percent of women had one deficiency and 10% of women had two deficiencies. In a population of prepregnant women in Ghana, anemia was common and most women were deficient in one or more micronutrients. Micronutrient status should be given more attention among women who expect to become pregnant and future research should examine the impact on subsequent pregnancy outcomes for the mother and her offspring.</style></abstract><notes><style face="normal" font="default" size="100%">L616959951&#xD;2017-06-29</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L616959951</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Periquet, B. A.</style></author><author><style face="normal" font="default" size="100%">Jammes, N. M.</style></author><author><style face="normal" font="default" size="100%">Lambert, W. E.</style></author><author><style face="normal" font="default" size="100%">Tricoire, J.</style></author><author><style face="normal" font="default" size="100%">Moussa, M. M.</style></author><author><style face="normal" font="default" size="100%">Garcia, J.</style></author><author><style face="normal" font="default" size="100%">Ghisolfi, J.</style></author><author><style face="normal" font="default" size="100%">Thouvenot, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Purpan Hospital, Toulouse, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Micronutrient levels in HIV-1-infected children</style></title><secondary-title><style face="normal" font="default" size="100%">Aids</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aids</style></full-title></periodical><pages><style face="normal" font="default" size="100%">887-93</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">1995/08/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Carotenoids/blood/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Erythrocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Fatty Acids, Unsaturated/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections/*blood/classification/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*hiv-1</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lycopene</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Micronutrients/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Prealbumin/deficiency/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Serum Albumin/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin A Deficiency/blood/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin E/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin E Deficiency/blood/complications</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0269-9370 (Print)&#xD;0269-9370</style></isbn><accession-num><style face="normal" font="default" size="100%">7576323</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Micronutrients (zinc, copper, selenium, vitamin A, E, and carotenoids) are essential for the integrity of host defences. This study was designed to determine the prevalence of abnormalities of the micronutrient levels in HIV-1-seropositive children. DESIGN: Prospective study. SETTING: The study was performed on HIV-1-infected children at the Paediatric Haematology and Oncology Unit of Toulouse Hospital, France. PATIENTS: Twenty-one children, suffering from HIV-1 infection and 21 control subjects of similar age (2-9 years) were included in the study. In the HIV-1-infected children, two subgroups were considered according to stage (non-AIDS or AIDS), based on the Centers for Disease Control and Prevention 1987 criteria. RESULTS: The first statistically significant deficiencies occurred at non-AIDS stage and were confirmed at AIDS stage: P &lt; 0.05 for lycopene, retinol, tocopherol and P &lt; 0.001 for transthyretin and serum albumin. Levels of copper (40%) and long-chain polyunsaturated fatty acids (21%) were higher in the non-AIDS group than the controls. CONCLUSION: Biological impairing of the micronutrient levels was observed in the non-AIDS stage without clinical sign. This information is useful in delineating eventual and well considered nutritional intervention strategies that may improve the clinical status of HIV-1-infected children and perhaps alter the course of their disease.</style></abstract><notes><style face="normal" font="default" size="100%">Periquet, B A&#xD;Jammes, N M&#xD;Lambert, W E&#xD;Tricoire, J&#xD;Moussa, M M&#xD;Garcia, J&#xD;Ghisolfi, J&#xD;Thouvenot, J&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;AIDS. 1995 Aug;9(8):887-93. doi: 10.1097/00002030-199508000-00009.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00002030-199508000-00009</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>358</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">358</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Irlam, J. H.</style></author><author><style face="normal" font="default" size="100%">Siegfried, N.</style></author><author><style face="normal" font="default" size="100%">Visser, M. E.</style></author><author><style face="normal" font="default" size="100%">Rollins, N. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.H. Irlam, University of Cape Town, Primary Health Care Directorate, E47 OMB, Groote Schuur Hospital, Cape Town, Western Cape, South Africa</style></auth-address><titles><title><style face="normal" font="default" size="100%">Micronutrient supplementation for children with HIV infection</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2013</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">chromium</style></keyword><keyword><style face="normal" font="default" size="100%">cobalt</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">iodine</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">molybdenum</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin K group</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">all cause mortality</style></keyword><keyword><style face="normal" font="default" size="100%">anthropometry</style></keyword><keyword><style face="normal" font="default" size="100%">appetite</style></keyword><keyword><style face="normal" font="default" size="100%">CD4 lymphocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">child nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">childhood mortality</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">hospital admission</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">virus load</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1469-493X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Micronutrient deficiencies are widespread and compound the effects of HIV disease in children, especially in poor communities. Micronutrient supplements may be effective and safe in reducing the burden of HIV disease. This review is an update of an earlier Cochrane review of micronutrient supplementation in children and adults which found that vitamin A and zinc are beneficial and safe in children exposed to HIV and living with HIV infection (Irlam 2010). Objectives: To assess whether micronutrient supplements are effective and safe in reducing mortality and morbidity in children with HIV infection. Search methods: The CENTRAL, EMBASE, and PubMed databases were searched for randomised controlled trials of micronutrient supplements (vitamins, trace elements, and combinations of these) using the search methods of the Cochrane HIV/AIDS Group. Selection criteria: Randomised controlled trials were selected that compared the effects of micronutrient supplements with other supplements, or placebo or no treatment on the primary outcomes of mortality, morbidity, and HIV-related hospitalisations. Indicators of HIV disease progession, anthropometric measures, and any adverse effects of supplementation were secondary outcomes. Data collection and analysis: Two reviewers independently screened and selected trials for inclusion, assessed the risk of bias using standardised criteria, and extracted data. Review Manager 5.1 was used to calculate the risk ratio (RR) for dichotomous data and the weighted mean difference (WMD) for continuous data, and to perform random effects meta-analysis where appropriate. Main results: We included three new studies in addition to the eight studies in the earlier version of the review (Irlam 2010). Eleven studies with a total of 2412 participants were therefore included: five trials of vitamin A, one trial of vitamin D, two trials of zinc, and three trials of multiple micronutrient supplements. All except one trial were conducted in African children. Vitamin A halved all-cause mortality in a meta-analysis of three trials in African children, had inconsistent impacts on diarrhoeal and respiratory morbidity, and improved short-term growth in a Tanzanian trial. No significant adverse effects were reported. A single small trial of vitamin D in North American adolescents and children demonstrated safety but no clinical benefits. Zinc supplements reduced diarrhoeal morbidity and had no adverse effects on disease progression in one small South African trial. Another trial in South African children with and without HIV infection did not show benefit from the the prophylactic use of zinc or multiple supplements versus vitamin A in the small subgroup of children with HIV infection. Multiple micronutrient supplements at twice the RDA did not alter mortality, growth, or CD4 counts at 12 months in Ugandan children aged one to five years. Short-term supplementation until hospital discharge significantly reduced the duration of all hospital admissions in poorly nourished South African children, and supplementation for six months after discharge improved appetite and nutritional indicators. Authors&apos; conclusions: Vitamin A supplementation is beneficial and safe in children with HIV infection. Zinc is safe and appears to have similar benefits on diarrhoeal morbidity in children with HIV as in children without HIV infection. Multiple micronutrient supplements have some clinical benefit in poorly nourished children with HIV infection. Further trials of single supplements (vitamin D, zinc, and selenium) are required to build the evidence base. The long-term effects and optimal composition and dosing of multiple micronutrient supplements require further investigation in children with diverse HIV disease status.</style></abstract><notes><style face="normal" font="default" size="100%">L620162248&#xD;2018-03-01&#xD;2018-03-09</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L620162248</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/14651858.CD010666</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24114375</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD010666</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">50</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boyce, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.M. Boyce Consulting, LLC, 62 Sonoma Lane, Middletown, CT 06457 USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Modern technologies for improving cleaning and disinfection of environmental surfaces in hospitals</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">10</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><edition><style face="normal" font="default" size="100%">2016/04/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrogen peroxide vapor</style></keyword><keyword><style face="normal" font="default" size="100%">Uv-c</style></keyword><keyword><style face="normal" font="default" size="100%">Ultraviolet light</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994 (Print)&#xD;2047-2994</style></isbn><accession-num><style face="normal" font="default" size="100%">27069623</style></accession-num><abstract><style face="normal" font="default" size="100%">Experts agree that careful cleaning and disinfection of environmental surfaces are essential elements of effective infection prevention programs. However, traditional manual cleaning and disinfection practices in hospitals are often suboptimal. This is often due in part to a variety of personnel issues that many Environmental Services departments encounter. Failure to follow manufacturer&apos;s recommendations for disinfectant use and lack of antimicrobial activity of some disinfectants against healthcare-associated pathogens may also affect the efficacy of disinfection practices. Improved hydrogen peroxide-based liquid surface disinfectants and a combination product containing peracetic acid and hydrogen peroxide are effective alternatives to disinfectants currently in widespread use, and electrolyzed water (hypochlorous acid) and cold atmospheric pressure plasma show potential for use in hospitals. Creating &quot;self-disinfecting&quot; surfaces by coating medical equipment with metals such as copper or silver, or applying liquid compounds that have persistent antimicrobial activity surfaces are additional strategies that require further investigation. Newer &quot;no-touch&quot; (automated) decontamination technologies include aerosol and vaporized hydrogen peroxide, mobile devices that emit continuous ultraviolet (UV-C) light, a pulsed-xenon UV light system, and use of high-intensity narrow-spectrum (405 nm) light. These &quot;no-touch&quot; technologies have been shown to reduce bacterial contamination of surfaces. A micro-condensation hydrogen peroxide system has been associated in multiple studies with reductions in healthcare-associated colonization or infection, while there is more limited evidence of infection reduction by the pulsed-xenon system. A recently completed prospective, randomized controlled trial of continuous UV-C light should help determine the extent to which this technology can reduce healthcare-associated colonization and infections. In conclusion, continued efforts to improve traditional manual disinfection of surfaces are needed. In addition, Environmental Services departments should consider the use of newer disinfectants and no-touch decontamination technologies to improve disinfection of surfaces in healthcare.</style></abstract><notes><style face="normal" font="default" size="100%">Boyce, John M&#xD;Journal Article&#xD;Review&#xD;England&#xD;Antimicrob Resist Infect Control. 2016 Apr 11;5:10. doi: 10.1186/s13756-016-0111-x. eCollection 2016.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4827199</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-016-0111-x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blum, M.</style></author><author><style face="normal" font="default" size="100%">David, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Modification of the cervical flora by IUCD</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Sex Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Sex Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">38, 40</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">83</style></number><edition><style face="normal" font="default" size="100%">1982/04/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">*Barrier Methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Unmedicated</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1982</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0301-5572 (Print)&#xD;0301-5572</style></isbn><accession-num><style face="normal" font="default" size="100%">12264790</style></accession-num><abstract><style face="normal" font="default" size="100%">The study objective was to examine the cervical flora during the insertion of an IUD and to determine whether the presence of the device in utero modified this flora. A secondary objective was to determine whether the colonization of the cervix with (occasionally) pathogenic bacteria warrants a prophylactic antibiotic treatment. IUDs were inserted in a group of 20 women, ranging in age from 23-40 years, at the Family Planning Clinic of Meir Hospital in Kfar Saba, Israel. The cervical bacterial flora was examined during insertion and again after a period of 3-12 months with the IUD in situ. None of the women received antibiotic or antifungal treatment for 3 months prior to or 12 months after insertion. The women were divided into 2 groups according to the type of IUD used. Group A consisted of 22 women with nonmedicated IUDs and Group B included 28 women with IUDs medicated with copper. A cervical swab was collected during insertion of the IUD and at 3-12 months afterwards. Of the 50 cervical cultures collected during the insertion, 48 (84%) were sterile, but only 27 of the cultures collected after 3-12 months with the IUD in utero were sterile. The medicated IUD had a more intense bacteriostatic effect on the bacterial cervical flora than the other devices. Among the copper IUDs the best results were obtained with the Nova T type and secondly with the Copper 7 (Gravigard). It is possible that the pathogenic organisms enter the uterine cavity and tubes from the cervix during insertion of the IUD. It may be concluded that during IUD insertion prophylactic treatment with a broad spectrum antibiotic would be indicated, but the study showed that this was not the case. The organisms isolated in the women studied were those normally found in the upper vagina and cervix and only occasionally became pathogenic. Medicated IUDs are preferable because of the bacteriostatic activity of the copper and to the fact that they are normally left in utero for a shorter time than the unmedicated IUDs.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Blum, M&#xD;David, F&#xD;Comparative Study&#xD;Journal Article&#xD;England&#xD;Br J Sex Med. 1982 Apr;9(83):38, 40.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>207</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Isrctn,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Multiple micro-nutrient supplementation of low-birth-weight infants in Pakistan: a randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN35833344</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN35833344</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01853129</style></accession-num><abstract><style face="normal" font="default" size="100%">INTERVENTION: The infants were exclusively breastfed and received the supplement or placebo daily for six months. The infants were followed up at home at mostly intervals by teams of research medical officers and community health nurses, up till 12 months of age. Following informed written consent the newborn infants were randomised to the following treatment groups in a blinded fashion using randomisation codes in blocks of 20. The randomisation codes were kept at the Aga Khan University Pharmacy Department and were available on phone to the research teams. Group A: received a one daily oral supplement providing moisture of iron, copper, zinc, vitamin A and D for six months along with the recommended daily allowance (RDA) of a standard multivitamin mixture (Surbex, Abbot) for six months Group B: received a placebo daily and standard multivitamin moisture (Surbex, Abbott) CONDITION: Low‐birth‐weight infants ; Neonatal Diseases ; Disorders related to short gestation and low birth weight, not elsewhere classified PRIMARY OUTCOME: 1. Growth (weight gain and linear growth); 2. Morbidity rates (days ill with diarrhea and respiratory infections) SECONDARY OUTCOME: Neurodevelopmental outcome at 6 and 12 months. This will be objectively evaluated in a blinded fashion by a team comprising of a pediatric neurologist and fully trained child development expert. INCLUSION CRITERIA: Six to twelve month old infants identified after birth at tertiary care hospital</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01853129/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">475</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, Y. S. E.</style></author><author><style face="normal" font="default" size="100%">Vidic, R. D.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V.L. Yu, Infectious Disease Section, VA Medical Center, University Dr. C, Pittsburgh, PA 15240, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Negative effect of high pH on biocidal efficacy of copper and silver ions in controlling Legionella pneumophila</style></title><secondary-title><style face="normal" font="default" size="100%">Applied and Environmental Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Applied and Environmental Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2711-2715</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">bicarbonate</style></keyword><keyword><style face="normal" font="default" size="100%">calcium ion</style></keyword><keyword><style face="normal" font="default" size="100%">carbon</style></keyword><keyword><style face="normal" font="default" size="100%">copper ion</style></keyword><keyword><style face="normal" font="default" size="100%">dissolved organic matter</style></keyword><keyword><style face="normal" font="default" size="100%">hot water</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">alkalinity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bactericidal activity</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">complex formation</style></keyword><keyword><style face="normal" font="default" size="100%">concentration response</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">ionization</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pH</style></keyword><keyword><style face="normal" font="default" size="100%">reduction (chemistry)</style></keyword><keyword><style face="normal" font="default" size="100%">water hardness</style></keyword><keyword><style face="normal" font="default" size="100%">water quality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><isbn><style face="normal" font="default" size="100%">0099-2240</style></isbn><abstract><style face="normal" font="default" size="100%">Copper-silver (Cu-Ag) ionization has effectively controlled Legionella spp. in the hot water systems of numerous hospitals. However, it was ineffective at controlling Legionella in one Ohio hospital despite the confirmation of adequate total concentrations of copper and silver ions. The pH of the water at this hospital was found to be 8.5 to 9.0. The purpose of this study was to investigate the impact of pH and other water quality parameters, including alkalinity (HCO3-), hardness (Ca2+ and Mg2+), and amount of dissolved organic carbon (DOC), on the control of Legionella by Cu-Ag ionization. Initial concentrations of Legionella and copper and silver ions used in batch experiments were 3 x 106 CFU/ml and 0.4 and 0.08 mg/liter, respectively. Changes in bicarbonate ion concentration (50, 100, and 150 mg/liter), water hardness (Ca2+ at 50 and 100 mg/liter; Mg2+ at 40 and 80 mg/liter), and level of DOC (0.5 and 2 mg/liter) had no significant impact on the efficacy of copper and silver ions in killing Legionella at a neutral pH. When the pH was elevated to 9 in these experiments, copper ions achieved only a 10-fold reduction in the number of Legionella organisms in 24 h, compared to a millionfold decrease at pH 7.0. Silver ions were able to achieve a millionfold reduction in 24 h at all ranges of water quality parameters tested. Precipitation of insoluble copper complexes was observed at a pH above 6.0. These results suggest that pH may be an important factor in the efficacy of copper-silver ionization in controlling Legionella in water systems.</style></abstract><notes><style face="normal" font="default" size="100%">L34601990&#xD;2002-06-19</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L34601990</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1128/AEM.68.6.2711-2715.2002</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">12039724</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AEM.68.6.2711-2715.2002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>216</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">216</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, T.</style></author><author><style face="normal" font="default" size="100%">Yu, S.</style></author><author><style face="normal" font="default" size="100%">Guo, L.</style></author><author><style face="normal" font="default" size="100%">Xiao, M.</style></author><author><style face="normal" font="default" size="100%">Xu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Sun, Center for Medical Science Research, Peking Union Medical College Hospital, Chinese Academy of Medical Science</style></auth-address><titles><title><style face="normal" font="default" size="100%">Network analysis of clinical strain virulence factor of Cryptococcus neoformans</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infection and Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infection and Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">346-347</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">galactose</style></keyword><keyword><style face="normal" font="default" size="100%">glycerol</style></keyword><keyword><style face="normal" font="default" size="100%">hydrogen peroxide</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">levodopa</style></keyword><keyword><style face="normal" font="default" size="100%">melanin</style></keyword><keyword><style face="normal" font="default" size="100%">metal ion</style></keyword><keyword><style face="normal" font="default" size="100%">sodium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">virulence factor</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial virulence</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">cryptococcosis</style></keyword><keyword><style face="normal" font="default" size="100%">high temperature</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">language</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">matrix assisted laser desorption ionization time of flight mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">salt stress</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">thickness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1876-035X&#xD;1876-0341</style></isbn><abstract><style face="normal" font="default" size="100%">Background and Purpose Cryptococcus is a member of the top three pathomycetes. It infects an average of 1 million people a year and brings huge clinical resource consumption. So, it is significant to study the virulence characteristics of clinical strains and their association with clinical feature. Methodology 104 Cryptococcus neoformans clinical strains were collection from 12 hospitals in Beijing (2016-2017) and Identification by MALDI-TOF MS. Phenotype of clinical strains were measured depend on colonies size on melanin induction medium (DOPA), capsule induction medium (DMEM + 5 % FBS), fermentable medium (galactose, glycerol, ethanol) and stress medium (Cu, Fe, NaCl, KCl, H2O2, DTT, SDS). They were also measured under 30 and 37?. Clinical stains were scored compared with standard strain H99. Virulence relativity analysis was done using R language “coreplot” package. The Student&apos;s t-test was performed to determine statistical significance. Results and Discussions Cryptococcus neoformans clinical strains were mainly sensitive to high temperature, high salinity, membrane stress. Among these clinical strains, significant differences were performed in thickness of capsule, which is an important virulence factor of Cryptococcus neoformans. Their behavior under high salt and metal ion pressure were closely related to the phenotype of fermentable medium. Conclusions By analyze the interaction between each virulence factor, we figured out an associated network among clinical strains. It has practical implications for assessing clinical manifestations in Cryptococcus infection.</style></abstract><notes><style face="normal" font="default" size="100%">L2004820986&#xD;2020-02-10</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2004820986</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jiph.2020.01.111</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jiph.2020.01.111</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>247</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chyderiotis, S.</style></author><author><style face="normal" font="default" size="100%">Legeay, C.</style></author><author><style face="normal" font="default" size="100%">Verjat-Trannoy, D.</style></author><author><style face="normal" font="default" size="100%">Le Gallou, F.</style></author><author><style face="normal" font="default" size="100%">Astagneau, P.</style></author><author><style face="normal" font="default" size="100%">Lepelletier, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Legeay, Unité de Prévention et de Lutte contre les Infections Nosocomiales, CHU d&apos;Angers, Université d&apos;Angers, 4 rue Larrey, Angers, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">New insights on antimicrobial efficacy of copper surfaces in the healthcare environment: a systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1130-1138</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">antibacterial activity</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial load</style></keyword><keyword><style face="normal" font="default" size="100%">checklist</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical outcome</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">data extraction</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">in vitro study</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Medline</style></keyword><keyword><style face="normal" font="default" size="100%">pathogen load</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">quality control</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1469-0691&#xD;1198-743X</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: Hospital-acquired infections (HAIs) are a major public health issue. The potential of antimicrobial copper surfaces in reducing HAIs’ rates is of interest but remains unclear. We conducted a systematic review of studies assessing the activity of copper surfaces (colony-forming unit (CFU)/surface, both in vitro and in situ) as well as clinical studies. In vitro study protocols were analysed through a tailored checklist developed specifically for this review, in situ studies and non-randomized clinical studies were assessed using the ORION (Outbreak Reports and Intervention studies Of Nosocomial infection) checklist and randomized clinical studies using the CONSORT guidelines. Methods: The search was conducted using PubMed database with the keywords ‘copper’ and ‘surfaces’ and ‘healthcare associated infections’ or ‘antimicrobial’. References from relevant articles, including reviews, were assessed and added when appropriate. Articles were added until 30 August 2016. Overall, 20 articles were selected for review including 10 in vitro, eight in situ and two clinical studies. Results: Copper surfaces were found to have variable antimicrobial activity both in vitro and in situ, although the heterogeneity in the designs and the reporting of the results prevented conclusions from being drawn regarding their spectrum and activity/time compared to controls. Copper effect on HAIs incidence remains unclear because of the limited published data and the lack of robust designs. Most studies have potential conflicts of interest with copper industries. Conclusions: Copper surfaces have demonstrated an antimicrobial activity but the implications of this activity in healthcare settings are still unclear. No clear effect on healthcare associated infections has been demonstrated yet.</style></abstract><notes><style face="normal" font="default" size="100%">L2000735590&#xD;2018-05-16&#xD;2019-01-28</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2000735590</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.cmi.2018.03.034</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">29605564</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.cmi.2018.03.034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">New studies link IUDs, infertility; say copper devices safer</style></title><secondary-title><style face="normal" font="default" size="100%">Contracept Technol Update</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contracept Technol Update</style></full-title></periodical><pages><style face="normal" font="default" size="100%">81-3</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">1985/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biology</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">*Infertility</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Reproduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Urogenital System</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Research</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Unmedicated--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Urogenital Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital System</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1985</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0274-726X (Print)&#xD;0274-726x</style></isbn><accession-num><style face="normal" font="default" size="100%">12313655</style></accession-num><abstract><style face="normal" font="default" size="100%">2 studies sponsored by the National Institute of Child Health and Human Development (NICHD) report direct evidence of a link between IUDs and infertility. Both studies indicate that copper-bearing IUDs are less likely than inert IUDs to lead to infertility, but increased risk was evident for both types of IUDs. 2 of the studies&apos; authors said the findings confirm the current practice of many clinicians to discourage women who have no children from using IUDs as their contraceptive method. 1 study involved about 90% of the infertility specialists in Seattle. Janet R. Daling, Ph.D., University of Washington School of Public Health and Community Medicine, and colleagues compared rates of IUD use in 159 childless women who had tubal infertility with an equal number of new mothers. They reached the following conclusions: using any IUD more than doubled (2.6 times) the risk of tubal infertility compared with not using an IUD; the type of IUD affected risk with Dalkon Shield users having 6.8 times the risk of tubal infertility compared with women who never used IUDs, Lippes Loop or Saf-Toil users having 3.2 times the risk, and Copper-7 or Copper-T users having 1.9 times the risk if a copper device was used at 1 time and a plastic device at another time but 1.3 times the risk if only a copper device was used; and the risk of tubal infertility for IUD users increased among women who did not have symptoms of infection as well as those who did. A 2nd larger study involved 7 infertility centers and collaborating hospitals. Dr. Daniel W. Cramer, Brigham and Women&apos;s Hospital in Boston, headed the investigation, which evaluated IUD use in 283 childless women with tubal infertility, 69 women with tubal infertility after 1 child, and 3833 new mothers. The Boston-based study found the following: overall the cumulative experience with all IUD use doubled (2.0 relative risk) the risk of tubal infertility; the type of IUD affected the risk of tubal infertility; no increased risk of infertility was apparent for women with a single sex partner; a high risk was apparent for women with a history of infection, pain, or bleeding with IUD use; and noncopper IUD users with 1 child had about 3 times the risk (2.8 relative risk) of never users of developing &quot;secondary&quot; tubal infertility or infertility associated with using an IUD after a 1st live birth. George Rubin, chief of the epidemiological studies branch of the Centers for Disease Control Division of Reproductive Health states that the new data confirm what has been good clinical practice for a number of years.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Journal Article&#xD;United States&#xD;Contracept Technol Update. 1985 Jun;6(6):81-3.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>369</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">369</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schneider, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P.M. Schneider, LexaMed, 705 Front Street, Toledo, OH 43605, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">New technologies and trends in sterilization and disinfection</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S81-S86</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">5 SUPPL.</style></number><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial survival</style></keyword><keyword><style face="normal" font="default" size="100%">bronchoscope</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">environmental exposure</style></keyword><keyword><style face="normal" font="default" size="100%">medical device contamination</style></keyword><keyword><style face="normal" font="default" size="100%">fiberoscope</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">instrument sterilization</style></keyword><keyword><style face="normal" font="default" size="100%">medical device</style></keyword><keyword><style face="normal" font="default" size="100%">medical technology</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">monitor</style></keyword><keyword><style face="normal" font="default" size="100%">nitrogen dioxide analyzer</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">sterilizer</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">waste management</style></keyword><keyword><style face="normal" font="default" size="100%">100NX</style></keyword><keyword><style face="normal" font="default" size="100%">Amsco</style></keyword><keyword><style face="normal" font="default" size="100%">Attest</style></keyword><keyword><style face="normal" font="default" size="100%">DuPont</style></keyword><keyword><style face="normal" font="default" size="100%">STERIZONE</style></keyword><keyword><style face="normal" font="default" size="100%">STERRAD</style></keyword><keyword><style face="normal" font="default" size="100%">Teflon</style></keyword><keyword><style face="normal" font="default" size="100%">V-PRO</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553&#xD;1527-3296</style></isbn><abstract><style face="normal" font="default" size="100%">Continued improvements in low-temperature sterilization systems have resulted in reduced processing times and expanded capabilities for instrument reprocessing. As the relationship of environmental surface contamination and health care-associated infections has become more defined, area disinfection systems and antimicrobial surface technologies have emerged as new strategies for disinfection of surfaces. Copyright © 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L368826883&#xD;2013-05-08&#xD;2013-05-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L368826883</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2012.12.007</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">100NX(advanced sterilization products,United States)&#xD;Amsco(Steris)&#xD;Attest(3M,United States)&#xD;DuPont&#xD;STERIZONE&#xD;STERRAD(advanced sterilization products)&#xD;Teflon&#xD;V-PRO(Steris,United States)</style></custom3><custom4><style face="normal" font="default" size="100%">3M(United States)&#xD;advanced sterilization products(United States)&#xD;Noxilizer(United States)&#xD;Steris(United States)</style></custom4><custom5><style face="normal" font="default" size="100%">23622756</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2012.12.007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hunt, A. P.</style></author><author><style face="normal" font="default" size="100%">Batka, A. E.</style></author><author><style face="normal" font="default" size="100%">Hosseinzadeh, M.</style></author><author><style face="normal" font="default" size="100%">Gregory, J. D.</style></author><author><style face="normal" font="default" size="100%">Haque, H. K.</style></author><author><style face="normal" font="default" size="100%">Ren, H.</style></author><author><style face="normal" font="default" size="100%">Meyerhoff, M. E.</style></author><author><style face="normal" font="default" size="100%">Lehnert, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, MI 48109.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nitric Oxide Generation On Demand for Biomedical Applications via Electrocatalytic Nitrite Reduction by Copper BMPA- and BEPA-Carboxylate Complexes</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Catal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ACS Catal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7746-7758</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2019/10/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">copper nitrite reductase</style></keyword><keyword><style face="normal" font="default" size="100%">electrocatalysis</style></keyword><keyword><style face="normal" font="default" size="100%">inhaled NO therapy</style></keyword><keyword><style face="normal" font="default" size="100%">intravenous catheters</style></keyword><keyword><style face="normal" font="default" size="100%">model complexes</style></keyword><keyword><style face="normal" font="default" size="100%">modulated NO-release</style></keyword><keyword><style face="normal" font="default" size="100%">nitric oxide</style></keyword><keyword><style face="normal" font="default" size="100%">nitrite reduction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2155-5435 (Print)</style></isbn><accession-num><style face="normal" font="default" size="100%">31592338</style></accession-num><abstract><style face="normal" font="default" size="100%">Intravascular (IV) catheters are essential devices in the hospital that are used to monitor a patient&apos;s blood and for administering drugs or nutrients. However, IV catheters are also prone to blood clotting at the point of insertion and infection by formation of robust bacterial biofilms on their surface. Nitric oxide (NO) is ideally suited to counteract both of these problems, due to its antimicrobial properties and its ability to inhibit platelet activation/aggregation. One way to equip catheters with NO releasing properties is by electrocatalytic nitrite reduction to NO by copper complexes in a multi-lumen configuration. In this work, we systematically investigate six closely related Cu(II) BMPA- and BEPA-carboxylate complexes (BMPA = bis-(2-methylpyridyl)amine); BEPA = bis-(2-ethylpyridyl)amine), using carboxylate groups of different chain lengths. The corresponding Cu(II) complexes were characterized using UV-Vis, EPR spectroscopy, and X-ray crystallography. Using detailed cyclic voltammetry (CV) and bulk electrocatalyic studies (with real-time NO quantification), in aqueous buffer, pH 7.4, we are able to derive clear reactivity relations between the ligand structures of the complexes, their Faradaic efficiencies for NO generation, their turnover frequencies (TOFs), and their redox potentials. Our results show that the complex [Cu(BEPA-Bu)](OAc) is the best catalyst with a high Faradaic efficiency over large nitrite concentration ranges and the expected best tolerance to oxygen levels. For this species, the more positive redox potential suppresses NO disproportionation, which is a major Achilles heel of the (faster) catalysts with the more negative reduction potentials.</style></abstract><notes><style face="normal" font="default" size="100%">Hunt, Andrew P&#xD;Batka, Allison E&#xD;Hosseinzadeh, Marjan&#xD;Gregory, Jordan D&#xD;Haque, Halima K&#xD;Ren, Hang&#xD;Meyerhoff, Mark E&#xD;Lehnert, Nicolai&#xD;R01 HL132037/HL/NHLBI NIH HHS/United States&#xD;Journal Article&#xD;United States&#xD;ACS Catal. 2019 Sep 6;9(9):7746-7758. doi: 10.1021/acscatal.9b01520. Epub 2019 Jul 15.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6779156</style></custom2><custom6><style face="normal" font="default" size="100%">NIHMS1042068</style></custom6><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acscatal.9b01520</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>364</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">364</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Keevil, B.</style></author><author><style face="normal" font="default" size="100%">Warnes, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">B. Keevil, Centre for Biological Sciences, University of Southampton, Southampton, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Norovirus inactivation on antimicrobial touch surfaces</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">stainless steel</style></keyword><keyword><style face="normal" font="default" size="100%">nickel</style></keyword><keyword><style face="normal" font="default" size="100%">phenformin</style></keyword><keyword><style face="normal" font="default" size="100%">chelating agent</style></keyword><keyword><style face="normal" font="default" size="100%">reactive oxygen metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">copper ion</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxyl radical</style></keyword><keyword><style face="normal" font="default" size="100%">superoxide</style></keyword><keyword><style face="normal" font="default" size="100%">cuprous ion</style></keyword><keyword><style face="normal" font="default" size="100%">cupric ion</style></keyword><keyword><style face="normal" font="default" size="100%">RNA</style></keyword><keyword><style face="normal" font="default" size="100%">virus RNA</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">Norovirus</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">inoculation</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">feces</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">gene transfer</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">monocyte</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">aerosol</style></keyword><keyword><style face="normal" font="default" size="100%">cell line</style></keyword><keyword><style face="normal" font="default" size="100%">virus genome</style></keyword><keyword><style face="normal" font="default" size="100%">gel electrophoresis</style></keyword><keyword><style face="normal" font="default" size="100%">plaque assay</style></keyword><keyword><style face="normal" font="default" size="100%">hand washing</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">room temperature</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">virus load</style></keyword><keyword><style face="normal" font="default" size="100%">assay</style></keyword><keyword><style face="normal" font="default" size="100%">virus inactivation</style></keyword><keyword><style face="normal" font="default" size="100%">mutation</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">ship</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Norovirus is the most common cause of gastroenteritis worldwide, primarily because of high infectivity, uncontrollable aerosol formation via vomitus and faeces, resistance to cleaning agents and persistence in the environment. Even low level surface contamination is a transmission risk because of the low infectious dose and inadequate hand hygiene. Objectives: Laboratory studies and clinical trials have demonstrated the use of antimicrobial copper alloy touch surfaces to reduce the spread of bacterial pathogens and antibiotic resistance gene transfer. Here we investigate the efficacy of copper alloys to inactivate norovirus. Methods: In the absence of infectivity assays for human norovirus, Infectivity of surrogate murine MNV-1 norovirus, untreated or exposed to touch surfaces, was assessed by plaque assay in a RAW 264.7 monocyte macrophage cell line. Copper alloy surfaces were compared to stainless steel as touch surfaces. Results are expressed as plaque forming units (pfu) per cm2. The role of Cu(I) or Cu(II) ions and reactive oxygen species (ROS) was assessed using specific chelators and quenchers. Viral RNA was extracted and purified and separated in non-denaturing gel electrophoresis. Results: Complete inactivation of approximately 5 x104 pfu per cm2 was observed on copper and copper nickel in 5-10 minutes or in 2 hours at room temperature for alloys containing lower percentage copper with an inoculum that dried in seconds, simulating hand contact. Virus exposed to stainless steel retained high infectivity at 2 hours. Inactivation was slower if the virus was inoculated as a wet inoculum simulating vomitus: complete inactivation occurred in 1 hour for copper and copper nickel, with significant reduction on other alloys but not stainless steel. The highest rate of inactivation was observed on immediate contact. These results were similar if virus burden was increased 50-fold. Virus inactivation was faster at 37oC and slower at 4oC. Cu(II) and particularly Cu(I) ions were essential for loss of infectivity but not superoxide or hydroxyl radicals. Exposure to copper alloys resulted in destruction of the viral genome, preventing potential mutation to copper resistance. Conclusion: The results support the use of antimicrobial copper surfaces to reduce the spread of norovirus in high risk areas such as closed environments including health care facilities and cruise ships.</style></abstract><notes><style face="normal" font="default" size="100%">L72036265&#xD;2015-10-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72036265</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>98</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">98</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Levin, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infectious Diseases and LIM 54, University of Sao Paulo, Brazil. gcih@hcnet.usp.br</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nosocomial legionellosis: prevention and management</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Rev Anti Infect Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Rev Anti Infect Ther</style></full-title></periodical><pages><style face="normal" font="default" size="100%">57-68</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2009/07/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/drug therapy/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Legionellosis/drug therapy/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Macrolides/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Quinolones/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1478-7210</style></isbn><accession-num><style face="normal" font="default" size="100%">19622057</style></accession-num><abstract><style face="normal" font="default" size="100%">Legionnaires&apos; disease (LD) can be nosocomial, community acquired or travel related. The source of Legionella infection is potable water systems that become colonized by the microorganism. Prevention studies involved mainly hospital water systems. Different strategies have been suggested but none are fully successful: engineering modifications, heating of water to temperatures above 59 degrees C, heating and flushing the plumbing with hot water (80 degrees C), water chlorination, silver-copper ionization of the water, UV-light disinfection of water, instant heating in order to avoid hot-water tanks and others. LD is widely underdiagnosed because laboratory methods are specific and suspicion index is usually low; therefore, the appropriate tests are not requested. In addition, all methods present limitations. No randomized controlled trials have been performed to study the treatment of legionellosis but comparative observational studies have been published, mostly involving community-acquired cases. Macrolides and quinolones presented similar results when comparing important outcomes, such as mortality and complications.</style></abstract><notes><style face="normal" font="default" size="100%">1744-8336&#xD;Levin, Anna S&#xD;Journal Article&#xD;Review&#xD;England&#xD;Expert Rev Anti Infect Ther. 2009 Feb;7(1):57-68. doi: 10.1586/14787210.7.1.57.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/14787210.7.1.57</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>326</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perl, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Perl, Johns Hopkins University, School of Medicine, Baltimore, MD, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel technology for environmental cleaning</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Microbiology, Immunology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Microbiology, Immunology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S10</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">quaternary ammonium derivative</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">titanium dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">chlorine dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">chlorine</style></keyword><keyword><style face="normal" font="default" size="100%">silver nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">cellulose acetate</style></keyword><keyword><style face="normal" font="default" size="100%">tolonium chloride</style></keyword><keyword><style face="normal" font="default" size="100%">rose bengal</style></keyword><keyword><style face="normal" font="default" size="100%">methylene blue</style></keyword><keyword><style face="normal" font="default" size="100%">troclosene</style></keyword><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">iodide</style></keyword><keyword><style face="normal" font="default" size="100%">biguanide</style></keyword><keyword><style face="normal" font="default" size="100%">triclosan</style></keyword><keyword><style face="normal" font="default" size="100%">surfactant</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">citric acid</style></keyword><keyword><style face="normal" font="default" size="100%">hydrogen peroxide</style></keyword><keyword><style face="normal" font="default" size="100%">silicon</style></keyword><keyword><style face="normal" font="default" size="100%">polymer</style></keyword><keyword><style face="normal" font="default" size="100%">copper oxide</style></keyword><keyword><style face="normal" font="default" size="100%">gold nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">tosylchloramide sodium</style></keyword><keyword><style face="normal" font="default" size="100%">technology</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">market</style></keyword><keyword><style face="normal" font="default" size="100%">landscape</style></keyword><keyword><style face="normal" font="default" size="100%">patient safety</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">yarn</style></keyword><keyword><style face="normal" font="default" size="100%">community</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">vapor</style></keyword><keyword><style face="normal" font="default" size="100%">monitor</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword><keyword><style face="normal" font="default" size="100%">filtration</style></keyword><keyword><style face="normal" font="default" size="100%">work</style></keyword><keyword><style face="normal" font="default" size="100%">aerosol</style></keyword><keyword><style face="normal" font="default" size="100%">turnover rate</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1684-1182</style></isbn><abstract><style face="normal" font="default" size="100%">With the emergence of multi drug resistant organisms, novel viruses and organisms that have a predilection for the environment; the contribution of the environment to transmission of resistant or significant organisms is now recognized so there are a myriad of products and equipment that attempt to improve cleaning and even disinfect the environment because even in the best of circumstances traditional cleaning is not perfect. In fact, in addition to some of the issues associated with complex surfaces with many nooks and crannies that are difficult to clean, there is also the need for rapid turn over to assure patient access to beds in a high turnover job that is not viewed as prime. Plus, materials with antimicrobial properties are being applied to high touch surfaces or products that may be reused to decrease the risk of cross contamination to assist with this effort. The focus on products, cleaning techniques and measurement of cleaning has become increasingly important in managing of healthcare facilities. We will discuss the role of product, process and the use of performance improvement strategies to enhance the cleanliness of healthcare facilities. We will also review measurement of the process and what works and what doesn&apos;t work. Of particular interest in the current market done is the use of technology to improve compliance. Compliance with basic practices such as cleaning is commonly poorer than we would like for many reasons including poor knowledge, limited supplies, and inconvenience. Hence, technology that can automate measurement and its use is very intriguing. However, the healthcare environment is becoming increasingly complex and if one goes into patient rooms they are filled with monitors and complicated equipment. We also work in an environment where we are asked to do more with less. Hence, the infection control community is challenged to rely on standard infection prevention strategies and has introduced different types of technology to facilitate work and improve patient safety. Technological solutions are emerging as part of the landscape and we will discuss some of these technologies and the challenges with some of these. Examples of different cleaning technologies for healthcare that are currently used, being evaluated or proposed[1] Disinfectants &amp; Cleaning tools: • Demand-release chlorine disinfectants : - Chlorine dioxide - Sodium dichloroisocyanurate - Chloramine-t7 • Super oxidized water • Microfiber mops • Microfiber wipes Soft Surface Technologies: • Copper oxide impregnation • Citric acid impregnation • Organosilane-based quaternary ammonium impregnation • Silver-impregnated yarn Hard Surface Technologies: • Copper and copper alloy cladding • Silver iodide and modified polyhexamethlyene biguanide coating • Silver nanoparticle incorporation • Triclosan incorporation • Quaternary ammonium salt surfactant coating • Microtopographic surfaces • Light-activated antimicrobial coatings • Cellulose acetate-containing toluidine blue O and rose Bengal • Silicon polymer-containing methylene blue and gold nanoparticles • Titanium dioxide coating Whole room technologies: • UV light • Combination of ozone/UV light/HEPA filtration • Hydrogen peroxide vapor or aerosolization • Titanium dioxide.</style></abstract><notes><style face="normal" font="default" size="100%">L72082230&#xD;2015-11-27</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72082230</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">351</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Domellöf, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nutritional care of premature infants: microminerals</style></title><secondary-title><style face="normal" font="default" size="100%">World review of nutrition and dietetics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World review of nutrition and dietetics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">121-139</style></pages><volume><style face="normal" font="default" size="100%">110</style></volume><keywords><keyword><style face="normal" font="default" size="100%">chromium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">iodine</style></keyword><keyword><style face="normal" font="default" size="100%">iron intake</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">molybdenum</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">administration and dosage</style></keyword><keyword><style face="normal" font="default" size="100%">birth weight</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">dietary reference intake</style></keyword><keyword><style face="normal" font="default" size="100%">dose response</style></keyword><keyword><style face="normal" font="default" size="100%">enteric feeding</style></keyword><keyword><style face="normal" font="default" size="100%">growth, development and aging</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">infant nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional requirement</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">parenteral nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">prematurity</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">very low birth weight</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1662-3975</style></isbn><abstract><style face="normal" font="default" size="100%">Microminerals, including iron, zinc, copper, selenium, manganese, iodine, chromium and molybdenum, are essential for a remarkable array of critical functions and need to be supplied in adequate amounts to preterm infants. Very low birth weight (VLBW) infants carry a very high risk of developing iron deficiency which can adversely affect neurodevelopment. However, a too high iron supply in iron-replete VLBW infants may induce adverse effects such as increased infection risks and impaired growth. Iron needs are influenced by birth weight, growth rates, blood losses (phlebotomy) and blood transfusions. An enteral iron intake of 2 mg/kg/day for infants with a birth weight of 1,500-2,500 g and 2-3 mg/kg/day for VLBW infants is recommended. Higher doses up to 6 mg/kg/day are needed in infants receiving erythropoietin treatment. Regular monitoring of serum ferritin during the hospital stay is advisable. Routine provision of iron with parenteral nutrition for VLBW infants is not recommended. Less certainty exists for the advisable intakes of other microminerals. It appears prudent to provide enterally fed VLBW infants with daily amounts per kilogram body weight of 1.4-2.5 mg zinc, 100-230 μg copper, 5-10 μg selenium, 1-15 μg manganese, 10-55 μg iodine, 0.03-2.25 μg chromium, and 0.3-5 μg molybdenum. Future scientific findings may justify deviations from these suggested ranges.</style></abstract><notes><style face="normal" font="default" size="100%">L603659021&#xD;2015-04-16</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L603659021</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1159/000358462</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24751625</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000358462</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>363</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">363</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manzoni, P.</style></author><author><style face="normal" font="default" size="100%">Mostert, M.</style></author><author><style face="normal" font="default" size="100%">Franco, C.</style></author><author><style face="normal" font="default" size="100%">Luparia, M.</style></author><author><style face="normal" font="default" size="100%">Tavella, E.</style></author><author><style face="normal" font="default" size="100%">Stronati, M.</style></author><author><style face="normal" font="default" size="100%">Farina, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Manzoni, Neonatology and NICU, A.O. Regina Margherita-S. Anna. S. Anna Hospital, Torino, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutritional interventions to prevent or treat bronchopulmonary dysplasia</style></title><alt-title><style face="normal" font="default" size="100%">Paediatr. Respir. Rev.</style></alt-title></titles><pages><style face="normal" font="default" size="100%">S36-S40</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">(Manzoni P., paolomanzoni@hotmail.com; Franco C.; Luparia M.; Tavella E.; Farina D.) Neonatology and NICU, A.O. Regina Margherita-S. Anna. S. Anna Hospital, Torino, Italy</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antifungal agent</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">glucocorticoid</style></keyword><keyword><style face="normal" font="default" size="100%">inositol</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">lactoferrin</style></keyword><keyword><style face="normal" font="default" size="100%">lung surfactant</style></keyword><keyword><style face="normal" font="default" size="100%">oxygen</style></keyword><keyword><style face="normal" font="default" size="100%">phospholipid</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">proteinase</style></keyword><keyword><style face="normal" font="default" size="100%">reactive oxygen metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">surfactant</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">xanthophyll</style></keyword><keyword><style face="normal" font="default" size="100%">zeaxanthin</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">acceleration</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">animal model</style></keyword><keyword><style face="normal" font="default" size="100%">arm muscle</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">bovine</style></keyword><keyword><style face="normal" font="default" size="100%">brain hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">breast feeding</style></keyword><keyword><style face="normal" font="default" size="100%">breast milk</style></keyword><keyword><style face="normal" font="default" size="100%">caloric intake</style></keyword><keyword><style face="normal" font="default" size="100%">catch up growth</style></keyword><keyword><style face="normal" font="default" size="100%">chemical binding</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">chronic lung disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">colostrum</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">death</style></keyword><keyword><style face="normal" font="default" size="100%">diet restriction</style></keyword><keyword><style face="normal" font="default" size="100%">differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">disease model</style></keyword><keyword><style face="normal" font="default" size="100%">drug combination</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">enteric feeding</style></keyword><keyword><style face="normal" font="default" size="100%">epithelium</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">fat intake</style></keyword><keyword><style face="normal" font="default" size="100%">feeding difficulty</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal tract</style></keyword><keyword><style face="normal" font="default" size="100%">growth rate</style></keyword><keyword><style face="normal" font="default" size="100%">guinea pig</style></keyword><keyword><style face="normal" font="default" size="100%">hemolytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">infancy</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">internalization</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine growth retardation</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">lung development</style></keyword><keyword><style face="normal" font="default" size="100%">lung dysplasia</style></keyword><keyword><style face="normal" font="default" size="100%">lung function</style></keyword><keyword><style face="normal" font="default" size="100%">lung weight</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">maturation</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic rate</style></keyword><keyword><style face="normal" font="default" size="100%">neonatal intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">newborn</style></keyword><keyword><style face="normal" font="default" size="100%">newborn morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">newborn period</style></keyword><keyword><style face="normal" font="default" size="100%">nomenclature</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient supply</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">oral drug administration</style></keyword><keyword><style face="normal" font="default" size="100%">oxidation</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">perinatal period</style></keyword><keyword><style face="normal" font="default" size="100%">postnatal growth</style></keyword><keyword><style face="normal" font="default" size="100%">precursor</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">protein intake</style></keyword><keyword><style face="normal" font="default" size="100%">protein synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">retrolental fibroplasia</style></keyword><keyword><style face="normal" font="default" size="100%">school child</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">stomach</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">very low birth weight</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">wellbeing</style></keyword><keyword><style face="normal" font="default" size="100%">wheezing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1526-0550</style></isbn><abstract><style face="normal" font="default" size="100%">Abbreviations: VLBW = very low birth weight (below 1500 g.) NICU = neonatal intensive care unit NEC = necrotizing enterocholitis ROP = retinopathy of prematurity BPD = bronchopulmonary dysplasia Abstract: Nutrients in the prenatal and perinatal period play a major role in the development of the immune system as well as in the ability to contrast infections. A remarkable body of evidence supports the hypothesis that availability of specific, essential nutrients in these periods is critical for the development and appropriate maturation of the respiratory tract. The lungs have been shown to be the target of the actions of a large number of nutrients which condition, directly or not, the onset of chronic lung disease and/or BPD in preterm infants. Decreased intakes of some of these nutrients have been associated with increased odds of developing BPD in preterm infants. Some of these nutrients play a preventative role thus contrasting respiratory infections and morbidity also during the first months of life. The present review aims at updating the current knowledge about the role of nutrition and specific nutrients in the prevention and management of BPD and - more generally - of respiratory morbidity in neonates and young infants. Introduction - nutritional needs of infants at risk of BPD: It is a common finding that preterm infants with ongoing BPD grow poorly in the NICU. Consistent evidence shows that VLBW preterm neonates with major morbidity including BPD have worse growth than VLBW without, and that the impaired growth sometimes extends over the first few years of life [1]. The question is: why do infants with BPD grow slowly? A number of reasons may account for this. Increased work required to breath, early use of corticosteroids, pre-existing intrauterine growth retardation, early postnatal growth retardation, or feeding problems related to inadequate intake or high metabolic rate [2,3]. In the latter case, decreased and inadequate nutritional intakes could be the key factor giving rise to decreased ability of the lungs to grow and differentiate, thus closing a vicious circle that is difficult to overcome. Historical studies on animal models (guinea pigs) give evidence that adequate nutrient supply plays an important role in growth and repair of the immature lung. In these experiments, guinea pigs exposed to food restriction displayed significantly reduced body and lung weight compared with fed controls [4]. The rate of pulmonary protein synthesis determined in vivo was reduced by 33%, thus impairing not only growth, but also repair ability of the immature lungs. Adequate nutrient supply is even more critical when considering that energy needs of infants with BPD is 15% to 25% above healthy controls [5], thus an energy intake of 140 to 150 kcal/kg/d may be necessary during periods of active disease. In line with this, both ESPGHAN statements and Cochrane reviews acknowledge that a higher caloric intake is beneficial for infants with BPD [6,7], thus prompting clinicians to face the difficulties to increase the feeds to an infant who is - per se - poorly responsive to such strategies since he is often mechanically ventilated and/or fed via orogastric tube. In addition, when infants with BPD achieve full enteral feedings and have similar protein-energy intakes to control infants, they often demonstrate similar rates of growth and arm muscle and fat accretion, but do not demonstrate catch-up growth. These observations support the speculation that early reductions in growth velocity contribute to the long-term growth failure in infants with BPD. According to this, currently it appears appropriate to assume that the protein needs of preterm infants with BPD are at least comparable to the protein needs of those without the disease, and therefore, protein intakes of 3.5 to 4 g protein/kg should be provided to meet needs for growth and anabolism. The role of lipid intake in infants with BPD also needs further investigation, in view of a possible correlation between early trophic feeding and BPD and between early versus delayed initiation of progressive enteral feedings for parenterally fed low birth weight infants and BPD. The role of specific nutrients: The neonatal period: Several studies have examined and demonstrated the properties of human milk in preventing many diseases of newborns and preterms infants, including infection, NEC, ROP, CLD / BPD. The mechanism that seems to be at the basis of this protective role is the presence in breast milk of numerous anti-oxidant agents (Vitamins E, A, D, inositol, lactoferrin, especially carotenoids like lutein and zeaxanthin, long chain polyunsaturated fatty acids, enzymes and anti-oxidants), which contrast oxidative stress, in turn implicated in the pathogenesis of the above listed diseases. The beneficial effect of human milk has been found to depend on the amounts ingested by the infant. A study exploring neonatal morbidities found out that the proportion of VLBWinfants featuring chronic lung disease dropped dramatically by 50% (from 37% to 19%) by increasing the average quantity of maternal milk ingestion to at least 50 ml/kg/day over the stay in NICU [8]. Vitamin A is essential for development and growth of the lung, as well as for integrity and healing of the epithelium lining the respiratory tract. Vitamin A also upregulates genes involved in alveolarization and surfactant production [9]. Preterm infants at birth have low levels of vitamin A and this has been associated with an increased risk of developing respiratory disease. Supplementation with vitamin A in these children has multiple beneficial effects, including reducing death or oxygen requirement at one month of age (typical RR 0.93, RD -0.05, NNT 20), reducing oxygen requirement at 36 weeks postmenstrual age (typical RR 0.87, RD -0.08, NNT 13) and reducing death or oxygen requirement at 36 weeks postmenstrual age (typical RR 0.91) [10]. According to this, administration of vitamin A is currently recommended in all VLBW infants. Inositol is an essential precursor of phospholipids, promoting maturation of several components of surfactant, and potentiating the glucocorticoid induced acceleration of differentiation of lung surfactant. Adequate nutritional intakes of inositol can prevent or decrease drastically the incidence of some negative outcomes of prematurity, including BPD. In line with this, inositol supplementation results in statistically significant and clinically important reductions in important short-term adverse neonatal outcomes, including BPD [11]. Vitamin E is an important anti-oxidant agent and its administration in VLBW infants has been proposed for the prevention of ROP, hemolytic anemia, intracranial hemorrhage, and also chronic lung disease. BPD has been assessed in six studies of vitamin E supplementation, involving 558 treated patients and 569 controls. From these studies, vitamin E supplementation did not significantly affect the risk of BPD (typical estimate RR 0.91, RD -0.02). Toxicity and side effects related to high doses of vitamin E have been described [12]. The postnatal, early infancy period: During early infancy, the available evidence in literature shows that duration of breastfeeding and the general nutritional status, rather than specific nutrients, impact on airway infections and respiratory morbidity. Nonetheless, recent studies have highlighted the importance of some specific nutrients, such as, zinc and other micronutrients, lactoferrin, vitamin D, lutein and carotenoids. A recent study evaluated the pulmonary function of 12 year old children born from mothers with asthma, comparing those who were breastfed with those who were not. Lung function was significantly better in children previously breastfed, even though their mothers had asthma, than in children not breastfed. This improvement was even more pronounced if breastfeeding was extended beyond 4 months of age [13]. Several nutritional interventions have been evaluated over the years with the aim of reducing the risk of lower respiratory tract infections in early childhood. Most results are inconclusive. Only supplementation with zinc as well as use of milk fortified with micronutrients (iron, zinc, selenium, copper, vitamins A, E and C) have proved to be effective in meeting endpoints [14]. A strong association exists between respiratory infections and inadequate growth, suggesting the need for interventions to decrease the incidence of underweight children and LBW (low birth weight). The balance between weight gain and respiratory well being, however, is very delicate, and perhaps still not entirely clear, as underlined by recent evidence indicating that the presence of asthma symptoms in preschool age may be associated with increased weight (children with excessive weight gain may be more frequently affected by episodes of recurrent wheezing) [15]. Lactoferrin is the most important protein in breast milk. Its concentration is much higher in colostrum than in mature milk and has a homology of 77% with lactoferrin present in bovine milk (in fact they have the same action and the same internalization by gut). Both have a very high survival during passage through the stomach after oral administration. The biological functions of lactoferrin are numerous, and among them anti-inflammatory, immune-modulating, anti-fungal, antibacterial actions, and inhibition of proteases. Lactoferrin can inhibit the formation of ROS (reactive oxygen species), by binding to iron thus attenuating oxidation [16]. One RCT, involving VLBW infants from 11 different Italian NICU, assessed the effects of administration of 100 mg/day of bovine lactoferrin alone or together with Lactobacillus CG compared with placebo, in preventing sepsis.</style></abstract><notes><style face="normal" font="default" size="100%">L613016892&#xD;2016-11-08</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L613016892</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molteno, C.</style></author><author><style face="normal" font="default" size="100%">Smit, I.</style></author><author><style face="normal" font="default" size="100%">Mills, J.</style></author><author><style face="normal" font="default" size="100%">Huskisson, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, University of Cape Town.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutritional status of patients in a long-stay hospital for people with mental handicap</style></title><secondary-title><style face="normal" font="default" size="100%">S Afr Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">S Afr Med J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1135-40</style></pages><volume><style face="normal" font="default" size="100%">90</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2001/02/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Anemia/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Anemia, Hypochromic/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biotin/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Body Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Ceruloplasmin/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/administration &amp; dosage/blood/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Down Syndrome/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospitals, Psychiatric</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intellectual Disability/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Iron/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrition Policy</style></keyword><keyword><style face="normal" font="default" size="100%">*Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Pantothenic Acid/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0256-9574 (Print)</style></isbn><accession-num><style face="normal" font="default" size="100%">11196037</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To investigate the general nutritional status of patients in Alexandra Hospital, Cape Town, and to determine whether dietary copper deficiency was causing anaemia in hospital patients. DESIGN: Descriptive and cross-sectional analytical studies. SETTING: A long-stay hospital for people with mental handicap. SUBJECTS: Information was obtained from the total hospital population. In addition, groups of 15 patients were selected from each of two specific wards, one with active and the other inactive patients. To determine whether copper deficiency was causing anaemia, a sample of 30 patients, divided into three groups (a hypochromic microcytic, a normochromic anaemic and a non-anaemic group) was studied. MAIN OUTCOME MEASURES: Body mass indices (BMI) and daily dietary intakes were compared with Recommended Daily Allowance (RDA) values. Serum copper and serum caeruloplasmin levels were used to detect possible copper deficiency. RESULTS: A considerable number of patients were found to be underweight (32% of males and 26% of females had BMIs &lt; 20). A smaller number were obese (6% of males and 17% of females had BMIs &gt; 30). Poor nutrition was more common in severely handicapped patients and those with acquired causes of their mental handicap. Subjects with Down syndrome were generally well nourished and occasionally obese. Poor dietary intakes of biotin, pantothenic acid, vitamin D and copper were encountered. The serum copper and caeruloplasmin values were found to be within normal limits. Patients with hypochromic, microcytic anaemia had higher serum copper and caeruloplasmin levels than those with normochromic anaemia and the control group. CONCLUSIONS: A number of nutritional problems among the inpatient population were found. Many were undernourished, while a smaller number of patients were overweight. In both the active and inactive wards macronutrient intakes were generally within normal limits. However, some micronutrient nutritional deficiencies were encountered. We were unable to establish that dietary copper deficiency was the cause of anaemia in our patients. Elevated serum copper and caeruloplasmin levels found in hypochromic, microcytic patients were thought to result from the existence of low-grade infection, associated with elevation of the acute-phase protein, caeruloplasmin.</style></abstract><notes><style face="normal" font="default" size="100%">Molteno, C&#xD;Smit, I&#xD;Mills, J&#xD;Huskisson, J&#xD;Comparative Study&#xD;Journal Article&#xD;South Africa&#xD;S Afr Med J. 2000 Nov;90(11):1135-40.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Viberga, I.</style></author><author><style face="normal" font="default" size="100%">Odlind, V.</style></author><author><style face="normal" font="default" size="100%">Berglund, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Riga Stradins University, Department of Obstetric and Gynecology, Lacplesa iela 9-37, Aizkraukle, Riga LV 5101, Latvia. i.viberga@apollo.lv</style></auth-address><titles><title><style face="normal" font="default" size="100%">&quot;Older&quot; age is a risk factor for pelvic inflammatory disease in intrauterine device users</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Obstet Gynecol Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Obstet Gynecol Scand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1202-7</style></pages><volume><style face="normal" font="default" size="100%">84</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">2005/11/25</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/*epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Sweden/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0001-6349 (Print)&#xD;0001-6349</style></isbn><accession-num><style face="normal" font="default" size="100%">16305709</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: To asses the role of a copper intrauterine device (IUD) per se in the development of pelvic inflammatory disease (PID) and complicated PID in women considered at low risk of PID. METHODS: Cases were 51 women admitted to hospital with a diagnosis of acute PID, and controls were 50 healthy women attending an outpatient clinic for routine gynecological check-up. The women were 25-45 years old. Data were analyzed and compared between groups using the statistical program package sas. RESULTS: IUD use was not associated with an increased risk of PID in general, but in women &gt; or =35 years, IUD use was associated with a risk of PID [odds ratio (OR) = 4.2, confidence interval (CI) 1.1-16.3]. When adjusting for smoking, educational level, employment, and microbial findings in women with PID, IUD use was associated with complicated PID in women &gt; or =35 years (OR = 33.9, CI 1.2-959.6), but not in younger women. When adjusting age and IUD use duration for each other in IUD users, age &gt; or =35 years was a significant risk factor for PID (OR = 4.9, CI 1.3-19.2), but not long (&gt; or =5 years) duration. In IUD users with PID, age &gt; or =35 years was a risk factor for a PID to be complicated in both the unadjusted and adjusted analysis (OR = 12.7, CI 1.6-102.3; OR = 12.1, CI 1.4-104.7), whereas long duration of IUD use was not. When adjusting for significant endocervical microbial findings, long duration of IUD use and age, only age &gt; or =35 years, remained significantly associated with both PID and complicated PID (OR = 5, CI 1.1-21.9; OR = 36, CI - 1.9-670). CONCLUSIONS: IUD use was not associated with PID in low-risk younger women, but in women &gt; or =35 years, IUD use was associated with an increased risk of PID. The study also demonstrates an association between IUD use and complicated PID in women &gt; or =35 years.</style></abstract><notes><style face="normal" font="default" size="100%">Viberga, Ilze&#xD;Odlind, Viveca&#xD;Berglund, Lars&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Acta Obstet Gynecol Scand. 2005 Dec;84(12):1202-7. doi: 10.1111/j.0001-6349.2005.00810.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.0001-6349.2005.00810.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>428</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">428</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stoppe, C.</style></author><author><style face="normal" font="default" size="100%">Kopp, R.</style></author><author><style face="normal" font="default" size="100%">Dembinski, R.</style></author><author><style face="normal" font="default" size="100%">Hasenbank, C.</style></author><author><style face="normal" font="default" size="100%">Rossaint, R.</style></author><author><style face="normal" font="default" size="100%">Spillner, J.</style></author><author><style face="normal" font="default" size="100%">Marx, G.</style></author><author><style face="normal" font="default" size="100%">Rex, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C. Stoppe, Department of Intensive Care, University Hospital Aachen, RWTH Aachen University, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Open-heart surgery with the use of cardiopulmonary bypass decreases blood levels of the essential trace elements selenium, copper and zinc</style></title><secondary-title><style face="normal" font="default" size="100%">Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">27-28</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><keywords><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">open heart surgery</style></keyword><keyword><style face="normal" font="default" size="100%">cardiopulmonary bypass</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">heart function</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">heart surgery</style></keyword><keyword><style face="normal" font="default" size="100%">anesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">surgical patient</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">0300-8126</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: The trace elements selenium (Se), copper (Cu) and zinc (Sn) are essential for the maintenance of the oxidative balance and play a pivotal role for the regulation of immunological, endothelial and cardiac function. In critically ill patients with SIRS, sepsis and/or multiorgan dysfunction, plasma levels of essential trace elements are frequently depleted and deficiencies were demonstrated to be associated with increased morbidity and mortality. Little is known about the effects of open-heart surgery using cardiopulmonary bypass (CPB) on the plasma levels of selenium, copper and zinc. Objectives: Aim of the present study was therefore to investigate the plasma levels of trace elements prior to and immediately after CPB. Methods: In this preliminary study, 31 consecutive patients who underwent cardiac surgery with the use of CPB were enrolled (age 63 ± 17 years; median Euroscore 5). Whole blood concentrations of selenium, copper and zinc were measured after induction of anesthesia and 1 hour after admission to the intensive care unit using atomic absorption spectrometry. Results: After end of surgery, all patients showed a significant decrease in plasma levels of selenium (from 90,7 ± 10,8 to 68,9 ± 9,8 μg/l; p &lt; 0,001), zinc (from 5,1 ± 0,7 to 4,1 ± 0,8 mg/l; p &lt; 0,001) and copper (from 0,80 ± 0,12 to 0,61mg/l ± 0,12; p &lt; 0,01). Conclusions: When compared to a normal collective, all cardiac surgical patients exhibited already prior to surgery a selenium depletion which was further aggravated by open-heart surgery using CPB. Further studies in a greater patient population are performed to analyse a possible relationship between intraoperative selenium depletion and the postoperative course.</style></abstract><notes><style face="normal" font="default" size="100%">L70371667&#xD;2011-04-01</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70371667</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s15010-009-1004-1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s15010-009-1004-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>317</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">317</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graham, J.</style></author><author><style face="normal" font="default" size="100%">Russo, C.</style></author><author><style face="normal" font="default" size="100%">Huntington, S.</style></author><author><style face="normal" font="default" size="100%">Kim, T.</style></author><author><style face="normal" font="default" size="100%">Vohra, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Graham, UCSF, Fresno Medical Center, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Organic copper algaecide toxicity: Case report and statewide poison center exposures review</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Toxicology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Toxicology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">772-773</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">copper derivative</style></keyword><keyword><style face="normal" font="default" size="100%">ethanolamine</style></keyword><keyword><style face="normal" font="default" size="100%">poison</style></keyword><keyword><style face="normal" font="default" size="100%">copper ion</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">North American</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">poison center</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">toxicology</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">pancreatitis</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">hemolysis</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">hyperbilirubinemia</style></keyword><keyword><style face="normal" font="default" size="100%">dementia</style></keyword><keyword><style face="normal" font="default" size="100%">erythema</style></keyword><keyword><style face="normal" font="default" size="100%">chelation</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">dysphagia</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">emergency ward</style></keyword><keyword><style face="normal" font="default" size="100%">leukocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">skin</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">methemoglobinemia</style></keyword><keyword><style face="normal" font="default" size="100%">Coloured person</style></keyword><keyword><style face="normal" font="default" size="100%">vital sign</style></keyword><keyword><style face="normal" font="default" size="100%">control system</style></keyword><keyword><style face="normal" font="default" size="100%">liver injury</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte disorder</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">blood smear</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">kidney injury</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">swimming pool</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1556-3650</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Organically complexed copper compounds are designed to release small amounts of copper ion into solution. Although commonly used as swimming pool algaecides, toxicity from these agents is rarely reported, in contrast to well-documented hazardous effects of inorganic copper compounds. Methods: After an index case with severe symptoms, we performed an IRB-approved retrospective review of our statewide poison control system&apos;s electronic database for organic copper algaecide exposures based on AAPCC code entry and free text search. Demographic and clinical data were captured, and animal or non-copper algaecide exposures were excluded. Case Report: An 89 year old woman with dementia was discovered by relatives to be vomiting near a bottle of copper ethanolamine complex. In the ED she had normal vital signs with episodes of green colored vomiting and diarrhea. She developed mild dysphagia and pharyngeal erythema, a mixed hyperbilirubinemia (total 3.2 mg/dL, direct 1.1, indirect 2.2) , and pancreatitis. Blood smear demonstrated evidence of oxidative stress with spherocytes and echinocytes, but no hemolysis. Copper levels were found to be elevated at 2002 mcg/dL (reference 70-175). Serial labs did not show significant hepatic injury, renal dysfunction, or methemoglobinemia. Her GI symptoms, pancreatitis, and hyperbilirubinemia improved over three days, and she was discharged. Poison Control Center Exposures Review: Excluding animal calls, miscoded cases, and the index patient, there were 55 cases reported to the statewide poison center database over a 12-year period. Most cases (84%) were home calls, involving 29 (52%) males with median age 41 years. There were 12 (22 %) oral exposures, 27 (49%) skin exposures, and 10 (18%) ocular exposures. The vast majority of patients remained asymptomatic and required no interventions or further care; one patient developed nausea/ vomiting and diarrhea, while another had a mild leukocytosis. Emergency department observation was done for 8 (30%) patients, and 2 patients required hospitalization. No patients were treated with chelation or other antidotal therapies. Conclusions: Organic copper-based algaecide exposures are relatively benign. Whereas asymptomatic patients can likely be watched at home, patients with moderate to severe symptoms should be evaluated in a health care setting for evidence of copperrelated injury such as hemolysis, hepatitis, corrosive effects, renal injury and pancreatitis. The index case serves as a reminder that older adults with dementia are vulnerable to accidental poisonings. These findings may help guide poison control center education, prevention, and referral efforts.</style></abstract><notes><style face="normal" font="default" size="100%">L72003750&#xD;2015-09-12</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72003750</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3109/15563650.2015.1071025</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/15563650.2015.1071025</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>154</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colville, A.</style></author><author><style face="normal" font="default" size="100%">Crowley, J.</style></author><author><style face="normal" font="default" size="100%">Dearden, D.</style></author><author><style face="normal" font="default" size="100%">Slack, R. C.</style></author><author><style face="normal" font="default" size="100%">Lee, J. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, University Hospital, Queen&apos;s Medical Centre, Nottingham.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outbreak of Legionnaires&apos; disease at University Hospital, Nottingham. Epidemiology, microbiology and control</style></title><secondary-title><style face="normal" font="default" size="100%">Epidemiol Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Epidemiol Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">105-16</style></pages><volume><style face="normal" font="default" size="100%">110</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1993/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">England/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, University</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/*epidemiology/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Personnel, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Water Microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1993</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0950-2688 (Print)&#xD;0950-2688</style></isbn><accession-num><style face="normal" font="default" size="100%">8432314</style></accession-num><abstract><style face="normal" font="default" size="100%">Twelve patients in a large teaching hospital contracted Legionnaires&apos; disease over a period of 11 months. The source was a domestic hot water system in one of the hospital blocks, which was run at a temperature of 43 degrees C. Five different subtypes of Legionella pneumophila serogroup 1 have been isolated from water in different parts of the hospital, over a period of time. Only one subtype, Benidorm RFLP 14, was implicated in disease. Circumstantial evidence suggested that the outbreak may have been due to recent colonization of the hot water system with a virulent strain of Legionella pneumophila. The outbreak was controlled by raising the hot water temperature to 60 degrees C, but careful surveillance uncovered two further cases in the following 30 months. Persistent low numbers of Legionella pneumophila were isolated from the domestic hot water of wards where Legionnaires&apos; disease had been contracted, until an electrolytic unit was installed releasing silver and copper ions into this supply.</style></abstract><notes><style face="normal" font="default" size="100%">Colville, A&#xD;Crowley, J&#xD;Dearden, D&#xD;Slack, R C&#xD;Lee, J V&#xD;Journal Article&#xD;England&#xD;Epidemiol Infect. 1993 Feb;110(1):105-16. doi: 10.1017/s0950268800050731.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2271972</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/s0950268800050731</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hellinger, W. C.</style></author><author><style face="normal" font="default" size="100%">Hasan, S. A.</style></author><author><style face="normal" font="default" size="100%">Bacalis, L. P.</style></author><author><style face="normal" font="default" size="100%">Thornblom, D. M.</style></author><author><style face="normal" font="default" size="100%">Beckmann, S. C.</style></author><author><style face="normal" font="default" size="100%">Blackmore, C.</style></author><author><style face="normal" font="default" size="100%">Forster, T. S.</style></author><author><style face="normal" font="default" size="100%">Tirey, J. F.</style></author><author><style face="normal" font="default" size="100%">Ross, M. J.</style></author><author><style face="normal" font="default" size="100%">Nilson, C. D.</style></author><author><style face="normal" font="default" size="100%">Mamalis, N.</style></author><author><style face="normal" font="default" size="100%">Crook, J. E.</style></author><author><style face="normal" font="default" size="100%">Bendel, R. E.</style></author><author><style face="normal" font="default" size="100%">Shetty, R.</style></author><author><style face="normal" font="default" size="100%">Stewart, M. W.</style></author><author><style face="normal" font="default" size="100%">Bolling, J. P.</style></author><author><style face="normal" font="default" size="100%">Edelhauser, H. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL 32224, USA. hellinger.walter@mayo.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">294-8</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2006/03/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anterior Eye Segment</style></keyword><keyword><style face="normal" font="default" size="100%">Cataract Extraction/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">*Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">*Equipment Contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/*epidemiology/etiology/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Medical Records</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Pollution</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823X (Print)&#xD;0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">16532418</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Toxic anterior segment syndrome (TASS), a complication of cataract surgery, is a sterile inflammation of the anterior chamber of the eye. An outbreak of TASS was recognized at an outpatient surgical center and its affiliated hospital in December 2002. METHODS: Medical records of patients who underwent cataract surgery during the outbreak were reviewed, and surgical team members who participated in the operations were interviewed. Potential causes of TASS were identified and eliminated. Feedwater from autoclave steam generators and steam condensates were analyzed by use of spectroscopy and ion chromatography. RESULTS: During the outbreak, 8 (38%) of 21 cataract operations were complicated by TASS, compared with 2 (0.07%) of 2,713 operations performed from January 1996 through November 2002. Results of an initial investigation suggested that cataract surgical equipment may have been contaminated by suboptimal equipment reprocessing or as a result of personnel changes. The frequency of TASS decreased (1 of 44 cataract operations) after reassignment of personnel and revision of equipment reprocessing procedures. Further investigation identified the presence of impurities (eg, sulfates, copper, zinc, nickel, and silica) in autoclave steam moisture, which was attributed to improper maintenance of the autoclave steam generator in the outpatient surgical center. When impurities in autoclave steam moisture were eliminated, no cases of TASS were observed after more than 1,000 cataract operations. CONCLUSION: Suboptimal reprocessing of cataract surgical equipment may evolve over time in busy, multidisciplinary surgical centers. Clinically significant contamination of surgical equipment may result from inappropriate maintenance of steam sterilization systems. Standardization of protocols for reprocessing of cataract surgical equipment may prevent outbreaks of TASS and may be of assistance during outbreak investigations.</style></abstract><notes><style face="normal" font="default" size="100%">Hellinger, Walter C&#xD;Hasan, Saiyid A&#xD;Bacalis, Laura P&#xD;Thornblom, Deborah M&#xD;Beckmann, Susan C&#xD;Blackmore, Carina&#xD;Forster, Terri S&#xD;Tirey, Jason F&#xD;Ross, Mary J&#xD;Nilson, Christian D&#xD;Mamalis, Nick&#xD;Crook, Julia E&#xD;Bendel, Rick E&#xD;Shetty, Rajesh&#xD;Stewart, Michael W&#xD;Bolling, James P&#xD;Edelhauser, Henry F&#xD;Journal Article&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2006 Mar;27(3):294-8. doi: 10.1086/501540. Epub 2006 Feb 22.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/501540</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>391</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guleri, A.</style></author><author><style face="normal" font="default" size="100%">Palmer, R.</style></author><author><style face="normal" font="default" size="100%">Jackson, P.</style></author><author><style face="normal" font="default" size="100%">Przybylo, M.</style></author><author><style face="normal" font="default" size="100%">Sharma, R.</style></author><author><style face="normal" font="default" size="100%">Peel, A.</style></author><author><style face="normal" font="default" size="100%">Bird, M.</style></author><author><style face="normal" font="default" size="100%">Moorhouse, L.</style></author><author><style face="normal" font="default" size="100%">Clitheroe, S.</style></author><author><style face="normal" font="default" size="100%">King, S.</style></author><author><style face="normal" font="default" size="100%">Zacharias, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Guleri, Blackpool, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outbreak report of multidrug-resistant Pseudomonas aeruginosa [MDR-PA] in a cardiac intensive care unit at a Lancashire cardiac centre</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">13</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><keywords><keyword><style face="normal" font="default" size="100%">water</style></keyword><keyword><style face="normal" font="default" size="100%">tap water</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">chlorine</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">aerosol</style></keyword><keyword><style face="normal" font="default" size="100%">tube</style></keyword><keyword><style face="normal" font="default" size="100%">clinical audit</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">mixer</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">molecular typing</style></keyword><keyword><style face="normal" font="default" size="100%">bacteremia</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">bone</style></keyword><keyword><style face="normal" font="default" size="100%">wound</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">teamwork</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">thorax</style></keyword><keyword><style face="normal" font="default" size="100%">reflex</style></keyword><keyword><style face="normal" font="default" size="100%">sensor</style></keyword><keyword><style face="normal" font="default" size="100%">hypothesis</style></keyword><keyword><style face="normal" font="default" size="100%">down regulation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">1198-743X</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Pseudomonas aeruginosa [PA] is a major opportunistic nosocomial pathogen. PA often colonises hospital and domestic water taps, sinks, drains, toilets and showers. We present an outbreak report, of 13 cases of MDR-PA infections (between Aug-Dec2010) in a cardiac intensive care, including outbreak investigations, management, saving a major expense and an interesting observation/hypothesis of downregulation of resistance mechanism in environmental outbreak strain. Methods: PA isolates from 13-patients in CITU and environment/ equipment were confirmed by VNTR molecular typing at Colindale. Over 200samples obtained from environment[tap water from sinks in CITU, theatre, water tanks, cleaner buckets and cloths, etc] and equipment. Case defined-MDR-PA isolated from symptomatic patient in CITU. Definition outbreak was unusual increase in cases with outbreak strain MDR-PA. Results: MDR-PA infections included chest, wound, bone and drain site infections. No bacteraemia recorded. Outbreak strain in 10 [of 13 patients] and most CITU sink tap water. Dissection/sampling of 2-sinks down to hot/cold water pipes revealed colonised spray unit of tap nozzle[picture] and sink trap. Interestingly, the environmental outbreak strain was uniformly sensitive PA while all patient isolates MDR-PA. Interventions: Regular outbreak committee meetings including press statement, action plan, team working [estates, cardiac division, Cleaners, Microbiologist and infection control]. Actions included - enhanced education/training, covert audit of compliance to IC protocols[handhygiene, ANTT &amp; patient material discarding practices]; Cleaners - separate disposable cloths; new protocol/high chlorine cleansers;audit of practice; Estates-change flexible hose to copper pipes, remove/clean/hyperchlorinate tap nozzle spray units and post intervention regular water testing; Close monitoring of situation. (Figure presented) Conclusions: Regular outbreak meetings; teamwork between microbiologist-estates-cleaners-cardiac division; planned/scientific/ logical comprehensive approach contained the outbreak; A reflex expense of approximately 80K in changing all sinks was prevented; The thermostatic mixer valve/flexible hose were negative for PA. Sensor tap mixer has been incriminated in other PA outbreak reports. Our hypothesis for the fully sensitive PA outbreak strain in environment is down regulation of resistance mechanism due to lack of antibiotic pressure. Pictures and stepwise outbreak management details to be presented.</style></abstract><notes><style face="normal" font="default" size="100%">L70822117&#xD;2012-08-10</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70822117</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1469-0691.2012.03801.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1469-0691.2012.03801.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>452</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">452</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mishra, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">V. Mishra, Department of Clinical Chemistry, Royal Liverpool University Hospital, Liverpool L7 8XP, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oxidative stress and role of antioxidant supplementation in critical illness</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Laboratory</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Laboratory</style></full-title></periodical><pages><style face="normal" font="default" size="100%">199-209</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">3-4</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">free radical</style></keyword><keyword><style face="normal" font="default" size="100%">glutamine</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">lycopene</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">sodium selenite</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">acute phase response</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">breast tenderness</style></keyword><keyword><style face="normal" font="default" size="100%">cause of death</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">combination chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">critical illness</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">drug efficacy</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug potentiation</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal symptom</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">ischemia</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">meta analysis</style></keyword><keyword><style face="normal" font="default" size="100%">monotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">pancreatitis</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">systemic inflammatory response syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">thrombophlebitis</style></keyword><keyword><style face="normal" font="default" size="100%">traumatology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><isbn><style face="normal" font="default" size="100%">1433-6510</style></isbn><abstract><style face="normal" font="default" size="100%">Sepsis or systemic inflammatory response (SIRS) to infection or to non-infectious stimuli such as trauma, surgery, pancreatitis or ischemia, is an increasingly common cause of morbidity and mortality in patients on intensive therapy unit (ITU). In critically ill patients, this accounts for 10% to 50% of all deaths. Oxidative stress has an important role in the development and manifestations of SIRS. Oxidative stress is an imbalance between the free radical production and the antioxidant defense. In critical illness, overwhelming inflammatory mediator response to infective or non-infective stimuli results in excessive production of free radicals (FR). The action of FR is normally limited by the antioxidant defense system of the body, but in critically ill patients the antioxidant capacity is likely to be compromised. Hence, provision of antioxidants to critically ill patients may help in removing the FR and therefore improving the clinical outcome. However, no study has yet provided conclusive evidence of the beneficial effect of antioxidant supplementation in critically ill patients. The clinical evidence provided so far shows that there are several factors which might determine the efficacy of antioxidant supplementation in critically ill patients. There is a need for large multicentre prospective randomized control trials to assess the effects of different types and doses of antioxidant supplementation in selected groups of patients with different types of critical illness.</style></abstract><notes><style face="normal" font="default" size="100%">L46656577&#xD;2007-05-09</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L46656577</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">17447658</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>284</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">284</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yelly Oktavia, S.</style></author><author><style face="normal" font="default" size="100%">Arifin, H.</style></author><author><style face="normal" font="default" size="100%">Yosmar, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Yelly Oktavia, Faculty of Pharmacy, University of Andalas, Padang, West Sumatera, Indonesia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Parenteral nutrition in neonatus and compatibility issues: A review article</style></title><secondary-title><style face="normal" font="default" size="100%">Asian Journal of Pharmaceutical and Clinical Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Asian Journal of Pharmaceutical and Clinical Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">54-64</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">catheter</style></keyword><keyword><style face="normal" font="default" size="100%">acetic acid</style></keyword><keyword><style face="normal" font="default" size="100%">aspartic acid</style></keyword><keyword><style face="normal" font="default" size="100%">calcium</style></keyword><keyword><style face="normal" font="default" size="100%">carbohydrate</style></keyword><keyword><style face="normal" font="default" size="100%">chloride</style></keyword><keyword><style face="normal" font="default" size="100%">chromium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cysteine</style></keyword><keyword><style face="normal" font="default" size="100%">electrolyte</style></keyword><keyword><style face="normal" font="default" size="100%">fat</style></keyword><keyword><style face="normal" font="default" size="100%">fluoride</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">glutamic acid</style></keyword><keyword><style face="normal" font="default" size="100%">iodide</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">molybdenum</style></keyword><keyword><style face="normal" font="default" size="100%">phosphorus</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">potassium dihydrogen phosphate</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">sodium</style></keyword><keyword><style face="normal" font="default" size="100%">taurine</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">tyrosine</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">air embolism</style></keyword><keyword><style face="normal" font="default" size="100%">artery injury</style></keyword><keyword><style face="normal" font="default" size="100%">caloric intake</style></keyword><keyword><style face="normal" font="default" size="100%">catheter complication</style></keyword><keyword><style face="normal" font="default" size="100%">catheter dislocation</style></keyword><keyword><style face="normal" font="default" size="100%">catheter embolization</style></keyword><keyword><style face="normal" font="default" size="100%">catheter infection</style></keyword><keyword><style face="normal" font="default" size="100%">child development</style></keyword><keyword><style face="normal" font="default" size="100%">child growth</style></keyword><keyword><style face="normal" font="default" size="100%">child nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">clinical effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">electrolyte disturbance</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">essential fatty acid deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">fat intake</style></keyword><keyword><style face="normal" font="default" size="100%">glucose blood level</style></keyword><keyword><style face="normal" font="default" size="100%">glucose infusion</style></keyword><keyword><style face="normal" font="default" size="100%">glucose tolerance</style></keyword><keyword><style face="normal" font="default" size="100%">hematothorax</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hyperglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertriglyceridemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypoglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">macronutrient</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic bone disease</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional requirement</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">parenteral nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">physical chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">pneumothorax</style></keyword><keyword><style face="normal" font="default" size="100%">prematurity</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">rat</style></keyword><keyword><style face="normal" font="default" size="100%">refeeding syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">vein thrombosis</style></keyword><keyword><style face="normal" font="default" size="100%">zeta potential</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">2455-3891&#xD;0974-2441</style></isbn><abstract><style face="normal" font="default" size="100%">Intravenous drug administration in Neonatal Intensive Care Unit is critical because of poor venous access, polymedication, fluid restriction, and low infusion rate. Since parenteral nutrition (PN) is infused intravenously, it is often considered as a vehicle for medication administration. Medications may be added to PN formulations in an effort to decrease fluid requirements, reduce the need for Y-site injections, reduce the possibility of line contamination due to manipulation, and decrease labor time required for drug administration. Risk is further increased by inadequate information on the physicochemical compatibility of drugs.</style></abstract><notes><style face="normal" font="default" size="100%">L614389070&#xD;2017-02-15&#xD;2017-03-20</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L614389070</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.22159/ajpcr.2017.v10i2.15697</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.22159/ajpcr.2017.v10i2.15697</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foley, J.</style></author><author><style face="normal" font="default" size="100%">Evans, D.</style></author><author><style face="normal" font="default" size="100%">Blackwell, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatric Dentistry, Dundee Dental Hospital, Dundee DD1 4HN, Scotland, UK. jennifer.i.foley@tuht.scot.nhs.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Partial caries removal and cariostatic materials in carious primary molar teeth: a randomised controlled clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Br Dent J</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br Dent J</style></full-title></periodical><pages><style face="normal" font="default" size="100%">697-701; discussion 689</style></pages><volume><style face="normal" font="default" size="100%">197</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2004/12/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aluminum Silicates</style></keyword><keyword><style face="normal" font="default" size="100%">Cariostatic Agents/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Dental Caries/*therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Dental Cavity Preparation/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Dental Cements</style></keyword><keyword><style face="normal" font="default" size="100%">Dental Restoration Failure</style></keyword><keyword><style face="normal" font="default" size="100%">Dental Restoration, Permanent/adverse effects/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glass Ionomer Cements</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Molar</style></keyword><keyword><style face="normal" font="default" size="100%">Periapical Abscess/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Statistics, Nonparametric</style></keyword><keyword><style face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Tooth, Deciduous</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0007-0610 (Print)&#xD;0007-0610</style></isbn><accession-num><style face="normal" font="default" size="100%">15592552</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine the durability and effectiveness of a black copper cement (BCC) and a conventional glass ionomer cement (GIC) when used to restore primary molars following partial caries removal (PCR) and to compare these results with conventional cavity preparation and restoration. DESIGN: Split-mouth randomised controlled clinical trial. SETTING: Department of Paediatric Dentistry, Dundee Dental Hospital, Dundee, 1998-1999. SUBJECTS: Patients with previously unrestored, matched carious cavities in non-pulpally involved primary molars. INTERVENTIONS: Three treatment groups: (1) Partial caries removal followed by lining with BCC and restoration with GIC (PCR:BCC); (2) Partial caries removal and restoration with GIC alone (PCR:GIC), and (3) Complete caries removal and conventional restoration (CR). Restoration durability and effectiveness was assessed both clinically and radiographically over 24 months.Main outcome measures Median survival time (MST) of restorations. RESULTS: Forty-four patients (F: 31; M: 13), mean age 6.8 years (range: 3.7-9.5), had 120 restorations placed (PCR:GIC: 43; CR: 41; PCR:BCC: 36). Eighty-six molars (29 patients) (PCR:GIC: 30; CR: 29; PCR:BCC: 27) were reviewed at 24 months. The median survival times (MST) with 25% and 75% quartiles in parenthesis were as follows: PCR:BCC, MST = 24 months (6, 24); PCR:GIC, MST = 24 months (24, 24) and CR, MST = 24 months (24, 24). The MST for PCR:BCC restorations was significantly less than for PCR:GIC and CR restorations (W = 1163.5, P = 0.028 and W = 1081.0, P = 0.004 respectively). CONCLUSION: There were no differences in the proportions of restorations lost between restoration types, although PCR:BCC restorations did have significantly more abscess/sinus formation over the 24-month study period.</style></abstract><notes><style face="normal" font="default" size="100%">Foley, J&#xD;Evans, D&#xD;Blackwell, A&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Br Dent J. 2004 Dec 11;197(11):697-701; discussion 689. doi: 10.1038/sj.bdj.4811865.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/sj.bdj.4811865</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larsson, B.</style></author><author><style face="normal" font="default" size="100%">Rodau, S.</style></author><author><style face="normal" font="default" size="100%">Patek, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pelvic inflammatory disease among women using copper IUDs, Progestasert, oral contraceptive pills or vaginal contraceptive pills: a 4-year prospective investigation</style></title><secondary-title><style face="normal" font="default" size="100%">Contracept Deliv Syst</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contracept Deliv Syst</style></full-title></periodical><pages><style face="normal" font="default" size="100%">237-42</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">1981/07/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Chemical Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptives, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Inorganic Chemicals</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Medicated</style></keyword><keyword><style face="normal" font="default" size="100%">Metals</style></keyword><keyword><style face="normal" font="default" size="100%">Parity</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword><keyword><style face="normal" font="default" size="100%">Spermatocidal Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaginal Creams, Foams, and Jellies</style></keyword><keyword><style face="normal" font="default" size="100%">*Adnexitis</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Ingredients And Chemicals</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud</style></keyword><keyword><style face="normal" font="default" size="100%">Iud Material</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Hormone Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">Nulliparity</style></keyword><keyword><style face="normal" font="default" size="100%">*Oral Contraceptives</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Tract Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Size</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal Spermicides</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaginal Tablet</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1981</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0143-6112 (Print)&#xD;0143-6112</style></isbn><accession-num><style face="normal" font="default" size="100%">12278910</style></accession-num><abstract><style face="normal" font="default" size="100%">Prospective data about PID (pelvic inflammatory disease) in parous and nulliparous women using either oral contraceptive combined pills (OC), IUDs of different types (Gravigard, Gravigard-P, CuT 200, Progestasert) or vaginal contraceptive tablets were evaluated. The PID rate in association with respective contraceptive methods is compared with the estimated incidence of PID in the population. 1177 women attending the Family Planning Center at Huddinge University Hospital during the period 1975-1979 participated in the study. IUD, OC or vaginal contraceptive tablets were given to the women according to their own choice. Prolonged use of copper IUD did not appear to increase risk of PID. Annual distribution of PID was even throughout the study period. Cultures resulted in the growth of gonococcus in 15% of cases of PID, and rate of infection was no more common among nulliparous than among parous adult females and/or teenagers using IUD. Incidence of PID in OC users was about half that in copper IUD users. A 5-fold increase was observed in acute salpingitis rate in IUD users versus OC users. A 3-fold increase was also noted in PID rate among IUD users compared with that in users of other methods. A significantly larger number of controls than patients with PID used OCs. A previous history of PID does not necessarily imply a greater risk of an IUD-causing PID.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Larsson, B&#xD;Rodau, S&#xD;Patek, E&#xD;Journal Article&#xD;England&#xD;Contracept Deliv Syst. 1981 Jul;2(3):237-42.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">33</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parsons, C.</style></author><author><style face="normal" font="default" size="100%">Costolo, B.</style></author><author><style face="normal" font="default" size="100%">Brown, P.</style></author><author><style face="normal" font="default" size="100%">Kathariou, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, 400 Sullivan Dr, Raleigh, NC 27695, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Penicillin-binding protein encoded by pbp4 is involved in mediating copper stress in Listeria monocytogenes</style></title><secondary-title><style face="normal" font="default" size="100%">FEMS Microbiol Lett</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FEMS Microbiol Lett</style></full-title></periodical><volume><style face="normal" font="default" size="100%">364</style></volume><number><style face="normal" font="default" size="100%">20</style></number><edition><style face="normal" font="default" size="100%">2017/10/14</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biofilms/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Transposable Elements</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Outbreaks</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Listeria monocytogenes/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Listeriosis/epidemiology/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Mutation/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillin-Binding Proteins/genetics/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmids/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Lactamase Inhibitors/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Lactams/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Listeria monocytogenes</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">copper homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">penicillin-binding protein</style></keyword><keyword><style face="normal" font="default" size="100%">virulence</style></keyword><keyword><style face="normal" font="default" size="100%">beta-lactam antibiotic resistance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0378-1097</style></isbn><accession-num><style face="normal" font="default" size="100%">29029084</style></accession-num><abstract><style face="normal" font="default" size="100%">Listeria monocytogenes raises major food safety and public health concerns due to its potential for severe foodborne disease and persistent colonization of food processing facilities. Copper is often employed to control pathogens in agriculture and is increasingly used in healthcare facilities, but mechanisms mediating tolerance of L. monocytogenes to copper remain poorly understood. A mariner-based mutant library of L. monocytogenes 2011L-2858, implicated in the 2011 listeriosis outbreak via whole cantaloupe, was screened for growth at sublethal levels of copper yielding mutant G2B4 with decreased copper tolerance. The transposon was localized in pbp4 (lmo2229 homolog), encoding a penicillin-binding protein (PBP). In addition to reduced copper tolerance, G2B4 exhibited increased susceptibility to beta-lactam antibiotics, reduced biofilm formation and reduced virulence in the Galleria mellonella model. Mutant phenotypes were fully restored upon genetic complementation of G2B4 with intact pbp4. Findings provide the first evidence for the role of a PBP in copper tolerance of L. monocytogenes and suggest that pbp4 may be a suitable target to enable the use of lower levels of copper or enhance the effectiveness of levels currently in use. Given the wide distribution of PBPs and their highly conserved nature, this could have profound impacts in regard to ecology and control of L. monocytogenes and other microorganisms.</style></abstract><notes><style face="normal" font="default" size="100%">1574-6968&#xD;Parsons, Cameron&#xD;Costolo, Ben&#xD;Brown, Phillip&#xD;Kathariou, Sophia&#xD;Journal Article&#xD;England&#xD;FEMS Microbiol Lett. 2017 Nov 1;364(20). pii: 4329268. doi: 10.1093/femsle/fnx207.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/femsle/fnx207</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">97</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamilton, D.</style></author><author><style face="normal" font="default" size="100%">Foster, A.</style></author><author><style face="normal" font="default" size="100%">Ballantyne, L.</style></author><author><style face="normal" font="default" size="100%">Kingsmore, P.</style></author><author><style face="normal" font="default" size="100%">Bedwell, D.</style></author><author><style face="normal" font="default" size="100%">Hall, T. J.</style></author><author><style face="normal" font="default" size="100%">Hickok, S. S.</style></author><author><style face="normal" font="default" size="100%">Jeanes, A.</style></author><author><style face="normal" font="default" size="100%">Coen, P. G.</style></author><author><style face="normal" font="default" size="100%">Gant, V. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dumfries and Galloway Royal Infirmary, Dumfries and Galloway, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Performance of ultramicrofibre cleaning technology with or without addition of a novel copper-based biocide</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">62-71</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2009/10/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Textiles/*microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">19819583</style></accession-num><abstract><style face="normal" font="default" size="100%">This study compared the bacterial removal performance of ultramicrofibre cloths and mops (UMF) moistened with water (UMF+water), with those moistened with a novel copper-based biocide (UMF+CuWB50, 300ppm) in several working hospital environments, specifically accident and emergency (A&amp;E) and three other wards. A total of 13 defined sampling sites (10 sites per ward) were sampled in order to retrieve, culture, and enumerate total viable (bacterial) counts (TVC) for each site. We sampled 1h before, and 1 and 4h after, cleaning three times per week. The trial ran for 7 weeks. Two wards were cleaned with UMF+water for 3 weeks, and UMF+CuWB50 for 4 weeks. The reverse applied to the other two wards in a cross-over design fashion, to eliminate ward- and time-specific bias. Multivariate statistical analyses were used to establish extent and significance of any perceived differences, and to eliminate the effects of potential confounders. Cleaning with UMF+water reduced TVC on the test surfaces by 30%, whereas cleaning with TVC+CuWB50 reduced TVC by 56%. CuWB50 had two separate effects; a direct antibacterial effect (evident shortly after cleaning), and a residual antibacterial effect that lasted approximately 2 weeks. The residual effect requires regular application of CuWB50 if it is to persist. This &apos;real life&apos; hospital implementation study demonstrates encouraging microbiological cleaning performance for UMF, which is further enhanced with CuWB50.</style></abstract><notes><style face="normal" font="default" size="100%">1532-2939&#xD;Hamilton, D&#xD;Foster, A&#xD;Ballantyne, L&#xD;Kingsmore, P&#xD;Bedwell, D&#xD;Hall, T J&#xD;Hickok, S S&#xD;Jeanes, A&#xD;Coen, P G&#xD;Gant, V A&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2010 Jan;74(1):62-71. doi: 10.1016/j.jhin.2009.08.006. Epub 2009 Oct 12.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2009.08.006</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arowojolu, A. O.</style></author><author><style face="normal" font="default" size="100%">Otolorin, E. O.</style></author><author><style face="normal" font="default" size="100%">Ladipo, O. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics &amp; Gynaecology, University College Hospital, Ibadan, Nigeria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Performances of copper T 380A and multiload copper 375/250 intrauterine contraceptive devices in a comparative clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">Afr J Med Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Afr J Med Med Sci</style></full-title></periodical><pages><style face="normal" font="default" size="100%">59-65</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1995/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Amenorrhea/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Design</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Nigeria</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Africa South Of The Sahara</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception Continuation</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception Termination</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptive Effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Usage</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Double-blind Studies</style></keyword><keyword><style face="normal" font="default" size="100%">English Speaking Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Insertion</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud Expulsion</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Iud--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Menstruation Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Reproductive Tract Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Report</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Western Africa</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0309-3913 (Print)&#xD;0309-3913</style></isbn><accession-num><style face="normal" font="default" size="100%">7495202</style></accession-num><abstract><style face="normal" font="default" size="100%">An evaluation of the performances of copper T 380A (TCU 380A) and multiload copper 375/250 (MLCU 375/250) intrauterine contraceptive devices (IUCDS) was carried out at University College Hospital, Ibadan, Nigeria (UCH) in a clinical comparative trial. The IUCDS showed similar low vent rates at one year of continuous use. The difference in cumulative net probabilities for termination due to pelvic inflammatory disease was weakly significant at the sixth month of follow up with MLCU 250 having the highest rate. (TCU 380A-0%; MLCU 375-0%; MLCU 250-3.1%; X2 = 6.0; P &lt; 0.05). This significant difference disappeared by the twelfth month of continuous use. Likewise, the difference in cumulative net probabilities for overall termination was significant at six months and insignificant at twelve months of follow up. The continuation rate after one year were 86%, 92% and 87% respectively for TCU 380A, MLCU 375 and MLCU 250. These rates were higher than 80% and 51% quoted for the previously available Lippes loop in the same environment [1,2]. It was therefore concluded that the three IUCDS are comparable in performances in the first year of use and could be used at our family planning clinic or any other clinic in a similar setting.&#xD;Between April 1988 and June 1991, health workers in Nigeria followed 300 women aged 20-40 who had had a copper releasing IUD inserted during menstruation at the family planning clinic of the University College Hospital in Ibadan. The double blind clinical trial compared the effectiveness and side effects of three copper releasing IUDs: Copper T380A, Multiload 375, and Multiload 250. 75.7% had used no contraception before admission to the study. Pelvic inflammatory disease (PID) occurred more often in the MLCU 250 group than the other two groups. Only two women were hospitalized for PID. These two women used the TCU 380A or MLCU 250. Many IUD users experienced abdominal pain during menstruation and TCU 380A users had the highest rate (27% vs. 21-24%). Heavy bleeding during menstruation was more common in TCU 380A and MLCU 375 users (5% and 4%, respectively, vs. 2%). Pelvic pain/cramps were present in 1-3% of women, but did not contribute to removal. The only case of uterine perforation was in a user of the TCU 380A. None of the MLCU 375 users experienced IUD expulsion, while two TCU 380A users experienced total expulsion and two and one MLCU 250 users experienced total and partial expulsion, respectively. PID was related to IUD removal at 6 months (3.1% vs. 0; p 0.05). The pregnancy rate at 6 months was 1.1% for the TCU 380A group and 0 for the other groups. At 12 months, it was 1.1% for the TCU 380A group and the MLCU 375 group and 0 for MLCU 250. The net 6-month IUD cumulative termination rate was highest in the TCU 380A group (11.1% vs. 3-7%; p 0.05). These differences were no longer significant at 12 months. The net 6- and 12-month IUD continuation rate was 97% and 92% for MLCU 375 compared to 88.9% for TCU 380A and 93% for MLCU 250 and 85.8% for TCU 380A and 87% for MLCU 250, respectively. These findings suggest that these three IUD devices could be used in the hospital&apos;s family planning clinic.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Arowojolu, A O&#xD;Otolorin, E O&#xD;Ladipo, O A&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Nigeria&#xD;Afr J Med Med Sci. 1995 Mar;24(1):59-65.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">88</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adam, I.</style></author><author><style face="normal" font="default" size="100%">Elhassan, E. M.</style></author><author><style face="normal" font="default" size="100%">Haggaz, A. E.</style></author><author><style face="normal" font="default" size="100%">Ali, A. A.</style></author><author><style face="normal" font="default" size="100%">Adam, G. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, University of Khartoum, Khartoum, Sudan. ishagadam@hotmail.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">A perspective of the epidemiology of malaria and anaemia and their impact on maternal and perinatal outcomes in Sudan</style></title><secondary-title><style face="normal" font="default" size="100%">J Infect Dev Ctries</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Infect Dev Ctries</style></full-title></periodical><pages><style face="normal" font="default" size="100%">83-7</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2011/03/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anemia/*epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">*Infectious Disease Transmission, Vertical</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/*epidemiology/mortality/parasitology/*transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Maternal Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">*Perinatal Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications, Parasitic/*epidemiology/mortality/parasitology</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sudan/epidemiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 2</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1972-2680</style></isbn><accession-num><style face="normal" font="default" size="100%">21389586</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Both malaria and anaemia have adverse effects on maternal and perinatal outcomes. Thus there is an urgent need to investigate the co-epidemiology of malaria and anaemia and their combined impact on maternal and perinatal outcomes in the different regions of Sudan. METHODOLOGY: Various cross-sectional and case control studies conducted during the years 2003-2010 to investigate the epidemiology of malaria and anaemia and their impact on maternal and perinatal outcomes in different regions of Sudan were compared. RESULTS: While 13.7% of antenatal attendants in New Halfa had peripheral microscopically detected Plasmodium falciparum malaria, placental malaria (using histological examinations) was prevalent in 32.0-40% and 19.5% of parturient women in New Halfa and Gadarif Hospitals, respectively. Malaria was a risk factor for anaemia in New Halfa and for stillbirths in Omdurman Maternity Hospital. Anaemia was present in 52.5%, 62.6% and 80.2% of pregnant women in Medani, New Halfa, and Gadarif Hospitals, respectively. In Gadarif, 57.3% of pregnant women had a folate deficiency, while 1% had a vitamin B12, deficiency. In Medani, zinc and copper deficiencies were detected in 45.0% and 4% of pregnant women, respectively. Anaemia was a risk factor for low birth weight in Al-Fashir, for fetal anaemia in New Halfa, and for stillbirth in Kassala Hospital. CONCLUSION: More care should be taken to ensure proper nutrition and malaria prevention such as bed nets and intermittent preventive treatments to avoid these diseases and their effects on maternal and perinatal outcomes.</style></abstract><notes><style face="normal" font="default" size="100%">1972-2680&#xD;Adam, Ishag&#xD;Elhassan, Elhassan M&#xD;Haggaz, Abd Elrahium D&#xD;Ali, Abdel Aziem A&#xD;Adam, Gamal K&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Italy&#xD;J Infect Dev Ctries. 2011 Mar 2;5(2):83-7. doi: 10.3855/jidc.1282.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3855/jidc.1282</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>378</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">378</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chung, J.</style></author><author><style face="normal" font="default" size="100%">Fung, E. B.</style></author><author><style face="normal" font="default" size="100%">Feusner, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Chung, Pediatrics, Hematology-Oncology, UC Davis Medical Center, Sacramento, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A pilot study to assess alterations in trace element status in pediatric patients with malignancies</style></title><secondary-title><style face="normal" font="default" size="100%">Blood</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Blood</style></full-title></periodical><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">21</style></number><keywords><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">C reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">marker</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">serum albumin</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">hematology</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">solid malignant neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional assessment</style></keyword><keyword><style face="normal" font="default" size="100%">height</style></keyword><keyword><style face="normal" font="default" size="100%">zinc deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">weight</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">plasma</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">mucosa inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">body weight loss</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">arm muscle</style></keyword><keyword><style face="normal" font="default" size="100%">wasting syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">prematurity</style></keyword><keyword><style face="normal" font="default" size="100%">malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system tumor</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">multivariate analysis</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">evidence based practice</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">dietary intake</style></keyword><keyword><style face="normal" font="default" size="100%">leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient</style></keyword><keyword><style face="normal" font="default" size="100%">food frequency questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">zinc urine level</style></keyword><keyword><style face="normal" font="default" size="100%">oncology</style></keyword><keyword><style face="normal" font="default" size="100%">cancer therapy</style></keyword><keyword><style face="normal" font="default" size="100%">analysis of variance</style></keyword><keyword><style face="normal" font="default" size="100%">central nervous system</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0006-4971</style></isbn><abstract><style face="normal" font="default" size="100%">Nutritional status of children with cancer is a surprisingly understudied area. While overt malnutrition is not common among US children with cancer, many experience weight loss or mild nutritional deficiencies. The Children&apos;s Oncology Group (COG) noted in one study that only 46% of responding institutions conducted a nutrition assessment on newly diagnosed children with cancer and only 52% had criteria for intervention (Ladas et al. 2006). Accordingly, the COG has called for more clinical studies in order to provide evidence-based guidelines for nutritional assessment and interventions for these patients. Zinc, a trace mineral used in hundreds of proteins in the body, is rarely assessed in these children. We hypothesized that there is increased incidence of zn deficiency in US children with cancer compared with the general population, and that low zn levels may be associated with increased incidence of common toxicities of treatment, including diarrhea, mucositis or infection. We report here an interim analysis. We designed a prospective trial of children with cancers diagnosed and treated at Children&apos;s Hospital and Research Center Oakland (CHRCO) from January 2011 through August 2012. Fifty children aged 1 mo to 18 years were enrolled and followed over a six month period. Diagnoses included 33 leukemias, 2 lymphomas, 2 CNS tumors and 13 other solid tumors. Children were enrolled within two weeks of diagnosis and prior to start of any supplemental nutrition. Exclusion criteria included prematurity and known malabsorptive or zn wasting syndromes. A control group of 50 healthy children were also recruited. Approval was obtained from the CHRCO IRB. Anthropometric measurements recorded included height, weight, mid upper arm muscle circumference (MUM C) and skinfolds. Laboratory markers measured included plasma zn, copper (cu), ceruloplasmin, serum albumin, c-reactive protein (CRP) and urine zn, cu and creatinine. Dietary assessment was performed using a self-administered food frequency questionnaire. No significant differences were seen in baseline assessments between the case and control groups. Average body mass index (BMI), height z-score and weight z-score were the same between the two groups. However, subanalysis of the solid tumor group showed a decreased BMI of 16.3 vs. 18.5 in the control group, p=0.01. Similarly, there were no differences in dietary intake of major nutrients, with both groups averaging well above the estimated average requirement (EAR). One notable exception was Vitamin D which was low in both groups but significantly lower in the case group, 37% of EAR vs. 55% of EAR, p&lt;0.01. As expected CRP was elevated in the case group at baseline, 0.85 vs. 0.09 in the control group, p=0.01. Similarly cu was elevated at 142.9 ± 51.2 vs. 111 ± 31.2, p&lt;0.01. However, zn was not decreased at baseline, 85.1 ± 20.8 vs. 84.5 ± 10.4. A larger proportion of the case cohort had low zn levels (&lt;70ug/dl) than did the control group (16% vs. 8%) but this did not reach statistical significance. However, zn decreased significantly in the case group over a six month period from 85.1 ± 20.8 to 72.7 ± 15.2, p=0.002. This difference was most marked in the adolescent leukemia/lymphoma group who demonstrated 30% decrease in zn levels and 60% of these subjects had low zn levels at 6 mo. Cu levels also dropped over the 6 month period, from 142.9 ± 51.2 to 123.5 ± 41.9, p=0.01. We performed ANOVA to evaluate zn and cu in the case cohort over time. Zn dropped significantly with a p value of 0.0015, as did cu with a p of 0.0001. Our data showed no significant deficiencies in plasma zn levels in children at diagnosis of cancer. However, plasma cu was elevated. Both zn and cu levels dropped over the initial 6 month course of treatment, most markedly in the leukemia/lymphoma group in contrast to a prior study which showed decreases only in a subgroup of solid tumors and not in the leukemia/lymphoma population (Malvy, et al. 1997). In multivariate analysis, variables correlating with low zn included plasma cu, age, MUMC and BM . CRP did not correlate with plasma zn levels, suggesting that low zn was a consequence of true nutritional deficit rather than an acute inflammatory response. Not all the data are mature at this time and we have yet to evaluate the relationship between plasma zn levels and toxicities of cancer treatment. Further analyses are needed to identify the conditions contributing to and the consequences of zn deficiency in this population.</style></abstract><notes><style face="normal" font="default" size="100%">L70963525&#xD;2013-01-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70963525</style></url><url><style face="normal" font="default" size="100%">http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/3183?maxtoshow=&amp;hits=80&amp;RESULTFORMAT=&amp;searchid=1&amp;FIRSTINDEX=1600&amp;displaysectionid=Poster+Session&amp;fdate=1/1/2012&amp;tdate=12/31/2012&amp;resourcetype=HWCIT</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arredondo-Alonso, S.</style></author><author><style face="normal" font="default" size="100%">Top, J.</style></author><author><style face="normal" font="default" size="100%">McNally, A.</style></author><author><style face="normal" font="default" size="100%">Puranen, S.</style></author><author><style face="normal" font="default" size="100%">Pesonen, M.</style></author><author><style face="normal" font="default" size="100%">Pensar, J.</style></author><author><style face="normal" font="default" size="100%">Marttinen, P.</style></author><author><style face="normal" font="default" size="100%">Braat, J. C.</style></author><author><style face="normal" font="default" size="100%">Rogers, M. R. C.</style></author><author><style face="normal" font="default" size="100%">van Schaik, W.</style></author><author><style face="normal" font="default" size="100%">Kaski, S.</style></author><author><style face="normal" font="default" size="100%">Willems, R. J. L.</style></author><author><style face="normal" font="default" size="100%">Corander, J.</style></author><author><style face="normal" font="default" size="100%">Schurch, A. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.&#xD;Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.&#xD;Department of Computer Science, Aalto University, Espoo, Finland.&#xD;Department of Mathematics and Statistics, Helsinki Institute of Information Technology (HIIT), University of Helsinki, Helsinki, Finland.&#xD;Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands rwillems@umcutrecht.nl jukka.corander@medisin.uio.no a.c.schurch@umcutrecht.nl.&#xD;Department of Mathematics and Statistics, Helsinki Institute of Information Technology (HIIT), University of Helsinki, Helsinki, Finland rwillems@umcutrecht.nl jukka.corander@medisin.uio.no a.c.schurch@umcutrecht.nl.&#xD;Pathogen Genomics, Wellcome Trust Sanger Institute, Cambridge, United Kingdom.&#xD;Department of Biostatistics, University of Oslo, Oslo, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Plasmids Shaped the Recent Emergence of the Major Nosocomial Pathogen Enterococcus faecium</style></title><secondary-title><style face="normal" font="default" size="100%">mBio</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">mBio</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2020/02/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Enterococcus faecium</style></keyword><keyword><style face="normal" font="default" size="100%">*long-read sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">*machine learning</style></keyword><keyword><style face="normal" font="default" size="100%">*nosocomial pathogen</style></keyword><keyword><style face="normal" font="default" size="100%">*plasmidome</style></keyword><keyword><style face="normal" font="default" size="100%">*source specificity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 11</style></date></pub-dates></dates><accession-num><style face="normal" font="default" size="100%">32047136</style></accession-num><abstract><style face="normal" font="default" size="100%">Enterococcus faecium is a gut commensal of humans and animals but is also listed on the WHO global priority list of multidrug-resistant pathogens. Many of its antibiotic resistance traits reside on plasmids and have the potential to be disseminated by horizontal gene transfer. Here, we present the first comprehensive population-wide analysis of the pan-plasmidome of a clinically important bacterium, by whole-genome sequence analysis of 1,644 isolates from hospital, commensal, and animal sources of E. faecium Long-read sequencing on a selection of isolates resulted in the completion of 305 plasmids that exhibited high levels of sequence modularity. We further investigated the entirety of all plasmids of each isolate (plasmidome) using a combination of short-read sequencing and machine-learning classifiers. Clustering of the plasmid sequences unraveled different E. faecium populations with a clear association with hospitalized patient isolates, suggesting different optimal configurations of plasmids in the hospital environment. The characterization of these populations allowed us to identify common mechanisms of plasmid stabilization such as toxin-antitoxin systems and genes exclusively present in particular plasmidome populations exemplified by copper resistance, phosphotransferase systems, or bacteriocin genes potentially involved in niche adaptation. Based on the distribution of k-mer distances between isolates, we concluded that plasmidomes rather than chromosomes are most informative for source specificity of E. faecium IMPORTANCE Enterococcus faecium is one of the most frequent nosocomial pathogens of hospital-acquired infections. E. faecium has gained resistance against most commonly available antibiotics, most notably, against ampicillin, gentamicin, and vancomycin, which renders infections difficult to treat. Many antibiotic resistance traits, in particular, vancomycin resistance, can be encoded in autonomous and extrachromosomal elements called plasmids. These sequences can be disseminated to other isolates by horizontal gene transfer and confer novel mechanisms to source specificity. In our study, we elucidated the total plasmid content, referred to as the plasmidome, of 1,644 E. faecium isolates by using short- and long-read whole-genome technologies with the combination of a machine-learning classifier. This was fundamental to investigate the full collection of plasmid sequences present in our collection (pan-plasmidome) and to observe the potential transfer of plasmid sequences between E. faecium hosts. We observed that E. faecium isolates from hospitalized patients carried a larger number of plasmid sequences compared to that from other sources, and they elucidated different configurations of plasmidome populations in the hospital environment. We assessed the contribution of different genomic components and observed that plasmid sequences have the highest contribution to source specificity. Our study suggests that E. faecium plasmids are regulated by complex ecological constraints rather than physical interaction between hosts.</style></abstract><notes><style face="normal" font="default" size="100%">2150-7511&#xD;Arredondo-Alonso, S&#xD;Top, J&#xD;McNally, A&#xD;Puranen, S&#xD;Pesonen, M&#xD;Pensar, J&#xD;Marttinen, P&#xD;Braat, J C&#xD;Rogers, M R C&#xD;van Schaik, W&#xD;Kaski, S&#xD;Willems, R J L&#xD;Corander, J&#xD;Schurch, A C&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;mBio. 2020 Feb 11;11(1). pii: mBio.03284-19. doi: 10.1128/mBio.03284-19.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC7018651</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/mBio.03284-19</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>341</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiebe, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Wiebe, University of British Columbia, Vancouver, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Post-abortion insertion of frameless copper IUDs: A comparison of early expulsion rates of IUDs inserted immediately post-abortion or at unrelated times</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Contraception and Reproductive Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Contraception and Reproductive Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S177-S178</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">abortion</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">reproductive health</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">perforation</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">uterus</style></keyword><keyword><style face="normal" font="default" size="100%">foreign body</style></keyword><keyword><style face="normal" font="default" size="100%">vaginal delivery</style></keyword><keyword><style face="normal" font="default" size="100%">dysmenorrhea</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">e-mail</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">surgical abortion</style></keyword><keyword><style face="normal" font="default" size="100%">ultrasound</style></keyword><keyword><style face="normal" font="default" size="100%">unplanned pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">laparoscope</style></keyword><keyword><style face="normal" font="default" size="100%">reassurance</style></keyword><keyword><style face="normal" font="default" size="100%">first trimester pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">pelvic examination</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1362-5187</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives : The purpose of this study was to compare the early expulsion rates and other complications in frameless copper IUDs (GyneFix Viz) inserted immediately after first trimester surgical abortions to those inserted into women who were not having abortions. Other studies with other IUDs have found higher early expulsion rates with immediate insertion but fewer unintended pregnancies in the following year compared with women who planned later insertions. Methods: This was a retrospective chart review of women who had IUDs inserted by five experienced physicians in two clinics between February and October of 2013. At a follow-up visit 6-8 weeks postinsertion, ultrasound and pelvic examinations were performed. Women who did not come in for the follow-up visit were contacted by phone or email. We compared rates of expulsion, infection, perforation, pregnancy and removal. Results: There were 152 women who had the IUDs inserted post-abortion and 331 who had insertions unrelated to abortion. There were follow- up data available on 377 women (87.3%); one clinic had 93.6% and the other 62.0% follow-ups. The two groups were similar with respect to mean age (28.0 vs 29.1 years) and history of dysmenorrhea (worst period pain score 5.2/10 vs 5.2/10). The women in the post abortion group were more likely to have had vaginal births (33.6% vs 10.4%). There were no significant differences with respect to expulsion rates or other complications. The post abortion group had two expulsions (2.0%), two pregnancies (2.0%), three removals (3.0%) and no perforations or infections. The unrelated group had four expulsions (1.4%), four removals (1.4%), two perforations (0.7%) and no infections or pregnancies. One removal was in a woman who wanted to get pregnant, one because she didn&apos;t like the idea of a foreign body in her uterus and the others for pain and bleeding. Both women who had perforations had the IUDs removed with a laparoscope and had no further complications. Conclusions : Complications rates are so low after IUD insertion that over 2000 subjects in each group would be required to compare rates of expulsion with a power of .80 and α of .05. This study with only 152 women in the post abortion group gives us some reassurance that frameless copper IUDs can be a good choice for insertions immediately post abortion.</style></abstract><notes><style face="normal" font="default" size="100%">L71462427&#xD;2014-05-22</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71462427</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3109/13625187.2014.894779.11</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/13625187.2014.894779.11</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>283</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">283</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bryan-McInnes, M.</style></author><author><style face="normal" font="default" size="100%">Kluge, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Bryan-McInnes, Tygerberg Hospital, Cape Town, South Africa</style></auth-address><titles><title><style face="normal" font="default" size="100%">Post-placental insertion of CopperT 380A intrauterine copper device\-a retrospective study at Tygerberg Hospital, Cape Town, South Africa</style></title><alt-title><style face="normal" font="default" size="100%">BJOG Int. J. Obstet. Gynaecol.</style></alt-title></titles><pages><style face="normal" font="default" size="100%">50-51</style></pages><volume><style face="normal" font="default" size="100%">124</style></volume><number><style face="normal" font="default" size="100%">(Bryan-McInnes M.; Kluge J.) Tygerberg Hospital, Cape Town, South Africa</style></number><keywords><keyword><style face="normal" font="default" size="100%">9 [(4 acetyl 3 hydroxy 2 propylphenoxy)methyl] 3 (1h tetrazol 5 yl) 4h pyrido[1,2 a]pyrimidin 4 one</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">cesarean section</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">endometritis</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">information processing</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">midwife</style></keyword><keyword><style face="normal" font="default" size="100%">perforation</style></keyword><keyword><style face="normal" font="default" size="100%">placenta</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">prenatal care</style></keyword><keyword><style face="normal" font="default" size="100%">puerperium</style></keyword><keyword><style face="normal" font="default" size="100%">remission</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">South Africa</style></keyword><keyword><style face="normal" font="default" size="100%">vaginal delivery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1471-0528</style></isbn><abstract><style face="normal" font="default" size="100%">The Copper-T 380A intrauterine contraceptive device (Cu-IUCD) is a safe and effective long-acting reversible form of contraception (LARC). It is used by over 100 million women worldwide so it is of great concern that in South Africa the use of IUCD is &lt;1%. In 2012 progestogen-only injectables and IUCDs were the only LARCs available in South Africa. A new protocol for postplacental insertion of the Cu-IUCD (PPIUCD) was introduced in Tygerberg, a secondary and tertiary level hospital, Cape Town in 2012 to encourage the uptake of this method. Before this, PPIUCD was an uncommon practice. The purpose of this study was to audit the implementation of this protocol and the IUCD outcomes, which included rate of return, complications (bleeding, infection, expulsion) and pregnancy at 1 year. According to the IUCD register, 523 women had the IUCD inserted between June 2013 and February 2014. Only pregnancies that were &gt;24 weeks of gestation or &gt;500 g were included. In all, 483 women&apos;s records were analysed as 35 had notes missing and five were excluded. Of these 483 women, 438 had an IUCD inserted and, for various reasons, 45 women did not receive an IUCD. During antenatal care, 110 women opted for the Cu-IUCD. Most women only made the decision to have the IUCD inserted around the time of delivery (316); 119 women were counselled during labour and of these 61 were in active labour. There were 49 women that were counselled in the postpartum period who accepted PPIUD insertion. Most patients were delivered by emergency caesarean section (308) compared with elective caesarean section (67) and vaginal deliveries (57). There were 38 cases identified with puerperal sepsis (8.6%) of which 20 (4.5%) were readmitted and five were diagnosed with endometritis (1.1%). In four of these five cases, the IUCD was removed but in all five there was complete resolution. All five women had signs of sepsis before the IUCD insertion and should not have received an IUCD according to the protocol. Only 119 (24.6%) returned for follow-up at Tygerberg with three expulsions (2.5%) and five partial expulsions (4.2%), 22 devices (18%) were removed for various reasons and there were no identified perforations. Only two patients (0.4%) were identified as pregnant within 1 year, however this was based on an electronic hospital antenatal clinic booking system within Cape Town and does not include midwife-led units.</style></abstract><notes><style face="normal" font="default" size="100%">L615337930&#xD;2017-04-18</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L615337930</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/1471-0528.14572</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/1471-0528.14572</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">95</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weaver, L.</style></author><author><style face="normal" font="default" size="100%">Michels, H. T.</style></author><author><style face="normal" font="default" size="100%">Keevil, C. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Healthcare Unit, University of Southampton, Biomedical Sciences Building, Bassett Crescent East, Southampton, UK. louise.weaver@esr.cri.nz</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential for preventing spread of fungi in air-conditioning systems constructed using copper instead of aluminium</style></title><secondary-title><style face="normal" font="default" size="100%">Lett Appl Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lett Appl Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-23</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2009/12/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Air Conditioning/*instrumentation</style></keyword><keyword><style face="normal" font="default" size="100%">Air Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Aluminum/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Candida albicans/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">*Construction Materials</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfectants/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Fungi/drug effects/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Fusarium/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillium chrysogenum/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Spores, Fungal/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0266-8254</style></isbn><accession-num><style face="normal" font="default" size="100%">19943884</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: As copper has been previously suggested as an antimicrobial surface, we tested the effectiveness of copper as an antifungal surface which could be used in air-conditioning systems as an alternative to aluminium. METHODS AND RESULTS: Coupons of copper (C11000) and aluminium were inoculated with fungal isolates (Aspergillus spp., Fusarium spp., Penicillium chrysogenum and Candida albicans) for various time periods. Culture on potato dextrose agar and an in situ viability assay using the fluorochrome FUN-1 were used to determine whether spores had survived. The results showed increased die off of fungal isolates tested compared to aluminium. In addition, copper also prevented the germination of spores present, thereby reducing the risk of the release of spores. CONCLUSIONS: Copper offered an antifungal surface and prevented subsequent germination of spores present. FUN-1 demonstrated that fungal spores entered into a viable but not culturable (VBNC) state on copper indicating the importance of using such methods when assessing the effect of an antifungal as culture alone may give false results. SIGNIFICANCE AND IMPACT OF STUDY: Copper offers a valuable alternative to aluminium which could be used in air-conditioning systems in buildings, particularly in hospital environments where patients are more susceptible to fungal infections.</style></abstract><notes><style face="normal" font="default" size="100%">1472-765x&#xD;Weaver, L&#xD;Michels, H T&#xD;Keevil, C W&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Lett Appl Microbiol. 2010 Jan;50(1):18-23. doi: 10.1111/j.1472-765X.2009.02753.x.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1472-765X.2009.02753.x</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>421</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">421</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alfaidy, N.</style></author><author><style face="normal" font="default" size="100%">Andrei, S.</style></author><author><style face="normal" font="default" size="100%">Micoud, J.</style></author><author><style face="normal" font="default" size="100%">Chauvet, S.</style></author><author><style face="normal" font="default" size="100%">Salomon, A.</style></author><author><style face="normal" font="default" size="100%">Charbonnier, P.</style></author><author><style face="normal" font="default" size="100%">Aude-Garcia, C.</style></author><author><style face="normal" font="default" size="100%">Feige, J. J.</style></author><author><style face="normal" font="default" size="100%">Benharouga, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">N. Alfaidy, iRTSV/CEA, INSERM U878, LAPV-ANGIO, Grenoble, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential role of cellular prion protein (PrPC) in placentation</style></title><secondary-title><style face="normal" font="default" size="100%">Reproductive Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Reproductive Sciences</style></full-title></periodical><pages><style face="normal" font="default" size="100%">165A</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">prion protein</style></keyword><keyword><style face="normal" font="default" size="100%">chelate</style></keyword><keyword><style face="normal" font="default" size="100%">small interfering RNA</style></keyword><keyword><style face="normal" font="default" size="100%">messenger RNA</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">reproduction</style></keyword><keyword><style face="normal" font="default" size="100%">gynecological examination</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">mouse</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">placenta</style></keyword><keyword><style face="normal" font="default" size="100%">inner ear</style></keyword><keyword><style face="normal" font="default" size="100%">vascularization</style></keyword><keyword><style face="normal" font="default" size="100%">wild type</style></keyword><keyword><style face="normal" font="default" size="100%">litter size</style></keyword><keyword><style face="normal" font="default" size="100%">decidua</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy outcome</style></keyword><keyword><style face="normal" font="default" size="100%">sensor</style></keyword><keyword><style face="normal" font="default" size="100%">placental transfer</style></keyword><keyword><style face="normal" font="default" size="100%">scrapie</style></keyword><keyword><style face="normal" font="default" size="100%">vertical transmission</style></keyword><keyword><style face="normal" font="default" size="100%">mother</style></keyword><keyword><style face="normal" font="default" size="100%">progeny</style></keyword><keyword><style face="normal" font="default" size="100%">prion disease</style></keyword><keyword><style face="normal" font="default" size="100%">pathology</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">first trimester pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">trophoblast</style></keyword><keyword><style face="normal" font="default" size="100%">giant cell</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1933-7191</style></isbn><abstract><style face="normal" font="default" size="100%">For placental transmission of scrapie to occur, normal cellular prion protein (PrPC), known to bind and chelate copper (Cu), must be converted to an abnormal infectious form known as PrPSc. The vertical transmission of PrPSc, from infected mothers to their offspring is believed to be one of the routes for the natural spread of animal and human prion diseases. Although the involvement of PrP in the pathology of these diseases has long been elucidated, the normal function of PrPC remains unknown. In recent data from our laboratory, we have shown that PrPC is highly expressed in human placenta during the first trimester of pregnancy suggesting its involvement in placentation. To get more insights into its role in the placenta, we i) further investigated its involvement in human and mouse placentation, ii) analyzed PrPC deficient (PrP-KO) and PrPC overexpressing (TGA20) mice, and iii) investigated their phenotype at 14,5 and 17,5 dpc. In human placenta, PrPC expression was the strongest in extravillous trophoblast cells (EVT), and Cu treatment of HTR cells (EVT cells line) significantly increased this expression. Using siRNA strategy to PrPC, we demonstrated that PrPC might control Cu-mediated angiogenic effect in EVT. In the mice, our results substantiated those found in human, demonstrating that the highest levels of PrPC were found during the first 10.5 dpc and the strongest expression was found in the giant cells. Analysis of PrP-KO mice showed that although the mice were alive and fertile, placental and embryonic sizes were significantly reduced (14,5 and 17,5 dpc) compared with wild type (C57Bl6); with a reduction in the labyrinth layer, and an increase in its vascularisation (histological assessment and CD31 mRNA expression). The litter size was however not affected. In the TGA20 mice, a significant reduction of the litter size was observed with a reduction in the decidua and the throphospongium layers compared to the wild type. We also observed a morphological change in the labyrinth vascularisation. Our data show that the expression levels of PrPC significantly affect the pregnancy outcome. These effects might in part be explained by the potential role of PrPC as a stress sensor sensitive to Cu.</style></abstract><notes><style face="normal" font="default" size="100%">L70494792&#xD;2011-08-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70494792</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/193371912010173s067</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/193371912010173s067</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Noyce, J. O.</style></author><author><style face="normal" font="default" size="100%">Michels, H.</style></author><author><style face="normal" font="default" size="100%">Keevil, C. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Healthcare Unit, University of Southampton, Southampton, UK. jon1@soton.ac.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential use of copper surfaces to reduce survival of epidemic meticillin-resistant Staphylococcus aureus in the healthcare environment</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">289-97</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2006/05/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin Resistance/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Stainless Steel/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*pharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701 (Print)&#xD;0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">16650507</style></accession-num><abstract><style face="normal" font="default" size="100%">Epidemic meticillin-resistant Staphylococcus aureus (EMRSA) emerged in the early 1980s with EMRSA-15 and -16 being the most prevalent strains within the UK. MRSA transmission between patients is largely via the hands of healthcare workers, and contamination of the hospital environment may occur. The objective of this study was to evaluate the effectiveness of copper and brass to reduce the viability of air-dried deposits of three MRSA strains [MRSA (NCTC 10442), EMRSA-1 (NCTC 11939) and EMRSA-16 (NCTC 13143)] compared with stainless steel. MRSA and EMRSA [10(7)colony-forming units (CFU)] were inoculated on to coupons (1 cm x 1 cm) of copper, brass or stainless steel and incubated at either 22 degrees C or 4 degrees C for various time periods. Viability was determined by resuspending removed CFUs and plating out on tryptone soy agar plates in addition to staining with the respiratory indicator fluorochrome 5-cyano-2,3-ditolyl tetrazolium. On pure copper surfaces, 10(7) MRSA, EMRSA-1 and EMRSA-16 were completely killed after 45, 60 and 90 min, respectively, at 22 degrees C. In contrast, viable organisms for all three strains were detected on stainless steel (grade 304) after 72 h at 22 degrees C. At 4 degrees C, complete kill was achieved on copper for all three strains within 6 h. The results demonstrate an antimicrobial effect of copper on MRSA, EMRSA-1 and -16 in contrast to stainless steel. Consequently, the contemporary application of stainless steel in hospital environments for work surfaces and door furniture is not recommended.</style></abstract><notes><style face="normal" font="default" size="100%">Noyce, J O&#xD;Michels, H&#xD;Keevil, C W&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2006 Jul;63(3):289-97. doi: 10.1016/j.jhin.2005.12.008. Epub 2006 May 2.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2005.12.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>462</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">462</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Exner, M.</style></author><author><style face="normal" font="default" size="100%">Kramer, A.</style></author><author><style face="normal" font="default" size="100%">Lajoie, L.</style></author><author><style face="normal" font="default" size="100%">Gebel, J.</style></author><author><style face="normal" font="default" size="100%">Engelhart, S.</style></author><author><style face="normal" font="default" size="100%">Hartemann, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Exner, Institute for Hygiene and Public Health, University of Bonn, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention and control of health care-associated waterborne infections in health care facilities</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S26-S40</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">5 SUPPL. 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">chlorine</style></keyword><keyword><style face="normal" font="default" size="100%">chlorine dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">drinking water</style></keyword><keyword><style face="normal" font="default" size="100%">prednisone</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">amoeba (life cycle stage)</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">chlorination</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">filtration</style></keyword><keyword><style face="normal" font="default" size="100%">fungus</style></keyword><keyword><style face="normal" font="default" size="100%">Gram negative bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">health care</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">health hazard</style></keyword><keyword><style face="normal" font="default" size="100%">health program</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">immunosuppressive treatment</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword><keyword><style face="normal" font="default" size="100%">treatment planning</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword><keyword><style face="normal" font="default" size="100%">water contamination</style></keyword><keyword><style face="normal" font="default" size="100%">water quality</style></keyword><keyword><style face="normal" font="default" size="100%">water treatment</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><abstract><style face="normal" font="default" size="100%">The current article is a review of the public health risks attributable to waterborne pathogens in health care. The consequences of health care-associated infections (HAIs) are discussed. Not only are Legionella spp involved in HAIs, but also Pseudomonas aeruginosa, other gram-negative microorganisms, fungi, and amoeba-associated bacteria. This is particularly noteworthy among immunocompromised patients. New prevention strategies and control measures brought about through advanced planning, facility remodelling and reconstruction, disinfection, and filtration have resulted in a significant reduction of the incidence of waterborne HAIs. The positive consequences of a comprehensive multibarrier approach including prevention and control programs in health care facilities are discussed. Environmental cultures are now integrated within the infection control program of some European countries. In high-risk areas, the application of disposable sterile point-of-use filters for faucets and shower heads appears to be the practice of choice to efficiently control waterborne pathogens and to prevent infections. © 2005 Association for Professionals in Infection Control and Epidemiology, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L44302023&#xD;2006-09-20</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L44302023</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2005.04.002</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">15940114</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2005.04.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Laleman, G.</style></author><author><style face="normal" font="default" size="100%">Magazani, K.</style></author><author><style face="normal" font="default" size="100%">Perriens, J. H.</style></author><author><style face="normal" font="default" size="100%">Badibanga, N.</style></author><author><style face="normal" font="default" size="100%">Kapila, N.</style></author><author><style face="normal" font="default" size="100%">Konde, M.</style></author><author><style face="normal" font="default" size="100%">Selemani, U.</style></author><author><style face="normal" font="default" size="100%">Piot, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre Regional de Lutte Contre le SIDA, Lubumbashi, Zaire.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of blood-borne HIV transmission using a decentralized approach in Shaba, Zaire</style></title><secondary-title><style face="normal" font="default" size="100%">Aids</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aids</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1353-8</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">1992/11/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Blood Banks/economics/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Donors</style></keyword><keyword><style face="normal" font="default" size="100%">Democratic Republic of the Congo</style></keyword><keyword><style face="normal" font="default" size="100%">Evaluation Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Antibodies/blood</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections/diagnosis/*prevention &amp; control/*transmission</style></keyword><keyword><style face="normal" font="default" size="100%">HIV-1/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">HIV-2/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mass Screening/*organization &amp; administration</style></keyword><keyword><style face="normal" font="default" size="100%">Quality Control</style></keyword><keyword><style face="normal" font="default" size="100%">*Regional Medical Programs/economics/standards</style></keyword><keyword><style face="normal" font="default" size="100%">*Transfusion Reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Africa South Of The Sahara</style></keyword><keyword><style face="normal" font="default" size="100%">*Blood Supply</style></keyword><keyword><style face="normal" font="default" size="100%">*Decentralization</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery Of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Education</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment And Supplies</style></keyword><keyword><style face="normal" font="default" size="100%">*Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">French Speaking Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Health</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">*Hiv Infections--prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">*Hiv Infections--transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Africa</style></keyword><keyword><style face="normal" font="default" size="100%">*Screening</style></keyword><keyword><style face="normal" font="default" size="100%">*Training Activities</style></keyword><keyword><style face="normal" font="default" size="100%">Training Programs</style></keyword><keyword><style face="normal" font="default" size="100%">Viral Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Zaire</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1992</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0269-9370 (Print)&#xD;0269-9370</style></isbn><accession-num><style face="normal" font="default" size="100%">1472338</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To prevent blood transfusion-acquired HIV infection with a decentralized approach to HIV screening of blood donors, using an instrument-free rapid test. SETTING: Shaba province, Zaire (496,877 km2). METHODS: The programme consisted of training health-care workers, distribution of a rapid HIV-antibody test (DuPont&apos;s HIVCHEK) for screening of all blood donations, and quality control of testing by a regional reference centre. RESULTS: Over a 2-year period, 11,940 rapid tests were distributed to 37 hospitals, covering 75% of all hospital beds outside the copper mine&apos;s health system in Shaba. Eighty-five per cent of the tests were used to screen blood donors (5.4% positive test rate) and 13% to test patients (39.7% positive test rate). At least 265 cases of HIV-positive blood donation were prevented, at an estimated cost of 137-279 ECU per case. Only 26% of initially positive specimens reached the central laboratory for supplemental testing, and sterile transfusion equipment and blood-grouping reagents were frequently unavailable. The lack of transport and communications and a deteriorating health system were major constraints. CONCLUSIONS: District hospitals in Africa are often long distances from major cities, difficult to reach for most of the year, and perform a small number of transfusions. In this context a classical centralized regional blood bank may not be a feasible option to ensure safe blood transfusions. However, safe blood transfusion can be achieved with a decentralized approach using a rapid test, provided that minimum standards of health-care services are available.&#xD;This program aimed at preventing blood transfusion-acquired HIV infection with a decentralized approach to HIV screening of blood donors using an instrument free raid test was initiated in Shaba province in Zaire (496,877 sq. km and included training of health care workers, distribution of a rapid HIV-antibody test (DuPont&apos;s HIVCHEK) for screening of all blood donations, and quality control of testing by a regional reference center. Over a 2-year period, 11,940 rapid tests were distributed to 37 hospitals, covering 75% of all hospital beds outside the copper mine&apos;s health system in Shaba. 85% of the tests were used to screen blood donors (5.4% positive test rate) and 13% to test patients (39.7% positive test rate). At least 265 cases of HIV-positive blood donation were prevented at an estimated cost of 137-279 ECU per case. Only 26% of initially positive specimens reached the central laboratory for supplemental testing, and sterile transfusion equipment and blood-grouping reagents were frequently unavailable. The lack of transport and communications and a deteriorating health system were major constraints. District hospitals in Africa are often long distances from major cities, difficult to reach for most of the year, and perform a small number of transfusions. In this context, a classical centralized regional blood bank may not be a feasible option to ensure safe blood transfusions. However, safe blood transfusion can be achieved with a decentralized approach using a rapid test, provided that minimum standards of health care services, are available.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Laleman, G&#xD;Magazani, K&#xD;Perriens, J H&#xD;Badibanga, N&#xD;Kapila, N&#xD;Konde, M&#xD;Selemani, U&#xD;Piot, P&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;AIDS. 1992 Nov;6(11):1353-8. doi: 10.1097/00002030-199211000-00019.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00002030-199211000-00019</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, Y. E.</style></author><author><style face="normal" font="default" size="100%">Stout, J. E.</style></author><author><style face="normal" font="default" size="100%">Yu, V. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Kaohsiung Normal University, Taiwan, ROC.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of hospital-acquired legionellosis</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Opin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Opin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">350-6</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2011/06/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Infection Control</style></keyword><keyword><style face="normal" font="default" size="100%">Legionellosis/*prevention &amp; control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0951-7375</style></isbn><accession-num><style face="normal" font="default" size="100%">21666459</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE OF REVIEW: The incidence of hospital-acquired legionellosis appears to be increasing. Presence of Legionella in the hospital drinking water is the only risk factor known with certainty to be predictive of risk for contracting Legionnaires&apos; disease. RECENT FINDINGS: Given the high frequency of infection by nonpneumophila and nonserogroup 1 species, both Legionella respiratory culture on selective media and urine antigen testing should be available in the hospital clinical microbiology laboratory. If the drinking water is contaminated by nonpneumophila or nonserogroup 1 species, Legionella culture on selective media must be available for patients with hospital-acquired pneumonia. The impact of PCR application for environmental water specimen remains to be elucidated. Its advantage is that it is a rapid test and its weakness is its low specificity. Copper-silver ionization disinfection and point-of-use (POU) filters have proved effective. Chlorine dioxide and monochloramine are under evaluation and their ultimate role remains to be elucidated. Routine Legionella cultures in concert with disinfectant levels are the best indicators for ensuring long-term efficacy. Percentage distal site positivity for Legionella in drinking water is accurate in predicting risk. Quantitative criteria (CFU/ml) have proven inaccurate and should be abandoned. SUMMARY: Infection control professionals, not healthcare facility personnel or engineers, should play the leadership role in selecting and evaluating the specific disinfection modality. Proactive measures of routine environmental cultures for hospital water and disinfection modalities allow for effective prevention of this high-profile hospital-acquired infection.</style></abstract><notes><style face="normal" font="default" size="100%">1473-6527&#xD;Lin, Yusen E&#xD;Stout, Janet E&#xD;Yu, Victor L&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Curr Opin Infect Dis. 2011 Aug;24(4):350-6. doi: 10.1097/QCO.0b013e3283486c6e.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/QCO.0b013e3283486c6e</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>269</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Friedenthal, J.</style></author><author><style face="normal" font="default" size="100%">Maxwell, S. M.</style></author><author><style face="normal" font="default" size="100%">Willson, S.</style></author><author><style face="normal" font="default" size="100%">McCulloh, D. H.</style></author><author><style face="normal" font="default" size="100%">Grifo, J.</style></author><author><style face="normal" font="default" size="100%">Goldman, K. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Friedenthal, NYU, Langone Medical Center, New York, NY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The progestin-containing intrauterine device (IUD) during ovarian stimulation and oocyte retrieval: Should it stayor should it go?</style></title><secondary-title><style face="normal" font="default" size="100%">Fertility and Sterility</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Fertility and sterility</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e12</style></pages><volume><style face="normal" font="default" size="100%">108</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">estradiol</style></keyword><keyword><style face="normal" font="default" size="100%">follitropin</style></keyword><keyword><style face="normal" font="default" size="100%">gestagen</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">cohort analysis</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">cryopreservation</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">maturity</style></keyword><keyword><style face="normal" font="default" size="100%">metaphase</style></keyword><keyword><style face="normal" font="default" size="100%">oocyte donation</style></keyword><keyword><style face="normal" font="default" size="100%">oocyte retrieval</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">ovarian reserve</style></keyword><keyword><style face="normal" font="default" size="100%">ovary hyperstimulation</style></keyword><keyword><style face="normal" font="default" size="100%">ovulation induction</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">retrospective study</style></keyword><keyword><style face="normal" font="default" size="100%">student</style></keyword><keyword><style face="normal" font="default" size="100%">Student t test</style></keyword><keyword><style face="normal" font="default" size="100%">university hospital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">1556-5653</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Progestin IUDs are effective long-acting reversible contraceptives and are popular among young women presenting for elective oocyte cryopreservation or oocyte donation. IUD removal and replacement is costly, requires additional procedures, and increases risk of unintended pregnancy; however, the impact of low-dose local progesterone during ovarian stimulation is unknown. We sought to assess the impact of a progestin IUD on ovarian stimulation and retrieval parameters. DESIGN: Retrospective cohort study MATERIALS AND METHODS: All patients undergoing oocyte retrieval with a documented IUDin situ prior to cycle start from 7/2011-6/2016 at a single academic medical center were identified. Exclusion criteria included those with a copper IUD or those whose IUD was placed at the time of oocyte retrieval. Age-matched controls without IUDsmeeting the above criteria were selected using a random number generator in a 3:1 ratio (Excel). Baseline demographics were collected: age, ovarian reserve testing (day 2 estradiol (E2) and follicle stimulating hormone (FSH)), and controlled ovarian hyperstimulation (COH) cycle parameters (initial and total gonodatropin dose, maximum E2 prior to retrieval). Primary outcomes included total number of oocytes retrieved and number of metaphase II (MII) oocytes retrieved. Data were analyzed using student&apos;s t-test, mean +/- standard deviation, with p&lt;0.05 considered significant. RESULTS: 32 patients with a progestin-containing IUD underwent ovarian stimulation and oocyte retrieval: 24 for elective oocyte cryopreservation and 8 for oocyte donation. 32,638 oocyte retrieval cycles were performed during this period, and 96 age-matched controls were identified. Results are summarized in Table 1. By design age was similar between groups. Ovarian reserve parameters were similar. The maximum E2 prior to retrieval was significantly higher in the control group than in the IUD group (2273 vs 2077, p&lt;0.05); there were no other differences in COH parameters. There was no difference in total number of oocytes or number of MII oocytes retrieved. There were infections or complications among women with IUDs. CONCLUSIONS: The presence of a progestin-containing IUD during ovarian stimulation and retrieval did not affect oocyte number or maturity. The lower estradiol level may not be clinically significant but warrants further investigation. These data are overall reassuring for patients and providers and suggest that IUDs can safely remain in situ during COH. However, larger, prospective studies should be conducted. (Table Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L618466138&#xD;2017-09-29</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L618466138</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casari, E.</style></author><author><style face="normal" font="default" size="100%">Ferrario, A.</style></author><author><style face="normal" font="default" size="100%">Montanelli, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbiology Unit, Clinical Laboratories, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy. erminia.casari@humanitas.it</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prolonged effect of two combined methods for Legionella disinfection in a hospital water system</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Ig</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Ig</style></full-title></periodical><pages><style face="normal" font="default" size="100%">525-32</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2008/04/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chlorine Compounds/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Heating</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, General</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Italy</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/drug effects/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Oxides/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Supply</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1120-9135 (Print)&#xD;1120-9135</style></isbn><accession-num><style face="normal" font="default" size="100%">18376573</style></accession-num><abstract><style face="normal" font="default" size="100%">This study was conducted in our 650 bed general hospital, which is situated on the southern outskirts of Milan (Italy). After a first nosocomial case of pneumonia (caused by Legionella pneumophila serogroup 1), we first used a conventional method (heat shock) without success. To solve the problem we then tried a copper-silver ionization system combined with a chlorine dioxide device. During the four years after the installation of these two systems we recorded a significant (p &lt; or = 0.05) reduction in Legionella colonization, and no new cases of Legionnaires&apos; disease were observed. Our results suggest that the Cu-Ag ionization system, combined with a chlorine dioxide device, is a highly promising method for the control of Legionella pneumophila in a hospital water distribution system.</style></abstract><notes><style face="normal" font="default" size="100%">Casari, E&#xD;Ferrario, A&#xD;Montanelli, A&#xD;Journal Article&#xD;Italy&#xD;Ann Ig. 2007 Nov-Dec;19(6):525-32.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">99</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Charonis, G.</style></author><author><style face="normal" font="default" size="100%">Larsson, P. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynecology, Central Hospital, Skovde, Sweden. georgios.charonis@vgregion.se</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prolonged use of intrauterine contraceptive device as a risk factor for tubo-ovarian abscess</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Obstet Gynecol Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Obstet Gynecol Scand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">680-4</style></pages><volume><style face="normal" font="default" size="100%">88</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2009/05/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Abscess/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adnexal Diseases/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvis</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Time Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">0001-6349</style></isbn><accession-num><style face="normal" font="default" size="100%">19412803</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: The intrauterine contraceptive device (IUCD) is the most preferred method of reversible contraception in the world today. The Swedish Medical Products Agency currently recommends that women who had a copper IUCD inserted around age 40 do not need to have it extracted until one year after the menopause. DESIGN: Retrospective study. SETTING: Skovde Central Hospital, Sweden. POPULATION: All 114 women receiving in-patient treatment for pelvic inflammatory disease (PID) over five years between January 2001 and December 2005. METHODS: Comparison between cases of tubo-ovarian abscesses and salpingitis with focus on the effects of IUCDs used continually for &gt;5 years after insertion. MAIN OUTCOME MEASURES: Age-adjusted risk of PID within or after five years of use, microbiological findings in blood, intraabdominal pus, cervical secretions or on extracted IUCDs. RESULTS: There were 31 cases of tubo-ovarian abscesses, 63 of salpingitis, four of endometritis, and 16 of mild genital infection. When comparing women with the same IUCD &gt; 5 years to women having the same IUCD &lt;or= 5 years, the risk of tubo-ovarian abscess was higher than the risk of salpingitis (OR 19.7; 95% CI 4.5-87.2). The risk remained significant after adjustment for age, both on multiple regression analysis (OR 13.5; 95% CI 2.5-72.9) and in stratified analysis for the age group 35-50 years (OR 12.0; 95% CI 1.8-81.7). Blood or abdominal cultures from patients operated upon were positive in 47.7% of the sampled cases. Intestinal tract microbes and upper respiratory tract microbes were more common than sexually transmitted infection microbes. CONCLUSIONS: The current Medical Products Agency recommendation that a woman nearing the end of her reproductive phase can safely use the same IUCD for a period exceeding five years is challenged.</style></abstract><notes><style face="normal" font="default" size="100%">1600-0412&#xD;Charonis, Georgios&#xD;Larsson, Per-Goran&#xD;Journal Article&#xD;United States&#xD;Acta Obstet Gynecol Scand. 2009;88(6):680-4. doi: 10.1080/00016340902893678.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/00016340902893678</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>417</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">417</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sattar, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.A. Sattar, Centre for Research on Environmental Microbiology (CREM), Faculty of Medicine, University of Ottawa, Ont., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Promises and pitfalls of recent advances in chemical means of preventing the spread of nosocomial infections by environmental surfaces</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S34-S40</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">5 SUPPL.</style></number><keywords><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">bicarbonate</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">disinfectant agent</style></keyword><keyword><style face="normal" font="default" size="100%">plant extract</style></keyword><keyword><style face="normal" font="default" size="100%">titanium dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">vinegar</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">disease transmission</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">environment</style></keyword><keyword><style face="normal" font="default" size="100%">environmental surface</style></keyword><keyword><style face="normal" font="default" size="100%">general device</style></keyword><keyword><style face="normal" font="default" size="100%">health care facility</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">infection prevention</style></keyword><keyword><style face="normal" font="default" size="100%">material coating</style></keyword><keyword><style face="normal" font="default" size="100%">registration</style></keyword><keyword><style face="normal" font="default" size="100%">safety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><abstract><style face="normal" font="default" size="100%">Hard, nonporous environmental surfaces in health care settings are now receiving due recognition for their role in the spread of several types of nosocomial pathogens. The corresponding increase in the means to decontaminate such surfaces to interrupt the spread of infections is leading to the marketing of a plethora of products and procedures, including the &quot;green&quot; variety, with varying claims of microbicidal activity, human and environmental safety, and materials compatibility. Limitations of the existing methods to assess environmental surface disinfectants and the regulations that govern their premarket registration make objective evaluations difficult. Label claims of many such products also do not reflect the realities of field use along with a strong tendency to focus on the &quot;bug de jour.&quot; Furthermore, whereas wiping is often an integral part of environmental surface decontamination, products meant for the purpose are rarely assessed with the physical effect of wiping incorporated. Many &quot;green&quot; products possess neither the spectrum of microbicidal activity nor the speed of action essential for use in health care settings. In general, &quot;self-sanitizing&quot; surfaces being marketed actively these days require greater scrutiny for field-relevant microbicidal activity as well as the potential to enhance microbicide resistance. The widening use of environmental surface disinfectants is also raising concerns on their human and environmental safety at many levels along with the realization that routine surface disinfection procedures in health care settings are frequently inadequate and possibly counterproductive. All this points to an urgent review of the basic procedures for assessing existing and new environmental surface disinfectants for their microbicidal activity, label claims, registration requirements, overall safety, and routine practices of environmental surface decontamination. © 2010 Association for Professionals in Infection Control and Epidemiology, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L358927588&#xD;2010-06-10&#xD;2010-07-07</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L358927588</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2010.04.207</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20569854</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2010.04.207</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cooper, M.</style></author><author><style face="normal" font="default" size="100%">McGeechan, K.</style></author><author><style face="normal" font="default" size="100%">Glasier, A.</style></author><author><style face="normal" font="default" size="100%">Coutts, S.</style></author><author><style face="normal" font="default" size="100%">McGuire, F.</style></author><author><style face="normal" font="default" size="100%">Harden, J.</style></author><author><style face="normal" font="default" size="100%">Boydell, N.</style></author><author><style face="normal" font="default" size="100%">Cameron, S. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.&#xD;Department of Obstetrics and Gynaecology, NHS Lothian, Edinburgh, UK.&#xD;School of Public Health, University of Sydney, Sydney, NSW, Australia.&#xD;Usher Institute of Population Health Science, University of Edinburgh, Edinburgh, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Provision of immediate postpartum intrauterine contraception after vaginal birth within a public maternity setting: Health services research evaluation</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Obstet Gynecol Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Obstet Gynecol Scand</style></full-title></periodical><edition><style face="normal" font="default" size="100%">2019/12/15</style></edition><keywords><keyword><style face="normal" font="default" size="100%">intrauterine contraception</style></keyword><keyword><style face="normal" font="default" size="100%">postpartum contraception</style></keyword><keyword><style face="normal" font="default" size="100%">postpartum intrauterine contraception</style></keyword><keyword><style face="normal" font="default" size="100%">postpartum intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">service delivery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 14</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0001-6349</style></isbn><accession-num><style face="normal" font="default" size="100%">31837002</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Expanding access to postpartum intrauterine contraception (PPIUC) can reduce unintended pregnancies and short inter-pregnancy intervals; however, provision across Europe is limited. Our aim was to determine the feasibility, clinical outcomes and patient satisfaction of providing immediate PPIUC after vaginal birth using a health services research model. MATERIAL AND METHODS: Phased introduction of PPIUC across two Lothian maternity hospitals; all women intending vaginal birth during the study period without a contraindication to use of the method were eligible to receive PPIUC. Midwives and obstetric doctors were trained in vaginal PPIUC insertion using Kelly forceps. Women received information antenatally and had PPIUC insertion of either a levonorgestrel intrauterine system or a copper intrauterine device within 48 hours of vaginal birth. Follow up was conducted in-person at 6 weeks postpartum and by telephone at 3, 6 and 12 months. Primary outcomes were: uptake, complications (infection, uterine perforation), expulsion and patient satisfaction at 6 weeks; and method of continuation up to 12 months. Secondary outcomes included hazard ratio for expulsion adjusted for demographic and insertion-related variables. RESULTS: Uptake of PPIUC was 4.6% of all vaginal births; 465/447 (96.1%) of those requesting PPIUC successfully received it and most chose a levonorgestrel intrauterine system (73%). At 6 weeks postpartum, the infection rate was 0.8%, there were no perforations and 98.3% of women said they would recommend the service. The complete expulsion rate was 29.8% (n = 113) and most had symptoms (n = 79). Of the additional 121 devices removed, 118 were because of partial expulsion. The rate of complete/partial expulsion was higher for insertions by midwives compared with those by doctors. The re-insertion rate after expulsion/removal was 87.6% and method continuation at 12 months was 79.6%. CONCLUSIONS: Routine PPIUC at vaginal birth is feasible. Complications were extremely rare. High expulsion rates may be observed in early stages of service introduction and with inexperienced providers. Re-insertion and therefore longer-term continuation rates of intrauterine contraception were very high. In settings with low rates of attendance for interval postpartum intrauterine contraception insertion, PPIUC could be a useful intervention to prevent unintended and closely spaced pregnancies.</style></abstract><notes><style face="normal" font="default" size="100%">1600-0412&#xD;Cooper, Michelle&#xD;ORCID: https://orcid.org/0000-0003-3367-3749&#xD;McGeechan, Kevin&#xD;Glasier, Anna&#xD;ORCID: https://orcid.org/0000-0002-5697-255X&#xD;Coutts, Shiona&#xD;McGuire, Frances&#xD;Harden, Jeni&#xD;Boydell, Nicola&#xD;Cameron, Sharon T&#xD;RG1903/Wellbeing of Women&#xD;RG1903/CSO_/Chief Scientist Office/United Kingdom&#xD;Journal Article&#xD;United States&#xD;Acta Obstet Gynecol Scand. 2019 Dec 14. doi: 10.1111/aogs.13787.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/aogs.13787</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">53</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pohjoranta, E.</style></author><author><style face="normal" font="default" size="100%">Mentula, M.</style></author><author><style face="normal" font="default" size="100%">Gissler, M.</style></author><author><style face="normal" font="default" size="100%">Suhonen, S.</style></author><author><style face="normal" font="default" size="100%">Heikinheimo, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Katiloopisto Hospital, PO Box 610, Helsinki 00029-HUS, Finland.&#xD;National Institute for Health and Welfare, Helsinki, Finland.&#xD;Centralized Family Planning, Department of Social Services and Health Care, City of Helsinki, Helsinki, Finland.&#xD;Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Katiloopisto Hospital, PO Box 610, Helsinki 00029-HUS, Finland oskari.heikinheimo@helsinki.fi.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Provision of intrauterine contraception in association with first trimester induced abortion reduces the need of repeat abortion: first-year results of a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Reprod</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hum Reprod</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2539-46</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">2015/09/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Abortion, Induced/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Finland/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy Trimester, First</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy, Unplanned</style></keyword><keyword><style face="normal" font="default" size="100%">abortion registry</style></keyword><keyword><style face="normal" font="default" size="100%">counselling</style></keyword><keyword><style face="normal" font="default" size="100%">induced abortion</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraception</style></keyword><keyword><style face="normal" font="default" size="100%">repeat abortion</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0268-1161</style></isbn><accession-num><style face="normal" font="default" size="100%">26370664</style></accession-num><abstract><style face="normal" font="default" size="100%">STUDY QUESTION: Can the need of subsequent abortion be reduced by providing intrauterine contraception as a part of the abortion service? SUMMARY ANSWER: Provision of intrauterine devices (IUDs) in association with first trimester abortion more than halved the incidence of repeat abortion during the first year of follow-up. WHAT IS KNOWN ALREADY: Following abortion, the incidence of subsequent abortion is high, up to 30-40%. In cohort studies, intrauterine contraception has reduced the need of repeat abortion by 60-70%. STUDY DESIGN, SIZE, DURATION: A randomized controlled trial. The main outcome measure was the incidence of subsequent induced abortions during the follow-up. Altogether 751 women seeking first trimester induced abortion were recruited and randomized into two groups. Randomization was accomplished by computer-assisted permuted-block randomization with random block sizes of four to six. The investigators did not participate in randomization, which was done before commencing the study. The participants were recruited between 18 October 2010 and 21 January 2013. PARTICIPANTS, SETTINGS, METHODS: The inclusion criteria were age &gt;/=18 years, duration of pregnancy &lt;/=12 weeks, accepting intrauterine contraception, residence in Helsinki and signing the informed consent form. Women with contraindications to intrauterine contraception, such as uterine anomaly, acute genital infection or pap-smear change requiring surgical treatment were ineligible to participate.This study was conducted in collaboration between the Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, and Centralized family planning of the City of Helsinki.The intervention group (n = 375) was provided with intrauterine contraception (either the levonorgestrel-releasing intrauterine system or copper-releasing intrauterine device) immediately following surgical abortion (18.1%) or at a follow-up 2-4 weeks after medical abortion (81.9%). Women in the control group were prescribed oral contraceptives and advised to contact their primary healthcare unit for a follow-up visit and further contraceptive services according to national guidelines. The women were followed-up to 28 February 2014 by using the Finnish National Abortion Registry, Helsinki University Hospital electronic database and clinical follow-up visit at 1 year. MAIN RESULTS AND THE ROLE OF CHANCE: The median age of the whole study group was 27 years and 44% had a history of induced abortion(s). During the follow-up year the number of women requesting subsequent abortion was significantly lower in the intervention than in the control group (9/375 [2.4%] versus 20/373 [5.4%], difference -3.0 [95% CI -6.0 to -0.2] percentage points, P = 0.038, according to intention-to-treat analysis and 5/346 [1.4%] versus 20/357 [5.6%], difference -4.2(-7.2 to -1.4) percentage points, P = 0.003, according to per-protocol analysis, respectively). Provision of intrauterine contraception was safe with rate of infection and expulsion similar to those reported previously. LIMITATIONS, REASONS FOR CAUTION: The power calculation was calculated for a 5-year follow-up. However, significant differences between the two groups were already seen after 1 year. The present study was performed in a single clinic, where, approximately 15% of all abortions in Finland are performed. WIDER IMPLICATIONS OF THE FINDINGS: In order to decrease the need of subsequent abortions, IUDs should be provided at the time of abortion. TRIAL REGISTRATION: The study was registered at www.clinicaltrials.gov (NCT01223521). TRIAL REGISTRATION DATE: 18 October 2010. DATE OF FIRST PATIENT&apos;S ENROLMENT: 18 October 2010.</style></abstract><notes><style face="normal" font="default" size="100%">1460-2350&#xD;Pohjoranta, Elina&#xD;Mentula, Maarit&#xD;Gissler, Mika&#xD;Suhonen, Satu&#xD;Heikinheimo, Oskari&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Hum Reprod. 2015 Nov;30(11):2539-46. doi: 10.1093/humrep/dev233. Epub 2015 Sep 14.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/humrep/dev233</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>299</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reeves, M.</style></author><author><style face="normal" font="default" size="100%">Hathaway, M.</style></author><author><style face="normal" font="default" size="100%">Oleaga, J. C.</style></author><author><style face="normal" font="default" size="100%">Katz, B.</style></author><author><style face="normal" font="default" size="100%">Tal, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Reeves, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomised trial of Veracept, a novel nitinol low-dose copper intrauterine contraceptive, compared to a copper T380S intrauterine contraceptive</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Contraception and Reproductive Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Contraception and Reproductive Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">49</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">nitinol</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">reproductive health</style></keyword><keyword><style face="normal" font="default" size="100%">European</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">contraception</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy rate</style></keyword><keyword><style face="normal" font="default" size="100%">ectopic pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">luteal phase</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">parity</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Likert scale</style></keyword><keyword><style face="normal" font="default" size="100%">surface area</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">1362-5187</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: To compare VeraCept, a novel low-profile nitinol intrauterine contraceptive with 175 square-mm of copper surface area, to a commercially available copper T380S. Methods: We performed a randomised subject-blinded comparison of VeraCept and a copper T380S in a 2:1 fashion. The primary outcome was total continuation at 12 months. We also examined pain on insertion, ease of placement, expulsion, satisfaction, tolerability and pregnancy. Satisfaction ratings were on a 5-point Likert scale. We have continued to follow participants and report data from insertion through an 18-month follow-up. Results: We enrolled women in a single clinic with 199 allocated to VeraCept and 101 to the T380S. Insertion was successful in 198 women for VeraCept and 100 for the T380S (p&gt;0.2). Mean age was 25 years, and median parity was 2 (range 1-4), with 39% having only had Caesarean deliveries. No women developed clinical infection or reported serious adverse events. In the VeraCept and T380S groups, mean pain at insertion was 1.4 and 2.4, respectively (p&lt;0.01). At the 12-month primary endpoint for VeraCept and T380S, respectively, continuation was 84% and 68% (p&lt;0.001). At the 18-month visit for VeraCept and T380S, respectively, continuation was 81% and 64% (p&lt;0.002) with partial and complete expulsions in 5.0% and 12.0% (p&lt;0.05) and removal for pain/bleeding in 3.5% and 17.0% (p&lt;0.01). One &apos;luteal phase&apos; pregnancy was identified at the first follow-up with conception estimated at one to one and a half weeks prior to VeraCept insertion. One ectopic pregnancy was identified at the 12-month follow-up in a VeraCept user. No intrauterine pregnancies were diagnosed after insertion. With 281.6 and 113.9 women-months total use, pregnancy rates were 0.36 (95% CI 0.01, 1.97) and 0.00 (95% CI 0.00, 3.18) per 100 woman-years for VeraCept and T380S, respectively. Conclusions: VeraCept resulted in less pain at insertion, fewer expulsions and higher total continuation than the T380S, with similar contraceptive efficacy to date.</style></abstract><notes><style face="normal" font="default" size="100%">L72324965&#xD;2016-07-23</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72324965</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.3109/13625187.2015.1135897</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/13625187.2015.1135897</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kandil, O. F.</style></author><author><style face="normal" font="default" size="100%">El-sheikha, Z.</style></author><author><style face="normal" font="default" size="100%">Hamza, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Randomized clinical study of the TCu-380 A and the TCu-200 B. IUDs</style></title><secondary-title><style face="normal" font="default" size="100%">Popul Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Popul Sci</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-40</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><edition><style face="normal" font="default" size="100%">1991/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Africa, Northern</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Rate</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Demography</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">Egypt</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning Services</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility</style></keyword><keyword><style face="normal" font="default" size="100%">*Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Hemorrhage</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper</style></keyword><keyword><style face="normal" font="default" size="100%">*Methods</style></keyword><keyword><style face="normal" font="default" size="100%">Middle East</style></keyword><keyword><style face="normal" font="default" size="100%">*Pain</style></keyword><keyword><style face="normal" font="default" size="100%">*Parity</style></keyword><keyword><style face="normal" font="default" size="100%">Population</style></keyword><keyword><style face="normal" font="default" size="100%">Population Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">*Research</style></keyword><keyword><style face="normal" font="default" size="100%">Signs and Symptoms</style></keyword><keyword><style face="normal" font="default" size="100%">Arab Countries</style></keyword><keyword><style face="normal" font="default" size="100%">*Bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception Continuation</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception Termination</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptive Effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Usage</style></keyword><keyword><style face="normal" font="default" size="100%">Demographic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility Measurements</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Iud--side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mediterranean Countries</style></keyword><keyword><style face="normal" font="default" size="100%">*Methodological Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiparity</style></keyword><keyword><style face="normal" font="default" size="100%">Northern Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Parity</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1991</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1110-7502 (Print)&#xD;1110-7502</style></isbn><accession-num><style face="normal" font="default" size="100%">12284660</style></accession-num><abstract><style face="normal" font="default" size="100%">Researchers followed 100 multiparous women who requested an IUD at the family planning clinic at El-Hussin University Hospital in Egypt 1, 3, 6, and 12 months after insertion of either the TCu-380 A or the TCu-200 B. They enrolled these women between September 1986-September 1987. The TCu-380 A had a higher continuation rate (89.7%) than the TCu-200 B (81.9%), but the difference was not significant (p=0.1). The continuation rate for TCu-380 A was higher than that of other studies (range 51.7-69.7%). The high continuation rate for TCu-380 A may have been due to careful selection of IUD candidates. For example, only multiparous women who had not had a pelvic infection after the last pregnancy and whose gynecological exam found no abnormalities were included. No one requested removal of the TCu-380 A because of bleeding and/or pain, but 8.7% of the TCu-200 B users did. Yet expulsion or displacement accounted for the leading reasons for removal of the TCu-380 A. Nevertheless the differences in reasons for removal between the 2 copper releasing IUDs were not statistically significant. No one with a TCu-380 A experienced a pregnancy, but the pregnancy rate for those with a TCu-200 B stood at 4 per 100 women-year. 46% of TCu-380 A users were 30 years old. Since higher pregnancy rates have occurred in women 30 years old at insertion than those 30 years old at insertion made the effectiveness rate of TCu-380 A all the more significant. In conclusion, if health workers properly screen women who wish to have an IUD, the TCu-380 A can be as effective in developing countries as it is in developed countries.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Kandil, O F&#xD;El-sheikha, Z&#xD;Hamza, A&#xD;Comparative Study&#xD;Journal Article&#xD;Egypt&#xD;Popul Sci. 1991 Jan;10:35-40.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>249</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lautenbach, E.</style></author><author><style face="normal" font="default" size="100%">Pegues, D.</style></author><author><style face="normal" font="default" size="100%">Fuchs, B.</style></author><author><style face="normal" font="default" size="100%">Martin, N.</style></author><author><style face="normal" font="default" size="100%">Nachamkin, I.</style></author><author><style face="normal" font="default" size="100%">Bilker, W.</style></author><author><style face="normal" font="default" size="100%">Tolomeo, P.</style></author><author><style face="normal" font="default" size="100%">Cressman, L.</style></author><author><style face="normal" font="default" size="100%">Omorgobe, J.</style></author><author><style face="normal" font="default" size="100%">Johnson, K.</style></author><author><style face="normal" font="default" size="100%">Han, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Lautenbach, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized controlled trial of the effect of accelerated copper textiles on healthcare-associated infections and multidrug-resistant organisms: The “investigating microbial pathogen activity of copper textiles” (impact) study</style></title><secondary-title><style face="normal" font="default" size="100%">Open Forum Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S568</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><keywords><keyword><style face="normal" font="default" size="100%">ceftriaxone</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">carbapenem-resistant Enterobacteriaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile infection</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">contamination</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">infectious agent</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">surgical intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">textile</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">2328-8957</style></isbn><abstract><style face="normal" font="default" size="100%">Background. Healthcare-associated infections (HAIs) and multidrug-resistant organisms (MDROs) remain critically important problems. Although copper has well-described antimicrobial properties, the impact of copper-impregnated linens on HAIs and MDROs in healthcare settings remains undefined. Methods. This study was conducted in a 24-bed medical ICU and a 24-bed surgical ICU from 1/12/16 to 7/31/16. Six beds in each ICU were randomized to CottonX™ accelerated copper linens (flat sheet, fitted sheet, pillow cover, gown) (Argaman Technologies Ltd.) and 18 beds to regular linens. Patients were enrolled if they were in the ICU for ≥3 days and were followed prospectively for development of an HAI (including C. difficile infection) and/or MDRO from ICU day 3 through 2 days after ICU discharge. MDROs were defined as a new clinical culture (i.e., no culture with the same organism in the prior year) with methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, or ceftriaxone-resistant or carbapenem-resistant Enterobacteriaceae. A patient could be included more than once for distinct ICU stays (“episodes”). Results. Among 1,021 subjects, the median age was 61 and 448 (44%) were female. Of 1,205 total episodes, 678 (56%) were in the MICU, 527 (44%) were in the SICU, and 351 (29%) were randomized to copper rooms. There were no significant differences between study groups with regard to demographics, comorbidities, indwelling devices, or antibiotic use. The overall rate (per 1,000 patient-days) of the composite outcome (HAI or MDRO) was 11.66 and 15.44 in copper and non-copper episodes, respectively, [incidence rate ratio (IRR) = 0.76 (95% CI, 0.46, 1.19); P = 0.22]. Rates of HAIs were 10.26 and 10.41 for copper and non-copper episodes, respectively ([IRR (95% CI) = 0.99 (0.57, 1.64); P = 0.97]. Rates of MDROs were 3.73 and 6.51 for copper and non-copper episodes, respectively [IRR (95% CI) = 0.57 (0.23, 1.26); P = 0.15]. Results were consistent when stratified by type of ICU. Conclusion. While not statistically significant, there was a nearly 50% lower rate of MDRO infection and colonization with use of CottonX™ accelerated copper linens, possibly in part due to decreases in environmental contamination. Future work should further explore the role of copper linens in reducing MDROs.</style></abstract><notes><style face="normal" font="default" size="100%">L629389883&#xD;2019-09-26</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L629389883</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1093/ofid/ofy210.1617</style></url><url><style face="normal" font="default" size="100%">https://watermark.silverchair.com/ofy210.1617.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAngwggJ0BgkqhkiG9w0BBwagggJlMIICYQIBADCCAloGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMafjSVN12nVxXxPu5AgEQgIICK-CJr-xxAFyHgb5j_Qc4jlN8Qy8vodCqBME2GikKIImgn4K_fYk6-r4u6li9YFHeQgDCANCSDXnni_Ew8bT3VX70hk7GaG16irqd-aWNk6fb3_B-PEOzZDGV_knAG115rMdK_BZh7LH-KhNN7NNeC4X5UXIOFpElqAYUmw2wfKaOEEGH4TGu3Ua6JWY9iKmYFPAdySxkYCiNOeEbZ0547jLpdu9_jGbjJPLBqezVeVRK-uHSsVXnHgzyWGgC0xOceE9tdF50dCQiEO4-EHERl0ku5v2Hhm-H5qWHURAAF6QrrKYs3nhIv96km3JtuvVWiNuvH7_B_vHVkBy8LysfOx44Kun0B4268dFLJ22fq-JyYzQFffU165L-zAKvYyB6nvfxwRo7Gb5z_4MtgbAEg-ki6YEW-2GOa7DPRczA_dS_JBHgnUOPN49ZJc3P6wqtfbK39lGP35Kq_D0hoWXylYPuJ-qHi4SQHt00lER3HUlU_SdPQ9x1xBQFrZb-lbLhxHzp56Zfyb56xo1NmYM1Zntt82uOQ1c8TTNctnPVZf6iykkpP9AUrOjN8HUeXrL259X6SujdIbNYicpHrDmlK3vUSyBjSQc3ZbFcwdOBhFlkl4Pq-G6NAoKDSngjL3oGLfX3VpO6sP7EjmzTfJVCIg8r805cv1Q9eoF5uCjPwIQALHLrr-LaEy4rarvZZ15MeuvEfywO6N8zSDrU26h8gh158QMTHLj0v8k4wg</style></url></related-urls><pdf-urls><url>internal-pdf://1212762599/Lautenbach-2018-A randomized controlled trial.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofy210.1617</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>324</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reeves, M. F.</style></author><author><style face="normal" font="default" size="100%">Hathaway, M. J.</style></author><author><style face="normal" font="default" size="100%">Canela Oleaga, J. M.</style></author><author><style face="normal" font="default" size="100%">Katz, B. H.</style></author><author><style face="normal" font="default" size="100%">Tal, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.F. Reeves, ContraMed, San Jose, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized single-blinded trial of veracept, a novel nitinol low-dose copper intrauterine contraceptive compared with a copper T380S intrauterine contraceptive</style></title><secondary-title><style face="normal" font="default" size="100%">Obstetrics and Gynecology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Obstetrics and gynecology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5S</style></pages><volume><style face="normal" font="default" size="100%">125</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">nitinol</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">low drug dose</style></keyword><keyword><style face="normal" font="default" size="100%">gynecologist</style></keyword><keyword><style face="normal" font="default" size="100%">college</style></keyword><keyword><style face="normal" font="default" size="100%">obstetrician</style></keyword><keyword><style face="normal" font="default" size="100%">American</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">cesarean section</style></keyword><keyword><style face="normal" font="default" size="100%">parity</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">luteal phase</style></keyword><keyword><style face="normal" font="default" size="100%">Likert scale</style></keyword><keyword><style face="normal" font="default" size="100%">surface area</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">0029-7844</style></isbn><abstract><style face="normal" font="default" size="100%">INTRODUCTION: We aimed to compare VeraCept, a novel lowprofile nitinol intrauterine contraceptive with 175 mm2 of copper surface area, with a commercially available copper T380S. METHODS: We performed a randomized subject-blinded comparison of VeraCept and a copper T380S in a two-to-one fashion. The primary outcome was total continuation. We also examined pain on insertion, ease of placement, expulsion, satisfaction, tolerability, and pregnancy. Satisfaction ratings were on a 5-point Likert scale. We report data from insertion through 9-month follow-up. RESULTS: We enrolled women in a single clinic with 199 allocated to VeraCept and 101 to the T380S. Insertion was successful in 198 women for VeraCept and 100 for the T380S (P&gt;.2). Mean age was 25 years, and median parity was two (range 1-4) with 39% having only had cesarean deliveries. No women developed clinical infection or reported serious adverse events. In the VeraCept and T380S groups, mean pain at insertion was 1.4 and 2.4, respectively (P&lt;.01). At the 9-month visit for VeraCept and T380S, respectively, continuation was 86% and 70% (P=.004) with partial and complete expulsions in 5.0% and 12.0% (P&lt;.05) and removal for pain or bleeding in 3.5% and 13.0% (P&lt;.05). No pregnancies were diagnosed after insertion with 1,562 and 643 women-months for VeraCept and T380S, respectively. One “luteal phase” pregnancy was identified at the first follow-up with conception estimated at 1-1.5 weeks before VeraCept insertion. CONCLUSION: VeraCept resulted in less pain at insertion, fewer expulsions, and higher total continuation than the T380S with equal contraceptive efficacy to date.</style></abstract><notes><style face="normal" font="default" size="100%">L72205883&#xD;2016-03-21</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72205883</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/01.AOG.0000463534.66148.e8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/01.AOG.0000463534.66148.e8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulpakko, J.</style></author><author><style face="normal" font="default" size="100%">Rantakokko-Jalava, K.</style></author><author><style face="normal" font="default" size="100%">Eerola, E.</style></author><author><style face="normal" font="default" size="100%">Hanninen, P. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medicity Research Laboratories and Laboratory of Biophysics, Institute of Biomedicine, Faculty of Medicine, University of Turku, Finland. Electronic address: jkkulp@utu.fi.&#xD;Clinical Microbiology Laboratory, Turku University Hospital and University of Turku, Finland.&#xD;Medicity Research Laboratories and Laboratory of Biophysics, Institute of Biomedicine, Faculty of Medicine, University of Turku, Finland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rapid time-resolved luminescence based screening of bacteria in urine with luminescence modulating biosensing phages</style></title><secondary-title><style face="normal" font="default" size="100%">Anal Biochem</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Anal Biochem</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21-26</style></pages><volume><style face="normal" font="default" size="100%">570</style></volume><edition><style face="normal" font="default" size="100%">2019/02/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteriophage M13/*chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Biosensing Techniques/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli/*isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lanthanoid Series Elements/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Luminescent Measurements</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections/diagnosis/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Urine/*microbiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0003-2697</style></isbn><accession-num><style face="normal" font="default" size="100%">30735666</style></accession-num><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are a common problem worldwide. The most prevalent causative pathogen of UTI is Escherichia coli, focus of this study. The current golden standard for detecting UTI is bacterial culture, creating a major workload for hospital laboratories - cost-effective and rapid mass screening of patient samples is needed. Here we present an alternative approach to screen patient samples with a single-step assay utilising time-resolved luminescence and luminescence modulating biosensing phages. Filamentous phage M13 was biopanned for binding luminescence quenching metal (copper) and further E. coli. The screening assay luminescence modulation was further enhanced by selecting right chemical environment for the functioning phage clones. Semi-specific interaction between phage, target bacteria and metal was detected by modulation in the signal of a weakly chelating, easily quenchable lanthanide complex. In the presence of the target pathogen, the phages collected quenching metal from solution to the bacterial surface changing the quenching effect on the lanthanide label and thus modulating the signal. Our method was compared with the bacterial culture data obtained from 70 patient samples. The developed proof-of-principle screening assay showed sensitivity and a specificity at the 90% mark when compared to culture method although some samples had high turbidity and even blood. The detection limit of E. coli was in the range of 1000-10 000 colony forming units/mL. Untreated urine sample was screened and time-resolved luminescence signal result was achieved within 10min in a single incubation step.</style></abstract><notes><style face="normal" font="default" size="100%">1096-0309&#xD;Kulpakko, Janne&#xD;Rantakokko-Jalava, Kaisu&#xD;Eerola, Erkki&#xD;Hanninen, Pekka E&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Anal Biochem. 2019 Apr 1;570:21-26. doi: 10.1016/j.ab.2019.01.011. Epub 2019 Feb 5.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ab.2019.01.011</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>342</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spitz, M.</style></author><author><style face="normal" font="default" size="100%">Aquino, J. H. W.</style></author><author><style face="normal" font="default" size="100%">Pereira, J. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Spitz, Rio de Janeiro, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurent chorea in the setting of infection and hyperglycemia in a teenager with hemichorea/hemiballismus as the first manifestation of type 1B diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">Movement Disorders</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Movement Disorders</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S196-S197</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><keywords><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">urea</style></keyword><keyword><style face="normal" font="default" size="100%">antistreptolysin</style></keyword><keyword><style face="normal" font="default" size="100%">haloperidol</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">antibody</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">ketone</style></keyword><keyword><style face="normal" font="default" size="100%">chorea</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">hyperglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">motor dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson disease</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">glycemic control</style></keyword><keyword><style face="normal" font="default" size="100%">involuntary movement</style></keyword><keyword><style face="normal" font="default" size="100%">brain</style></keyword><keyword><style face="normal" font="default" size="100%">insulin dependent diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">nail infection</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">muscle hypotonia</style></keyword><keyword><style face="normal" font="default" size="100%">neurologic examination</style></keyword><keyword><style face="normal" font="default" size="100%">leg</style></keyword><keyword><style face="normal" font="default" size="100%">glucosuria</style></keyword><keyword><style face="normal" font="default" size="100%">girl</style></keyword><keyword><style face="normal" font="default" size="100%">urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">blood gas</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">acidosis</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">blood osmolarity</style></keyword><keyword><style face="normal" font="default" size="100%">corpus striatum</style></keyword><keyword><style face="normal" font="default" size="100%">neuroimaging</style></keyword><keyword><style face="normal" font="default" size="100%">dengue</style></keyword><keyword><style face="normal" font="default" size="100%">basal ganglion</style></keyword><keyword><style face="normal" font="default" size="100%">glucose blood level</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0885-3185</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: To describe an atypical case of hemichorea/hemiballismus, the first manifestation of diabetes type 1, which exacerbated in two occasions when the patient had infections and subsequently developed elevated glucose levels. Background: Chorea may be secondary to non-ketotic hyperglycemia, but such situation has rarely been described in adolescents, particularly as the single and first manifestation of diabetes type 1. Most patients described in the literature achieve symptomatic and neuroimaging improvement as the glucose levels are controlled. Methods: Case report of a previously healthy 14 year-old girl with sudden onset of choreic movements on her left upper and lower limbs in 2009. The neurological examination was unremarkable, except for of the abnormal movements and a mild hypotonia on the left. Initial laboratory showed normal urea and creatinine and a blood glucose of 349 mg/dL. The estimated blood osmolarity was 313,2 mOsm/Kg (280-300). There was no acidosis on blood gas measure. Urinalysis showed 4+ glycosuria without ketones. Serum copper and ceruloplasmine, anti-GAD antibodies and anti-streptolysin O were negative. Results: Brain CT (Figure 1) and MRI disclosed an area of hyperdensity/hyperintensity affecting the right striatum. Despite adequate glucose control, the involuntary movements persisted and haloperidol was prescribed, with satisfactory but not complete resolution of the chorea. In 2012 the patient was stable, with only discrete involuntary movements of the left halux. In March 2012 the patient had dengue fever and in October 2013 she had a severe nail infection. In both occasions there was decompensation of the diabetes and the abnormal movements became more evident, improving shortly after glycemic control. A follow up brain MRI in 2012 showed persistent signal abnormalities in the basal ganglia on the right. Conclusions: Although not common, hyperglicemia must be considered in the differential diagnosis of acute hemichoreahemiballismus in children and adolescents, particularly because it is a potentially reversible cause. The typical clinical course in these cases is progressive clinical and radiological improvement, once glycemic control is achieved, but in some cases recurrent chorea can be observed in the context of hyperglycemia. (Figure Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L71496568&#xD;2014-06-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71496568</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1002/mds.25914</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mds.25914</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jprn, Umin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduction of antibiotic treatment initiation events by replacing regular textiles with biocidal copper oxide impregnated textiles: crossover, double blind and placebo controlled clinical study</style></title><secondary-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000021723</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000021723</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-01843432</style></accession-num><abstract><style face="normal" font="default" size="100%">INTERVENTION: A double‐blind cross‐over study. During period I, one ward received copper oxide impregnated textiles (linen, patients clothes and towels), and the other received Control untreated textiles; in period III the ward that received the treated textiles received the control textiles and vis versa. During Period II both wards received usual textiles. The textiles were coded with different colors and the personal staff was blinded to which were the treated or control textiles. There were no differences in the nosocomial prevention measures implemented in the wards during the study. A double‐blind cross‐over study. During period I, one ward received copper oxide impregnated textiles (linen, patients clothes and towels), and the other received Control untreated textiles; in period III the ward that received the treated textiles received the control textiles and vis versa. During Period II both wards received usual textiles. The textiles were coded with different colors and the personal staff was blinded to which were the treated or control textiles. There were no differences in the nosocomial prevention measures implemented in the wards during the study. CONDITION: prevention of nosocomial infections in long term care facilities PRIMARY OUTCOME: Antibiotic treatment initiation (ATI) events: a clinical presentation in which it was decided to administer antimicrobial therapy per 1000 hospitalization days during the study periods. SECONDARY OUTCOME: fever days: number of days during which the axillary temperature was above 37.6C per 1000 hospitalization days during the study periods.; Antibiotic usage: the number of days antibiotics were administrated per 1000 hospitalization days. The antibiotics defined daily dose (DDD) per 1000 patient days was calculated according to the WHO Collaborating Center for Drug Statistics Methodology guidelines, during the study periods. INCLUSION CRITERIA: All patients in the wards</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01843432/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">36</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Souli, M.</style></author><author><style face="normal" font="default" size="100%">Antoniadou, A.</style></author><author><style face="normal" font="default" size="100%">Katsarolis, I.</style></author><author><style face="normal" font="default" size="100%">Mavrou, I.</style></author><author><style face="normal" font="default" size="100%">Paramythiotou, E.</style></author><author><style face="normal" font="default" size="100%">Papadomichelakis, E.</style></author><author><style face="normal" font="default" size="100%">Drogari-Apiranthitou, M.</style></author><author><style face="normal" font="default" size="100%">Panagea, T.</style></author><author><style face="normal" font="default" size="100%">Giamarellou, H.</style></author><author><style face="normal" font="default" size="100%">Petrikkos, G.</style></author><author><style face="normal" font="default" size="100%">Armaganidis, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">14th Department of Internal Medicine,National and Kapodistrian University of Athens,School of Medicine,University General Hospital Attikon,Athens,Greece.&#xD;22nd Department of Critical Care,National and Kapodistrian University of Athens,School of Medicine,University General Hospital Attikon,Athens,Greece.&#xD;36th Department of Internal Medicine,Diagnostic and Therapeutic Center of Athens &quot;Hygeia,&quot;Athens,Greece.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction of Environmental Contamination With Multidrug-Resistant Bacteria by Copper-Alloy Coating of Surfaces in a Highly Endemic Setting</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infect Control Hosp Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">765-771</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2017/05/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Alloys</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Load</style></keyword><keyword><style face="normal" font="default" size="100%">Beds/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance, Multiple, Bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment Contamination/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Equipment and Supplies, Hospital/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fomites/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacteria/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Intensive Care Units</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/isolation &amp; purification</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0899-823x</style></isbn><accession-num><style face="normal" font="default" size="100%">28473010</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE To evaluate the efficacy of copper-coating in reducing environmental colonization in an intensive-care unit (ICU) with multidrug-resistant-organism (MDRO) endemicity DESIGN Interventional, comparative crossover trial SETTING The general ICU of Attikon University hospital in Athens, Greece PATIENTS Those admitted to ICU compartments A and B during the study period METHODS Before any intervention (phase 1), the optimum sampling method using 2 nylon swabs was validated. In phase 2, 6 copper-coated beds (ie, with coated upper, lower, and side rails) and accessories (ie, coated side table, intravenous [i.v.] pole stands, side-cart handles, and manual antiseptic dispenser cover) were introduced as follows: During phase 2a (September 2011 to February 2012), coated items were placed next to noncoated ones (controls) in both compartments A and B; during phase 2b (May 2012 to January 2013), all copper-coated items were placed in compartment A, and all noncoated ones (controls) in compartment B. Patients were randomly assigned to available beds. Environmental samples were cultured quantitatively for clinically important bacteria. Clinical and demographic data were collected from medical records. RESULTS Copper coating significantly reduced the percentage of colonized surfaces (55.6% vs 72.5%; P&lt;.0001), the percentage of surfaces colonized by MDR gram-negative bacteria (13.8% vs 22.7%; P=.003) or by enterococci (4% vs 17%; P=.014), the total bioburden (2,858 vs 7,631 cfu/100 cm2; P=.008), and the bioburden of gram-negative isolates, specifically (261 vs 1,266 cfu/100 cm2; P=.049). This effect was more pronounced when the ratio of coated surfaces around the patient was increased (phase 2b). CONCLUSIONS Copper-coated items in an ICU setting with endemic high antimicrobial resistance reduced environmental colonization by MDROs. Infect Control Hosp Epidemiol 2017;38:765-771.</style></abstract><notes><style face="normal" font="default" size="100%">1559-6834&#xD;Souli, Maria&#xD;Antoniadou, Anastasia&#xD;Katsarolis, Ioannis&#xD;Mavrou, Irini&#xD;Paramythiotou, Elisabeth&#xD;Papadomichelakis, Evangelos&#xD;Drogari-Apiranthitou, Maria&#xD;Panagea, Theofano&#xD;Giamarellou, Helen&#xD;Petrikkos, George&#xD;Armaganidis, Apostolos&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Infect Control Hosp Epidemiol. 2017 Jul;38(7):765-771. doi: 10.1017/ice.2017.52. Epub 2017 May 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cambridge.org/core/services/aop-cambridge-core/content/view/E40B680532F64DC16DFD55CD73EE85F5/S0899823X17000526a.pdf/div-class-title-reduction-of-environmental-contamination-with-multidrug-resistant-bacteria-by-copper-alloy-coating-of-surfaces-in-a-highly-endemic-setting-div.pdf</style></url></related-urls><pdf-urls><url>internal-pdf://1444738305/Souli-2017-Reduction of Environmental Contamin.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/ice.2017.52</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">43</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marcus, E. L.</style></author><author><style face="normal" font="default" size="100%">Yosef, H.</style></author><author><style face="normal" font="default" size="100%">Borkow, G.</style></author><author><style face="normal" font="default" size="100%">Caine, Y.</style></author><author><style face="normal" font="default" size="100%">Sasson, A.</style></author><author><style face="normal" font="default" size="100%">Moses, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chronic Ventilator-Dependent Division, Herzog Hospital, Jerusalem, Israel. Electronic address: elm@zahav.net.il.&#xD;Infection Control Unit, Herzog Hospital, Jerusalem, Israel.&#xD;Cupron Inc, Herzelia, Israel.&#xD;Chronic Ventilator-Dependent Division, Herzog Hospital, Jerusalem, Israel.&#xD;Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction of health care-associated infection indicators by copper oxide-impregnated textiles: Crossover, double-blind controlled study in chronic ventilator-dependent patients</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">401-403</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2016/12/31</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Infective Agents/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Over Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Utilization</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Health Services Research</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Oxides/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia, Ventilator-Associated/*epidemiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Textiles/microbiology/*statistics &amp; numerical data</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Fever</style></keyword><keyword><style face="normal" font="default" size="100%">Long-term care facility</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanical ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">Medical textiles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">28034536</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Copper oxide has potent wide-spectrum biocidal properties. The purpose of this study is to determine if replacing hospital textiles with copper oxide-impregnated textiles reduces the following health care-associated infection (HAI) indicators: antibiotic treatment initiation events (ATIEs), fever days, and antibiotic usage in hospitalized chronic ventilator-dependent patients. METHODS: A 7-month, crossover, double-blind controlled trial including all patients in 2 ventilator-dependent wards in a long-term care hospital. For 3 months (period 1), one ward received copper oxide-impregnated textiles and the other received untreated textiles. After a 1-month washout period of using regular textiles, for 3 months (period 2) the ward that received the treated textiles received the control textiles and vice versa. The personnel were blinded to which were treated or control textiles. There were no differences in infection control measures during the study. RESULTS: There were reductions of 29.3% (P = .002), 55.5% (P &lt; .0001), 23.0% (P &lt; .0001), and 27.5% (P &lt; .0001) in the ATIEs, fever days (&gt;37.6 degrees C), days of antibiotic treatment, and antibiotic defined daily dose per 1,000 hospitalization days, respectively, when using the copper oxide-impregnated textiles. CONCLUSIONS: Use of copper oxide-impregnated biocidal textiles in a long-term care ward of ventilator-dependent patients was associated with a significant reduction of HAI indicators and antibiotic utilization. Using copper oxide-impregnated biocidal textiles may be an important measure aimed at reducing HAIs in long-term care medical settings.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Marcus, Esther-Lee&#xD;Yosef, Hana&#xD;Borkow, Gadi&#xD;Caine, Yehezkel&#xD;Sasson, Ady&#xD;Moses, Allon E&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;United States&#xD;Am J Infect Control. 2017 Apr 1;45(4):401-403. doi: 10.1016/j.ajic.2016.11.022. Epub 2016 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272359/1-s2.0-S0196655316X0017X/1-s2.0-S0196655316310859/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEIn%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJIMEYCIQDbC0IS318nIG8vl2jmj%2FM1AcgVJM95I2nNgIl3888nEAIhALPioF4y122HQMnK9oCPyYkdSE0r5N5%2FejM1pox3USgaKr0DCIL%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQAhoMMDU5MDAzNTQ2ODY1Igy%2FyXlL3i1Cr%2BbQ4JQqkQMNnGRlirYATYHbn3zDkYUY9JQnPfIcjaPfgEdRd3Onf%2BNmsiVX8a%2Bny8k0W%2B1eqTTW4b%2FEPfv%2Bmyrvs5d7y1NXRe%2BLxb%2FTZu40n6MGhf%2FsVwbzLaw2RMCjdAPzPqkaK47UmHPcYNnR2r5%2BJ19FAX6I%2F1K6NHVL1B3KqP5ZDU8hFnssCiBjW%2FnnWvOKZrvHYjztoTEUL3x4u1K%2FBBKrZXt%2BKw1lrqbvAjcLbovMHe1b%2Fh6lGejJBqbIZkDDcOVIOWLdaMU%2BHcdrMdFN0AlyQiSDyaCiB2TZuNHmhIU1Ihzlp1k6rLMDc8ATl0z9tHmEeJGSb9P3o%2B2YQlig6HDEno4iRMPwZL7Ec%2BUoG2CPXacUiHObCgSGeGZhWr4OM1Qg3qg7%2BhWlFuJirVgLBvL41zmLUNhhW%2BHnUMEmerEJUGDiCYaIsCQrjP4PlMzeiAVrWNIg93v3%2F%2FG8aDEwqm%2BS37vetB6GePxPH8yr4%2Bd8P%2Fl5Y0TSsx8h6NsazGw%2FEv9nexMpHJZnXiExb5UvRJOIWsD9fTDw7%2B%2FzBTrqAaE2zvXFtdGYBFFuZsK6BzHfcBRNDtv4eEGwVMq7Ix3k36fCtx%2Br1uFjEOniAsMish4J4XIuGvO2icncLTQ4MN4OU0q7gEoojwAJUqaaFWSc5%2B08Iur6ng9UDE7QEtFFmWOwJAyaZTOftBO9gJEPuPLd2Isw0cW8P4aAqcM1YmsiOuXVaoCYU5LilatxDrICuEJduLy8nS7tEJ3HIvNIaGGN8TIwQYENxFLmWWdCHtDJMeDQk3aFVXtmwA1kqmWq2%2BpDPDUzRl03mKw6RhuAoKFhecwwbTHLVCQNekQeqNzWxVK19ws%2FjnvyYg%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200326T015720Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTYVL7NJCGN%2F20200326%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=a8ed278494b6b18f7dcb951ef0a68aab55938379a96b7934c0d74f26232fe485&amp;hash=0414ee1639abf4898ea0ccab5370431a02ea3eabecf81bdc402be807ea6c4038&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S0196655316310859&amp;tid=spdf-f8994756-d76f-4c2c-af14-84eb0089d3ef&amp;sid=b55cb6f75e12284bca8a0eb9c40a5781e75agxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://3150313595/Marcus-2017-Reduction of health care-associate.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2016.11.022</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Reduction of healthcare-associated infection related events by replacing regular hospital textiles with copper oxide impregnated textiles: crossover, double-blind, controlled study in chronic, ventilator-dependent patients</style></title><secondary-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open forum infectious diseases</style></full-title></periodical><volume><style face="normal" font="default" size="100%">3</style></volume><keywords><keyword><style face="normal" font="default" size="100%">*healthcare associated infection</style></keyword><keyword><style face="normal" font="default" size="100%">*textile</style></keyword><keyword><style face="normal" font="default" size="100%">*ventilated patient</style></keyword><keyword><style face="normal" font="default" size="100%">*visually impaired person</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">Clothing</style></keyword><keyword><style face="normal" font="default" size="100%">Conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">Controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">Crossover procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">Drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fever</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Infection control</style></keyword><keyword><style face="normal" font="default" size="100%">Long term care</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02080508</style></accession-num><abstract><style face="normal" font="default" size="100%">Background. Healthcare‐associated infections (HAI) contribute to morbidity, mortality and healthcare costs. Our objective was to determine whether replacing regular textiles with copper oxide biocidal textiles reduces antibiotic treatment initiation (ATI) events, fever days and antibiotic usage among chronic ventilator patients. Methods. We conducted a seven months&apos; (15 February to 15 September 2015) double‐blind controlled crossover study, divided into 2 intervention periods of 3 months. The periods were separated by a 1‐month washout period. All patients in 2 similar adjacent ventilator‐dependent wards in a long‐term care hospital were included in the study. During Period I, one ward received copper oxide impregnated linen, hospital patients&apos; clothes and towels, and the other ward received “control” untreated textiles; in Period III the ward that received the treated textiles received the “control” textiles and vice versa. During Period II both wards received usual hospital textiles. The textiles were color coded and all personnel were blinded to which were the treated or control textiles. The infection control measures were the same in both wards. ATI events, fever days, antibiotic treatment days and antibiotics defined daily dose (DDD) were recorded and calculated per 1000 hospitalization days (HD). Results. There were 29.19% (P = .002), 55.45% (P &lt; .0001), 22.97% (P &lt; .0001), and 29.22% (P &lt; .001) relative reductions in the ATI events, fever days, antibiotic treatment days and DDD per 1000 HD, respectively, that occurred when using the copper impregnated textiles. In one ward there were 25.63% (P = .093), 49.15% (P &lt; .0001), 17.93% (P = .003) and 18.42% (P &lt; .001) and in the second ward 34.68% (P = .007), 65.08% (P &lt; .0001), 30.30% (P &lt; .0001) and 41.52%, relative reductions in ATI events, fever days, days of antibiotic administration, and DDD per 1000 HD, respectively, when using the treated compared with the untreated textiles. Conclusion. The use of copper oxide impregnated biocidal textiles in a longterm care ward of ventilator‐dependent patients was associated with a significant reduction of HAI‐related events and antibiotic administration. Using biocidal textiles may be an important measure aimed at reducing HAI in long‐term care medical settings.</style></abstract><work-type><style face="normal" font="default" size="100%">Journal: Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02080508/full</style></url><url><style face="normal" font="default" size="100%">https://watermark.silverchair.com/ofw172.127.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAncwggJzBgkqhkiG9w0BBwagggJkMIICYAIBADCCAlkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMmwRfwb3jvxu9i2FQAgEQgIICKn4pTBWcng226sjSDrQtl2hhdiyauiDOQtEX00T7Q0cTXqvz9l8C_hZHabdjfVz8kgJOXr8pHWTaJgHFsFiqQen0xzlDUAYhS1VmwJpUQ32qJ_7mWBm2cGG-eoNZfHbk88RifZcFSElD68i3oVxy2bTgNY57X7-b2UzPeC2jhVZJaJFYEux_HpAiiYnhmgg1HERPBfJf6p9FqLuFWeFElZt6wDgtI9K8vi7EbKQF3KeCrGCERwJobNHMfblzphy1USKJ6sxvbOJHTnz95J7vy0gnDOwy-cxeMMyM0IxMe9Lxo_y-_LEnkalGsZFlim3Q7_FdeygP3zu0SHtsWpXofcYAdfCbpkuN5k3TZMPfBYafZxQ7oO9I6zJhoQRn-tu1lvJh-wk2MPMk8ZeJMe1qXJJkL72MCrn1UxIASCIQ_f7fObdP8w7LUk0obtl2CE9syQLifAdfY7DQLekHAJ56_LqIsNcI0z_k5wKvR8AumGNjx5Vf-BlYr0Jl5qVW9TcmtpupHuv0j559etOSFe73giZr1hak1wlBVASR_5JORbrT8St03FakSR9xbY-Bzx-241YoOxwZEchX9RKCEwJMWoYa2oXLtnJBkgWjnBNzv_-7WAxc1exEXhBYJOXA-Q2PvU0Rqu2ZdLHI4hBVb1ZhX0PinGwVVq6w3fZvsgnjwkyzOHpU7Wh4LJ2eNzFSHCsALVAF4QrqPpm5SNLGviHcp3X3WJkxEFnowiJ7</style></url></related-urls><pdf-urls><url>internal-pdf://4150092728/2016-Reduction of healthcare-associated infect.pdf</url></pdf-urls></urls><custom3><style face="normal" font="default" size="100%">EMBASE 627784337</style></custom3><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ofid/ofw172.127</style></electronic-resource-num></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">66</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lazary, A.</style></author><author><style face="normal" font="default" size="100%">Weinberg, I.</style></author><author><style face="normal" font="default" size="100%">Vatine, J. J.</style></author><author><style face="normal" font="default" size="100%">Jefidoff, A.</style></author><author><style face="normal" font="default" size="100%">Bardenstein, R.</style></author><author><style face="normal" font="default" size="100%">Borkow, G.</style></author><author><style face="normal" font="default" size="100%">Ohana, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Brain Injury Division, Reuth Medical Center, 2 Ha&apos;Hayil blvd, Tel Aviv 61092, Israel. Electronic address: lazary@reuth.org.il.&#xD;Brain Injury Division, Reuth Medical Center, 2 Ha&apos;Hayil blvd, Tel Aviv 61092, Israel.&#xD;Outpatient and Research Division, Reuth Medical Center, Tel Aviv, Israel; Department of Rehabilitation Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.&#xD;Microbiology Laboratory, Kaplan Medical Center, Rehovot, Israel.&#xD;Cupron Scientific, Herzliya, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction of healthcare-associated infections in a long-term care brain injury ward by replacing regular linens with biocidal copper oxide impregnated linens</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">23-9</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><edition><style face="normal" font="default" size="100%">2014/03/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/economics/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bedding and Linens/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Injuries/complications/drug therapy/pathology/*rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/complications/drug therapy/economics/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacteria/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Negative Bacterial Infections/complications/drug</style></keyword><keyword><style face="normal" font="default" size="100%">therapy/economics/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacteria/drug effects/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Gram-Positive Bacterial Infections/complications/drug</style></keyword><keyword><style face="normal" font="default" size="100%">therapy/economics/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Long-Term Care/economics</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Acquired brain injury</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper oxide</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare-associated infections</style></keyword><keyword><style face="normal" font="default" size="100%">Long-term care</style></keyword><keyword><style face="normal" font="default" size="100%">Textiles</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1201-9712</style></isbn><accession-num><style face="normal" font="default" size="100%">24614137</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Contaminated textiles in hospitals contribute to endogenous, indirect-contact, and aerosol transmission of nosocomial related pathogens. Copper oxide impregnated linens have wide-spectrum antimicrobial, antifungal, and antiviral properties. Our aim was to determine if replacing non-biocidal linens with biocidal copper oxide impregnated linens would reduce the rates of healthcare-associated infections (HAI) in a long-term care ward. METHODS: We compared the rates of HAI in two analogous patient cohorts in a head injury care ward over two 6-month parallel periods before (period A) and after (period B) replacing all the regular non-biocidal linens and personnel uniforms with copper oxide impregnated biocidal products. RESULTS: During period B, in comparison to period A, there was a 24% reduction in the HAI per 1000 hospitalization-days (p&lt;0.05), a 47% reduction in the number of fever days (&gt;38.5 degrees C) per 1000 hospitalization-days (p&lt;0.01), and a 32.8% reduction in total number of days of antibiotic administration per 1000 hospitalization-days (p&lt;0.0001). Accordingly there was saving of approximately 27% in costs of antibiotics, HAI-related treatments, X-rays, disposables, labor, and laundry, expenses during period B. CONCLUSIONS: The use of biocidal copper oxide impregnated textiles in a long-term care ward may significantly reduce HAI, fever, antibiotic consumption, and related treatment costs.</style></abstract><notes><style face="normal" font="default" size="100%">1878-3511&#xD;Lazary, A&#xD;Weinberg, I&#xD;Vatine, J-J&#xD;Jefidoff, A&#xD;Bardenstein, R&#xD;Borkow, G&#xD;Ohana, N&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Canada&#xD;Int J Infect Dis. 2014 Jul;24:23-9. doi: 10.1016/j.ijid.2014.01.022. Epub 2014 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://pdf.sciencedirectassets.com/272991/1-s2.0-S1201971214X00081/1-s2.0-S1201971214000599/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEIn%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIHNYMQQLyBQz2sE3fbbTD3dQGPsHZcOz90ZaIM%2F%2F9mPyAiASLW0CLvRIDCzLWEvUFAmzOVPbeZRqAvXJ%2BxKFx0QMySq9AwiC%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAIaDDA1OTAwMzU0Njg2NSIMx%2BGVKbpMmc2%2BERI0KpEDhkHnEwLsZO7PneAXGaC5fwF4xSX1QEEoUqUvQNG%2BE3IatLNZoKWlK8335renViBnCNGdPA1b6KOEQ8q6kAHkTq3FSpEgNvS3IpF3qfafgJa0ZPcfNIxAuDQKBGMrxFbkrMx5oG5s7pjJrixQW6bEVEe8esggNkBly31YNAdIT450WADAR3GJV1YAfYTTYaeOciwQ10PO0pwVOM7%2FpswwbFibj9vAuijrzONHO%2BXnCujT04SQr5Dqukaz%2FKGYrbiDScJjUxJQE08HlbMYXwoTun6FiJ%2FxC9ZEZc5YwfiH56SooF5f75B5wYAiRmZO3hcrMdUQWO%2BqeFmbBh76%2FBoAC5PybvYXih1FyJQoJw6C8o%2FuAwWo2E%2BSknBsYF7uhD7sm%2FQ94anWU8LDUdmS8gZoE19eiq81sQPVYLAmboMn88iRyH%2BXU3T5%2F9Nko7xiOPt%2BeNnN4o728nwuQ0Vysca6jCfKNfiFbVDQ3A6s%2Fi7uxd8hxYLkSaTasDGkmyy1WeKXdfNaFKTRExmfO%2Fu9XsfCcK0wo%2Frv8wU67AFg64v86nfJGOJC28K1VwJXh4EtTqEUhSt1KKxVffAuE5aRz4pOS32q8Pik8LSNCek5nXHpmkdfpJdYRY9x99EPCXuqWVke6DYyaiVZeEyfK22uBtqjubeqk9n61MmcTul3aSHp%2BxwoBII08o8IZYd8wNv8%2BDqkgHanat7iuJbIAeRJWGVpvKjeFDbSphFj90UhblFZ6U7%2BEGHmeRTJZxIDiAXqqtDyzQpUxd2j65BYLzZ4TjKnEWlGzHjnV%2BrxRaYAvGwLmGW9uUvR9uIuDhDGY%2FwpHZsFMIvhqrFD%2F9aFPBAoRKiGkTXNIKeVSg%3D%3D&amp;X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20200326T015732Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=300&amp;X-Amz-Credential=ASIAQ3PHCVTY7TSYMIOH%2F20200326%2Fus-east-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=114f74330d87ea358cdd74ab3611d2eb9216b1e6c3c15ad8016abd44a53f18bb&amp;hash=2ac48129c96c351343746a8b2d485b8a1b6b773f34a1f999245e923feb1f800f&amp;host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&amp;pii=S1201971214000599&amp;tid=spdf-8ab38440-49c6-4b1c-859e-240e748e454c&amp;sid=b55cb6f75e12284bca8a0eb9c40a5781e75agxrqa&amp;type=client</style></url></related-urls><pdf-urls><url>internal-pdf://2574199572/Lazary-2014-Reduction of healthcare-associated.pdf</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijid.2014.01.022</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berger, M. M.</style></author><author><style face="normal" font="default" size="100%">Eggimann, P.</style></author><author><style face="normal" font="default" size="100%">Heyland, D. K.</style></author><author><style face="normal" font="default" size="100%">Chiolero, R. L.</style></author><author><style face="normal" font="default" size="100%">Revelly, J. P.</style></author><author><style face="normal" font="default" size="100%">Day, A.</style></author><author><style face="normal" font="default" size="100%">Raffoul, W.</style></author><author><style face="normal" font="default" size="100%">Shenkin, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Adult Intensive Care Medicine &amp; Burn Centre, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland. Mette.Berger@chuv.ch</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction of nosocomial pneumonia after major burns by trace element supplementation: aggregation of two randomised trials</style></title><secondary-title><style face="normal" font="default" size="100%">Crit Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Crit Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">R153</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2006/11/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Burn Units</style></keyword><keyword><style face="normal" font="default" size="100%">Burns/*complications</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/*etiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Selenium/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Wound Healing</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><isbn><style face="normal" font="default" size="100%">1364-8535</style></isbn><accession-num><style face="normal" font="default" size="100%">17081282</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Nosocomial pneumonia is a major source of morbidity and mortality after severe burns. Burned patients suffer trace element deficiencies and depressed antioxidant and immune defences. This study aimed at determining the effect of trace element supplementation on nosocomial or intensive care unit (ICU)-acquired pneumonia. METHODS: Two consecutive, randomised, double-blinded, supplementation studies including two homogeneous groups of 41 severely burned patients (20 placebo and 21 intervention) admitted to the burn centre of a university hospital were combined. Intervention consisted of intravenous trace element supplements (copper 2.5 to 3.1 mg/day, selenium 315 to 380 mug/day, and zinc 26.2 to 31.4 mg/day) for 8 to 21 days versus placebo. Endpoints were infections during the first 30 days (predefined criteria for pneumonia, bacteraemia, wound, urine, and other), wound healing, and length of ICU stay. Plasma and skin (study 2) concentrations of selenium and zinc were determined on days 3, 10, and 20. RESULTS: The patients, 42 +/- 15 years old, were burned on 46% +/- 19% of body surface: the combined characteristics of the patients did not differ between the groups. Plasma trace element concentrations and antioxidative capacity were significantly enhanced with normalisation of plasma selenium, zinc, and glutathione peroxidase concentrations in plasma and skin in the trace element-supplemented group. A significant reduction in number of infections was observed in the supplemented patients, which decreased from 3.5 +/- 1.2 to 2.0 +/- 1.0 episodes per patient in placebo group (p &lt; 0.001). This was related to a reduction of nosocomial pneumonia, which occurred in 16 (80%) patients versus seven (33%) patients, respectively (p &lt; 0.001), and of ventilator-associated pneumonia from 13 to six episodes, respectively (p = 0.023). CONCLUSION: Enhancing trace element status and antioxidant defences by selenium, zinc, and copper supplementation was associated with a decrease of nosocomial pneumonia in critically ill, severely burned patients.</style></abstract><notes><style face="normal" font="default" size="100%">1466-609x&#xD;Berger, Mette M&#xD;Eggimann, Philippe&#xD;Heyland, Daren K&#xD;Chiolero, Rene L&#xD;Revelly, Jean-Pierre&#xD;Day, Andrew&#xD;Raffoul, Wassim&#xD;Shenkin, Alan&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Crit Care. 2006;10(6):R153. doi: 10.1186/cc5084.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC1794452</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/cc5084</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">30</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Demir, N.</style></author><author><style face="normal" font="default" size="100%">Basaranoglu, M.</style></author><author><style face="normal" font="default" size="100%">Huyut, Z.</style></author><author><style face="normal" font="default" size="100%">Deger, I.</style></author><author><style face="normal" font="default" size="100%">Karaman, K.</style></author><author><style face="normal" font="default" size="100%">Sekeroglu, M. R.</style></author><author><style face="normal" font="default" size="100%">Tuncer, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">a Department of Pediatrics, Division of Neonatology , Yuzuncu Yil University School of Medicine , Van , Turkey.&#xD;b Department of Medical Biochemistry , Yuzuncu Yil University School of Medicine , Van , Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The relationship between mother and infant plasma trace element and heavy metal levels and the risk of neural tube defect in infants</style></title><secondary-title><style face="normal" font="default" size="100%">J Matern Fetal Neonatal Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Matern Fetal Neonatal Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1433-1440</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2017/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Fetal Blood/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Gestational Age</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Metals, Heavy/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Neural Tube Defects/*chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Trace Elements/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Heavy metal</style></keyword><keyword><style face="normal" font="default" size="100%">neonate</style></keyword><keyword><style face="normal" font="default" size="100%">neural tube defect</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1476-4954</style></isbn><accession-num><style face="normal" font="default" size="100%">29199526</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine levels of trace elements [copper (Cu), zinc (Zn), selenium (Se), and cobalt (Co)] and heavy metals [arsenic (As), mercury (Hg), lead (Pb), and cadmium (Cd)] in the plasma of mothers and infants and investigate the relationship between those levels and neural tube defects (NTD). METHODS: A total of 100 neonates diagnosed with NTD and placed in the Neonatal Intensive Care Unit of Yuzuncu Yil University, Turkey between May 2013 and December 2016 comprised the study group. The control group consisted of 70 healthy neonates not diagnosed with NTD or any other congenital anomalies. For both the groups, mother and infant plasma levels of Cu, Zn, Co, Cd, Se, Hg, As, and Pb were measured and compared. Plasma levels of Cu, Zn, Co, Cd, Se, Hg, As, and Pb were measured and compared between two groups of mothers and infants. FINDINGS: Mother and infant plasma levels of trace elements Zn and Se were determined to be significantly lower in the study group compared with the control group, while Cu levels were significant elevated in the study group (all p values &lt; .05). Plasma levels of heavy metals As, Pb, and Cd were found to be significantly higher in the NTD control group (p &lt; .05 for all). There was no association between maternal infection, maternal smoking status, history of miscarriage, or history of NTD with the development of NTD (p &gt; .05). Differences in maternal age, birth weight, length of gestation, and infant gender for the two groups were also determined not to be statistically significant. RESULTS: High plasma levels of heavy metals As, Pb, and Cd and trace element Cu were identified as risk factors for the development of NTD. At the same time, low plasma levels of trace elements Zn and Se were also found to be risk factors for NTD. However, no association between Hg and Co plasma levels and increased risk for the development of NTD was observed. This study, while being the most comprehensive case study to date investigating the relationship between heavy metals and trace element levels and increased risk of NTD, nonetheless highlights the need for further research in order to make definite statements regarding this relationship.</style></abstract><notes><style face="normal" font="default" size="100%">1476-4954&#xD;Demir, Nihat&#xD;Basaranoglu, Murat&#xD;Huyut, Zubeyir&#xD;Deger, Ibrahim&#xD;Karaman, Kamuran&#xD;Sekeroglu, M Ramazan&#xD;Tuncer, Oguz&#xD;Journal Article&#xD;England&#xD;J Matern Fetal Neonatal Med. 2019 May;32(9):1433-1440. doi: 10.1080/14767058.2017.1408064. Epub 2017 Dec 3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/14767058.2017.1408064</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>344</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">344</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gungor, M.</style></author><author><style face="normal" font="default" size="100%">Belge Kurutas, E.</style></author><author><style face="normal" font="default" size="100%">Ciragil, P.</style></author><author><style face="normal" font="default" size="100%">Aral, M.</style></author><author><style face="normal" font="default" size="100%">Kokoglu, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Gungor, Toros University, Vocational School, Department of Medical, Mersin, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relationship between trace elements and oxidative stress in patients with brucella melitensis</style></title><secondary-title><style face="normal" font="default" size="100%">Turkish Journal of Biochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Turkish Journal of Biochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">92</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><keywords><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">catalase</style></keyword><keyword><style face="normal" font="default" size="100%">scavenger</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">malonaldehyde</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella melitensis</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">standardization</style></keyword><keyword><style face="normal" font="default" size="100%">accreditation</style></keyword><keyword><style face="normal" font="default" size="100%">plasma</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">clergy</style></keyword><keyword><style face="normal" font="default" size="100%">university</style></keyword><keyword><style face="normal" font="default" size="100%">flame</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0250-4685</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: This is the first report regarding to investigate the activities of erythrocyte catalase (CAT) and superoxide dismutase (SOD), levels of plasma malondialdehyde (MDA), and serum zinc (Zn), copper (Cu) and selenium (Se) concentrations which were measured in patients with Brucella melintensis, and results were compared with those of healthy individuals. Materials and Methods: The investigation included 25 patient with Brucella melitensis (age: 34.4±4.5 years) and 20 healthy subjects (age: 33.6±5.0 years) as control group who were admitted to Department of Infection Diseases, Faculty of Medicine, Kahramanmaras Sutcu Imam University. The activities of erythrocyte CAT and SOD, levels of plasma MDA were measured spectrophotometrically. Serum Zn, Cu and Se concentrations were measured with flame atomic absorption spectrometry. Results: The mean of erythrocyte CAT and SOD activities and serum Zn and Se concentrations were significantly lower among patients compared with controls (p &lt;0.001). However, levels of plasma MDA and serum Cu in patients were significantly increased compare to controls (p&lt;0.001). A significant positive correlation was found between levels of plasma MDA and serum Cu concentrations in patients with Brucella melitensis. Conclusions: Decreased Zn and Se levels, antioxidant system insufficiency and increased levels of MDA and Cu were shown in patients with Brucella melitensis. Supplementary trace element antioxidative process may increase scavenger enzyme activities and also clinical symptoms may be amelioration in these patients.</style></abstract><notes><style face="normal" font="default" size="100%">L71836412&#xD;2015-04-10</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71836412</style></url></related-urls><pdf-urls><url>internal-pdf://0549693697/TBDmalatyaKitapVER2.pdf</url></pdf-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">Turkish&#xD;English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>318</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">318</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Belge Kurutas, E.</style></author><author><style face="normal" font="default" size="100%">Gungor, M.</style></author><author><style face="normal" font="default" size="100%">Ciragil, P.</style></author><author><style face="normal" font="default" size="100%">Aral, M.</style></author><author><style face="normal" font="default" size="100%">Kokoglu, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">E. Belge Kurutas, Sutcu Imam University, Faculty of Medicine, Department of Biochemistry, Kahramanmaras, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relationship of trace elements and oxidative stress in patients with brucella melitensis</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Chemistry and Laboratory Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Chemistry and Laboratory Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S1396</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><keywords><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">catalase</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">scavenger</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">malonaldehyde</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella melitensis</style></keyword><keyword><style face="normal" font="default" size="100%">European</style></keyword><keyword><style face="normal" font="default" size="100%">clinical chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">plasma</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword><keyword><style face="normal" font="default" size="100%">university</style></keyword><keyword><style face="normal" font="default" size="100%">clergy</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">normal human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella</style></keyword><keyword><style face="normal" font="default" size="100%">flame</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1434-6621</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND-AIM This is the first report regarding to investigate the activities of erythrocyte catalase (CAT) and superoxide dismutase (SOD), levels of plasma malondialdehyde (MDA), and serum zinc (Zn), copper (Cu) and selenium (Se) concentrations were measured in patients with brucella melintensis, and results were compared with those of healthy individuals. METHODS The investigation included 25 patient with Brucella melitensis (age: 34.4±4.5) and 20 healthy subjects (age: 33.6±5.0) as control group who were admitted to Department of Infection Diseases, Faculty of Medicine, Kahramanmaras Sutcu Imam University. The activities of erythrocyte catalase (CAT) and superoxide dismutase (SOD), levels of plasma MDA were measured as spectrophotometric. Serum Zn, Cu and Se concentrations were measured with flame atomic absorption spectrometry. RESULTS The mean of erythrocyte CAT and SOD activities and serum Zn and Se concentrations were significantly lower among patients compared with controls (p&lt;0.001). However levels of plasma MDA in patients were comparable to controls and the mean NO levels in patients were significantly higher than controls (p&gt;0.001). A significant positive correlation was found between levels of plasma MDA and serum Cu concentrations in patients with Brucella melitensis. CONCLUSION Decreased Zn and Se levels, antioxidant system insufficiency and increased levels of MDA and Cu were shown in patients with Brucella melitensis. Supplementary trace element antioxidative process may increase scavenger enzyme activities and also clinical symptoms may be amelioration in these patients.</style></abstract><notes><style face="normal" font="default" size="100%">L71911684&#xD;2015-06-15</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71911684</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1515/cclm-2015-5036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1515/cclm-2015-5036</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ivankovic, T.</style></author><author><style face="normal" font="default" size="100%">Dikic, J.</style></author><author><style face="normal" font="default" size="100%">du Roscoat, S. R.</style></author><author><style face="normal" font="default" size="100%">Dekic, S.</style></author><author><style face="normal" font="default" size="100%">Hrenovic, J.</style></author><author><style face="normal" font="default" size="100%">Ganjto, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Science, University of Zagreb, Rooseveltov trg 6, 10000 Zagreb, Croatia E-mail: tomislav.ivankovic@biol.pmf.hr.&#xD;Innovation Center of the Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, Belgrade, Serbia.&#xD;Laboratoire 3SR, Universite Grenoble-Alpes/CNRS/G-INP, UMR 5521, Grenoble, France.&#xD;Zagreb Wastewater - Management and Operation Ltd, Culinecka cesta 287, Zagreb, Croatia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Removal of emerging pathogenic bacteria using metal-exchanged natural zeolite bead filter</style></title><secondary-title><style face="normal" font="default" size="100%">Water Sci Technol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Water Sci Technol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1085-1098</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2019/12/05</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Silver</style></keyword><keyword><style face="normal" font="default" size="100%">*Zeolites</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0273-1223 (Print)&#xD;0273-1223</style></isbn><accession-num><style face="normal" font="default" size="100%">31799952</style></accession-num><abstract><style face="normal" font="default" size="100%">Hospital wastewaters can become a route for dissemination of antibiotic-resistant bacteria to the environment if not properly treated. Some of these bacteria are able to survive conventional disinfection treatments (e.g. chlorination, UV irradiation), which evokes the need for novel disinfection methods. The metal-exchanged zeolites were tested as novel antibacterial agents for wastewater treatment. The natural zeolite clinoptilolite enriched with silver (AgNZ) showed far better antibacterial activity towards hospital pathogenic bacterium Acinetobacter baumannii when compared with copper-exchanged zeolite (CuNZ), with minimal bactericidal concentration of 0.25-2 (AgNZ) compared with 32-64 mg L(-1) (CuNZ) in a batch system and respective log 5.6 reduction compared with log 0.5 reduction in a flow system with pure bacterial culture. In the flow system with real effluent wastewater from the treatment plant, the removal of carbapenem-resistant bacteria using AgNZ was 90-100% during the 4 days of the experimental run. These results indicate that the AgNZ efficiently removes pathogenic bacteria from the wastewater, including A. baumannii, and is promising as a disinfectant material in a bead filter system.</style></abstract><notes><style face="normal" font="default" size="100%">Ivankovic, Tomislav&#xD;Dikic, Jelena&#xD;du Roscoat, Sabine Rolland&#xD;Dekic, Svjetlana&#xD;Hrenovic, Jasna&#xD;Ganjto, Marin&#xD;Journal Article&#xD;England&#xD;Water Sci Technol. 2019 Sep;80(6):1085-1098. doi: 10.2166/wst.2019.348.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">wst_2019_348</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2166/wst.2019.348</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brabin, L.</style></author><author><style face="normal" font="default" size="100%">Gogate, A.</style></author><author><style face="normal" font="default" size="100%">Gogate, S.</style></author><author><style face="normal" font="default" size="100%">Karande, A.</style></author><author><style face="normal" font="default" size="100%">Khanna, R.</style></author><author><style face="normal" font="default" size="100%">Dollimore, N.</style></author><author><style face="normal" font="default" size="100%">de Koning, K.</style></author><author><style face="normal" font="default" size="100%">Nicholas, S.</style></author><author><style face="normal" font="default" size="100%">Hart, C. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Liverpool School of Tropical Medicine, England.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reproductive tract infections, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India</style></title><secondary-title><style face="normal" font="default" size="100%">Bull World Health Organ</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bull World Health Organ</style></full-title></periodical><pages><style face="normal" font="default" size="100%">277-87</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">1998/09/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections/*epidemiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">India/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infections/*epidemiology/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Infertility/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/*microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">*Acquired Immunodeficiency Syndrome--women</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">*Case Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Hiv Infections--women</style></keyword><keyword><style face="normal" font="default" size="100%">India</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Infertility--women</style></keyword><keyword><style face="normal" font="default" size="100%">Measurement</style></keyword><keyword><style face="normal" font="default" size="100%">*Pelvic Inflammatory Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Reproduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Reproductive Tract Infections--women</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Report</style></keyword><keyword><style face="normal" font="default" size="100%">*Sexually Transmitted Diseases--women</style></keyword><keyword><style face="normal" font="default" size="100%">Southern Asia</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Viral Diseases</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><isbn><style face="normal" font="default" size="100%">0042-9686 (Print)&#xD;0042-9686</style></isbn><accession-num><style face="normal" font="default" size="100%">9744248</style></accession-num><abstract><style face="normal" font="default" size="100%">Reported are the prevalence of reproductive tract infections and their contribution to pelvic inflammatory disease (PID), as well as the seroprevalence of human immunodeficiency virus (HIV), among women living in three inner city wards of Mumbai, India. Women aged &lt; or = 35 years were recruited and screened as cases if they had been admitted to hospital for gynaecological investigation for suspected PID (n = 151) or infertility (n = 295); controls were healthy fertile women attending for laparoscopic tubal ligation (n = 2433). The women were mainly of low socioeconomic status. A total of 59.4% were migrants and 14.9% of these came to Mumbai to seek treatment. Cases reported a history of adverse pregnancy outcomes significantly more often than controls, and 30.5% of suspected PID cases had previously undergone laparoscopic tubal ligation. At examination 24.2% of cases and 8.4% of controls had a vaginal discharge. Pelvic infection was confirmed in 42.0% of suspected PID cases and 14.6% of infertile cases for whom diagnostic laparoscopy was performed. The prevalence of sexually transmitted diseases was low: Chlamydia trachomatis was found in 0.2%; and Neisseria gonorrhoeae was cultured from the cervix in only four cases. Neither of these infections was detected in laparoscopic aspirates. The prevalence of HIV1/2 infections in unlinked samples was 1.9%. Sexually transmitted diseases were not major factors leading to gynaecological morbidity. Heterosexual spread of HIV infection to this population of married women is still relatively low but needs to be carefully monitored. The gynaecological morbidity detected may be a consequence of widespread use of invasive methods of fertility regulation.&#xD;A case-control study conducted in 1993-95 among women 35 years of age and younger living in three inner-city wards of Mumbai, India, investigated the prevalence of reproductive tract infections and their contribution to pelvic infection. Enrolled as cases were 151 women admitted to the hospital with suspected pelvic inflammatory disease (PID) and 295 infertile women; 2433 healthy fertile women undergoing laparoscopic tubal ligation served as controls. Adverse pregnancy outcomes were reported significantly more often by cases than controls. 31.8% of suspected PID cases, 9.1% of infertile women, and 53.1% of tubal ligation patients reported ever-use of a contraceptive method, primarily a copper IUD. At examination, 24.2% of cases and 8.4% of controls had a vaginal discharge. Pelvic infection was confirmed in 42.0% of suspected PID cases and in 14.6% of infertile women in whom diagnostic laparoscopy was performed. HIV prevalence was 1.9% in unlinked samples. The prevalence of other sexually transmitted diseases (STDs) was under 1%. The gynecologic morbidity recorded in this study is presumed to be a result of widespread use of invasive methods of fertility regulation, not STDs.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Brabin, L&#xD;Gogate, A&#xD;Gogate, S&#xD;Karande, A&#xD;Khanna, R&#xD;Dollimore, N&#xD;de Koning, K&#xD;Nicholas, S&#xD;Hart, C A&#xD;Journal Article&#xD;Switzerland&#xD;Bull World Health Organ. 1998;76(3):277-87.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC2305716</style></custom2><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">93</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luca, E.</style></author><author><style face="normal" font="default" size="100%">Crivoi, F.</style></author><author><style face="normal" font="default" size="100%">Gales, C.</style></author><author><style face="normal" font="default" size="100%">Popescu, E.</style></author><author><style face="normal" font="default" size="100%">Ciubotariu, D.</style></author><author><style face="normal" font="default" size="100%">Nechifor, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Dental Medicine, Department of Protetics, University of Medicine and Pharmacy &quot;Gr. T. Popa&quot; Iasi.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Research on serum and saliva concentration of some bivalent cations in patient with suppurations of the oro-maxillo-facial area</style></title><secondary-title><style face="normal" font="default" size="100%">Rev Med Chir Soc Med Nat Iasi</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Rev Med Chir Soc Med Nat Iasi</style></full-title></periodical><pages><style face="normal" font="default" size="100%">899-903</style></pages><volume><style face="normal" font="default" size="100%">113</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2010/03/03</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Calcium/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Cations, Divalent/blood/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Face/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Manganese/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Maxillary Diseases/blood/*metabolism/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Mouth Diseases/blood/*metabolism/microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Saliva/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Suppuration/blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/blood/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0048-7848 (Print)&#xD;0048-7848</style></isbn><accession-num><style face="normal" font="default" size="100%">20191852</style></accession-num><abstract><style face="normal" font="default" size="100%">UNLABELLED: Bivalent cations, such as calcium, magnesium, zinc, copper and manganese play important roles in some physiological and pathological processes on the human body. AIM: To determine possible modifications in serum and saliva concentration of total-Ca2+, total-Mg2+, Zn2+ and Cu2+ in patients with suppurative infections of the oro-maxillo-facial area and eventually their significance for the mentioned pathology. MATERIAL AND METHOD: Study included 47 patients with suppurative infections of the oro-maxillo-facial area, hospitalised during 2006-2008 in the oro-maxillo-facial clinic of &quot;Sfantul Spiridon&quot; Hospital Iasi and 43 healthy control volunteers. RESULTS: Results revealed decreased serum Zn2+ (0.94 +/- 0.21 vs. 1.39 +/- 0.14 mg/L, p &lt; 0.01), decreased serum Zn2+/Cu2+ ratio and increased serum and saliva total-Mg2+ concentration (27.34 +/- 2.61 mg/mL in patients vs. 23.83 +/- 1.61 mg/L in healthy controls- serum, p &lt; 0.05 and 3.79 +/- 0.41 mg/mL in patients vs. 3.21 +/- 0.40 mg/mL in healthy controls - saliva, p &lt; 0.05) in patients with suppurative infections of the oro-maxillo-facial area vs. healthy controls. There were no statistically significant differences in total-Ca2+ concentrations in saliva and serum. Our data are in agreement with medical literature revealing zinc deficiency as a predisposition factor to infection. CONCLUSION: We consider that a significant increase in total-Mg2+ saliva concentration, as well as a decrease in Zn2+/Cu2+ serum ratio could be considered a marker for predisposition to oro-maxillar suppurations.</style></abstract><notes><style face="normal" font="default" size="100%">Luca, Elena&#xD;Crivoi, Florina&#xD;Gales, Cristina&#xD;Popescu, Eugenia&#xD;Ciubotariu, Diana&#xD;Nechifor, M&#xD;Journal Article&#xD;Romania&#xD;Rev Med Chir Soc Med Nat Iasi. 2009 Jul-Sep;113(3):899-903.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jablonska-Kaszewska, I.</style></author><author><style face="normal" font="default" size="100%">Drobinska-Jurowiecka, A.</style></author><author><style face="normal" font="default" size="100%">Dabrowska, E.</style></author><author><style face="normal" font="default" size="100%">Trocha, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Diseases, Endocrinology and Hemostatic Disorders, Medical University of Gdansk, Gdansk, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Results of treatment of Wilson&apos;s disease--own observations</style></title><secondary-title><style face="normal" font="default" size="100%">Med Sci Monit</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Med Sci Monit</style></full-title></periodical><pages><style face="normal" font="default" size="100%">9-14</style></pages><volume><style face="normal" font="default" size="100%">9 Suppl 3</style></volume><edition><style face="normal" font="default" size="100%">2004/05/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatolenticular Degeneration/*drug therapy/physiopathology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Penicillamine/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1234-1010 (Print)&#xD;1234-1010</style></isbn><accession-num><style face="normal" font="default" size="100%">15156603</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Causative treatment of genetically determined Wilson&apos;s disease (WD) has been impossible so far, although gene therapy could be real in the future. Nowadays the principle of treatment is the elimination of the excess of easily mobilized copper, bound by chelating agents, the most important of which is d-penicillamine, through the kidneys. Blocking of the intestinal absorption of copper by administration of zinc preparations, which additionally induce hepatic metallothionein synthesis, is also possible. The aim of our study was to present own observations and results of treatment of Wilson&apos;s disease. MATERIAL/METHODS: During the last 16 years, we have observed 33 patients aged 13-60 (mean age 27 years) with various forms of WD. The studied group consisted of 11 females and 21 males, admitted to hospital or seen at the Specialistic Outpatient Department of Hepatology with various diagnoses. In addition to standard laboratory tests, the levels of ceruloplasmin, serum and urine copper, as well as the activity of some hepatic enzymes, proteins and HBV/HCV infection markers were determined. The patients were also examined by a neurologist and an ophthalmologist, with psychiatric consultation if necessary. Taking into account the overall clinical presentation, the patients were divided into the following groups according to the form of the disease: fulminant, acute, hepatic, hepatic with neurological and psychiatric symptoms, neuropsychiatric, asymptomatic. RESULTS: All the patients were initially treated with d-penicillamine. In most of them, no side effects were observed. The treatment was continued according to the levels of copper excreted with urine (for 10 years at the longest). After obtaining clinical improvement with reduced amount of copper excreted with 24-h urine, we tapered d-penicillamine doses or even discontinued the drug, introducing zinc preparations. In asymptomatic carriers, zinc preparations were used throughout the period of treatment. CONCLUSIONS: Early institution of chelation treatment is associated with good prognosis both in hepatic and neurological forms of WD. Zinc preparations are effective and safe in neurological and oligosymptomatic forms of the disease.</style></abstract><notes><style face="normal" font="default" size="100%">Jablonska-Kaszewska, Irena&#xD;Drobinska-Jurowiecka, Anna&#xD;Dabrowska, Ewa&#xD;Trocha, Hanna&#xD;Journal Article&#xD;United States&#xD;Med Sci Monit. 2003 Aug;9 Suppl 3:9-14.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Caddell, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Thomas Jefferson University Department of Pediatrics, Philadelphia, PA 19107-6799, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A review of evidence for a role of magnesium and possibly copper deficiency in necrotizing enterocolitis</style></title><secondary-title><style face="normal" font="default" size="100%">Magnes Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Magnes Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">55-66</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1996/03/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/blood/*deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis, Pseudomembranous/epidemiology/*etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Free Radicals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature, Diseases/epidemiology/*etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Intestines/*physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Magnesium Deficiency/blood/complications/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/physiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1996</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0953-1424 (Print)&#xD;0953-1424</style></isbn><accession-num><style face="normal" font="default" size="100%">8819095</style></accession-num><abstract><style face="normal" font="default" size="100%">Necrotizing enterocolitis (NEC) is a neonatal disorder of unknown cause characterized by rapid necrosis of the bowel, primarily the ileum and colon. It is a worldwide problem. NEC is the most common gastrointestinal emergency in the neonatal intensive care unit, and ranks second as a cause of neonatal death. The incidence of NEC is inversely proportional to the birth weight and the degree of maturity. Infants born at or before 28 weeks gestational age have not received 80 per cent of the magnesium and 67 per cent of the copper found at term. Congenital deficiencies of these essential minerals may be compounded by high renal or gastrointestinal losses and high metabolic demand during the preterm infant&apos;s accelerated growth. Platelet thrombi appear early in the intestinal microvasculature in NEC. Platelet thrombosis and release of vasoconstrictor, platelet aggregating thromboxane A2 (TXA2) in human NEC appears to potentiate the intestinal ischaemia and necrosis in neonates who develop NEC. Magnesium and copper deficiency each enhance the synthesis of TXA2. Plasma levels of the inflammatory cytokines tumour necrosis factor (TNF) and interleukin-6 (IL-6) are increased in NEC and in magnesium deficiency; these experimentally produce shock and tissue injury, especially of the intestine. The synthesis of the potent vasoconstrictor endothelin is increased in magnesium deficiency. NEC has been regarded as a luminal insult that causes local generation of destructive oxygen free radicals. Tissues from animals deficient in magnesium are more susceptible to oxidative injury and lipid peroxidation than tissues from normal animals. Magnesium and copper deficiency impair antioxidant defence through decreased synthesis of glutathione and reduced activity of Cu/Zn superoxide dismutase, respectively. Although the aetiology of NEC is unknown, there appears to be sufficient data to implicate magnesium and possibly copper deficiencies in the pathogenesis. Consequences of deficiency of one or both minerals may include increased synthesis or activity of injurious mediators: IL-1, IL-6, TNF, TXA2, endothelin, and oxygen free radicals. A prospective trial of magnesium supplementation, but not copper supplementation, in very premature neonates can be recommended, with NEC as one of the outcome measures.</style></abstract><notes><style face="normal" font="default" size="100%">Caddell, J L&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;Magnes Res. 1996 Mar;9(1):55-66.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>438</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">438</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heyland, D. K.</style></author><author><style face="normal" font="default" size="100%">Jones, N.</style></author><author><style face="normal" font="default" size="100%">Cvijanovich, N. Z.</style></author><author><style face="normal" font="default" size="100%">Wong, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D. K. Heyland, Department of Medicine, Queen&apos;s University, Kingston, ON K7L 2V7, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Review: Zinc supplementation in critically ill patients: A key pharmaconutrient?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Parenteral and Enteral Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Parenteral and Enteral Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">509-519</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">gluconate zinc</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">transcription factor</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">zinc sulfate</style></keyword><keyword><style face="normal" font="default" size="100%">acute gastroenteritis</style></keyword><keyword><style face="normal" font="default" size="100%">acute pancreatitis</style></keyword><keyword><style face="normal" font="default" size="100%">acute phase response</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">burn</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">confidence interval</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill patient</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">fever</style></keyword><keyword><style face="normal" font="default" size="100%">glucose homeostasis</style></keyword><keyword><style face="normal" font="default" size="100%">head injury</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune system</style></keyword><keyword><style face="normal" font="default" size="100%">immunity</style></keyword><keyword><style face="normal" font="default" size="100%">immunology</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">kidney failure</style></keyword><keyword><style face="normal" font="default" size="100%">length of stay</style></keyword><keyword><style face="normal" font="default" size="100%">lethargy</style></keyword><keyword><style face="normal" font="default" size="100%">medical research</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">myalgia</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">vomiting</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><isbn><style face="normal" font="default" size="100%">0148-6071</style></isbn><abstract><style face="normal" font="default" size="100%">The purpose of the present paper is to provide a rationale for zinc supplementation as a potential therapeutic agent in critically ill patients by describing its role in health and disease, conducting a systematic review of current randomized trials in critical care, considering optimum route and dose of administration, and making recommendations for future research. Normal zinc homeostasis is required for a functional immune system, adequate antioxidant capacity, glucose homeostasis, and wound healing. In addition, zinc is a required cofactor for many enzymes, transcription factors, and replication factors. In non-critically ill patients, zinc supplementation has been associated with an improvement in markers of immune function. In critically ill patients, only 4 randomized trials have examined the effect of zinc supplementation on clinical outcomes. When all 4 studies were aggregated, zinc supplementation was associated with a nonsignificant reduction in mortality (relative risk = 0.63, 95% confidence intervals 0.25-1.59, P =.33) and length of stay in intensive care (-0.35 days, -0.85 to 0.15; P =.17). Thus, because of the paucity of clinical data, there is inadequate evidence to recommend the routine use of high-dose zinc supplementation in the critically ill. A first step would be to determine the optimal dose that has a maximal positive effect on underlying inflammatory, immunologic, and metabolic processes yet is safe and tolerated by critically ill patients. Subsequently, large, rigorously designed, randomized trials are required to elucidate the efficacy of such doses of zinc supplementation in this patient population. © 2008 American Society for Parenteral and Enteral Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">L352208923&#xD;2008-09-18</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L352208923</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1177/0148607108322402</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">18669902</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/0148607108322402</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiang, X.</style></author><author><style face="normal" font="default" size="100%">Zhang, Q.</style></author><author><style face="normal" font="default" size="100%">Zhang, Z.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gastroenterology, Peking University People&apos;s Hospital, Beijing 100044, China.&#xD;Email: liuyulan@pkuph.edu.cn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[The risks of long-term proton pump inhibitors use]</style></title><secondary-title><style face="normal" font="default" size="100%">Zhonghua Yi Xue Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zhonghua Yi Xue Za Zhi</style></full-title></periodical><pages><style face="normal" font="default" size="100%">284-8</style></pages><volume><style face="normal" font="default" size="100%">94</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">2014/04/16</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Bone Density</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrins/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Hemoglobins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Proton Pump Inhibitors/*administration &amp; dosage/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin B 12/blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0376-2491 (Print)&#xD;0376-2491</style></isbn><accession-num><style face="normal" font="default" size="100%">24731496</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To explore the risks of long-term proton pump inhibitors (PPI) use. METHODS: A total of 79 study subjects were selected from patients seeking health care at outpatient gastroenterology clinic at Peking University People&apos;s Hospital during January 2011 to June 2013. Long-term PPI use was defined as taking PPI for at least one year. They were divided into study (n = 79) and control (n = 47) groups after matching for age and gender. The study group had 43 females and 36 males with an average age of (63 +/- 10) years. And the control group had 28 females and 19 males with an average age of (63 +/- 9) years. Data collected were demographic characteristics, clinical diagnosis, detailed dosing information of PPI. serum hemochrome, serum gastrin, vitamin B(12), serum iron, magnesium, calcium, copper, zinc, bone density of hip joint and lumbar vertebra L(1-4). Statistic analysis was performed with SPSS software (t and chi(2) test). RESULTS: The medium duration of PPI use was 3.07(1-15) years. Daily usage was a full or half amount of pharmaceutical directed dosage. Questionnaires regarding appetite, defecation, infection, otalgia change in long-term PPI use indicated:among them, 77(97.5%) cases had no appetite change and 2 (2.5%) improved. And 73 cases (92.4%) had no change or 2 cases improved (2.5%) in bowel movements habits while another 4 cases (5.1%) changed into loose stools. Lung or intestinal infection was not found. No case had an onset of otalgia related with PPI intake. Among PPI users, 14 cases (17.7%) appeared to have gastric polyps. T value of total bone density of hip and inter-hip was -0.93 +/- 1.04 and -0.61 +/- 0.91 respectively in the study group. And both were lower than those in the control group (-0.44 +/- 1.12, -0.19 +/- 0.94; t = -2.49, -2.35; P = 0.014, 0.021). No statistical differences existed in T value of neck of hip, as well as total T value and T value of each L(1-4) between study and control groups (all P &gt; 0.05). Higher serum Mg compared to control group ((1.03 +/- 0.08) vs (0.97 +/- 0.07) mmol/L, t = 4.13, P = 0.000). No difference of serum calcium, copper, iron, zinc, vitamin B(12), folic acid and Hb,MCV,MCH between study and control groups (all P &gt; 0.05). Higher serum gastrin versus normal range and controls were found in the study group ((108 +/- 28) vs 100 vs (79 +/- 26) ng/L, t = 2.56, 5.78; both P &lt; 0.05). Taking manual routine dosage have higher hip and lumbar osteoporosis than half-dosage, and bone density decreased and normal bone density ratios are lower(all P &lt; 0.05). CONCLUSIONS: Long-term use of PPI with small or average dosage may slightly decrease hip density and increase serum gastrin. However, there is little effect on vitamin B(12) and minerals.</style></abstract><notes><style face="normal" font="default" size="100%">Jiang, Xuan&#xD;Zhang, Qingwen&#xD;Zhang, Zhenyu&#xD;Liu, Yulan&#xD;English Abstract&#xD;Journal Article&#xD;China&#xD;Zhonghua Yi Xue Za Zhi. 2014 Jan 28;94(4):284-8.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">chi</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">96</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casey, A. L.</style></author><author><style face="normal" font="default" size="100%">Adams, D.</style></author><author><style face="normal" font="default" size="100%">Karpanen, T. J.</style></author><author><style face="normal" font="default" size="100%">Lambert, P. A.</style></author><author><style face="normal" font="default" size="100%">Cookson, B. D.</style></author><author><style face="normal" font="default" size="100%">Nightingale, P.</style></author><author><style face="normal" font="default" size="100%">Miruszenko, L.</style></author><author><style face="normal" font="default" size="100%">Shillam, R.</style></author><author><style face="normal" font="default" size="100%">Christian, P.</style></author><author><style face="normal" font="default" size="100%">Elliott, T. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Hospitals Birmingham NHS Foundation Trust, The Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of copper in reducing hospital environment contamination</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">72-7</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2009/11/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria, Aerobic/*drug effects/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">19931938</style></accession-num><abstract><style face="normal" font="default" size="100%">The environment may act as a reservoir for pathogens that cause healthcare-associated infections (HCAIs). Approaches to reducing environmental microbial contamination in addition to cleaning are thus worthy of consideration. Copper is well recognised as having antimicrobial activity but this property has not been applied to the clinical setting. We explored its use in a novel cross-over study on an acute medical ward. A toilet seat, set of tap handles and a ward entrance door push plate each containing copper were sampled for the presence of micro-organisms and compared to equivalent standard, non-copper-containing items on the same ward. Items were sampled once weekly for 10 weeks at 07:00 and 17:00. After five weeks, the copper-containing and non-copper-containing items were interchanged. The total aerobic microbial counts per cm(2) including the presence of &apos;indicator micro-organisms&apos; were determined. Median numbers of microorganisms harboured by the copper-containing items were between 90% and 100% lower than their control equivalents at both 07:00 and 17:00. This reached statistical significance for each item with one exception. Based on the median total aerobic cfu counts from the study period, five out of ten control sample points and zero out of ten copper points failed proposed benchmark values of a total aerobic count of &lt;5cfu/cm(2). All indicator micro-organisms were only isolated from control items with the exception of one item during one week. The use of copper-containing materials for surfaces in the hospital environment may therefore be a valuable adjunct for the prevention of HCAIs and requires further evaluation.</style></abstract><notes><style face="normal" font="default" size="100%">1532-2939&#xD;Casey, A L&#xD;Adams, D&#xD;Karpanen, T J&#xD;Lambert, P A&#xD;Cookson, B D&#xD;Nightingale, P&#xD;Miruszenko, L&#xD;Shillam, R&#xD;Christian, P&#xD;Elliott, T S J&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2010 Jan;74(1):72-7. doi: 10.1016/j.jhin.2009.08.018. Epub 2009 Nov 20.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2009.08.018</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fidancı, İ</style></author><author><style face="normal" font="default" size="100%">Arıkan, F. İ</style></author><author><style face="normal" font="default" size="100%">Bilge, Y. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">İ. Fidancı, Ankara Eğitim Araştırma Hastanesi, Pediatri Bölümü, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of the micronutrients; Vitamin A, Vitamin B12, Iron, Zinc, Copper levels of children with lower respiratory tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Cocuk Enfeksiyon Dergisi</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cocuk Enfeksiyon Dergisi</style></full-title></periodical><pages><style face="normal" font="default" size="100%">105-109</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">C reactive protein</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">child hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">childhood mortality</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">crackle</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infant</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">lower respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">preschool child</style></keyword><keyword><style face="normal" font="default" size="100%">tachypnea</style></keyword><keyword><style face="normal" font="default" size="100%">wheezing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1308-5271&#xD;1307-1068</style></isbn><abstract><style face="normal" font="default" size="100%">Objective: Lower respiratory tract infection is common in children younger than 5 years and is the leading infection cause of childhood mortality and hospitalization. Deficiencies in vitamin A, zinc (ZN), copper (Cu), iron (Fe), and micronutrients, such as vitamin B12, are thought to be causes of respiratory tract infections as a trigger. We aimed to detect levels of the micronutrients vitamin A, Zn, Cu, Fe, and vitamin B12 in children with lower respiratory tract infections. Material and Methods: A total of 98 patients between 1 month and 5 years of age with a diagnosis of lower respiratory tract infection were enrolled between February 2011-2012 at Ankara Eğitim ve Araştırma Hospital, Clinic of Child Health and Diseases. The control group included 47 healthy children with the same age who did not have any pathologic findings and history of chronic diseases. In these patients, the clinical and radiological findings of acute phase reactants, vitamin A, vitamin B12, Zn, Cu, and Fe levels were studied, and the groups were compared. Results: Of the patients in the study, 63 (64.3%) were men and 35 (35.7%) were females; mean age was 21.4 (±17.6) (1-60) months. The most common findings on physical examination were tachypnea in 85 (86.7%), cracles 73 (74.5%), and rhonchi 59 (60.2%), respectively. White blood cell (WBC) (p=0.001), sedimentation (Sed) (p&lt;0.001), and CRP (p=0.010) levels were significantly higher in the patient group. Vitamin A levels in all patients (p=0.001) and Fe levels (p=0.001) were found to be significantly lower than the control group. Zn level was lower in the patient group than in the control group but was not statistically significant. C and vitamin B12 levels in terms of the difference between groups was detected. Conclusion: In patients with lower respiratory tract infection, vitamin A, Zn, and Fe levels were lower. In patients diagnosed with lower respiratory tract infections vitamin A and Zn supplementation is recommended. Fe is recommended to prevent lower respiratory tract infections.</style></abstract><notes><style face="normal" font="default" size="100%">L604537206&#xD;2015-06-02</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L604537206</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.5152/ced.2014.1319</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5152/ced.2014.1319</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">Turkish</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>469</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">469</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berger, M. M.</style></author><author><style face="normal" font="default" size="100%">Shenkin, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M.M. Berger, Surgical ICU and Burns Centre, CHUV-BH 08.660, CH 1011 Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of trace elements and other antioxidants in the critically ill</style></title><secondary-title><style face="normal" font="default" size="100%">Care of the Critically Ill</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Care of the Critically Ill</style></full-title></periodical><pages><style face="normal" font="default" size="100%">120-125</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetylcysteine</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">free radical</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">reactive oxygen metabolite</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">aerobic metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">brain injury</style></keyword><keyword><style face="normal" font="default" size="100%">burn</style></keyword><keyword><style face="normal" font="default" size="100%">cell function</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">critical illness</style></keyword><keyword><style face="normal" font="default" size="100%">drug absorption</style></keyword><keyword><style face="normal" font="default" size="100%">drug bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">drug effect</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">immunity</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory disease</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">metabolic regulation</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nutrient supply</style></keyword><keyword><style face="normal" font="default" size="100%">organ injury</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">tissues</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">wound healing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><isbn><style face="normal" font="default" size="100%">0266-0970</style></isbn><abstract><style face="normal" font="default" size="100%">Trace elements (TE) and vitamins have many functions which make them particularly important in the critically ill. The non-nutritional antioxidant effects now appear at least as important as the previously known activities in metabolic pathways, since these impact not only the function of cells, but also on tissue and organ systems, especially immune function. Vitamins contribute to the antioxidant defences. Reactive oxygen species (ROS) production belongs to aerobic metabolism: their dissemination through the tissues and their disposal is controlled under normal circumstances by endogenous antioxidants including vitamins (A, E, C) and enzyme systems containing trace elements (copper, manganese, selenium, and zinc). During the inflammatory response with characterises critical illness, free radical production increases and may overwhelm the endogenous antioxidant defences, creating an unbalance, called oxidative stress. Clinical trials in brain injury, burns, trauma, inflammatory and septic patients have investigated the impact of early micronutrient supplementation (selenium, vitamin C, and vitamin E), on the inflammatory and immune responses in acute conditions. The doses have ranged between 5-20 times the actual recommendations. Significant improvements have been shown: reduction of organ failure and of infectious complications, improvement of neurological outcome and wound healing, reduction of ICU stay, and reduction of mortality. Considering this evidence, patients with an intense inflammatory response may benefit from early supplementation, as well as those who have demonstrable large micronutrient losses, and organ failure.</style></abstract><notes><style face="normal" font="default" size="100%">L36958069&#xD;2003-08-18</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L36958069</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>389</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">389</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burjonrappa, S. C.</style></author><author><style face="normal" font="default" size="100%">Miller, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.C. Burjonrappa, Department of Nutrition and Pediatrics, Maimonides Infants and Children&apos;s Hospital, Brooklyn, NY 11219, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of trace elements in parenteral nutrition support of the surgical neonate</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pediatric Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pediatric Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">760-771</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">chromium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">molybdenum</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">diet supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">lung dysplasia</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">necrotizing enterocolitis</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">parenteral nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">pediatric surgery</style></keyword><keyword><style face="normal" font="default" size="100%">physiology</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">surgical technique</style></keyword><keyword><style face="normal" font="default" size="100%">toxicity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0022-3468&#xD;1531-5037</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Parenteral nutrition (PN) has transformed the outcome for neonates with surgical problems in the intensive care unit. Trace element supplementation in PN is a standard practice in many neonatal intensive care units. However, many of these elements are contaminants in PN solutions, and contamination levels may, in themselves, be sufficient for normal metabolic needs. Additional supplementation may actually lead to toxicity in neonates whose requirements are small. Methods: An electronic search of the MEDLINE, Cochrane Collaboration, and SCOPUS English language medical databases was performed for the key words &quot;trace elements,&quot; &quot;micro-nutrients, &quot; and &quot;parenteral nutrition additives.&quot; Studies were categorized based on levels of evidence offered, with randomized controlled trials and meta-analyses accorded the greatest importance at the apex of the data pool and case reports and animal experiments the least importance. Articles were reviewed with the primary goal of developing uniform recommendations for trace element supplementation in the surgical neonate. The secondary goals were to review the physiologic role, metabolic demands, requirements, losses, deficiency syndromes, and toxicity symptoms associated with zinc, copper, chromium, selenium, manganese, and molybdenum supplementation in PN. Results: Zinc supplementation must begin at initiation of PN. All other trace elements can be added to PN 2 to 4 weeks after initiation. Copper and manganese need to be withheld if the neonate develops PN-associated liver disease. The status of chromium supplementation is currently being actively debated, with contaminant levels in PN being sufficient in most cases to meet neonatal requirements. Selenium is an important component of antioxidant enzymes with a role in the pathogenesis of neonatal surgical conditions such as necrotizing enterocolitis and bronchopulmonary dysplasia. Premature infants are often selenium deficient, and early supplementation has shown a reduction in sepsis events in this age group. Conclusion: Appropriate supplementation of trace elements in surgical infants is important, and levels should be monitored. In certain settings, it may be more appropriate to individualize trace element supplementation based on the predetermined physiologic need rather than using bundled packages of trace elements as is the current norm. Balance studies of trace element requirements should be performed to better establish clinical recommendations for optimal trace element dosing in the neonatal surgical population. © 2012 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">L364621871&#xD;2012-04-23&#xD;2012-04-25</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L364621871</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.jpedsurg.2012.01.015</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">22498394</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jpedsurg.2012.01.015</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>331</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">331</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leuck, A. M.</style></author><author><style face="normal" font="default" size="100%">Johnson, J. R.</style></author><author><style face="normal" font="default" size="100%">Hunt, M. A.</style></author><author><style face="normal" font="default" size="100%">Dhody, K.</style></author><author><style face="normal" font="default" size="100%">Kazempour, K.</style></author><author><style face="normal" font="default" size="100%">Ferrieri, P.</style></author><author><style face="normal" font="default" size="100%">Kline, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.-M. Leuck, D-416 Mayo Building, MMC 250, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety and efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-associated bacteriuria: A pilot randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">260-265</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">antimicrobial urinary catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Foley balloon catheter</style></keyword><keyword><style face="normal" font="default" size="100%">silver impregnated urinary catheter</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">polyurethan</style></keyword><keyword><style face="normal" font="default" size="100%">silicone</style></keyword><keyword><style face="normal" font="default" size="100%">silver</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">catheter associated bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">catheter infection</style></keyword><keyword><style face="normal" font="default" size="100%">catheter removal</style></keyword><keyword><style face="normal" font="default" size="100%">clinical effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">coagulase negative Staphylococcus</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">device safety</style></keyword><keyword><style face="normal" font="default" size="100%">dysuria</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">oliguria</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">surgical patient</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urine retention</style></keyword><keyword><style face="normal" font="default" size="100%">urine volume</style></keyword><keyword><style face="normal" font="default" size="100%">LUBRI SIL I.C.</style></keyword><keyword><style face="normal" font="default" size="100%">TIC Foley system</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1527-3296&#xD;0196-6553</style></isbn><abstract><style face="normal" font="default" size="100%">Background: The purpose of this study was to evaluate the safety of a novel silver-impregnated Foley catheter system designed to prevent catheter-associated bacteriuria and funguria, assess recruitment feasibility for a future pivotal trial, and preliminarily assess efficacy. Methods: This single-center, randomized controlled trial at a university hospital involved adult neurosurgical patients expected to have a urinary catheter for ≥24 hours. Subjects were randomized to a novel silver-impregnated (test) Foley catheter system or a control system. They were followed for 30 days (or until discharge) while catheterized and for up to 48 hours after catheter removal, with daily bacteriuria testing and assessment for symptoms of infection and catheter intolerance. Results: Ninety-five subjects were randomized (intention-to-treat [ITT] population). Of these, 61 subjects (64%) had a catheter for ≥24 hours without perioperative antibiotics beyond 24 hours (evaluable population). In the ITT population, 11 of 95 (12%) subjects had an asymptomatic bacteriuria (ABU) event. Compared with controls, test system recipients had a trend toward longer time to ABU in the ITT population (P =.08, log-rank test) and a longer time to ABU in the evaluable population (P =.03). All 6 ABU events caused by gram-negative bacilli occurred in the control group. Conclusion: In this pilot randomized trial the test system was well tolerated and seemingly effective in preventing catheter-associated bacteriuria, especially with gram-negative bacilli. A pivotal study is warranted.</style></abstract><notes><style face="normal" font="default" size="100%">L602562838&#xD;2015-03-04&#xD;2015-03-10</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L602562838</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2014.11.021</style></url></related-urls></urls><custom3><style face="normal" font="default" size="100%">LUBRI SIL I.C.(Bard,United States)&#xD;TIC Foley system</style></custom3><custom5><style face="normal" font="default" size="100%">25728152</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2014.11.021</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schulze-Robbecke, R.</style></author><author><style face="normal" font="default" size="100%">Jung, K. D.</style></author><author><style face="normal" font="default" size="100%">Pullmann, H.</style></author><author><style face="normal" font="default" size="100%">Hundgeburth, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hygiene-Institut, Universitat Bonn.</style></auth-address><titles><title><style face="normal" font="default" size="100%">[Sanitizing a hospital hot water system contaminated with Legionella pneumophila]</style></title><secondary-title><style face="normal" font="default" size="100%">Zentralbl Hyg Umweltmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zentralbl Hyg Umweltmed</style></full-title></periodical><pages><style face="normal" font="default" size="100%">84-100</style></pages><volume><style face="normal" font="default" size="100%">190</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">1990/05/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Carbon Dioxide/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Hot Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/drug effects/*growth &amp; development/radiation effects</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Ultraviolet Rays</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply/*standards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1990</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><orig-pub><style face="normal" font="default" size="100%">Sanierung eines mit Legionella pneumophila kontaminierten Krankenhaus-Warmwassersystems.</style></orig-pub><isbn><style face="normal" font="default" size="100%">0934-8859 (Print)&#xD;0934-8859</style></isbn><accession-num><style face="normal" font="default" size="100%">2118357</style></accession-num><abstract><style face="normal" font="default" size="100%">A number of measures were taken to control Legionella pneumophila in a hospital hot water system over a period of 18 months, including (i) raising the temperature of the water leaving the central storage tanks from initially 55-60 degrees C to approximately 73 degrees C, (ii) heat shock treatment of the whole system with water temperatures above 70 degrees C and (iii) increasing the daily return flow from the hospital circulation system from initially 30 m3 to 120 m3. In addition, (iv) three UV irradiation devices were installed on the inlet and outlets of the storage tanks and (v) an attempt was made to decontaminate the water system by means of CO2. Measures (i) and (iii) were demonstrated to be effective for permanent control of Legionellae in the system. Measures (ii) and (v) proved to have only a short term effect of several days and measure (iv) did not show any effect on the presence of Legionellae at all. The extent of Legionella contamination of the water samples correlated negatively with water temperature and depended on the position of the outlets within the hospital. Different pipe materials (copper, plastics) could not be shown to have any influence on the extent of water contamination with Legionella. The findings of the survey indicate that especially the peripheral areas of the hot water system were colonized by Legionellae.</style></abstract><notes><style face="normal" font="default" size="100%">Schulze-Robbecke, R&#xD;Jung, K D&#xD;Pullmann, H&#xD;Hundgeburth, J&#xD;English Abstract&#xD;Journal Article&#xD;Germany&#xD;Zentralbl Hyg Umweltmed. 1990 May;190(1-2):84-100.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">ger</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>231</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reihman, A. E.</style></author><author><style face="normal" font="default" size="100%">Bailey, K. E.</style></author><author><style face="normal" font="default" size="100%">Levy, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A.E. Reihman, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Aurora, CO, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sarcoidosis has some nerve</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Respiratory and Critical Care Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Respiratory and Critical Care Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">199</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">antinuclear antibody</style></keyword><keyword><style face="normal" font="default" size="100%">aquaporin 4</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin G</style></keyword><keyword><style face="normal" font="default" size="100%">infliximab</style></keyword><keyword><style face="normal" font="default" size="100%">methotrexate</style></keyword><keyword><style face="normal" font="default" size="100%">oligoclonal band</style></keyword><keyword><style face="normal" font="default" size="100%">steroid</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">cancer patient</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">demyelinating disease</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug megadose</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">endobronchial ultrasonography</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">heart</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human cell</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">lower limb</style></keyword><keyword><style face="normal" font="default" size="100%">lumbar puncture</style></keyword><keyword><style face="normal" font="default" size="100%">lymph node biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">lymphocytosis</style></keyword><keyword><style face="normal" font="default" size="100%">lymphoma</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mediastinoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">mediastinum lymphadenopathy</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">micturition</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">myelitis</style></keyword><keyword><style face="normal" font="default" size="100%">neurosarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient</style></keyword><keyword><style face="normal" font="default" size="100%">paresthesia</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">plasma exchange</style></keyword><keyword><style face="normal" font="default" size="100%">proprioception</style></keyword><keyword><style face="normal" font="default" size="100%">sarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">sensation</style></keyword><keyword><style face="normal" font="default" size="100%">Sjoegren syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">sphincter</style></keyword><keyword><style face="normal" font="default" size="100%">syphilis</style></keyword><keyword><style face="normal" font="default" size="100%">thoracic spinal cord</style></keyword><keyword><style face="normal" font="default" size="100%">thorax</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1535-4970</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Sarcoidosis is a multi-organ autoimmune disease characterized by non-caseating granulomas. The central nervous system (CNS) is involved in 5-15% of cases, with spinal cord involvement occurring in less than 1%. Neurologic dysfunction as the sole initial manifestation of sarcoidosis occurs in 10-17% of cases. Here we present a case of sarcoidosis presenting as longitudinally extensive transverse myelitis (LETM). Case: A 35-year-old male with no medical history presented with two months of progressive bilateral lower extremity paresthesias, difficulty ambulating, and incomplete voiding. Physical exam was notable for decrease in sensation from T10 to S2, decreased lower extremity proprioception, and decreased sphincter tone. He was admitted to the hospital for neurologic evaluation. Spinal MRI showed a heterogeneous enhancing lesion within the thoracic cord at T7-T8 and T3-T4, with longitudinally extensive central cord signal abnormality from T3-T10 consistent with LETM. Evaluation for underlying etiology included normal copper and vitamin B12 levels, negative aquaporin-4-IgG, negative anti-nuclear antibody, and negative HIV and syphilis testing. Lumbar puncture showed a lymphocytosis and elevated protein (27 nucleated cells with 74% lymphocytes, protein 101) with negative oligoclonal bands, normal IgG index, negative infectious studies, and negative cytology. Chest CT showed hilar and mediastinal lymphadenopathy. He underwent endobronchial ultrasound with lymph node biopsy. Pathology revealed non-caseating granulomas. Confirmatory mediastinoscopy with lymph node sampling showed non-caseating granulomas with negative fungal and mycobacterial staining and cultures. Flow cytometry was negative for lymphoma. He was diagnosed with LETM secondary to neurosarcoidosis and was started on high dose steroids. Given poor clinical response, he underwent plasma exchange with symptom improvement and lesion stability on MRI. He was managed as an outpatient with infliximab, methotrexate, and steroid taper. Discussion: LETM is a CNS demyelinating disorder manifesting as inflammation of the spinal cord over greater than 3 vertebral segments. LETM is commonly associated with the autoimmune disorder neuromyelitis opitica, but has also been linked to CNS paraneoplastic disorders, post-infectious phenomenon, Sjogren&apos;s syndrome, and multiple sclerosis. It is a rare initial presentation of sarcoidosis. Distinguishing sarcoidosis from other etiologies of LETM is important given need for early recognition of sarcoidosis&apos; extra-pulmonary manifestations, including ocular and cardiac involvement. Differences in treatment are also significant. Infliximab has been shown to be an effective treatment for sarcoidosis, while worsening CNS demyelinating disease from other etiologies. Neurosarcoidosis should be considered in the differential diagnosis of patients presenting with LETM given differences in long-term management when compared to other demyelinating disorders.</style></abstract><notes><style face="normal" font="default" size="100%">L630355258&#xD;2020-01-01</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L630355258</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">67</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Humphreys, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Microbiology, The Royal College of Surgeons in Ireland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Self-disinfecting and microbiocide-impregnated surfaces and fabrics: what potential in interrupting the spread of healthcare-associated infection?</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">848-53</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2013/11/23</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biofilms</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfectants</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/instrumentation/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Polyethylene Glycols</style></keyword><keyword><style face="normal" font="default" size="100%">Protective Clothing</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">Titanium</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">decontamination and hospital hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">polyethylene glycol</style></keyword><keyword><style face="normal" font="default" size="100%">titanium dioxide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1058-4838</style></isbn><accession-num><style face="normal" font="default" size="100%">24265359</style></accession-num><abstract><style face="normal" font="default" size="100%">Innovative technologies have identified approaches to developing self-disinfecting surfaces or fabrics to minimize healthcare-associated infection (HCAI). These include altering the structure or surface to minimize the attachment of microbes or to delay the development of biofilm, using compounds that are activated in the presence of light to reduce the microbial burden, and incorporating a heavy metal such as silver or copper with intrinsic antimicrobial activity. Most technologies for surfaces and fabrics have been assessed in vitro and have been shown to reduce bacterial numbers by &gt;/=2 logs. However, apart from copper -impregnated surfaces, there have been few trials in a clinical setting. Copper-impregnated surfaces result in reduced microbial surface counts on surfaces commonly found in clinical areas compared with controls, and 1 study has assessed HCAI and colonization rates. However, larger and better-designed studies are required to determine if these approaches augment current hygiene regimens, especially when these are optimally implemented.</style></abstract><notes><style face="normal" font="default" size="100%">1537-6591&#xD;Humphreys, Hilary&#xD;Journal Article&#xD;Review&#xD;United States&#xD;Clin Infect Dis. 2014 Mar;58(6):848-53. doi: 10.1093/cid/cit765. Epub 2013 Nov 21.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/cit765</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, M. G.</style></author><author><style face="normal" font="default" size="100%">Attaway, H. H.</style></author><author><style face="normal" font="default" size="100%">Fairey, S. E.</style></author><author><style face="normal" font="default" size="100%">Howard, J.</style></author><author><style face="normal" font="default" size="100%">Mohr, D.</style></author><author><style face="normal" font="default" size="100%">Craig, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA schmidtm@musc.edu.&#xD;Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.&#xD;Highpoint Health, Lawrenceburg, Indiana, USA.&#xD;Mercy Health West Hospital, Cincinnati, Ohio, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Self-Disinfecting Copper Beds Sustain Terminal Cleaning and Disinfection Effects throughout Patient Care</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></full-title></periodical><volume><style face="normal" font="default" size="100%">86</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/11/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">antimicrobial copper</style></keyword><keyword><style face="normal" font="default" size="100%">environmental services</style></keyword><keyword><style face="normal" font="default" size="100%">health care-associated infections (HAI)</style></keyword><keyword><style face="normal" font="default" size="100%">near patient</style></keyword><keyword><style face="normal" font="default" size="100%">self-disinfecting copper</style></keyword><keyword><style face="normal" font="default" size="100%">terminal cleaning and disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">terminal cleaning and disinfection (TC&amp;D)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0099-2240</style></isbn><accession-num><style face="normal" font="default" size="100%">31704675</style></accession-num><abstract><style face="normal" font="default" size="100%">Microbial burden associated with near-patient touch surfaces results in a greater risk of health care-associated infections (HAIs). Acute care beds may be a critical fomite, as traditional plastic surfaces harbor the highest concentrations of bacteria associated with high-touch surfaces in a hospital room&apos;s patient zone. Five high-touch intensive care unit (ICU) bed surfaces encountered by patients, health care workers, and visitors were monitored by routine culture to assess the effect U.S. Environmental Protection Agency (U.S. EPA)-registered antimicrobial copper materials have on the microbial burden. Despite both daily and discharge cleaning and disinfection, each control bed&apos;s plastic surfaces exceeded bacterial concentrations recommended subsequent to terminal cleaning and disinfection (TC&amp;D) of 2.5 aerobic CFU/cm(2) Beds with self-disinfecting (copper) surfaces harbored significantly fewer bacteria throughout the patient stay than control beds, at levels below those considered to increase the likelihood of HAIs. With adherence to routine daily and terminal cleaning regimes throughout the study, the copper alloy surfaces neither tarnished nor required additional cleaning or special maintenance. Beds encapsulated with U.S. EPA-registered antimicrobial copper materials were found to sustain the microbial burden below the TC&amp;D risk threshold levels throughout the patient stay, suggesting that outfitting acute care beds with such materials may be an important supplement to controlling the concentration of infectious agents and thereby potentially reducing the overall HAI risk.IMPORTANCE Despite cleaning efforts of environmental service teams and substantial compliance with hand hygiene best practices, the microbial burden in patient care settings often exceeds concentrations at which transfer to patients represents a substantial acquisition risk for health care-associated infections (HAIs). Approaches to limit HAI risk have relied on designing health care equipment and furnishings that are easier to clean and/or the use of no-touch disinfection interventions such as germicidal UV irradiation or vapor deposition of hydrogen peroxide. In a clinical trial evaluating the largest fomite in the patient care setting, the bed, a bed was encapsulated with continuously disinfecting antimicrobial copper surfaces, which reduced the bacteria on surfaces by 94% and sustained the microbial burden below the terminal cleaning and disinfection risk threshold throughout the patient&apos;s stay. Such an intervention, which continuously limits microbes on high-touch surfaces, should be studied in a broader range of health care settings to determine its potential long-range efficacy for reducing HAI.</style></abstract><notes><style face="normal" font="default" size="100%">1098-5336&#xD;Schmidt, Michael G&#xD;Attaway, Hubert H&#xD;Fairey, Sarah E&#xD;Howard, Jayna&#xD;Mohr, Denise&#xD;Craig, Stephanie&#xD;Journal Article&#xD;United States&#xD;Appl Environ Microbiol. 2019 Dec 13;86(1). pii: AEM.01886-19. doi: 10.1128/AEM.01886-19. Print 2019 Dec 13.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6912075</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/aem.01886-19</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>368</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">368</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weber, D. J.</style></author><author><style face="normal" font="default" size="100%">Rutala, W. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.J. Weber, Department of Medicine, University of North Carolina, 2163 Bioinformatics, Chapel Hill, NC, 27599-7030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Self-disinfecting surfaces: Review of current methodologies and future prospects</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American journal of infection control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S31-S35</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">5 SUPPL.</style></number><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">quaternary ammonium derivative</style></keyword><keyword><style face="normal" font="default" size="100%">triclosan</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">irradiation</style></keyword><keyword><style face="normal" font="default" size="100%">self disinfecting surface</style></keyword><keyword><style face="normal" font="default" size="100%">silver impregnation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0196-6553&#xD;1527-3296</style></isbn><abstract><style face="normal" font="default" size="100%">Methods to improve disinfection of environmental surfaces in hospital rooms include improving cleaning/disinfection by environmental service workers through education and feedback on cleaning effectiveness (eg, use of fluorescent dyes), &quot;no-touch&quot; methods (eg, UV-C light), and self-disinfecting surfaces. Self-disinfecting surfaces can be created by impregnating or coating surfaces with heavy metals (eg, silver or copper), germicides (eg, triclosan), or miscellaneous methods (eg, light-activated antimicrobials). These methods are under active investigation but to date have not been assessed for their ability to reduce health care-associated infections. Copyright © 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">L368826877&#xD;2013-05-08&#xD;2013-05-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L368826877</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.ajic.2012.12.005</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">23622745</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2012.12.005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>40</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">40</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coppin, J. D.</style></author><author><style face="normal" font="default" size="100%">Villamaria, F. C.</style></author><author><style face="normal" font="default" size="100%">Williams, M. D.</style></author><author><style face="normal" font="default" size="100%">Copeland, L. A.</style></author><author><style face="normal" font="default" size="100%">Zeber, J. E.</style></author><author><style face="normal" font="default" size="100%">Jinadatha, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Research, Central Texas Veterans Healthcare System, Temple, TX.&#xD;Department of Nursing, Central Texas Veterans Health Care System, Temple, TX.&#xD;VA Central Western Massachusetts Healthcare System, Leeds, MA; Center for Applied Health Research, Temple, TX; Department of Medicine, College of Medicine, Texas A&amp;M Health Science Center, Bryan, TX.&#xD;Center for Applied Health Research, Temple, TX; Department of Medicine, College of Medicine, Texas A&amp;M Health Science Center, Bryan, TX; Department of Medicine, Central Texas Veterans Health Care System, Temple, TX.&#xD;Department of Medicine, College of Medicine, Texas A&amp;M Health Science Center, Bryan, TX; Department of Medicine, Central Texas Veterans Health Care System, Temple, TX. Electronic address: chetan.jinadatha@va.gov.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Self-sanitizing copper-impregnated surfaces for bioburden reduction in patient rooms</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">692-694</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2017/02/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biofouling/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Disinfectants</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Patients&apos; Rooms</style></keyword><keyword><style face="normal" font="default" size="100%">*Surface-Active Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Surface disinfection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">28237738</style></accession-num><abstract><style face="normal" font="default" size="100%">Novel self-sanitizing copper oxide-impregnated solid surfaces have the potential to influence bioburden levels, potentially lowering the risk of transmission of pathogens in patient care environments. Our study showed persistently lower microbial burden over a 30-hour sampling period on a copper-impregnated tray table compared with a standard noncopper surface in occupied patient rooms after thorough initial disinfection.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Coppin, John D&#xD;Villamaria, Frank C&#xD;Williams, Marjory D&#xD;Copeland, Laurel A&#xD;Zeber, John E&#xD;Jinadatha, Chetan&#xD;Journal Article&#xD;United States&#xD;Am J Infect Control. 2017 Jun 1;45(6):692-694. doi: 10.1016/j.ajic.2017.01.012. Epub 2017 Feb 22.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2017.01.012</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>261</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hussain, S. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.S. Hussain, National Board of Examination, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">A serendipitous rechallenge of an innocuous drug-a case report of Quetiapine hepatotoxicity Dr. Sameer Sakkeer Hussain∗, Dr. Benoy Sebastian∗∗ ∗junior resident, ∗∗ Consultant, Department of Gastroenterology, Medical trust Hospital, Kochi, Kerala</style></title><secondary-title><style face="normal" font="default" size="100%">Hepatology International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hepatology International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S478-S479</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin glucuronide</style></keyword><keyword><style face="normal" font="default" size="100%">cation</style></keyword><keyword><style face="normal" font="default" size="100%">cytochrome P450 3A4</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B core antibody</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B surface antigen</style></keyword><keyword><style face="normal" font="default" size="100%">immunoglobulin M</style></keyword><keyword><style face="normal" font="default" size="100%">isoenzyme</style></keyword><keyword><style face="normal" font="default" size="100%">lithium</style></keyword><keyword><style face="normal" font="default" size="100%">lorazepam</style></keyword><keyword><style face="normal" font="default" size="100%">procalcitonin</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">unclassified drug</style></keyword><keyword><style face="normal" font="default" size="100%">abdomen</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">anamnesis</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar disorder</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">blood clotting disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Brucella</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">consultation</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug withdrawal</style></keyword><keyword><style face="normal" font="default" size="100%">electrolyte blood level</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme linked immunosorbent assay</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">gastroenterology</style></keyword><keyword><style face="normal" font="default" size="100%">gene rearrangement</style></keyword><keyword><style face="normal" font="default" size="100%">hepatic encephalopathy</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">hypertransaminasemia</style></keyword><keyword><style face="normal" font="default" size="100%">international normalized ratio</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">psychiatrist</style></keyword><keyword><style face="normal" font="default" size="100%">resident</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">Simplexvirus</style></keyword><keyword><style face="normal" font="default" size="100%">trust</style></keyword><keyword><style face="normal" font="default" size="100%">urine culture</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1936-0541</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Introduction We present a case of Quetiapine induced hepatotoxicity; a drug not well known for its hepatotoxicity. The drug was suspected to be the culprit and stopped but the patient unknowingly restarted the medi-cation which acted as a rechallenge and caused hepatitis with mild coagulopathy. Patient recovered uneventfully after withdrawal of drug. Method: Discussion Quetiapine is a dibenzothiazepine, an atypical antipsychotic agent. It is metabolized via the hepatic oxidase system via the cytochrome P4503A4 isoenzyme. Quetiapine is generally considered to be a non hepatotoxic drug. Very limited case reports of Quetiapine induced hepatotoxicity have been described in literature. This case report sheds light to the fact that drugs previously considered safe also are potential causes of DILI. There needs to be a high degree of suspicion for DILI so that the offending drug can be identified and withdrawn causing minimal damage to the patient. Result: Case presentation 34 year old female attended the OP department after complaining of severe fatigue. She was on treatment for bipolar affective disorder with Sodium divalproate, Lithium, Lorazepam and Quetiapine. Her investigations revealed mild transaminitis (SGOT-130 and SGPT-126) with normal bilirubin, alkaline phosphatase and INR levels. Her CBC, RFT, Serum electrolytes, RBS, TFT and USG Abdomen were within normal limits. The following day her transaminitis worsened with SGOT-431, SGPT-422 and INR-1.3(test-16.7, control-14.0). IgMAntiHAV, IgMHEV, Hbsag (ELISA), Total anti HbC, HCV (ELISA) were negative. Non hepatotropic viruses like IgM HSV and EBV were negative as well. Autoimmune workup of ANA, AMA, AntiLKM1 and Anti SM were negative. 24 hour urine copper-17 mcg/d (&lt;50), Serum ceruloplasmin-26.2 mg/d (15-60). Her serum lithium levels was 0.45 mEq/L (0.8-1.2-Therapeutic range) and Ferritin-113 ng/ml. Brucella IgM, Lyme IgM, and Weil felix were negative. Blood and urine cultures showed no growth. Procalcitonin was 1.1([2-Sepsis) A strong suspicion of DILI lead to cessation of anti psychotics in liaison with psychiatrist. Sodium divalproate and lithium were tapered and quetiapine continued along with lorazepam. There was gradual worsening of her LFT&apos;s in spite of the drug rearrangements. Finally after much deliberation Quetiapine was also stopped. This led to improvement in her LFT&apos;s (SGOT-82, SGPT-256). Nine days later she had severe fatigue and a repeat LFT showed the following picture-Total Bilirubin-1.6, Direct bilirubin-0.6, SGOT-1276, SGPT-1258, ALP-182 and INR of 1.4. She had no features of hepatic encephalopathy or bleeding manifestations. On closer scrutiny she revealed she had restarted Quetiapine 6 days back. Quetiapine was withdrawn and she was restarted on Lithium and Sodium divalproate. She improved with standard supportive care and was discharged. Her LFT&apos;s came back to normal over a period of 45 days. Conclusion: Our case report highlights the fact that the drug list causing DILI is ever expanding. Drug review should be an integral part of clinical history taking. Rechallenge had accidentally happened in our case pinpointing to the exact culprit.</style></abstract><notes><style face="normal" font="default" size="100%">L621419524&#xD;2018-04-02</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L621419524</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s12072-018-9852-3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12072-018-9852-3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>136</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Airede, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, University of Maiduguri Teaching Hospital, Borno State, Nigeria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serial copper and ceruloplasmin levels in African newborns with emphasis on the sick and stable preterm infant, and their antioxidant capacities</style></title><secondary-title><style face="normal" font="default" size="100%">Early Hum Dev</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Early Hum Dev</style></full-title></periodical><pages><style face="normal" font="default" size="100%">199-210</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">1998/11/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antioxidants</style></keyword><keyword><style face="normal" font="default" size="100%">Ceruloplasmin/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Enterocolitis, Necrotizing/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Premature/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Nigeria/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory Distress Syndrome, Newborn/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Sepsis/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Africa South Of The Sahara</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Biology</style></keyword><keyword><style face="normal" font="default" size="100%">*Blood Proteins</style></keyword><keyword><style face="normal" font="default" size="100%">Demographic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">English Speaking Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Hemic System</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant</style></keyword><keyword><style face="normal" font="default" size="100%">*Infant, Premature</style></keyword><keyword><style face="normal" font="default" size="100%">Nigeria</style></keyword><keyword><style face="normal" font="default" size="100%">Physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Population</style></keyword><keyword><style face="normal" font="default" size="100%">Population Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Report</style></keyword><keyword><style face="normal" font="default" size="100%">*Serum Copper Level</style></keyword><keyword><style face="normal" font="default" size="100%">Western Africa</style></keyword><keyword><style face="normal" font="default" size="100%">Youth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0378-3782 (Print)&#xD;0378-3782</style></isbn><accession-num><style face="normal" font="default" size="100%">9808071</style></accession-num><abstract><style face="normal" font="default" size="100%">Literature on serum copper (Cu) and its antioxidant protein (ceruloplasmin) in the African newborn is infrequent, and more reports are evident from developed or affluent societies. We, therefore, studied longitudinally our newborns to delineate their Cu and ceruloplasmin (CLP) status. All infants were born between July 1st, 1991 and June 30th, 1992 at the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria. The preterm infants (PI) (gestational age &lt; or = 36 weeks) were divided into 2 cohorts; A, sick and B, stable; commencing with n = 30 in each group. The groups were matched in respect to gender, gestational age, birthweight, Apgar scores and socioeconomic class. Cu levels were contemporaneously also determined in 30 (M:F, 17:13) stable full-term infants (appropriate-for-dates). Cu determination was made with atomic absorption spectrophotometry and CLP according to colorimetric P-phenylenediamine assay. Sick PI (cohort A) had significantly lower mean (SD) Cu and CLP levels at birth; 0.1 (0.2) micromol/ml and 0.5 (0.8) micromol/dl vs 0.6 (0.2) micromol/ml and 12.5 (1.2) micromol/dl in stable PI (cohort B), respectively; P &lt; 0.05. Cu level was significantly increased by 4 weeks in cohort A; P &lt; 0.001 (n = 25) and approached levels of the stable PI (0.7 (0.3) vs 0.8 (0.2) micromol/ml). Concerning CLP, however, catch-up of levels was delayed till 8 weeks, and a triphasic pattern of linear rise in Cu (both cohorts, but more prominent in A) and CLP (cohort A) was discernible by 24 weeks. The sick PI had mean (SD) serum CLP levels of 0.5 (0.8) micromol/dl, 5.9 (1.4), 15.2 (2.6), 17.3 (2.9), 21.2 (3.8), 25.1 (4.7) and 23.7 (3.8) micromol/dl at birth, 4, 8, 12, 20, and 24 weeks, respectively and were similar from 8 weeks in cohort B. Generally, CLP paralleled serum Cu levels. Cu levels in the full-term infant (FI) were higher at birth and became similar to PI&apos;s from 12 weeks, but were overtaken by levels in PI (both cohorts) at 24 weeks. The FI&apos;s Cu was significantly elevated by 8 weeks; mean (SD), 0.81 (0.16) micromol/ml vs 1.25 (0.19) micromol/ml; P &lt; 0.01, paired t-test. Decreased growth rate, nonpitting pedal edema, exaggerated physiological anaemia and chronic lung disease were few morbidities noted in association with very low Cu and CLP levels (n = 15). Newborns with serum Cu and CLP&gt;0.2 micromol/ml and &gt;2.3 micromol/dl, respectively, did not have a poor outcome. It is tempting to suggest that absent serum CLP activity may portend a poor prognosis. Our findings (number albeit small) could be taken as a preliminary normative data for further comparisons.&#xD;Newborn infants were studied longitudinally to assess their serum copper (Cu) and ceruloplasmin (CLP) status. All infants were born between July 1, 1991, and June 30, 1992, at the University of Maiduguri Teaching Hospital, Maiduguri, Nigeria. Preterm infants (PI) of a maximum gestational age 36 weeks were divided into sick (A) and stable (B) cohorts, beginning with 30 in each of the 2 groups. The groups were matched with respect to gender, gestational age, birth weight, Apgar scores, and socioeconomic class. Cu levels were also determined in 30 stable, full-term infants. Sick PIs had significantly lower mean Cu and CLP levels at birth, while Cu level was significantly increased by 4 weeks in cohort A and approached levels of the stable PIs. With regard to CLP, catch-up of levels was delayed until 8 weeks, and a triphasic pattern of linear rise in Cu and CLP was discernible by 24 weeks. Sick PIs had mean serum CLP levels of 0.5 mcmol/dl, 5.9, 15.2, 17.3, 21.2, 25.1, and 23.7 mcmol/dl at birth, 4, 8, 12, 20, and 24 weeks, respectively, and were similar from 8 weeks in cohort B. Generally, CLP paralled serum Cu levels. Cu levels in the full-term infant (FI) were higher at birth and became similar to PIs from 12 weeks, but were overtaken by levels in PI at 24 weeks. FIs&apos; Cu was significantly elevated by 8 weeks. Decreased growth rate, nonpitting pedal edema, exaggerated physiological anemia, and chronic lung disease were morbidities noted in association with very low Cu and CLP levels. Newborns with serum Cu and CLP higher than 0.2 mcmol/ml and 2.3 mcmol/dl, respectively, did not have a poor outcome.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Airede, A I&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Ireland&#xD;Early Hum Dev. 1998 Oct;52(3):199-210. doi: 10.1016/s0378-3782(98)00015-2.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0378-3782(98)00015-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>474</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">474</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ertan, P.</style></author><author><style face="normal" font="default" size="100%">Yereli, K.</style></author><author><style face="normal" font="default" size="100%">Kurt, Ö</style></author><author><style face="normal" font="default" size="100%">Balcioǧlu, I. C.</style></author><author><style face="normal" font="default" size="100%">Onaǧ, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Yereli, Celal Bayar Univ. School of Medicine, Department of Parasitology, 45010 Manisa, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serological levels of zinc, copper and iron elements among Giardia lamblia infected children in turkey</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatrics International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatrics International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">286-288</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">feces analysis</style></keyword><keyword><style face="normal" font="default" size="100%">gastrointestinal infection</style></keyword><keyword><style face="normal" font="default" size="100%">Giardia intestinalis</style></keyword><keyword><style face="normal" font="default" size="100%">giardiasis</style></keyword><keyword><style face="normal" font="default" size="100%">hospital department</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">iron blood level</style></keyword><keyword><style face="normal" font="default" size="100%">malabsorption</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">sample</style></keyword><keyword><style face="normal" font="default" size="100%">serology</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">Turkey (republic)</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><isbn><style face="normal" font="default" size="100%">1328-8067</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Giardiasis, an intestinal protozoan infection caused by Giardia lamblia, is common in Turkey, especially among children aged between 2- and 14-years-old. Effects of giardiasis on serological levels of zinc, copper and iron elements were assessed in this study. Methods: A total of 45 children, aged between 2- and 14-years-old, who were admitted to the Pediatrics Department of Celal Bayar University Medical School with gastrointestinal complaints and diagnosed as having giardiasis by stool examinations in the Parasitology Department, were enrolled as the study group (SG). The control group (CG) consisted of 45 age-matched healthy children. Serological levels of zinc, copper and iron were measured by atomic absorption spectrophotometer in all samples. Results: As a result of the study, serum zinc levels were 67.43 ± 17.72 μg/dL and 145.20 ± 9.13 μg/dL, copper levels were 198.45 ± 39.14 μg/dL and 150 ± 21.14 μg/dL and iron levels were 87.98 ± 18.31 μg/dL and 160.45 ± 45.40 μg/dL, in SG and CG, respectively. When compared separately as SG and CG, there was a statistically significant difference between the serological levels of all these elements. Conclusion: These results revealed that giardiasis increased the serological levels of copper, like other infectious agents. However, zinc and iron levels decreased during giardiasis due to malabsorption.</style></abstract><notes><style face="normal" font="default" size="100%">L34827728&#xD;2002-08-11</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L34827728</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1046/j.1442-200X.2002.01550.x</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">11982898</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1442-200X.2002.01550.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Songchitsomboon, S.</style></author><author><style face="normal" font="default" size="100%">Komindr, S.</style></author><author><style face="normal" font="default" size="100%">Komindr, A.</style></author><author><style face="normal" font="default" size="100%">Kulapongse, S.</style></author><author><style face="normal" font="default" size="100%">Puchaiwatananon, O.</style></author><author><style face="normal" font="default" size="100%">Udomsubpayakul, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum copper and zinc levels in Thai patients with various diseases</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Assoc Thai</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Assoc Thai</style></full-title></periodical><pages><style face="normal" font="default" size="100%">701-6</style></pages><volume><style face="normal" font="default" size="100%">82</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">1999/10/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular Diseases/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Communicable Diseases/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Digestive System Diseases/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lung Diseases/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Reference Values</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Thailand</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*blood/metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1999</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0125-2208 (Print)&#xD;0125-2208</style></isbn><accession-num><style face="normal" font="default" size="100%">10511772</style></accession-num><abstract><style face="normal" font="default" size="100%">This study was conducted to evaluate the possible alteration of serum Cu and Zn levels in 118 medical inpatients (53 women and 65 men) in Ramathibodi Hospital. Patients were classified according to their main clinical diseases: pulmonary (n = 12), renal (14), infectious (30), malignant (9), cardiovascular (22), GI &amp; hepatic (13) and hematological (18) diseases. Significantly increased serum Cu concentrations were found in patients with pulmonary, malignant, cardiovascular and infectious diseases; moreover, 75, 75, 50 and 37 per cent of these diseases, respectively, had serum levels greater than the normal mean + 2SD (23.6 mumol/L). Besides, 5 per cent of patients (3 in renal, 1 in infectious and 2 in GI &amp; hepatic diseases) had low serum Cu levels suggestive of Cu depletion. By contrast, significantly decreased serum Zn concentrations were found in patients with GI &amp; hepatic, infectious, renal, cardiovascular and malignant diseases. Serum Zn levels below the normal mean - 2SD (8.1 mumol/L) were presented in 46, 37, 29, 23 and 22 per cent of cases, respectively. It was found that serum Cu/Zn ratio in our patients not only with cancer but also with other diseases were statistically significant from the normal group. Hence, the use of serum Cu/Zn ratios as markers for the diagnosis of cancer or for staging tumors must be interpreted cautiously.</style></abstract><notes><style face="normal" font="default" size="100%">Songchitsomboon, S&#xD;Komindr, S&#xD;Komindr, A&#xD;Kulapongse, S&#xD;Puchaiwatananon, O&#xD;Udomsubpayakul, U&#xD;Clinical Trial&#xD;Comparative Study&#xD;Controlled Clinical Trial&#xD;Journal Article&#xD;Thailand&#xD;J Med Assoc Thai. 1999 Jul;82(7):701-6.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moreno, T.</style></author><author><style face="normal" font="default" size="100%">Artacho, R.</style></author><author><style face="normal" font="default" size="100%">Navarro, M.</style></author><author><style face="normal" font="default" size="100%">Perez, A.</style></author><author><style face="normal" font="default" size="100%">Ruiz-Lopez, M. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Nutricion y Bromatologia, Facultad de Farmacia, Universidad de Granada, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum copper concentration in HIV-infection patients and relationships with other biochemical indices</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Total Environ</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21-6</style></pages><volume><style face="normal" font="default" size="100%">217</style></volume><number><style face="normal" font="default" size="100%">1-2</style></number><edition><style face="normal" font="default" size="100%">1998/08/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections/*pathology/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Nutritional Status</style></keyword><keyword><style face="normal" font="default" size="100%">Sex Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Spain</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0048-9697 (Print)&#xD;0048-9697</style></isbn><accession-num><style face="normal" font="default" size="100%">9695170</style></accession-num><abstract><style face="normal" font="default" size="100%">We have determined the degree of abnormalities in serum copper concentrations in HIV-seropositive individuals. The study was conducted at the Virgen de las Nieves Universitary Hospital in Granada (Spain). A total of 142 HIV-infected individuals and 84 control subjects were included in the study. The HIV-infected subjects were divided into three groups following the 1993 criteria of the Center for Disease Control and Prevention (Atlanta, USA). Serum copper levels in HIV-infected subjects were significantly higher than those found in control individuals (P &lt; 0.001). Moreover, there were no statistically significant (P &gt; 0.05) differences in serum Cu levels among the three groups considered although serum Cu enhancement occurred at the beginning of the infection process (group A). This increase then remains constant in advanced stages of HIV infection (groups B and C). The mean serum Cu concentration in women (1.41 mg/l) was not significantly higher than that found in men (1.39 mg/l) (P &gt; 0.05). Linear regression analyses between serum copper concentrations and nutritional or biochemical indices (prealbumin, albumin, transferrin, lymphocytes CD4, body mass index, weight) were not statistically correlated (P &gt; 0.05). These data suggest that copper which is an acute phase reactant, may be a useful marker of HIV activity and progression to AIDS as in other chronic infective diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Moreno, T&#xD;Artacho, R&#xD;Navarro, M&#xD;Perez, A&#xD;Ruiz-Lopez, M D&#xD;Journal Article&#xD;Netherlands&#xD;Sci Total Environ. 1998 Jun 30;217(1-2):21-6. doi: 10.1016/s0048-9697(98)00158-2.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s0048-9697(98)00158-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>425</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">425</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bilbis, L. S.</style></author><author><style face="normal" font="default" size="100%">Idowu, D. B.</style></author><author><style face="normal" font="default" size="100%">Saidu, Y.</style></author><author><style face="normal" font="default" size="100%">Lawal, M.</style></author><author><style face="normal" font="default" size="100%">Njoku, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Y. Saidu, Departments of Biochemistry, Department of Biochemistry, Usmanu Danfodiyo University, P.M.B. 2346, Sokoto, Nigeria</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum levels of antioxidant vitamins and mineral elements of human immunodeficiency virus positive subjects in Sokoto, Nigeria</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of African Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of African Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">235-239</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">mineral</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">CD4 lymphocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">CD4+ T lymphocyte</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">mineral blood level</style></keyword><keyword><style face="normal" font="default" size="100%">Nigeria</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">sex differentiation</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0975-5764&#xD;1596-3519</style></isbn><abstract><style face="normal" font="default" size="100%">Background : Undernourishment and micronutrient deficiencies exacerbate immunosuppression, oxidative stress, acceleration of human immunodeficiency virus (HIV) replication and CD4 T-cell depletion in HIV-infected individuals. Materials and Methods : The current work reports the serum levels of antioxidant vitamins (vitamins A, C and E) and minerals (Zn, Fe, Cu) in 90 HIV positive subjects attending the Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto, Nigeria. The serum levels of the micronutrients were correlated with the CD4 count of the subjects. Results : The results showed that the HIV positive subjects have significantly lower (P &lt; 0.05) levels of vitamins A, C and E. Also, serum Zn, Fe, Cu and CD4 count were also significantly (P &lt; 0.05) lower compared with the HIV negative subjects. Micronutrient deficiencies were more pronounced in HIV positive subjects with CD4 counts less than 200 cell/l. The results based on age and sex showed no significant (P &gt; 0.05) difference. Vitamins A, E and C and Zn and Fe showed positive correlation with CD4 count of the HIV positive subjects. Conclusion : The results suggest that the HIV subjects in the study area have lowered serum levels of antioxidant micronutrients and that the levels decrease with increase in the severity of the infection. These may increase the chances of the symptomatic and asymptomatic subjects progressing into full-blown Acquired Immunodeficiency Syndrome.</style></abstract><notes><style face="normal" font="default" size="100%">L359789915&#xD;2010-10-27&#xD;2010-11-02</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L359789915</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.4103/1596-3519.70963</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20935424</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.4103/1596-3519.70963</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>264</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abulizi, G.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y. Y.</style></author><author><style face="normal" font="default" size="100%">Mijiti, P.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author><author><style face="normal" font="default" size="100%">Abuduxikuer, G.</style></author><author><style face="normal" font="default" size="100%">Cai, J.</style></author><author><style face="normal" font="default" size="100%">Dong, Z. H.</style></author><author><style face="normal" font="default" size="100%">Naizhaer, G.</style></author><author><style face="normal" font="default" size="100%">Yang, X. W.</style></author><author><style face="normal" font="default" size="100%">Maimaiti, M.</style></author><author><style face="normal" font="default" size="100%">Ling, Lu</style></author><author><style face="normal" font="default" size="100%">Abudurexiti, G.</style></author><author><style face="normal" font="default" size="100%">Tuerxun, G.</style></author><author><style face="normal" font="default" size="100%">Aierken, K.</style></author><author><style face="normal" font="default" size="100%">Jiang, Y. J.</style></author><author><style face="normal" font="default" size="100%">Li, Li</style></author><author><style face="normal" font="default" size="100%">Zhu, M. Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Abulimiti, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">G. Abulizi, 5th Department of Gynecology, Affiliated Tumor Hospital of Xinjiang Medical University, No. 789 Suzhou East Road, Urumqi City, Xinjiang Uyghur Autonomous Region, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum Se, Ni, and As are associated with HPV infection and CIN2+ among uyghur women in rural China</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Cancer</style></full-title></periodical><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">arsenic</style></keyword><keyword><style face="normal" font="default" size="100%">cadmium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">nickel</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">arsenic blood level</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">cadmium blood level</style></keyword><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">disease association</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">inductively coupled plasma atomic emission spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">iron blood level</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">manganese blood level</style></keyword><keyword><style face="normal" font="default" size="100%">nickel blood level</style></keyword><keyword><style face="normal" font="default" size="100%">papillomavirus infection</style></keyword><keyword><style face="normal" font="default" size="100%">risk factor</style></keyword><keyword><style face="normal" font="default" size="100%">rural population</style></keyword><keyword><style face="normal" font="default" size="100%">selenium blood level</style></keyword><keyword><style face="normal" font="default" size="100%">uterine cervix carcinoma in situ</style></keyword><keyword><style face="normal" font="default" size="100%">Uygur (people)</style></keyword><keyword><style face="normal" font="default" size="100%">women&apos;s health</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1471-2407</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Cervical cancer incidence and mortality is high in Uyghur ethnics. Their life style and dietary habit were different from other ethnics living together. Study on the role of trace elements in HPV infection and cervical lesion of Uyghur minority is needed for future intervention and prevention work. Methods: In total, 833 Uyghur women were randomly selected from the screening site and hospital. The concentrations of the trace elements As, Fe, Cd, Ni, Cu, Zn, Mn, and Se were determined by atomic absorption spectrophotometry and inductively coupled plasma atomic emission spectroscopy. Univariate analysis was performed with chi-squared test between the HPV-positive and HPV-negative groups and between the case group and the control group. Multivariate analysis was performed with logistic regression. Results: An As concentration ≥ 0.02 mg/kg was a risk factor for HPV infection (OR &gt; 1, P &lt; 0.05), and Ni concentration ≥ 0.1232 mg/kg and Se concentration ≥ 0.02 mg/kg were protective factors (OR &lt; 1, P &lt; 0.05). Concentrations of Fe ≥ 6.9153 mmol/L and As ≥0.02 mg/kg were risk factors for CIN2+ (OR &gt; 1, P &lt; 0.05), and concentrations of Ni ≥0.0965 mg/kg and Se ≥0.02 mg/kg were protective factors (OR &lt; 1, P &lt; 0.05). Conclusions: Low serum concentrations of Se and Ni and a high serum concentration of As might be related to HPV infection and CIN2+ in Uyghur women in rural China.</style></abstract><notes><style face="normal" font="default" size="100%">L627916413&#xD;2019-06-18&#xD;2019-06-21</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L627916413</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1186/s12885-018-4734-6</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">30257641</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12885-018-4734-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akkas, I.</style></author><author><style face="normal" font="default" size="100%">Ince, N.</style></author><author><style face="normal" font="default" size="100%">Sungur, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infectious Diseases, Oltu State Hospital, Ministry of Health, Erzurum, Turkey.&#xD;Department of Infectious Diseases and Clinical Microbiology, Duzce University Faculty of Medicine, Duzce, Turkey.&#xD;Department of Biostatistics, Duzce University Faculty of Medicine, Duzce, Turkey.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum trace element and heavy metal levels in patients with sepsis</style></title><secondary-title><style face="normal" font="default" size="100%">Aging Male</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aging Male</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-5</style></pages><edition><style face="normal" font="default" size="100%">2020/03/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Trace elements</style></keyword><keyword><style face="normal" font="default" size="100%">critically ill</style></keyword><keyword><style face="normal" font="default" size="100%">heavy metals</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">serum levels</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 17</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1368-5538</style></isbn><accession-num><style face="normal" font="default" size="100%">32183594</style></accession-num><abstract><style face="normal" font="default" size="100%">Background and objectives: Sepsis is defined as a life-threatening organ dysfunction syndrome, which occurs when the body&apos;s immune response to infection is impaired. The aim of the present study was to investigate serum Iron, Copper, Zinco, Cobalt, Chromium, Selenium, Vanadium, Nickel, Cadmium, and Aliminium levels in patients with sepsis.Materials and methods: This prospective and observational study was conducted at a tertiary care university hospital of Turkey from 2015 to 2016, and comprised patients with sepsis. Serum concentrations of 10 elements were analyzed using inductively coupled plasma mass spectrometry. Analyses were performed at the laboratory of Duzce University Scientific and Technological Research Application and Research Center. A total of 87 participants (52 men, 35 women; average age, 74.11 +/- 14.26) were enrolled.Results: When evaluated in terms of trace elements, a significant difference was noted between the sepsis and control groups in terms of the levels of the five elements. Chromium, Iron, Nickel, Copper, and Cadmium levels were significantly higher in the sepsis group.Conclusion: Our study indicated in particular, Iron, Copper, Chromium, Nickel, and Cadmium levels were elevated in patients with sepsis.</style></abstract><notes><style face="normal" font="default" size="100%">1473-0790&#xD;Akkas, Idris&#xD;Ince, Nevin&#xD;Sungur, Mehmet Ali&#xD;Journal Article&#xD;England&#xD;Aging Male. 2020 Mar 17:1-5. doi: 10.1080/13685538.2020.1740200.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/13685538.2020.1740200</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>255</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Monaghan, T.</style></author><author><style face="normal" font="default" size="100%">Jilani, T.</style></author><author><style face="normal" font="default" size="100%">Frankowski, M.</style></author><author><style face="normal" font="default" size="100%">Spiewak, K.</style></author><author><style face="normal" font="default" size="100%">Brindell, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">T. Monaghan, NIHR Nottingham Digestive Diseases Biomedical Research Centre, Nottingham University Teaching Hospitals NHS Trust, University of Nottingham, Nottingham, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum trace metal concentrations in clostridium difficile infection and their relationship to disease severity</style></title><secondary-title><style face="normal" font="default" size="100%">Gut</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gut</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A195-A196</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><keywords><keyword><style face="normal" font="default" size="100%">cadmium</style></keyword><keyword><style face="normal" font="default" size="100%">cobalt</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">nickel</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">toxin</style></keyword><keyword><style face="normal" font="default" size="100%">trace metal</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial virulence</style></keyword><keyword><style face="normal" font="default" size="100%">Charlson Comorbidity Index</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile infection</style></keyword><keyword><style face="normal" font="default" size="100%">colon resection</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">creatinine blood level</style></keyword><keyword><style face="normal" font="default" size="100%">decision tree</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic test accuracy study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">infection sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">megacolon</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">predictive value</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">pseudomembranous colitis</style></keyword><keyword><style face="normal" font="default" size="100%">rank sum test</style></keyword><keyword><style face="normal" font="default" size="100%">regression analysis</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1468-3288</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction Trace metals play a central role in host-pathogen interactions, impacting both microbial growth/pathogenicity and antimicrobial host immune defences. The main objective of this study was to determine the relationship between serum trace metal concentrations and severity of C. difficile infection (CDI). Methods We analysed biobanked serum samples previously collected from a single-centre prospective observational study in which we recruited consecutive hospitalised patients&gt;18 years with symptomatic toxin-positive C. difficile diarrhoea. Severe C. difficile was defined as WCC &gt;15xl09/L or an increase in serum creatinine &gt;1.5 above baseline, or pseudomembranous colitis, megacolon, need for colectomy or septic shock requiring ICU admission. Selected trace metal (iron, selenium, zinc, cadmium, cobalt, copper, magnesium, manganese, nickel and lead) concentrations in sera were determined by inductively-coupled mass spectrometry (ICP-MS). Mean biometal concentrations were compared between mild and severe CDI cases using Mann-Whitney test. Univariate and multivariate regression analyses were used to identify clinical and biochemical factors associated with risk of severe CDI. Results A total of 224 serum samples derived from 149 patients [n = 65 male; mean age (S.D.) 65.7 years (16.4); n = 84 female; 68.3 years (19.3)] were included. The median concentrations (lg/L) of iron, zinc and selenium were significantly lower in severe CDI cases compared with those with mild infection. Using CART decision tree analysis, 4 variables (peak WCC, selenium, Charlson co-morbidity index and magnesium) were found to be good predictors of severe CDI with sensitivity, specificity, accuracy, positive predictive value, negative predictive value and ROC of 84.8%, 98.9%, 94.3%, 97.5%, 93.1% and 0.848, respectively. Conclusions Novel therapeutic interventions that modulate the availability of trace metals may substantially impact on disease outcomes in CDI. Mechanistic studies are required to establish the source of metals detected and to determine their relevance to oxidative stress, impaired immune response and the promotion of C. difficile bacterial virulence.</style></abstract><notes><style face="normal" font="default" size="100%">L623565507&#xD;2018-08-27</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L623565507</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1136/gutjnl-2018-BSGAbstracts.389</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/gutjnl-2018-BSGAbstracts.389</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>160</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Deghaidy, F. S.</style></author><author><style face="normal" font="default" size="100%">Mahklady, F. A.</style></author><author><style face="normal" font="default" size="100%">Makhlouf, L. M.</style></author><author><style face="normal" font="default" size="100%">el-Ayat, A. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Serum zinc and copper levels in bilharzial patients</style></title><secondary-title><style face="normal" font="default" size="100%">J Egypt Soc Parasitol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Egypt Soc Parasitol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">205-9</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">1989/06/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anemia/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Schistosomiasis mansoni/*blood/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1989</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1110-0583 (Print)&#xD;1110-0583</style></isbn><accession-num><style face="normal" font="default" size="100%">2496179</style></accession-num><abstract><style face="normal" font="default" size="100%">Serum zinc and copper levels were determined for fifty cases with positive infestation of Schistosoma mansoni at Ismailia General Hospital. In the early infected cases, serum zinc and copper concentrations showed small alteration to lower and higher values, respectively, compared to the reference. Those with a long history of infection, serum zinc showed a big decrease in its concentration but serum copper showed a great extent of increasement in its level comparing to the reference values. The study recommended the administration of zinc dietary to counter balance the trace metals redistribution.</style></abstract><notes><style face="normal" font="default" size="100%">Deghaidy, F S&#xD;Mahklady, F A&#xD;Makhlouf, L M&#xD;el-Ayat, A A&#xD;Journal Article&#xD;Egypt&#xD;J Egypt Soc Parasitol. 1989 Jun;19(1):205-9.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kassu, A.</style></author><author><style face="normal" font="default" size="100%">Yabutani, T.</style></author><author><style face="normal" font="default" size="100%">Mulu, A.</style></author><author><style face="normal" font="default" size="100%">Tessema, B.</style></author><author><style face="normal" font="default" size="100%">Ota, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Parasitology, College of Medicine and Health Sciences, University of Gondar, P.O. Box 196, Gondar, Ethiopia. Afeworkkassu@yahoo.com</style></auth-address><titles><title><style face="normal" font="default" size="100%">Serum zinc, copper, selenium, calcium, and magnesium levels in pregnant and non-pregnant women in Gondar, Northwest Ethiopia</style></title><secondary-title><style face="normal" font="default" size="100%">Biol Trace Elem Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biol Trace Elem Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">97-106</style></pages><volume><style face="normal" font="default" size="100%">122</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2008/01/19</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Ethiopia</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Seropositivity/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnesium/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Selenium/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0163-4984 (Print)&#xD;0163-4984</style></isbn><accession-num><style face="normal" font="default" size="100%">18202835</style></accession-num><abstract><style face="normal" font="default" size="100%">Pregnant women in developing countries are vulnerable to multiple micronutrient deficiencies. Studies assessing serum levels of the micronutrients and magnitude of their deficiencies are very scarce in African subjects. This study was aimed at determining serum levels of micronutrients in 375 pregnant (42 HIV seropositive) and 76 non-pregnant women (20 HIV seropositive) who visited the University of Gondar Hospital, Gondar, Ethiopia. Serum concentrations of zinc,\ copper, selenium, calcium, and magnesium were determined using an inductively coupled plasma mass spectrometer. Irrespective of HIV serostatus, pregnant women had significantly higher serum concentrations of copper and copper/zinc ratio and significantly lower magnesium compared to those in non-pregnant women (P &lt; 0.05). Except for selenium, which was significantly lower in HIV-seropositive pregnant women (P &lt; 0.05), the mean serum concentrations of zinc, copper, calcium, and magnesium were not significantly different between pregnant women by HIV serostatus. The prevalence of deficiency in zinc, magnesium, selenium, and calcium in the pregnant women, irrespective of their HIV serostatus, was 66.7%, 25.6%, 21.9%, and 9.3%, respectively. The magnitude of deficiency in zinc, magnesium, and selenium was significantly higher in HIV seropositive pregnant women (76.2%, 52.4%, and 45.2%) than that in HIV-seronegative pregnant women (65.5%, 22.2%, and 18.9%) and in HIV-seronegative non-pregnant women (42.9%, 8.1%, and 30.4%; P &lt; 0.05). Deficiency in one, two, three, or four mineral elements was observed in 44.8%, 14.4%, 9.9%, and 5.1% of the pregnant women, respectively. Only 25.9% of the pregnant women and 44.7% of the non-pregnant women were not deficient in any of the micronutrients. The high prevalence of micronutrient deficiencies in pregnant and non-pregnant women in Gondar, Ethiopia warrants the need for strategies on prevention and control of the deficiencies.</style></abstract><notes><style face="normal" font="default" size="100%">Kassu, Afework&#xD;Yabutani, Tomoki&#xD;Mulu, Andargachew&#xD;Tessema, Belay&#xD;Ota, Fusao&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Biol Trace Elem Res. 2008 May;122(2):97-106. doi: 10.1007/s12011-007-8067-6. Epub 2008 Jan 17.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12011-007-8067-6</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>332</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pazgan-Simon, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Pazgan-Simon, WSS Im. Gromkowskiego We Wrocławiu, Zakład Chorób Zakaźnych i Hepatologii, Uniwersytet Medyczny We Wrocławiu, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Severe cholestatic liver injury in a fitness-obsessed white collar</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical and Experimental Hepatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical and Experimental Hepatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">68</style></pages><volume><style face="normal" font="default" size="100%">1</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">albumin</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">anabolic agent</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">cetirizine</style></keyword><keyword><style face="normal" font="default" size="100%">cholesterol</style></keyword><keyword><style face="normal" font="default" size="100%">colestyramine</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">gamma glutamyltransferase</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">liver enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">ursodeoxycholic acid</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">albumin dialysis</style></keyword><keyword><style face="normal" font="default" size="100%">alpha 1 antitrypsin deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">cholestasis</style></keyword><keyword><style face="normal" font="default" size="100%">cholestatic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">communicable disease</style></keyword><keyword><style face="normal" font="default" size="100%">copper metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme assay</style></keyword><keyword><style face="normal" font="default" size="100%">hospital patient</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">iron metabolism disorder</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">lawyer</style></keyword><keyword><style face="normal" font="default" size="100%">liver biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">liver toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">malaise</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">muscle mass</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">skin color</style></keyword><keyword><style face="normal" font="default" size="100%">spleen</style></keyword><keyword><style face="normal" font="default" size="100%">toxic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">urine</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">2449-8238</style></isbn><abstract><style face="normal" font="default" size="100%">A 32-year-old male, a lawyer, without significant medical history was admitted to the Department of Infectious Diseases at the J. Gromkowski Voivodeship Specialist Hospital in Wrocław with the symptoms of cholestatic liver injury. He reported the onset of symptoms including yellow skin coloration, urine darkening and malaise, a few days preceding the admission. On being asked multiple times, the patient admitted having taken anabolic steroids of unknown brand in order to increase his muscle mass gain, as gym workout had always been his passion. The laboratory tests on admission revealed the increased level of liver enzymes (ALT 346 IU/L; AST 109 U/L, Alkaline Phosphatase 152 IU/L and GGTP 36 IU/L), cholesterol assay of 283 mg%, TG level of 250 mg%, total bilirubin level of 9.6 mg% (which increased throughout the hospitalisation up to 26.5 mg/ dL). The physical examination revealed significant jaundice with the liver and spleen not exceeding the costal margin. The diagnostic tests excluded hepatotropic viral infection, iron and copper metabolism disorder, autoimmune hepatitis and α1-antitrypsin deficiency. Due to a very severe pruritus and increasing jaundice, as well as failure to control the symptoms with pharmacological agents (glucocorticosteroids, luminal, anti-histamine agents, cholestyramine) the patient underwent albumin dialysis twice, which led to a transient decrease of bilirubin level and a partial resolution of pruritus. 5 days after the dialysis, the bilirubin level increased again to 23.5 mg/dL. At the same time, pruritus worsened significantly to the extent not observed before. 2 subsequent albumin dialyses were performed which led to relative decrease of bilirubin level and partial resolution of pruritus. The attempt to introduce ursodeoxycholic acid induced another episode of severe pruritus. Eventually, after a 2-month inpatient treatment which led to some clinical improvement due to the use of anti-histamine agent (cetirizine) as well as cholestyramine and glucocorticosteroids, when the laboratory enzyme assays were ALT 124 IU/L, AST 72 IU/L, FA 130 IU/L, GGTP 94 IU/L and bilirubin 8.2 mg/dl, liver biopsy was performed, which revealed toxic, drug-induced liver injury, most likely related to the use of anabolic steroids. Conclusions: 1. The use of anabolic steroids led not only to the increased muscle mass gain but more importantly it induced cholestatic hepatitis in our patient. 2. Albumin dialysis is effective in resolving pruritus secondary to cholestasis.</style></abstract><notes><style face="normal" font="default" size="100%">L619618072&#xD;2017-12-15</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L619618072</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schofield, C.</style></author><author><style face="normal" font="default" size="100%">Ashworth, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Severe malnutrition in children: high case-fatality rates can be reduced</style></title><secondary-title><style face="normal" font="default" size="100%">Afr Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Afr Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17-8</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">2002/09/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Age Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Biology</style></keyword><keyword><style face="normal" font="default" size="100%">*Body Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">*Child</style></keyword><keyword><style face="normal" font="default" size="100%">Demography</style></keyword><keyword><style face="normal" font="default" size="100%">*Developing Countries</style></keyword><keyword><style face="normal" font="default" size="100%">*Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Fluid Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Health</style></keyword><keyword><style face="normal" font="default" size="100%">*Health Planning Guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">*Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">*Nutrition Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional Physiological Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Population</style></keyword><keyword><style face="normal" font="default" size="100%">Population Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Population Dynamics</style></keyword><keyword><style face="normal" font="default" size="100%">*Therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrate Metabolic Effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Case Fatality Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Death Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Demographic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucose Metabolism Effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrition Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">*Oral Rehydration</style></keyword><keyword><style face="normal" font="default" size="100%">*Recommendations</style></keyword><keyword><style face="normal" font="default" size="100%">*Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Youth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1997</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0141-9536 (Print)&#xD;0141-9536</style></isbn><accession-num><style face="normal" font="default" size="100%">12321237</style></accession-num><abstract><style face="normal" font="default" size="100%">This article offers a protocol for reducing high case fatality rates from malnutrition. Most child deaths from malnutrition occur in the first few days of treatment. Treatment should involve stabilization followed by rehabilitation. The article describes the treatment procedures for hypoglycemia, hypothermia, dehydration, and missed infections and discusses feeding during the stabilization and rehabilitation phases of treatment. All severely malnourished children have excess body sodium but high intracellular and low plasma levels. Malnourished children have deficiencies of potassium and magnesium that may take 2 weeks to correct. Edema is partly due to deficiencies in potassium and magnesium. A high sodium intake can be corrected by rehydrating with a modified oral rehydration solution and the special starter formula. Family food should be prepared without salt. Magnesium and potassium should be added directly to foods. All severely malnourished children have vitamin and mineral deficiencies. Deficiencies may include vitamin A, zinc, copper, selenium, and folic acid. Multivitamin supplements can correct for micronutrient deficiencies. It is advised that zinc should not be ignored, since it is responsible for repair of intestinal mucosa, halting diarrhea, healing of ulcerated skin lesions, restoration of appetite, improved immune function, and lean tissue synthesis. Iron should not be given until growth starts, infections are controlled, and antioxidant status is improved (usually 1 week after admission). Early introduction of iron poses a risk of enhancing pathogen increases and stimulating production of toxic free radicals. Relapses can be reduced by training parents how to feed their child frequently with energy and nutrient dense foods. The regimen was tested in a South African project and found to reduce mortality from 30% to 20%. After greater hospital attention to treatment of sepsis and hypoglycemia, case fatality declined to 6%.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Schofield, C&#xD;Ashworth, A&#xD;Journal Article&#xD;England&#xD;Afr Health. 1997 Sep;19(6):17-8.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">PIP</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>323</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">323</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimitropoulos, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Dimitropoulos, University Hospital of Larissa, Department of Urology, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sexual dysfunction caused by intrauterine device migration to the urinary bladder: A case report</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Sexual Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Sexual Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">270-271</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">contraceptive agent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">adverse device effect</style></keyword><keyword><style face="normal" font="default" size="100%">anesthesia</style></keyword><keyword><style face="normal" font="default" size="100%">bladder perforation</style></keyword><keyword><style face="normal" font="default" size="100%">bladder wall</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">clinical evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">coitus</style></keyword><keyword><style face="normal" font="default" size="100%">complication</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">cystoscopy</style></keyword><keyword><style face="normal" font="default" size="100%">dislocation</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">dyspareunia</style></keyword><keyword><style face="normal" font="default" size="100%">echography</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">Female Sexual Function Index</style></keyword><keyword><style face="normal" font="default" size="100%">Foley balloon catheter</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">forceps</style></keyword><keyword><style face="normal" font="default" size="100%">hematuria</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human cell</style></keyword><keyword><style face="normal" font="default" size="100%">husband</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine device migration</style></keyword><keyword><style face="normal" font="default" size="100%">latex allergy</style></keyword><keyword><style face="normal" font="default" size="100%">lesser pelvis</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte</style></keyword><keyword><style face="normal" font="default" size="100%">low back pain</style></keyword><keyword><style face="normal" font="default" size="100%">lubrication</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">married woman</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">medical record</style></keyword><keyword><style face="normal" font="default" size="100%">orgasm</style></keyword><keyword><style face="normal" font="default" size="100%">outpatient department</style></keyword><keyword><style face="normal" font="default" size="100%">palpation</style></keyword><keyword><style face="normal" font="default" size="100%">pelvic examination</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">surgery</style></keyword><keyword><style face="normal" font="default" size="100%">urethra</style></keyword><keyword><style face="normal" font="default" size="100%">urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">uterus perforation</style></keyword><keyword><style face="normal" font="default" size="100%">X ray</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><isbn><style face="normal" font="default" size="100%">1743-6109</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction / Patient Information: Intrauterine devices (IUD&apos;s) are the most widely used reversible way of contraception worldwide; however, their use is accompanied by a vast variety of complications, including device dislocation. The aim of the current report is to present a case of IUD migration to the urinary bladder that caused significant sexual dysfunction in a 38 years old woman. Clinical Presentation: A 38 years old married woman presented to our outpatient clinic, complaining of gradually evolving dyspareunia within the past 12 months. Patient also reported episodes of lower urinary tract infection, with severe suprapubic pain, urge and mild macroscopic hematuria as main symptoms, treated with antibiotics. No medical history was revealed. According to patient&apos;s medical records, a Copper IUD was inserted 18 months ago, as contraceptive method due to her husband&apos;s latex allergy. Sexual history revealed significant pain during penetration that ceased at the end of coitus. Further evaluation showed low sexual desire and reduced lubrication, orgasms and satisfaction. Frequency of sexual intercourses was also reported significantly decreased. During the last 30 days, 2 sexual intercourses took place compared to 10 to 15 per month 12 months before, according to the patient. Female Sexual Function Index (FSFI) was used to evaluate patient&apos;s sexual functioning. Patient&apos;s total FSFI score was 19.5, with a score &lt; 26.55 indicating sexual dysfunction. A global pattern of sexual dysfunction was revealed, as all FSFI domains were pathological, further confirming patient&apos;s complains. Physical and pelvic examination did not reveal any significant findings except for a mild tenderness at deep palpation of suprapubic area. Urinalysis showed 6-7 leukocytes and 10-12 erythorocytes per high power field. A KUB x-ray confirmed the presence of IUD in lesser pelvis. Pelvic ultrasonography revealed an elongated echogenic mass 1.5 cm in size in urinary bladder. Cystoscopy revealed the IUD embedded in the upper posterior wall of the bladder. Treatment: Under anesthesia, IUD was completely removed out of bladder with the use of endoscopic forceps. Careful inspection of bladder lumen revealed a small perforation of the upper posterior bladder wall, where IUD was found embedded. An indwelling, transurethral Foley catheter was placed to manage bladder perforation. Patient was discharged on 3rd postoperative day. No complications occurred. During a follow up evaluation 6 months after the IUD removal, patient was asymptomatic and no UTI episode was reported. A significant improvement of intercourse frequency and sexual functioning was reported, with normal FSFI score. Discussion: Urinary tract symptoms dominate in the presentation of a woman with an IUD migrated to the bladder. However, sexual history can also reveal sexual complaints are usually omitted because women are embarrassed to report or consider insignificant; at the same time, physicians do not screen for symptoms of sexual disorders. Conclusion / Take home message: Perforations of the uterus due to IUD insertion are rare and usually accompanied by pelvic or loin pain and urinary tract symptoms. The present case report shows that a rapid or progressive development of sexual disorders in a woman with an IUD should also raise the suspicion of dislocation of the device that requires careful evaluation.</style></abstract><notes><style face="normal" font="default" size="100%">L619608813&#xD;2017-12-15</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L619608813</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>393</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">393</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, J.</style></author><author><style face="normal" font="default" size="100%">Murphy, P.</style></author><author><style face="normal" font="default" size="100%">Turok, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. Jacobson, University of Utah, School of Medicine, Salt Lake City, UT, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sexually transmitted infection prevalence in women choosing the copper-T 380A IUD for emergency contraception</style></title><secondary-title><style face="normal" font="default" size="100%">Contraception</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Contraception</style></full-title></periodical><pages><style face="normal" font="default" size="100%">323</style></pages><volume><style face="normal" font="default" size="100%">85</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper intrauterine device</style></keyword><keyword><style face="normal" font="default" size="100%">intrauterine contraceptive device</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">emergency contraception</style></keyword><keyword><style face="normal" font="default" size="100%">reproductive health</style></keyword><keyword><style face="normal" font="default" size="100%">sexually transmitted disease</style></keyword><keyword><style face="normal" font="default" size="100%">Chlamydia</style></keyword><keyword><style face="normal" font="default" size="100%">gonorrhea</style></keyword><keyword><style face="normal" font="default" size="100%">sexuality</style></keyword><keyword><style face="normal" font="default" size="100%">predictive value</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><isbn><style face="normal" font="default" size="100%">0010-7824</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: This study determined the sexually transmitted infection (STI) prevalence in women who chose the copper-T 380A IUD for EC. Method: Women presenting for EC who chose the copper IUD had gonorrhea and chlamydia testing prior to IUD insertion. The laboratory results were then compared to a modification of Morrison&apos;s historical criteria for STI testing. This included history of prior STI, age b25 years old, and two or more sexual partners in the preceding 3 months. Results: Of the 176 women who received the copper IUD for EC, seven tested positive for chlamydia and none tested positive for gonorrhea. The prevalence of STI in this group was 4.0%. Of the women who tested positive for chlamydia, 28% had a history of prior STI, 85% were under 25 years old, and 43% had two or more partners in the prior 3 months. The sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio and posttest probability for prior STI were 28.6%, 74.6%, 4.4%, 96.2%, 1.1 and 5%; for age &lt;25 years old, results were 85.7%, 36.7%, 5.3%, 98.4%, 1.4 and 7%, and for two or more sexual partners in the prior 3 months, results were 42.9%, 70.4%, 5.7%, 96.7%, 1.5 and 10%. There were no cases of PID. Conclusions: The low prevalence of STIs in this group of women presenting for EC and choosing the copper IUD does not allow the use of Morrison&apos;s historical criteria for identification and testing of only at-risk individuals.</style></abstract><notes><style face="normal" font="default" size="100%">L70672960&#xD;2012-02-29</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70672960</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1016/j.contraception.2011.11.045</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.contraception.2011.11.045</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">92</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mda, S.</style></author><author><style face="normal" font="default" size="100%">van Raaij, J. M.</style></author><author><style face="normal" font="default" size="100%">de Villiers, F. P.</style></author><author><style face="normal" font="default" size="100%">MacIntyre, U. E.</style></author><author><style face="normal" font="default" size="100%">Kok, F. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics and Child Health, and; 5Institute for Human Nutrition, University of Limpopo, Medunsa Campus, Pretoria 0204, South Africa. siyazi.mda@wur.nl</style></auth-address><titles><title><style face="normal" font="default" size="100%">Short-term micronutrient supplementation reduces the duration of pneumonia and diarrheal episodes in HIV-infected children</style></title><secondary-title><style face="normal" font="default" size="100%">J Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Nutr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">969-74</style></pages><volume><style face="normal" font="default" size="100%">140</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2010/03/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhea/complications/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">HIV Infections/complications/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Length of Stay</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/complications/*drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Trace Elements/*therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins/*therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-3166</style></isbn><accession-num><style face="normal" font="default" size="100%">20335632</style></accession-num><abstract><style face="normal" font="default" size="100%">The duration of pneumonia and of diarrhea is reported to be longer in HIV-infected than in uninfected children. We assessed the effect of a multi-micronutrient supplement on the duration of hospitalization in HIV-infected children. In a double-blind, randomized trial, HIV-infected children (4-24 mo) who were hospitalized with diarrhea or pneumonia were enrolled (n = 118) and given a daily dose of a multi-micronutrient supplement (containing vitamins A, B complex, C, D, E, and folic acid, as well as copper, iron, and zinc at levels based on recommended daily allowances) or a placebo until discharge from the hospital. Children&apos;s weights and heights were measured after enrollment and micronutrient concentrations were measured before discharge. On recovery from diarrhea or pneumonia, the children were discharged and the duration of hospitalization was noted. Anthropometric indices and micronutrient concentrations did not differ between children who received supplements and those who received placebos. Overall, the duration of hospitalization was shorter (P &lt; 0.05) among children who were receiving supplements (7.3 +/- 3.9 d) (mean +/- SD) than in children who were receiving placebos (9.0 +/- 4.9); this was independent of admission diagnosis. In children admitted with diarrhea, the duration of hospitalization was 1.6 d (19%) shorter among children receiving supplements than in those receiving placebos, and hospitalization for pneumonia was 1.9 d (20%) shorter among children receiving supplements. Short-term multi-micronutrient supplementation significantly reduced the duration of pneumonia or diarrhea in HIV-infected children who were not yet receiving antiretroviral therapy and who remained alive during hospitalization.</style></abstract><notes><style face="normal" font="default" size="100%">1541-6100&#xD;Mda, Siyazi&#xD;van Raaij, Joop M A&#xD;de Villiers, Francois P R&#xD;MacIntyre, Una E&#xD;Kok, Frans J&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;J Nutr. 2010 May;140(5):969-74. doi: 10.3945/jn.109.110312. Epub 2010 Mar 24.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/jn.109.110312</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kung, M. L.</style></author><author><style face="normal" font="default" size="100%">Tai, M. H.</style></author><author><style face="normal" font="default" size="100%">Lin, P. Y.</style></author><author><style face="normal" font="default" size="100%">Wu, D. C.</style></author><author><style face="normal" font="default" size="100%">Wu, W. J.</style></author><author><style face="normal" font="default" size="100%">Yeh, B. W.</style></author><author><style face="normal" font="default" size="100%">Hung, H. S.</style></author><author><style face="normal" font="default" size="100%">Kuo, C. H.</style></author><author><style face="normal" font="default" size="100%">Chen, Y. W.</style></author><author><style face="normal" font="default" size="100%">Hsieh, S. L.</style></author><author><style face="normal" font="default" size="100%">Hsieh, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address: kungmeilang@gmail.com.&#xD;Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; Center for Neuroscience, National Sun Yat-Sen University, Kaohsiung, Taiwan; Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: minghongtai@gmail.com.&#xD;Department of Chemistry, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address: phoebe00315@yahoo.com.tw.&#xD;Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: dechwu@yahoo.com.&#xD;Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: wejewu@cc.kmu.edu.tw.&#xD;Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: bewen90@yahoo.com.tw.&#xD;Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan; Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan. Electronic address: hunghs@mail.cmu.edu.tw.&#xD;Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: kjh88kmu@gmail.com.&#xD;Department of Pharmacology, National Cheng Kung University, Tainan, Taiwan. Electronic address: yunwen_chen@mail.ncku.edu.tw.&#xD;Department of Seafood Science, National Kaohsiung Marine University, Kaohsiung, Taiwan. Electronic address: kungmeilang@gmail.com.&#xD;Department of Chemistry, National Sun Yat-sen University, Kaohsiung, Taiwan; Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: kungmeilang@gmail.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Silver decorated copper oxide (Ag@CuO) nanocomposite enhances ROS-mediated bacterial architecture collapse</style></title><secondary-title><style face="normal" font="default" size="100%">Colloids Surf B Biointerfaces</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Colloids Surf B Biointerfaces</style></full-title></periodical><pages><style face="normal" font="default" size="100%">399-407</style></pages><volume><style face="normal" font="default" size="100%">155</style></volume><edition><style face="normal" font="default" size="100%">2017/05/02</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Infections/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli/drug effects/metabolism/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Scanning</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Nanocomposites/*chemistry/toxicity/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive Oxygen Species/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Salmonella enterica/drug effects/metabolism/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/drug effects/metabolism/ultrastructure</style></keyword><keyword><style face="normal" font="default" size="100%">Ag@CuO nanocomposites</style></keyword><keyword><style face="normal" font="default" size="100%">CuO nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">Nosocomial infections</style></keyword><keyword><style face="normal" font="default" size="100%">Ros</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0927-7765</style></isbn><accession-num><style face="normal" font="default" size="100%">28460302</style></accession-num><abstract><style face="normal" font="default" size="100%">The increasing prevalence of hospital-acquired infection and the evolution and increasing resistance of pathogens toward antibiotics can cause serious health problems and disease-related mortality. In this study, we introduce a simple process and inexpensive method to synthesize CuO nanoparticles and silver-functionalized copper oxide (Ag@CuO) nanocomposites as well as to validate their potential antibacterial efficiency against the following three common nosocomial infection-associated bacterial pathogens: E. coli, S. enterica and S. aureus. We show that Ag@CuO significantly disturbs pathogen growth and viability compared with CuO. Further, we find that Gram-positive S. aureus is susceptible to CuO-induced cell structure damage, while Ag@CuO can induce more extensive architectural destruction and ROS generation in both Gram-positive and Gram-negative bacterial pathogens. This study indicates that Ag@CuO nanoparticles can act as a disinfection system and can be used in antibacterial applications for the future prevention of nosocomial infection in medical and/or health institutions.</style></abstract><notes><style face="normal" font="default" size="100%">1873-4367&#xD;Kung, Mei-Lang&#xD;Tai, Ming-Hong&#xD;Lin, Pei-Ying&#xD;Wu, Deng-Chyang&#xD;Wu, Wen-Jeng&#xD;Yeh, Bi-Wen&#xD;Hung, Huey-Shan&#xD;Kuo, Chao-Hung&#xD;Chen, Yun-Wen&#xD;Hsieh, Shu-Ling&#xD;Hsieh, Shuchen&#xD;Journal Article&#xD;Netherlands&#xD;Colloids Surf B Biointerfaces. 2017 Jul 1;155:399-407. doi: 10.1016/j.colsurfb.2017.04.041. Epub 2017 Apr 23.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.colsurfb.2017.04.041</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">7</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Colin, M.</style></author><author><style face="normal" font="default" size="100%">Charpentier, E.</style></author><author><style face="normal" font="default" size="100%">Klingelschmitt, F.</style></author><author><style face="normal" font="default" size="100%">Bontemps, C.</style></author><author><style face="normal" font="default" size="100%">De Champs, C.</style></author><author><style face="normal" font="default" size="100%">Reffuveille, F.</style></author><author><style face="normal" font="default" size="100%">Gangloff, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universite de Reims Champagne-Ardenne, EA 4691 Biomateriaux et Inflammation en site Osseux (BIOS), SFR CAP-Sante, France.&#xD;Universite de Reims Champagne-Ardenne, EA 4691 Biomateriaux et Inflammation en site Osseux (BIOS), SFR CAP-Sante, France; Universite de Reims Champagne-Ardenne, UFR de Pharmacie, Service de Microbiologie, France.&#xD;Dynamique des genomes et adaptation microbienne, UMR1128, Universite de Lorraine, INRA Vandoeuvre-les-Nancy, France.&#xD;Universite de Reims Champagne-Ardenne, Inserm UMR-S 1250 P3Cell, SFR CAP-Sante, Laboratoire de Bacteriologie - Virologie - Hygiene hospitaliere, CHU Reims, 51100 Reims, France.&#xD;Universite de Reims Champagne-Ardenne, EA 4691 Biomateriaux et Inflammation en site Osseux (BIOS), SFR CAP-Sante, France; Universite de Reims Champagne-Ardenne, UFR de Pharmacie, Service de Microbiologie, France. Electronic address: sophie.gangloff@univ-reims.fr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Specific antibacterial activity of copper alloy touch surfaces in five long-term care facilities for older adults</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">283-292</style></pages><volume><style face="normal" font="default" size="100%">104</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2019/12/07</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria/growth &amp; development/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Long-Term Care</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability</style></keyword><keyword><style face="normal" font="default" size="100%">Nursing Homes</style></keyword><keyword><style face="normal" font="default" size="100%">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial surfaces</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial identification</style></keyword><keyword><style face="normal" font="default" size="100%">Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Healthcare-associated infections</style></keyword><keyword><style face="normal" font="default" size="100%">Long-term care facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Maldi-tof</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">31809775</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Pathogens involved in healthcare-associated infections can quickly spread in the environment, particularly to frequently touched surfaces, which can be reservoirs for pathogens. AIM: The purpose of this study was to investigate naturally occurring bacterial contamination on touch surfaces in five French long-term care facilities and to compare bacterial populations recovered from copper and control surfaces. METHODS: More than 1300 surfaces were sampled. The collected bacteria were identified to obtain a global view of the cultivable bacterial populations colonizing touch surfaces. Haemolytic colonies and putative pathogens were also screened using specific agar plates and then identified with matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. In total, more than 3400 colonies were analysed. FINDINGS: Staphylococcus and Micrococcus were the two predominant genera present on touch surfaces, respectively occurring on 51.8% and 48.0% of control surfaces. In these facilities with relatively low bioburden, copper surfaces efficiently reduced the occurrence frequencies of three genera: Staphylococcus, Streptococcus and Roseomonas. Pathogenic species such as Staphylococcus aureus, Enterococcus faecalis and E. faecium were observed in very few samples. In addition, meticillin-resistant S. aureus was observed on five control surfaces and one copper surface. CONCLUSION: Contamination of healthcare facilities touch surfaces can be the source for the spread of bacteria through the institution. This in situ study shows that the frequency of the contamination as well as the specific bacterial population bioburden is reduced on copper alloy surfaces.</style></abstract><notes><style face="normal" font="default" size="100%">1532-2939&#xD;Colin, M&#xD;Charpentier, E&#xD;Klingelschmitt, F&#xD;Bontemps, C&#xD;De Champs, C&#xD;Reffuveille, F&#xD;Gangloff, S C&#xD;Journal Article&#xD;England&#xD;J Hosp Infect. 2020 Mar;104(3):283-292. doi: 10.1016/j.jhin.2019.11.021. Epub 2019 Dec 3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2019.11.021</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>376</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">376</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tuck, K.</style></author><author><style face="normal" font="default" size="100%">Mass, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">K. Tuck, Neurology, Oregon Health and Sciences University, Portland, OR, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sporadic creutzfeld jakob disease in a 33 year old male with prior cerebral instrumentation</style></title><secondary-title><style face="normal" font="default" size="100%">Neurology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">trichloroethylene</style></keyword><keyword><style face="normal" font="default" size="100%">prion protein</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">thyrotropin</style></keyword><keyword><style face="normal" font="default" size="100%">Creutzfeldt Jakob disease</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">devices</style></keyword><keyword><style face="normal" font="default" size="100%">neurology</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">sporadic Creutzfeldt Jakob disease</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">prion disease</style></keyword><keyword><style face="normal" font="default" size="100%">brain</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">Mexico</style></keyword><keyword><style face="normal" font="default" size="100%">neurosurgery</style></keyword><keyword><style face="normal" font="default" size="100%">smoke</style></keyword><keyword><style face="normal" font="default" size="100%">United Kingdom</style></keyword><keyword><style face="normal" font="default" size="100%">artifact</style></keyword><keyword><style face="normal" font="default" size="100%">hydrocephalus</style></keyword><keyword><style face="normal" font="default" size="100%">case control study</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">family history</style></keyword><keyword><style face="normal" font="default" size="100%">aphasia</style></keyword><keyword><style face="normal" font="default" size="100%">medical procedures</style></keyword><keyword><style face="normal" font="default" size="100%">spine</style></keyword><keyword><style face="normal" font="default" size="100%">onset age</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">myoclonus</style></keyword><keyword><style face="normal" font="default" size="100%">nuclear magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">hospice</style></keyword><keyword><style face="normal" font="default" size="100%">pathology</style></keyword><keyword><style face="normal" font="default" size="100%">tissues</style></keyword><keyword><style face="normal" font="default" size="100%">autopsy</style></keyword><keyword><style face="normal" font="default" size="100%">paresthesia</style></keyword><keyword><style face="normal" font="default" size="100%">arm</style></keyword><keyword><style face="normal" font="default" size="100%">limb</style></keyword><keyword><style face="normal" font="default" size="100%">electroencephalogram</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0028-3878</style></isbn><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To present an unusual case of Creutzfeldt-Jakob Disease (CJD) in a a 33 year old. BACKGROUND: CJD is a transmissible spongiform encephalopathy caused by accumulation of abnormal prion proteins in the brain. About 85% of cases are sporadic CJD (sCJD) with an unknown mechanism of transmission. The median age of onset for sCJD is 60. Over 400 cases of transmission via medical procedure have been identified worldwide. However only 6 via surgical instrumentation and none since the 1980s. A case control study comparing 753 sCJD patients and 210 controls found no difference in rates of neurosurgery. DESIGN/METHODS: Case report. RESULTS: A 33 year old male with ventriculo-peritoneal shunt placed at age 11 for hydrocephalus of unknown cause experienced progressive deficits over 3 months. Right arm paresthesias and myoclonus gradually spread to all limbs. MRI brain and c-spine were normal. CSF studies showed elevated protein. ESR, B12/MMA, folate, TSH, copper, ceruloplasmin, Lyme and RPR were all normal. He rapidly developed ataxia, aphasia and confusion. The patient was admitted for further evaluation. Family history was noncontributory. He took no medications. He did not smoke, drink or take drugs. He traveled to Mexico 3 years prior and England in 2002. Repeat DWI MRI showed shunt artifact and asymmetrical cortical ribbon hyperintensity. EEG showed generalized slowing and tri-phasic waveforms. CSF 14-3-3 was positive and Tau was elevated at 14,738 pg/mL (&lt;1150). A diagnosis of probable CJD was made and the patient was discharged to hospice. On autopsy, tissue was transmitted to the National Prion Disease Pathology Surveillance Center in Cleveland. Results were consistent with sCJD. CONCLUSIONS: This is an unusual presentation of sCJD as the patient is young. Although often considered as a cause of transmission of sCJD, surgical instrumentation is exceedingly rare. It is unlikely that this patient&apos;s shunt placement was the source of his prion disease.</style></abstract><notes><style face="normal" font="default" size="100%">L71131240&#xD;2013-08-12</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71131240</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">41</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shafaghi, R.</style></author><author><style face="normal" font="default" size="100%">Mostaghimi, J.</style></author><author><style face="normal" font="default" size="100%">Pershin, V.</style></author><author><style face="normal" font="default" size="100%">Ringuette, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">a Centre for Advanced Coating Technologies, Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 3G8, Canada.&#xD;b Department of Cell and Systems Biology, University of Toronto, Toronto, ON M5S 3G5, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sporicidal efficacy of thermal-sprayed copper alloy coating</style></title><secondary-title><style face="normal" font="default" size="100%">Can J Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Can J Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">384-391</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2017/02/09</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus subtilis/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Canada</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Spores, Bacterial/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Stainless Steel</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus subtilis spores</style></keyword><keyword><style face="normal" font="default" size="100%">focused ion beam sectioning</style></keyword><keyword><style face="normal" font="default" size="100%">nanofleurs</style></keyword><keyword><style face="normal" font="default" size="100%">nanoflowers</style></keyword><keyword><style face="normal" font="default" size="100%">revetement d&apos;alliage de cuivre pulverise thermiquement</style></keyword><keyword><style face="normal" font="default" size="100%">sectionnement par faisceaux d&apos;ions focalises</style></keyword><keyword><style face="normal" font="default" size="100%">spores de Bacillus subtilis</style></keyword><keyword><style face="normal" font="default" size="100%">sporicidal</style></keyword><keyword><style face="normal" font="default" size="100%">sporicide</style></keyword><keyword><style face="normal" font="default" size="100%">thermal-sprayed copper alloy coating</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0008-4166</style></isbn><accession-num><style face="normal" font="default" size="100%">28177787</style></accession-num><abstract><style face="normal" font="default" size="100%">Approximately 200 000 Canadians acquire healthcare-associated bacterial infections each year and several-fold more acquire food-borne bacterial illnesses. Bacterial spores are particularly problematic because they can survive on surfaces for several months. Owing to its sporicidal activity, copper alloy sheet metal is sometimes used in hospital settings, but its widespread use is limited by cost and incompatibility with complex furniture and instrument designs and topographies. A potential alternative is the use of thermal spray technology to coat surfaces with copper alloys. We compared the sporicidal activity of thermally sprayed copper alloy on stainless steel with that of copper alloy sheet metal against Bacillus subtilis spores. Spores remained intact for at least 1 week on uncoated stainless steel, whereas spore fragmentation was initiated within 2 h of exposure to either copper surface. Less than 15% of spores were viable 2 h after exposure to either copper surface, as compared with stainless steel. By day 7, only degraded spores and petal-like nanoflowers were present on the copper surfaces. Nanoflowers, which are laminar arrangements of thin crystal sheets composed of carbon - copper phosphate, appeared to be derived from the degraded spores. Altogether, these results indicate that a thermal-sprayed copper alloy coating on stainless steel provides sporicidal activity similar to that afforded by copper alloy sheet metal.</style></abstract><notes><style face="normal" font="default" size="100%">1480-3275&#xD;Shafaghi, Romina&#xD;Mostaghimi, Javad&#xD;Pershin, Valerian&#xD;Ringuette, Maurice&#xD;Journal Article&#xD;Canada&#xD;Can J Microbiol. 2017 May;63(5):384-391. doi: 10.1139/cjm-2016-0638. Epub 2017 Jan 19.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1139/cjm-2016-0638</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ashjari, H. R.</style></author><author><style face="normal" font="default" size="100%">Dorraji, M. S. S.</style></author><author><style face="normal" font="default" size="100%">Fakhrzadeh, V.</style></author><author><style face="normal" font="default" size="100%">Eslami, H.</style></author><author><style face="normal" font="default" size="100%">Rasoulifard, M. H.</style></author><author><style face="normal" font="default" size="100%">Rastgouy-Houjaghan, M.</style></author><author><style face="normal" font="default" size="100%">Gholizadeh, P.</style></author><author><style face="normal" font="default" size="100%">Kafil, H. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Applied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran.&#xD;Applied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran. Electronic address: dorraji@znu.ac.ir.&#xD;Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.&#xD;Iranian Center of Excellence in Health Management, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: kafilhs@tbzmed.ac.ir.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Starch-based polyurethane/CuO nanocomposite foam: Antibacterial effects for infection control</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Biol Macromol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1076-1082</style></pages><volume><style face="normal" font="default" size="100%">111</style></volume><edition><style face="normal" font="default" size="100%">2018/01/26</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*chemistry/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infections/*diet therapy/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Metal Nanoparticles/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Nanocomposites/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Polymers/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Polyurethanes/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Spectroscopy, Fourier Transform Infrared</style></keyword><keyword><style face="normal" font="default" size="100%">Starch/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">CuO nanoparticles</style></keyword><keyword><style face="normal" font="default" size="100%">High tensile strength</style></keyword><keyword><style face="normal" font="default" size="100%">Open cell polyurethane foam</style></keyword><keyword><style face="normal" font="default" size="100%">Starch powder</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0141-8130</style></isbn><accession-num><style face="normal" font="default" size="100%">29366900</style></accession-num><abstract><style face="normal" font="default" size="100%">In the present study, a new method for the synthesis of the open cell flexible polyurethane foams (PUFs) was developed by using starch powder and the modification of closed cell foam formulation. Starch is the second largest polymeric carbohydrate as a macromolecule on this planet with a large number of glucose units. Copper oxide nanoparticles (CuO NPs) were synthesized by thermal degradation method at different temperatures of 400, 600 and 800 degrees C as antimicrobial agents. The antimicrobial activity of CuO NPs and commercial CuO powder against the main causes of hospital infections were tested. CuO600 was the most effective antimicrobial agent and enhanced polymer matrix tensile strength with starch powder as new polyurethane foams (PUFs) cell opener with high tensile strength. The effects of parameters on tensile strength were optimized using response surface methodology (RSM). CuO NPs and PUF had optimal conditions and were characterized by X-ray diffraction (XRD), transmission electron microscopy (TEM), scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FT-IR). Foam synthesized at the optimal conditions had an open cell structure with high tensile strength and efficient antimicrobial activity that made them suitable to be used as an antimicrobial hospital mattress to control hospital infections.</style></abstract><notes><style face="normal" font="default" size="100%">1879-0003&#xD;Ashjari, Hamid Reza&#xD;Dorraji, Mir Saeed Seyed&#xD;Fakhrzadeh, Vahid&#xD;Eslami, Hosein&#xD;Rasoulifard, Mohammad Hossein&#xD;Rastgouy-Houjaghan, Mehrdad&#xD;Gholizadeh, Pourya&#xD;Kafil, Hossein Samadi&#xD;Journal Article&#xD;Netherlands&#xD;Int J Biol Macromol. 2018 May;111:1076-1082. doi: 10.1016/j.ijbiomac.2018.01.137. Epub 2018 Jan 31.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijbiomac.2018.01.137</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>416</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">416</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yim, C. W.</style></author><author><style face="normal" font="default" size="100%">Chau, T. N.</style></author><author><style face="normal" font="default" size="100%">Ng, W. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.W. Yim, Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, Hong Kong</style></auth-address><titles><title><style face="normal" font="default" size="100%">Steatotic hepatitis associated with thalidomide</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Rheumatic Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Rheumatic Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">253</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><keywords><keyword><style face="normal" font="default" size="100%">thalidomide</style></keyword><keyword><style face="normal" font="default" size="100%">hydroxychloroquine</style></keyword><keyword><style face="normal" font="default" size="100%">prednisolone</style></keyword><keyword><style face="normal" font="default" size="100%">reticulin</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B surface antigen</style></keyword><keyword><style face="normal" font="default" size="100%">dapsone</style></keyword><keyword><style face="normal" font="default" size="100%">corticosteroid</style></keyword><keyword><style face="normal" font="default" size="100%">antinuclear antibody</style></keyword><keyword><style face="normal" font="default" size="100%">alanine aminotransferase</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">lipid</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">smooth muscle antibody</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">rheumatology</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">liver function test</style></keyword><keyword><style face="normal" font="default" size="100%">stain</style></keyword><keyword><style face="normal" font="default" size="100%">monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">sensory neuropathy</style></keyword><keyword><style face="normal" font="default" size="100%">body weight</style></keyword><keyword><style face="normal" font="default" size="100%">liver biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">mononuclear cell</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">necrosis</style></keyword><keyword><style face="normal" font="default" size="100%">liver cell</style></keyword><keyword><style face="normal" font="default" size="100%">steatosis</style></keyword><keyword><style face="normal" font="default" size="100%">liver fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">myeloma</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory cell</style></keyword><keyword><style face="normal" font="default" size="100%">liver function</style></keyword><keyword><style face="normal" font="default" size="100%">constipation</style></keyword><keyword><style face="normal" font="default" size="100%">drowsiness</style></keyword><keyword><style face="normal" font="default" size="100%">discoid lupus erythematosus</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">blood cell count</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis B</style></keyword><keyword><style face="normal" font="default" size="100%">pain</style></keyword><keyword><style face="normal" font="default" size="100%">diet restriction</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">rash</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1756-1841</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Thalidomide is effective in the management of refractory discoid cutaneous lupus disease. Common adverse events include constipation, sensory neuropathy and drowsiness. We report a lupus case of non-viral steatotic hepatitis associated with thalidomide. Case history: A 45 year-old gentleman with refractory discoid lupus erythematosus was referred to our rheumatology clinic. He had been on stable dosage of hydroxychloroquine and corticosteroid for more than three months but the lesions remained disturbing. The baseline complete blood count, renal and liver function tests were all normal. Hepatitis B and C were both negative. Anti-nuclear antibodies were positive while anti-ENA and antidsDNA were both negative. We initiated thalidomide at 50 mg daily in November 2006 and escalated the dose gradually to 150 mg daily. Hydroxychloroquine was stopped while the dosage of prednisolone was kept at 10 mg daily. There was gradual improvement of skin rash in terms of the extent and pain. In March 2007, we noticed a surge in alanine transaminase to 200 I.U./L (baseline 32 I.U./L), which remained in the range of 200-300 I.U./L in the subsequent months. Fasting glucose, lipid profile, serum copper and caeruloplasmin were all normal. Anti-mitochondrial and anti-smooth muscle antibodies were both negative. He was a non-alcoholic and did not have exposure to other medications. He did not have significant change in his body weight either. Liver biopsy showed chronic inflammatory cells, mainly mononuclear cells. There were sparse lymphohistiocytic cells in the absence of ductal inflammation or piecemeal necrosis. Hepatocytes showed macro- and microvesicular steatosis. Reticulin stain showed focal periportal fibrosis but no bridging fibrosis, Orcein stain was negative for HBsAg. Thalidomide was stopped in February 2008 because of sensory neuropathy. There had been no alteration in the dosing of prednisolone over the period. Dapsone was added to control the discoid lesions. Subsequent monitoring of liver function tests demonstrated a gradual decrease of ALT from 223 I.U./L in December 2007 to 86 I.U./L in March 2008, and eventually to 33 I.U./L in September 2008. Discussion: Non-viral steatotic hepatitis is a rare but severe adverse event of thalidomide. In the English literature, there had been one case report in a myeloma patient. We report the first lupus patient who developed such complication. This report illustrated the importance of liver function monitoring in patients receiving thalidomide.</style></abstract><notes><style face="normal" font="default" size="100%">L70198436&#xD;2010-07-16</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70198436</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1756-185X.2010.01524.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1756-185X.2010.01524.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>430</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">430</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fallah, M.</style></author><author><style face="normal" font="default" size="100%">Assar, R.</style></author><author><style face="normal" font="default" size="100%">Maghsood, A. H.</style></author><author><style face="normal" font="default" size="100%">Rezaei, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">M. Fallah, University of Medical Science, Parasitology and Mycology, Hamadan, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Study of the relationship between serum level of iron, zinc and copper with giardiasis in children, Hamadan, west of Iran</style></title><secondary-title><style face="normal" font="default" size="100%">Tropical Medicine and International Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tropical Medicine and International Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">219</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><keywords><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">giardiasis</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">tropical medicine</style></keyword><keyword><style face="normal" font="default" size="100%">public health</style></keyword><keyword><style face="normal" font="default" size="100%">Iran</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">emporiatrics</style></keyword><keyword><style face="normal" font="default" size="100%">control group</style></keyword><keyword><style face="normal" font="default" size="100%">serum</style></keyword><keyword><style face="normal" font="default" size="100%">feces analysis</style></keyword><keyword><style face="normal" font="default" size="100%">absorption</style></keyword><keyword><style face="normal" font="default" size="100%">case control study</style></keyword><keyword><style face="normal" font="default" size="100%">questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">blood sampling</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption</style></keyword><keyword><style face="normal" font="default" size="100%">student</style></keyword><keyword><style face="normal" font="default" size="100%">software</style></keyword><keyword><style face="normal" font="default" size="100%">Giardia intestinalis</style></keyword><keyword><style face="normal" font="default" size="100%">protozoon</style></keyword><keyword><style face="normal" font="default" size="100%">parasite</style></keyword><keyword><style face="normal" font="default" size="100%">small intestine</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">chronic diarrhea</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><isbn><style face="normal" font="default" size="100%">1360-2276</style></isbn><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Giardia lamblia is a protozoan parasite of the small intestine that causes extensive morbidity worldwide, including Iran, especially among children aged 2-14 years. Giardiasis is a cosmopolitan infection that chronic diarrhea, mal absorption, and impairment of growth of children may occur. In this case-control study, effects of giardiasis on serum level of iron, zinc and copper elements were assessed in Hamadan, west of Iran, in the year 2007. METHODS: Thirty children, 2-14 years old with giardiasis as case group (confirmed by stool examination) and 45 healthy children, negative for G. lamblia (without any clinical symptoms) confirmed by 3 consecutive stool examination as the control group enrolled in the study. Demographic data collected by a questionnaire, blood samples was taken from both case and control groups. Serums were separated and transported to laboratory and kept in the freezer -20°C. The level of iron, copper and zinc in the serums were measured by the method of atomic absorption spectrophotometery. Average amount of iron, copper and zinc in case and control groups were compared with t-student test and P &lt; 0.05 considered statistically significant. Data analyzed by SPSS software, version 10. RESULTS: The mean of level of copper in serums was 117.06 26.54 and 126.17 18.46 in case and control groups respectively. Difference between two groups was not significant statistically. The mean of level of iron was 72.33 16.98 and 93.49 20.23 in case and control groups and, the mean of zinc in serums was 88.74 22.97 and 105.34 16.06 in case and control groups respectively. Differences between means of iron and zinc in two groups were significant statistically (P0 &lt; 0.00). CONCLUSION: These results reveal that giardiasis decreases the level of iron and zinc in the serum of the infected children but does not change the level of copper.</style></abstract><notes><style face="normal" font="default" size="100%">L70253068&#xD;2010-09-07</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70253068</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1111/j.1365-3156.2009.02354-2.x</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-3156.2009.02354-2.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>240</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chattopadhyay, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.K. Chattopadhyay, Pratap Bagan Bankura Near Bangiya Gramin Bikash Bank, Bankura, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Superoxide dismutase: A biomarker for early diagnosis of tuberculosis</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical and Diagnostic Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical and Diagnostic Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">BC01-BC03</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">biological marker</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">sodium cyanide</style></keyword><keyword><style face="normal" font="default" size="100%">superoxide dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">blood sampling</style></keyword><keyword><style face="normal" font="default" size="100%">bronchiectasis</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">early diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme activity</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">kidney function</style></keyword><keyword><style face="normal" font="default" size="100%">liver function</style></keyword><keyword><style face="normal" font="default" size="100%">lung carcinoma</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">multidrug resistant tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">spectrophotometry</style></keyword><keyword><style face="normal" font="default" size="100%">tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">tuberculosis control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">0973-709X&#xD;2249-782X</style></isbn><abstract><style face="normal" font="default" size="100%">Introduction: Tuberculosis (TB) is a major public health concern in developing countries. Traditional diagnostic methods such as microscopic detection of organism and histopathological examination are limited in their capacity to provide information on prognosis and treatment efficiency. Abundantly secreted extracellular Superoxide Dismutase (SOD) protects the Mycobacterium tuberculosis (MTB), and elevated levels of the biomolecule are found in tissues and fluids of tubercular patients. Aim: To estimate the levels of serum SOD in lung control disease and tubercular patients; assess the diagnostic potential of SOD assay for detection of tuberculosis at an early onset stage and quantify the serum SOD activity to monitor the course of infection and determine the effectiveness of the anti-Tubercular (anti-TB) drug treatment. Materials and Methods: The present observational study was conducted on 180 participants at B.S. Medical College and Hospital, Bankura, West Bengal, India. The participants were divided into three groups: Group 1: Normal Control (n=30), Group 2: Disease Control/Lung-Disease Control (n=27) and Group 3: Tubercular Subjects (3A-Pulmonary TB and 3B-Extra-pulmonary TB) (n=76). Serum SOD levels of the participants were measured spectrophotometrically. The serum SOD levels of the patients were re-measured after one-month of A-TB drug treatment. In addition, to increase the specificity of the test, the serum of tubercular subjects was incubated with different concentrations of Sodium Cyanide (NaCN) and then assayed for SOD activity. The level of significance was assessed using Student’s t-test. Results: The serum SOD level in tubercular subjects (both pulmonary and extra-pulmonary; with treatment started between 0-15 days) were significantly (p-value &lt;0.01) elevated as compared to the control and lung-disease subjects. Significant decrease in serum SOD levels was observed after one-month of A-TB drug treatment signifying a decrease in mycobacterial load in host tissues. The iron co-factored SOD secreted by M.tuberculosisis was found to be resistant to NaCN whereas Copper-Zinc (Cu-Zn) co-factored SOD was inhibited by NaCN. Conclusion: The serum SOD assay, used in the present study, differentiated between human and mycobacterial origin-SOD, on incubation with NaCN, and diagnosed pulmonary as well as extra-pulmonary TB cases with confidence. Thus, it can be used as a simple, rapid, inexpensive, yet highly sensitive and specific-assay for detection of both human and bovine tuberculosis and primary and secondary drug-resistant cases.</style></abstract><notes><style face="normal" font="default" size="100%">L2002222925&#xD;2019-07-31&#xD;2019-08-05</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L2002222925</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.7860/JCDR/2019/35298.12968</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7860/JCDR/2019/35298.12968</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koklic, T.</style></author><author><style face="normal" font="default" size="100%">Urbancic, I.</style></author><author><style face="normal" font="default" size="100%">Zdovc, I.</style></author><author><style face="normal" font="default" size="100%">Golob, M.</style></author><author><style face="normal" font="default" size="100%">Umek, P.</style></author><author><style face="normal" font="default" size="100%">Arsov, Z.</style></author><author><style face="normal" font="default" size="100%">Drazic, G.</style></author><author><style face="normal" font="default" size="100%">Pintaric, S.</style></author><author><style face="normal" font="default" size="100%">Dobeic, M.</style></author><author><style face="normal" font="default" size="100%">Strancar, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Condensed Matter Physics, Jozef Stefan Institute, Ljubljana, Slovenia.&#xD;NAMASTE Center of Excellence, Ljubljana, Slovenia.&#xD;University of Oxford, John Radcliffe Hospital, The Weatherall Institute of Molecular Medicine, Human Immunology Unit, Headington, Oxford, United Kingdom.&#xD;Institute of Microbiology and Parasitology, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.&#xD;Department of Materials Chemistry, National Institute of Chemistry, Ljubljana, Slovenia.&#xD;Institute of Environmental and Animal Hygiene with Animal Behaviour, Veterinary Faculty, University of Ljubljana, Ljubljana, Slovenia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Surface deposited one-dimensional copper-doped TiO2 nanomaterials for prevention of health care acquired infections</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0201490</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2018/07/27</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/chemical synthesis/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Catalysis</style></keyword><keyword><style face="normal" font="default" size="100%">*Coated Materials, Biocompatible/chemical synthesis/chemistry/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/instrumentation/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Methicillin-Resistant Staphylococcus aureus/drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nanostructures/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Nanotubes/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Photochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcal Infections/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">Titanium/*chemistry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1932-6203</style></isbn><accession-num><style face="normal" font="default" size="100%">30048536</style></accession-num><abstract><style face="normal" font="default" size="100%">Bacterial infections acquired in healthcare facilities including hospitals, the so called healthcare acquired or nosocomial infections, are still of great concern worldwide and represent a significant economical burden. One of the major causes of morbidity is infection with Methicillin Resistant Staphylococcus aureus (MRSA), which has been reported to survive on surfaces for several months. Bactericidal activity of copper-TiO2 thin films, which release copper ions and are deposited on glass surfaces and heated to high temperatures, is well known even when illuminated with very weak UVA light of about 10 muW/cm2. Lately, there is an increased intrerest for one-dimensional TiO2 nanomaterials, due to their unique properties, low cost, and high thermal and photochemical stability. Here we show that copper doped TiO2 nanotubes produce about five times more .OH radicals as compared to undoped TiO2 nanotubes and that effective surface disinfection, determined by a modified ISO 22196:2011 test, can be achieved even at low intensity UVA light of 30 muW/cm2. The nanotubes can be deposited on a preformed surface at room temperature, resulting in a stable deposition resistant to multiple washings. Up to 103 microorganisms per cm2 can be inactivated in 24 hours, including resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA) and Extended-spectrum beta-lactamase Escherichia coli (E. coli ESBL). This disinfection method could provide a valuable alternative to the current surface disinfection methods.</style></abstract><notes><style face="normal" font="default" size="100%">1932-6203&#xD;Koklic, Tilen&#xD;Urbancic, Iztok&#xD;Zdovc, Irena&#xD;Golob, Majda&#xD;Umek, Polona&#xD;Arsov, Zoran&#xD;Drazic, Goran&#xD;Pintaric, Stefan&#xD;Dobeic, Martin&#xD;Strancar, Janez&#xD;Orcid: 0000-0001-8032-132x&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;PLoS One. 2018 Jul 26;13(7):e0201490. doi: 10.1371/journal.pone.0201490. eCollection 2018.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6062141</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0201490</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">62</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mann, E. E.</style></author><author><style face="normal" font="default" size="100%">Manna, D.</style></author><author><style face="normal" font="default" size="100%">Mettetal, M. R.</style></author><author><style face="normal" font="default" size="100%">May, R. M.</style></author><author><style face="normal" font="default" size="100%">Dannemiller, E. M.</style></author><author><style face="normal" font="default" size="100%">Chung, K. K.</style></author><author><style face="normal" font="default" size="100%">Brennan, A. B.</style></author><author><style face="normal" font="default" size="100%">Reddy, S. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sharklet Technologies, Inc, 12635 E. Montview Blvd, Suite 160, Aurora, CO 80045, USA.&#xD;Department of Materials Science and Engineering, University of Florida, Gainesville, FL, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Surface micropattern limits bacterial contamination</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrob Resist Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">28</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><edition><style face="normal" font="default" size="100%">2014/09/19</style></edition><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994 (Print)&#xD;2047-2994</style></isbn><accession-num><style face="normal" font="default" size="100%">25232470</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Bacterial surface contamination contributes to transmission of nosocomial infections. Chemical cleansers used to control surface contamination are often toxic and incorrectly implemented. Additional non-toxic strategies should be combined with regular cleanings to mitigate risks of human error and further decrease rates of nosocomial infections. The Sharklet micropattern (MP), inspired by shark skin, is an effective tool for reducing bacterial load on surfaces without toxic additives. The studies presented here were carried out to investigate the MP surfaces capability to reduce colonization of methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) compared to smooth control surfaces. METHODS: The MP and smooth surfaces produced in acrylic film were compared for remaining bacterial contamination and colonization following inoculation. Direct sampling of surfaces was carried out after inoculation by immersion, spray, and/or touch methods. Ultimately, a combination assay was developed to assess bacterial contamination after touch transfer inoculation combined with drying (persistence) to mimic common environmental contamination scenarios in the clinic or hospital environment. The combination transfer and persistence assay was then used to test antimicrobial copper beside the MP for the ability to reduce MSSA and MRSA challenge. RESULTS: The MP reduced bacterial contamination with log reductions ranging from 87-99% (LR = 0.90-2.18; p &lt; 0.05) compared to smooth control surfaces. The MP was more effective than the 99.9% pure copper alloy C11000 at reducing surface contamination of S. aureus (MSSA and MRSA) through transfer and persistence of bacteria. The MP reduced MSSA by as much as 97% (LR = 1.54; p &lt; 0.01) and MRSA by as much as 94% (LR = 1.26; p &lt; 0.005) compared to smooth controls. Antimicrobial copper had no significant effect on MSSA contamination, but reduced MRSA contamination by 80% (LR = 0.70; p &lt; 0.005). CONCLUSION: The assays developed in this study mimic hospital environmental contamination events to demonstrate the performance of a MP to limit contamination under multiple conditions. Antimicrobial copper has been implemented in hospital room studies to evaluate its impact on nosocomial infections and a decrease in HAI rate was shown. Similar implementation of the MP has potential to reduce the incidence of HAIs although future clinical studies will be necessary to validate the MP&apos;s true impact.</style></abstract><notes><style face="normal" font="default" size="100%">Mann, Ethan E&#xD;Manna, Dipankar&#xD;Mettetal, Michael R&#xD;May, Rhea M&#xD;Dannemiller, Elisa M&#xD;Chung, Kenneth K&#xD;Brennan, Anthony B&#xD;Reddy, Shravanthi T&#xD;Journal Article&#xD;England&#xD;Antimicrob Resist Infect Control. 2014 Sep 17;3:28. doi: 10.1186/2047-2994-3-28. eCollection 2014.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4166016</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/2047-2994-3-28</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">64</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zeiger, M.</style></author><author><style face="normal" font="default" size="100%">Solioz, M.</style></author><author><style face="normal" font="default" size="100%">Edongue, H.</style></author><author><style face="normal" font="default" size="100%">Arzt, E.</style></author><author><style face="normal" font="default" size="100%">Schneider, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">INM - Leibniz Institute for New Materials, Campus D2 2, 66123, Saarbrucken, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Surface structure influences contact killing of bacteria by copper</style></title><secondary-title><style face="normal" font="default" size="100%">Microbiologyopen</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbiologyopen</style></full-title></periodical><pages><style face="normal" font="default" size="100%">327-32</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/04/18</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Copper/chemistry/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli/*drug effects/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy, Electron, Scanning</style></keyword><keyword><style face="normal" font="default" size="100%">Surface Properties</style></keyword><keyword><style face="normal" font="default" size="100%">Antibacterial activity</style></keyword><keyword><style face="normal" font="default" size="100%">contact killing</style></keyword><keyword><style face="normal" font="default" size="100%">copper surfaces</style></keyword><keyword><style face="normal" font="default" size="100%">electrodeposition</style></keyword><keyword><style face="normal" font="default" size="100%">nosocomial infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-8827</style></isbn><accession-num><style face="normal" font="default" size="100%">24740976</style></accession-num><abstract><style face="normal" font="default" size="100%">Copper kills bacteria rapidly by a mechanism that is not yet fully resolved. The antibacterial property of copper has raised interest in its use in hospitals, in place of plastic or stainless steel. On the latter surfaces, bacteria can survive for days or even weeks. Copper surfaces could thus provide a powerful accessory measure to curb nosocomial infections. We here investigated the effect of the copper surface structure on the efficiency of contact killing of Escherichia coli, an aspect which so far has received very little attention. It was shown that electroplated copper surfaces killed bacteria more rapidly than either polished copper or native rolled copper. The release of ionic copper was also more rapid from electroplated copper compared to the other materials. Scanning electron microscopy revealed that the bacteria nudged into the grooves between the copper grains of deposited copper. The findings suggest that, in terms of contact killing, more efficient copper surfaces can be engineered.</style></abstract><notes><style face="normal" font="default" size="100%">2045-8827&#xD;Zeiger, Marco&#xD;Solioz, Marc&#xD;Edongue, Hervais&#xD;Arzt, Eduard&#xD;Schneider, Andreas S&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;Microbiologyopen. 2014 Jun;3(3):327-32. doi: 10.1002/mbo3.170. Epub 2014 Apr 17.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC4082706</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mbo3.170</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">90</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mikolay, A.</style></author><author><style face="normal" font="default" size="100%">Huggett, S.</style></author><author><style face="normal" font="default" size="100%">Tikana, L.</style></author><author><style face="normal" font="default" size="100%">Grass, G.</style></author><author><style face="normal" font="default" size="100%">Braun, J.</style></author><author><style face="normal" font="default" size="100%">Nies, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut fur Mikrobiologie, Martin-Luther-Universitat Halle-Wittenberg, Kurt-Mothes-Str. 3, 06099 Halle, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Survival of bacteria on metallic copper surfaces in a hospital trial</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Microbiol Biotechnol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Appl Microbiol Biotechnol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1875-9</style></pages><volume><style face="normal" font="default" size="100%">87</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">2010/05/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial Viability/*drug effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0175-7598</style></isbn><accession-num><style face="normal" font="default" size="100%">20449737</style></accession-num><abstract><style face="normal" font="default" size="100%">Basic chemistry of copper is responsible for its Janus-faced feature: on one hand, copper is an essential trace element required to interact efficiently with molecular oxygen. On the other hand, interaction with reactive oxygen species in undesired Fenton-like reactions leads to the production of hydroxyl radicals, which rapidly damage cellular macromolecules. Moreover, copper cations strongly bind to thiol compounds disturbing redox-homeostasis and may also remove cations of other transition metals from their native binding sites in enzymes. Nature has learned during evolution to deal with the dangerous yet important copper cations. Bacterial cells use different efflux systems to detoxify the metal from the cytoplasm or periplasm. Despite this ability, bacteria are rapidly killed on dry metallic copper surfaces. The mode of killing likely involves copper cations being released from the metallic copper and reactive oxygen species. With all this knowledge about the interaction of copper and its cations with cellular macromolecules in mind, experiments were moved to the next level, and the antimicrobial properties of copper-containing alloys in an &quot;everyday&quot; hospital setting were investigated. The alloys tested decreased the number of colony-forming units on metallic copper-containing surfaces by one third compared to control aluminum or plastic surfaces. Moreover, after disinfection, repopulation of the surfaces was delayed on copper alloys. This study bridges a gap between basic research concerning cellular copper homeostasis and application of this knowledge. It demonstrates that the use of copper-containing alloys may limit the spread of multiple drug-resistant bacteria in hospitals.</style></abstract><notes><style face="normal" font="default" size="100%">1432-0614&#xD;Mikolay, Andre&#xD;Huggett, Susanne&#xD;Tikana, Ladji&#xD;Grass, Gregor&#xD;Braun, Jorg&#xD;Nies, Dietrich H&#xD;Comparative Study&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Germany&#xD;Appl Microbiol Biotechnol. 2010 Aug;87(5):1875-9. doi: 10.1007/s00253-010-2640-1. Epub 2010 May 7.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00253-010-2640-1</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weaver, L.</style></author><author><style face="normal" font="default" size="100%">Michels, H. T.</style></author><author><style face="normal" font="default" size="100%">Keevil, C. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental Healthcare Unit, School of Biological Sciences, University of Southampton, Southampton, UK. lw14@soton.ac.uk</style></auth-address><titles><title><style face="normal" font="default" size="100%">Survival of Clostridium difficile on copper and steel: futuristic options for hospital hygiene</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">145-51</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2008/01/22</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alloys/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridium difficile/drug effects/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Dyes/administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Occupational Health</style></keyword><keyword><style face="normal" font="default" size="100%">Spores, Bacterial/growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Stainless Steel/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Tetrazolium Salts/administration &amp; dosage</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701 (Print)&#xD;0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">18207284</style></accession-num><abstract><style face="normal" font="default" size="100%">Clostridium difficile is rapidly becoming a major cause of hospital-acquired infections worldwide, due in part to transmission of the faecal pathogen between contaminated hands and contact surfaces. Accordingly, this study evaluated survival of C. difficile vegetative cells and spores on the contact surface commonly found in healthcare settings, stainless steel, compared to five copper alloys (65-100% copper content). C. difficile requires prolonged incubation to grow and therefore the total number and number of viable cells was estimated using a fluorescence dual-staining technique. For viability assessment the redox dye 5-cyano-2,3-ditolyl tetrazolium (CTC) was used to measure metabolic activity. Results demonstrated that copper alloys with a copper content &gt;70% provide a significant reduction in survival of C. difficile vegetative cells and spores on copper alloys compared with stainless steel. Complete death of spores was observed after 24-48 h on copper alloys whereas no significant death rate was observed on stainless steel even after 168 h. The use of CTC gave comparable results to culture and offers a more rapid viability analysis (8 h) than culture. The results suggest that using copper alloys in hospitals and other healthcare facilities could offer the potential to reduce spread of C. difficile from contaminated surfaces.</style></abstract><notes><style face="normal" font="default" size="100%">Weaver, L&#xD;Michels, H T&#xD;Keevil, C W&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Hosp Infect. 2008 Feb;68(2):145-51. doi: 10.1016/j.jhin.2007.11.011. Epub 2008 Jan 22.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2007.11.011</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>343</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">343</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haseeb, A.</style></author><author><style face="normal" font="default" size="100%">Engel, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Haseeb, University of Utah, School of Medicine, Salt Lake City, UT, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Surviving painless jaundice-A test for patient and physician</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S442</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><keywords><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">warfarin</style></keyword><keyword><style face="normal" font="default" size="100%">clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">paracetamol</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin glucuronide</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">liver enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">ursodeoxycholic acid</style></keyword><keyword><style face="normal" font="default" size="100%">isoniazid</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">physician</style></keyword><keyword><style face="normal" font="default" size="100%">jaundice</style></keyword><keyword><style face="normal" font="default" size="100%">internal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">toxic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">liver injury</style></keyword><keyword><style face="normal" font="default" size="100%">liver function test</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">injury</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">liver necrosis</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">register</style></keyword><keyword><style face="normal" font="default" size="100%">imaging</style></keyword><keyword><style face="normal" font="default" size="100%">liver cell damage</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">pruritus</style></keyword><keyword><style face="normal" font="default" size="100%">international normalized ratio</style></keyword><keyword><style face="normal" font="default" size="100%">implantable cardioverter defibrillator</style></keyword><keyword><style face="normal" font="default" size="100%">urine</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">emergency care</style></keyword><keyword><style face="normal" font="default" size="100%">tree</style></keyword><keyword><style face="normal" font="default" size="100%">pancreas</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis A</style></keyword><keyword><style face="normal" font="default" size="100%">offender</style></keyword><keyword><style face="normal" font="default" size="100%">epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">alpha 1 antitrypsin deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">celiac disease</style></keyword><keyword><style face="normal" font="default" size="100%">abdomen</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">computer assisted tomography</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">punishment</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol consumption</style></keyword><keyword><style face="normal" font="default" size="100%">bile duct</style></keyword><keyword><style face="normal" font="default" size="100%">neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">ischemic cardiomyopathy</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">hyperbilirubinemia</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">consultation</style></keyword><keyword><style face="normal" font="default" size="100%">invasive procedure</style></keyword><keyword><style face="normal" font="default" size="100%">data base</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol abuse</style></keyword><keyword><style face="normal" font="default" size="100%">ultrasound</style></keyword><keyword><style face="normal" font="default" size="100%">acute sinusitis</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">education</style></keyword><keyword><style face="normal" font="default" size="100%">decreased appetite</style></keyword><keyword><style face="normal" font="default" size="100%">law</style></keyword><keyword><style face="normal" font="default" size="100%">library</style></keyword><keyword><style face="normal" font="default" size="100%">watchful waiting</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVE 1: Diagnose drug induced liver injury. LEARNING OBJECTIVE 2: Recognize when to manage markedly elevated bilirubin levels with watchful waiting and no invasive testing. CASE: A 92-year-old male with a history of ischemic cardiomyopathy and atrial fibrillation on chronic Coumadin therapy, presented to the acute-care-clinic with complaints of painless jaundice, pruritus, dark urine, and decreased appetite. The patient denied any history of hepatitis or alcohol use. Laboratory findings were significant for elevated total bilirubin 17.5 mg/dl, direct bilirubin 10.8 mg/dl, INR 4.8, alkaline phosphatase 1023 U/L, AST 230 U/L, and ALT 227 U/L. CT scan of the abdomen showed no abnormalities of the liver, pancreas or biliary tree. Initial assessment included a full review of his medication history. Two weeks prior to his current presentation, he later recalled completing a seven-day course of amoxicillin/ clavulanate for a diagnosis of acute sinusitis. This was thought to be the culprit for his drug induced liver injury. Given the elevated INR, the patient&apos;s Coumadin was stopped and his INR returned to therapeutic range within 4 days. The patient was treated symptomatically for his pruritus and started on Ursodiol when his bilirubin level surpassed 30 mg/dL. The patient&apos;s liver enzymes and total bilirubin peaked 1 week after the initial presentation and then started to gradually downtrend. Although he felt better within 4 weeks, it took nearly 4 months for his laboratory values to normalize. No invasive procedures or additional imaging were performed, and no specialty consultations (save a phone call) were obtained. DISCUSSION: The differential diagnosis of jaundice is large. To narrow the list, the pattern of hepatocellular, cholestatic, or isolated hyperbilirubinemia can be discerned from the liver function test (LFT) pattern. Once neoplasms and dilated bile ducts have been excluded with imaging, and the usual infectious and toxic exposures and alcohol disqualified by history, and inherited disorder made unlikely by the patient&apos;s age, suddenly the possible diagnoses are fairly small. What seemed to be a death sentence on presentation for our patient, was rapidly becoming good news. Drug induced liver injury (DILI) has an incidence of 13.9+2.4 cases/100,000 and is estimated to affect 44,000 individuals annually in the United States. Despite the low incidence, 10 % of the patients with drug-induced jaundice will die. Most cases of DILI are due to either a dose dependent acetaminophen-type reaction or an idiosyncratic reaction. The data from prospective registries, such as the Drug Induced Liver Injury Network, indicates amoxicillin/clavulanate as a major culprit of idiosyncratic reactions. DILI can be classified based on the pattern of the liver injury: hepatocellular, cholestatic, or mixed. DILI remains a diagnostic challenge. Diagnosis of DILI is usually made through the process of causality assessment, which interestingly is similar to any criminal investigation. A few steps include: “Was the drug in the right place at the right time?”, “Does this drug have a prior record?”, “Are the characteristics of liver injury consistent with the implicated drug?”, “Are there other more reasonable explanations for the liver injury?”. Depending on the case scenario and the comorbidities, testing for Hepatitis A, B, C and sometimes E, iron/copper overload, alpha-1-antitrypsin deficiency, Celiac disease, alcohol abuse, and ultrasound of the liver are to be undertaken before diagnosing DILI. Amoxicillin/clavulanate is known to cause cholestatic or mixed liver injury with jaundice approximately 2 to 3 weeks after the medication has been stopped, as seen in our case described above. Hence, prior medication history is key in making the diagnosis. Improvement of the liver function tests is slower with drugs that induce a cholestatic injury compared to hepatocellular injury. Hepatic necrosis is uncommon in cholestatic injury, thereby having a lower mortality when compared to the other patterns. The rates of epatic necrosis are 3 % in amoxicillin/clavulanate, compared to 65 % with isoniazid related hepatocellular injury. Elderly patients, like in our case, are prone to cholestatic/mixed pictures of DILI. Several strategies can be used to prevent DILI, which include patient/physician education, liver function test screening, and active legislation to restrict the potentially toxic drugs. Clinicians can utilize the National Library of Medicine “LiverTox” database, which uses prospective registries as an excellent point of care resource to identify potential drug culprits. When presented with patients such as our elderly gentleman, with impressively high lab values which continue to increase, the fallback is often to consult or proceed with invasive testing. Sometimes the best medicine is to do nothing.</style></abstract><notes><style face="normal" font="default" size="100%">L71495789&#xD;2014-06-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71495789</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">81</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, M. G.</style></author><author><style face="normal" font="default" size="100%">Attaway, H. H.</style></author><author><style face="normal" font="default" size="100%">Sharpe, P. A.</style></author><author><style face="normal" font="default" size="100%">John, J., Jr.</style></author><author><style face="normal" font="default" size="100%">Sepkowitz, K. A.</style></author><author><style face="normal" font="default" size="100%">Morgan, A.</style></author><author><style face="normal" font="default" size="100%">Fairey, S. E.</style></author><author><style face="normal" font="default" size="100%">Singh, S.</style></author><author><style face="normal" font="default" size="100%">Steed, L. L.</style></author><author><style face="normal" font="default" size="100%">Cantey, J. R.</style></author><author><style face="normal" font="default" size="100%">Freeman, K. D.</style></author><author><style face="normal" font="default" size="100%">Michels, H. T.</style></author><author><style face="normal" font="default" size="100%">Salgado, C. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical University of South Carolina, Department of Microbiology and Immunology, Charleston, South Carolina, USA. schmidtm@musc.edu</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sustained reduction of microbial burden on common hospital surfaces through introduction of copper</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Microbiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Microbiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2217-23</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2012/05/04</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Bacteria/classification/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfectants/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0095-1137</style></isbn><accession-num><style face="normal" font="default" size="100%">22553242</style></accession-num><abstract><style face="normal" font="default" size="100%">The contribution of environmental surface contamination with pathogenic organisms to the development of health care-associated infections (HAI) has not been well defined. The microbial burden (MB) associated with commonly touched surfaces in intensive care units (ICUs) was determined by sampling six objects in 16 rooms in ICUs in three hospitals over 43 months. At month 23, copper-alloy surfaces, with inherent antimicrobial properties, were installed onto six monitored objects in 8 of 16 rooms, and the effect that this application had on the intrinsic MB present on the six objects was assessed. Census continued in rooms with and without copper for an additional 21 months. In concert with routine infection control practices, the average MB found for the six objects assessed in the clinical environment during the preintervention phase was 28 times higher (6,985 CFU/100 cm(2); n = 3,977 objects sampled) than levels proposed as benign immediately after terminal cleaning (&lt;250 CFU/100 cm(2)). During the intervention phase, the MB was found to be significantly lower for both the control and copper-surfaced objects. Copper was found to cause a significant (83%) reduction in the average MB found on the objects (465 CFU/100 cm(2); n = 2714 objects) compared to the controls (2,674 CFU/100 cm(2); n = 2,831 objects [P &lt; 0.0001]). The introduction of copper surfaces to objects formerly covered with plastic, wood, stainless steel, and other materials found in the patient care environment significantly reduced the overall MB on a continuous basis, thereby providing a potentially safer environment for hospital patients, health care workers (HCWs), and visitors.</style></abstract><notes><style face="normal" font="default" size="100%">1098-660x&#xD;Schmidt, Michael G&#xD;Attaway, Hubert H&#xD;Sharpe, Peter A&#xD;John, Joseph Jr&#xD;Sepkowitz, Kent A&#xD;Morgan, Andrew&#xD;Fairey, Sarah E&#xD;Singh, Susan&#xD;Steed, Lisa L&#xD;Cantey, J Robert&#xD;Freeman, Katherine D&#xD;Michels, Harold T&#xD;Salgado, Cassandra D&#xD;P30 CA008748/CA/NCI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;United States&#xD;J Clin Microbiol. 2012 Jul;50(7):2217-23. doi: 10.1128/JCM.01032-12. Epub 2012 May 2.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC3405627</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/jcm.01032-12</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bankier, C.</style></author><author><style face="normal" font="default" size="100%">Matharu, R. K.</style></author><author><style face="normal" font="default" size="100%">Cheong, Y. K.</style></author><author><style face="normal" font="default" size="100%">Ren, G. G.</style></author><author><style face="normal" font="default" size="100%">Cloutman-Green, E.</style></author><author><style face="normal" font="default" size="100%">Ciric, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Civil, Environmental and Geomatic Engineering, University College London, London, WC1E 7JE, UK.&#xD;Department of Mechanical Engineering, University College London, London, WC1E 7JE, UK.&#xD;School of Engineering and Technology, University of Hertfordshire, Hatfield, AL10 9AB, UK.&#xD;Department of Microbiology, Virology, and Infection Prevention Control, Great Ormond Street Hospital NHS Foundation Trust, London, WCIN 3JH, UK.&#xD;Department of Civil, Environmental and Geomatic Engineering, University College London, London, WC1E 7JE, UK. l.ciric@ucl.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Synergistic Antibacterial Effects of Metallic Nanoparticle Combinations</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sci Rep</style></full-title></periodical><pages><style face="normal" font="default" size="100%">16074</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2019/11/07</style></edition><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2045-2322</style></isbn><accession-num><style face="normal" font="default" size="100%">31690845</style></accession-num><abstract><style face="normal" font="default" size="100%">Metallic nanoparticles have unique antimicrobial properties that make them suitable for use within medical and pharmaceutical devices to prevent the spread of infection in healthcare. The use of nanoparticles in healthcare is on the increase with silver being used in many devices. However, not all metallic nanoparticles can target and kill all disease-causing bacteria. To overcome this, a combination of several different metallic nanoparticles were used in this study to compare effects of multiple metallic nanoparticles when in combination than when used singly, as single elemental nanoparticles (SENPs), against two common hospital acquired pathogens (Staphylococcus aureus and Pseudomonas. aeruginosa). Flow cytometry LIVE/DEAD assay was used to determine rates of cell death within a bacterial population when exposed to the nanoparticles. Results were analysed using linear models to compare effectiveness of three different metallic nanoparticles, tungsten carbide (WC), silver (Ag) and copper (Cu), in combination and separately. Results show that when the nanoparticles are placed in combination (NPCs), antimicrobial effects significantly increase than when compared with SENPs (P &lt; 0.01). This study demonstrates that certain metallic nanoparticles can be used in combination to improve the antimicrobial efficiency in destroying morphologically distinct pathogens within the healthcare and pharmaceutical industry.</style></abstract><notes><style face="normal" font="default" size="100%">2045-2322&#xD;Bankier, C&#xD;Matharu, R K&#xD;Cheong, Y K&#xD;ORCID: http://orcid.org/0000-0002-3737-6285&#xD;Ren, G G&#xD;ORCID: http://orcid.org/0000-0001-8865-1526&#xD;Cloutman-Green, E&#xD;Ciric, L&#xD;Journal Article&#xD;England&#xD;Sci Rep. 2019 Nov 5;9(1):16074. doi: 10.1038/s41598-019-52473-2.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC6831564</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41598-019-52473-2</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leite, T. O. C.</style></author><author><style face="normal" font="default" size="100%">Novais, J. S.</style></author><author><style face="normal" font="default" size="100%">de Carvalho, B. L. C.</style></author><author><style face="normal" font="default" size="100%">Ferreira, V. F.</style></author><author><style face="normal" font="default" size="100%">Miceli, L. A.</style></author><author><style face="normal" font="default" size="100%">Fraga, L.</style></author><author><style face="normal" font="default" size="100%">Abrahim-Vieira, B.</style></author><author><style face="normal" font="default" size="100%">Rodrigues, C. R.</style></author><author><style face="normal" font="default" size="100%">Sa Figueiredo, A. M.</style></author><author><style face="normal" font="default" size="100%">Castro, H. C.</style></author><author><style face="normal" font="default" size="100%">Cunha, A. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universidade Federal Fluminense, Instituto de Quimica, Departamento de Quimica Organica, Programa de Pos- Graduacao em Quimica, 24020-141, Niteroi, Rio de Janeiro. Brazil.&#xD;Universidade Federal Fluminense, Programas de Pos-Graduacao em Patologia (HUAP) e em Ciencias e Biotecnologia (PPBI), 24020-150, Niteroi, Rio de Janeiro. Brazil.&#xD;Universidade Federal do Rio de Janeiro, Instituto de Quimica, Departamento de Quimica Organica, 21941-909, Rio de Janeiro. Brazil.&#xD;Universidade Federal Fluminense, Faculdade de Farmacia, 24241-000, Departamento de Tecnologia Farmaceutica, Niteroi, Rio de Janeiro. Brazil.&#xD;Universidade Federal do Rio de Janeiro, Instituto de Microbiologia Professor Paulo de Goes, Programa de Pos- Graduacao em Ciencias Farmaceuticas e Faculdade de Farmacia, 21941-902, Rio de Janeiro. Brazil.&#xD;Universidade Federal do Rio de Janeiro,Laboratorio de Modelagem Molecular e QSAR (MODMOLQSAR), Faculdade de Farmacia, 21941-902, Rio de Janeiro. Brazil.&#xD;Universidade Federal do Rio de Janeiro, Programa de Pos-Graduacao em Ciencias Farmaceuticas da Faculdade de Farmacia, 21941-902, Rio de Janeiro. Brazil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Synthesis, in vitro and in silico studies of indolequinone derivatives against clinically relevant bacterial pathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Top Med Chem</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Top Med Chem</style></full-title></periodical><edition><style face="normal" font="default" size="100%">2019/12/24</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">Indolequinone</style></keyword><keyword><style face="normal" font="default" size="100%">Mrsa</style></keyword><keyword><style face="normal" font="default" size="100%">Molecular Docking</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus Aureus</style></keyword><keyword><style face="normal" font="default" size="100%">beta-Enamino Ketones</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1568-0266</style></isbn><accession-num><style face="normal" font="default" size="100%">31868148</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: According to the World Health Organization, antimicrobial resistance is one of the most important public health threats of the 21st century. Therefore, there is an urgent need for the development of antimicrobial agents with new mechanism of action, especially those capable of evading known resistance mechanisms. OBJECTIVE: we described the synthesis, in vitro antimicrobial evaluation, and in silico analysis of a series of 1H-indole-4,7-dione derivatives. METHODS: The new series of 1H-indole-4,7-diones was prepared with good yield by using a copper(II)-mediated reaction between bromoquinone and beta-enamino ketones bearing alkyl or phenyl groups attached to the nitrogen atom. The antimicrobial potential of indole derivatives was assessed. Molecular docking studies were also performed using AutoDock 4.2 for Windows. Characterization of all compounds was confirmed by one- and two-dimensional NMR techniques 1H and 13C NMR spectra [1H, 13C - APT, 1H x 1H - COSY, HSQC and HMBC], IR and mass spectrometry analysis. RESULTS: Several indolequinone compounds showed effective antimicrobial profile against Gram- positive (MIC = 16 mug.mL-1) and Gram-negative bacteria (MIC = 8 mug.mL-1) similar to antimicrobials current on the market. The 3-acetyl-1-(2,5-dimethylphenyl)-1H-indole-4,7-dione derivative exhibited an important effect against different biofilm stages formed by a serious hospital life-threatening resistant strain of Methicillin-Resistant Staphylococcus aureus (MRSA). A hemocompatibility profile analysis based on in vitro hemolysis assays revealed the low toxicity effects of this new series. Indeed, in silico studies showed a good pharmacokinetics and toxicological profiles for all indolequinone derivatives, reinforcing their feasibility to display a promising oral bioavailability. An elucidation of the promising indolequinone derivatives binding mode was achieved, showing interactions with important sites to biological activity of S. aureus DNA gyrase. These results highlighted 3-acetyl-1-(2-hydroxyethyl)-1H-indole-4,7-dione derivative as broad-spectrum antimicrobial prototype to be further explored for treating bacterial infections. CONCLUSION: The highly substituted indolequinones were obtained in moderate to good yields. The pharmacological study indicated that these compounds should be exploited in the search for a leading substance in a project aimed at obtaining new antimicrobials effective against Gram- negative bacteria.</style></abstract><notes><style face="normal" font="default" size="100%">1873-4294&#xD;Leite, Talita Odriane Custodio&#xD;Novais, Juliana Silva&#xD;de Carvalho, Beatriz Lima Cosenza&#xD;Ferreira, Vitor Francisco&#xD;Miceli, Leonardo Alves&#xD;Fraga, Leticia&#xD;Abrahim-Vieira, Barbara&#xD;Rodrigues, Carlos Rangel&#xD;Sa Figueiredo, Agnes Marie&#xD;Castro, Helena Carla&#xD;Cunha, Anna Claudia&#xD;Journal Article&#xD;United Arab Emirates&#xD;Curr Top Med Chem. 2019 Dec 22. pii: CTMC-EPUB-103138. doi: 10.2174/1568026620666191223110518.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/1568026620666191223110518</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>424</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">424</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peterson, S.</style></author><author><style face="normal" font="default" size="100%">Chen, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Peterson, Rush University Medical Center, 1653 West Congress Parkway, 370 Pavilion, Chicago, IL 60612, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systemic approach to parenteral nutrition in the ICU</style></title><secondary-title><style face="normal" font="default" size="100%">Current Drug Safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Drug Safety</style></full-title></periodical><pages><style face="normal" font="default" size="100%">33-40</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">acetic acid</style></keyword><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">amino acid</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">biotin</style></keyword><keyword><style face="normal" font="default" size="100%">calcium</style></keyword><keyword><style face="normal" font="default" size="100%">carbohydrate</style></keyword><keyword><style face="normal" font="default" size="100%">chloride</style></keyword><keyword><style face="normal" font="default" size="100%">chromium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">electrolyte</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">glucose</style></keyword><keyword><style face="normal" font="default" size="100%">lipid emulsion</style></keyword><keyword><style face="normal" font="default" size="100%">magnesium</style></keyword><keyword><style face="normal" font="default" size="100%">manganese</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">pantothenic acid</style></keyword><keyword><style face="normal" font="default" size="100%">phosphorus</style></keyword><keyword><style face="normal" font="default" size="100%">potassium</style></keyword><keyword><style face="normal" font="default" size="100%">protein</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">retinol</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">sodium</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">unindexed drug</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin K group</style></keyword><keyword><style face="normal" font="default" size="100%">blood clotting disorder</style></keyword><keyword><style face="normal" font="default" size="100%">candidemia</style></keyword><keyword><style face="normal" font="default" size="100%">catheter infection</style></keyword><keyword><style face="normal" font="default" size="100%">central venous catheter</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">energy expenditure</style></keyword><keyword><style face="normal" font="default" size="100%">fatty liver</style></keyword><keyword><style face="normal" font="default" size="100%">glucose blood level</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypercapnia</style></keyword><keyword><style face="normal" font="default" size="100%">hyperglycemia</style></keyword><keyword><style face="normal" font="default" size="100%">hypertriglyceridemia</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">macronutrient</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional requirement</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">parenteral nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">patient safety</style></keyword><keyword><style face="normal" font="default" size="100%">patient selection</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacy (shop)</style></keyword><keyword><style face="normal" font="default" size="100%">physical chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">prescription</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory distress</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">thrombophlebitis</style></keyword><keyword><style face="normal" font="default" size="100%">thrombosis</style></keyword><keyword><style face="normal" font="default" size="100%">treatment indication</style></keyword><keyword><style face="normal" font="default" size="100%">uremia</style></keyword><keyword><style face="normal" font="default" size="100%">vascular access</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">1574-8863</style></isbn><abstract><style face="normal" font="default" size="100%">The nutrition support clinician must understand and evaluate all components of parenteral nutrition (PN) to maximize benefits while avoiding unfavorable consequences for the patients in the intensive care unit. The various aspects in caring for the PN patient include appropriate patient selection, intravenous access choice and maintenance, and individualized PN prescription to meet each patient&apos;s unique macronutrient and micronutrient requirements. Once the PN prescription has been determined, the clinician should also be familiar with the compounding process to ensure the final solution is safe for infusion. PN is one of the most complex solutions prepared in the pharmacy with numerous ingredients. Due to the number of components in the PN solution, physicochemical incompatibilities are a common and serious problem, thus specific compounding sequence and guidelines must be followed to avoid precipitation of mixed products. Once the PN solution is ready for infusion, protocols should be in place to assure safe administration. Close monitoring for tolerance of electrolytes and macronutrients, as well as glucose control is necessary initially; whereas monitoring of specific micronutrients is crucial in long-term PN usage. A standardized process for ordering, preparing, administering and monitoring PN is recommended to assure patient safety. © 2010 Bentham Science Publishers Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">L358617091&#xD;2010-04-21&#xD;2010-05-19</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L358617091</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2174/157488610789869139</style></url><url><style face="normal" font="default" size="100%">http://www.benthamdirect.org/pages/all_b_bypublication.php</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">20210717</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/157488610789869139</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>365</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">365</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Efstathiou, P.</style></author><author><style face="normal" font="default" size="100%">Kouskouni, E.</style></author><author><style face="normal" font="default" size="100%">Karageorgou, K.</style></author><author><style face="normal" font="default" size="100%">Manolidou, Z.</style></author><author><style face="normal" font="default" size="100%">Papanikolaou, S.</style></author><author><style face="normal" font="default" size="100%">Tseroni, M.</style></author><author><style face="normal" font="default" size="100%">Logothetis, E.</style></author><author><style face="normal" font="default" size="100%">Petropoulou, C.</style></author><author><style face="normal" font="default" size="100%">Karyoti, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Efstathiou, National Health Operations Centre, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">The testing procedure of antimicrobial copper&apos;s Cu+ final product as a method of assurance and certification of its antimicrobial efficacy</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">certification</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">procedures</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium</style></keyword><keyword><style face="normal" font="default" size="100%">cell culture technique</style></keyword><keyword><style face="normal" font="default" size="100%">random sample</style></keyword><keyword><style face="normal" font="default" size="100%">parameters</style></keyword><keyword><style face="normal" font="default" size="100%">algorithm</style></keyword><keyword><style face="normal" font="default" size="100%">humidity</style></keyword><keyword><style face="normal" font="default" size="100%">school</style></keyword><keyword><style face="normal" font="default" size="100%">side effect</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">microflora</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">2047-2994</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: The aim of this study is to record the testing procedure of antimicrobial copper&apos;s Cu+ final products implemented in different facilities in order to reduce microbial flora. Methods: In areas where Cu+ [Intensive Care Unit (ICU) and schools] has already been implemented, random samples were collected for microbiological cultures using both wet and dry method (technique). The samples were collected in 3 different time - periods: during, 2 and 6 months after the implementation. All product manufacturing stages were recorded and taken into account by the construction company as well as maintenance and cleaning procedures of Cu+ surfaces and objects. Culture techniques in all samples collected were identical. 256 Cu+ surfaces and objects were tested and over 768 cultures for bacteria and viruses were taken, deriving all from 4 different facilities. Results: The antimicrobial effectiveness of the surveyed Cu+ objects and surfaces varied between 90-95%. Parameters such as multiple use, cleaning materials, conditions of humidity and dryness, appear not to affect the effectiveness of Cu+. The algorithm of the product testing procedure was recorded. Conclusion: The management of the facilities where Cu+ was implemented, demanded that the final Cu+ product was tested. The testing procedure of the Cu+ final product was a requirement from the management whose facilities were implemented. The above procedure is a method of implementations&apos; assurance and certification, gives further value to the innovative implementation of antimicrobial alloys and ensures the possible side effects of distortion of the raw material and fake product manufacturing (FALSE).</style></abstract><notes><style face="normal" font="default" size="100%">L72036421&#xD;2015-10-17</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72036421</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>377</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">377</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ross Eckard, A.</style></author><author><style face="normal" font="default" size="100%">Hebbar, G.</style></author><author><style face="normal" font="default" size="100%">Easley, K. A.</style></author><author><style face="normal" font="default" size="100%">Hudson, M. L.</style></author><author><style face="normal" font="default" size="100%">Umpierrez, G.</style></author><author><style face="normal" font="default" size="100%">Shenvi, N.</style></author><author><style face="normal" font="default" size="100%">Rosebush, J. C.</style></author><author><style face="normal" font="default" size="100%">Frediani, J. K.</style></author><author><style face="normal" font="default" size="100%">Kiener, A. J.</style></author><author><style face="normal" font="default" size="100%">Ruff, J. H.</style></author><author><style face="normal" font="default" size="100%">Tangpricha, V.</style></author><author><style face="normal" font="default" size="100%">Blumberg, H. M.</style></author><author><style face="normal" font="default" size="100%">Ziegler, T. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Ross Eckard, Emory University, School of Medicine, Atlanta, GA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trace element levels are linked to CD4 counts and HIV-1 RNA in a cohort of inner-city HIV+ patients admitted with respiratory symptoms</style></title><secondary-title><style face="normal" font="default" size="100%">Antiviral Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antiviral Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">A59-A60</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><keywords><keyword><style face="normal" font="default" size="100%">CD4 antigen</style></keyword><keyword><style face="normal" font="default" size="100%">trace element</style></keyword><keyword><style face="normal" font="default" size="100%">RNA</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">testolactone</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">city</style></keyword><keyword><style face="normal" font="default" size="100%">workshop</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">adverse drug reaction</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">blood</style></keyword><keyword><style face="normal" font="default" size="100%">supplementation</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">diet restriction</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional status</style></keyword><keyword><style face="normal" font="default" size="100%">nonparametric test</style></keyword><keyword><style face="normal" font="default" size="100%">unemployment</style></keyword><keyword><style face="normal" font="default" size="100%">immune status</style></keyword><keyword><style face="normal" font="default" size="100%">blood level</style></keyword><keyword><style face="normal" font="default" size="100%">body fat</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword><keyword><style face="normal" font="default" size="100%">lean body weight</style></keyword><keyword><style face="normal" font="default" size="100%">impedance</style></keyword><keyword><style face="normal" font="default" size="100%">body composition</style></keyword><keyword><style face="normal" font="default" size="100%">body mass</style></keyword><keyword><style face="normal" font="default" size="100%">body weight change</style></keyword><keyword><style face="normal" font="default" size="100%">developing country</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">nutritional assessment</style></keyword><keyword><style face="normal" font="default" size="100%">homelessness</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">socioeconomics</style></keyword><keyword><style face="normal" font="default" size="100%">zinc deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">vulnerable population</style></keyword><keyword><style face="normal" font="default" size="100%">health</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial (topic)</style></keyword><keyword><style face="normal" font="default" size="100%">nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">tuberculosis</style></keyword><keyword><style face="normal" font="default" size="100%">acquired immune deficiency syndrome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1359-6535</style></isbn><abstract><style face="normal" font="default" size="100%">Background: Trace elements (TE) are essential to normal pulmonary and immune function, and deficiencies are associated with many diseases in non-HIV populations. TE supplementation, specifically with zinc (Zn), selenium (Se) and copper (Cu), decreases the number and severity of respiratory tract infections (RTIs) in some studies. In HIV, Zn and Se deficiencies are associated with lower CD4 counts, impaired virological control and increased tuberculosis risk, especially in developing countries, but few studies have evaluated blood Cu concentrations. We determined blood TE concentrations and associations with HIV variables in a cohort of low socioeconomic HIV patients admitted for RTIs to an inner-city US hospital. Methods: Consecutive patients admitted to the respiratory isolation ward of Grady Memorial Hospital in Atlanta, GA, USA with symptoms suspicious for pulmonary TB were enrolled. Patients were stratified based on HIV status. Fasting blood was collected and stored in TE-free cryovials. Serum concentrations of Zn, Se and Cu were measured at the USDA Human Nutrition Research Center, Grand Forks, ND, USA by spectrometric methods. Data were collected for demographics, socioeconomics, medical history and HIV factors. Nutritional assessment included supplement use, recent dietary and/or weight changes, body mass index, body composition by bioelectrical impedance analysis for total lean body mass and body fat, and subjective global assessment of nutritional status. Non-parametric tests and Spearman correlations were used to compare groups and investigate TE associations, respectively. Results: A total of 18 HIV+ and 21 HIV- subjects were enrolled. All had non-TB RTIs and/or non-infectious causes of respiratory symptoms. HIV+ subjects had a median age of 42 years, 72% male, and 94% Blacks, and had high rates of homelessness and unemployment (22% and 72%, respectively [HIV population similar except age 52 years; P&lt;0.01]). HIV duration was 14 years (8, 19); most patients were non-compliant with antiretroviral therapy and had poor immune status and virological control (median [IQR] CD4 count: 85 cells/μ1-242], HIV-1 RNA 89,610 copies/ml [44,150-126,630]). In HIV+ subjects, median (IQR) concentrations for TEs were within reference ranges (Se 98 μ [81-116], Cu 1.4 μg/ml [1.1-1.7], Zn 0.8 μg/ml [0.6-1.0]; HIV similar]. However, 6%, 6% and 39% of HIV+ subjects were Se, Cu and Zn deficient, respectively. Cu concentrations were negatively correlated with HIV-1 RNA levels (r=-0.8; P&lt;0.01) and Se concentrations were positively correlated with CD4 counts (r=0.6; P=0.01). Discussion: This HIV+ cohort is representative of lowincome people with AIDS in metropolitan Atlanta. More than 1/3 exhibited Zn deficiency. Notably, Se was associated with CD4 counts, and, for the first time, we identified a relationship between Cu and virological status. Clinical trials are needed to determine if supplementation with specific TEs, alone or in combination, may help to improve health in this vulnerable population.</style></abstract><notes><style face="normal" font="default" size="100%">L71281041&#xD;2014-01-08</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L71281041</style></url></related-urls><pdf-urls><url>internal-pdf://2827254722/Lipo_for_18.6.pdf</url></pdf-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berger, M. M.</style></author><author><style face="normal" font="default" size="100%">Spertini, F.</style></author><author><style face="normal" font="default" size="100%">Shenkin, A.</style></author><author><style face="normal" font="default" size="100%">Wardle, C.</style></author><author><style face="normal" font="default" size="100%">Wiesner, L.</style></author><author><style face="normal" font="default" size="100%">Schindler, C.</style></author><author><style face="normal" font="default" size="100%">Chiolero, R. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Surgical ICU and Burns Centre, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Mette.Berger@chuv.hospvd.ch</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Clin Nutr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">365-71</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">1998/08/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Burns/*complications/immunology/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leukocyte Count</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pneumonia/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Trace Elements/*administration &amp; dosage/blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9165 (Print)&#xD;0002-9165</style></isbn><accession-num><style face="normal" font="default" size="100%">9701195</style></accession-num><abstract><style face="normal" font="default" size="100%">Infections remain the leading cause of death after major burns. Trace elements are involved in immunity and burn patients suffer acute trace element depletion after injury. In a previous nonrandomized study, trace element supplementation was associated with increased leukocyte counts and shortened hospital stays. This randomized, placebo-controlled trial studied clinical and immune effects of trace element supplements. Twenty patients, aged 40 +/- 16 y (mean +/- SD), burned on 48 +/- 17% of their body surfaces, were studied for 30 d after injury. They consumed either standard trace element intakes plus supplements (40.4 micromol Cu, 2.9 micromol Se, and 406 micromol Zn; group TE) or standard trace element intakes plus placebo (20 micromol Cu, 0.4 micromol Se, and 100 micromol Zn; group C) for 8 d. Demographic data were similar for both groups. Mean plasma copper and zinc concentrations were below normal until days 20 and 15, respectively (NS). Plasma selenium remained normal for group TE but decreased for group C (P &lt; 0.05 on days 1 and 5). Total leukocyte counts tended to be higher in group TE because of higher neutrophil counts. Proliferation to mitogens was depressed compared with healthy control subjects (NS). The number of infections per patient was significantly (P &lt; 0.05) lower in group TE (1.9 +/- 0.9) than in group C (3.1 +/- 1.1) because of fewer pulmonary infections. Early trace element supplementation appears beneficial after major burns; it was associated with a significant decrease in the number of bronchopneumonia infections and with a shorter hospital stay when data were normalized for burn size.</style></abstract><notes><style face="normal" font="default" size="100%">Berger, M M&#xD;Spertini, F&#xD;Shenkin, A&#xD;Wardle, C&#xD;Wiesner, L&#xD;Schindler, C&#xD;Chiolero, R L&#xD;Clinical Trial&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Am J Clin Nutr. 1998 Aug;68(2):365-71. doi: 10.1093/ajcn/68.2.365.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ajcn/68.2.365</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>407</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">407</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, D. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">D.T. Smith, Emory-Atlanta Veterans Affairs Medical Center, Decatur, GA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transformation to acute leukemia and sepsis in a patient with myelodysplastic syndrome initially presenting with chronic skin ulcerations</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S499</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><keywords><keyword><style face="normal" font="default" size="100%">antibiotic agent</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">iron</style></keyword><keyword><style face="normal" font="default" size="100%">cyanocobalamin</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">thyrotropin</style></keyword><keyword><style face="normal" font="default" size="100%">heavy metal</style></keyword><keyword><style face="normal" font="default" size="100%">azacitidine</style></keyword><keyword><style face="normal" font="default" size="100%">hypertensive factor</style></keyword><keyword><style face="normal" font="default" size="100%">myelodysplastic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">patient</style></keyword><keyword><style face="normal" font="default" size="100%">internal medicine</style></keyword><keyword><style face="normal" font="default" size="100%">acute leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">skin ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">society</style></keyword><keyword><style face="normal" font="default" size="100%">sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">dysplasia</style></keyword><keyword><style face="normal" font="default" size="100%">anemia</style></keyword><keyword><style face="normal" font="default" size="100%">leg</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow</style></keyword><keyword><style face="normal" font="default" size="100%">transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">neutropenia</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">blood smear</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">granulocyte</style></keyword><keyword><style face="normal" font="default" size="100%">myeloblast</style></keyword><keyword><style face="normal" font="default" size="100%">cause of death</style></keyword><keyword><style face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">blood cell</style></keyword><keyword><style face="normal" font="default" size="100%">preleukemia</style></keyword><keyword><style face="normal" font="default" size="100%">macrocytic anemia</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil</style></keyword><keyword><style face="normal" font="default" size="100%">alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">virus infection</style></keyword><keyword><style face="normal" font="default" size="100%">intoxication</style></keyword><keyword><style face="normal" font="default" size="100%">diseases</style></keyword><keyword><style face="normal" font="default" size="100%">therapy</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">hematopoietic cell</style></keyword><keyword><style face="normal" font="default" size="100%">transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">survival rate</style></keyword><keyword><style face="normal" font="default" size="100%">refractory anemia with excess blasts</style></keyword><keyword><style face="normal" font="default" size="100%">etiology</style></keyword><keyword><style face="normal" font="default" size="100%">acute myeloid leukemia</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">healing</style></keyword><keyword><style face="normal" font="default" size="100%">medical history</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">dyspnea</style></keyword><keyword><style face="normal" font="default" size="100%">exercise</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">examination</style></keyword><keyword><style face="normal" font="default" size="100%">vital sign</style></keyword><keyword><style face="normal" font="default" size="100%">leukocyte count</style></keyword><keyword><style face="normal" font="default" size="100%">platelet count</style></keyword><keyword><style face="normal" font="default" size="100%">occult blood</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium culture</style></keyword><keyword><style face="normal" font="default" size="100%">Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default" size="100%">hepatitis A</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">virus</style></keyword><keyword><style face="normal" font="default" size="100%">toxicology</style></keyword><keyword><style face="normal" font="default" size="100%">erythrocyte</style></keyword><keyword><style face="normal" font="default" size="100%">thrombocyte</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">cytogenetics</style></keyword><keyword><style face="normal" font="default" size="100%">radiography</style></keyword><keyword><style face="normal" font="default" size="100%">bone scintiscanning</style></keyword><keyword><style face="normal" font="default" size="100%">tissues</style></keyword><keyword><style face="normal" font="default" size="100%">bone infection</style></keyword><keyword><style face="normal" font="default" size="100%">ulcer</style></keyword><keyword><style face="normal" font="default" size="100%">blood transfusion</style></keyword><keyword><style face="normal" font="default" size="100%">biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">induction chemotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory failure</style></keyword><keyword><style face="normal" font="default" size="100%">septic shock</style></keyword><keyword><style face="normal" font="default" size="100%">pneumonia</style></keyword><keyword><style face="normal" font="default" size="100%">artificial ventilation</style></keyword><keyword><style face="normal" font="default" size="100%">neoplasm</style></keyword><keyword><style face="normal" font="default" size="100%">infectious complication</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVES: 1. Recognize the clinical and pathological features of myelodysplastic syndrome (MDS), as well as the other common etiologies for dysplasia that must be excluded in making the diagnosis of MDS. 2. Identify the complications of MDS and the risk for conversion to acute myeloid leukemia (AML), with infection being the most common cause of death in these patients. CASE INFORMATION: A 62-year-old male presented with 3 months of non-healing skin ulcers on his legs. His medical history included atrial fibrillation and hypertension. He was taking no medications. He reported dyspnea on exertion and fatigue upon review of systems. On examination, he was not in distress but was tachycardic and hypertensive. Other vital signs were normal. He was pale and cardiac exam only revealed an irregular heartbeat. The rest of his exam was normal except for mildly exudative superficial skin ulcers on his legs. Laboratory investigations revealed a WBC count of 800 cells/ mm3, hemoglobin 7.0 g/dL (MCV 108 fL), and platelet count 30,000 cells/mm3. Iron, B12, folate, and TSH levels were normal but his ferritin level was elevated. Fecal occult blood testing was negative. Bacterial cultures were negative. HIV, EBV, CMV, and Hepatitis A, B, and C virus testing were all negative. Heavy metal and toxicology panels were also negative. A blood smear revealed macroovalocytic red cells, neutropenia, and decreased platelets. A bone marrow biopsy showed hypercellular marrow with 15-20% myeloblasts. Immunohistochemistry and cytogenetics suggested high-gradeMDS. Further investigations with plain radiography and a bone scan of his legs excluded any deeper tissue or bone infection. The patient&apos;s ulcers improved with antibiotics. He was maintained on prophylactic antibiotics given his neutropenia. He received blood transfusions for his symptomatic anemia. His MDS was treated with azacitidine. He became transfusion-dependent and later unresponsive to further transfusions. He was readmitted 2months after initial presentation where a repeat bonemarrow biopsy now showed 20-25% blasts. The diagnosis of AML was considered given the rise in blasts and he was started on induction chemotherapy. Unfortunately, the patient developed respiratory failure and septic shock due to pneumonia. He died despite intravenous antibiotics, vasopressors, and mechanical ventilation. IMPLICATIONS/DISCUSSION: MDS is a group of myeloid neoplasms characterized by dysplasia and ineffective blood cell production resulting in anemia or other cytopenias with a risk for conversion to acute leukemia. Initially MDS was termed “preleukemia” from case reports of refractory cytopenias evolving into acute leukemia. MDS should be suspected in patients with an unexplained macrocytic anemia and other cytopenias. The symptoms of MDS are nonspecific. MDS is rare in young patients but increases dramatically in the elderly. Blood smear abnormalities include macroovalocytes, hyposegmented granulocytes, and hypogranular neutrophils. The diagnosis of MDS requires bone marrow testing, with at least 10% dysplasia seen. Other causes of dysplasia must be excluded: B12/ folate/copper deficiencies, alcoholism, viral infections, medications, lead/arsenic poisoning, and other primary bone marrow disorders. MDS is categorized by the number of cytopenias and blasts present. Therapy is limited in MDS and prognosis is poor. Treatment includes transfusions, chemotherapy, and allogenic hematopoietic cell transplant. While chemotherapy is not very effective in MDS, it may help control any disease-related symptoms or complications. Allo-SCT is considered for patients with high risk disease and is the only curative option. Patients with MDS may suffer from symptomatic anemia, infection, bleeding, or progression to acute leukemia. Neutropenia and granulocyte dysfunction are responsible for the high incidence of infection in MDS, which is the primary cause of death. Patients with high risk MDS or transformation to AML have a survival rate of less than 10%. The risk for conversion is highest in patient like ours with refractory anemia with excess blasts. Later, his myeloblasts increased to above 20%, the level required for the diagnosis of AML. Our patient was started on induction chemo upon discovery of leukemic transformation. Unfortunately, he developed infectious complications and died shortly thereafter.</style></abstract><notes><style face="normal" font="default" size="100%">L70654198&#xD;2012-02-03</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L70654198</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s11606-011-1730-9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11606-011-1730-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">20</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mitra, D.</style></author><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Kang, E. T.</style></author><author><style face="normal" font="default" size="100%">Neoh, K. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical and Biomolecular Engineering , National University of Singapore , Kent Ridge, 117576 , Singapore.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Transparent Copper-Based Antibacterial Coatings with Enhanced Efficacy against Pseudomonas aeruginosa</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Appl Mater Interfaces</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ACS Appl Mater Interfaces</style></full-title></periodical><pages><style face="normal" font="default" size="100%">73-83</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2018/12/12</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anti-Bacterial Agents/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Chitosan/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Coated Materials, Biocompatible/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa/*growth &amp; development</style></keyword><keyword><style face="normal" font="default" size="100%">Stainless Steel/*chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Edta</style></keyword><keyword><style face="normal" font="default" size="100%">P. aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">antibacterial coating</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">proteolytic activity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1944-8244</style></isbn><accession-num><style face="normal" font="default" size="100%">30525426</style></accession-num><abstract><style face="normal" font="default" size="100%">Bacterial surface contamination is a major cause of hospital-associated infections. Antibacterial coatings can play an important role in reducing bacterial transmission via inanimate surfaces in healthcare settings. In this work, transparent copper-based antibacterial coatings were fabricated on commercial poly(vinyl fluoride) and stainless steel. Acrylated quaternized chitosan and ethylenediaminetetraacetic acid were covalently grafted on the substrate for complexation with copper ions. The number of viable Staphylococcus aureus in a droplet [containing approximately 10(4) colony forming units (CFU)], deposited on the copper-containing coating decreased by approximately 96% within 60 min at 25 degrees C. With Pseudomonas aeruginosa, one of the most virulent and hardest to kill bacteria, no CFU could be observed within the same time span (killing efficacy &gt;99.8% based on the detection limit). An increase in copper release from the coating was observed in the presence of P. aeruginosa, which was postulated to be due to the proteolytic activity of P. aeruginosa. The higher efficacy of the coating against P. aeruginosa compared to S. aureus is thus attributed to this increased copper release from the coating, which resulted in extensive bacterial membrane damage and death. The copper-containing coating on poly(vinyl fluoride) retained its antibacterial efficacy after 100 wipes with a water-wetted cloth or isopropanol wipes, demonstrating its durability and long-term efficacy. The coating did not exhibit significant cytotoxicity toward mammalian fibroblasts, further demonstrating its potential for mitigating bacterial transmission in a clinical setting.</style></abstract><notes><style face="normal" font="default" size="100%">1944-8252&#xD;Mitra, Debirupa&#xD;Li, Min&#xD;Kang, En-Tang&#xD;ORCID: http://orcid.org/0000-0003-0599-7834&#xD;Neoh, Koon Gee&#xD;ORCID: http://orcid.org/0000-0002-2700-1914&#xD;Journal Article&#xD;United States&#xD;ACS Appl Mater Interfaces. 2019 Jan 9;11(1):73-83. doi: 10.1021/acsami.8b09640. Epub 2018 Dec 21.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acsami.8b09640</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cramer, D. W.</style></author><author><style face="normal" font="default" size="100%">Schiff, I.</style></author><author><style face="normal" font="default" size="100%">Schoenbaum, S. C.</style></author><author><style face="normal" font="default" size="100%">Gibson, M.</style></author><author><style face="normal" font="default" size="100%">Belisle, S.</style></author><author><style face="normal" font="default" size="100%">Albrecht, B.</style></author><author><style face="normal" font="default" size="100%">Stillman, R. J.</style></author><author><style face="normal" font="default" size="100%">Berger, M. J.</style></author><author><style face="normal" font="default" size="100%">Wilson, E.</style></author><author><style face="normal" font="default" size="100%">Stadel, B. V.</style></author><author><style face="normal" font="default" size="100%">et al.,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tubal infertility and the intrauterine device</style></title><secondary-title><style face="normal" font="default" size="100%">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">N Engl J Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">941-7</style></pages><volume><style face="normal" font="default" size="100%">312</style></volume><number><style face="normal" font="default" size="100%">15</style></number><edition><style face="normal" font="default" size="100%">1985/04/11</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Educational Status</style></keyword><keyword><style face="normal" font="default" size="100%">Fallopian Tube Diseases/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infertility, Female/epidemiology/*etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices/*adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Devices, Copper/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvic Inflammatory Disease/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Salpingitis/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Sexual Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Smoking</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">*Adnexal Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Biology</style></keyword><keyword><style face="normal" font="default" size="100%">*Clinical Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods--complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Fallopian Tubes</style></keyword><keyword><style face="normal" font="default" size="100%">*Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">*Genital Effects, Female</style></keyword><keyword><style face="normal" font="default" size="100%">Genitalia</style></keyword><keyword><style face="normal" font="default" size="100%">Genitalia, Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Infections</style></keyword><keyword><style face="normal" font="default" size="100%">*Infertility--etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Copper Releasing--complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Unmedicated--complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud--complications</style></keyword><keyword><style face="normal" font="default" size="100%">Physiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Population At Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Reproduction</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Tubal Effects--etiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Urogenital Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital System</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1985</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0028-4793 (Print)&#xD;0028-4793</style></isbn><accession-num><style face="normal" font="default" size="100%">3974684</style></accession-num><abstract><style face="normal" font="default" size="100%">To study the association between intrauterine devices (IUDs) and pelvic inflammatory disease, we compared contraceptive histories in 4185 while women--283 nulliparous women with primary tubal infertility, 69 women with secondary tubal infertility, and 3833 women admitted for delivery at seven collaborating hospitals from 1981 to 1983. The relative risk of tubal infertility associated with IUD use was calculated by means of multivariate logistic regression to control for confounding factors, including region, year of menarche, religion, education, smoking, and reported number of sexual partners. The adjusted risk of primary tubal infertility associated with any IUD use before a first live birth was 2.0 (95 per cent confidence limits, 1.5 to 2.6) relative to nonuse. Users of the Dalkon Shield had an adjusted risk of 3.3 (1.7 to 6.1), users of the Lippes Loop or Saf-T-Coil had a risk of 2.9 (1.7 to 5.2), and users of copper IUDs had a risk of 1.6 (1.1 to 2.4). Women who reported having only one sexual partner had no increased risk of primary tubal infertility associated with IUD use. The adjusted risk of secondary tubal infertility associated with use of a copper IUD after a first live birth was not statistically significant (1.5; 95 per cent confidence limits, 0.8 to 3.0), whereas the risk from similar use of noncopper devices was significant (2.8; 1.3 to 5.9). We conclude that tubal infertility is associated with IUD use, but less so with copper IUDs.&#xD;The association between prior use of an IUD and subsequent infertility due to tubal disease was investigated in a multicenter case-control study. The study population included 283 nulliparous white women with promary tubal infertility, 69 white women with secondary tubal infertility, and 3833 controls admitted for delivery at 7 collaborating hospitals in 1981-83. Cases with tubal disease tended to be older, less educated, more likely to be smokers, and to have had more sexual partners than controls. The relative risk of tubal infertility associated with IUD use was calculated by means of multivariate logistic regression to control for these factors as well as region, year of menarche, and religion. The adjusted risk of promary tubal infertility associated with any IUD use before a 1st live birth was 2.0 (95% confidence limits, 1.5-2.6) relative to non-use. Users of the Dalkon Shield had an adjusted risk of 3.3 (1.7-6.1), users of the Lippes Loop or Saf-T-Coil had a risk of 2.9 (1.7-5.2), and users of copper IUDs had a risk of 1.6 (1.1-2.4). IUD use on the part of women with history of genital or pelvic infection doubled the baseline risk of tubal infertility. Women who reported having only 1 sexual partner, however, had no increased risk of primary tubal infertility associated with IUD use. The adjusted risk of secondary tubal infertility associated with use of the copper IUD after a 1st live birth was not statistically significant (1.5; 95% confidence limits, 0.8-3.0); the risk from similar use of non-copper devices, on the other hand, was significant (2.8;1.3-5.9). These results confirm as assoiciation between past IUD use and subsequent tubal infection. On the basis of this study, it is estimated that the IUD accounts for tubal disease in 88,000 (16%) of the 550,000 cases of infertility-producing tubal disease in the US. It is recommended that, with the possible exception of women with a single partner at low risk for sexually transmitted diseases, the IUD should not be a contraceptive method of 1st choice for nulliparous women. For the woman who has 1 child, however, the use of copper devices may offer a relatively safe alternative to other methods.&#xD;eng</style></abstract><notes><style face="normal" font="default" size="100%">Cramer, D W&#xD;Schiff, I&#xD;Schoenbaum, S C&#xD;Gibson, M&#xD;Belisle, S&#xD;Albrecht, B&#xD;Stillman, R J&#xD;Berger, M J&#xD;Wilson, E&#xD;Stadel, B V&#xD;N01-HD-02822/HD/NICHD NIH HHS/United States&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;N Engl J Med. 1985 Apr 11;312(15):941-7. doi: 10.1056/NEJM198504113121502.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/nejm198504113121502</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>281</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haydek, J. P.</style></author><author><style face="normal" font="default" size="100%">Xu, K. M.</style></author><author><style face="normal" font="default" size="100%">Poppens, E. S.</style></author><author><style face="normal" font="default" size="100%">Wilkinson, J.</style></author><author><style face="normal" font="default" size="100%">El Rassi, F.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J.P. Haydek, Emory University, School of Medicine, Atlanta, GA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tube troubles: An uncommon cause of neutropenia</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of General Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S626</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">copper chloride</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">mineral</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">bariatric surgery</style></keyword><keyword><style face="normal" font="default" size="100%">bone marrow biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">congenital malformation</style></keyword><keyword><style face="normal" font="default" size="100%">consensus</style></keyword><keyword><style face="normal" font="default" size="100%">contracture</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">copper deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">cystic fibrosis</style></keyword><keyword><style face="normal" font="default" size="100%">depigmentation</style></keyword><keyword><style face="normal" font="default" size="100%">diarrhea</style></keyword><keyword><style face="normal" font="default" size="100%">differential diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">disease course</style></keyword><keyword><style face="normal" font="default" size="100%">drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">enteric feeding</style></keyword><keyword><style face="normal" font="default" size="100%">epilepsy</style></keyword><keyword><style face="normal" font="default" size="100%">febrile neutropenia</style></keyword><keyword><style face="normal" font="default" size="100%">flow cytometry</style></keyword><keyword><style face="normal" font="default" size="100%">fluorescence in situ hybridization</style></keyword><keyword><style face="normal" font="default" size="100%">Foley balloon catheter</style></keyword><keyword><style face="normal" font="default" size="100%">hair</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalization</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">hypoplasia</style></keyword><keyword><style face="normal" font="default" size="100%">immobility</style></keyword><keyword><style face="normal" font="default" size="100%">inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default" size="100%">internist</style></keyword><keyword><style face="normal" font="default" size="100%">leg</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">lymphadenopathy</style></keyword><keyword><style face="normal" font="default" size="100%">malabsorption</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">megaloblast</style></keyword><keyword><style face="normal" font="default" size="100%">meningoencephalitis</style></keyword><keyword><style face="normal" font="default" size="100%">mentally disabled person</style></keyword><keyword><style face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style face="normal" font="default" size="100%">muscle weakness</style></keyword><keyword><style face="normal" font="default" size="100%">myelodysplastic syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">neutrophil count</style></keyword><keyword><style face="normal" font="default" size="100%">stomach tube</style></keyword><keyword><style face="normal" font="default" size="100%">platelet count</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><isbn><style face="normal" font="default" size="100%">0884-8734</style></isbn><abstract><style face="normal" font="default" size="100%">LEARNING OBJECTIVE #1: Recognize copper deficiency as a cause of neutropenia that should be considered in cases without identified etiology. LEARNING OBJECTIVE #2: Develop a low threshold for assessing copper deficiency in patients receiving tube feeds chronically. CASE: A 47-year-old man with profound cognitive impairment and epilepsy secondary to infantile meningoencephalitis was admitted from his long-term care facility for neutropenic fever and diarrhea. He was quadriplegic, with permanent gastrostomy tube and Foley catheters in place. His admission exam was pertinent for normal temperature, chronic contractures in the arms and legs. His gastrostomy tube and Foley catheter sites appeared normal, without signs of infection. There was no lymphadenopathy or organomegaly. Initial laboratory investigation identified a white blood cell count of 2,600 cells per microliter with an absolute neutrophil count of 260 cells per microliter, hemoglobin of 12.3 grams per deciliter, and platelet count of 342,000 cells per microliter. Bone marrow biopsy was performed which showed a mild myeloid hypoplasia with megaloblastic and megaloblastoid features. Cytogenetic evaluation, flow cytometry and myelodysplastic syndrome fluorescence in situ hybridization panel was normal. A serum copper level resulted at 2 micrograms per deciliter. Daily intravenous copper chloride was started. Within two days, the patient&apos;s absolute neutrophil count returned to 5,300 cells per microliter. The patient&apos;s diarrhea resolved without intervention during the hospital stay. He was subsequently discharged to his long-term care facility with oral copper supplementation. IMPACT: This case highlights the importance of considering copper deficiency in cases of neutropenia without identified cause. In particular, institutionalized patients and those undergoing chronic enteral feeding are at high risk for developing nutritional deficiencies. DISCUSSION: Internists commonly encounter neutropenia. Although vitamin- and mineral-associated neutropenias are less common compared to other etiologies, they should always be included in the differential diagnosis. Copper deficiency is clinically characterized by fragile hair, skin depigmentation, muscle weakness, neurological and hematological abnormalities. It frequently results from malabsorptive diseases, including cystic fibrosis, inflammatory bowel disease or malabsorption following bariatric surgery. In the case of our cognitively impaired, quadriplegic patient, his only manifestation of copper deficiency was neutropenia. Patients chronically bed-bound due to underlying neurological diseases and on permanent tube feeding are at high risk of developing copper deficiency. There is currently no consensus about the most appropriate dose, duration, route and form of copper supplementation. In this case, our patient responded quickly to daily 2.5 mg intravenous copper chloride, a dose and formulation reported in other case reports. His copper level returned to normal range after 2 days&apos; supplementation.</style></abstract><notes><style face="normal" font="default" size="100%">L615581484&#xD;2017-04-26</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L615581484</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nilsson, C. G.</style></author><author><style face="normal" font="default" size="100%">Allonen, H.</style></author><author><style face="normal" font="default" size="100%">Diaz, J.</style></author><author><style face="normal" font="default" size="100%">Luukkainen, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Two years&apos; experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study</style></title><secondary-title><style face="normal" font="default" size="100%">Fertil Steril</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Fertil Steril</style></full-title></periodical><pages><style face="normal" font="default" size="100%">187-92</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">1983/02/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Brazil</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptives, Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptives, Oral, Combined</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptives, Oral, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Finland</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intrauterine Device Expulsion</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Copper/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Intrauterine Devices, Medicated/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Levonorgestrel</style></keyword><keyword><style face="normal" font="default" size="100%">*Norgestrel</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatient Clinics, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Pain</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Random Allocation</style></keyword><keyword><style face="normal" font="default" size="100%">Uterine Hemorrhage/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Age Distribution</style></keyword><keyword><style face="normal" font="default" size="100%">Amenorrhea</style></keyword><keyword><style face="normal" font="default" size="100%">Bleeding</style></keyword><keyword><style face="normal" font="default" size="100%">*Comparative Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraception Termination</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptive Agents, Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Contraceptive Agents, Progestin</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive Methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Examinations And Diagnoses</style></keyword><keyword><style face="normal" font="default" size="100%">Family Planning</style></keyword><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Ingredients And Chemicals</style></keyword><keyword><style face="normal" font="default" size="100%">Inorganic Chemicals</style></keyword><keyword><style face="normal" font="default" size="100%">Insertion</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud Material</style></keyword><keyword><style face="normal" font="default" size="100%">*Iud, Hormone Releasing</style></keyword><keyword><style face="normal" font="default" size="100%">*Levonorgestrel</style></keyword><keyword><style face="normal" font="default" size="100%">Metals</style></keyword><keyword><style face="normal" font="default" size="100%">Parity</style></keyword><keyword><style face="normal" font="default" size="100%">*Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy, Unplanned</style></keyword><keyword><style face="normal" font="default" size="100%">Reproduction</style></keyword><keyword><style face="normal" font="default" size="100%">*Reproductive Control Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Research Methodology</style></keyword><keyword><style face="normal" font="default" size="100%">*Retention</style></keyword><keyword><style face="normal" font="default" size="100%">*Size</style></keyword><keyword><style face="normal" font="default" size="100%">Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Use-effectiveness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1983</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0015-0282 (Print)&#xD;0015-0282</style></isbn><accession-num><style face="normal" font="default" size="100%">6401636</style></accession-num><abstract><style face="normal" font="default" size="100%">A randomized comparative performance study of two levonorgestrel intrauterine devices (IUDs) and a copper (Nova-T) IUD (Leiras, Turku, Finland) was performed at two clinics in Finland and one in Brazil. The 24-month cumulative event rates per 100 women are reported. Six thousand woman-months of use were recorded with the levonorgestrel IUD and 3000 with the Nova-T device. Pregnancy rates at 2 years of use were 0.6 and 0 with the two levonorgestrel IUDs and 3.3 with the Nova-T IUD. Removal rates because of bleeding and/or pain were low with all three IUDs: 7.5, 7.6, and 7.1, respectively, at 24 months. Recordings of the number of days of bleeding showed significantly fewer days of bleeding during use of the levonorgestrel IUDs than the Nova-T IUD from the second month of use onward, until the end of the second year. No infections were recorded in association with use of the levonorgestrel IUDs, and only one termination because of infection was recorded for the Nova-T IUD. The continuation rates of use at 24 months were 66.6, 60.7, and 71.9 for the two levonorgestrel IUDs and the Nova-T IUD, respectively; the differences were not statistically significant.</style></abstract><notes><style face="normal" font="default" size="100%">Nilsson, C G&#xD;Allonen, H&#xD;Diaz, J&#xD;Luukkainen, T&#xD;Clinical Trial&#xD;Comparative Study&#xD;Journal Article&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;Fertil Steril. 1983 Feb;39(2):187-92.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>226</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rana, P.</style></author><author><style face="normal" font="default" size="100%">Han, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Rana, University of Southern California, Los Angeles, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A unique case of liver disease in pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S1328</style></pages><volume><style face="normal" font="default" size="100%">114</style></volume><keywords><keyword><style face="normal" font="default" size="100%">bile acid</style></keyword><keyword><style face="normal" font="default" size="100%">bilirubin</style></keyword><keyword><style face="normal" font="default" size="100%">endogenous compound</style></keyword><keyword><style face="normal" font="default" size="100%">fibrinogen</style></keyword><keyword><style face="normal" font="default" size="100%">haptoglobin</style></keyword><keyword><style face="normal" font="default" size="100%">lactate dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">liver enzyme</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrial trifunctional protein alpha subunit</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin</style></keyword><keyword><style face="normal" font="default" size="100%">acute liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">aspartate aminotransferase level</style></keyword><keyword><style face="normal" font="default" size="100%">asthenia</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">blood cell count</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">conference abstract</style></keyword><keyword><style face="normal" font="default" size="100%">fatty liver</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">fetus distress</style></keyword><keyword><style face="normal" font="default" size="100%">follow up</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">kidney function</style></keyword><keyword><style face="normal" font="default" size="100%">physical examination</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">proteinuria</style></keyword><keyword><style face="normal" font="default" size="100%">serology</style></keyword><keyword><style face="normal" font="default" size="100%">symptomatology</style></keyword><keyword><style face="normal" font="default" size="100%">triplets</style></keyword><keyword><style face="normal" font="default" size="100%">ultrasound</style></keyword><keyword><style face="normal" font="default" size="100%">urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">uterus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><isbn><style face="normal" font="default" size="100%">1572-0241</style></isbn><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Pregnancy-related liver disease is seen in up to 3% of all pregnancies. Pregnancy-related etiologies include hyperemesis gravidarum, pre-eclampsia, HELLP, intrahepatic cholestasis of pregnancy, and acute fatty liver of pregnancy (AFLP). Given the significant morbidity and mortality associated with these conditions, there is a need for early recognition. Here we present a unique case of pregnancy-related liver disease in an asymptomatic patient. Despite a thorough evaluation for liver and non-liver related causes, her lack of symptomatology and associated laboratory findings made establishing a definitive diagnosis difficult. CASE DESCRIPTION/METHODS: 30 year-old woman G1P0 at 29 weeks gestation with dichorionic triamniotic triplets presented with generalized weakness. Her past medical and surgical histories were otherwise non-contributory and her only medication included prenatal vitamins. The physical exam was unremarkable except for a gravid uterus. Throughout her hospital course, she remained normotensive. Admission labs were significant for an abnormal liver profile: AST 200 U/L, ALT 349 U/L, ALP 121 U/L, and total bilirubin 0.5 mg/dL, compared to a previous normal baseline. Complete blood count and renal function were normal. Abdominal ultrasound (US) showed increased liver echogenicity consistent with fatty liver disease. Additional work-up revealed a normal coagulation profile, fibrinogen, lactate dehydrogenase, and haptoglobin. Urinalysis was negative for proteinuria. Serologies for viral and autoimmune hepatitis were negative. Total bile acids were mildly elevated at 9.3 umol/L (normal &lt; 6.8umol/L) and 24-hour urinary copper was normal. Though she remained asymptomatic, liver enzymes continued to uptrend. On day 16 she underwent urgent C-section due to rising liver enzymes and evidence of fetal distress. Liver enzymes continued to rise until POD1 before rapidly declining. DISCUSSION: This was a unique case of pregnancy-related liver disease of unknown etiology, but most consistent with an early manifestation of AFLP. We suspected AFLP based on the steatosis noted on US, however, since we could not check her children for LCHAD deficiency a definitive diagnosis could not be made. Surveillance US showing resolution of steatosis would have helped confirm the diagnosis however the patient was lost to follow up. This was an interesting presentation of AFLP as most cases are discovered in women presenting with acute liver failure; this case was unique in that it was discovered unexpectedly. (Figure Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L630840882&#xD;2020-02-12</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L630840882</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.14309/01.ajg.0000599104.36672.4c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.14309/01.ajg.0000599104.36672.4c</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>372</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">372</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niiyama, N.</style></author><author><style face="normal" font="default" size="100%">Sasahara, T.</style></author><author><style face="normal" font="default" size="100%">Mase, H.</style></author><author><style face="normal" font="default" size="100%">Abe, M.</style></author><author><style face="normal" font="default" size="100%">Saito, H.</style></author><author><style face="normal" font="default" size="100%">Katsuoka, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Dermatology, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of copper alloy for preventing transmission of methicillin-resistant Staphylococcus aureus contamination in the dermatology ward</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Dermato-Venereologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Dermato-Venereologica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">294-300</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">bacterial DNA</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">doripenem</style></keyword><keyword><style face="normal" font="default" size="100%">linezolid</style></keyword><keyword><style face="normal" font="default" size="100%">pazufloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial cell</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial count</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial strain</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial transmission</style></keyword><keyword><style face="normal" font="default" size="100%">bactericidal activity</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium colony</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium contamination</style></keyword><keyword><style face="normal" font="default" size="100%">bacterium detection</style></keyword><keyword><style face="normal" font="default" size="100%">bed sheet</style></keyword><keyword><style face="normal" font="default" size="100%">case report</style></keyword><keyword><style face="normal" font="default" size="100%">colony forming unit</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">film</style></keyword><keyword><style face="normal" font="default" size="100%">genotype</style></keyword><keyword><style face="normal" font="default" size="100%">hospital bed</style></keyword><keyword><style face="normal" font="default" size="100%">hospital equipment</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">material coating</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">methicillin resistant Staphylococcus aureus infection</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">nucleotide sequence</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus</style></keyword><keyword><style face="normal" font="default" size="100%">surface property</style></keyword><keyword><style face="normal" font="default" size="100%">ward</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">0001-5555&#xD;1651-2057</style></isbn><abstract><style face="normal" font="default" size="100%">Metallic copper has been shown signifcantly to reduce methicillin-resistant Staphylococcus aureus (MRSA) contamination of the ambient surroundings of the beds of MRSA-carrying patients in dermatology wards. The aim of this study was to determine whether a bed sheet made of copper-coated film will reduce the spread of MRSA contamination in the environment of a heavily-colonized patient. The bacterial count was highest on the bed sheet. MRSA cell counts on the surface of the non-film-coated control sheet were high (6,600-11,000 colony forming units (cfu)), but those on the copper film were considerably lower (20-130 cfu). Use of metallic copper on the bed sheets of patients who are likely to be a source of MRSA contamination may help to prevent the spread of MRSA contamination in hospital wards. © 2013 The Authors.</style></abstract><notes><style face="normal" font="default" size="100%">L368836520&#xD;2013-05-09&#xD;2013-05-17</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L368836520</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2340/00015555-1472</style></url><url><style face="normal" font="default" size="100%">http://www.medicaljournals.se/acta/content/download.php?doi=10.2340/00015555-1472</style></url></related-urls></urls><custom4><style face="normal" font="default" size="100%">Mitsui(Japan)</style></custom4><custom5><style face="normal" font="default" size="100%">23038099</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.2340/00015555-1472</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dziewulski, D. M.</style></author><author><style face="normal" font="default" size="100%">Ingles, E.</style></author><author><style face="normal" font="default" size="100%">Codru, N.</style></author><author><style face="normal" font="default" size="100%">Strepelis, J.</style></author><author><style face="normal" font="default" size="100%">Schoonmaker-Bopp, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bureau of Water Supply Protection, New York State Department of Health, Albany, NY; School of Public Health, Department of Environmental Health Sciences, State University at Albany, Rensselaer, NY. Electronic address: dmd14@nyhealth.gov.&#xD;Central Regional Office, New York State Department of Health, Syracuse, NY.&#xD;Bureau of Water Supply Protection, New York State Department of Health, Albany, NY.&#xD;Wadsworth Center, New York State Department of Health, Albany, NY.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of copper-silver ionization for the control of legionellae in alkaline environments at health care facilities</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Infect Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Infect Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">971-6</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">2015/07/08</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Colony Count, Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Cross Infection/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Health Facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella/*drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Legionellosis/microbiology/*prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Legionnaires&apos; Disease/microbiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Silver/*pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Supply/standards</style></keyword><keyword><style face="normal" font="default" size="100%">*Alkaline environment</style></keyword><keyword><style face="normal" font="default" size="100%">*Chlorine dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">*Copper-silver ionization (CSI)</style></keyword><keyword><style face="normal" font="default" size="100%">*Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">*Legionella</style></keyword><keyword><style face="normal" font="default" size="100%">*Legionellosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">*Percentage positivity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0196-6553</style></isbn><accession-num><style face="normal" font="default" size="100%">26149750</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: There are multiple treatment options for the control of legionellae in premise hot water systems. Water chemistry plays a role in the efficacy of these treatments and should be considered when selecting a treatment. This study demonstrated the efficacy of copper-silver ionization (CSI) under alkaline water conditions in 2 health care facilities. METHODS: Monitoring for copper (Cu) and silver (Ag) ions was performed, and the corresponding percentage of positive Legionella cultures was monitored. Low Legionella colony forming units (CFU), with a mean &lt;10 CFU/100 mL, and &lt;/=30% positive culture for each sampling period, along with no recurrent disease, were considered indicative of control. RESULTS: CSI treatment was shown to reduce both the number of CFU found and the percentage of samples found to be culture positive. After treatment was established, culture positivity was, for example, reduced from 70% (&gt;10(3) CFU/100 mL) to consistently &lt;30% (38 CFU/100 mL). CONCLUSION: Control of legionellae in premise water systems may be a complex process requiring long-term assessments for adequate control. This work found that CSI could be successful in controlling Legionella under alkaline water conditions, and the evidence suggests that Ag ions are responsible for the control of Legionella pneumophila 1, L pneumophila 6, and L anisa.</style></abstract><notes><style face="normal" font="default" size="100%">1527-3296&#xD;Dziewulski, David M&#xD;Ingles, Erin&#xD;Codru, Neculai&#xD;Strepelis, John&#xD;Schoonmaker-Bopp, Dianna&#xD;UE2 EH000725/EH/NCEH CDC HHS/United States&#xD;Journal Article&#xD;Research Support, U.S. Gov&apos;t, P.H.S.&#xD;United States&#xD;Am J Infect Control. 2015 Sep 1;43(9):971-6. doi: 10.1016/j.ajic.2015.05.018. Epub 2015 Jul 3.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ajic.2015.05.018</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sintusek, P.</style></author><author><style face="normal" font="default" size="100%">Kyrana, E.</style></author><author><style face="normal" font="default" size="100%">Dhawan, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">P. Sintusek, Pediatric Liver, GI and Nutrition Center, King&apos;s College Hospital, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Utility of serum zinc level to predict severity of Wilson disease</style></title><secondary-title><style face="normal" font="default" size="100%">Hepatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Hepatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">276A</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">acute liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">child</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">demography</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">genetic predisposition</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">human tissue</style></keyword><keyword><style face="normal" font="default" size="100%">liver transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">medical record</style></keyword><keyword><style face="normal" font="default" size="100%">mutation</style></keyword><keyword><style face="normal" font="default" size="100%">nonalcoholic fatty liver</style></keyword><keyword><style face="normal" font="default" size="100%">statistical significance</style></keyword><keyword><style face="normal" font="default" size="100%">tertiary care center</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">0270-9139</style></isbn><abstract><style face="normal" font="default" size="100%">BACKGROUND: Wilson disease (WD) is an autosomal recessive disorder characterised by copper accumulation. Zinc (Zn), a copper antagonist used as treatment in WD, can inhibit copper absorption in intestine by up regulation of metallothionines (MTs). However, there has been no study of the link between Zn and WD severity. our aim were to evaluate serum Zn level in a variety of liver diseases and to study its correlation with the new Wilson index (WI) score (1) used to predict severity of WD. METHODS: Medical records of 26 patients with WD (8 WD with acute liver failure (ALF) and 18 WD-non-ALF) and 69 patients with non-WD (31 nonalcoholic fatty liver disease (NAFLD), 29 autoimmune hepatitis (AIH) and 9 indeterminate cause of ALF), who had initial serum Zn data before disease diagnosis, were reviewed in our tertiary hospital from 2005 to 2015. All WD children had disease causing mutations identified and the new WI score was calculated in all. Corrected Zn was calculated by Corrected Znpatient = (0.25×Znnormal) + ((albuminnormal albuminpatient)×( Znpatient - (0.25×Znnormal)). Correlation between corrected Zn level and score from new WI were statistically analyzed by Pearson Correlation. RESULTS: WD-ALF had lower corrected Zn level compared to WD-non- ALF, NAFLD, AIH and indeterminate cause of ALF (7.3 (5.2- 11.6), 13.8 (6.1-20.2), 13.7 (11.2-16.7), 9.9 (5.3-31.4) and 11.4 (7.6-17.8), respectively, P &lt; 0.05). The demographic data and laboratory results are shown in table. Indeed, there was significant correlation between corrected Zn level and new WI score in WD patients (r = - 0.554, P value = 0.004). Conclusions: Serum Zn level can predict phenotypic severity of WD. Particularly, low serum Zn level can discriminate WD-ALF from indeterminate cause of ALF. (1) Dhawan A, Taylor RM, Cheeseman P, et al. Wilson&apos;s disease in children: 37-year experience and revised King&apos;s score for liver transplantation. (Table Presented).</style></abstract><notes><style face="normal" font="default" size="100%">L612593895&#xD;2016-11-11</style></notes><work-type><style face="normal" font="default" size="100%">Conference Abstract</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L612593895</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>263</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sintusek, P.</style></author><author><style face="normal" font="default" size="100%">Kyrana, E.</style></author><author><style face="normal" font="default" size="100%">Dhawan, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">A. Dhawan, Paediatric Liver, GI and Nutrition Centre, MowatLabs, King&apos;s College Hospital, Denmark Hill, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Value of serum zinc in diagnosing and assessing severity of liver disease in children with wilson disease</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pediatric Gastroenterology and Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pediatric Gastroenterology and Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">377-382</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">ceruloplasmin</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease protein</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">abdominal distension</style></keyword><keyword><style face="normal" font="default" size="100%">acute liver failure</style></keyword><keyword><style face="normal" font="default" size="100%">acute stress</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase blood level</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">ascites</style></keyword><keyword><style face="normal" font="default" size="100%">autoimmune hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">ceruloplasmin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">childhood disease</style></keyword><keyword><style face="normal" font="default" size="100%">chronic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic accuracy</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic test accuracy study</style></keyword><keyword><style face="normal" font="default" size="100%">diagnostic value</style></keyword><keyword><style face="normal" font="default" size="100%">disease severity assessment</style></keyword><keyword><style face="normal" font="default" size="100%">England</style></keyword><keyword><style face="normal" font="default" size="100%">false negative result</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">foot edema</style></keyword><keyword><style face="normal" font="default" size="100%">gene mutation</style></keyword><keyword><style face="normal" font="default" size="100%">hematemesis</style></keyword><keyword><style face="normal" font="default" size="100%">histopathology</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">incidental finding</style></keyword><keyword><style face="normal" font="default" size="100%">jaundice</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory test</style></keyword><keyword><style face="normal" font="default" size="100%">liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">liver function test</style></keyword><keyword><style face="normal" font="default" size="100%">liver ischemia</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">medical record review</style></keyword><keyword><style face="normal" font="default" size="100%">nonalcoholic fatty liver</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">provocation test</style></keyword><keyword><style face="normal" font="default" size="100%">receiver operating characteristic</style></keyword><keyword><style face="normal" font="default" size="100%">sensitivity and specificity</style></keyword><keyword><style face="normal" font="default" size="100%">splenomegaly</style></keyword><keyword><style face="normal" font="default" size="100%">toxic hepatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Wilson disease</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><isbn><style face="normal" font="default" size="100%">1536-4801&#xD;0277-2116</style></isbn><abstract><style face="normal" font="default" size="100%">Objectives: Wilson disease (WD) is a rare inborn error of copper metabolism with diverse manifestations. There has been no study of zinc (Zn), the copper&apos;s antagonist, in WD diagnosis and severity so far. Our aims were to evaluate serum Zn in WD and its correlation with the disease severity score (revised WD index). Although the ATP7B mutation analysis is highly accurate for WD diagnosis, it may not be readily available in a resource-limiting setting. We proposed a disease diagnostic score (Proposed WD diagnostic score) which incorporates serum Zn. Methods: Medical records of WD and non-WD children seen at King&apos;s College Hospital from 2005 to 2015 were reviewed for the selected parameters using the Proposed WD diagnostic score. Available serum Zn data in WD children before disease diagnosis and the calculated severity score were statistically analyzed. Diagnostic values of the Proposed WD diagnostic score were evaluated. Results: Serum Zn level was significantly lower in 8 WD-acute liver failure (ALF) (5.8 [4.1-8.3] μmol/L) compared to 18 WD-non-ALF (13.5 [6.1-22.2] μmol/L) and 9 ALF from indeterminate cause (9.8 [7.0-12.1] μmol/L) (P &lt; 0.001). Serum Zn significantly correlated with the revised WD index (r = -0.554, P = 0.004). The Proposed WD diagnostic score that included serum Zn level as 1 of the parameters had sensitivity and specificity of 87% and 99.2%, respectively. Conclusions: Serum Zn is a novel parameter for diagnosis and correlates with severity of WD. The Proposed WD diagnostic score is useful while awaiting ATP7B mutation analysis.</style></abstract><notes><style face="normal" font="default" size="100%">L624836539&#xD;2018-11-20&#xD;2018-11-26</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L624836539</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1097/MPG0000000000002007</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">29668570</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MPG0000000000002007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>466</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">466</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meydani, S. N.</style></author><author><style face="normal" font="default" size="100%">Leka, L. S.</style></author><author><style face="normal" font="default" size="100%">Fine, B. C.</style></author><author><style face="normal" font="default" size="100%">Dallal, G. E.</style></author><author><style face="normal" font="default" size="100%">Keusch, G. T.</style></author><author><style face="normal" font="default" size="100%">Singh, M. F.</style></author><author><style face="normal" font="default" size="100%">Hamer, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S.N. Meydani, Nutritional Immunology Laboratory, Jean Mayer USDA-HNRCA, Tufts University, 711 Washington St, Boston, MA 02111, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin E and respiratory tract infections in elderly nursing home residents: A randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">828-836</style></pages><volume><style face="normal" font="default" size="100%">292</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">alpha tocopherol</style></keyword><keyword><style face="normal" font="default" size="100%">ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">beta carotene</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">ferritin</style></keyword><keyword><style face="normal" font="default" size="100%">fish oil</style></keyword><keyword><style face="normal" font="default" size="100%">folic acid</style></keyword><keyword><style face="normal" font="default" size="100%">placebo</style></keyword><keyword><style face="normal" font="default" size="100%">pyridoxine</style></keyword><keyword><style face="normal" font="default" size="100%">riboflavin</style></keyword><keyword><style face="normal" font="default" size="100%">selenium</style></keyword><keyword><style face="normal" font="default" size="100%">thiamine</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">aged</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic therapy</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">common cold</style></keyword><keyword><style face="normal" font="default" size="100%">controlled clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">double blind procedure</style></keyword><keyword><style face="normal" font="default" size="100%">elderly care</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">health service</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">immune response</style></keyword><keyword><style face="normal" font="default" size="100%">incidence</style></keyword><keyword><style face="normal" font="default" size="100%">long term care</style></keyword><keyword><style face="normal" font="default" size="100%">major clinical study</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">morbidity</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">nursing home</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">randomization</style></keyword><keyword><style face="normal" font="default" size="100%">randomized controlled trial</style></keyword><keyword><style face="normal" font="default" size="100%">residential care</style></keyword><keyword><style face="normal" font="default" size="100%">respiratory tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">risk assessment</style></keyword><keyword><style face="normal" font="default" size="100%">statistical analysis</style></keyword><keyword><style face="normal" font="default" size="100%">United States</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin blood level</style></keyword><keyword><style face="normal" font="default" size="100%">vitamin supplementation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><isbn><style face="normal" font="default" size="100%">0098-7484</style></isbn><abstract><style face="normal" font="default" size="100%">Context: Respiratory tract infections are prevalent in elderly individuals, resulting in increased morbidity, mortality, and use of health care services. Vitamin E supplementation has been shown to improve immune response in elderly persons. However, the clinical importance of these findings has not been determined. Objective: To determine the effect of 1 year of vitamin E supplementation on respiratory tract infections in elderly nursing home residents. Design, Setting, and Participants: A randomized, double-blind, placebo-controlled trial was conducted from April 1998 to August 2001 at 33 long-term care facilities in the Boston, Mass, area. A total of 617 persons aged at least 65 years and who met the study&apos;s eligibility criteria were enrolled; 451 (73%) completed the study. Intervention: Vitamin E (200 IU) or placebo capsule administered daily; all participants received a capsule containing half the recommended daily allowance of essential vitamins and minerals. Main Outcome Measures: Incidence of respiratory tract infections, number of persons and number of days with respiratory tract infections (upper and lower), and number of new antibiotic prescriptions for respiratory tract infections among all participants randomized and those who completed the study. Results: Vitamin E had no significant effect on incidence or number of days with infection for all, upper, or lower respiratory tract infections. However, fewer participants receiving vitamin E acquired 1 or more respiratory tract infections (60% vs 68%; risk ratio [RR], 0.88; 95% confidence interval [CI], 0.76-1.00; P=.048 for all participants; and 65% vs 74%; RR, 0.88; 95% CI, 0.75-0.99; P=.04 for completing participants), or upper respiratory tract infections (44% vs 52%; RR, 0.84; 95% CI, 0.69-1.00; P=.05 for all participants; and 50% vs 62%; RR, 0.81; 95% CI, 0.66-0.96; P=.01 for completing participants). When common colds were analyzed in a post hoc subgroup analysis, the vitamin E group had a lower incidence of common cold (0.67 vs 0.81 per person-year; RR, 0.83; 95% CI, 0.68-1.01; P=.06 for all participants; and 0.66 vs 0.83 per person-year; RR, 0.80; 95% CI, 0.64-0.98; P=.04 for completing participants) and fewer participants in the vitamin E group acquired 1 or more colds (40% vs 48%; RR, 0.83; 95% CI, 0.67-1.00; P=.05 for all participants; and 46% vs 57%; RR, 0.80; 95% CI, 0.64-0.96; P=.02 for completing participants). Vitamin E had no significant effect on antibiotic use. Conclusions: Supplementation with 200 IU per day of vitamin E did not have a statistically significant effect on lower respiratory tract infections in elderly nursing home residents. However, we observed a protective effect of vitamin E supplementation on upper respiratory tract infections, particularly the common cold, that merits further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">L39079669&#xD;2004-08-30</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L39079669</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1001/jama.292.7.828</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">15315997</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.292.7.828</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blanc, D. S.</style></author><author><style face="normal" font="default" size="100%">Carrara, P.</style></author><author><style face="normal" font="default" size="100%">Zanetti, G.</style></author><author><style face="normal" font="default" size="100%">Francioli, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Hospital Preventive Medicine, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Water disinfection with ozone, copper and silver ions, and temperature increase to control Legionella: seven years of experience in a university teaching hospital</style></title><secondary-title><style face="normal" font="default" size="100%">J Hosp Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Hosp Infect</style></full-title></periodical><pages><style face="normal" font="default" size="100%">69-72</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2005/04/13</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Copper</style></keyword><keyword><style face="normal" font="default" size="100%">Disinfection/instrumentation/*methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Environmental Monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Heating/*methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, University</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infection Control/methods/standards</style></keyword><keyword><style face="normal" font="default" size="100%">Ions</style></keyword><keyword><style face="normal" font="default" size="100%">Legionella pneumophila/*growth &amp; development/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Maintenance and Engineering, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">*Ozone</style></keyword><keyword><style face="normal" font="default" size="100%">Sanitary Engineering</style></keyword><keyword><style face="normal" font="default" size="100%">*Silver</style></keyword><keyword><style face="normal" font="default" size="100%">Switzerland</style></keyword><keyword><style face="normal" font="default" size="100%">Temperature</style></keyword><keyword><style face="normal" font="default" size="100%">*Water Microbiology</style></keyword><keyword><style face="normal" font="default" size="100%">Water Purification/instrumentation/*methods/standards</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0195-6701 (Print)&#xD;0195-6701</style></isbn><accession-num><style face="normal" font="default" size="100%">15823660</style></accession-num><abstract><style face="normal" font="default" size="100%">The efficacy of ozonation, copper-silver ionization and increased temperature in controlling Legionella spp. in the hot water distribution networks of a university hospital was evaluated. Two separate water distribution networks were studied; network 1 which supplies the surgical intensive care units, and network 2 which supplies the medical intensive care units and the emergency room. Network 1 has been disinfected by ozonation since 1995, and network 2 has been disinfected by ionisation since 1999. The hot water temperature was increased from 50 to 65 degrees C in 1998 and 2000 in networks 1 and 2, respectively. Water samples and swabs of the water outlets were cultured for Legionella spp. between four and six times each year, providing data before and after implementation of the disinfection procedures. There was no significant difference in the proportion of samples positive for Legionella spp. after ozonation in network 1 or after ionization in network 2. In both networks, there was a significant reduction in legionella isolates after increasing the hot water temperature to 65 degrees C. Maintaining the hot water temperature above 50 degrees C throughout both networks proved to be the most effective control measure in our hospital.</style></abstract><notes><style face="normal" font="default" size="100%">Blanc, D S&#xD;Carrara, Ph&#xD;Zanetti, G&#xD;Francioli, P&#xD;Comparative Study&#xD;Evaluation Study&#xD;Journal Article&#xD;England&#xD;J Hosp Infect. 2005 May;60(1):69-72. doi: 10.1016/j.jhin.2004.10.016.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2004.10.016</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>359</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">359</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chirca, I.</style></author><author><style face="normal" font="default" size="100%">Salgado, C. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">C.D. Salgado, Infectious Diseases, Medical University of South Carolina, MSC 752, 135 Rutledge Ave, Charleston, SC 29425, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">What strategies are in place to control microbial burden in hospital environments and how could these change in the future?</style></title><secondary-title><style face="normal" font="default" size="100%">Future Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Future Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1051-1054</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">adenosine triphosphate</style></keyword><keyword><style face="normal" font="default" size="100%">alloy</style></keyword><keyword><style face="normal" font="default" size="100%">antiinfective agent</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">gold nanoparticle</style></keyword><keyword><style face="normal" font="default" size="100%">hydrogen peroxide</style></keyword><keyword><style face="normal" font="default" size="100%">methylene blue</style></keyword><keyword><style face="normal" font="default" size="100%">silicone</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">Clostridioides difficile</style></keyword><keyword><style face="normal" font="default" size="100%">cost effectiveness analysis</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">devices</style></keyword><keyword><style face="normal" font="default" size="100%">hand washing</style></keyword><keyword><style face="normal" font="default" size="100%">health care personnel</style></keyword><keyword><style face="normal" font="default" size="100%">hospital</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">infection control</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella</style></keyword><keyword><style face="normal" font="default" size="100%">medical device</style></keyword><keyword><style face="normal" font="default" size="100%">microbial contamination</style></keyword><keyword><style face="normal" font="default" size="100%">microorganism</style></keyword><keyword><style face="normal" font="default" size="100%">nonhuman</style></keyword><keyword><style face="normal" font="default" size="100%">pathogen load</style></keyword><keyword><style face="normal" font="default" size="100%">patient care</style></keyword><keyword><style face="normal" font="default" size="100%">practice guideline</style></keyword><keyword><style face="normal" font="default" size="100%">priority journal</style></keyword><keyword><style face="normal" font="default" size="100%">protective equipment</style></keyword><keyword><style face="normal" font="default" size="100%">Pseudomonas</style></keyword><keyword><style face="normal" font="default" size="100%">reduction (chemistry)</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword><keyword><style face="normal" font="default" size="100%">vancomycin resistant Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">vapor</style></keyword><keyword><style face="normal" font="default" size="100%">Wart virus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><isbn><style face="normal" font="default" size="100%">1746-0913&#xD;1746-0921</style></isbn><notes><style face="normal" font="default" size="100%">L369810103&#xD;2013-09-23</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L369810103</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.2217/fmb.13.99</style></url></related-urls></urls><custom5><style face="normal" font="default" size="100%">24020731</style></custom5><electronic-resource-num><style face="normal" font="default" size="100%">10.2217/fmb.13.99</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">349</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blazejewski, C.</style></author><author><style face="normal" font="default" size="100%">Wallet, F.</style></author><author><style face="normal" font="default" size="100%">Nseir, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">S. Nseir, Centre de Réanimation, Hôpital R.-Salengro, CHRU de Lille, F-59037 Lille Cedex, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">What&apos;s new in room decontamination in the intensive care unit?</style></title><secondary-title><style face="normal" font="default" size="100%">Reanimation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Reanimation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">256-262</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">chlorine dioxide</style></keyword><keyword><style face="normal" font="default" size="100%">ozone</style></keyword><keyword><style face="normal" font="default" size="100%">aerosol</style></keyword><keyword><style face="normal" font="default" size="100%">cleaning</style></keyword><keyword><style face="normal" font="default" size="100%">disinfection system</style></keyword><keyword><style face="normal" font="default" size="100%">health care personnel</style></keyword><keyword><style face="normal" font="default" size="100%">hospital infection</style></keyword><keyword><style face="normal" font="default" size="100%">intensive care unit</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">ultraviolet radiation</style></keyword><keyword><style face="normal" font="default" size="100%">vaporization</style></keyword><keyword><style face="normal" font="default" size="100%">water vapor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1951-6959&#xD;1624-0693</style></isbn><abstract><style face="normal" font="default" size="100%">The environment plays a central role in the transmission of hospital-acquired pathogens. Current cleaning methods are microbiologically ineffective. Improvements in environmental cleaning are associated with a decrease in the rate of hospital-acquired infections. To improve terminal cleaning, automated room disinfection systems containing hydrogen peroxide (H2O2) are more and more considered. Two technologies are available: aerosolization and vaporization. Dry-H2O2 vaporization is microbiologically efficient (in vitro and in situ). Its use is associated with endemic colonization and outbreak control. H2O 2 aerosolization effectiveness is still in assessment. Evidence is lacking to recommend others technologies (ultraviolet, ozone, chlorine dioxide, steam, high-efficiency particulate air-filtration, ultra microfiber, copper-based biocide). All methods are associated with extra-cost and longer waiting-time between two admissions. Safety for healthcare workers is not proved. © 2014 Société de réanimation de langue française (SRLF) and Springer-Verlag.</style></abstract><notes><style face="normal" font="default" size="100%">L373496311&#xD;2014-07-18&#xD;2014-07-24</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L373496311</style></url><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1007/s13546-014-0884-y</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s13546-014-0884-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">French</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>298</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">World Congress of Cardiology Scientific Sessions 2016, WCC 2016</style></title><secondary-title><style face="normal" font="default" size="100%">Global Heart</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Global Heart</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">cardiology</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">risk</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">dyslipidemia</style></keyword><keyword><style face="normal" font="default" size="100%">laboratory</style></keyword><keyword><style face="normal" font="default" size="100%">population</style></keyword><keyword><style face="normal" font="default" size="100%">electrocardiogram</style></keyword><keyword><style face="normal" font="default" size="100%">body weight gain</style></keyword><keyword><style face="normal" font="default" size="100%">pregnant woman</style></keyword><keyword><style face="normal" font="default" size="100%">female</style></keyword><keyword><style face="normal" font="default" size="100%">male</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive defect</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">nurse</style></keyword><keyword><style face="normal" font="default" size="100%">screening</style></keyword><keyword><style face="normal" font="default" size="100%">atrial fibrillation</style></keyword><keyword><style face="normal" font="default" size="100%">adrenal gland</style></keyword><keyword><style face="normal" font="default" size="100%">hemodynamics</style></keyword><keyword><style face="normal" font="default" size="100%">Russian Federation</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">Swiss</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword><keyword><style face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">particulate matter</style></keyword><keyword><style face="normal" font="default" size="100%">Asia</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">premature mortality</style></keyword><keyword><style face="normal" font="default" size="100%">tobacco</style></keyword><keyword><style face="normal" font="default" size="100%">drug dependence</style></keyword><keyword><style face="normal" font="default" size="100%">sodium urine level</style></keyword><keyword><style face="normal" font="default" size="100%">heart rehabilitation</style></keyword><keyword><style face="normal" font="default" size="100%">pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">vaccination</style></keyword><keyword><style face="normal" font="default" size="100%">influenza</style></keyword><keyword><style face="normal" font="default" size="100%">salt intake</style></keyword><keyword><style face="normal" font="default" size="100%">nursing</style></keyword><keyword><style face="normal" font="default" size="100%">community</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">athlete</style></keyword><keyword><style face="normal" font="default" size="100%">city</style></keyword><keyword><style face="normal" font="default" size="100%">Saudi Arabia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><isbn><style face="normal" font="default" size="100%">2211-8179</style></isbn><abstract><style face="normal" font="default" size="100%">The proceedings contain 631 papers. The topics discussed include: automatic implementation of the athlete&apos;s Seattle criteria leads to less than ten percent of abnormal electrocardiograms in general young population of Swiss males; the combined relevance of alcohol and tobacco to premature mortality in 200,000 Russians: a prospective study in western Siberia; state of central hemodynamics and sympathetic-adrenal system in pregnant women with hypertension with different weight gain during the period of gestation; prevalence, treatment, and control of hypertension and/or dyslipidemia in Korean adults: results from the multinational Pan-Asia dyslipidemia and hypertension diagnosis and treatment gap assessment study (PANDA); applicability of a non-laboratory- and a laboratory based cardiovascular disease risk score across seven regions of the world; association between physical dependence and cognitive impairment in phase 1 of cardiac rehabilitation program; feasibility of practice nurses screening for atrial fibrillation using smartphone ECG during flu-vaccinations; estimation of salt intake by 24-hour urinary sodium excretion: findings from the cardiovascular outcomes in a Papuan population and estimation of risk (copper) study; the role of the global nursing community in CVD prevention: preparing leaders and taking action; and effect of airborne particulate matter on cardiovascular diseases in Dammam and Al-Khobar Cities of Kingdom Saudi Arabia.</style></abstract><notes><style face="normal" font="default" size="100%">L72314336&#xD;2016-06-29</style></notes><work-type><style face="normal" font="default" size="100%">Conference Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L72314336</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Embase</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>415</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">415</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mahdi, J. K.</style></author><author><style face="normal" font="default" size="100%">Al-Jawher, M. H.</style></author><author><style face="normal" font="default" size="100%">Mahdi, N. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">J. K. Mahdi, Department of Chemical Industries, Technical Institute, College of Medicine, University of Basrah, Basrah, Iraq</style></auth-address><titles><title><style face="normal" font="default" size="100%">Zinc and copper levels in hydatid cyst fluid and patient&apos;s blood</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the Pakistan Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the Pakistan Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">580-581</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">alcohol dehydrogenase</style></keyword><keyword><style face="normal" font="default" size="100%">alkaline phosphatase</style></keyword><keyword><style face="normal" font="default" size="100%">carbonate dehydratase</style></keyword><keyword><style face="normal" font="default" size="100%">carboxypeptidase</style></keyword><keyword><style face="normal" font="default" size="100%">copper</style></keyword><keyword><style face="normal" font="default" size="100%">DNA polymerase</style></keyword><keyword><style face="normal" font="default" size="100%">RNA polymerase</style></keyword><keyword><style face="normal" font="default" size="100%">thymidine kinase</style></keyword><keyword><style face="normal" font="default" size="100%">zinc</style></keyword><keyword><style face="normal" font="default" size="100%">adult</style></keyword><keyword><style face="normal" font="default" size="100%">article</style></keyword><keyword><style face="normal" font="default" size="100%">atomic absorption spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">clinical article</style></keyword><keyword><style face="normal" font="default" size="100%">controlled study</style></keyword><keyword><style face="normal" font="default" size="100%">copper blood level</style></keyword><keyword><style face="normal" font="default" size="100%">echinococcosis</style></keyword><keyword><style face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style face="normal" font="default" size="100%">human</style></keyword><keyword><style face="normal" font="default" size="100%">physical chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">protein synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">stomach absorption</style></keyword><keyword><style face="normal" font="default" size="100%">zinc blood level</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><isbn><style face="normal" font="default" size="100%">0030-9982</style></isbn><abstract><style face="normal" font="default" size="100%">Eighteen patients with hydatid disease from Basrah General Hospital were involved in the study during 2007. Their ages ranged from 23-56 years with mean of 33.55 ± 10.4 years. The control group consisted of 25 apparantly healthy individuals. Zinc and copper levels in the sera and hydatid fluids were estimated by atomic absorption spectrophotometer. Mean values of zinc and copper concentrations in sera of patients were 124.33 ± 30.04mg/dl and 88.05 ± 15.91mg/dl respectively in comparing with those of the control group (P&lt;0.0001). On the other hand, mean values of both zinc and copper levels in sera of patients were lower than those of the hydatid cyst fluids which were statistically significant. There was a positive correlation between sera zinc and copper concentrations of patients and the control group while negative correlations were observed with other relationships.</style></abstract><notes><style face="normal" font="default" size="100%">L359159624&#xD;2010-07-21&#xD;2010-08-25</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">http://www.embase.com/search/results?subaction=viewrecord&amp;from=export&amp;id=L359159624</style></url></related-urls><pdf-urls><url>internal-pdf://3093357768/2175.pdf</url></pdf-urls></urls><custom5><style face="normal" font="default" size="100%">20578612</style></custom5><remote-database-name><style face="normal" font="default" size="100%">Embase&#xD;Medline</style></remote-database-name><language><style face="normal" font="default" size="100%">English</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">el-Kholy, M. S.</style></author><author><style face="normal" font="default" size="100%">Gas Allah, M. A.</style></author><author><style face="normal" font="default" size="100%">el-Shimi, S.</style></author><author><style face="normal" font="default" size="100%">el-Baz, F.</style></author><author><style face="normal" font="default" size="100%">el-Tayeb, H.</style></author><author><style face="normal" font="default" size="100%">Abdel-Hamid, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Public Health, and Biochemistry, Ain Shams University.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Zinc and copper status in children with bronchial asthma and atopic dermatitis</style></title><secondary-title><style face="normal" font="default" size="100%">J Egypt Public Health Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Egypt Public Health Assoc</style></full-title></periodical><pages><style face="normal" font="default" size="100%">657-68</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">5-6</style></number><edition><style face="normal" font="default" size="100%">1990/01/01</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Asthma/*blood/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Ceruloplasmin/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/analysis/*blood/deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Deficiency Diseases/*blood/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Dermatitis, Atopic/*blood/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Diet Surveys</style></keyword><keyword><style face="normal" font="default" size="100%">Egypt/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hair/chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, General</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, University</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/analysis/*blood/deficiency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1990</style></year></dates><isbn><style face="normal" font="default" size="100%">0013-2446 (Print)&#xD;0013-2446</style></isbn><accession-num><style face="normal" font="default" size="100%">2134100</style></accession-num><abstract><style face="normal" font="default" size="100%">The study comprised 40 children of both sexes aged from 2 to 12 years, 22 suffering from bronchial asthma and 18 suffering from atopic dermatitis. Twenty healthy children of comparable age and sex to the patients were studied as controls. All the children were subjected to full history including dietetic questionnaire, thorough examination, and to estimation of serum IgE, serum ceruloplasmin, and zinc and copper levels in both serum and hairs. The mean concentrations of zinc in serum and hairs were respectively 70.3 +/- 13.2 micrograms/100 ml and 167.5 +/- 23.0 micrograms/gm in asthmatic cases and 65.9 +/- 11.7 micrograms/100 ml and 164.8 +/- 23.6 micrograms/gm in those with atopic dermatitis. These levels were significantly (p less than 0.001) decreased in comparison to the control values (88.4 +/- 11.0 micrograms/100 ml and 194.5 +/- 18.6 micrograms/gm). On the other hand, a significant (p less than 0.001) increase in serum and hairs copper was demonstrated in both allergic groups compared to the controls. Mean copper values were respectively 79.5 +/- 8.06 micrograms/100 ml and 18.7 +/- 1.9 micrograms/gm in the asthmatic cases and 81.4 +/- 8.4 micrograms/100 ml and 17.8 +/- 2.08 micrograms/gm in cases with atopic dermatitis. The control mean concentrations were 67.95 +/- 6.37 micrograms/100 ml and 14.5 +/- 2.53 micrograms/gm respectively. Significant (p less than 0.001) higher levels of serum ceruloplasmin were observed in the allergic patients compared to the controls and were correlated with the hypercupremia. The results were discussed and a good dietetic intake of high biological value protein and zinc supplement was recommended to these patients in order to correct their disturbances especially the hypozincemia which could lead to exaggeration of their allergic conditions. The field of trace elements metabolism has grown rapidly over the past few years, particularly after the development of novel techniques as the atomic absorption spectrophotometry which had allowed the reliable measurements of several trace elements in tissues and so had opened a new field for many researches (Henkin, 1976). Zinc and copper are involved in cell and tissue growth. Zinc plays an important role in DNA and protein synthesis and is intimately involved with copper as cofactors in several important enzyme systems. The effects of many pathological conditions as congestive heart failure, pneumonia, rheumatic heart diseases, bronchitis, recurrent infection, hemolytic anemia, psoriasis, and malnutrition on the levels of serum zinc, copper, and other trace elements have been of interest to investigators for a number of years (Sinha and Gabrieli, 1970; David et al., 1984).(ABSTRACT TRUNCATED AT 400 WORDS)</style></abstract><notes><style face="normal" font="default" size="100%">el-Kholy, M S&#xD;Gas Allah, M A&#xD;el-Shimi, S&#xD;el-Baz, F&#xD;el-Tayeb, H&#xD;Abdel-Hamid, M S&#xD;Journal Article&#xD;England&#xD;J Egypt Public Health Assoc. 1990;65(5-6):657-68.</style></notes><urls></urls><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>214</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">214</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nct,</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Zinc Supplementation in Type 2 Diabetics</style></title><secondary-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT01309620</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">https://clinicaltrials.gov/show/NCT01309620</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><accession-num><style face="normal" font="default" size="100%">CN-02017416</style></accession-num><abstract><style face="normal" font="default" size="100%">Study participants Forty male type 2 diabetics, recruited from the outpatient clinic at the National University Hospital, Singapore, will be randomized to receive two tablets of either 100 mg zinc gluconate (GNC, USA) or placebo (99% microcystalline cellulose, 1% magnesium stearate) per day for 3 months. Subjects aged 21 years and above who fulfilled the American Diabetes Association criteria for the diagnosis of type 2 diabetes mellitus will be included in this study. We will exclude those who: had consumed over‐the counter or prescription drugs, vitamin/mineral supplements or traditional Chinese remedies, suffered acute infection less than 30‐days prior to the start of the study, had been diagnosed with active neuropsychiatric disease or hematological diseases, had hemoglobin less than 10g/dL, had previous use of narcotic drugs or regular alcohol intake in excess of 14 units per week. Each participant will provide written informed consent prior to their participation in this study. Supplementation and sampling of blood and urine A hospital research pharmacist will be engaged to randomize, blind the assigned treatment groups and count the remaining tablets so as to assess compliance. Blood and spot urine samples will be taken following an 8‐hour fast at baseline (before supplementation), days 3 and 7, months 1, 2 and 3 during supplementation and 1 month following the intake of zinc or placebo (washout). An aliquot of blood will be collected in plain or EDTA tubes for serum or plasma separation respectively. Markers of oxidative damage Blood samples collected into EDTA tubes will be centrifuged, indomethacin and butylated hydroxytoluene added into the plasma, and fresh urine samples placed in polypropylene tubes. The prepared samples will be stored at ‐80oC until analysis. Oxidative stress related biomarkers, F2‐IsoPs, F4‐NPs, HETEs, COPs and allantoin, will be measured by gas chromatography‐mass spectrometry using methods as previously described. Briefly, mixed heavy isotopes, 8‐iso‐PGF2α‐d4, IPF2α‐VI‐d4, [18O2] F4‐NP (gift from Prof. Jason D. Morrow (deceased), Eiscosanoid Core Laboratory at Vanderbilt University), 5(S)‐HETE‐d8, 12(S)‐HETE‐d8, 15(S)‐HETE‐d8, 20‐HETE‐d6 and arachidonic acid‐d8 and docosahexaenoic acid‐d5, and 7‐OH cholesterol‐d7, 24‐OH cholesterol‐d7 and 26 (27)‐OH cholesterol‐d5 and 7‐keto‐cholesterol‐d7 will be added into plasma for quantification of the oxidative stress markers. To measure the total (free and esterified) forms of F2‐IsoPs, F4‐NPs and HETEs products, 1 M potassium hydroxide prepared in methanol will be added to plasma (1:1) and hydrolysis performed at 37oC for 30 minutes. Thereafter, methanol, 5 M HCl and 40 mM formic acid (pH 4.6) will be sequentially added and mixed. The plasma mix will then purified using anionic exchange solid phase extraction (SPE). To measure the free forms in plasma and urine (F2‐IsoPs and HETEs), 40 mM formic acid (pH 4.5) will be added to the plasma or urine sample, mixed and then purified by SPE. Urinary creatinine levels will be measured to standardize urinary F2‐IsoPs and HETEs (Sigma Diagnostic kit, USA). The purified samples will then be derivatized and analyzed using gas chromatography (Hewlett‐Packard 6890, Agilent Technologies, USA) coupled to a mass selective detector (Hewlett‐Packard 5973N, Agilent Technologies, USA) (GC‐MS). For F2‐IsoPs, F4‐NPs, HETEs (a mixture of 5(S)‐, 12(S)‐, 15(S)‐ and 20‐HETEs), and total arachidonate and total docosahexanoate measurements, negative chemical ionization (NCI) mode will be applied and chromatographic separations will be carried out on a fused silica capillary column coated with cross‐linked 5% phenylmethylsiloxane (HP‐5, Agilent Technologies, USA). To determine COPs, electron ionization mode will be applied and chromatographic separations carried out on a fused silica capillary column coated with cross‐linked 5% phenylmethylsiloxane (Ultra 2 J&amp;W, USA). Concentrations of the lipid oxidation products will be alculated by comparing the peak area of each compound with the relevant deuterated internal standard. For allantoin and urate analysis, 25 ul plasma will be centrifuged using Nanosep filters (10 kDa) and to the filtrate, 25 ul of 4 mM 15N allantoin and 100 ul acetonitrile will be added, mixed and then dried under nitrogen gas. The dried sample will then be derivatized with 50 ml N‐(butyl‐dimethyl‐silyl)‐2,2,2‐trifluoro‐N‐methyl‐acetamide (MTBSTFA) in pyridine (1:1 v/v) at 50oC for 2 h. Allantoin will be analyzed by GC‐MS. Separations will be carried out on a fused silica capillary column coated with cross‐linked 5% phenylmethylsiloxane (Ultra 2, Agilent, USA). Derivatized allantoin samples (1 µl) will be injected into the GC‐MS. Quantification of allantoin will be calculated by comparison with the heavy isotope. For urate analysis, 80 ul water will be added to 20 ul plasma, mixed and then centrifuged using Nanosep filters (10 kDa). The filtrate will then be injected into an HPLC (Agilent Technologies, USA) coupled to a UV detector. Chromatographic separation will be achieved using 250 mm Zorbax SB‐C8 columns under isocratic condition where 2 mM NH4H2PO4 (pH 2.95) will be used for the mobile phase. The area of the eluted uric acid peak will be measured and the concentration determined against the linear calibration curve constructed with the samples spiked with pure urate. Clinical parameters of serum and hematological indices Blood glucose, HbA1c and insulin, serum hsCRP, cholesterol, LDL, HDL, triglyceride and iron will be measured using the Cobas C111 analyzer (Roche Diagnostics, Switzerland). Serum zinc and copper levels will be determined at the Referral Laboratory at the Singapore General Hospital, and white and red blood counts, hemoglobin, hematocrit concentrations, platelets, neutrophils and lymphocytes, will be assessed using the Full Blood Count Analyzer (Sysmex, Japan). Vascular indices The technique of pulse wave analysis will be used to determine the aortic pressure and augmentation index (AIx). Pulse wave velocity recordings will be made from the radial artery using a Millar tonometer, and data will be collected and analyzed using the SphygmoCor (SphygmoCor 2000 v7.0, PWV Medical, Sydney, Australia), which allowed continuous recording of the radial artery pressure waveform. The AIx will be calculated by dividing the difference in pressure between the first and second systolic peaks of the aortic pressure waveform by the calculated aortic pulse pressure. Measurement of plasma nitrate/nitrite will be adapted from that of Tsikas. In brief, to 200 µl of plasma heavy label 15N NO3‐ and 15N NO2‐ will be added, 800 µl acetone and 100 µl pentafluorobenzyl bromide (PFBBr) will be added, mixed and incubated at 50°C for 60 min. The acetone portion will be evaporated under nitrogen and then 500 µl of toluene will be added and mixed vigorously for 1 min. The organic extract will be obtained by centrifuging at 2000 rpm for 5 min at 4°C. Derivatized samples will be analyzed by GC‐MS/NCI. Separations will be carried out on a fused silica capillary column coated with cross‐linked 5% phenyl methyl siloxane. Derivatized samples (1µl) will be injected into the GC injection port using a splitless mode. Quantification of nitrate/nitrite will be calculated by comparing the peak area of each compound with the relevant heavy labelled internal standard 15N NO3‐ and 15N NO2‐. Statistical analyses Statistical analysis will be performed using by GraphPad Prism version 5.0 for Macintosh (GraphPad Prism Software, CA, USA). All values will be expressed as mean SD. Paired Student&apos;s t‐test will be performed between baseline and each time point during supplementation and after the wash‐out period. Any significant changes detected by Student&apos;s t‐test will be confirmed by ANOVA with repeated measures to assess the effects of zinc over time.</style></abstract><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02017416/full</style></url></related-urls></urls></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">78</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saad, A. A.</style></author><author><style face="normal" font="default" size="100%">Doka, Y. A.</style></author><author><style face="normal" font="default" size="100%">Osman, S. M.</style></author><author><style face="normal" font="default" size="100%">Magzoub, M.</style></author><author><style face="normal" font="default" size="100%">Ali, N. I.</style></author><author><style face="normal" font="default" size="100%">Adam, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Khartoum, PO Box 102, Khartoum, Sudan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Zinc, copper and C-reactive protein in children with severe Plasmodium falciparum malaria in an area of unstable malaria transmission in eastern Sudan</style></title><secondary-title><style face="normal" font="default" size="100%">J Trop Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Trop Pediatr</style></full-title></periodical><pages><style face="normal" font="default" size="100%">150-3</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2012/10/30</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Analysis of Variance</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers/blood</style></keyword><keyword><style face="normal" font="default" size="100%">C-Reactive Protein/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Copper/*blood</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Malaria, Falciparum/blood/*transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Plasmodium falciparum/isolation &amp; purification</style></keyword><keyword><style face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style face="normal" font="default" size="100%">Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sudan</style></keyword><keyword><style face="normal" font="default" size="100%">Zinc/*blood</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0142-6338</style></isbn><accession-num><style face="normal" font="default" size="100%">23104565</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Few data exist on the role of trace element in the pathogenesis of severe malaria. OBJECTIVES: The study was conducted at Kassala Hospital, eastern Sudan, to investigate the role of zinc, copper and C-reactive protein levels in children with severe Plasmodium falciparum malaria. METHODS: Zinc, copper and C-reactive protein levels were measured in sera of three groups of children (35 in each arm): those with severe malaria, those with uncomplicated P. falciparum malaria and healthy controls. RESULTS: Although the zinc levels were significantly lower, the levels of copper and C-reactive protein were significantly higher in patients with severe P. falciparum. There was a significant inverse correlation between zinc and C-reactive protein and significant positive correlation between copper and C-reactive protein. CONCLUSION: The change in zinc and copper may play a role in pathogenesis of P. falciparum malaria.</style></abstract><notes><style face="normal" font="default" size="100%">1465-3664&#xD;Saad, Alfarazdeg A&#xD;Doka, Yassir A&#xD;Osman, Shamselfalah M&#xD;Magzoub, Mamoun&#xD;Ali, Naji I&#xD;Adam, Ishag&#xD;Journal Article&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;J Trop Pediatr. 2013 Apr;59(2):150-3. doi: 10.1093/tropej/fms056. Epub 2012 Oct 26.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/tropej/fms056</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="CopperTIAB.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\CopperTIAB.enl">CopperTIAB.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="wdfsvw5zr5ffdqesfatv0e22waftxtrtf2fa">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asemota, E. A.</style></author><author><style face="normal" font="default" size="100%">Okafor, I. M.</style></author><author><style face="normal" font="default" size="100%">Okoroiwu, H. U.</style></author><author><style face="normal" font="default" size="100%">Ekong, E. R.</style></author><author><style face="normal" font="default" size="100%">Anyanwu, S. O.</style></author><author><style face="normal" font="default" size="100%">Efiong, E. E.</style></author><author><style face="normal" font="default" size="100%">Udomah, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Laboratory Science, University of Calabar, Calabar, Nigeria.&#xD;Department of Biochemistry, Federal University Lafia, Nasarawa, Nigeria.&#xD;Department of Haematology, Usman Danfodio University of Sokoto, Sokoto, Nigeria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Zinc, copper, CD4 T-cell count and some hematological parameters of HIV-infected subjects in Southern Nigeria</style></title><secondary-title><style face="normal" font="default" size="100%">Integr Med Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Integr Med Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">53-60</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">2018/04/10</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anemia</style></keyword><keyword><style face="normal" font="default" size="100%">CD4 count</style></keyword><keyword><style face="normal" font="default" size="100%">Hiv</style></keyword><keyword><style face="normal" font="default" size="100%">Serum copper</style></keyword><keyword><style face="normal" font="default" size="100%">Serum zinc</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2213-4220 (Print)&#xD;2213-4220</style></isbn><accession-num><style face="normal" font="default" size="100%">29629291</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: Low concentration of trace elements has been associated with poor prognosis and mortality in HIV infection. Methods: A cross sectional study was conducted among 100 HIV-infected subjects (70 were on ART treatment, while 30 were ART naive). Fifty (50) apparently healthy controls were enrolled. Concentration of serum levels of zinc and copper was done using atomic absorption spectrometric method, while complete blood count was determined using automated blood analyzer. CD4(+) T-cell count was done using cyflow cytometer. Aim and setting: The aim of this study was to investigate the level of some trace elements and some hematological parameters of HIV-seropositive subjects attending University of Calabar Teaching Hospital Clinic as well as prevalence of trace elements deficiency and anemic status and compare same with HIV-seronegative control. Results: Mean serum zinc, CD4(+) T-cell count, Hb, PCV, RBC, MXD, were significantly (p &lt; 0.05) reduced in the HIV-infected subjects, while copper/zinc ratio, MCV, MCH and platelet count were significantly (p &lt; 0.05) raised in the HIV-infected subjects. The serum Cu level was comparable (p &gt; 0.05) with the control. ART treatment had no effect on all the parameters assessed except CD4(+) T-cell count. Twenty five percent (25%), 3% and 56% of the HIV-infected subjects were zinc deficient, copper deficient and anemic, respectively. Gender was found as a predictor of zinc deficiency. Copper and zinc showed weak positive correlation with CD4(+) T-cell count. Conclusion: ART treatment did not complement zinc status in HIV infection while improving CD4(+) T-cell count, hence the need to consider supplementation.</style></abstract><notes><style face="normal" font="default" size="100%">Asemota, Enosakhare A&#xD;Okafor, Ifeyinwa M&#xD;Okoroiwu, Henshaw U&#xD;Ekong, Ewaro R&#xD;Anyanwu, Stanley Obialor&#xD;Efiong, Esienanwan Esien&#xD;Udomah, Francis&#xD;Journal Article&#xD;Netherlands&#xD;Integr Med Res. 2018 Mar;7(1):53-60. doi: 10.1016/j.imr.2018.01.008. Epub 2018 Feb 13.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">PMC5884009</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.imr.2018.01.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>